EP2185537A1 - Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions - Google Patents

Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions

Info

Publication number
EP2185537A1
EP2185537A1 EP08789003A EP08789003A EP2185537A1 EP 2185537 A1 EP2185537 A1 EP 2185537A1 EP 08789003 A EP08789003 A EP 08789003A EP 08789003 A EP08789003 A EP 08789003A EP 2185537 A1 EP2185537 A1 EP 2185537A1
Authority
EP
European Patent Office
Prior art keywords
methyl
butyl
pentyl
propyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08789003A
Other languages
German (de)
French (fr)
Inventor
Mark E. Schnute
Jeffery Neal Carroll
Cathleen Elizabeth Hanau
Matthew David Mcreynolds
Jeffrey Allen Scholten
Joseph J. Mcdonald
Margaret L. Grapperhaus
Mark Alan Massa
Peter G. Ruminski
Michelle Ann Schmidt
Joseph Walter Strohbach
Bruce Cameron Hamper
Theresa R. Fletcher
Michael David Rogers
Patrick Michael O'brien
Joe Nahra
Mark Anthony Morris
William Howard Roark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of EP2185537A1 publication Critical patent/EP2185537A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • This invention relates to pyrimidine and pyridine derivatives Such compounds have been shown to inhibit matrix metalloproteinase enzymes These compounds are useful for treating diseases resulting from MMP-mediated tissue breakdown such as heart disease, cardiac insufficiency, inflammatory bowel disease, multiple sclerosis, osteoarthritis, rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, fibrotic disorders in the kidney, lung, and/or osteoporosis
  • diseases resulting from MMP-mediated tissue breakdown such as heart disease, cardiac insufficiency, inflammatory bowel disease, multiple sclerosis, osteoarthritis, rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases
  • Matrix metalloproteinases are naturally occurring enzymes found in most mammals Over-expression and activation of MMPs, or an imbalance between MMPs and inhibitors of MMPs, have been suggested as factors in the pathogenesis of diseases characterized by the breakdown of extracellular matrix or connective tissues To date, 24 different members of the MMP family have been identified in vertebrates, 23 of which are found in human, including collagenases (MMP-1 , MMP-8, MMP-13), gelatinases (MMP-2 and MMP-9), stromelysins (MMP-3, MMP-10, MMP-1 1 ), mat ⁇ lysins (MMP-7 and MMP-26), membrane-type (MMT-14, MMP-15, MMP-16, MMT-17, MMP-24, MMT-25), as well as metalloelastases (MMP-12, MMP-19, MMP-20, MMP-22, MMP-23) (See Visse and Nagase (2003) Circ Res 92 827-839)
  • MMP inhibitors A major limitation on the use of currently known MMP inhibitors is their lack of specificity for any particular enzyme.
  • MMPs are generally categorized based on their substrate specificity, and indeed the collagenase subfamily of MMP-1 , MMP-8, and MMP-13 selectively cleave native interstitial collagens, and thus are associated only with diseases linked to such interstitial collagen tissue This is evidenced by the recent discovery that MMP-13 alone is over- expressed in breast carcinoma, while MMP-1 alone is over expressed in papillary carcinoma (see Chen et al , J Amer Chem Soc , 2000,122 9648-54)
  • Selective inhibitors of MMP-13 include a compound named WAY 170523, which has been reported by Chen et al , supra, 2000 Other selective inhibitors of MMP-13 are reported in International Patent Application Publication No WO 05/105760 Other selective inhibitors of MMP-13 are reported in U S Patent Application Publication No US20030229103 Other selective inhibitors of MMP-13 are reported in U S Patent Application Publication No US20040167120 Other selective inhibitors of M M P- 13 are reported in U S Patent Application Publication No US20050004111 Other selective inhibitors of MMP-13 are reported in U S Patent Application Publication No US20060173183 Other selective inhibitors of MMP-13 are reported in International Patent Application Publication No WO 06/128184 Other selective inhibitors of MMP-13 are reported in Co-assigned International Patent Application Publication No WO 02/64572 Other selective inhibitors of MMP-13 are reported in Co- assigned International Patent Application Publication No WO 02/64599 U S Patent No 6,008,243 discloses inhibitors of MMP-13 However, no selective or nonselect
  • Q is N or C-R c , provided that if Q is C-R c , M is N,
  • W is phenyl-(Ci- 6 alkylenyl), pyr ⁇ dyl-(C,- 6 alkylenyl), or 9-membered heteroaryl-(C,- 6 alkylenyl), wherein said phenyl, pyridyl, or 9-membered heteroaryl is substituted by one or more groups selected from R 30 and R 31 , Y is Ci- 6 alkyl, d- 6 haloalkyl, or C 1 ⁇ hydroxyalkyl, L is 5-membered heteroaryl,
  • R 6 rs H, CN, -OR 23 , -SO 2 R 37 , -NR 24 C( O)R 23 , -NR 24 SO 2 R 37 , or N ⁇ N
  • R 7 is -(C 1 .,, alkyl), -(Ci- ⁇ haloalkyl), -(C 14 atkylene)OH, -NR 38 R 39 , -NHSO 2 CH 3 , or -OR 25
  • R 9 is -(Ce alkylene)R 28 , -NHR 24 , or -OR 25
  • R 10 Is H, F, CN, R 12 , or -C( O)R 7 ,
  • R b , R°, R 8 , R 20 , R 22 , R 24 , R 25 , R 33 , R 34 . and R 35 are independently H or -(C 6 alkyl), R 21 Is H, F, or R 12 ,
  • R 23 is H, -(C 1-6 alkyl), or -(C 6 alkylene)OH
  • R 26 is H, OH, halo, NH 2 , or SH
  • R 28 is H, NH 2 , or -OR 29 ,
  • R 29 is H 1 (C 14 alkyl), or -C(O)(C 14 alkyl), R 30 is H or F,
  • R 32 is -(C t4 alkyl) optionally substituted with one, two, or three F
  • R 36 is -(C 1-6 alkyl) or -(C 34 cycloalkyl)
  • R 37 is -(C 14 alkyl), -(C 34 cycloalkyl), or -(C 14 alkylene)OH
  • R 38 and R 39 are independently H, -(C 14 alkyl), or R 38 and R 39 taken together form a 5- or 6- membered heterocycloalkyl, or a pharmaceutically-acceptable salt thereof
  • This invention also includes pharmaceutically acceptable salts, solvates and hydrates of compounds of Formula I This invention also includes all tautomers and stereochemical isomers of these compounds
  • This invention also is directed, in part, to a method for treating an MMP-13 mediated disorder in a mammal
  • disorders include rheumatoid arthritis and osteoarthritis
  • the method comprises administering a compound of Formula I or a pharmaceutically acceptable salt thereof, to the mammal in an amount that is therapeuticalty-effective to treat the condition
  • R a is C L6 alkyl, 1 ,4- dioxanyl, piperidinyl, cyclohexyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydropyranonyl, pyrrolidinyl, cyclopentyl, 7-oxa-b ⁇ cyclo[2 2 1]heptanyl, piperazinyl, 1 ,1 '-d ⁇ oxoth ⁇ omorphol ⁇ nyl, tetrahydro-1 ,1 '-d ⁇ oxoth ⁇ opyranyl, tetrahydrothiopyranyl, ptperidinonyl, tetrahydrofuryl, pyrrolidinonyl, or oxazolidinonyl, wherein said alkyl may be substituted by one or more substitu
  • R 3 is C,. 6 alkyl, 1 ,4- dioxanyl substituted by R 10 and R 21 , piperidinyl substituted by R 2 and R 3 or by R 4 , cyclohexyl substituted by R 2 and R 3 or by R 4 , morpholinyl substituted by R 4 , thiomorpholinyl substituted by R 10 and R 21 , tetrahydropyranyl substituted by R 3 and R 11 or by R 10 and R 21 , tetrahydropyranonyl, pyrrolidinyl substituted by R 2 and R 3 or by R 4 , cyclopentyl substituted by R 2 and R 3 , 7-oxa- b ⁇ cyclo[2 2 1]heptanyl, piperazinyl substituted by R 4 and R 5 , 1 ,1'-d ⁇ oxoth ⁇ omorpho! ⁇ nyl, tetrahydro-1
  • Another embodiment of the invention is a compound of Formula I wherein R a is C,. 6 alkyl,
  • X is N or CH, provided that when X is N, G is (C 2 - 3 a!kylenyl)-R a , wherein said C 1 ⁇ alkylenyl may be substituted by one or more substituents selected from OH and F.
  • Another embodiment of the invention is a compound of Formula I wherein R a is C 1 ⁇ alkyl,
  • R a is C 1 ⁇ alkyl
  • Another embodiment of the invention is a compound of Formula I wherein R a is C 1 ⁇ alkyl, wherein said alkyl may be substituted by one or more -OR 34
  • Another embodiment of the invention is a compound of Formula I wherein R a is
  • G is (C 1 3 alkylenyl)-R a or R a , wherein said C 1 . 3 alkylenyl may be substituted by one or more substituents selected from OH and F 1
  • W is phenyl-(C r6 alkylenyl), pyridyl-(Cr 6 alkylenyl), or 9-membered heteroaryl-(C r6 alkylenyl), wherein said phenyl, pyridyl, or 9-membered heteroaryl is substituted by one or more groups selected from R 30 and R 31 ,
  • Y is C r6 alkyl, Cr 6 haloalkyl, or C r6 hydroxyalkyl
  • L is 5-membered heteroaryl
  • RR 55 iss H or -(C 1 ⁇ alkyl), wherein said C 1 ⁇ alkyl may be substituted by one or more R 26 substituents,
  • R 7 is -(C 6 alkyl), -(C 6 haloalkyl), -(C 6 alkylene)OH, -NR 38 R 39 , -NHSO 2 CH 3 , or -OR 25
  • R 9 is -(Cn 3 alkylene)R 28 , -NHR 24 , or -OR 25 ,
  • R 21 is H, F, or R 12 ,
  • R 23 is H, -(C 1-6 alkyl), or -(C 1-6 alkylene)OH,
  • R 26 is H, OH, halo, NH 2 , or SH,
  • R 30 is H or F
  • R 32 is -(Ci-e alkyl) optionally substituted with one, two, or three F,
  • R 36 is -(C 1 ⁇ alkyl) or -(C 3 ⁇ cycloalkyl), and
  • R 37 is -(C 1-6 alkyl), -(C 3-6 cycloalkyl), or -(C 1 ⁇ alkylene)OH
  • R 38 and R 39 are independently H, -(C 1-6 alkyl), or R 38 and R 39 taken together form a 5- or 6- membered heterocycloalkyl, or a pharmaceutically-acceptable salt thereof
  • R a , W, Y, and L are as defined heremabove for Formula Il
  • Another embodiment of the invention is a compound of Formula UA wherein L is triazolyl, tetrazolyl, or oxadiazolyl
  • Another embodiment of the invention is a compound of Formula HA wherein L is
  • Another embodiment of the invention is a compound of Formula IIA-1
  • R a , W, and Y are as defined heremabove for Formula Il
  • Another embodiment of the invention is a compound of Formula IIA-2
  • R a , W, and Y are as defined heremabove for Formula Il
  • Another embodiment of the invention is a compound of Formula IIA-3
  • R a , W, and Y are as defined heremabove for Formula Il
  • Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4
  • Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4
  • R a is C 1-6 alkyl
  • alkyl may be substituted by one or more substituents
  • Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4 wherein R a is C 1-6 alkyl, wherein said alkyl may be substituted by one or more -OR 34
  • Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4
  • Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4 wherein Y is methyl
  • Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4 wherein W is phenyl-(C r6 alkylenyl), wherein said phenyl is substituted by one or more groups selected from R 30 and R 3 '
  • Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4 wherein W is phenylmethyl, wherein said phenyl is substituted by one or more groups selected from R 30 and R 31
  • Another embodiment of the invention is a compound shown in Table 1
  • G is (C 1 ⁇ alkylenyl)-R a or R a , wherein said C,. 3 alkylenyl may be substituted by one or more substituents selected from OH and F,
  • W is phenyl-(Cr 6 alkylenyl), pyr ⁇ dyl-(Cr 6 alkylenyl), or 9-membered heteroaryl-(Cr 6 alkylenyl), wherein said phenyl, py ⁇ dyl, or 9-membered heteroaryl is substituted by one or more groups selected from R 30 and R 3 ',
  • Y is C re alkyl, C,- ⁇ haloalkyl, or C,- 6 hydroxyalkyl
  • L is 5-membered heteroaryl
  • R 3 is H, F, CN, or -OR 22
  • R 5 is H or -(Ci- ⁇ alkyl), wherein said C 1-6 alkyl may be substituted by one or more R 26 substituents,
  • R 7 is -(C 1-6 alkyl), -(C,* haloalkyl), -(C,* alkylene)OH, -NR 38 R 39 , -NHSO 2 CH 3 , or -OR 25
  • R 9 is -(C 1-6 alkylene)R 28 , -NHR 24 , or -OR 25
  • R 12 is -(C 1 * alkyl), wherein said C, 6 alkyl may be substituted by one or more substituents selected from CN, -OR 23 , -SR 23 , -SO 2 R 37 , -NR 8 R 33
  • R 21 is H, F, or R 12 ,
  • R 23 is H, -(C 1 * alkyl), or -(C 1 * alkylene)OH
  • R 26 is H, OH, halo, NH 2 , or SH
  • R 28 is H, NH 2 , or -OR 29
  • R 30 is H or F
  • R 32 is -(C 1 * alkyl) optionally substituted with one, two, or three F
  • R 36 is -(C 1 * alkyl) or -(C 3 * cycloalkyl)
  • R 37 is -(C,* alkyl), -(C 3 * cycloalkyl), or -(C 1 * alkylene)OH
  • R 38 and R 39 are independently H, -(C 1 * alkyl), or R 38 and R 39 taken together form a 5- or 6- membered heterocycloalkyl, or a pharmaceutically-acceptable salt thereof
  • R a , R b , W, and Y are as defined hereinabove for Formula III
  • Another embodiment of the invention is a compound of Formula IHA wherein L is triazolyl, tetrazolyl, or oxadiazolyl
  • Another embodiment of the invention is a compound of Formula IIIA-1 wherein R a , R D , W, and Y are as defined hereinabove for Formula III
  • Another embodiment of the invention is a compound of Formula IIIA-2
  • R ->a , R Dd , W, and Y are as defined hereinabove for Formula III
  • Another embodiment of the invention is a compound of Formula IIIA-3
  • R 1 R 1 W, and Y are as defined hereinabove for Formula III
  • Another embodiment of the invention is a compound of Formula IIIA-4
  • W 1 and Y are as defined hereinabove for Formula III
  • Another embodiment of the invention is a compound of Formula IHA, IIIA-1 , IIIA-2, IIIA-3, or
  • Another embodiment of the invention is a compound of Formula IHA, IIIA-1 , IIIA-2, IIIA-3, or
  • Another embodiment of the invention is a compound of Formula IDA, IIIA-1 , IIIA-2, IIIA-3, or IIIA-4 wherein R a is C 1 ⁇ alkyl, wherein said alkyl may be substituted by one or more -OR 34
  • Another embodiment of the invention is a compound of Formula IHA, IIIA-1 , IIIA-2, IIIA-3, or
  • R a is methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1-pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, 1 -hexyl, aziridinyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, pipe ⁇ dinyl, piperazinyl, oxiranyl, oxetanyl, tetrahydrofuryl, dioxolyl, tetrahydropyranyl, dioxanyl, oxazetidinyl, isoxazolidinyl, oxazolidmyl, morpholinyl, oxazinanyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohex
  • Y is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1 -pentyl, 2-pentyl, 2,2- dimethylpropyl, or 1 -hexyl, wherein Y may be substituted by OH or by one or more substituents selected from F, Cl, and Br,
  • L is triazolyl, tetrazolyl, or oxadiazolyl
  • R 5 is H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1 -pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2- dimethylethyl, 1 -pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, or 1 -hexyl, may be substituted by one or more R 26 substituents,
  • R 7 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1 -pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, 1 -hexyl, -NHR 24 , or -OR 25 , wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1 -pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, or 1-hexyl may be substituted by OH or by one or more substituents selected from F, Cl, and Br, R 9 is -(C 1 ⁇ alkylene)R 28 , -NHR 24 , or -OR 25 ,
  • R 31 is Cl, Br, -OR 32 , methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1- pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, 1-hexyl, or -OCH 2 CH 2 OR 25 ,
  • R 32 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1 -pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, or 1-hexyl, wherein R 32 may be substituted with one, two, or three F,
  • R 36 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1 -pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, or 1 -hexyl
  • R 37 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1 -pentyl, 2-pentyl,
  • 2,2-d ⁇ methylpropyl, or 1 -hexyl wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2- dimethylethyl, 1 -pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, 1-hexyl, may be substituted by OH, or a pharmaceutically-acceptable salt thereof
  • Another embodiment of the invention is a compound of Formula IHA, IIIA-1 , IIIA-2, IIIA-3, or IIIA-4 wherein Y is methyl
  • Y is Cr 6 alkyl, C t - 6 haloalkyl, or C r6 hydroxyalkyl
  • L is 5-membered heteroaryl
  • R 3 Is H, F, CN, or -OR 22 ,
  • R 5 is H or -(C 1 ⁇ alkyl), wherein said Ci -6 alkyl may be substituted by one or more R 26 substituents,
  • R 7 is -(C 1 ⁇ alkyl), -(C 1-6 haloalkyl), -(C 1-6 alkylene)OH, -NR 38 R 39 , -NHSO 2 CH 3 , or -OR 25
  • R 9 is -(C 1 * alKylene)R 28 , -NHR 24 , or -OR 25
  • R B , R c , R 8 , R 20 , R 22 , R 24 , R 25 , R 33 , R 34 , and R 35 are independently H or -(C 1-6 alkyl), R 21 ⁇ s H, F, or R 12 ,
  • R 23 is H, -(C 1 .* alkyl), or -(C 1-6 alkylene)OH
  • R 26 is H, OH, halo, NH 2 , or SH
  • R 28 is H, NH 2 , or -OR 29
  • R 30 is H or F
  • R 32 is -(Ct- 6 alkyl) optionally substituted with one, two, or three F
  • R 36 is -(C 1-6 alkyl) or -(C 3-6 cycloalkyl)
  • R 37 is -(C 1-6 alkyl), -(C 3-6 cycloalkyl), or -(C 1 ⁇ alkylene)OH
  • R 38 and R 39 are independently H, -(C 1-6 alkyl), or R 38 and R 39 taken together form a 5- or 6- membered heterocycloalkyl, or a pharmaceutically-acceptable salt thereof
  • R a , R c , W 1 Y, and L are as defined heremabove for Formula IV
  • Another embodiment of the invention is a compound of Formula IVA wherein L is triazolyl, tetrazolyl, or oxadiazolyl
  • Another embodiment of the invention is a compound of Formula IVA- 1
  • R 3 , R c , W, Y, and L are as defined hereinabove for Formula IV
  • Another embodiment of the invention is a compound of Formula IVA-3
  • R a , R c , W, Y, and L are as defined hereinabove for Formula IV
  • Another embodiment of the invention is a compound of Formula IVA-4
  • R a , R c , W, Y, and L are as defined hereinabove for Formula IV
  • Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or
  • R a is C 6 alkyl
  • Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or
  • Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or IVA-4 wherein R a is C 1-6 alkyl, wherein said alkyl may be substituted by one or more -OR 34
  • Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or
  • Another embodiment of the invention is a compound of Formula IVA, IVA- 1 , IVA-2, IVA-3, or
  • R 2 is CH(CH 3 )OH, C(CH 3 ) 2 OH, -NR 8 C(O)(C, . ⁇ ; alkylene)R 28 , or -NR 8 SO 2 R 36 , R 10 Is CH(CH 3 )OH, or C(CH 3 ) 2 OH, and
  • Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or IVA-4 wherein Y is methyl
  • Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or IVA-4 wherein W is phenyl-(Cr 6 alkylenyl), wherein said phenyl is substituted by one or more groups selected from R 30 and R 31
  • Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or IVA-4 wherein W is phenylmethyl, wherein said phenyl is substituted by one or more groups selected from R 30 and R 31
  • Another embodiment of the invention is a compound shown in Table 2
  • Another embodiment of the invention is a compound of Formula I 1 II, III, or IV wherein G is -CH 2 R 3 , -CH 2 CH 2 R 3 , -CH(R a )CH 3> -CH 2 CH 2 CH 2 R 3 , -CH 2 CH(CH 3 )R 3 ,
  • R a is methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1 -pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, 1 -hexyl, aziridinyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, oxiranyl, oxetanyl, tetrahydrofuryl, dioxolyl, tetrahydropyranyl, dioxanyl, oxazetidinyl, isoxazolidinyl, oxazolidinyl, morpholinyl, oxazinanyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein said methyl, e
  • W is phenyl-(d- 6 alkylenyl), pyr ⁇ dyl-(C 1 - 6 alkylenyl), or IHdOIyI-(Cr 6 alkylenyl), wherein said C t . 6 alkylene is methylene, ethylene, 1 -propylene, 2-propylene, 1-butylene, 2-butylene, 2,2- dimethylethylene, 1-pentylene, 2-pentylene, 2,2-d ⁇ methylpropylene, or 1-hexylene, and wherein said phenyl, pyridyl, or indolyl is substituted by one or more groups selected from R 30 and R 3 ⁇
  • Y is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1-pentyl, 2-pentyl, 2,2- dimethylpropyl, or 1-hexyl, wherein Y may be substituted by OH or by one or more substituents selected from F, Cl, and Br, L is triazolyl, tetrazolyl, or oxadiazolyl,
  • R 7 is methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1-pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, 1-hexyl, -NHR 24 , or -OR 25 , wherein said methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1 -pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, or 1 -hexyl may be substituted by OH or by one or more substituents selected from F, Cl, and Br, R 9 is -(C 6 alkylene)R 28 , -NHR 24 , or -OR 25 ,
  • R b , R c , R 8 , R 20 , R 22 , R 24 , R 25 , R 33 , R 34 , and R 35 are independently H, methyl, ethyl, 1 -propyl, 2- propyl, 1-b ⁇ tyl, 2-butyl, 2,2-d ⁇ methylethyl, 1 -pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, or 1 -hexyl,
  • R 23 is H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methyletbyl, 1-pentyl, 2-pentyl,
  • 2,2-d ⁇ methylpropyl, or 1-hexyl wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, 1-hexyl, may be substituted by OH,
  • R 26 is H, OH 1 F, Cl, Br 1 NH 2 , or SH,
  • R 31 is Cl, Br, -OR 32 , methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1 - pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, 1-hexyl, or -OCH 2 CH 2 OR 25 ,
  • R 32 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1-pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, or 1-hexyl, wherein R 32 may be substituted with one, two, or three F,
  • R 36 is methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1-pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, or 1-hexyl, and
  • R 37 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1 -pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, 1 -hexyl, may be substituted by OH, or a pharmaceutically-acceptable salt thereof
  • Another embodiment of the invention is a compound shown in Table 3
  • Another embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a compound as described heremabove, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent
  • Another embodiment of the invention is a method for inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal an MMP-13 inhibiting amount of a compound described heremabove, or a pharmaceutically acceptable salt thereof
  • Another embodiment of the invention is a method for treating a disease mediated by an MMP- 13 enzyme, comprising administering to a patient suffering from such a disease a nontoxic effective amount of a compound described heremabove, or a pharmaceutically acceptable salt thereof
  • Another embodiment of the invention is a method for treating arthritis, comprising administering to a patient suffering from an arthritis disease a nontoxic antiarthritic effective amount of a compound described heremabove, or a pharmaceutically acceptable salt thereof
  • Another embodiment of the invention is a method for treating osteoarthritis, comprising administering to a patient suffering from osteoarthritis a nontoxic effective amount of a compound described heremabove, or a pharmaceutically acceptable salt thereof
  • Another embodiment of the invention is a method for treating rheumatoid arthritis, comprising administering to a patient suffering from rheumatoid arthritis a nontoxic effective amount of a compound described heremabove, or a pharmaceutically acceptable salt thereof
  • Another embodiment of the invention is a method for treating psoriatic arthritis, comprising administering to a patient suffering from psoriatic arthritis a nontoxic effective amount of a compound described hereinabove, or a pharmaceutically acceptable salt thereof
  • Another embodiment of the invention is a method for treating a cancer, comprising administering to a patient suffering from a cancer a nontoxic anti-cancer effective amount of a compound described hereinabove, or a pharmaceutically acceptable salt thereof
  • Another embodiment of the invention is a method for treating inflammation, comprising administering to a patient suffering from inflammation a nontoxic effective amount of a compound described hereinabove, or a pharmaceutically acceptable salt thereof
  • Another embodiment of the invention is a method for treating chronic obstructive pulmonary disease, comprising administering to a patient suffering from chronic obstructive pulmonary disease a nontoxic effective amount of a compound described hereinabove, or a pharmaceutically acceptable salt thereof
  • Another embodiment of the invention is a method for treating psoriasis, comprising administering to a patient suffering from psoriasis a nontoxic effective amount of a compound described hereinabove, or a pharmaceutically acceptable salt thereof.
  • Another embodiment of the invention is a method for treating asthma, comprising administering to a patient suffering from asthma a nontoxic effective amount of a compound described hereinabove, or a pharmaceutically acceptable salt thereof
  • Another embodiment of the invention is a method for treating inflammatory bowel disease, comprising administering to a patient suffering from inflammatory bowel disease a nontoxic effective amount of a compound described hereinabove, or a pharmaceutically acceptable salt thereof
  • the term "arthritis”, which is synonymous with the phrase “arthritic condition” includes osteoarthritis, rheumatoid arthritis, degenerative joint disease, spondyloarthropathies, gouty arthritis, systemic lupus erythematosus, juvenile arthritis, and psoriatic arthritis
  • An allosteric inhibitor of MMP-13 having an anti-arthritic effect is a compound as defined above that inhibits the progress, prevents further progress, or reverses progression, in part or in whole, of any one or more symptoms of any one of the arthritic diseases and disorders listed above
  • alkyl refers to a straight or branched chain monovalent hydrocarbon radical
  • a C 1-6 alkyl radical is a straight or branched chain monovalent hydrocarbon radical having 1 to 6 carbon atoms
  • Examples of C 1-6 alkyl radicals include methyl, ethyl, 1 -propyl, 2- propyl, 1 -butyl, 2-butyl, 2,2-d ⁇ methylethyl, 1 -pentyl, 2-pentyl, 2,2-d ⁇ methylpropyl, and 1 -hexyl
  • alkylene refers to a straight or branched chain divalent hydrocarbon radical
  • a C 1 ⁇ alkylene radical is a straight or branched chain divalent hydrocarbon radical having 1 to 6 carbon atoms
  • Examples of C 1 ⁇ alkylene radicals include methylene, ethylene, 1 - propylene, 2-propylene, 1 -butylene, 2-butylene, 2,2-d ⁇ methylethylene, 1 -pentylene, 2-pentylene, 2,2- dimethylpropylene, and 1-hexylene
  • cycloalkyl refers to a cyclic monovalent hydrocarbon radical
  • a C 3-6 cycloalkyl radical is a cyclic monovalent hydrocarbon radical having 1 to 6 carbon atoms
  • Examples of C 3-6 cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl
  • IC 50 means the concentration of a compound, usually expressed as ⁇ M or nM, required to inhibit an enzyme's catalytic activity by 50%
  • carrier damage means a disorder of hyaline cartilage and subchondral bone characterized by hypertrophy of tissues in and around the involved joints, which may or may not be accompanied by deterioration of hyaline cartilage surface
  • treating which is related to the terms “treat” and “treated”, means administration of an invention combination as defined above that inhibits the progress, prevents further progress, or reverses progression, in part or in whole, of any one or more symptoms of any one of the diseases and disorders listed above
  • invention compound means a compound of Formula I, or a pharmaceutically acceptable salt thereof, as fully defined above
  • NSAID is an acronym for the phrase “nonsteroidal anti-inflammatory drug", which means any compound which inhibits cyclooxygenase-1 ("COX-1") and cyclooxygenase-2
  • Most NSAIDs fall within one of the following five structural classes (1 ) propionic acid derivatives, such as ibuprofen, naproxen, naprosyn, diclofenac, and ketoprofen, (2) acetic acid derivatives, such as tolmetin and sulindac, (3) fenamic acid derivatives, such as mefenamic acid and meclofenamic acid, (4) biphenylcarboxylic acid derivatives, such as diflunisal and flufenisal, and (5) oxicams, such as piroxim, peroxicam, sudoxicam, and isoxicam
  • Other useful NSAIDs include aspirin, acetominophen, indomethacin, and phenylbutazone Selective inhibitors of cyclooxygena
  • a selective inhibitor of COX-2 is a compound that inhibits COX-2 selectively versus COX-1 such that a ratio of IC 50 for a compound with COX-1 divided by a ratio of IC 50 for the compound with COX-2 is greater than, or equal to, 5, where the ratios are determined in one or more assays All that is required to determine whether a compound is a selective COX-2 inhibitor is to assay a compound in one of a number of well know assays in the art
  • drugs which is synonymous with the phrases “active components”, “active compounds”, and “active ingredients”, includes celecoxib, or a pharmaceutically acceptable salt thereof, valdecoxib, or a pharmaceutically acceptable salt thereof, and an allosteric inhibitor of MMP- 13, and may further include one or two of the other therapeutic agents described above
  • An allosteric inhibitor of MMP-13 is any compound of Formula I that binds allosterically into the S1 ' site of the MMP- 13 enzyme, including the S1 ' channel, and/or the S1 " site, without ligating, coordinating, or binding the catalytic zinc of the MMP-13
  • Certain of the invention compounds possess one or more chiral centers, and each center may exist in the R or S configuration
  • the scope of the present invention encompasses any diastereomeric, enantiomeric, or epimeric form of invention compound, as well as mixtures thereof
  • Compounds of Formula I may be prepared as single enantiomer or as a mixture of individual enantiomers which includes racemic mixtures Methods to obtain preferentially a single enantiomer from a mixture of individual enantiomers or a racemic mixture are well known to those ordinarily skilled in the art of organic chemistry Such methods include but are not limited to preferential crystallization of diastereomeric salts (e g tartrate or cam
  • certain invention compounds may exist as geometric isomers such as the
  • Z isomer of a compound of Formula I, as well as mixtures thereof, is encompassed within the scope of the present invention
  • Certain invention compounds can exist as two or more tautomeric forms Tautomeric forms of the invention compounds may interchange, for example, via enolization/de-enolization, 1 ,2-hydr ⁇ de, 1 ,3-hydr ⁇ de, or 1 ,4-hydr ⁇ de shifts, and the like Any tautomeric form of a compound of Formula I, as well as mixtures thereof, Is encompassed within the scope of the present invention
  • Some compounds of the present invention have cycloalkyl groups, which may be substituted at more than one carbon atom, in which case all geometric forms thereof, both cis and trans, and mixtures thereof, are within the scope of the present invention
  • isotopically-labelled compounds of Formula I which are identical to those recited above, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 180, 17O 1 31 P, 32P, 35S, 18F and 36Cl, respectively
  • Compounds of the present invention and pharmaceutically acceptable salts of said compounds which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention
  • Certain isotopically labelled compounds of the present invention for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays Tritiated, i
  • invention compounds are capable of further forming nontoxic pharmaceutically acceptable salts, including, but not limited to, acid addition and/or base salts
  • acid addition salts are formed from basic invention compounds
  • base addition salts are formed from acidic invention compounds All of these forms are within the scope of the compounds useful in the invention
  • Pharmaceutically acceptable acid addition salts of the basic invention compounds include nontoxic salts derived from inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, hydrofluoric, phosphorous, and the like, as well nontoxic salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc
  • Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, tnfluoroacetate, propionate, caprylate, isobutyrate, ox
  • a nontoxic pharmaceutically acceptable base addition salt of an acidic invention compound may be prepared by contacting the free acid form of the compound with a metal cation such as an alkali or alkaline earth metal cation, or an amine, especially an organic amine
  • a metal cation such as an alkali or alkaline earth metal cation, or an amine, especially an organic amine
  • suitable metal cations include sodium cation (Na"), potassium cation (K * ), magnesium cation (Mg 2+ ), calcium cation (Ca 2* ), and the like
  • suitable amines are N,N'-d ⁇ benzylethylened ⁇ am ⁇ ne, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamme, A/-methylglucam ⁇ ne, and procaine
  • a base addition salt of an acidic invention compound may be prepared by contacting the free acid form of the compound with a sufficient amount of a desired base to produce the salt in the conventional manner
  • the free acid form of the compound may be regenerated by contacting the salt form so formed with an acid, and isolating the free acid of the compound in the conventional manner
  • the free acid forms of the invention compounds differ from their respective salt forms somewhat in certain physical properties such as solubility, crystal structure, hygroscopicity, and the like, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention
  • compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined above, together with a pharmaceutically acceptable carrier, diluent, or excipient
  • the present invention also relates to the formulation of a compound of the present invention alone or with one or more other therapeutic agents which are to form the intended combination, including wherein said different drugs have varying half-lives, by creating controlled-release forms of said drugs with different release times which achieves relatively uniform dosing, or, in the case of non- human patients, a medicated feed dosage form in which said drugs used in the combination are present together in admixture in the feed composition
  • co-administration in which the combination of drugs is achieved by the simultaneous administration of said drugs to be given in combination, including co-administration by means of different dosage forms and routes of administration, the use of combinations in accordance with different but regular and continuous dosing schedules whereby desired plasma levels of said drugs involved are maintained in the patient being treated, even though the individual drugs making up said combination are not being administered to said patient simultaneously
  • a therapeutically effective amount, or, simply, effective amount, of a compound of Formula I will generally be from about 1 to about 300 mg/kg of subject body weight of the compound of Formula I, or a pharmaceutically acceptable salt thereof Typical doses will be from about 10 to about 5000 mg/day for an adult subject of normal weight for each component of the combination
  • regulatory agencies such as, for example, the Food and Drug Administration (“FDA") in the U S may require a particular therapeutically effective amount
  • a number of factors will generally be considered by the medical practitioner or veterinarian in view of the experience of the medical practitioner or veterinarian, including the Food and Drug Administration guidelines, or guidelines from an equivalent agency, published clinical studies, the subject's (e g , mammal's) age, sex, weight and general condition, as well as the type and extent of the disease, disorder or condition being treated, and the use of other medications, if any, by the subject
  • the administered dose may fall within the ranges or concentrations recited above, or may vary outside them, ⁇ e, either below or above those ranges, depending upon the requirements of the individual subject, the severity of the condition being treated, and the particular therapeutic formulation being employed Determination of a proper dose for a particular situation is within the skill of the medical or veterinary arts Generally, treatment
  • compositions described briefly here and more fully below, of an invention combination may be produced by formulating the invention combination in dosage unit form with a pharmaceutical carrier
  • dosage unit forms are tablets, capsules, pills, powders, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers containing either one or some larger number of dosage units and capable of being subdivided into individual doses
  • the compounds of Formula I may be formulated separately
  • suitable pharmaceutical carriers including pharmaceutical diluents
  • suitable pharmaceutical carriers are gelatin capsules, sugars such as lactose and sucrose, starches such as corn starch and potato starch, cellulose derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, and cellulose acetate phthalate, gelatin, talc, stearic acid, magnesium stearate, vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and oil of theobroma, propylene glycol, glycerin, sorbitol, polyethylene glycol, water, agar, alginic acid, isotonic saline, and phosphate buffer solutions, as well as other compatible substances norr ⁇ ally used in pharmaceutical formulations
  • compositions to be employed in the invention can also contain other components such as coloring agents, flavoring agents, and/or preservatives These materials, if present, are usually used in relatively small amounts
  • compositions can, if desired, also contain other therapeutic agents commonly employed to treat any of the above-listed diseases and disorders
  • the percentage of the active ingredients of a compound of Formula I, or a pharmaceutically acceptable salt thereof, in the foregoing compositions can be varied within wide limits, but for practical purposes it is preferably present in a total concentration of at least 10% in a solid composition and at least 2% in a primary liquid composition The most satisfactory compositions are those in which a much higher proportion of the active ingredients are present, for example, up to about 95%
  • Preferred routes of administration of a compound of Formula I are oral or parenteral
  • another route of administration may be preferred depending upon the condition being treated
  • topical administration or administration by injection may be preferred for treating conditions localized to the skin or a joint
  • Administration by transdermal patch may be preferred where, for example, it is desirable to effect sustained dosing
  • IV intravenous
  • a useful oral dosage is between 20 and 800 mg, of a compound of Formula I, or a pharmaceutically acceptable salt thereof
  • the dosage is within the dosing range used in treatment of the above-listed diseases, or as would be determined by the needs of the patient as described by the physician
  • Compounds of Formula I may be administered in any form Preferably, administration is in unit dosage form
  • a unit dosage form of the compound of Formula I to be used in this invention may also comprise other compounds useful in the therapy of diseases described above
  • a further description of pharmaceutical formulations useful for administering the compounds of Formula I and invention combinations is provided below
  • the invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described herein
  • TNF- ⁇ inhibitors such as anti-TNF monoclonal antibodies and TNF receptor immunoglobulin molecules (such as Enbrel®), low dose methotrexate, lefunimide, hydroxychloroquine, d-penicillamine, auranofin or parenteral or oral gold
  • Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin, COX-2 inhibitors such as etoricoxib and rofecoxib, analgesics and intraarticular therapies such as corticosteroids and hyaluronic acids such as hyalgan and synvisc
  • NSAID's standard non-steroidal anti-inflammatory agents
  • piroxicam such as piroxicam, diclofenac, propionic acids such as naproxen, flurbiprofen, fenoprofen, keto
  • the active ingredient of the present invention may be administered in combination with inhibitors of other mediators of inflammation, comprising one or more members selected from the group consisting essentially of the classes of such inhibitors and examples thereof which include, matrix metalloproteinase inhibitors, aggrecanase inhibitors, TACE inhibitors, leucotriene receptor antagonists, IL-1 processing and release inhibitors, ILra, H1 -receptor antagonists, k ⁇ n ⁇ n-B1 - and B2 - receptor antagonists, prostaglandin inhibitors such as PGD-, PGF- PGI2 - and PGE-receptor antagonists, thromboxane A2 (TXA2-) inhibitors, 5- and 12-l ⁇ poxygenase inhibitors, leukot ⁇ ene LTC4 - , LTD4/LTE4 - and LTB4 -inhibitors, PAF-receptor antagonists, gold in the form of an aurothio group together with various hydrophilic groups, immunosuppressive agents,
  • the compounds of the present invention may also be used in combination with anticancer agents such as endostatin and angiostatin or cytotoxic drugs such as adriamycin, daunomycin, cis- platinum, etoposide, taxol, taxotere and alkaloids, such as vincristine and antimetabolites such as methotrexate
  • anticancer agents such as endostatin and angiostatin or cytotoxic drugs such as adriamycin, daunomycin, cis- platinum, etoposide, taxol, taxotere and alkaloids, such as vincristine and antimetabolites such as methotrexate
  • the compounds of the present invention may also be used in combination with antihypertensives and other cardiovascular drugs intended to offset the consequences of atherosclerosis, including hypertension, myocardial ischemia including angina, congestive heart failure and myocardial infarction, selected from vasodilators such as hydralazine, ⁇ -adrenergic receptor antagonists such as propranolol, calcium channel blockers such as nifedipine, ⁇ 2-adrenerg ⁇ c agonists such as clonidine, ⁇ - adrenergic receptor antagonists such as prazosin and HMG-CoA-reductase inhibitors (anti- hypercholesterolemics) such as lovastatin or atorvastatin
  • vasodilators such as hydralazine
  • ⁇ -adrenergic receptor antagonists such as propranolol
  • calcium channel blockers such as nifedipine
  • the compounds of the present invention may also be administered in combination with one or more antibiotic, antifungal, antiprotozoal, antiviral or similar therapeutic agents
  • the compounds of the present invention may also be used in combination with CNS agents such as antidepressants (such as sertraline), anti-Parkinsonian drugs (such as L-dopa, requip, mirapex, MAOB inhibitors such as selegine and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, nicotine agonists, dopamine agonists and inhibitors of neuronal nitric oxide synthase) and anti-Alzheimer's drugs such as donepezil, tacrine, COX-2 inhibitors, propentofylline or metryfonate
  • CNS agents such as antidepressants (such as sertraline), anti-Parkinsonian drugs (such as L-dopa, requip, mirapex, MAOB inhibitors such as selegine and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NM
  • the compounds of the present invention may also be used in combination with osteoporosis agents such as raloxifene, lasofoxifene, droloxifene or fosomax and immunosuppressant agents such as FK-506 and rapamycin
  • osteoporosis agents such as raloxifene, lasofoxifene, droloxifene or fosomax
  • immunosuppressant agents such as FK-506 and rapamycin
  • Compounds of Formula I may be used in combination with a COX-2 selective inhibitor, more preferably celecoxib, valdecoxib, parecoxib, lumiracoxib, or rofecoxib, or with compounds such as etanercept, infliximab, leflunomide, or methotrexate, and the like
  • Compounds of Formula I may be used in combination with biological therapeutics useful for treating arthritic conditions, including CP-870, etanercept (a tumor necrosis factor alpha ("TNF-alpha”) receptor immunoglobulin molecule, trade names ENBREL® and ENBREL ENTANERCEPT® by Immunex Corporation, Seattle, Washington), infliximab (an anti-TNF-alpha chimeric IgG 1 K monoclonal antibody, tradename REMICADE® by Centocor, lnc , Malvern, Pennsylvania), methotrexate (tradename RHEUMATREX® by American Cyanamid Company, Wayne, New Jersey), and adalimumab (a human monoclonal anti-TNF-alpha antibody, tradename HUMIRA® by Abbott Laboratories, Abbott Park, Illinois)
  • biological therapeutics useful for treating arthritic conditions including CP-870, etanercept (a tumor necrosis factor alpha ("TNF-alpha") receptor immunoglobulin molecule
  • the invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I 1 or a pharmaceutically acceptable salt thereof
  • the invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof
  • the invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof
  • Other mammalian diseases and disorders which are treatable by administration of an invention combination alone, or contained in a pharmaceutical composition as defined below, include fever (including rheumatic fever and fever associated with influenza and other viral infections), common cold, dysmenorrhea, menstrual cramps, inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, bronchitis, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity, cachexia, allergic reactions, allergic contact hypersensitivity, cancer (such as solid tumor cancer including colon cancer, breast cancer, lung cancer and prostrate cancer, hematopoietic malignancies including leukemias and lymphomas, Hodgkin's disease, aplastic anemia, skin cancer and familiar adenomatous polyposis), tissue ulceration, peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis, recurrent gastrointestinal lesion, gastrointestinal bleeding, coagulation, anemia, synovitis,
  • This invention also relates to a method of or a pharmaceutical composition for treating inflammatory processes and diseases comprising administering a compound of this invention to a mammal, including a human, cat, livestock or dog, wherein said inflammatory processes and diseases are defined as above and said inhibitory compound is used in combination with one or more other therapeutically active agents under the following conditions A) where a joint has become seriously inflamed as well as infected at the same time by bacteria, fungi, protozoa and/or virus, said inhibitory compound is administered in combination with one or more antibiotic, antifungal, antiprotozoal and/or antiviral therapeutic agents;
  • inhibitory compound is administered in combination with inhibitors of other mediators of inflammation, comprising one or more members independently selected from the group consisting essentially of
  • prostaglandin inhibitors selected from the group consisting of PGD-, PGF- PGI 2 - and PGE-receptor antagonists,
  • immunosuppressive agents selected from the group consisting of cyclosporine, azathiopnne and methotrexate,
  • anti-gout agents including colchicine, xanthine oxidase inhibitors including allopu ⁇ nol, and uricosuric agents selected from probenecid, sulfinpyrazone and benzbromarone, where older mammals are being treated for disease conditions, syndromes and symptoms found in geriatric mammals, said inhibitory compound is administered in combination with one or more members independently selected from the group consisting essentially of
  • 2 anti-hypertensives and other cardiovascular drugs intended to offset the consequences of atherosclerosis, hypertension, myocardial ischemia, angina, congestive heart failure and myocardial infarction, selected from the group consisting of a diuretics, b vasodilators, c ⁇ -adrenergic receptor antagonists, d angiotensm-ll converting enzyme inhibitors (ACE-inhibitors), alone or optionally together with neutral endopeptidase inhibitors, e angiotensin Il receptor antagonists, f renin inhibitors, g calcium channel blockers, h sympatholytic agents, 1 ⁇ 2 -adrenerg ⁇ c agonists, j ⁇ -adrenerg ⁇ c receptor antagonists, and k HMG-CoA-reductase inhibitors (anti-hypercholesterolemics),
  • the invention method is useful in human and veterinary medicines for treating mammals suffering from one or more of the above-listed diseases and disorders
  • An allosteric inhibitor of MMP-13 may be readily identified by one of ordinary skill in the pharmaceutical or medical arts by assaying an alkyne test compound for inhibition of MMP-13 as described, for example, in Biological Methods 1 or 2 of International Patent Application Pub No WO 04/014366US200400488637179822, the content of which are herein incorporated by reference
  • Allosteric inhibition of MMP-13 may be identified by one of ordinary skill in the pharmaceutical or medical arts by assaying the test invention compound for inhibition of MMP-13 in the presence of an inhibitor to the catalytic zinc of MMP-13 as described, for example, in Biological Methods 3 or 4 of International Patent Application Pub No WO 04/014366US200400488637179822, the content of which are herein incorporated by reference
  • a compound having an anti-inflammatory, an analgesic, anti-arthritic, or a cartilage damage inhibiting effect, or any combination of these effects may be readily identified by one of ordinary skill in the pharmaceutical or medical arts by assaying the compound in any number of well known assays for measuring determining the compound's effects on cartilage and or other joint tissue damage, arthritis, inflammation, or pain
  • assays include in vitro assays that utilize cartilage samples and in vivo assays in whole animals that measure cartilage degradation, inhibition of inflammation, or pain alleviation
  • an amount of a compound or control vehicle may be administered with a cartilage-damaging agent to cartilage such as IL- 1 , and the cartilage damage inhibiting effects in both tests studied by gross examination or histopathologic examination of the cartilage, or by measurement of biological markers of cartilage damage such as, for example, proteoglycan content or hydroxyprolme content, or by biomarkers of type Il collagen degradation such as CTX-II or TIINE (Sunyer et al , Osteo Cartilage 12 (2004) (Suppl B), p P84)
  • an amount of a compound or control vehicle may be administered with a cartilage damaging agent to an animal or may be administered in the absence of cartilage damaging agents, to animals that have surgery-induced or spontaneous OA lesions in the knee
  • Examples of surgery-induced animal models include the rat medial meniscus tear model or the dog anterior cruciate ligament transaction
  • the amount to be administered in an assay is dependent upon the particular assay employed, but in any event is not higher than the well known maximum amount of a compound that the particular assay can effectively accommodate
  • compounds having pain-alleviating properties may be identified using any one of a number of in vivo animal models of pain
  • compositions described herein, or a pharmaceutically acceptable salt thereof that are >10, >20, >50, >100, or >1000 times more potent versus MMP-13 than versus at least two of any other MMP enzyme or TACE
  • Still other aspects of the present invention are compounds of Formula I 1 or a pharmaceutically acceptable salt thereof, that are selective inhibitors of MMP-13 versus 2, 3, 4, 5, 6, or 7 other MMP enzymes, or versus TACE and 1 , 2, 3, 4, 5, 6, or 7 other MMP enzymes
  • selectivity of a compound of Formula I, or a pharmaceutically acceptable salt thereof is a multidimensional characteristic that includes the number of other MMP enzymes and TACE over which selectivity for MMP-13 inhibition is present and the degree of selectivity of inhibition of MMP-13 over another particular MMP or TACE, as measured by, for example, the IC 50 in ⁇ M of the compound for the inhibition of the other MMP enzyme or TACE divided by the IC 50 in ⁇ M of the compound for the inhibition of MMP-13
  • one aspect of the present invention is novel compounds that are selective inhibitors of the enzyme MMP-13
  • a selective inhibitor of MMP-13 as used in the present invention, is a compound that is 25X more potent in vitro versus MMP-13 than versus at least one other matrix metalloproteinase enzyme such as, for example, MMP-1 , MMP-2, MMP-3, MMP-7, MMP- 8, MMP-9, or MMP-14, or versus TACE
  • a preferred aspect of the present invention is novel compounds that are selective inhibitors of MMP-13 versus MMP-1
  • the invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, which has an IC 5O with any MMP enzyme that is less than or equal to 50 ⁇ M
  • compounds of Formula I 1 or a pharmaceutically acceptable salt thereof which have an IC 50 with a human full-length MMP-13 ("hMMP-13FL”) or a human MMP-13 catalytic domain (“hMMP-13CD”) that is less than or equal to 50 ⁇ M
  • compounds of Formula I, or a pharmaceutically acceptable salt thereof which have an IC 50 with a human full-length MMP-13 (“hMMP-13FL”) or a human MMP-13 catalytic domain (“hMMP-13CD”) that is less than or equal to 10 ⁇ M
  • Examples of biological methods useful for determining IC 50 S for compounds with an MMP are described herein
  • the advantages of using an invention compound in a method of the instant invention include the nontoxic nature of the compounds at and substantially above therapeutically effective doses, their ease of preparation, the fact that the compounds are well-tolerated, and the
  • the present invention compounds more effectively target a particular disease that is responsive to inhibition of MMP-13 with fewer undesirable side effects than similar compounds that inhibit MMP-13 that are not invention compounds
  • the instant invention compounds of Formula I, or a pharmaceutically acceptable salt thereof do not directly, or indirectly via a bridging water molecule, ligate, coordinate to, or bind to the catalytic zinc cation of MMP-13, but instead bind at a different location from where natural substrate binds to MMP- 13
  • the binding requirements of an allosteric MMP-13 binding site are unique to MMP-13, and account for the specificity of the invention compounds for inhibiting MMP-13 over any other MMP enzyme See J Chem Biol , 2005(12), 181 -189 Indeed, prior art inhibitors of MMP-13 bind to the catalytic zinc cations of other MMP enzymes as well as to the catalytic zinc cation of MMP-13, and are consequently significantly less selective inhibitors of MMP-13 enzyme
  • Syntheses of some invention compounds may utilize starting materials, intermediates, or reaction products that contain a reactive functional group During chemical reactions, a reactive functional group may be protected from reacting by a protecting group that renders the reactive functional group substantially inert to the reaction conditions employed
  • a protecting group is introduced onto a starting material prior to carrying out the reaction step for which a protecting group is needed Once the protecting group is no longer needed, the protecting group can be removed
  • protecting groups such as the following may be utilized to protect ammo, hydroxyl, and other groups carboxylic acyl groups such as, for example, formyl, acetyl, and trifluoroacetyl, alkoxycarbonyl groups such as, for example, ethoxycarbonyl, tert-butoxycarbonyl (BOC), /?,/
  • compounds of the formula A1 employed in Chart A wherein Q is CH and U is N may be prepared as described in Chart G starting from compounds F1 obtained as described above
  • Compounds F1 may be chlorinated (e g POCI 3 , PCI 5 ) and then reacted with an alkanol (e g methanol) to provide compounds of the formula G1
  • Cyanation of G1 in the presence of a palladium catalyst affords G2 which is subsequently hydrolyzed under basic conditions (e Q potassium hydroxide) to provide carboxylic acids of the formula G3
  • Esterification of carboxylic acids G3 with pentafluorophenyl trifluoroacetate affords diesters of the formula G4
  • the sequential addition of a primary amine of the formula W-NH 2 followed by ammonia provides amides G5
  • Dehydration of the primary amide by treatment with POCI 3 affords the corresponding nitriles G6 which react with sodium azide to provide tetrazoles of the formula
  • compounds of formula I3 may be prepared by reacting a compound of formula 11 (prepared as described in Chart C or Chart F) with an alcohol (G-OH) under Mitsunobu coupling conditions (e g Ph 3 P, di-tert-butyl azodicarboxylate) to provide I2 wherein G is a group V-Z as described above and in which reactive functional groups may be protected
  • a compound of formula 11 may be reacted with a compound G-X in the presence of a base (e g tertiary amine, sodium hydride) wherein X is Cl, Br, I, alkylsulfonate ester, or arylsulfonate ester
  • a base e g tertiary amine, sodium hydride
  • X is Cl, Br, I, alkylsulfonate ester, or arylsulfonate ester
  • the reagents G-OH or G-X are either commercially available or prepared as described below (Charts
  • reagents G-X employed in Chart A and Chart I above wherein X is an alkylsulfonate ester or arylsulfonate ester are prepared by reaction of an alcohol G-OH with and alkyl- or arylsulfonyl chloride in the presence of a base (e g triethylamine or pyridine)
  • a base e g triethylamine or pyridine
  • Representative examples are shown in Charts J - L wherein the alcohol G-OH may be prepared by literature procedures, e g J1 , tert-butyl (f?)-2-(hydroxymethyl)morphol ⁇ ne-4-carboxylate and tert-butyl (S)-2-(hydroxymethyl)morphol ⁇ ne-4- carboxylate (Yanagisawa, H Heterocycles, 1993, 35, 105-109), K1 , (R)-(1 , 4-d ⁇ oxan-2-yl)methanol and (S)
  • G-X may be prepared as described below According to Chart M, (5,5- b ⁇ s(hydroxymethyl)-1 ,4-d ⁇ oxan-2-yl)methyl 4-methylbenzenesulfonate (M2) is prepared from rac- ((2R * ,5R * )-5-(hydroxymethyl)-1 ,4-d ⁇ oxan-2-yl)methyl 4-methylbenzenesulfonate (L2) by oxidation under Swern conditions to afford M1 which is then reacted with formaldehyde under basic conditions
  • rac-(2S*,5R * )-methyl 5-((tosyloxy)methyl)-1 ,4-d ⁇ oxane-2-carboxylate (N3) is prepared from trans-dimethyl 1 ,4-d ⁇ oxane-2,5-d ⁇ carboxylate (N1 ) (Summerbell, R K J Am Chem Soc 1954, 76, 6401-6407) by first partial saponification to
  • cis- and trans-(4-hydroxy-4-(hydroxymethyl)cyclohexyl)methyl 4- methylbenzenesulfonate may be prepared by reacting 1 ,4-d ⁇ oxasp ⁇ ro[4 5]dec-8-ylmethanol with p-toluenesulfonyl chloride in pyridine to afford P2
  • the resulting ketal is subjected to acidic hydrolysis to provide (4-oxocyclohexyl)methyl 4-methylbenzenesulfonate (P3)
  • Epoxidation of ketone P3 with trimethylsulfoxonium ylide affords P4 which upon acid promoted oxirane ring opening provides P5
  • reagents of the formula G-X including 6-(iodomethyl)-tetrahydro-2H-pyran-3- yl)methanol (Q4) and (5-((tosyloxy)methyl)-tetrahydro-2/-/-pyran-2-yl)methyl acetate (Q6) may be prepared starting from diethylmalonate 6-(lodomethyl)-tetrahydro-2H-pyran-3-yl)methanol (Q4) is prepared analogous to previously described procedures in which diethylmalonate is alkylated with 1 - bromo-3-butene to afford Q2 (Dele ⁇ s, G Tetrahedron 1988, 44, 4243-4258) and then subsequently Q2 is reduced with lithium aluminium hydride to afford 2-(but-3-enyl)propane-1 ,3-d ⁇ ol (Q3) (Ramos Tombo, G M Tetrahedron Lett 1986, 27, 5707-5710) Cyclization of Q3
  • reagents of the formula G-X including rac-((2R*,5S * )-5-hydroxy-tetrahydro-2H- pyran-2-yl)methyl 4-methylbenzenesulfonate (R3) and (5-hydroxy-5-(hydroxymethyl)-tetrahydro-2/-/- pyran-2-yl)methyl 4-methylbenzenesulfonate (R6) may be prepared (3,4-D ⁇ hydro-2H-pyran-2- yl)methanol (R1 ) is treated with p-toluenesulfonyl chloride in pyridine to afford sulfonylester R2 Analogous to literature precedent (Zhang, S Bioorg Med Chem 2006, 14, 3953-3966), reaction of R2 under hydroboration/oxidation conditions (BH 3 , NaOH, H 2 O 2 ) affords rac-((2F?
  • re/-(1 R,2S,4S)-7-oxa-b ⁇ cyclo[2 2 1]heptan-2-ylmethyl 4-methylbenzenesulfonate may be prepared by initially reacting furan with ethyl acrylate in the presence of zinc iodide to afford the cycloadduct S1 Alkene S1 is then treated with hydrogen and palladium on carbon in ethanol to provide a mixture of isomers which are separated by silica gel chromatography to afford S2 Saponification of S2 with aqueous sodium hydroxide provides carboxylic acid S3 which may be reacted with 1 ,1'-carbonyld ⁇ m ⁇ dazole and sodium borohydride to afford alcohol S4
  • the desired tosylate S5 is provided by reacting the resulting alcohol with p-toluenesulfonyl chloride in the presence of an amine base
  • (6-oxop ⁇ per ⁇ d ⁇ n-3-yl)methyl 4-methylbenzenesulfonate may be prepared by reacting 6-hydroxyn ⁇ cot ⁇ n ⁇ c acid (T1 ) with hydrogen in the presence of a palladium catalyst to afford carboxylic acid T2
  • the resulting acid is treated with 1 ,1 '-carbonyld ⁇ m ⁇ dazole and sodium borohyd ⁇ de to provide alcohol T3 which is then reacted with p-toluenesulfonyl chloride in the presence of an amine base to provide tosylate T4
  • reagents of the formula G-X may be prepared where lactam carboxylic acids of the formula U1 (where R may include but is not limited to hydrogen, methyl, ethyl, and iso-propyl) obtained as described by E Valentin et al (Tetrahedron Asymmetry, 2001 , 12, 3241 -3249) are reacted with 1 ,1 '-carbonyld ⁇ m ⁇ dazole and sodium borohydride to provide alcohols of the formula U2 The resulting alcohols are reacted with p-toluenesulfonyl chloride in the presence of an amine base to provide tosylates of the formula U3 CHART V
  • (S)- ⁇ /-Boc 3-(hydroxymethyl)pyrrol ⁇ d ⁇ ne (V4) is prepared from (R)-1 - phenylethanamine by cyclization with dimethyl 2-oxosucc ⁇ nate in refluxing toluene to provide V2 Lactam V2 is then reduced with lithium aluminium hydride to provide ((S)-I -((S)-1 - phenylethyl)pyrrol ⁇ d ⁇ n-3-yl)methanol (V3) The alcohol is reacted with hydrogen gas in the presence of Pd(OH) 2 on carbon, and the resulting amine is treated with di-tert-butyl dicarbonate to provide V4 In a similar manner, (R)-N-Boc 3-(hydroxymethyl)pyrrol ⁇ d ⁇ ne is prepared from (S)-i -phenylethanam ⁇ ne
  • reagents of the formula G-X specifically (tetrahydro-2/-/-th ⁇ opyran-4-yl)methyl 4- methylbenzenesulfonate may be prepared Tetrahydroth ⁇ opyran-4-one is reacted with lithium chloride and samarium diiodide to afford tetrahydro-2H-th ⁇ opyran-4-carbon ⁇ tr ⁇ le (W1 ) which is then hydrolyzed under basic conditions (e g NaOH) to provide the corresponding carboxylic acid W2 The carboxylic acid is reacted with 1 ,1 '-carbonyld ⁇ m ⁇ dazole and sodium borohydride to provide alcohol W3 Tosylate W4 is then prepared by treating W3 with p-toluenesulfonyl chloride in the presence of an amine base
  • reagents of the formula G-X as depicted in formula X5 may be prepared L- Se ⁇ ne methyl ester is treated with benzaldehyde and NaBH(OAc) 3 to afford benzylamme X1 which is subsequently coupled (BDP, 1 -HOBT, diisopropylethylamme) with ⁇ /-(tert-butoxycarbonyl)glyc ⁇ ne to provide X2
  • the tert-butylcarbamate is removed under acidic conditions (HCI/chloroform) and the resulting product is cyclized under basic conditions (5% aq NaHCO 3 ) to provide p ⁇ per ⁇ z ⁇ ne-2,5-d ⁇ one X3
  • Piperizine X4 is then prepared by reduction of X3 with a metal hydride (e g lithium aluminium hydride) and the product is subsequently reacted with alkyl sulfonyl chlorides in the presence of an amine base to provide
  • compounds of the formula DD1 may be oxidized in the presence of oxone to provide tetrahydroth ⁇ opyran-1 ,1 -d ⁇ one derivatives of the formula DD2 CHART EE
  • Azides of the formula G-N 3 employed in Charts FF - Il may be prepared alcohols G-OH obtained commercially or prepared as described in Charts J - X
  • the alcohol G-OH may be converted to a sulfonate ester which is then subjected to substitution by a nucleophilic azide source (e g sodium azide) CHART JJ
  • a nucleophilic azide source e g sodium azide
  • Reagents of the formula G-X such as ((2S,5R)-5-(hydroxymethyl)-1 ,4-d ⁇ oxan-2-yl)methyl 4- methylbenzenesulfonate (JJ6) may be prepared as described in Chart JJ /?-Ep ⁇ chlorohydr ⁇ n, JJ 1 , was reacted with benzyl alcohol using boron trifluoride etherate as an acid catalyst to provide the alcohol of formula JJ2
  • the alcohol of formula JJ2 was reacted with the S-glycidol tosylate using boron trifluoride etherate as an acid catalyst to provide the alcohol of formula JJ3
  • the alcohol of formula JJ3 was cychzed under basic conditions (e g , aqueous sodium hydroxide) to provide the alcohol of formula JJ4
  • the alcohol of formula JJ4 was reacted with p-toluenesulfonyl chloride in the presence of an amine base (e g
  • the compounds of Formula (I) may be prepared as single enantiomer or as a mixture of individual enantiomers which includes racemic mixtures
  • Methods to obtain preferentially a single enantiomer from a mixture of individual enantiomers or a racemic mixture are well known to those ordinarily skilled in the art of organic chemistry
  • Such methods include but are not limited to preferential crystallization of diastereomeric salts (e g tartrate or camphor sulfonate), covalent de ⁇ vatization by a chiral, non- racemic reagent followed by separation of the resulting diastereomers by common methods (e g crystallization, chromatographic separation, or distillation) and chemical reversion to scalemic compound, Simulated Moving Bed technology, or high/medium-pressure liquid chromatography or supercritical fluid chromatography employing a chiral stationary phase
  • These techniques may be performed on the final compounds of Formula (I) or on any intermediates to compounds of Formula (I) which bear a stereo

Abstract

The prsent invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as anti-inflammatory agents.

Description

Pyrimidine and Pyridine Derivatives and Their Pharmaceutical Use and Compositions
Field of the Invention
This invention relates to pyrimidine and pyridine derivatives Such compounds have been shown to inhibit matrix metalloproteinase enzymes These compounds are useful for treating diseases resulting from MMP-mediated tissue breakdown such as heart disease, cardiac insufficiency, inflammatory bowel disease, multiple sclerosis, osteoarthritis, rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, fibrotic disorders in the kidney, lung, and/or osteoporosis
Background of the Invention
Matrix metalloproteinases (sometimes referred to as MMPs) are naturally occurring enzymes found in most mammals Over-expression and activation of MMPs, or an imbalance between MMPs and inhibitors of MMPs, have been suggested as factors in the pathogenesis of diseases characterized by the breakdown of extracellular matrix or connective tissues To date, 24 different members of the MMP family have been identified in vertebrates, 23 of which are found in human, including collagenases (MMP-1 , MMP-8, MMP-13), gelatinases (MMP-2 and MMP-9), stromelysins (MMP-3, MMP-10, MMP-1 1 ), matπlysins (MMP-7 and MMP-26), membrane-type (MMT-14, MMP-15, MMP-16, MMT-17, MMP-24, MMT-25), as well as metalloelastases (MMP-12, MMP-19, MMP-20, MMP-22, MMP-23) (See Visse and Nagase (2003) Circ Res 92 827-839) These enzymes have been implicated with a number of diseases which result from breakdown of connective tissue, including such diseases as rheumatoid arthritis, osteoarthritis, osteoporosis, periodontitis, multiple sclerosis, gingivitis, corneal epidermal and gastric ulceration, atherosclerosis, neointima! proliferation which leads to restenosis and ischemic heart failure, and tumor metastasis Inhibiting matrix metalloproteinase enzymes, thereby curtailing and/or eliminating the breakdown of connective tissues that results in the disease states, is a recognized method for preventing and treating these and other diseases
There is a catalytic zinc domain in matrix metalloproteinases that is typically the focal point for inhibitor design The modification of substrates by introducing zinc-chelating groups has generated potent inhibitors such as peptide hydroxamates and thiol-containing peptides Peptide hydroxamates and the natural endogenous inhibitors of MMPs (TIMPs) have been used successfully to treat animal models of cancer and inflammation MMP inhibitors have also been used to prevent and treat congestive heart failure and other cardiovascular diseases, see, e.g , U S Patent No 5,948,780
A major limitation on the use of currently known MMP inhibitors is their lack of specificity for any particular enzyme Recent data has established that specific MMP enzymes are associated with some diseases, with no effect on others The MMPs are generally categorized based on their substrate specificity, and indeed the collagenase subfamily of MMP-1 , MMP-8, and MMP-13 selectively cleave native interstitial collagens, and thus are associated only with diseases linked to such interstitial collagen tissue This is evidenced by the recent discovery that MMP-13 alone is over- expressed in breast carcinoma, while MMP-1 alone is over expressed in papillary carcinoma (see Chen et al , J Amer Chem Soc , 2000,122 9648-54)
Selective inhibitors of MMP-13 include a compound named WAY 170523, which has been reported by Chen et al , supra, 2000 Other selective inhibitors of MMP-13 are reported in International Patent Application Publication No WO 05/105760 Other selective inhibitors of MMP-13 are reported in U S Patent Application Publication No US20030229103 Other selective inhibitors of MMP-13 are reported in U S Patent Application Publication No US20040167120 Other selective inhibitors of M M P- 13 are reported in U S Patent Application Publication No US20050004111 Other selective inhibitors of MMP-13 are reported in U S Patent Application Publication No US20060173183 Other selective inhibitors of MMP-13 are reported in International Patent Application Publication No WO 06/128184 Other selective inhibitors of MMP-13 are reported in Co-assigned International Patent Application Publication No WO 02/64572 Other selective inhibitors of MMP-13 are reported in Co- assigned International Patent Application Publication No WO 02/64599 U S Patent No 6,008,243 discloses inhibitors of MMP-13 However, no selective or nonselective inhibitor of MMP-13 has been approved and marketed for the treatment of any disease in any mammal Accordingly, the need continues to find new low molecular weight compounds that are potent and selective MMP inhibitors, and that have an acceptable therapeutic index of toxicity/potency to make them amenable for use clinically in the prevention and treatment of the associated disease states
Summary of the Invention The present invention provides compounds of Formula I
wherein
G is (Ci 3 alkylenyl)-Ra or Ra, wherein said C,.3 alkylenyl may be substituted by one or more substituents selected from OH and F, Ra is Ci-s alkyl, 3- to 7-membered heterocycloalkyl, or 3- to 8-membered cycloalkyl, wherein said C1^ alkyl may be substituted by one or more substituents selected from F, -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R36, and wherein said heterocycloalkyl and cycloalkyl may be substituted by one or more substituents selected from R2, R3, R4, R5, R10, R11, and R21, M is N or C-Rb,
Q is N or C-Rc, provided that if Q is C-Rc, M is N,
W is phenyl-(Ci-6 alkylenyl), pyrιdyl-(C,-6 alkylenyl), or 9-membered heteroaryl-(C,-6 alkylenyl), wherein said phenyl, pyridyl, or 9-membered heteroaryl is substituted by one or more groups selected from R30 and R31, Y is Ci-6 alkyl, d-6 haloalkyl, or C1^ hydroxyalkyl, L is 5-membered heteroaryl,
R2 is H, F, CN, -OR5, R12, -C(=O)R7, -NR6R33, -NRβC(=O)R9, -NR8SO2R36, or -SO2R12, R3 Is H, F1 CN, or -OR22, R4 is H, -(C1 6 alkylene)R6, -C(=O)R9, or -SO2R12, R5 is H or -(C1-6 alkyl), wherein said C14 alkyl may be substituted by one or more R substituents,
S /O R23
1 \\ //
R6 rs H, CN, -OR23, -SO2R37, -NR24C(=O)R23, -NR24SO2R37, or N~N R7 is -(C1.,, alkyl), -(Ci-β haloalkyl), -(C14 atkylene)OH, -NR38R39, -NHSO2CH3, or -OR25, R9 is -(Ce alkylene)R28, -NHR24, or -OR25, R10 Is H, F, CN, R12, or -C(=O)R7,
R i i |S Hi F, CN, -OR6, R12, -C(=O)R7, -NR8R33, -NReC(=O)R9, -NR8SO2R36, or -SO2R12, R12 is -(C14 alkyl), wherein said C1 6 alkyl may be substituted by one or more substituents selected from CN, -OR23, -SR23, -SO2R37, -NR8R33, -NR24C(=O)R23, and -NR24SO2R23, provided that any one carbon atom of said C14 alkyl is not substituted by more than one CN or more than one -OR23,
Rb, R°, R8, R20, R22, R24, R25, R33, R34. and R35 are independently H or -(C6 alkyl), R21 Is H, F, or R12,
R23 is H, -(C1-6 alkyl), or -(C6 alkylene)OH, R26 is H, OH, halo, NH2, or SH, R28 is H, NH2, or -OR29,
R29 is H1 (C14 alkyl), or -C(O)(C14 alkyl), R30 is H or F,
R31 is F, Cl, Br, -CN, -C(=O)NH2, -OH, -OR32, -OCH2CH2OR25, R32, ,or (C14 alkyl) optionally substituted by -OR25 or -OCH2CH2OR25 where R30 and R31 when adjacent may be taken together to constitute a group of the formula -
O-(CH2)n- or -0-(CHz)n-O-, n is 1 or 2,
R32 is -(Ct4 alkyl) optionally substituted with one, two, or three F, R36 is -(C1-6 alkyl) or -(C34 cycloalkyl), and R37 is -(C14 alkyl), -(C34 cycloalkyl), or -(C14 alkylene)OH,
R38 and R39 are independently H, -(C14 alkyl), or R38 and R39 taken together form a 5- or 6- membered heterocycloalkyl, or a pharmaceutically-acceptable salt thereof
This invention also includes pharmaceutically acceptable salts, solvates and hydrates of compounds of Formula I This invention also includes all tautomers and stereochemical isomers of these compounds
This invention also is directed, in part, to a method for treating an MMP-13 mediated disorder in a mammal Such disorders include rheumatoid arthritis and osteoarthritis The method comprises administering a compound of Formula I or a pharmaceutically acceptable salt thereof, to the mammal in an amount that is therapeuticalty-effective to treat the condition
Detailed Description of the Invention
One embodiment of the invention is a compound of Formula I as shown above Another embodiment of the invention is a compound of Formula I wherein Ra is CL6 alkyl, 1 ,4- dioxanyl, piperidinyl, cyclohexyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydropyranonyl, pyrrolidinyl, cyclopentyl, 7-oxa-bιcyclo[2 2 1]heptanyl, piperazinyl, 1 ,1 '-dιoxothιomorpholιnyl, tetrahydro-1 ,1 '-dιoxothιopyranyl, tetrahydrothiopyranyl, ptperidinonyl, tetrahydrofuryl, pyrrolidinonyl, or oxazolidinonyl, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -Ci=O)NR34R35, -NR34R35, -NR34Cl=O)R35, or -NR34SO2R35, and wherein said 1 ,4- dioxyl, piperidinyl, cyclohexyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydropyranonyl, pyrrolidinyl, cyclopentyl, 7-oxa-bιcyclo[2 2 1]heptanyl, piperazinyl, 1 ,1 '-dιoxothιomorpholιnyl, tetrahydro-1 ,1 '-dιoxothιopyranyl, tetrahydrothiopyranyl, piperidinonyl, tetrahydrofuryl, pyrrolidinonyl, or oxazolidinonyl may be substituted by one or more substituents selected from R2, R3, R4, R5, R10, R11, and R21
Another embodiment of the invention is a compound of Formula I wherein R3 is C,.6 alkyl, 1 ,4- dioxanyl substituted by R10 and R21, piperidinyl substituted by R2 and R3 or by R4, cyclohexyl substituted by R2 and R3 or by R4, morpholinyl substituted by R4, thiomorpholinyl substituted by R10 and R21, tetrahydropyranyl substituted by R3 and R11 or by R10 and R21, tetrahydropyranonyl, pyrrolidinyl substituted by R2 and R3 or by R4, cyclopentyl substituted by R2 and R3, 7-oxa- bιcyclo[2 2 1]heptanyl, piperazinyl substituted by R4 and R5, 1 ,1'-dιoxothιomorpho!ιnyl, tetrahydro-1 ,1 '- dioxotbiopyranyl, tetranydroth/opyranyl, piperidinonyl substituted by R5, tetrahydrofuryl substituted by R3 and R11, pyrrolidinonyl substituted by R5, oxazolidinonyl substituted by R5, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R35
Another embodiment of the invention is a compound of Formula I wherein Ra is C,.6 alkyl,
, or , wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R35, and
X is N or CH, provided that when X is N, G is (C2-3 a!kylenyl)-Ra, wherein said C1^ alkylenyl may be substituted by one or more substituents selected from OH and F.
Another embodiment of the invention is a compound of Formula I wherein Ra is C1^ alkyl,
R , wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -Ci=O)NR34R35, -NR34R35, -NR34Ci=O)R35, or -NR34SO2R35 Another embodiment of the invention is a compound of Formula I wherein Ra is C1^ alkyl, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R35
Another embodiment of the invention is a compound of Formula I wherein Ra is C1^ alkyl, wherein said alkyl may be substituted by one or more -OR34 Another embodiment of the invention is a compound of Formula I wherein Ra is
Another embodiment of the invention is a compound of Formula I wherein Ra is
Another embodiment of the invention is a compound of Formula Il
wherein G is (C1 3 alkylenyl)-Ra or Ra, wherein said C1.3 alkylenyl may be substituted by one or more substituents selected from OH and F1
Ra is C1^ alkyl, 3- to 7-membered heterocycloalkyl, or 3- to 8-membered cycloalkyl, wherein said C1 6 alkyl may be substituted by one or more substituents selected from F, -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34C(O)R35, or -NR34SO2R36, and wherein said heterocycloalkyl and cycloalkyl may be substituted by one or more substituents selected from R2, R3, R4, R5, R10, R11 , and R21,
W is phenyl-(Cr6 alkylenyl), pyridyl-(Cr6 alkylenyl), or 9-membered heteroaryl-(Cr6 alkylenyl), wherein said phenyl, pyridyl, or 9-membered heteroaryl is substituted by one or more groups selected from R30 and R31,
Y is Cr6 alkyl, Cr6 haloalkyl, or Cr6 hydroxyalkyl, L is 5-membered heteroaryl,
R2 is H, F, CN, -OR5, R12, -C(=O)R7, -NR8R33, -NR8C(=O)R9, -NR8SO2R36, or -SO2R12, R3 Is H, F, CN, or -OR22, R4 is H, -(C1-S alkylene)R6, -C(=0)R9, or -SO2R12,
RR55 .iss H or -(C1^ alkyl), wherein said C1^ alkyl may be substituted by one or more R26 substituents,
W //
R6 is H, CN, -OR23, -SO2R37, -NR24C(=O)R23, -NR24SO2R37, or N~N
R7 is -(C6 alkyl), -(C6 haloalkyl), -(C6 alkylene)OH, -NR38R39, -NHSO2CH3, or -OR25, R9 is -(Cn3 alkylene)R28, -NHR24, or -OR25,
R10 Is H1 F1 CN, R12, or -C(=O)R7, R11 is H, F, CN, -OR5, R12, -C(=O)R7, -NR8R33, -NR8C(O)R9, -NR8SO2R36, or -SO2R12, R12 is -(C, .a alkyl), wherein said C, 6 alkyl may be substituted by one or more substituents selected from CN, -OR23, -SR23, -SO2R37, -NR8R33, -NR24C(=O)R23, and -NR24SO2R23, provided that any one carbon atom of said C1^ alkyl is not substituted by more than one CN or more than one -OR23, Rb, Rc, R8, R20, R22, R24, R25, R33, R34, and R35 are independently H or -(C1-6 alkyl),
R21 is H, F, or R12,
R23 is H, -(C1-6 alkyl), or -(C1-6 alkylene)OH,
R26 is H, OH, halo, NH2, or SH,
R28 is H, NH2, or -OR29, R29 is H, (C6 alkyl), or -C(=O)(C,.β alkyl),
R30 is H or F,
R31 is F, Cl, Br, -CN, -C(=O)NH2, -OH, -OR32, -OCH2CH2OR25, R32, ,or (C6 alkyl) optionally substituted by -OR25 or -OCH2CH2OR25 where R30 and R3' when adjacent may be taken together to constitute a group of the formula O-(CH2)n- or -O-(CH2)n-O-, n is 1 or 2,
R32 is -(Ci-e alkyl) optionally substituted with one, two, or three F,
R36 is -(C1^ alkyl) or -(C3^ cycloalkyl), and
R37 is -(C1-6 alkyl), -(C3-6 cycloalkyl), or -(C1^ alkylene)OH, R38 and R39 are independently H, -(C1-6 alkyl), or R38 and R39 taken together form a 5- or 6- membered heterocycloalkyl, or a pharmaceutically-acceptable salt thereof
Another embodiment of the invention is a compound of Formula HA
wherein Ra, W, Y, and L are as defined heremabove for Formula Il Another embodiment of the invention is a compound of Formula UA wherein L is triazolyl, tetrazolyl, or oxadiazolyl Another embodiment of the invention is a compound of Formula HA wherein L is
Another embodiment of the invention is a compound of Formula HA wherein L is
Another embodiment of the invention is a compound of Formula IIA-1
wherein Ra, W, and Y are as defined heremabove for Formula Il
Another embodiment of the invention is a compound of Formula IIA-2
wherein Ra, W, and Y are as defined heremabove for Formula Il Another embodiment of the invention is a compound of Formula IIA-3
IIA-3 wherein Ra, W, and Y are as defined heremabove for Formula Il Another embodiment of the invention is a compound of Formula IIA-4
wherein Ra, W, and Y are as defined heremabove for Formula Il Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4
wherein Ra is C1-S alkyl, be substituted by one or more substituents selected from -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R35
Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4
wherein Ra is C1-6 alkyl, R4
, or , wherein said alkyl may be substituted by one or more substituents
35 selected from -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34Ci=O)R35, or -NR34SO2R
Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4 wherein Ra is C1^ alkyl, wherein said alkyl may be substituted by one or more substttuents selected from -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R35
Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4 wherein Ra is C1-6 alkyl, wherein said alkyl may be substituted by one or more -OR34
Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4
Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4 wherein Y is methyl
Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4 wherein W is phenyl-(Cr6 alkylenyl), wherein said phenyl is substituted by one or more groups selected from R30 and R3'
Another embodiment of the invention is a compound of Formula HA, IIA-1 , IIA-2, IIA-3, or IIA-4 wherein W is phenylmethyl, wherein said phenyl is substituted by one or more groups selected from R30 and R31 Another embodiment of the invention is a compound shown in Table 1
Another embodiment of the invention is a compound of Formula
wherein G is (C1^ alkylenyl)-Ra or Ra, wherein said C,.3 alkylenyl may be substituted by one or more substituents selected from OH and F,
Ra is C1^ alkyl, 3- to 7-membered heterocycloalkyl, or 3- to 8-membered cycloalkyl, wherein said Ci 6 alkyl may be substituted by one or more substituents selected from F, -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R36, and wherein said heterocycloalkyl and cycloalkyl may be substituted by one or more substituents selected from R2, R3, R4, R5, R10, R11, and R21,
W is phenyl-(Cr6 alkylenyl), pyrιdyl-(Cr6 alkylenyl), or 9-membered heteroaryl-(Cr6 alkylenyl), wherein said phenyl, pyπdyl, or 9-membered heteroaryl is substituted by one or more groups selected from R30 and R3',
Y is C re alkyl, C,-β haloalkyl, or C,-6 hydroxyalkyl, L is 5-membered heteroaryl,
R2 is H, F, CN, -OR5, R12, -C(=O)R7, -NR8R33, -NR8C(=O)R9, -NR8SO2R36, or -SO2R12, R3 is H, F, CN, or -OR22, R4 is H, -(C6 alkylene)R6, -C(=O)R9, or -SO2R12,
R5 is H or -(Ci-β alkyl), wherein said C1-6 alkyl may be substituted by one or more R26 substituents,
S .0 R23
1 \\ // R6 is H, CN, -OR23, -SO2R37, -NR24C(=O)R23, -NR24SO2R37, or N~N
R7 is -(C1-6 alkyl), -(C,* haloalkyl), -(C,* alkylene)OH, -NR38R39, -NHSO2CH3, or -OR25, R9 is -(C1-6 alkylene)R28, -NHR24, or -OR25, R10 is H, F, CN, R12, or -C(=O)R7, R11 is H, F, CN, -OR5, R12, -C(=O)R7, -NR8R33, -NR8C(=O)R9, -NR8SO2R36, or -SO2R12, R12 is -(C1* alkyl), wherein said C, 6 alkyl may be substituted by one or more substituents selected from CN, -OR23, -SR23, -SO2R37, -NR8R33, -NR24C(=O)R23, and -NR24SO2R23, provided that any one carbon atom of said C1-6 alkyl is not substituted by more than one CN or more than one -OR23, Rb, Rc, R8, R20, R22, R24, R25, R33, R34, and R35 are independently H or -(C1* alkyl),
R21 is H, F, or R12,
R23 is H, -(C1* alkyl), or -(C1* alkylene)OH, R26 is H, OH, halo, NH2, or SH, R28 is H, NH2, or -OR29, R29 is H, (C1* alkyl), or -C(=0)(C,* alkyl),
R30 is H or F,
R31 is F, Cl, Br, -CN, -C(=O)NH2, -OH, -OR32, -OCH2CH2OR25, R32, ,or (C1* alkyl) optionally substituted by -OR25 or -OCH2CH2OR25 where R30 and R31 when adjacent may be taken together to constitute a group of the formula O-(CH2)n- or -0-(CH2VO-, n is 1 or 2,
R32 is -(C1* alkyl) optionally substituted with one, two, or three F, R36 is -(C1* alkyl) or -(C3* cycloalkyl), and R37 is -(C,* alkyl), -(C3* cycloalkyl), or -(C1* alkylene)OH, R38 and R39 are independently H, -(C1* alkyl), or R38 and R39 taken together form a 5- or 6- membered heterocycloalkyl, or a pharmaceutically-acceptable salt thereof
Another embodiment of the invention is a compound of Formula IDA
wherein Ra, Rb, W, and Y are as defined hereinabove for Formula III
Another embodiment of the invention is a compound of Formula IHA wherein L is triazolyl, tetrazolyl, or oxadiazolyl
Another embodiment of the invention is a compound of Formula IHA wherein L is
Another embodiment of the invention is a compound of Formula HIA wherein L is
Another embodiment of the invention is a compound of Formula IIIA-1 wherein Ra, RD, W, and Y are as defined hereinabove for Formula III Another embodiment of the invention is a compound of Formula IIIA-2
wherein R ->a , R Dd , W, and Y are as defined hereinabove for Formula III Another embodiment of the invention is a compound of Formula IIIA-3
wherein R 1 R 1 W, and Y are as defined hereinabove for Formula III Another embodiment of the invention is a compound of Formula IIIA-4
wherein W1 and Y are as defined hereinabove for Formula III Another embodiment of the invention is a compound of Formula IHA, IIIA-1 , IIIA-2, IIIA-3, or
IIIA-4 wherein R3 is Cue alkyl,
be substituted by one or more substituents selected from -OR34, -SR34, -C^=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R35
Another embodiment of the invention is a compound of Formula IHA, IIIA-1 , IIIA-2, IIIA-3, or
one or more substituents selected from -OR34, -SR34, -C^=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R35
Another embodiment of the invention is a compound of Formula IHA, IIIA-1 , IIIA-2, IIIA-3, or IIIA-4 wherein Ra is d.6 alkyl, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R35
Another embodiment of the invention is a compound of Formula IDA, IIIA-1 , IIIA-2, IIIA-3, or IIIA-4 wherein Ra is C1^ alkyl, wherein said alkyl may be substituted by one or more -OR34
Another embodiment of the invention is a compound of Formula IHA, IIIA-1 , IIIA-2, IIIA-3, or
IIIA-4 wherein Ra is R1 1
Another embodiment of the invention is a compound of Formula IHA wherein Ra is methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1 -hexyl, aziridinyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, pipeπdinyl, piperazinyl, oxiranyl, oxetanyl, tetrahydrofuryl, dioxolyl, tetrahydropyranyl, dioxanyl, oxazetidinyl, isoxazolidinyl, oxazolidmyl, morpholinyl, oxazinanyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl may be substituted by one or more substituents selected from -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R36, and wherein said aziridinyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, pipeπdinyl, piperazinyl, oxiranyl, oxetanyl, tetrahydrofuryl, dioxolyl, tetrahydropyranyl, dioxanyl, oxazetidinyl, isoxazolidinyl, oxazolidmyl, morpholinyl, oxazinanyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl may be substituted by one or more substituents selected from R2, R3, R4, R5, R10, R11, and R21, W is phenyl-(Cr6 alkylenyl), pyridy>-(C-i-6 alkylenyl), or ιndolyl-(C,-6 alkylenyl), wherein said C1 6 alkylene is methylene, ethylene, 1 -propylene, 2-propylene, 1-butylene, 2-butylene, 2,2- dimethylethylene, 1 -pentylene, 2-pentylene, 2,2-dιmethylpropylene, or 1-hexylene, and wherein said phenyl, pyridyl, or indolyl is substituted by one or more groups selected from R30 and R31,
Y is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2- dimethylpropyl, or 1 -hexyl, wherein Y may be substituted by OH or by one or more substituents selected from F, Cl, and Br,
L is triazolyl, tetrazolyl, or oxadiazolyl,
R4 is H, -(C1^ alkylene)Rδ, -C(=O)R9, or -SO2R12, wherein said C6 alkylene is methylene, ethylene, 1 -propylene, 2-propylene, 1-butylene, 2-butylene, 2,2-dιmethylethylene, 1 -pentylene, 2- pentylene, 2,2-dιmethylpropylene, or 1-hexylene, and wherein said phenyl, pyridyl, or indolyl is substituted by one or more groups selected from R30 and R31,
R5 is H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2- dimethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl, may be substituted by one or more R26 substituents,
R7 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1 -hexyl, -NHR24, or -OR25, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl may be substituted by OH or by one or more substituents selected from F, Cl, and Br, R9 is -(C1^ alkylene)R28, -NHR24, or -OR25,
R12 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein R12 may be substituted by one or more substituents selected from CN, -OR23, -SO2R37, -NR8R33, -NR24C(=O)R23, and -NR24SO2R23, provided that any one carbon atom of R12 is not substituted by more than one CN or more than one -OR23, Rb, Rc, R8, R20, R22, R24, R25, R33, R34, and R35 are independently H, methyl, ethyl, 1 -propyl, 2- propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl,,
R23 ts H1 methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2- dimethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, may be substituted by OH, R26 is H, OH, F, Cl, Br, NH2, or SH, R29 is H, -C(=O)CH3, -Ci=O)CH2CH3, -C(=O)(CH2)2CH3) -C(=O)CH(CH3)2, -C(=O)(CH2)3CH3, -C(=O)CH(CH3)CH2CH3, -C(=O)CH2CH(CH3)2, -C(=O)(CH2)4CH3l -Ct=O)CH2CH(CH3)CH2CH3, -C(=O)CH2C(CH3)3, or -C(=O)(CH2)5CH3,
R31 is Cl, Br, -OR32, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1- pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, or -OCH2CH2OR25,
R32 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein R32 may be substituted with one, two, or three F,
R36 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl, and R37 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl,
2,2-dιmethylpropyl, or 1 -hexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2- dimethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, may be substituted by OH, or a pharmaceutically-acceptable salt thereof
Another embodiment of the invention is a compound of Formula IHA, IIIA-1 , IIIA-2, IIIA-3, or IIIA-4 wherein Y is methyl
Another embodiment of the invention is a compound of Formula IV
wherein G is (C1^ alkylenyl)-Ra or Ra, wherein said C1 3 alkylenyl may be substituted by one or more substituents selected from OH and F, Ra is C1-6 alkyl, 3- to 7-membered heterocycloalkyl, or 3- to 8-membered cycloalkyl, wherein said Ci-6 alkyl may be substituted by one or more substituents selected from F, -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34Ci=O)R35, or -NR34SO2R36, and wherein said heterocycloalkyl and cycloalkyl may be substituted by one or more substituents selected from R2, R3, R4, R5, R10, R11, and R21, W is phenyl-(C1-6 alkylenyl), pyrιdyl-(C1-6 alkylenyl), or 9-membered heteroaryl-(Cr6 alkylenyl), wherein said phenyl, pyridyl, or 9-membered heteroaryl is substituted by one or more groups selected from R30 and R3',
Y is Cr6 alkyl, Ct-6 haloalkyl, or Cr6 hydroxyalkyl,
L is 5-membered heteroaryl, R2 is H, F, CN, -OR5, R12, -C(=O)R7, -NR6R33, -NR8C(=O)R9, -NR8SO2R36, or -SO2R12,
R3 Is H, F, CN, or -OR22,
R4 is H, -(C^ alkylene)R6, -C(=O)RS, or -SO2R12,
R5 is H or -(C1^ alkyl), wherein said Ci-6 alkyl may be substituted by one or more R26 substituents,
R6 is H, CN, -OR23, -SO2R37, -NR24C(=O)R23, -NR24SO2R37, or N~N R7 is -(C1^ alkyl), -(C1-6 haloalkyl), -(C1-6 alkylene)OH, -NR38R39, -NHSO2CH3, or -OR25, R9 is -(C1* alKylene)R28, -NHR24, or -OR25, R10 Is H, F, CN, R12, or -C(=O)R7,
R11 is H, F, CN, -OR5, R12, -C(=O)R7, -NR8R33, -NR8C(=O)R9, -NR8SO2R36, or -SO2R12, R12 is -(Ci-6 alkyl), wherein said C6 alkyl may be substituted by one or more substituents selected from CN, -OR23, -SR23, -SO2R37, -NR8R33, -NR24C(=O)R23, and -NR24SO2R23, provided that any one carbon atom of said C1-6 alkyl is not substituted by more than one CN or more than one -OR23,
RB, Rc, R8, R20, R22, R24, R25, R33, R34, and R35 are independently H or -(C1-6 alkyl), R21 ιs H, F, or R12,
R23 is H, -(C1.* alkyl), or -(C1-6 alkylene)OH, R26 is H, OH, halo, NH2, or SH, R28 is H, NH2, or -OR29, R29 is H, (C1-6 alkyl), or -C(=O)(C,4 alkyl), R30 is H or F,
R31 is F, Cl, Br, -CN, -C(=O)NH2, -OH, -OR32, -OCH2CH2OR25, R32, ,or (C1-6 alkyl) optionally substituted by -OR25 or -OCH2CH2OR25 where R30 and R31 when adjacent may be taken together to constitute a group of the formula O-(CH2)n- or -O-(CH2)n-O-, n is 1 or 2,
R32 is -(Ct-6 alkyl) optionally substituted with one, two, or three F, R36 is -(C1-6 alkyl) or -(C3-6 cycloalkyl), and R37 is -(C1-6 alkyl), -(C3-6 cycloalkyl), or -(C1^ alkylene)OH,
R38 and R39 are independently H, -(C1-6 alkyl), or R38 and R39 taken together form a 5- or 6- membered heterocycloalkyl, or a pharmaceutically-acceptable salt thereof
Another embodiment of the invention is a compound of Formula IVA
wherein Ra, Rc, W1 Y, and L are as defined heremabove for Formula IV Another embodiment of the invention is a compound of Formula IVA wherein L is triazolyl, tetrazolyl, or oxadiazolyl
Another embodiment of the invention is a compound of Formula IVA wherein L is
Another embodiment of the invention is a compound of Formula IVA wherein L is
Another embodiment of the invention is a compound of Formula IVA- 1
IVA- 1 wherein Ra, Rc, W, Y, and L are as defined hereinabove for Formula IV Another embodiment of the invention is a compound of Formula IVA-2
wherein R3, Rc, W, Y, and L are as defined hereinabove for Formula IV Another embodiment of the invention is a compound of Formula IVA-3
wherein Ra, Rc, W, Y, and L are as defined hereinabove for Formula IV Another embodiment of the invention is a compound of Formula IVA-4
wherein Ra, Rc, W, Y, and L are as defined hereinabove for Formula IV Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or
IVA-4 wherein Ra is C6 alkyl, R4 be substituted by one or more substituents selected from -OR34, -SR34, -Cf=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R35
Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or
, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -Ci=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R35
Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or IVA-4 wherein Ra is C1-6 alkyl, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -Ci=O)NR34R35, -NR34R35, -NR34Ci=O)R35, or -NR34SO2R35
Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or IVA-4 wherein Ra is C1-6 alkyl, wherein said alkyl may be substituted by one or more -OR34
Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or
IVA-4 wherein Ra
Another embodiment of the invention is a compound of Formula IVA, IVA- 1 , IVA-2, IVA-3, or
IVA-4 wherein Ra is R2 >11
, or
R2 is CH(CH3)OH, C(CH3)2OH, -NR8C(O)(C, .<; alkylene)R28, or -NR8SO2R36, R10 Is CH(CH3)OH, or C(CH3)2OH, and
R11 is CH(CH3)OH, C(CH3)2OH, -NR8C(=O)(C1-6 alkylene)R28, or -NR8SO2R36 Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or IVA-4 wherein Y is methyl
Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or IVA-4 wherein W is phenyl-(Cr6 alkylenyl), wherein said phenyl is substituted by one or more groups selected from R30 and R31
Another embodiment of the invention is a compound of Formula IVA, IVA-1 , IVA-2, IVA-3, or IVA-4 wherein W is phenylmethyl, wherein said phenyl is substituted by one or more groups selected from R30 and R31 Another embodiment of the invention is a compound shown in Table 2
Another embodiment of the invention is a compound of Formula I1 II, III, or IV wherein G is -CH2R3, -CH2CH2R3, -CH(Ra)CH3> -CH2CH2CH2R3, -CH2CH(CH3)R3,
-CH(Ra)CH2CH3, or Ra, wherein said CH, CH2, and CH3 groups may be substituted by one or more substituents selected from OH and F,
Ra is methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1 -hexyl, aziridinyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, oxiranyl, oxetanyl, tetrahydrofuryl, dioxolyl, tetrahydropyranyl, dioxanyl, oxazetidinyl, isoxazolidinyl, oxazolidinyl, morpholinyl, oxazinanyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl may be substituted by one or more substituents selected from -OR34, -SR34, -C(=O)NR34R35,
-NR34R35, -NR34C(=O)R35, or -NR34SO2R36, and wherein said aziridinyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, oxiranyl, oxetanyl, tetrahydrofuryl, dioxolyl, tetrahydropyranyl, dioxanyl, oxazetidinyl, isoxazolidinyl, oxazolidinyl, morpholinyl, oxazinanyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl may be substituted by one or more substituents selected from R2, R3, R4, R5, R10, R11, and R21,
W is phenyl-(d-6 alkylenyl), pyrιdyl-(C1-6 alkylenyl), or IHdOIyI-(Cr6 alkylenyl), wherein said Ct. 6 alkylene is methylene, ethylene, 1 -propylene, 2-propylene, 1-butylene, 2-butylene, 2,2- dimethylethylene, 1-pentylene, 2-pentylene, 2,2-dιmethylpropylene, or 1-hexylene, and wherein said phenyl, pyridyl, or indolyl is substituted by one or more groups selected from R30 and R3\
Y is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2- dimethylpropyl, or 1-hexyl, wherein Y may be substituted by OH or by one or more substituents selected from F, Cl, and Br, L is triazolyl, tetrazolyl, or oxadiazolyl,
R4 is H, -(C1^ alkylene)R6, -C(=O)R9, or -SO2R12, wherein said C1^ alkylene is methylene, ethylene, 1 -propylene, 2-propylene, 1 -butylene, 2-butylene, 2,2-dιmethylethylene, 1 -pentylene, 2- pentylene, 2,2-dιmethylpropylene, or 1-hexylene, and wherein said phenyl, pyridyl, or indolyl is substituted by one or more groups selected from R30 and R31, R5 is H, methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl,
2,2-dιmethylpropyl, or 1 -hexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl, may be substituted by one or more R26 substituents,
R7 is methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, -NHR24, or -OR25, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl may be substituted by OH or by one or more substituents selected from F, Cl, and Br, R9 is -(C6 alkylene)R28, -NHR24, or -OR25,
R12 is methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl, wherein R12 may be substituted by one or more substituents selected from CN, -OR23, -SO2R37, -NR8R33, -NR24C(=O)R23, and -NR24SO2R23, provided that any one carbon atom of R12 is not substituted by more than one CN or more than one -OR23,
Rb, Rc, R8, R20, R22, R24, R25, R33, R34, and R35 are independently H, methyl, ethyl, 1 -propyl, 2- propyl, 1-bυtyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl,, R23 is H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethyletbyl, 1-pentyl, 2-pentyl,
2,2-dιmethylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, may be substituted by OH,
R26 is H, OH1 F, Cl, Br1 NH2, or SH,
R29 is H, -C(=O)CH3, -C(=O)CH2CH3, -C(=O)(CH2)2CH3, -C(=O)CH(CH3)2, -C(=O)(CH2)3CH3, -C(=O)CH(CH3)CH2CH3, -C(=O)CH2CH(CH3)2, -C(=O)(CH2)4CH3, -C(=O)CH2CH(CH3)CH2CH3, -C(=O)CH2C(CH3)3, or -C(=O)(CH2)5CH3l
R31 is Cl, Br, -OR32, methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1 - pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, or -OCH2CH2OR25,
R32 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein R32 may be substituted with one, two, or three F,
R36 is methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, and
R37 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1 -hexyl, may be substituted by OH, or a pharmaceutically-acceptable salt thereof
Another embodiment of the invention is a compound shown in Table 3
Table 3
Example Compound Name N o.
1 Λy-(4-Fluoro-3-methoxybenzyl)-6-(2-((^rans-4-amιnocyclohexyl)methyl)-
2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde
Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-((<rans-4-
((methylsulfonyl)arnιno)cyc!ohexyl)methyl)-2/-/-tetrazol-5- yl)pyπmιdιne-4-carboxamιde Λ/-(3-Chloro-4-fluorobenzyl)-6-(2-((<rans-4-amιnocyclohexyl)methyl)-2H- tetrazol-5-yl)pyrιmιdιne-4-carboxamιde
W-(3-Cnloro-4-fluorobenzyl)-6-(2-((/ra/?s-4-
((methylsulfonyl)amιno)cyclohexyl)methyl)-2H-tetrazol-5- yl)pyrιmιdιneO1 -4-carboxamιde /V-(3-Methoxybenzyl)-6-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde Table 3
Example Compound Name N o.
6 Λ/-(3-Methoxybenzyl)-2-methyl-6-(2-«(trans-4-
(methylsulfonamιdo)cyclohexyl)methyl)-2H-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde
7 Λ/-(3-Methoxybenzyl)-6-(2-((frans-4-acetamιdocyclohexyl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
8 Λ/-(3-Methoxybenzyl)-6-(2-(((fraπs)-4-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde N-(4-F!uoro-3-methoxybenzyl)-6-(2-(<rans-4-amιnocyclohexyl)methyl)-
2H-tetrazol-5-yl)-2-methylpyπmιdιne-4-carboxamιde
10 W-(4-F!uoro-3-methoxybenzyl)-2-methyl-6-(2-((/rans-4-
(methylsulfonamιdo)cyclohexyl)methyl)-2H-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde
1 1 Λl-(4-Fluoro-3-methoxybenzyl)-6-(2-((<rans-4- acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιπnιdιne-4-carboxamιde 2 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(((frans)-4-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde 3 Λ/-(3-(2-Hydroxyethoxy)benzyl)-6-(2-(((frans)-4- aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4- carboxamide 4 W-(3-(2-Hydroxyethoxy)benzyl)-6-(2-(((/rans)-4- acetamιdocyclohexyl)methy!)-2H-tetrazo!-5-yl)-2- me(hylpyrιmιdιne-4-carboxamιde 5 Λ/-(3-(2-Hydroxyethoxy)benzyl)-2-methyl-6-(2-(((frans)-4-
(methylsulfonamιdo)cyclohexyl)methyl)-2H-tetrazol-5- yl)pyπmιdιne-4-carboxamιde 6 Λ/-(3-(2-Hydroxyethoxy)benzyl)-6-(2-(((fraπs)-4-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde 7 Λ/-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-((((rans)-4- acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde 8 Λ/-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-2-methy!-6-(2-(((frans)-4-
(methy!sulfonamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde 9 Λ/-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((frans)-4-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2H-tetrazo!-5-y!)-2- methylpyπmιdιne-4-carboxamιde 0 /rans-Methyl 4-((5-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2/-/-tetrazol-2- yl)methyl)cyclohexanecarboxylate Table 3
Example Compound Name N o.
21 trans-4-((5-(6-((4-Flυoro-3-melhoxybenzyl}carbamoyl)-2- methylpyrιmιdιn-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylιc acid
22 (frans)-Methyl 4-((5-(6-((3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2/-/-tetrazo!-2- yl)methyl)cyc!ohexanecarboxy!ate 3 (/raπs)-4-((5-(6-((3-Methoxybenzyl)carbamoy!)-2-methy!pyrιmιdιn-4-yl)-
2AV-tetrazol-2-yl)methyl)cyclohexanecarboxylιc acιd 4 Λ/-(3-Methoxybenzyl)-6-(2-(((/rans-4-cyanocyclohexyl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde 5 W-(4-Fluoro-3-methoxybenzyl)-6-(2-(((/rans-4-cyanocyclohexy!)me{hyl)-
2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde 6 Λ/-(3-(2-Hydroxyethoxy)benzyl)-6-(2-(((fraπs)-4- cyanocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide 7 Λ/-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((/rans-4- cyanocyclohexy^methyl^H-tetrazol-S-yO^-methylpyrimidme^- carboxamide 8 N-(3-Methoxybenzyl)-6-(2-((((rans)-4-hydroxy-4-
(hydroxymethy!)cyc!ohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde 9 Λ/-(3-Methoxybenzyl)-6-(2-(((c/s)-4-hydroxy-4-
(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde 0 W-(3-chloro-4-fluorobenzyl)-6-(2-((fraπs-4-hydroxy-4-
(hydroxymethyl)cyclohexy!)mBthy!)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde 1 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(((1 S*,3R*)-3- aminocyclopentyl^ethyO^H-tetrazol-S-yO^-methylpyrimidine- 4-carboxamιde 2 Λac-Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(((1 S*,3fT)-3- acetamιdocyclopentyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιnnιdιne-4-carboxamιde 3 (+)-Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(((1 S*,3f?*)-3- acetamιdocyclopentyl)methyl)-2/-/-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde 4 (-)-N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((1 R*,3S*)-3- acetamidocyclopentyOmethyO-^H-tetrazol-S-yl)^- methylpyrιmιdιne-4-carboxamιde 5 rac-Λ/-(4-F!uoro-3-methoxybenzy!)-2-methyl-6-(2-(((1 S*,3R*)-3-
(methylsulfonamιdo)cyclopentyl)methyl)-2H-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde 6 (+)-Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2-(((1 fr,3S*)-3-
(methy!sυlfonamιdo)cyc!opentyl)methyl)-2H-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde Table 3
Example Compound Name N o.
37 (-)-Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2-(((1 S*,3/?*)-3-
(methylsulfonamιdo)cyclopentyl)methyl)-2H-tetrazol-5- yl)pyπmιdιne-4-carboxamιde
38 /V-(3-Methoxybenzyl)-2-methyl-6-(2-((S)-morpholιn-2-ylmethyl)-2H- tetrazol-5-yl)pyrιmιdιne-4-carboxamιde 9 Λ/-(3-Methoxybenzyl)-6-(2-(((S)-4-acetylmorpholιn-2-yl)methyl)-2/-/- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde 0 W-(3-Methoxybenzyl)-2-methyl-6-(2-(((f?)-4-(methylsulfonyl)morpholin-2- yl)methyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde 1 N-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2-((S)-morpho!in-2-ylmethyl)-
2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde 2 N-(4-fluoro-3-methoxybenzyl)-6-(2-(((S)-4-acetylmorpholιn-2-yl)methyl)-
2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde 3 Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6'(2-(((R)-4-
(methylsulfonyl)morpholιn-2-yl)methyl)-2H-tetrazol-5- yl)pyπmιdιne-4-carboxamιde 4 Λ/-(3-Methoxybenzyl)-2-methyl-6-(2-((R)-morpholιn-2-ylmethyl)-2/-/- tetrazo!-5-y!)pyrιmιdιne-4-carboxamιde 5 N-(3-Methoxybenzyl)-6-(2-(((f?)-4-acetylmorpholιn-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyπmιdιne-4-carboxamιde
46 N-(3-Methoxybenzyl)-2-methyl-6-(2-(((S)-4-(methy!su!fonyl)morpho!ιn-2- yl)methyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde 7 /V-(3-Chloro-4-fluorobenzyl)-2-methyl-6-(2-((S)-morpholιn-2-ylmethyl)-
2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde 8 Λ/-(3-Chloro-4-fluorobenzyl)-2-methyl-6-(2-(((f?)-4-
(methylsulfonyl)morpholιn-2-yl)methyl)-2H-tetrazol-5- yl)pyπmtdιne-4-carboxamιde 9 Λ/-(3-Ethyl-4-fluorobenzyl)-2-methyl-6-(2-((S)-morpholιn-2-ylmethyl)-2H- tetrazol-5-yl)pyrιmιdιne-4-carboxamιde 0 N-(3-Ethyl-4-fluorobenzyl)-2-methyl-6-(2-(((R)-4-
(methylsulfonyl)morpholιn-2-yl)methyl)-2H-tetrazol-5- y!)pyrιmιdιne-4-carboxamιde 1 rac-6-(2-((1 ,4-Dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-Λ/-(3- methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde 2 rac-6-(2-((1 ,4-Dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-Λ/-(4-fluoro-3- methoxybenzyl)-2-methyipyrιmιdιne-4-carboxamιde 3 6-(2-(((R)-1 ,4-dιoxan-2-yl)methyl)-2/-Metrazol-5-yl)-Λ/-(3- methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde 4 6-(2-(((/?)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-Λ/-(4-fluoro-3- methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde Table 3
Example Compound Name N o.
55 6-{2-(((f?)-1 ,4-d(oxan-2-yl)methyl)-2W-tetrazol-5-yl)-Λ/-(3-chloro-4- fluorobenzy!)-2-methylpyrιmιdιne-4-carboxamιde
56 6-(2-(((f?)-1 ,4-Dιoxan-2-yl)methyl)-2H-tetrazo!-5-yl)-Λ/-(4-fluoro-3-(2- nydroxyethoxy)benzyl)-2-methylpyπmιdιne-4-carboxamιde
57 6-(2-(((S)-1 ,4-dιoxan-2-y!)methyl)-2H-tetrazol-5-yl)-Λ/-(3- methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde
58 6-(2-(((S)-1 ,4-d(θxan-2-yl)methyl)-2W-tetrazol-5-yl)-Λ/-(4-fluoro-3- methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde
59 6-(2-(((S)-1 ,4-dtoxan-2-yl)methyl)-2H-tetrazol-5-yl)-Λ/-(3-chloro-4- fluorobenzyl)-2-methylpyrιmιdιne-4-carboxamιde 0 6-(2-(((S)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-Λ/-(4-fluoro-3-(2- hydroxyethoxy)benzyl)-2-methylpyrιmιdιne-4-carboxamιde 1 rac-Λ/-(3-Methoxybenzyl)-6-(2-(((2S*,5/?*)-5-(hydroxymethyl)-1 ,4-dιoxaπ-
2-yl)methyl)-2H-tetrazo!-5-yl)-2-methylpyrιmιdιne-4-carboxamιde 2 Λ/-(3-Methoxybenzyl)-6-(2-(((2S,5f?)-5-(hydroxymethyl)-1 ,4-dιoxan-2- yl)me(hyl)-2W-tetrazol-5-yl)-2-me(hylpyπmιdιne-4-carboxamιde 3 Λ/-(3-Methoxybenzyl)-6-(2-(((2R,5S)-5-(hydroxymethy!)-1 ,4-dιoxan-2- yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde 4 rac-/V-(4-F!uoro-3-methoxybenzyl)-6-(2-(((2S*,5f?*)-5-(hydroxymethyl)-
1 ,4-dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide 5 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5/?)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide 6 Λ/-(4-F!uoro-3-methoxybenzyl)-6-(2-(((2R,5S)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide 7 /•ac-Λ/-(4-Fluoro-3-methylbenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethy!)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide 8 Λ/-(4-Fluoro-3-methylbenzyl)-6-(2-(((2S,5/?)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazo!-5-yl)-2-methy!pyπmιdιne-4- carboxamide 9 Λ/-(4-Fluoro-3-methylbenzyl)-6-(2-(((2/?,5S)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide 0 rac-Λ/-(4-Fluoro-3-(trιfluoromethyl)benzyl)-6-(2-(((2S*,5R*)-5-
(hydroxymethyl)-1 ,4-dιoxan-2-y!)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde 1 rac-N-(3-Ethyl-4-fluorobenzy!)-6-(2-(((2S*,5R*)-5-(hydroxymethy!)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide 2 Λ/-(3-Ethyl-4-fluorobenzyl)-6-(2-(((2S,5f?)-5-(hydroxymethyl)-1 ,4-dιoxan-
2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyπmιdιne-4-carboxamιde3 Λ/-(3-Ethyl-4-fluorobenzyl)-6-(2-(((2R,5S)-5-(hydroxymethyl)-1 ,4-dιoxan-
2-y!)me(hyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxam!de4 rac-Λ/-(4-Fluoro-3-ιsopropylbenzyl)-6-(2-(((2S*,5f?*)-5-(hydroxymethyl)-
1 ,4-dιoxan-2-y!)methyl)-2H-tetrazol-5-yl)-2-methylpyπmιdιne-4- carboxamide Table 3
Example Compound Name N o.
75 rac-/V-(3-Cyclopropyl-4-fluorobenzyl)-6-(2-(((2S*,5/?*)-5-
(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde
76 rac-Λ/-(3-Cyano-4-fluorobenzyl)-6-{2-({(2S*,5R*)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide
77 rac-Λ/-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((2S*,5/?*)-5-
(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde
78 Aac-A/-(3-Chloro-4-fluorobenzyl)-6-(2-(((2S*,5/?*)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide
79 /V-(3-Chloro-4-fluorobenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide
80 Λ/-(3-Bromo-4-fluorobenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-2-methy!pyrιmιdιne-4- carboxamide
81 Λ/-(4-Fluoro-3-hydroxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethy!)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide
82 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2R,5/?)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-y!)-2-methylpyrιmιdιne-4- carboxamide
83 Λ/-(3-Chloro-4-fluorobenzyl)-6-(2-((5,5-bιs(hydroxymethyl)-1 ,4-dιoxan-2- yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
84 Λ/-(3-Methoxybenzyl)-6-(2-((5,5-bιs(hydroxymethyl)-1 ,4-dιoxan-2- yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
85 rac-(2S*,5S*)-Methyl 5-((5-(6-((3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2- carboxylate
86 rac-(2S*,5S*)-5-((5-(6-((3-Methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-
4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylιc acid
87 rac-(2S*,5S*)-methyl 5-((5-(6-((4-fluoro-3-methoxybenzy!)carbamoyl)-2- methylpyπmιdιn-4-yl)-2H-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2- carboxylate
88 rac-(2S*,5S*)-5-((5-(6-((4-Flυoro-3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2- carboxyhc acid
89 (2S,5S)-5-((5-(6-((4-Fluoro-3-methoxybenzyl)carbamoy!)-2- methy!pyπmιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2- carboxyhc acid
90 (2S,5S)-Methyl 5-((5-(6-((4-Fluoro-3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2H-tetrazo!-2-yl)methyl)-1 ,4-dιoxane-2- carboxylate Table 3
Example Compound Name N o.
91 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5S)-5-(2-hydroxypropan-2-yl)-
1 ,4-dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide
90 (2S,5S)-Methyl 5-((5-(6-((4-Fluoro-3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-y!)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2- carboxylate
91 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5S)-5-(2-hydroxypropan-2-yl)-
1 ,4-dιoxan-2-yl)methyl)-2H-(etrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide 2 rac-(2S*,5S*)-Methy! 5-((5-(6-((3-chloro-4-fluorobenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2H-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2- carboxylate 3 rac-(2S*,5S*)-5-((5-(6-((3-Chloro-4-fluorobenzyl)carbamoy!)-2- methylpyrιmιdιn-4-yl)-2H-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2- carboxylic acid 4 rac-(2S*,5S*)-Methyl 5-((5-(6-((3-bromo-4-fluorobenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2- carboxylate 5 Λac-(2S*,5S*)-5-((5-(6-((3-Bromo-4-fluorobenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2H-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2- carboxylic acid 6 Λac-W-(3-Methoxybenzyl)-6-(2-(((2S*,5/?*)-5-(amιnomethyl)-1 ,4-dιoxan-
2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde 7 rac-/V-(3-Methoxybenzyl)-6-(2-(((2S*,5f?*)-5-(acetamιdomethyl)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyπmιdιne-4- carboxamide 8 rac-/\/-(3-Methoxybenzyl)-6-(2-(((2S*,5R*)-5-(acetamidomethyl)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide 9 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2f?*,5R*)-5-(hydroxymethyl)- tetrahydro-2H-pyran-2-yl)methyl)-2/-/-tetrazol-5-yl)-2- methy!pyrιmιdιne-4-carboxamιde 00 /V-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2R*,5R*)-5-(hydroxymethyl)- tetrahydro-2/-/-pyran-2-yl)methyl)-2H-tetrazol-5-yl)-2- methylpyπmιdιne-4-carboxamιde 01 /V-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)- tetrahydro-2H-pyran-2-yl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde Table 3
Example Compound Name N o.
102 Λ/-(4-fluoro-3-me(hoxyben2yl)-6-(2-(((2S*,5/?*)-5-(hydroxymethyl)- tetrahydro-2H-pyran-2-yl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde
103 W-(3-Methoxybenzyl)-6-(2-(((2f?*,5S*)-5-hydroxy-tetrahydro-2H-pyran-2- yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
104 Λ/-(3-Methoxybenzyl)-6-(2-(((2f?*,5S*)-5-hydroxy-tetrahydro-2H-pyran-2- yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
105 (+)-A/-(4-Fluoro-3-methoxybenzy!)-6-(2-(((2R*,5S*)-5-hydroxy- tetrahydro-2H-pyran-2-yl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde
106 (-)-Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S*,5R'r)-5-hydroxy-tetrahydro-
2H-pyran-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyπmιdιne-4- carboxamide
107 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2f?*,5S*)-5-hydroxy-5-
(hydroxymethyl)-tetrahydro-2H-pyran-2-yl)methyl)-2H-tetrazo!-5- y!)-2-methylpyπmιdιne-4-carboxamιde
108 rac-/V-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2R*,5/?*)-5-hydroxy-5-
(hydroxymethyl)-tetrahydro-2H-pyran-2-yl)methyl)-2/-/-tetrazol-5- yl)-2-methylpyrιmιdιne-4-carboxamιde
109 rac-N-(3-Methoxybenzyl)-6-(1-(((2R*,5S*)-5-(hydroxymethyl)-1 ,4-dιoxan-
2-yl)methyl)-1 H- 1 ,2,4-trιazol-3-yl)-2-methylpyrιmιdιne-4- carboxamide
1 10 Λ/-(3-Methoxybenzyl)-6-(1 -((frans-4-amιnocyclohexyl)methyl)-1 H-1 ,2,4- trιazol-3-yl)-2-methylpyrιmιdιne-4-carboxamιde
11 1 N-(3-Methoxybenzy!)-6-(1 -(((frans)-4-acetamιdocyclohexyl)methyl)-1 H-
1 ,2,4-trιazol-3-yl)-2-methylpyrιmιdιne-4-carboxamιde
112 /V-(3-Methoxybenzyl)-2-methyl-6-(1-(((<Λaπs)-4-
(methylsulfonamιdo)cyclohexyl)methyl)-1 H-1 ,2,4-tπazol-3- yl)pyrιmιdιne-4-carboxamιde 13 2-((^aπs)-4-((3-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4- yl)-1H-1 ,2,4-trιazol-1-yl)methyl)cyclohexylamιno)-2-oxoethyl acetate 14 Λ/-(3-Methoxybenzyl)-6-(1 -(((frans)-4-(2- hydroxyacetamidojcyclohexyOmethyl^iH-i ^^-tnazol-S-yl)^- methylpyrιmιdιne-4-carboxamιde 15 rac-/V-(4-Fluoro-3-methoxybenzyl)-6-(1-(((2/?*,5S*)-5-(hydroxymethyl)-
1 ,4-dιoxan-2-yl)methyl)- 1 H- 1 ,2,4-tπazol-3-yl)-2- methylpyrιmιdιne-4-carboxamιde 16 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(1-(((rans-4-amιnocyclohexyl)methyl)-
1 H-1 ,2,4-tπazol-3-yl)-2-methylpyrιmιdιne-4-carboxamιde 17 N-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(1 -((/rans-4-
(methylsulfonamιdo)cyclohexyl)methyl)-1 H-1 ,2,4-tπazol-3- yl)pyrιmιdιne-4-carboxamιde Table 3
Example Compound Name N o.
118 Λ/-(4-fluoro-3-methoxybenzyl)-6-(1-((/Λa/?s-4- acetamιdocyclohexyl)methyl)-1H-1 ,2,4-trιazol-3-yl)-2- methylpyrιmιdιne-4-carboxamιde
119 W-(4-Fluoro-3-methoxybenzy!)-6-(1-((frans-4-(2- hydroxyacetamιdo)cyclohexyl)methyl)-1H-1 ,2,4-trιazol-3-yl)-2- methylpyrιmιdιne-4-carboxamιde
120 Λ/-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-2-methyl-6-( 1 -((trans-4-
(methy!sulfonamιdo)cyclohexyl)methyl)-1 H-1 ,2,4-trιazol-3- yl)pyrιmιdιne-4-carboxamιde
121 W-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-(1-((frans-4- acetamidocyclohexyl)methy!)-1H-1 ,2,4-triazol-3-y!)-2- methylpyπmιdιne-4-carboxamιde
122 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(5-((<rans-4-amιnocyclohexyl)methyl)-
1 ,2,4-oxadιazol-3-yl)-2-methylpyrιmιdιne-4-carboxamιde
123 Λ/-(4-fluoro-3-methoxybenzyl)-6-(5-((frans-4- acetamidocyclohexyl)methyl)-1 ,2,4-oxadiazol-3-yl)-2- methylpyrιmιdιne-4-carboxamιde
124 Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(5-((fraπs-4-
(methylsulfonamιdo)cyclohexyl)methyl)-1 ,2,4-oxadιazol-3- yl)pyrιmιdιne-4-carboxamιde 25 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(3-hydroxypropyl)-2H-te(razol-5-yl)-
2-methylpyrιmιdιne-4-carboxamιde 26 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-((S)-3-hydroxy-2-methylpropyl)-2H-
(e(razol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde 27 A/-(4-Fluoro-3-methoxybenzyl)-6-(2-((f?)-3-hydroxy-2-methylpropy!)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde 28 Ay-(4-Fluoro-3-methoxybenzyl)-6-(1-(((2S,5R)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-1 /-/-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4- carboxamide 29 W-(4-Fluoro-3-methoxybenzyl)-6-(1 -(((S)-4-acetylmorpholin-2-yl)methyl)-
1 H- 1 ,2,3-tπazol-4-yl)-2-methy!pyπmιdιne-4-carboxamιde30 Λ/-(3-Methoxybenzyl)-2-methyl-6-(1-((S)-morpholιn-2-ylmethyl)-1 H-1 ,2,3- trιazol-4-yl)pyrιmιdιne-4-carboxamιde 31 Λf-(3-Methoxybenzyl)-6-(1 -(((S)-4-acetylmorpholιn-2-yl)methyi)-1 H- 1 ,2,3- trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde 32 Λ/-(3-Methoxybenzyl)-2-methyl-6-(1 -(((R)-4-(methylsulfonyl)morpholιn-2- yl)methyl)-1H-1 ,2,3-triazol-4-yl)pyrimidine-4-carboxamide 33 Λ/-(3-Methoxybenzyl)-6-(1 -(((2S,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2- yl)methyl)-1H-1 ,2,3-trιazol-4-yl)-2-metnylpyrιmιdιne-4- carboxamtde 34 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(1 -(((/raπs)-4-amιnocyclohexyl)methyl)-
1 H- 1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde Table 3
Example Compound Name N o.
135 N-(4-Fluoro-3-methoxybenzyl)-6-(1 -(((trans)-A- acetamidocyclohexyl )methyl )- 1 H- 1 ,2 ,3-trιazol-4-yl)-2- methylpyrιmιdιne-4-carboxamιde
136 N-(4-Fluoro-3-methoxybenzyl)-6-(1-(((frans)-4-(2- hydroxyacetamιdo)cyclohexyl)methyl)-1 H-1 ,2,3-trιazol-4-y!)-2- methylpyrιmtdιne-4-carboxamιde
1 37 /V-(4-Fluoro-3-methoxybenzyl)-6-(1 -(((1/?,3S)-3- amιnocyclopentyl)methyl)-1 H-1 ,2,3-tπazol-4-yl)-2- methylpyrιmιdιne-4-carboxamιde
138 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(1-(((1 R,3S)-3- acetamιdocyclopentyl)methyl)-1/-/-1 ,2,3-trιazol-4-yl)-2- methylpyrιmιdιne-4-carboxamιde
139 Λ/-(4-fluoro-3-methoxybenzyl)-6-(1-(((1 R,3S)-3-(2- hydroxyacetamιdo)cyclopentyl)methyl)-1 H-1 ,2,3-trιazol-4-yl)-2- methylpyπmιdιne-4-carboxamιde
140 N-(4-F!uoro-3-methoxybenzyl)-2-methyl-6-( 1 -((( 1 R,3S)-3-
(methylsulfonamιdo)cyclopentyl)methyl)-1 H-1 ,2,3-trιazol-4- yl)pyrιmιdιne-4-carboxamιde 41 W-(4-Fluoro-3-methoxybenzy!)-6-(1-(((1 S,3R)-3- amιnocyclopentyl)methyl)-1 H-1 ,2,3-trιazol-4-y!)-2- methylpyrιmιdιne-4-carboxamιde 42 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(1-(((1S,3/?)-3- acetamιdocyclopentyl)methyl)-1 H-1 ,2,3-trιazo!-4-yl)-2- methylpyπmιdιne-4-carboxamιde 43 N-(4-Flυoro-3-methoxybenzyl)-6-(1 -(((1 S,3R)-3-(2- hydroxyacetamιdo)cyclopentyl)methyl)-1H-1 ,2,3-trιazol-4-yl)-2- methylpyrιmιdιne-4-carboxamιde 44 W-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(1-(((1 S,3f?)-3-
(methylsulfonamιdo)cyclopentyl)methyl)-1 H-1 ,2,3-trιazol-4- yl)pyrιmιdιne-4-carboxamιde 45 6-(1-(((S)-1 ,4-Dioxan-2-yl)methyl)-1 H-1 ,2,3-tnazol-4-yl)-W-(4-fluoro-3- methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde 46 6-(1-(((R)-1 ,4-Dιoxan-2-yl)methyl)-1 H-1 ,2,3-trιazol-4-yl)-Λ'-(4-f)uoro-3- methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde 47 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(1-(((2S,5R)-5-amιno-tetrahydro-2H- pyran-2-yl)methyl)-1H-1 ,2,3-tπazol-4-yl)-2-methylpyπmιdιne-4- carboxamide 48 N-(4-Fluoro-3-methoxybenzyl)-6-(1 -(((2S,5R)-5-acetamιdo-tetrahydro-
2H-pyran-2-yl)methyl)-1H-1 ,2,3-trιazol-4-yl)-2-methylpyπmιdιne- 4-carboxamιde Table 3
Example Compound Name N o.
149 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(5-(((2S,5R)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-1 ,2,4-oxadιazol-3-yl)-2-methylpyrιmιdιne-4- carboxamide
150 6-(5-((2/?)-1 ,4-Dιoxan-2-ylmethyl)-1 ,2,4-oxadιazol-3-yl)-W-(4-fluoro-3- methoxybenzy!)-2-methylpyrιrrudιne-4-carboxamιde
151 6-(5-((2S)- 1 ,4-Dioxan-2-ylmethyl)-1 ,2,4-oxadιazol-3-yl)-Λ/-(4-fluoro-3- methoxybenzyl)-2-methylpynmιdιne-4-carboxamιde
152 Λ/-(4-Fluoro-3-methoxybenzyl)-6-(3-(((fraπs)-4- acetamιdocyc!ohexy!)methyl)ιsoxazol-5-yl)-2-methylpyπmιdιne- 4-carboxamιde
153 /V-(3-Methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnamιde
154 Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-(((/rans)-4-
(methylsulfonamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5- yl)pιcolιnamιde
155 /V-(3-Methoxybenzyl)-4-(2-(((tørts)-4-
(ethylsυlfonamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicohnamide
156 N-(3-Methoxybenzy\)-4-(2-(((trans}-4-
(cyclopropanesulfonamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)- 6-methylpιcolιnamιde
157 Λ/-(3-Methoxybenzyl)-4-(2-(((/raπs)-4-
(butylsulfonamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
158 N-(3-Methoxybenzyl)-4-(2-(((/rans)-4-acetamιdocyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
159 N-(3-Methoxybenzyl)-4-(2-(((/raπs)-4-ιsobutyramιdocyclohexyl)methyl)-
2H-tetrazol-5-yl)-6-methylpιcolιnamιde
160 2-((<rans)-4-((5-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-
2/-/-tetrazol-2-yl)methyl)cyclohexylamιno)-2-oxoethyl acetate
161 Λ/-(3-Methoxybenzyl)-4-(2-(((frans)-4-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2H-tetrazo!-5-yl)-6- methylpicolinamide
162 Λ/-(3-Methoxybenzyl)-4-(2-(((frans)-4-(2-hydroxy-2- methylpropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
163 W-(3-Methoxybenzyl)-4-(2-((Urans)-4-((S)-2- hydroxypropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
164 Λ/-(3-Methoxybenzyl)-4-(2-(((<rans)-4-(3- amιnopropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
165 Λ/-(3-Methoxybenzyl)-4-(2-(((/rans)-4-(2- methoxyacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
166 Λ/-(3-Methoxybenzyl)-4-(2-(((^ans)-4-(3- methoxypropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide Table 3
Example Compound Name N o.
167 /V-(3-Methoxybenzyl)-4-(2-(((tams)-4-(2- amιnoacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
168 W-(3-Methoxybenzyl)-4-(2-(((to}/?s)-4-(3- hydroxypropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
169 1 -((^a/?s)-4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-
2H-tetrazol-2-yl)methyl)cyc!ohexyl)-3-methylurea
170 N-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)-
2A7-tetrazol-5-yl)-6-methylpιcolιnamιde
171 Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4- acetamidocyclohexyOmethyl^H-tetrazol-δ-ylJ-e- methylpicolmamide
172 N-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-(3- amιnopropanamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
173 N-(4-Fluoro-3-methoxybenzyl)-4-(2-(((/rans)-4-(2- methoxyacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
174 Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-(3- methoxypropanamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
175 W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((fra/7S)-4-(2- amιnoacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
176 2-((<raπs)-4-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexylamιno)-2- oxoethyl acetate
177 Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((/rans)-4-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
178 N-(4-Fluoro-3-methoxybenzyl)-4-(2-(((<rans)-4-(3- hydroxypropanamidojcyclohexyOmethyO^H-tetrazol-S-yO-θ- methylpicolinamide
179 /V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-(2-hydroxy-2- methylpropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicohnamide
180 /V-(3-Ethoxybenzyl)-6-methy!-4-(2-(((/ra/7s)-4-
(methylsυlfonamιdo)cyclohexyl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde
181 W-(4-Fluoro-3-(hydroxymethyl)benzyl)-6-methyl-4-(2-(((/ra/7s)-4-
(methytsulfonamιdo)cyclohexyl)rrιethyl)-2H-tetrazol-5- yl)pιcolιnamιde
182 Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-(((/rans)-4-
(methylsulfonamido)cyclohexyl)methyl)-2H-tetrazol-5- yt)pιcolιnamιde
183 W-(3-(Hydroxymethyl)benzyl)-6-methyl-4-(2-(((frans)-4-
(methylsulfonamιdo)cyclohexyl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde Table 3
Example Compound Name N o.
184 N-(3-(2-Hydroxyethoxy)benzyl)-6-melhyl-4-(2-(((/Λaw)-4-
(methylsulfonamιdo)cyclohexyl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde
185 /V-(4-Fluoro-3-methylbenzyl)-4-(2-(((Jraπs)-4-amιnocyclohexyl)methyl)-
2H-tetrazol-5-yl)-6-methylpιcolιnamιde
186 N-(4-fluoro-3-methylbenzyl)-6-methyl-4-(2-(((<rans)-4-
(methylsulfonamιdo)cyclohexyl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde
187 N-(4-Fluoro-3-methylbenzyl)-4-(2-(((<rans)-4- acetamιdocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicohnamide
188 N-(4-Fluoro-3-methy!benzyl)-4-(2-(((frans)-4-(3- amιnopropanamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide
189 Λ/-(4-Fluoro-3-methylbenzyl)-4-(2-((((rans)-4-(2- methoxyacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
190 2-((fraπs)-4-((5-(2-((4-Fluoro-3-methylbenzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexylamιno)-2- oxoethyl acetate
191 Λ/-(4-Fluoro-3-methylbenzyl)-4-(2-(((<rans)-4-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
192 N-(4-Fluoro-3-methylbenzyl)-4-(2-(((<rans)-4-(3- methoxypropanamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide
193 N-(4-fluoro-3-methy!benzy!)-4-(2-(((trans)-4-(2- amιnoacetamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
194 Λ/-(3-Chloro-4-fluorobenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)-
2H-tetrazol-5-yl)-6-methylpιcolιnamιde
195 /V-(3-Chloro-4-fluorobeπzyl)-6-methyl-4-(2-(((f/-aπs)-4-
(methylsulfonamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5- yl)picolinamide
196 Λ/-(3-Chloro-4-fluorobeπzyl)-4-(2-{((frans)-4- acetamidocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
197 N-(3-Cb\oro-4-f\uorohenzy\)-4-(2-(((trans)-4-(3- amιnopropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
198 Λ/-(3-Chloro-4-fluorobenzyl)-4-(2-(((/rans)-4-(2- methoxyacetamιdo)cyclohexy!)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
199 2-((^ans)-4-((5-(2-((3-Chloro-4-fluorobenzyl)carbamoyl)-6-methylpyrιdιn-
4-yl)-2/-/-tetrazol-2-yl)methyl)cyclohexylamιno)-2-oxoethy! acetate
200 Λ/-(3-Chloro-4-fluorobenzyl)-4-(2-(((frans)-4-(2- hydroxyacetamιdo)cyc!ohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide Table 3
Example Compound Name N o.
201 Λ/-(3-Chloro-4-flυorobenzyl)-4-(2-(((frans)-4-(3- methoxypropanamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide
202 /V-(3-Chloro-4-f!uorobenzyl)-4-(2-(((fraπs)-4-(2- amιnoacetamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
203 Λ/-(4-Fluoro-3-((2-hydroxyethoxy)methyl)benzyl)-6-methyl-4-(2-(((^aπs)-
4-(methylsulfonamιdo)cyclohexyl)methyl)-2H-tetrazol-5- y!)pιcolιnamιde
204 4-(2-(((^a/7s)-4-Acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-Λ/-((6- hydroxypyrιdιn-2-yl)methyl)-6-methylpιcolιnamιde
205 Λ/-(3-(Hydroxymethyl)benzyl)-4-(2-(((fraπs)-4- acetamιdocyclohexyl)methyl)-2>-/-tetrazol-5-yl)-6- methylpicolinamide
206 Λ/-(3-(2-Hydroxyethoxy)benzyl)-4-(2-(((fraA?s)-4- acetamιdocyclohexyl)methy!)-2H-tetrazol-5-yl)-6- methylpicohnamide
207 /V-(4-F!uoro-3-(hydroxymethyl)benzyl)-4-(2-(((frans)~4- acetamidocyclohexyOmethyO-^H-tetrazol-S-yO-θ- methylpicolinamide
208 N-(3-Ethoxybenzyl)-4-(2-(((/rans)~4-acetamidocyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
209 Λ/-(3-Methoxybenzyl)-4-(2-(((c/s)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-
5-yl)-6-methylpιcolιnamιde
210 N-(3-Methoxybenzyl)-6-methyl-4-(2-(((c/s)-4-
(methylsulfonamιdo)cyclohexyl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde
211 A/-(3-Methoxybenzyl)-4-(2-(((αs)-4-acetamιdocyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
212 Λ/-(3-Methoxybenzyl)-4-(2-(((c/s)-4-(3- amιnopropanamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
213 N-(3-Methoxybenzyl)-4-(2-(((c/s)-4-(2- methoxyacetamιdo)cyclohexyl)methy!)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
214 2-((c/s)-4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexylamιno)-2-oxoethyl acetate
215 Λ/-(3-Methoxybenzyl)-4-(2-(((c/s)-4-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide
216 A/-(3-Methoxybenzyl)-4-(2-(((c/s)-4-(3- methoxypropanamidoJcyclohexyOmethyO^H-tetrazol-δ-yO-e- methylpicolmamide
217 N-(3-Methoxybenzyl)-4-(2-(((cιs)-4-(2- amιnoacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
218 /V-(3-Methoxybenzyl)-4-(2-(((c/s)-4-(2-hydroxy-2- methylpropanamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide Table 3
Example Compound Name N o.
219 Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((c/s)-4-amιnocyclohexyl)methyl)-
2H-tetrazo!-5-y!)-6-methylpιcolιnamιde
220 N-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-(2-hydroxy-2- methylpropanamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
221 N-(4-Fuoro-3-methoxybe^zyl)-4-(2-(((c/s)-4-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
222 N-(4-Fluoro-3-methoxybenzyl)-4-(2-(((c/s)-4- acetamιdocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
223 rac-Λ/-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-amιnocyc!ohexyl)methyl)-
2H-tetrazol-5-yl)-6-metnylpιcolιnamιde
224 rac-Λ/-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-(3- amιnopropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
225 rac-N-(3-Methoxybenzyl)-4-(2-(((1 S*,3f?*)-3- acetamidocyclohexyOmethyO^H-tetrazol-S-yO-G- methylpicolmamide
226 Λ/-(3-Methoxybenzy!)-4-(2-(((1 S*,3R*)-3-acetamιdocyclohexyl)methyl)-
2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
227 Λ/-(3-Methoxybenzyl)-4-(2-(((1f?*,3S*)-3-acetamιdocyclohexyl)methyl)-
2H-tetrazol-5-yl)-6-methylpιcolιnamιde
228 rac-Λ/-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-(2- methoxyacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
229 rac-2-((1 /?*,3S*)-3-((5-(2-((3-methoxybenzyl)carbamoyl)-6- methylpyπdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexylamιno)-2- oxoethyl acetate
230 rac-/V-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
231 W-(3-Methoxybenzyl)-4-(2-(((1R*,3S*)-3-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
232 N-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
233 rac-Λ/-(4-Fluoro-3-methoxybenzy!)-4-(2-(((1 S*,3R*)-3- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
234 rac-2-((1f?*,3S*)-3-((5-(2-((4-Fluoro-3-methoxybenzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexylamιno)-2- oxoethyl acetate
235 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((1S*,3fr)-3-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
236 /V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((1 S*,3R*)-3-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide Table 3
Example Compound Name N o.
237 /V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((1 R*,3S*)-3-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicohnamide
238 rac-/V-(3-Methoxybenzyl)-4-(2-(((1 S' ,3R*)-3-(3- methoxypropanamιdo)cyclohexy!)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide
239 rac-/V-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-(2- amιnoacetamιdo)cyclohexyl)methy!)-2H-tetrazol-5-y!)-6- methylpicolmamide
240 rac-Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-(((1 S*,3R*)-3-
(methylsulfonamιdo)cyclohexyl)methyl)-2H-tetrazo!-5- yl)pιcolιnamιde
241 rac-W-(3-Me(hoxybenzyl)-4-(2-(((1/?*,3/?*)-3-amιnocyclohexyl)methyl)-
2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
242 rac-/V-(3-Methoxybenzyl)-4-(2-(((1 R*,3R*)-3-(2- metboxyacetamιdo)cyclohexyl)methy!)-2A7-tetrazol-5-yl)-6- methylpicolinamide
243 rac-N-(3-Methoxybenzyl)-4-(2-(((1 R*,3R*)-3- acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
244 rac-2-((1 f?*,3/?*)-3-((5-(2-((3-methoxybenzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexylamιno)-2- oxoethyl acetate
245 rac-W-(3-Methoxybenzyl)-4-(2-(((1R*,3R*)-3-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
246 Λac-Λ/-(3-Methoxybenzyl)-4-(2-(((1 R*,3R*)-3-(3- methoxypropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
247 rac-Λ/-(3-Methoxybenzyl)-4-(2-(((1tf*,3R*)-3-(2- amιnoacetamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
248 rac-Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-(((1R*,3/:?*)-3-
(methylsulfonamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5- yl)pιcolιnamιde
249 rac-Λ/-(3-Methoxybenzyl)-4-(2-(((1 S*,3f?*)-3-amιnocyclopentyl)methyl)-
2H-tetrazol-5-yl)-6-methylpιcolιnamιde
250 rac-Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-(((1 S*,3R*)-3-
(methylsulfoπamιdo)cyclopentyl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde
251 rac-/V-(3-Methoxybenzyl)-4-(2-(((1 S*,3/?*)-3-
(ethylsulfonamιdo)cyclopentyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicotinamide
252 rac-A/-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3- acetamιdocyclopentyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
253 rac-/V-(3-Methoxybenzyl)-4-(2-(((1 S* ,3R*)-3-(2- hydroxyacetamιdo)cyclopentyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicohnamide Table 3
Example Compound Name N o.
254 rac-/V-(3-Methoxybenzyl)-4-(2-(((1 S*,3/?*)-3-(3- hydroxypropanamιdo)cydopentyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
255 (trans)-Methyl 4-((5-(2-((4-fluorobenzyl)carbamoy!)-6-methylpyrιdιn-4- yl)-2H-tetrazo!-2-yl)methyl)cyclohexanecarboxylate
256 (/rans)-4-((5-(2-((4-Fluorobenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexanecarboxylιc acid
257 N-(4-Fluorobenzyl)-6-methyl-4-(2-(((frans)-4-
(methylsulfonylcarbamoyl)cydohexyl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde
258 Λ/-(4-Fluorobenzyl)-4-(2-(((/raπs)-4-(2-hydroxyacetyl)cyclohexy!)methy!)-
2H-tetrazol-5-yl)-6-methylpιcolιnamιde
259 (trans)-Melhy\ 4-((5-(2-((3-(hydroxymethyl)benzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2/-/-tetrazol-2- yl)methyl)cyclohexanecarboxylate
260 (/Λa/7s)-4-((5-(2-((3-(Hydroxymethyl)benzyl)carbamoyl)-6-methylpyrιd!n-
4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylιc acιd
261 (frans)-Methyl 4-((5-(2-((3-hydroxybenzyl)carbamoyl)-6-methylpyrιdιn-4- yl)-2/-/-tetrazol-2-yl)methyl)cyclohexanecarboxylate
262 (/rans)-4-((5-(2-((3-Hydroxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/- tetrazol-2-yl)methyl)cyclohexanecarboxylιc acid
263 (trans)-Methγ\ 4-((5-(2-((3-(3-methoxypropoxy)benzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2/-/-tetrazol-2- yl)methyl)cyclohexanecarboxylate
264 (frans)-4-((5-(2-((3-(3-Methoxypropoxy)benzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)- methyl)cyclohexanecarboxylιc acid
265 (frans)-Methyl 4-((5-(2-((3,4-dιfluorobenzyl)carbamoyl)-6-methylpyrιdιn-
4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate
266 (frans)-4-((5-(2-((3,4-Dιfluorobenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-
2H-tetrazol-2-yl)methy!)cyclohexanecarboxylιc acid
267 (fraπs)-Methyl 4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4- yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate
268 (/raπs)-4-((5-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyπdιn-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexanecarboxylιc acid
269 Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-(((<rans)-4-(pιperιdιne-1 - carbonyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)picolinamide
270 4-(2-(((^ans)-4-((2-Methoxyethyl)carbamoyl)cyclohexyl)methyl)-2H- tetrazol-5-yl)-Λ/-(3-methoxybenzyl)-6-methylpιcolιnamιde
271 Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-(((<rans)-4-(morpholιne-4- carbonyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)pιcolιnamιde
272 Λ/-(3-Methoxybenzyl)-4-(2-(((<rans)-4-
(dιmethylcarbamoyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
273 Λ/-(3-Methoxybenzyl)-4-(2-(((^rans)-4-
(isopropylcarbamoyOcyclohexyOmethyO^W-tetrazol-S-yO-e- methylpicolinamide
274 4-(2-((((rans)-4-((2-Amιno-2-oxoethyl)carbamoyl)cyclohexyl)methyl)-2H- tetrazol-5-yl)-Λ/-(3-methoxybenzyl)-6-methylpιcolιnamιde Table 3
Example Compound Name N o.
275 /V-(3-Methoxybenzyl)-6-methyl-4-(2-(((fraπs)-4-
(methylcarbamoyOcyclohexyOmethyl^H-tetrazol-S- yl)pιcolιnamιde
276 /V-(3-Methoxybenzyl)-4-(2-(((fraπs)-4-
(ethylcarbamoyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
277 4-(2-(((fraπs)-4-((2-Hydroxyethyl)carbamoyl)cyclohexyl)methyl)-2H- tetrazol-5-yl)-N-(3-methoxybenzyl)-6-rnethylpιcolιnamιde
278 Λ/-(3-Methoxybenzyl)-4-(2-(((/rans)-4-carbamoylcyclohexyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnamιde
279 Λ/-(3-Methoxybenzyl)-4-(2-(((frans)-4-cyanocyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
280 /V-(3-Methoxybenzyl)-4-(2-(((^ar?s)-4-(2- hydroxyacetyOcyclohexyOmethyO^H-tetrazol-δ-yO-θ- methylpicolinamide
281 (trans)-Meihyl 4-((5-(2-((3-(Dιfluoromethoxy)benzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate
282 (/ra/7s)-4-((5-(2-((3-(Difluoromelhoxy)benzyl)carbamoyl)-6-methylpyridin-
4-yl)-2/-/-tetrazol-2-yl)methyl)cyclohexanecarboxylιc acid
283 Λ/-(3-(Dιfluoromethoxy)benzyl)-4-(2-(((<rans)-4-
(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
284 (Zrans)-Methyl 4-((5-(2-((4-Fluoro-3-methylbenzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2/-/-tetrazol-2- yl)methyl)cyclohexanecarboxylate
285 (frans)-4-((5-(2-((4-Fluoro-3-methylbenzyl)carbamoyl)-6-methylpyrιdιn-4- yl)-2/-/-tetrazol-2-yl)methyl)cyclohexanecarboxylιc acid
286 Λ/-(4-Fluoro-3-methy(benzyl)-4-(2-(((/rans)-4- carbamoylcyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
287 Λ/-(4-Fluoro-3-methylbenzyl)-4-(2-(((<rans)-4-cyanocyclohexyl)methyl)-
2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
288 (frans)-Methy! 4-((5-(2-((3-Ethylbenzy!)carbamoyl)-6-methylpyπdιn-4-yl)-
2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate
289 (frans)-4-((5-(2-((3-Ethylbenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2A7- tetrazol-2-yl)methyl)cyclohexanecarboxylιc acid
290 Λ/-(3-Ethylbenzyl)-4-(2-(((^ans)-4-carbamoylcyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
291 (trans)-Me\by\ 4-((5-(2-((3-Cyanobenzyl)carbamoyl)-6-methylpyπdιn-4- yl)-2/-/-tetrazol-2-yl)methyl)cyclohexanecarboxylate
292 (frans)-4-((5-(2-((3-Cyanobenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexanecarboxylιc acid
293 (frans)-Methyl 4-((5-(2-((3-Ethoxybenzyl)carbamoyl)-6-methylpyrιdιn-4- yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate
294 (/rans)-4-((5-(2-((3-Ethoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexanecarboxylιc acid
295 W-(3-Ethoxybenzyl)-4-(2-((((rans)-4-carbamoylcyclohexyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnamιde Table 3
Example Compound Name N o.
296 W-(3-Ethoxybenzyl)-4-(2-(((/Λa/?s)-4-cyanocyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
297 (Zrans)-Methyl 4-((5-(2-((4-Fluoro-3-methoxybenzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2W-tetrazol-2- yl)methyl)cyclohexanecarboxylate
298 ((raπs)-4-((5-(2-((4-Fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-
4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylιc acid
299 N-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4- carbamoylcyclohexyl )methyl )-2H-tetrazol-5-yl)-6- methylpicolinamide
300 N-(4-Fluoro-3-methoxybenzy!)-4-(2-((((rans)-4-cyanocyclohexyl)methyl)-
2H-tetrazol-5-yl)-6-methylpιcolιnamιde
301 (/raπs)-Methyl 4-((5-(2-((3-Chloro-4-f)uorobenzyl)carbamoyl)-6- methylpyπdιn-4-y!)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate
302 (/raπs)-4-((5-(2-((3-Chloro-4-fluorobenzyl)carbamoyl)-6-methylpyrιdιn-4- yl)-2H-tetrazo!-2-y!)methyl)cyclohexanecarboxylιc acid
303 Λ/-(3-Chloro-4-fluorobenzyl)-4-(2-(((<rans)-4- carbamoylcyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
304 Λ/-(3-Chloro-4-fluorobenzyl)-4-(2-(((/rans)-4-cyanocyclohexyl)methyl)-
2AV-tetrazol-5-yl)-6-methy!pιcolιnamιde
305 (^rans)-Methyl 4-((5-(2-((4-Fluoro-3-(trιfluoromethyl)benzyl)carbamoyl)-
6-methylpyrιdιn-4-yl)-2H-tetrazol-2- yl)methyl)cyc!ohexanecarboxylate
306 (frans)-4-((5-(2-((4-Fluoro-3-(tnfluoromethyl)benzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylιc acid
307 Λ/-((2,3-Dιhydrobenzofuran-5-yl)methyl)-4-(2-(((^aπs)-4-
(hydroxymethyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicohnamide
308 W-(3-(Trιfluoromethyl)benzyl)-4-(2-(((frans)-4-
(hydroxyme(hyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
309 /V-(3-(Tπfluoromethoxy)benzy!)-4-(2-(((/rans)-4-
(hydroxymethyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
310 W-(3-Ch!orobenzyl)-4-(2-(((^rans)-4-(hydroxymethyl)cyclohexyl)methyl)-
2/-/-tetrazol-5-yl)-6-methylpιco!ιnamιde
31 1 N-(3-Methylbenzyl)-4-(2-(((/rans)-4-(hydroxymethyl)cyclohexyl)methyl)-
2H-tetrazol-5-yl)-6-methylpιcolιnamιde
312 Λ/-(3-Ethylbenzyl)-4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-
2H-tetrazo!-5-yl)-6-methylpιcolιnamιde
313 W-(3-lsopropoxybenzyl)-4-(2-(((fraπs)-4-
(hydroxymethyl)cyc!ohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
314 Λ/-(3-Ethoxybenzyl)-4-(2-(((/Λaπs)-4-(hydroxymethyl)cyclohexyl)methyl)-
2H-tetrazol-5-yl)-6-methylpιcolιnamιde Table 3
Example Compound Name N o.
315 /V-(3,4-Dιfluorobenzyl)-4-(2-(((frans)-4-
(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
316 /V-(4-Fluoro-3-methylbenzyl)-4-(2-(((fraπs)-4-
(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide
317 N-(4-Flυoro-3-(tnflυoromethy\)benzy\)-4-(2-(((trans)-4-
(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide
318 Λ/-(3-(Hydroxymethyl)benzyl)-4-(2-(((to3/?s)-4-
(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
319 W-(3-Hydroxybenzy!)-4-(2-(((/Λ3/7s)-4-
(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide
320 Λ/-(3-Fluoro-5-methoxybenzyl)-4-(2-(((/rans)-4-
(hydroxymethyl)cyclohexy!)methy!)-2H-tetrazo!-5-yl)-6- methylpicolmamide
321 /V-((2,3-Dihydrobenzofuran-6-yl)methyl)-4-(2-(((<rans)-4-
(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide
322 Λ/-(3-Methoxybenzyl)-4-(2-(((^ans)-4-
(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide
323 Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((trans)-4-
(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
324 Λ/-(3-Bromobenzyl)-4-(2-(((fraπs)-4-(hydroxymethyl)cyclohexyl)methyl)-
2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
325 Λ/-(3-(2-Hydroxyethoxy)benzyl)-4-(2-(((^rans)-4-
(hydroxymethyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
326 Λ/-(3-Propoxybenzyl)-4-(2-(((<rans)-4-
(hydroxymethyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
327 Λ/-((2,3-Dιhydrobenzo[b][1 ,4]dιoxιn-6-yl)methyl)-4-(2-(((/raπs)-4-
(hydroxymethyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
328 4-(2-(((frans)-4-(Hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-W-
((2-methoxypyrιdιn-4-yl)methyl)-6-methylpιcolιnamιde
329 Λ/-(4-Fluoroben2yl)-4-(2-(((^aπs)-4-(hydroxymethyl)cyclohexyl)methyl)-
2/-/-tetrazol-5-yl)-6-methylpιco!ιnamιde
330 Λ/-(3-Methoxybenzyl)-4-(2-(((c/s)-4-(hydroxymethyl)cyclohexyl)methyl)-
2W-tetrazol-5-yl)-6-methy!pιcolιnamιde
331 Λ/-(3-Methoxybenzyl)-4-(2-(((fraπs)-4-(2-hydroxypropan-2- yl)cyclohexyl)methy!)-2H-tetrazol-5-yl)-6-methylpιco!ιnamιde
332 /V-(4-F!uoro-3-methoxybenzyl)-4-(2-(((frans)-4-(2-hydroxypropan-2- yOcyclohexyOmethy^^H-tetrazol-S-yO-θ-methylpicolinamide
333 W-(3-Methoxybenzyl)-4-(2-(((frans)-4-hydroxycyclohexy!)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde Table 3
Example Compound Name N o.
334 W-(3-Methoxybenzyl)-4-(2-(((c/s)-4-hydroxycyclohexyl)methyl)-2AV- tetrazol-5-yl)-6-methylpιcolιnamιde
335 Λ/-(4-Fluoro-3-methylbenzyl)-4-(2-(((/Λans)-4-hydroxycyclohexyl)methyl)-
2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
336 N-(4-Fluoro-3-methylbenzyl)-4-(2-(((cιs)-4-hydroxycyclohexyl)methyl)-
2f/-tetrazol-5-yl)-6-methylpιcolιnamιde
337 /V-(3-Chloro-4-fluorobenzyl)-4-(2-(((/rans)-4-hydroxycyclohexyl)methyl)-
2H-tetrazol-5-y!)-6-methylpιcolιnamιde
338 Λ/-(3-Chloro-4-fluorobenzyl)-4-(2-(((c/s)-4-hydroxycyclohexyl)methyl)-
2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
339 Λ/-(3-Ethoxybenzyl)-4-(2-((((rans)-4-hydroxycyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
340 A/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((^aπs)-4- hydroxycyclohexyl)methyl)-2H-tetrazot-5-yt)-6- methylpicolinamide
341 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((3- oxocyclopentyl)methyl)-2/-/-tetrazol-5-yl)pιcolιnamιde
342 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((1R*,3R*)-3- hydroxycyclopentyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
343 Λac-Λ/-(4-Fluoro-3-methoxybenzy!)-4-(2-(((1 R*,3S*)-3- hydroxycyclopentyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicohnamide
344 Λ/-(3-Methoxybenzyl)-4-(2-(((c/s)-4-hydroxy-4-
(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
345 Λ/-(3-Methoxybenzyl)-4-(2-(((<raπs)-4-hydroxy-4-
(hydroxymethyl)cyclohexyl)methyl)-2/7-tetrazol-5-yl)-6- methylpicolmamide
346 Λ/-(3-(2-Hydroxyethoxy)benzyl)-6-methyl-4-(2-(((frans)-4-
(methylsulfonylmethyl)cyclohexyl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde
347 Λ/-(3-Hydroxybenzyl)-6-methyl-4-(2-(((/rans)-4-
(methylsulfonylmethyl)cyclohexyl)methyl)-2H-tetrazol-5- yl)picolinamide
348 W-(3-Chloro-4-fluorobenzyl)-6-methyl-4-(2-(((<rans)-4-
(methylsulfonylmethyl)cyclohexyl)methyl)-2/-/-tetrazol-5- yl)pιcolιnamιde
349 Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-(((/rans)-4-
(methylsulfonylmethyl)cyclohexyl)methyl)-2H-tetrazol-5- yOpicolinamide
350 Λ/-(3-(Hydroxymethyl)benzyl)-6-methyl-4-(2-(((frans)-4-
(methylsu!fony!methyl)cyc!ohexyl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde
351 /V-(3-Methoxybenzyl)-4-(2-(((frans)-4-(amιnomethyl)cyclohexyl)methyl)-
2H-tetrazol-5-yl)-6-methylpιcolιnamιde
352 W-(3-Methoxybeπzyl)-4-(2-(((^aπs)-4-
(acetamidomethyOcyclohexyOmethyO^H-tetrazol-δ-yO-θ- methylpicolinamide Table 3
Example Compound Name N o.
353 N-(3-Melhoxybenzy\)-6-methy\-4-(2-(((trans)-4-
(methylsulfonamιdomethyl)cyclohexyl)methyl)-2/-/-tetrazol-5- yl)pιcolιnamιde
354 /V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((//-3A7s)-4-
(aminomethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
355 /•ac-Λ/-(3-Methoxybenzyl)-4-(2-(((1/?*,3S*)-3-
(hydroxymethyl)cyclopentyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicohnamide
356 rac-Λ/-(3-Methoxybenzyl)-4-(2-(((1 R*,3S*)-3-
(amιnomethyl)cyclopentyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide
357 rac-/V-(3-Methoxybenzyl)-6-methyl-4-(2-(((1 FT ,3S*)-3-
(methy!su!fonamιdomethyl)cyclopentyl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde
358 A/-(3-Methoxybenzyl)-6-methyl-4-(2-((S)-pιperιdιn-3-ylmethyl)-2H- tetrazo!-5-yl)pιcolιnamιde
359 Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-(((f?)-1-(methylsulfonyl)pιperιdιn-3- yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde
360 Λ/-(3-Methoxybenzyl)-4-(2-(((S)-1-acetylpιperιdιn-3-y!)ιnnethy!)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
361 Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-((f?)-pιperιdιn-3-ylmethyl)-2H- tetrazol-5-yl)pιcolιnamιde
362 Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-(((S)-1 -(methylsulfonyl)pιperιdιn-3- yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde
363 Λ/-(3-Methoxybenzyl)-4-(2-(((R)-1-acetylpιperιdιn-3-yl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
364 Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((S)-pιperιdιn-3-ylmethyl)-
2/-/-tetrazol-5-yl)pιcolιnamιde
365 Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-(((R)-1 -
(methylsulfonyl)pιperιdιn-3-yl)methyl)-2/-/-tetrazol-5- yl)pιcolιnamιde
366 Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((S)-1 -acetylpιperιdιn-3-yl)methy!)-
2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
367 A/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((R)-pipendin-3-ylmethyl)-
2/-/-tetrazol-5-yl)pιcolιnamιde
368 Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-(((S)- 1 -
(methylsulfonyl)pιperιdιn-3-yl)methyl)-2/-/-tetrazol-5- yl)pιcolιnamιde
369 N-(4-Fluoro-3-methoxybenzyl)-4-(2-(((R)-1 -acetylpιperιdιn-3-yl)methyl)-
2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
370 Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((f?)-pyrrolιdιn-3-ylmethyl)-
2H-tetrazol-5-yl)pιcolιnamιde
371 Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-(((S)-1-
(methylsulfonyl)pyrrolιdιn-3-yl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde
372 W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((f?)-1-acetylpyrrolιdιn-3-yl)methyl)-
2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
373 2-((f?)-3-((5-(2-((4-Fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-
4-yl)-2W-tetrazol-2-yl)methyl)pyrrolιdιn-1-yl)-2-oxoethyl acetate Table 3
Example Compound Name N o.
374 Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((f?)-1-(2-hydroxyacetyl)pyrrolιdιπ-3- yl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde
375 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-((1-benzyl-5-oxopyrrolιdιn-3- yl)methyl)-2AY-tetrazol-5-yl)-6-rr)efhylpιcolιnamιde
376 N-(3-(2-Hydroxyethoxy)benzyl)-6-methyl-4-(2-((1 -
(methylsulfonyl)pιperιdιn-4-yl)methyl)-2/-/-tetrazol-5- yl)pιcolιnamιde
377 Λ/-(3-Ethoxybenzyl)-6-methyl-4-(2-((1-(methylsulfonyl)pιpeπdιn-4- yl)methyl)-2A7-tetrazol-5-yl)pιcolιnamιde
378 W-(4-Fluoro-3-methylbenzyl)-6-methyl-4-(2-((1-(methylsulfonyl)pιperιdιn-
4-yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde
379 Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-(pιperιdιn-4-ylmethyl)-2/-/-tetrazol-5- yl)pιco!ιnamιde
380 Λ/-(3-Methoxybenzyl)-4-(2-((1-(2-hydroxy-2-methylpropanoyl)pιperιdιn-4- yl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
381 Λ/-(3-Methoxybenzyl)-4-(2-((1-(3-amιnopropanoyl)pιperιdιn-4-yl)methyl)-
2/-/-tetrazoϊ-5-yl)-6-methylpιcolιnamιde
382 Λ/-(3-Methoxybenzyl)-4-(2-((1-(2-amιnoacetyl)pιperιdιn-4-yl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
383 Λ/-(3-Me(hoxybenzyl)-4-(2-((1-acetylpιperιdιn-4-yl)methyl)-2/-/-tetrazol-5- yl)-6-methylpιcolιnamιde
384 W-(3-Methoxybenzy!)-6-methyl-4-(2-((1-(methylsulfony!)pιperιdιn-4- yl)methyl)-2/-/-tetrazol-5-yl)pιcolιnamιde
385 Λ/-(3-Methoxybenzyl)-4-(2-((1 -ιsobutyrylpιperιdιn-4-yl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnamιde
386 Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-((1-(methylcarbamoyl)pιperιdιn-4- yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde
387 W-(3-Chloro-4-fluoroben2yl)-6-methyl-4-(2-(pιpeπdιn-4-ylme»hyl)-2/-/- tetrazol-5-yl)pιcolιnamιde
388 Λ/-(3-Chloro-4-fluorobenzyl)-6-methyl-4-(2-((1-(methylsulfony!)pιperιdιn-
4-yl)methy))-2H-tetrazol-5-yl)pιcolιnamιde
389 Λ/-(4-Fluoro-3-(trιfluoromethyl)benzyl)-6-methyl-4-(2-(pιperιdιn-4- ylmethyl)-2/-/-tetrazol-5-yl)pιcolιnamιde
390 W-(4-F!uoro-3-(tπfluoromethyl)benzyl)-6-methyl-4-(2-((1-
(methylsulfonyl)pιperιdιn-4-yl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde
391 /V-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-(pιpeπdιn-4-ylmethyl)-2/-/- tetrazol-5-yl)pιcolιnamιde
392 Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((1-
(methylsulfonyl)pιperιdιn-4-yl)methyl)-2W-tetrazol-5- yOpicolinamide
393 A/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((R)-morpholιn-2-ylmethyl)-
2/-/-tetrazol-5-yl)pιcolιnamιde
394 /V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((R)-4-acetylmorpholιn-2-yl)methyl)-
2H-tetrazol-5-yl)-6-methylpιco!ιnamιde
395 /V-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((S)-morpholιn-2-y!methyl)-
2H-tetrazol-5-yl)pιcolιnamιde
396 A/-(4-F!uoro-3-methoxybenzyl)-4-(2-(((S)-4-acetylmorpholιn-2-yl)methy!)-
2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde Table 3
Example Compound Name N o.
397 Λ/-(4-Fluoro-3-methoxybenzyl)-6-methy!-4-(2-(((R)-4-
(methylsulfonyl)morpholιn-2-yl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde
398 Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-((S)-morpholιn-2-ylmethyl)-2AV- tetrazo!-5-yl)ptcolιnamιde
399 Λ/-(3-Methoxybenzyl)-4-(2-(((S)-4-acetylmorpholιn-2-yl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
400 Λ/-(3-Methoxybenzy!)-6-methyl-4-(2-(((R)-4-(methylsu!fonyl)morpholιn-2- yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde
401 rac-4-(2-((1 ,4-Dιoxan-2-yl)methyl)-2/L/-tetrazol-5-yl)-A/-(4-fluoro-3- methoxybenzyl)-6-methylpιcolιnamιde
402 rac-4-(2-((1 ,4-Dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-Λ/-(4-fluoro-3- methylbenzyl)-6-methylpιcolιnamιde
403 rac-Λ/-(3-Methoxybenzyl)-4-(2-(((2S*,5R*)-5-(hydroxymethy!)-1 ,4-dιoxan-
2-yl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
404 Λ/-(3-Methoxybenzyl)-4-(2-(((2S,5R)-5-(hydroxymethyl)- 1 ,4-dιoxan-2- yl)methyl)-2/-/-tetrazol-5-y!)-6-methylpιcolιnamιde
405 Λ/-(3-Methoxybenzyl)-4-(2-(((2f?,5S)-5-(hydroxymethyl)-1 ,4-dιoxan-2- yl)methyl)-2AV-tetrazol-5-yl)-6-methylpιcolιnamιde
406 rac-(2S*,5S*)-Methyl 5-((5-(2-((3-methoxybenzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2- carboxylate
407 rac-(2S*,5S*)-5-((5-(2-((3-Methoxybenzyl)carbamoy!)-6-methylpyrιdιn-4- yl)-2H-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylιc acid
408 rac-/V-(3-Methoxybenzy!)-4-(2-(((2S*,5S*)-5-(2-hydroxypropan-2-yl)-1 ,4- dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
409 rac-/V-(3-Methoxybenzyl)-4-(2-(((2S*,5S*)-5-carbamoyl-1 ,4-dιoxan-2- yl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde
410 rac-N-(3-Methoxybenzyl)-4-(2-(((2S*,5S*)-5-cyano-1 ,4-dιoxan-2- yl)methyl)-2/-/-tetrazol-5-y!)-6-methylpιcolιnamιde
41 1 rac-Λ/-(3-Methoxybenzyl)-4-(2-(((2S*,5/?*)-5-cyano-1 ,4-dιoxan-2- yl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
412 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((2S*,5f?*)-5-(hydroxymethyl)-
1 ,4-dioxan-2-yl)methyl)-2W-(etrazol-5-yl)-6-methylpicolinamide
413 rac-(2S*,5S*)-Methyl 5-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2- carboxylate 14 rac-(2S*,5S*)-5-((5-(2-((4-Fluoro-3-methoxybenzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2- carboxylic acid 15 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((2S*,5S*)-5-(2-hydroxypropan-
2-yl)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide 16 rac-A/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((2S*,5S*)-5-carbamoyl-1 ,4- dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde 17 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((2S*,5S*)-5-cyano-1 ,4-dιoxan-
2-yl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde 18 rac-N-(4-F!uoro-3-methoxybenzy!)-4-(2-(((2S*,5R*)-5-cyano-1 ,4-dιoxan-
2-yl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde Table 3
Example Compound Name N o.
419 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((2S*,5S*)-5-(2-hydroxyacetyl)-
1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde
420 rac-(2S*,5S*)-Methyl 5-((5-(2-((3-chloro-4-fluorobenzyl)carbamoyl)-6- methylpyndin-4-yl)-2AV-tetrazol-2-yl)methyl)- 1 ,4-dιoxane-2- carboxylate
421 rac-(2S*,5S*)-5-((5-(2-((3-Chloro-4-fluorobenzyl)carbamoyl)-6- methylpyπdιn-4-yl)-2W-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2- carboxylic acid
422 rac-Λ/-(3-Methoxybenzyl)-4-(2-(((2R*,5S*)-5-(amιnomethyl)-1 ,4-dιoxan-
2-yl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
423 rac-N-(3-Methoxybenzyl)-6-methyl-4-(2-(((2R*,5S*)-5-
(methylsulfonamιdomethyl)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol- 5-yl)pιcolιnamιde
424 rac-Λ/-(3-Methoxybenzyl)-4-(2-(((2/?*,5S*)-5-(acetamιdomethyl)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde 25 W-(3-Methoxybenzyl)-6-methyl-4-(2-((tetrahydrofuran-2-yl)methyl)-2H- tetrazol-5-yl)pιcolιnamιde 26 Λ/-(4-Fluoro-3-methylbenzyl)-6-methyl-4-(2-((tetrahydro-2H-pyran-4- yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde 27 rac-Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2H-pyran-2- yl)methyl)-2/-/-tetrazol-5-yl)pιcolιnamιde 28 (-)-Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2A7-pyran-2- yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde 29 (+)-Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2/-/-pyran-2- yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde 30 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2/-/-pyran-
2-yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde 31 rac-Λ/-(4-Fluoro-3-methylbenzy!)-6-methyl-4-(2-((tetrahydro-2H-pyran-2- yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde 32 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2/-/-pyran-
3-yl)methyl)-2H-tetrazol-5-yl)pιcolιnamtde 33 rac-Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-(((etrahydro-2H-pyran-3- yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde 34 rac-/V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((2S*,5/?*)-5-hydroxy- tetrahydro-2H-pyran-2-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide 35 Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-((1 S*,2S*,4f?*)-7-oxa- bιcyclo[2 2 1]heptan-2-ylmethyl)-2H-tetrazol-5-yl)-6- methylpicolmamide 36 Ethyl 4-((5-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyπdιn-4-yl)-2/-/- tetrazol-2-yl)methyl)bιcyclo[2 2 2]octane-1-carboxylate 37 4-((5-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol-2-yl)methyl)bιcyclo[2 2 2]octane-1-carboxylιc acid38 W-(3-Methoxybenzyl)-4-(2-((4-(hydroxymethyl)bιcyclo[2 2 2]octan-1- yl)methy!)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde 39 4-(2-((4-(Hydroxymethyl)pentacyclo[4 2 0 O25 O3 β O4 7]oct-1 -yl)methyl)-
2/-/-tetrazol-5-yl)-Λ/-(3-methoxybenzyl)-6-methylpyrιdιne-2- carboxamide 40 4-((5-(2-(((3-Methoxybenzyl)amιno)carbonyl)-6-methylpyrιdιn-4-yl)-2/-/- tetrazol-2-yl)methyl)cubane-1-carboxylιc acid Table 3
Example Compound Name N o.
441 4-(2-((4-(Amιnocarbony!)pentacyclo[4 2 0 O25 O3 8 O4 7]oct-1-yl)methyl)-
2H-tetrazol-5-yl)-/V-(3-methoxybenzyl)-6-methylpyrιdιne-2- carboxamide
442 4-(2-((4-Cyanopentacyclo[4 2 0 O2 5 O3 8 O4 7]oct-1-yl)methyl)-2H-tetrazol-
5-yl)-N-(3-methoxybenzyl)-6-methylpyπdιne-2-carboxamιde
443 Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-((S)-3-methylbutan-2-yl)-2H- tetrazol-5-yl)pιcolιnamιde
444 Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-((R)-3-hydroxy-2-methylpropyi)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
445 W-(4-Fluoro-3-methoxybenzyl)-4-(2-((S)-3-hydroxy-2-methylpropyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
446 Λ/-(4-Fluoro-3-methylbenzyl)-4-(2-ιsobutyl-2H-tetrazol-5-yl)-6- mefhylpicolinamide
447 N-(4-Fluoro-3-methoxybenzyl)-4-(2-ιsobutyl-2H-tetrazol-5-yl)-6- methylpicolmamide
448 /V-(3-Methoxybenzyl)-4-(2-ιsobutyl-2AY-tetrazol-5-yl)-6- methylpicohnamide
449 6-((4-(2-lsobutyl-2/-/-tetrazol-5-yl)-2-methylpιcolιnamιdo)methyl)-1 /-/- ιndole-2-carboxamιde
450 Λ/-(3-me(hoxybenzyl)-4-(1 -(((fraπs)-4-amιnocyclohexyl)methyl)-1 H-1 ,2,4- trιazol-3-yl)-6-methylpιcolιnamιde
451 Λ/-(3-Methoxybenzyl)-6-methyl-4-(1-(((fraπs)-4-
(methylsulfonamιdo)cyclohexyl)methyl)-1 H- 1 ,2,4-trιazol-3- yl)pιcolιnamιde
452 Λ/-(3-Methoxybenzyl)-4-(1 -(((<rans)-4-acetamιdocyclohexyl)methy!)-1/-/-
1 ,2,4-trιazol-3-yl)-6-methylpιcolιnamιde
453 2-((^ans)-4-((3-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-
1H-1 ,2,4-trιazol-1 -yl)methyl)cyclohexylamιno)-2-oxoethyl acetate
454 Λ/-(3-Methoxybenzyl)-4-(1-(((frans)-4-(2- hydroxyacetamιdo)cyc!ohexyl)methy!)-1 H-1 ,2,4-tπazol-3-yl)-6- methylpicohnamide
455 /V-(4-Fluoro-3-methoxybenzyl)-4-(1 -(((/rans)-4-amιnocyclohexyl)methyl)-
1H-1 ,2,4-trιazol-3-yl)-6-methylpιcolιnamιde 56 Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(1-(((<rans)-4-
(methylsulfonamido)cyclohexyl)methy!)-1H-1 ,2,4-triazol-3- yOpicolmamide 57 W-(4-Fluoro-3-methoxybenzyl)-4-(1 -({(trans)-4- acetamιdocyclohexyl)methyl)-1 H-λ ,2,4-trιazol-3-yl)-6- methylpicolmamide 58 2-((frans)-4-((3-(2-((4-Fluoro-3-methoxybenzyl)carbamoyl)-6- methylpyrιdιn-4-y|)-1 H-1 ,2,4-trιazol-1 - yl)methyl)cyclohexylamιno)-2-oxoethyl acetate 59 Ay-(4-Fluoro-3-methoxybenzyl)-4-(1-(((^aπs)-4-(2- hydroxyacetamιdo)cyclohexyl)methyl)-1 H-1 ,2,4-trιazol-3-yl)-6- methylpicolinamide 60 W-(4-Fluoro-3-methylbenzyl)-4-(1 -((((rans)-4-amιnocyclohexyl)methyl)-
1 H-1 ,2,4-trιazol-3-yl)-6-methylpιcolιnamιde Table 3
Example Compound Name N o.
461 Λ/-(4-Fluoro-3-methylbenzyl)-6-methyl-4-(1-(((frans)-4-
(methylsulfonamιdo)cyclohexyl)methyl)-1 H- 1 ,2,4-trιazol-3- yl)picolinamide
462 Λ/-(4-Fluoro-3-methylbenzyl)-4-(1-(((/Λa/?s)-4- acetamidocyclohexyl)methyl)-1H-1 ,2,4-triazol-3-yl)-6- methylpicolinamide
463 2-((/rans)-4-((3-(2-((4-Fluoro-3-methylbenzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-1H-1 ,2,4-trιazol-1- yl)methyl)cyclohexylamιno)-2-oxoethyl acetate
464 N-(4-Fluoro-3-methylbenzyl)-4-(1-(((/rans)-4-(2- hydroxyacetamιdo)cyclohexyl)methyl)-1H-1 ,2,4-trιazol-3-yl)-6- methylpicohnamidemide
465 Λ/-(3-Methoxybenzyl)-4-(1-(((trans)-4-
(hydroxymethyl)cyclohexyl)methyl)-1 H- 1 ,2,4-trιazol-3-yl)-6- methylpicolmamide
466 rac-Λ/-(3-Methoxybenzyl)-4-(1 -(((2S*,5/?*)-5-(hydroxymethyl)-1 ,4-dιoxan-
2-yl)methyl)-1H-1 ,2,4-trιazol-3-yt)-6-methylpιcolιnamιde
467 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-4-(1-(((2S*)5fr)-5-(hydroxymethyl)-
1 ,4-dιoxan-2-yl)methyl)-1H-1 ,2,4-trιazol-3-yl)-6- methylpicolinamide
468 rac-Λ/-(4-Fluoro-3-methylbenzyl)-4-(1 -(((2S*,5R*)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-1H-1 ,2,4-trιazol-3-yl)-6-methylpιcolιnamιde
Another embodiment of the invention is a pharmaceutical composition comprising a compound as described heremabove, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent Another embodiment of the invention is a method for inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal an MMP-13 inhibiting amount of a compound described heremabove, or a pharmaceutically acceptable salt thereof
Another embodiment of the invention is a method for treating a disease mediated by an MMP- 13 enzyme, comprising administering to a patient suffering from such a disease a nontoxic effective amount of a compound described heremabove, or a pharmaceutically acceptable salt thereof
Another embodiment of the invention is a method for treating arthritis, comprising administering to a patient suffering from an arthritis disease a nontoxic antiarthritic effective amount of a compound described heremabove, or a pharmaceutically acceptable salt thereof
Another embodiment of the invention is a method for treating osteoarthritis, comprising administering to a patient suffering from osteoarthritis a nontoxic effective amount of a compound described heremabove, or a pharmaceutically acceptable salt thereof
Another embodiment of the invention is a method for treating rheumatoid arthritis, comprising administering to a patient suffering from rheumatoid arthritis a nontoxic effective amount of a compound described heremabove, or a pharmaceutically acceptable salt thereof Another embodiment of the invention is a method for treating psoriatic arthritis, comprising administering to a patient suffering from psoriatic arthritis a nontoxic effective amount of a compound described hereinabove, or a pharmaceutically acceptable salt thereof
Another embodiment of the invention is a method for treating a cancer, comprising administering to a patient suffering from a cancer a nontoxic anti-cancer effective amount of a compound described hereinabove, or a pharmaceutically acceptable salt thereof
Another embodiment of the invention is a method for treating inflammation, comprising administering to a patient suffering from inflammation a nontoxic effective amount of a compound described hereinabove, or a pharmaceutically acceptable salt thereof Another embodiment of the invention is a method for treating chronic obstructive pulmonary disease, comprising administering to a patient suffering from chronic obstructive pulmonary disease a nontoxic effective amount of a compound described hereinabove, or a pharmaceutically acceptable salt thereof
Another embodiment of the invention is a method for treating psoriasis, comprising administering to a patient suffering from psoriasis a nontoxic effective amount of a compound described hereinabove, or a pharmaceutically acceptable salt thereof.
Another embodiment of the invention is a method for treating asthma, comprising administering to a patient suffering from asthma a nontoxic effective amount of a compound described hereinabove, or a pharmaceutically acceptable salt thereof Another embodiment of the invention is a method for treating inflammatory bowel disease, comprising administering to a patient suffering from inflammatory bowel disease a nontoxic effective amount of a compound described hereinabove, or a pharmaceutically acceptable salt thereof
For the purposes of this invention, the term "arthritis", which is synonymous with the phrase "arthritic condition", includes osteoarthritis, rheumatoid arthritis, degenerative joint disease, spondyloarthropathies, gouty arthritis, systemic lupus erythematosus, juvenile arthritis, and psoriatic arthritis An allosteric inhibitor of MMP-13 having an anti-arthritic effect is a compound as defined above that inhibits the progress, prevents further progress, or reverses progression, in part or in whole, of any one or more symptoms of any one of the arthritic diseases and disorders listed above
As used herein, the term "alkyl" refers to a straight or branched chain monovalent hydrocarbon radical For example, a C1-6 alkyl radical is a straight or branched chain monovalent hydrocarbon radical having 1 to 6 carbon atoms Examples of C1-6 alkyl radicals include methyl, ethyl, 1 -propyl, 2- propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, and 1 -hexyl
As used herein, the term "alkylene" refers to a straight or branched chain divalent hydrocarbon radical For example, a C1^ alkylene radical is a straight or branched chain divalent hydrocarbon radical having 1 to 6 carbon atoms Examples of C1^ alkylene radicals include methylene, ethylene, 1 - propylene, 2-propylene, 1 -butylene, 2-butylene, 2,2-dιmethylethylene, 1 -pentylene, 2-pentylene, 2,2- dimethylpropylene, and 1-hexylene
As used herein, the term "cycloalkyl" refers to a cyclic monovalent hydrocarbon radical For example, a C3-6 cycloalkyl radical is a cyclic monovalent hydrocarbon radical having 1 to 6 carbon atoms Examples of C3-6 cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl
The term "IC50" means the concentration of a compound, usually expressed as μM or nM, required to inhibit an enzyme's catalytic activity by 50% As used herein, the phrase "cartilage damage" means a disorder of hyaline cartilage and subchondral bone characterized by hypertrophy of tissues in and around the involved joints, which may or may not be accompanied by deterioration of hyaline cartilage surface
The phrase "treating", which is related to the terms "treat" and "treated", means administration of an invention combination as defined above that inhibits the progress, prevents further progress, or reverses progression, in part or in whole, of any one or more symptoms of any one of the diseases and disorders listed above
The phrase "invention compound" means a compound of Formula I, or a pharmaceutically acceptable salt thereof, as fully defined above
The term "NSAID" is an acronym for the phrase "nonsteroidal anti-inflammatory drug", which means any compound which inhibits cyclooxygenase-1 ("COX-1") and cyclooxygenase-2 Most NSAIDs fall within one of the following five structural classes (1 ) propionic acid derivatives, such as ibuprofen, naproxen, naprosyn, diclofenac, and ketoprofen, (2) acetic acid derivatives, such as tolmetin and sulindac, (3) fenamic acid derivatives, such as mefenamic acid and meclofenamic acid, (4) biphenylcarboxylic acid derivatives, such as diflunisal and flufenisal, and (5) oxicams, such as piroxim, peroxicam, sudoxicam, and isoxicam Other useful NSAIDs include aspirin, acetominophen, indomethacin, and phenylbutazone Selective inhibitors of cyclooxygenase-2 as described above may be considered to be NSAIDs also
A selective inhibitor of COX-2 is a compound that inhibits COX-2 selectively versus COX-1 such that a ratio of IC50 for a compound with COX-1 divided by a ratio of IC50 for the compound with COX-2 is greater than, or equal to, 5, where the ratios are determined in one or more assays All that is required to determine whether a compound is a selective COX-2 inhibitor is to assay a compound in one of a number of well know assays in the art
The term "drugs", which is synonymous with the phrases "active components", "active compounds", and "active ingredients", includes celecoxib, or a pharmaceutically acceptable salt thereof, valdecoxib, or a pharmaceutically acceptable salt thereof, and an allosteric inhibitor of MMP- 13, and may further include one or two of the other therapeutic agents described above
An allosteric inhibitor of MMP-13 is any compound of Formula I that binds allosterically into the S1 ' site of the MMP- 13 enzyme, including the S1 ' channel, and/or the S1 " site, without ligating, coordinating, or binding the catalytic zinc of the MMP-13 Certain of the invention compounds possess one or more chiral centers, and each center may exist in the R or S configuration The scope of the present invention encompasses any diastereomeric, enantiomeric, or epimeric form of invention compound, as well as mixtures thereof Compounds of Formula I may be prepared as single enantiomer or as a mixture of individual enantiomers which includes racemic mixtures Methods to obtain preferentially a single enantiomer from a mixture of individual enantiomers or a racemic mixture are well known to those ordinarily skilled in the art of organic chemistry Such methods include but are not limited to preferential crystallization of diastereomeric salts (e g tartrate or camphor sulfonate), covalent denvatization by a chiral, non- racemic reagent followed by separation of the resulting diastereomers by common methods (e g crystallization, chromatographic separation, or distillation) and chemical reversion to scalemtc compound, Simulated Moving Bed technology, or high/mediυm-pressure liquid chromatography employing a chiral stationary phase These techniques may be performed on the final compounds of Formula I or on any intermediates to compounds of Formula I which bear a stereogenic center Also, to facilitate separation by any of the methods described above, the compounds of Formula I or any intermediates to the compounds of Formula I which bear a stereogenic center may be transiently reacted with an achiral reagent, separated, and then reverted to scalemic compound by standard synthetic techniques
Additionally, certain invention compounds may exist as geometric isomers such as the entgegen (E) and zusammen (Z) isomers of 1 ,2-dιsubstιtuted alkenyl groups or cis and trans isomers of disubstituted cyclic groups Any cis, trans, syn, anti, entgegen (E), or zusammen (Z) isomer of a compound of Formula I, as well as mixtures thereof, is encompassed within the scope of the present invention
Certain invention compounds can exist as two or more tautomeric forms Tautomeric forms of the invention compounds may interchange, for example, via enolization/de-enolization, 1 ,2-hydrιde, 1 ,3-hydrιde, or 1 ,4-hydrιde shifts, and the like Any tautomeric form of a compound of Formula I, as well as mixtures thereof, Is encompassed within the scope of the present invention
Some compounds of the present invention have cycloalkyl groups, which may be substituted at more than one carbon atom, in which case all geometric forms thereof, both cis and trans, and mixtures thereof, are within the scope of the present invention
Encompassed within the scope of the present invention are isotopically-labelled compounds of Formula I, which are identical to those recited above, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 180, 17O1 31 P, 32P, 35S, 18F and 36Cl, respectively Compounds of the present invention and pharmaceutically acceptable salts of said compounds which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention Certain isotopically labelled compounds of the present invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays Tritiated, i e , 3H and carbon-14, i e , 14C, isotopes are particularly preferred for their ease of preparation and detectability Further, substitution with heavier isotopes such as deuterium, i e , 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances Isotopically labelled compounds of those described above in this invention can generally be prepared by carrying out the procedures incorporated by reference above or disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent
Some of the invention compounds are capable of further forming nontoxic pharmaceutically acceptable salts, including, but not limited to, acid addition and/or base salts The acid addition salts are formed from basic invention compounds, whereas the base addition salts are formed from acidic invention compounds All of these forms are within the scope of the compounds useful in the invention
Pharmaceutically acceptable acid addition salts of the basic invention compounds include nontoxic salts derived from inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, hydrofluoric, phosphorous, and the like, as well nontoxic salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, tnfluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, malate, tartrate, methanesulfonate, and the like Also contemplated are salts of amino acids such as arginate and the like and gluconate or galacturonate An acid addition salt of a basic invention compound is prepared by contacting the free base form of the compound with a sufficient amount of a desired acid to produce a nontoxic salt in the conventional manner The free base form of the compound may be regenerated by contacting the acid addition salt so formed with a base, and isolating the free base form of the compound in the conventional manner The free base forms of compounds prepared according to a process of the present invention differ from their respective acid addition salt forms somewhat in certain physical properties such as solubility, crystal structure, hygroscopicity, and the like, but otherwise free base forms of the invention compounds and their respective acid addition salt forms are equivalent for purposes of the present invention
A nontoxic pharmaceutically acceptable base addition salt of an acidic invention compound may be prepared by contacting the free acid form of the compound with a metal cation such as an alkali or alkaline earth metal cation, or an amine, especially an organic amine Examples of suitable metal cations include sodium cation (Na"), potassium cation (K*), magnesium cation (Mg2+), calcium cation (Ca2*), and the like Examples of suitable amines are N,N'-dιbenzylethylenedιamιne, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamme, A/-methylglucamιne, and procaine
A base addition salt of an acidic invention compound may be prepared by contacting the free acid form of the compound with a sufficient amount of a desired base to produce the salt in the conventional manner The free acid form of the compound may be regenerated by contacting the salt form so formed with an acid, and isolating the free acid of the compound in the conventional manner The free acid forms of the invention compounds differ from their respective salt forms somewhat in certain physical properties such as solubility, crystal structure, hygroscopicity, and the like, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention
Certain invention compounds can exist in unsolvated forms as well as solvated forms, including hydrated forms In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are encompassed within the scope of the present invention
The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined above, together with a pharmaceutically acceptable carrier, diluent, or excipient
The present invention also relates to the formulation of a compound of the present invention alone or with one or more other therapeutic agents which are to form the intended combination, including wherein said different drugs have varying half-lives, by creating controlled-release forms of said drugs with different release times which achieves relatively uniform dosing, or, in the case of non- human patients, a medicated feed dosage form in which said drugs used in the combination are present together in admixture in the feed composition There is further provided in accordance with the present invention co-administration in which the combination of drugs is achieved by the simultaneous administration of said drugs to be given in combination, including co-administration by means of different dosage forms and routes of administration, the use of combinations in accordance with different but regular and continuous dosing schedules whereby desired plasma levels of said drugs involved are maintained in the patient being treated, even though the individual drugs making up said combination are not being administered to said patient simultaneously
A therapeutically effective amount, or, simply, effective amount, of a compound of Formula I will generally be from about 1 to about 300 mg/kg of subject body weight of the compound of Formula I, or a pharmaceutically acceptable salt thereof Typical doses will be from about 10 to about 5000 mg/day for an adult subject of normal weight for each component of the combination In a clinical setting, regulatory agencies such as, for example, the Food and Drug Administration ("FDA") in the U S may require a particular therapeutically effective amount
In determining what constitutes a nontoxic effective amount or a therapeutically effective amount of a compound of Formula I for treating, preventing, or reversing one or more symptoms of any one of the diseases and disorders described above that are being treated according to the invention methods, a number of factors will generally be considered by the medical practitioner or veterinarian in view of the experience of the medical practitioner or veterinarian, including the Food and Drug Administration guidelines, or guidelines from an equivalent agency, published clinical studies, the subject's (e g , mammal's) age, sex, weight and general condition, as well as the type and extent of the disease, disorder or condition being treated, and the use of other medications, if any, by the subject As such, the administered dose may fall within the ranges or concentrations recited above, or may vary outside them, ιe, either below or above those ranges, depending upon the requirements of the individual subject, the severity of the condition being treated, and the particular therapeutic formulation being employed Determination of a proper dose for a particular situation is within the skill of the medical or veterinary arts Generally, treatment may be initiated using smaller dosages of the compound of Formula I that are less than optimum for a particular subject Thereafter, the dosage can be increased by small increments until the optimum effect under the circumstance is reached For convenience, the total daily dosage may be divided and administered in portions during the day, if desired
Pharmaceutical compositions, described briefly here and more fully below, of an invention combination may be produced by formulating the invention combination in dosage unit form with a pharmaceutical carrier Some examples of dosage unit forms are tablets, capsules, pills, powders, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers containing either one or some larger number of dosage units and capable of being subdivided into individual doses Alternatively, the compounds of Formula I may be formulated separately
Some examples of suitable pharmaceutical carriers, including pharmaceutical diluents, are gelatin capsules, sugars such as lactose and sucrose, starches such as corn starch and potato starch, cellulose derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, and cellulose acetate phthalate, gelatin, talc, stearic acid, magnesium stearate, vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and oil of theobroma, propylene glycol, glycerin, sorbitol, polyethylene glycol, water, agar, alginic acid, isotonic saline, and phosphate buffer solutions, as well as other compatible substances norrηally used in pharmaceutical formulations
The compositions to be employed in the invention can also contain other components such as coloring agents, flavoring agents, and/or preservatives These materials, if present, are usually used in relatively small amounts The compositions can, if desired, also contain other therapeutic agents commonly employed to treat any of the above-listed diseases and disorders
The percentage of the active ingredients of a compound of Formula I, or a pharmaceutically acceptable salt thereof, in the foregoing compositions can be varied within wide limits, but for practical purposes it is preferably present in a total concentration of at least 10% in a solid composition and at least 2% in a primary liquid composition The most satisfactory compositions are those in which a much higher proportion of the active ingredients are present, for example, up to about 95%
Preferred routes of administration of a compound of Formula I are oral or parenteral However, another route of administration may be preferred depending upon the condition being treated For exampled, topical administration or administration by injection may be preferred for treating conditions localized to the skin or a joint Administration by transdermal patch may be preferred where, for example, it is desirable to effect sustained dosing
It should be appreciated that the different routes of administration may require different dosages For example, a useful intravenous ("IV") dose is between 5 and 50 mg, and a useful oral dosage is between 20 and 800 mg, of a compound of Formula I, or a pharmaceutically acceptable salt thereof The dosage is within the dosing range used in treatment of the above-listed diseases, or as would be determined by the needs of the patient as described by the physician
Compounds of Formula I may be administered in any form Preferably, administration is in unit dosage form A unit dosage form of the compound of Formula I to be used in this invention may also comprise other compounds useful in the therapy of diseases described above A further description of pharmaceutical formulations useful for administering the compounds of Formula I and invention combinations is provided below
The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described herein
The active components of the invention combinations, may be formulated together or separately and may be administered together or separately The particular formulation and administration regimens used may be tailored to the particular patient and condition being treated by a practitioner of ordinary skill in the medical or pharmaceutical arts For the treatment of rheumatoid arthritis, the compounds of the invention may be combined with agents such as TNF-σ inhibitors such as anti-TNF monoclonal antibodies and TNF receptor immunoglobulin molecules (such as Enbrel®), low dose methotrexate, lefunimide, hydroxychloroquine, d-penicillamine, auranofin or parenteral or oral gold
The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of osteoarthritis Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin, COX-2 inhibitors such as etoricoxib and rofecoxib, analgesics and intraarticular therapies such as corticosteroids and hyaluronic acids such as hyalgan and synvisc
The active ingredient of the present invention may be administered in combination with inhibitors of other mediators of inflammation, comprising one or more members selected from the group consisting essentially of the classes of such inhibitors and examples thereof which include, matrix metalloproteinase inhibitors, aggrecanase inhibitors, TACE inhibitors, leucotriene receptor antagonists, IL-1 processing and release inhibitors, ILra, H1 -receptor antagonists, kιnιn-B1 - and B2 - receptor antagonists, prostaglandin inhibitors such as PGD-, PGF- PGI2 - and PGE-receptor antagonists, thromboxane A2 (TXA2-) inhibitors, 5- and 12-lιpoxygenase inhibitors, leukotπene LTC4 - , LTD4/LTE4 - and LTB4 -inhibitors, PAF-receptor antagonists, gold in the form of an aurothio group together with various hydrophilic groups, immunosuppressive agents, e g , cyclospoπne, azathiopπne and methotrexate, anti-inflammatory glucocorticoids, penicillamine, hydroxychloroquine, anti-gout agents, e g , colchicine, xanthine oxidase inhibitors, e g , allopurinol and uricosuric agents, e g , probenecid, sulfinpyrazone and benzbromarone
The compounds of the present invention may also be used in combination with anticancer agents such as endostatin and angiostatin or cytotoxic drugs such as adriamycin, daunomycin, cis- platinum, etoposide, taxol, taxotere and alkaloids, such as vincristine and antimetabolites such as methotrexate
The compounds of the present invention may also be used in combination with antihypertensives and other cardiovascular drugs intended to offset the consequences of atherosclerosis, including hypertension, myocardial ischemia including angina, congestive heart failure and myocardial infarction, selected from vasodilators such as hydralazine, β-adrenergic receptor antagonists such as propranolol, calcium channel blockers such as nifedipine, α2-adrenergιc agonists such as clonidine, α- adrenergic receptor antagonists such as prazosin and HMG-CoA-reductase inhibitors (anti- hypercholesterolemics) such as lovastatin or atorvastatin
The compounds of the present invention may also be administered in combination with one or more antibiotic, antifungal, antiprotozoal, antiviral or similar therapeutic agents
The compounds of the present invention may also be used in combination with CNS agents such as antidepressants (such as sertraline), anti-Parkinsonian drugs (such as L-dopa, requip, mirapex, MAOB inhibitors such as selegine and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, nicotine agonists, dopamine agonists and inhibitors of neuronal nitric oxide synthase) and anti-Alzheimer's drugs such as donepezil, tacrine, COX-2 inhibitors, propentofylline or metryfonate
The compounds of the present invention may also be used in combination with osteoporosis agents such as raloxifene, lasofoxifene, droloxifene or fosomax and immunosuppressant agents such as FK-506 and rapamycin Compounds of Formula I may be used in combination with a COX-2 selective inhibitor, more preferably celecoxib, valdecoxib, parecoxib, lumiracoxib, or rofecoxib, or with compounds such as etanercept, infliximab, leflunomide, or methotrexate, and the like
Compounds of Formula I may be used in combination with biological therapeutics useful for treating arthritic conditions, including CP-870, etanercept (a tumor necrosis factor alpha ("TNF-alpha") receptor immunoglobulin molecule, trade names ENBREL® and ENBREL ENTANERCEPT® by Immunex Corporation, Seattle, Washington), infliximab (an anti-TNF-alpha chimeric IgG 1 K monoclonal antibody, tradename REMICADE® by Centocor, lnc , Malvern, Pennsylvania), methotrexate (tradename RHEUMATREX® by American Cyanamid Company, Wayne, New Jersey), and adalimumab (a human monoclonal anti-TNF-alpha antibody, tradename HUMIRA® by Abbott Laboratories, Abbott Park, Illinois)
The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I1 or a pharmaceutically acceptable salt thereof
The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof
The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof
Other mammalian diseases and disorders which are treatable by administration of an invention combination alone, or contained in a pharmaceutical composition as defined below, include fever (including rheumatic fever and fever associated with influenza and other viral infections), common cold, dysmenorrhea, menstrual cramps, inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, bronchitis, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity, cachexia, allergic reactions, allergic contact hypersensitivity, cancer (such as solid tumor cancer including colon cancer, breast cancer, lung cancer and prostrate cancer, hematopoietic malignancies including leukemias and lymphomas, Hodgkin's disease, aplastic anemia, skin cancer and familiar adenomatous polyposis), tissue ulceration, peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis, recurrent gastrointestinal lesion, gastrointestinal bleeding, coagulation, anemia, synovitis, gout, ankylosing spondylitis, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joint implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic aneurysm and brain aortic aneurysm), periarteritis nodosa, congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neuralgia, neurodegenerative disorders (acute and chronic), autoimmune disorders, Huntmgton's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain (including low back and neck pain, headache and toothache), gingivitis, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, conjunctivitis, abnormal wound healing, muscle or joint sprains or strains, tendonitis, skin disorders (such as psoriasis, eczema, scleroderma and dermatitis), myasthenia gravis, polymyositis, myositis, bursitis, burns, diabetes (including types I and Il diabetes, diabetic retinopathy, neuropathy and nephropathy), tumor invasion, tumor growth, tumor metastasis, corneal scarring, scleritis, immunodeficiency diseases (such as AIDS in humans and FLV, FIV in cats), sepsis, premature labor, hypoprothrombmemia, hemophilia, thyroiditis, sarcoidosis, Behcet's syndrome, hypersensitivity, kidney disease, Rickettsial infections (such as Lyme disease, Erlichiosis), Protozoan diseases (such as malaria, giardia, coccidia), reproductive disorders (preferably in livestock), epilepsy, convulsions, and septic shock
One of ordinary skill in the art will appreciate that the compounds of the invention are useful in treating a diverse array of diseases. One of ordinary skill in the art will also appreciate that when using the compounds of the invention in the treatment of a specific disease that the compounds of the invention may be combined with various existing therapeutic agents used for that disease This invention also relates to a method of or a pharmaceutical composition for treating inflammatory processes and diseases comprising administering a compound of this invention to a mammal, including a human, cat, livestock or dog, wherein said inflammatory processes and diseases are defined as above and said inhibitory compound is used in combination with one or more other therapeutically active agents under the following conditions A) where a joint has become seriously inflamed as well as infected at the same time by bacteria, fungi, protozoa and/or virus, said inhibitory compound is administered in combination with one or more antibiotic, antifungal, antiprotozoal and/or antiviral therapeutic agents;
B) where a multi-fold treatment of pain and inflammation is desired, said inhibitory compound is administered in combination with inhibitors of other mediators of inflammation, comprising one or more members independently selected from the group consisting essentially of
1 NSAIDs,
2 H1 -receptor antagonists, 3 kinin-B, - and B2 -receptor antagonists,
4 prostaglandin inhibitors selected from the group consisting of PGD-, PGF- PGI2 - and PGE-receptor antagonists,
5 thromboxane A2 (TXA2-) inhibitors,
6 5-, 12- and 15-lιpoxygenase inhibitors, 7 leukotπene LTC4 -, LTD4/LTE4 - and LTB4 -inhibitors,
8 PAF-receptor antagonists,
9 gold in the form of an aurothio group together with one or more hydrophilic groups,
10 immunosuppressive agents selected from the group consisting of cyclosporine, azathiopnne and methotrexate,
11 anti-inflammatory glucocorticoids,
12 penicillamine,
13 hydroxychloroquine,
14 anti-gout agents including colchicine, xanthine oxidase inhibitors including allopuπnol, and uricosuric agents selected from probenecid, sulfinpyrazone and benzbromarone, where older mammals are being treated for disease conditions, syndromes and symptoms found in geriatric mammals, said inhibitory compound is administered in combination with one or more members independently selected from the group consisting essentially of
1 cognitive therapeutics to counteract memory loss and impairment,
2 anti-hypertensives and other cardiovascular drugs intended to offset the consequences of atherosclerosis, hypertension, myocardial ischemia, angina, congestive heart failure and myocardial infarction, selected from the group consisting of a diuretics, b vasodilators, c β-adrenergic receptor antagonists, d angiotensm-ll converting enzyme inhibitors (ACE-inhibitors), alone or optionally together with neutral endopeptidase inhibitors, e angiotensin Il receptor antagonists, f renin inhibitors, g calcium channel blockers, h sympatholytic agents, 1 σ2-adrenergιc agonists, j σ-adrenergιc receptor antagonists, and k HMG-CoA-reductase inhibitors (anti-hypercholesterolemics),
3 vinca alkaloids selected from a vinblastine, and b vincristine,
4 growth hormone secretagogues,
5 strong analgesics,
6 local and systemic anesthetics, and
7 H2 -receptor antagonists, proton pump inhibitors and other gastroprotective agents
The invention method is useful in human and veterinary medicines for treating mammals suffering from one or more of the above-listed diseases and disorders
An allosteric inhibitor of MMP-13 may be readily identified by one of ordinary skill in the pharmaceutical or medical arts by assaying an alkyne test compound for inhibition of MMP-13 as described, for example, in Biological Methods 1 or 2 of International Patent Application Pub No WO 04/014366US200400488637179822, the content of which are herein incorporated by reference Allosteric inhibition of MMP-13 may be identified by one of ordinary skill in the pharmaceutical or medical arts by assaying the test invention compound for inhibition of MMP-13 in the presence of an inhibitor to the catalytic zinc of MMP-13 as described, for example, in Biological Methods 3 or 4 of International Patent Application Pub No WO 04/014366US200400488637179822, the content of which are herein incorporated by reference
Further, a compound having an anti-inflammatory, an analgesic, anti-arthritic, or a cartilage damage inhibiting effect, or any combination of these effects, may be readily identified by one of ordinary skill in the pharmaceutical or medical arts by assaying the compound in any number of well known assays for measuring determining the compound's effects on cartilage and or other joint tissue damage, arthritis, inflammation, or pain These assays include in vitro assays that utilize cartilage samples and in vivo assays in whole animals that measure cartilage degradation, inhibition of inflammation, or pain alleviation
For example with regard to assaying cartilage damage in vitro, an amount of a compound or control vehicle may be administered with a cartilage-damaging agent to cartilage such as IL- 1 , and the cartilage damage inhibiting effects in both tests studied by gross examination or histopathologic examination of the cartilage, or by measurement of biological markers of cartilage damage such as, for example, proteoglycan content or hydroxyprolme content, or by biomarkers of type Il collagen degradation such as CTX-II or TIINE (Sunyer et al , Osteo Cartilage 12 (2004) (Suppl B), p P84) Further, in vivo studies to assay cartilage damage and/or joint degeneration may be performed as follows an amount of a compound or control vehicle may be administered with a cartilage damaging agent to an animal or may be administered in the absence of cartilage damaging agents, to animals that have surgery-induced or spontaneous OA lesions in the knee Examples of surgery-induced animal models include the rat medial meniscus tear model or the dog anterior cruciate ligament transaction model The effects of the compound being assayed in the animals for effects on cartilage integrity and/or joint structure may be evaluated by gross examination or histopathologic examination of the affected joιnt(s), and respose to compounds further characterized by measurement of biological markers of cartilage damage such as, for example, proteoglycan content or hydroxyprolme content or biomarkers of type Il collagen degradation such as CTX-II or TIINE in biological fluids such as urine, plasma, serum or synovial fluids Effect of the compounds may also be assessed by observation of the effects in an acute model on functional limitations of the affected joint
Several methods of identifying a compound with cartilage damage inhibiting properties are described below The amount to be administered in an assay is dependent upon the particular assay employed, but in any event is not higher than the well known maximum amount of a compound that the particular assay can effectively accommodate
Similarly, compounds having pain-alleviating properties may be identified using any one of a number of in vivo animal models of pain
Still similarly, compounds having anti-inflammatory properties may be identified using any one of a number of in vivo animal models of inflammation For example, for an example of inflammation models, see United States patent number 6,329,429, which is incorporated herein by reference
Still similarly, compounds having anti-arthritic properties may be identified using any one of a number of in vivo animal models of arthritis For example, for an example of arthritis models, see also United States patent number 6,329,429
Other embodiments of the present invention are compounds described herein, or a pharmaceutically acceptable salt thereof, that are >10, >20, >50, >100, or >1000 times more potent versus MMP-13 than versus at least two of any other MMP enzyme or TACE
Still other aspects of the present invention are compounds of Formula I1 or a pharmaceutically acceptable salt thereof, that are selective inhibitors of MMP-13 versus 2, 3, 4, 5, 6, or 7 other MMP enzymes, or versus TACE and 1 , 2, 3, 4, 5, 6, or 7 other MMP enzymes It should be appreciated that selectivity of a compound of Formula I, or a pharmaceutically acceptable salt thereof, is a multidimensional characteristic that includes the number of other MMP enzymes and TACE over which selectivity for MMP-13 inhibition is present and the degree of selectivity of inhibition of MMP-13 over another particular MMP or TACE, as measured by, for example, the IC50 in μM of the compound for the inhibition of the other MMP enzyme or TACE divided by the IC50 in μM of the compound for the inhibition of MMP-13
As discussed above, one aspect of the present invention is novel compounds that are selective inhibitors of the enzyme MMP-13 A selective inhibitor of MMP-13, as used in the present invention, is a compound that is 25X more potent in vitro versus MMP-13 than versus at least one other matrix metalloproteinase enzyme such as, for example, MMP-1 , MMP-2, MMP-3, MMP-7, MMP- 8, MMP-9, or MMP-14, or versus TACE A preferred aspect of the present invention is novel compounds that are selective inhibitors of MMP-13 versus MMP-1
The invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, which has an IC5O with any MMP enzyme that is less than or equal to 50 μM Preferred are compounds of Formula I1 or a pharmaceutically acceptable salt thereof, which have an IC50 with a human full-length MMP-13 ("hMMP-13FL") or a human MMP-13 catalytic domain ("hMMP-13CD") that is less than or equal to 50 μM More preferred are compounds of Formula I, or a pharmaceutically acceptable salt thereof, which have an IC50 with a human full-length MMP-13 ("hMMP-13FL") or a human MMP-13 catalytic domain ("hMMP-13CD") that is less than or equal to 10 μM Examples of biological methods useful for determining IC50S for compounds with an MMP are described herein The advantages of using an invention compound in a method of the instant invention include the nontoxic nature of the compounds at and substantially above therapeutically effective doses, their ease of preparation, the fact that the compounds are well-tolerated, and the ease of topical, IV, or oral administration of the drugs
Another important advantage is that the present invention compounds more effectively target a particular disease that is responsive to inhibition of MMP-13 with fewer undesirable side effects than similar compounds that inhibit MMP-13 that are not invention compounds This is so because the instant invention compounds of Formula I, or a pharmaceutically acceptable salt thereof, do not directly, or indirectly via a bridging water molecule, ligate, coordinate to, or bind to the catalytic zinc cation of MMP-13, but instead bind at a different location from where natural substrate binds to MMP- 13 The binding requirements of an allosteric MMP-13 binding site are unique to MMP-13, and account for the specificity of the invention compounds for inhibiting MMP-13 over any other MMP enzyme See J Chem Biol , 2005(12), 181 -189 Indeed, prior art inhibitors of MMP-13 bind to the catalytic zinc cations of other MMP enzymes as well as to the catalytic zinc cation of MMP-13, and are consequently significantly less selective inhibitors of MMP-13 enzyme The invention compounds which are invention compounds, and pharmaceutically acceptable salts thereof, are thus therapeutically superior to other inhibitors of MMP-13, or even TACE, because of fewer undesirable side effects from inhibition of the other MMP enzymes or TACE For example, virtually all prior art MMP inhibitors tested clinically to date have exhibited an undesirable side effect known as musculoskeletal syndrome ("MSS") MSS is associated with administering an inhibitor of multiple MMP enzymes or an inhibitor of a particular MMP enzyme such as MMP-1 MSS will be significantly reduced in type and severity by administering the invention compound instead of any prior art MMP-13 inhibitor, or a pharmaceutically acceptable salt thereof The invention compounds are superior to similar compounds that interact with the catalytic zinc cation of the MMP-13 enzyme as discussed above, even if similar compounds show some selectivity for the MMP-13
General Synthetic Procedures
Intermediates for the synthesis of a compound of Formula I, or a pharmaceutically acceptable salt thereof, may be prepared by one of ordinary skill in the art of organic chemistry by adapting various synthetic procedures incorporated by reference above or that are well-known in the art of organic chemistry These synthetic procedures may be found in the literature Alternatively, a skilled artisan may find methods useful for preparing the intermediates in the chemical literature by searching widely available databases such as, for example, those available from the Chemical Abstracts Service, Columbus, Ohio, or MDL Information Systems GmbH (formerly Beilstein Information Systems GmbH), Frankfurt, Germany Preparations of the invention compounds may use starting materials, reagents, solvents, and catalysts that may be purchased from commercial sources or they may be readily prepared by adapting procedures in the references or resources cited above Commercial sources of starting materials, reagents, solvents, and catalysts useful in preparing invention compounds include, for example, The Aldrich Chemical Company, and other subsidiaries of Sigma-Aldrich Corporation, St Louis, Missouri, BACHEM, BACHEM A G , Switzerland, or Lancaster Synthesis Ltd, United Kingdom
Syntheses of some invention compounds may utilize starting materials, intermediates, or reaction products that contain a reactive functional group During chemical reactions, a reactive functional group may be protected from reacting by a protecting group that renders the reactive functional group substantially inert to the reaction conditions employed A protecting group is introduced onto a starting material prior to carrying out the reaction step for which a protecting group is needed Once the protecting group is no longer needed, the protecting group can be removed It is well within the ordinary skill in the art to introduce protecting groups during a synthesis of a compound of Formula I1 or a pharmaceutically acceptable salt thereof, and then later remove them Procedures for introducing and removing protecting groups are well known Thus, for example, protecting groups such as the following may be utilized to protect ammo, hydroxyl, and other groups carboxylic acyl groups such as, for example, formyl, acetyl, and trifluoroacetyl, alkoxycarbonyl groups such as, for example, ethoxycarbonyl, tert-butoxycarbonyl (BOC), /?,/?,/?-tπchloroethoxycarbonyl (TCEC), and /?-ιodoethoxycarbonyl, aralkyloxycarbonyl groups such as, for example, benzyloxycarbonyl (CBZ), para-methoxybenzyloxycarbonyl, and 9-fluorenylmethyloxycarbonyl (FMOC), trialkylsilyl groups such as, for example, trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBDMS), and other groups such as, for example, triphenylmethyl (trityl), tetrahydropyranyl, vinyloxycarbonyl, ortho-nitrophenylsulfenyl, diphenylphosphinyl, para-toluenesulfonyl (Ts), mesyl, tπfluoromethanesulfonyl, and benzyl Examples of procedures for removal of protecting groups include hydrogenolysis of CBZ groups using, for example, hydrogen gas at 50 psi in the presence of a hydrogenation catalyst such as 10% palladium on carbon, acidolysis of BOC groups using, for example, hydrogen chloride in dichloromethane, tπfluoroacetic acid (TFA) in dichloromethane, and the like, reaction of silyl groups with fluoride ions, and reductive cleavage of TCEC groups with zinc metal
The following schemes are representative of the methods that can be used to prepare compounds of Formula I Starting materials may be obtained by procedures described in the schemes, by procedures well known to one of ordinary skill in organic chemistry, and/or may be obtained commercially
The following schemes are representative of the methods that can be used to prepare compounds of Formula I Starting materials may be obtained by procedures described in the schemes, by procedures well known to one of ordinary skill in organic chemistry, and/or may be obtained commercially CHART A
A1 A2
Compounds of formula (I) wherein L is a tetrazole (U = N) or triazole (U = CH) may be prepared as described in Chart A A compound of formula A1 is reacted with an alcohol (G-OH) under Mitsunobu coupling conditions (e g Ph3P, di-tert-butyl azodicarboxylate) wherein G is a group V-Z as described above and in which reactive functional groups may be protected Alternatively, a compound of formula A1 may be reacted with a compound G-X in the presence of a base (e g tertiary amine, sodium hydride) wherein X is Cl, Br, I, alkylsulfonate ester, or arylsulfonate ester The reagents G-OH or G-X are either commercially available or prepared as described below (Charts J - X) The above reaction conditions may afford one or more positional isomers about the five-membered heterocycle including A2 (Chart A), B1 , or B2 (Chart B) Determination of the structural isomer formed is readily possible by someone skilled in the art employing NMR techniques (e g H1 , gHSQC, gHMBC, gHMBC-N15, and 1d NOE experiments) or single crystal X-ray analysis
CHART B
B1 B2
CHART C
C4 C3
Compounds of the formula A1 employed in Chart A are prepared as described in Charts C - H below Hydrolysis of 4,6-dιchloropyπmιdιnes of the formula C1 under strongly acidic conditions provide compounds of the formula C2 (Henze, H R J Org Chem 1952, 77, 1320-1326) Compounds of the formula C1 are commercially available (Y = H and CH3) or may be prepared by literature procedures wherein Y = (CH2)L3CH3, CH(CH3)C2H5, and CH2CH(CHs)2 (Henze, H R J Org Chem 1952, 77, 1320-1326), Y = CH(CH3)2 (Gershon, H J Med Chem 1964, 7, 808-81 1 ), Y = CF3 (Inoue, S J Org Chem 1961 , 26, 4504-4508), Y = CH2F (Elvidge, J A J Chem Soc , C, 1968, 2188-2198) or by analogous procedures to those described in these references Carbonylation of compounds C2 with carbon monoxide and an alcohol solvent (e g methanol) in the presence of a palladium catalyst provides esters of the formula C3 Subsequent chlorination of esters C3 followed by reaction with tetraethylammonium cyanide provides compounds of the formula C5 The reaction of cyano derivatives with sodium azide in the presence of zinc bromide provides the tetrazoles C6 which subsequently are reacted with a primary amine of the formula W-NH2 to provide compounds of the formula C7 Alternatively, cyano derivatives C5 may be reacted with the amine W-NH2 first to provide C8 which subsequently is subjected to tetrazole formation to provide C7
CHART D
D4
Compounds of the formula A1 employed in Chart A wherein Q is N and U is CH may be prepared as described in Chart D starting from 4,6-dιchloropyrιmιdιnes of the formula C1 obtained as described above Carbonylation of compounds C1 with carbon monoxide and an alcohol solvent (e g methanol) in the presence of a palladium catalyst provides esters of the formula D1 Treatment of esters D1 with less than two equivalents of a primary amine of the formula W-NH2 affords amides D2 which are then subsequently reacted with ammonia to provide bis-amides of the formula D3 Condensation of D3 with dimethylformamide dimethylacetal followed by reaction with hydrazine (Mustazza, C J Heterocyclic Chem 2001 , 38, 1 1 19-1 129) affords tπazoles of the formula D4 Alternatively as described in Chart E, triazoles of the formula D4 may be prepared by reacting nitriles of the formula C8 with hydrazine to provide E1 which is then heated with formic acid CHART E
E1
CHART F
F7 Compounds of the formula A1 employed in Chart A wherein Q is CH and U is N may be prepared as described in Chart F Carboxylic acids of the formula F1 are commercially available (Y = H and CH3) or may be prepared by literature procedures wherein Y = CH2CH3 (Tracy, A H J Org Chem 1941 , 6, 70-76), Y = CH2CH2CH3, CH(CH3)2, C(CH3)3 (Libermann, D Bull Soc Chim Fr 1958, 687-694) or by analogous procedures to those described in these references Compounds F1 may be chlorinated (e g POCI3, PCI5) and then reacted with tert-butylamme to provide compounds of the formula F3 Further oxidation of secondary amides F3 by treatment with POCI3 affords the corresponding nitriles F4 The reaction of cyano derivatives F4 with sodium azide in the presence of zinc bromide provides the tetrazoles F5 Carbonylation of compounds F5 with carbon monoxide and an alcohol solvent (e g methanol) in the presence of a palladium catalyst provides esters of the formula F6 which are subsequently reacted with a primary amine of the formula W-NH2 to provide compounds of the formula F7
CHART G
Alternatively, compounds of the formula A1 employed in Chart A wherein Q is CH and U is N may be prepared as described in Chart G starting from compounds F1 obtained as described above Compounds F1 may be chlorinated (e g POCI3, PCI5) and then reacted with an alkanol (e g methanol) to provide compounds of the formula G1 Cyanation of G1 in the presence of a palladium catalyst affords G2 which is subsequently hydrolyzed under basic conditions (e Q potassium hydroxide) to provide carboxylic acids of the formula G3 Esterification of carboxylic acids G3 with pentafluorophenyl trifluoroacetate affords diesters of the formula G4 The sequential addition of a primary amine of the formula W-NH2 followed by ammonia provides amides G5 Dehydration of the primary amide by treatment with POCI3 affords the corresponding nitriles G6 which react with sodium azide to provide tetrazoles of the formula G7 Intermediates of the formula G5 may also be transformed to triazole derivatives useful in Chart A wherein Q is CH and U is CH as described in Chart H Condensation of primary carboxamides G5 with dimethylformamide dimethylacetal followed by reaction with hydrazine (Mustazza, C J Heterocyclic Chem 2001 , 38, 1 1 19-1 129) affords triazoles of the formula H1
CHART H
H1
CHART I
11 I2
I3
As described in Chart I, compounds of formula I3 may be prepared by reacting a compound of formula 11 (prepared as described in Chart C or Chart F) with an alcohol (G-OH) under Mitsunobu coupling conditions (e g Ph3P, di-tert-butyl azodicarboxylate) to provide I2 wherein G is a group V-Z as described above and in which reactive functional groups may be protected Alternatively, a compound of formula 11 may be reacted with a compound G-X in the presence of a base (e g tertiary amine, sodium hydride) wherein X is Cl, Br, I, alkylsulfonate ester, or arylsulfonate ester The reagents G-OH or G-X are either commercially available or prepared as described below (Charts J - X) The resulting ester is then reacted with a primary amine of the formula W-NH2 to provide compounds of the formula I3 CHART J
J1 J2
CHART K
K1 K1
CHART L
The reagents G-X employed in Chart A and Chart I above wherein X is an alkylsulfonate ester or arylsulfonate ester are prepared by reaction of an alcohol G-OH with and alkyl- or arylsulfonyl chloride in the presence of a base (e g triethylamine or pyridine) Representative examples are shown in Charts J - L wherein the alcohol G-OH may be prepared by literature procedures, e g J1 , tert-butyl (f?)-2-(hydroxymethyl)morpholιne-4-carboxylate and tert-butyl (S)-2-(hydroxymethyl)morpholιne-4- carboxylate (Yanagisawa, H Heterocycles, 1993, 35, 105-109), K1 , (R)-(1 , 4-dιoxan-2-yl)methanol and (S)-(1.4-dιoxan-2-yl)methanol (Kim, H Y Bioorg Med Chem Lett 2005, -/5, 3207-321 1 ) Tosylation of trans-2,5-bιs-(hydroxymethyl)-1 ,4-dιoxane (L1 ) (Summerbell, R K J Am Chem Soc 1954, 76, 6401 -6407) affords rac-((2/?*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4- methylbenzenesulfonate (L2) which upon resolution by chiral supercritical fluid chromatography provides the corresponding (2R,5R)- and (2S,5S)-ιsomers CHART M
M1 M2
CHART N
N1 N2
N3
Additional examples of G-X may be prepared as described below According to Chart M, (5,5- bιs(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (M2) is prepared from rac- ((2R*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (L2) by oxidation under Swern conditions to afford M1 which is then reacted with formaldehyde under basic conditions According to Chart N, rac-(2S*,5R*)-methyl 5-((tosyloxy)methyl)-1 ,4-dιoxane-2-carboxylate (N3) is prepared from trans-dimethyl 1 ,4-dιoxane-2,5-dιcarboxylate (N1 ) (Summerbell, R K J Am Chem Soc 1954, 76, 6401-6407) by first partial saponification to provide carboxylic acid N2 Subsequent reduction of the carboxylic acid functional group with borane dimethylsulfide followed by the reaction of the resulting alcohol with p-toluenesulfonyl chloride in pyridine affords N3
CHART O
01 02
O4 03
05 06
07
According to Chart O, (trans^-cyanocyclohexyOmethyl 4-methylbenzenesulfonate (07) is prepared by reacting 1 ,4-dιoxa-spιro[4 5]decan-8-one with tosyl-methyl-isocyanide in the presence of potassium t- butoxide to afford 1 ,4-dιoxa-spιro[4 5]decane-8-carbonιtrιle (O2) Acidic hydrolysis of the resulting ketal followed by Wittig olefination with methoxy methyl tπphenylphosphonium ylide and acid hydrolysis provides trans-4-formylcyclohexanecarbonιtrιle (05) Reduction of the aldehyde functional group with sodium borohydride and reaction of the resulting alcohol with p-toluenesulfonyl chloride in pyridine affords 07 CHART P
HOv TΛyoη ^ TSOW"~Y°~
O'
P1 P2
P4 P3
P5
According to Chart P, cis- and trans-(4-hydroxy-4-(hydroxymethyl)cyclohexyl)methyl 4- methylbenzenesulfonate (P5) may be prepared by reacting 1 ,4-dιoxaspιro[4 5]dec-8-ylmethanol with p-toluenesulfonyl chloride in pyridine to afford P2 The resulting ketal is subjected to acidic hydrolysis to provide (4-oxocyclohexyl)methyl 4-methylbenzenesulfonate (P3) Epoxidation of ketone P3 with trimethylsulfoxonium ylide affords P4 which upon acid promoted oxirane ring opening provides P5
CHART Q
Q4 Q3
Q5 Q6
According to Chart Q, reagents of the formula G-X including 6-(iodomethyl)-tetrahydro-2H-pyran-3- yl)methanol (Q4) and (5-((tosyloxy)methyl)-tetrahydro-2/-/-pyran-2-yl)methyl acetate (Q6) may be prepared starting from diethylmalonate 6-(lodomethyl)-tetrahydro-2H-pyran-3-yl)methanol (Q4) is prepared analogous to previously described procedures in which diethylmalonate is alkylated with 1 - bromo-3-butene to afford Q2 (Deleπs, G Tetrahedron 1988, 44, 4243-4258) and then subsequently Q2 is reduced with lithium aluminium hydride to afford 2-(but-3-enyl)propane-1 ,3-dιol (Q3) (Ramos Tombo, G M Tetrahedron Lett 1986, 27, 5707-5710) Cyclization of Q3 by reaction with iodine and sodium bicarbonate provides Q4 as a mixture of diastereomers (PCT Application WO2005/080317) The individual isomers of Q4 may be obtained through separation by chiral supercritical fluid chromatography 6-(lodomethy!)-tetrahydro-2/-/-pyran-3-yl)methanol (Q4) may be further reacted with an acetate salt to afford Q5 The resulting alcohol is treated with p-toluenesulfonyl chloride in the presence of an amine base to provide (5-((tosyloxy)methyl)-tetrahydro-2/-/-pyran-2-yl)methyl acetate (06) CHART R
R1 R2
R4 R3
R5 R6
According to Chart R, reagents of the formula G-X including rac-((2R*,5S*)-5-hydroxy-tetrahydro-2H- pyran-2-yl)methyl 4-methylbenzenesulfonate (R3) and (5-hydroxy-5-(hydroxymethyl)-tetrahydro-2/-/- pyran-2-yl)methyl 4-methylbenzenesulfonate (R6) may be prepared (3,4-Dιhydro-2H-pyran-2- yl)methanol (R1 ) is treated with p-toluenesulfonyl chloride in pyridine to afford sulfonylester R2 Analogous to literature precedent (Zhang, S Bioorg Med Chem 2006, 14, 3953-3966), reaction of R2 under hydroboration/oxidation conditions (BH3, NaOH, H2O2) affords rac-((2F?*,5S*)-5-hydroxy- tetrahydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate (R3) Oxidation of R3 under Swern conditions provides (5-oxo-tetrahydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate (R4) Epoxidation of ketone R4 with trimethylsulfoxonium ylide affords R5 which upon acid promoted oxirane ring opening provides R6
CHART S
S1
S3 S2
S4 S5
According to Chart S, re/-(1 R,2S,4S)-7-oxa-bιcyclo[2 2 1]heptan-2-ylmethyl 4-methylbenzenesulfonate may be prepared by initially reacting furan with ethyl acrylate in the presence of zinc iodide to afford the cycloadduct S1 Alkene S1 is then treated with hydrogen and palladium on carbon in ethanol to provide a mixture of isomers which are separated by silica gel chromatography to afford S2 Saponification of S2 with aqueous sodium hydroxide provides carboxylic acid S3 which may be reacted with 1 ,1'-carbonyldιιmιdazole and sodium borohydride to afford alcohol S4 The desired tosylate S5 is provided by reacting the resulting alcohol with p-toluenesulfonyl chloride in the presence of an amine base By employing these same procedures and the other S2 isomer separated by chromatography, re/-(1 R,2S,4S)-7-oxa-bιcyc!o[2 2 1]heptan-2-y!methy! 4-methylbenzenesυlfonate may be prepared
CHART T
T1 T2
T4 T3
According to Chart T, (6-oxopιperιdιn-3-yl)methyl 4-methylbenzenesulfonate (T4) may be prepared by reacting 6-hydroxynιcotιnιc acid (T1 ) with hydrogen in the presence of a palladium catalyst to afford carboxylic acid T2 The resulting acid is treated with 1 ,1 '-carbonyldιιmιdazole and sodium borohydπde to provide alcohol T3 which is then reacted with p-toluenesulfonyl chloride in the presence of an amine base to provide tosylate T4
CHART U
According to Chart U, reagents of the formula G-X may be prepared where lactam carboxylic acids of the formula U1 (where R may include but is not limited to hydrogen, methyl, ethyl, and iso-propyl) obtained as described by E Valentin et al (Tetrahedron Asymmetry, 2001 , 12, 3241 -3249) are reacted with 1 ,1 '-carbonyldιιmιdazole and sodium borohydride to provide alcohols of the formula U2 The resulting alcohols are reacted with p-toluenesulfonyl chloride in the presence of an amine base to provide tosylates of the formula U3 CHART V
V1 V2
V3 V4
According to Chart V, (S)-Λ/-Boc 3-(hydroxymethyl)pyrrolιdιne (V4) is prepared from (R)-1 - phenylethanamine by cyclization with dimethyl 2-oxosuccιnate in refluxing toluene to provide V2 Lactam V2 is then reduced with lithium aluminium hydride to provide ((S)-I -((S)-1 - phenylethyl)pyrrolιdιn-3-yl)methanol (V3) The alcohol is reacted with hydrogen gas in the presence of Pd(OH)2 on carbon, and the resulting amine is treated with di-tert-butyl dicarbonate to provide V4 In a similar manner, (R)-N-Boc 3-(hydroxymethyl)pyrrolιdιne is prepared from (S)-i -phenylethanamιne
CHART W
W1
W2 W3
W4 According to Chart W, reagents of the formula G-X specifically (tetrahydro-2/-/-thιopyran-4-yl)methyl 4- methylbenzenesulfonate (W4) may be prepared Tetrahydrothιopyran-4-one is reacted with lithium chloride and samarium diiodide to afford tetrahydro-2H-thιopyran-4-carbonιtrιle (W1 ) which is then hydrolyzed under basic conditions (e g NaOH) to provide the corresponding carboxylic acid W2 The carboxylic acid is reacted with 1 ,1 '-carbonyldιιmιdazole and sodium borohydride to provide alcohol W3 Tosylate W4 is then prepared by treating W3 with p-toluenesulfonyl chloride in the presence of an amine base
CHART X
X5
According to Chart X, reagents of the formula G-X as depicted in formula X5 may be prepared L- Seπne methyl ester is treated with benzaldehyde and NaBH(OAc)3 to afford benzylamme X1 which is subsequently coupled (BDP, 1 -HOBT, diisopropylethylamme) with Λ/-(tert-butoxycarbonyl)glycιne to provide X2 The tert-butylcarbamate is removed under acidic conditions (HCI/chloroform) and the resulting product is cyclized under basic conditions (5% aq NaHCO3) to provide pιperιzιne-2,5-dιone X3 Piperizine X4 is then prepared by reduction of X3 with a metal hydride (e g lithium aluminium hydride) and the product is subsequently reacted with alkyl sulfonyl chlorides in the presence of an amine base to provide compounds of the formula X5 where R may be but is not limited to methyl, ethyl, propyl, and iso-propyl CHART Y
Compounds of the general formula Y1 and Y2 (wherein J and K are independently CH2 or O) may be further elaborated as described in Chart Y Compounds of the formula Y1 may be oxidized to the carboxylic acid by reaction with an appropriate oxidizing agent (e g pyridinium dichromate) to provide Y3 (X = OH) Similarly, saponification of compounds of the formula Y2 under basic conditions (e g sodium hydroxide) may provide compounds of the formula Y3 (X = OH) Treatment of the resulting carboxylic acids Y3 with oxalyl chloride followed by reaction with ammonia affords the primary amides Y3 (X = NH2) The primary amide may then be reacted with a strong dehydrating agent (e g POCI3) to provide nitriles of the formula Y4
CHART Z
Compounds of the general formula Z1 (wherein J and K are independently CH2 or O) may be further elaborated as described in Chart Z Alcohols of the formula Z1 (X = OH) may be reacted with p- toluenesulfonyl chloride in the presence of an amine base to afford compounds of the formula Z1 (Y = OTs) Subsequent reaction of Z1 (X = OTs) with ammonia in a solvent such as methanol provides amines of the formula Z2 The resulting amine may be reacted with alkyl halides or with alkanals in the presence of a reducing agent to provide compounds of the formula Z3 (R = C,.6alkyl) Alternatively, the amine Z2 may be reacted with carboxylic acid halides to provide compounds of the formula Z3 (R = COR23) or with sulfonyl chlorides to provide compounds of the formula Z3 (R = SO2R37) CHART AA
AA1 AA2
Compounds of the general formula AA1 may be further elaborated as described in Chart AA The amine may be reacted with alkyl halides or with alkanals in the presence of a reducing agent to provide compounds of the formula AA2 (R = C,.6alkyl) Alternatively, the amine AA1 may be reacted with carboxylic acid halides to provide compounds of the formula AA2 (R = COR9) or with sulfonyl chlorides to provide compounds of the formula AA2 (R = SO2R36)
CHART BB
BB1 BB2
Compounds of the general formula BB1 may be further elaborated as described in Chart BB The amine may be reacted with alkyl halides or with alkanals in the presence of a reducing agent to provide compounds of the formula BB2 (R = C1-6alkyl) Alternatively, the amine BB1 may be reacted with carboxylic acid halides to provide compounds of the formula BB2 (R = COR9) or with sulfonyl chlorides to provide compounds of the formula BB2 (R = SO2R12) CHART CC
CC1 CC2
Compounds of the general formula CC 1 (where X is CH2 or O) may be further elaborated as described in Chart CC The amine may be reacted with alkyl halides or with alkanals in the presence of a reducing agent to provide compounds of the formula CC2 (R = C1-6alkyl) Alternatively, the amine CC1 may be reacted with carboxylic acid halides to provide compounds of the formula CC2 (R = R9) or with sulfonyl chlorides to provide compounds of the formula CC2 (R = R12)
CHART DD
DD1 DD2
As described in Chart DD, compounds of the formula DD1 may be oxidized in the presence of oxone to provide tetrahydrothιopyran-1 ,1 -dιone derivatives of the formula DD2 CHART EE
EE4 EE3
Compounds of formula (I) in which L is an oxadiazole ring may be prepared as described in Chart EE Nitriles of the formula EE1 obtained as described in Chart C and Chart G above are treated with hydroxylamine hydrochloride under basic conditions (e g sodium hydroxide) to provide compounds of the formula EE2 Compounds EE2 are then reacted with compounds of the formula G-CO2H in the presence of an activating agent (e g N-hydroxybenzotriazole) and a coupling reagent (e g polymer supported carbodiimide resin) to afford compounds of the formula EE3 which upon heating in the presence of a base provide EE4
CHART FF
Compounds of formula (I) in which L is a 1 ,2,3-trιazole ring, M is N, and Q is N may be prepared as described in Chart FF Esters of the formula C4 obtained as described in Chart C are reacted with trialkylsilylacetylene (where R may be but not limited to methyl, ethyl, isopropyl) under Sonogashira coupling conditions (e g catalytic CuI1 Ph3P, and (Ph3P)2PdCI2) to provide alkynes FF1 which are subsequently treated with lithium hydroxide to afford carboxylic acids of the formula FF2 Treatment of FF2 with a primary amine of the formula W-NH2 in the presence of O-(7-azabenzotrιazol-1 -yl)- N,N,N',N'-tetramethyluronιum hexafluorophosphate provides amides of the formula FF3 Cyclization of FF3 with azides of the formula G-N3 in the presence of catalytic copper(ll) sulfate and sodium ascorbate provide 1 ,2,3-trιazoles of the formula FF4 CHART GG
Compounds of formula (I) in which L is a 1 ,2,3-trιazole ring, M is N, and Q is N may be prepared as described in Chart GG Esters of the formula C3 obtained as described in Chart C are reacted with a primary amine of the formula W-NH2 to provide amides of the formula GG1 Treatment of hydroxypyrimidmes GG 1 with oxalyl chloride/DMF affords chloropyrimidines of the formula GG2 Amides GG2 are reacted with trialkylsilylacetylene (where R may be but not limited to methyl, ethyl, isopropyl) under Sonogashira coupling conditions (e g catalytic CuI, Ph3P, and (Ph3P)2PdCI2) to provide alkynes GG3, which are subsequently treated with a fluoride ion source (e g potassium fluoride) to afford terminal alkynes of the formula GG4 Cyclization of GG4 with azides of the formula G-N3 in the presence of catalytic copper(ll) sulfate and sodium ascorbate provide 1 ,2,3-trιazoles of the formula FF4 CHART HH
HH3 HH2
FF4
Compounds of formula (I) in which L is a 1 ,2,3-trιazole ring, M is N, and Q is N may be prepared as described in Chart HH Esters of the formula FF1 obtained as described in Chart FF are reacted with a fluoride ion source (e g potassium fluoride) to afford terminal alkynes of the formula HH 1 Cyclization of HH1 with azides of the formula G-N3 in the presence of catalytic copper(ll) sulfate and sodium ascorbate provide 1 ,2,3-trιazoles of the formula HH2 which are subsequently treated with lithium hydroxide to afford carboxylic acids of the formula HH3 Treatment of HH3 with a primary amine of the formula W-NH2 in the presence of O-(7-azabenzotrιazol-1 -yl)-N,N,N',N'- tetramethyluromum hexafluorophosphate provides amides of the formula FF4 CHART Il
113 112
FF4
Compounds of formula (I) in which L is a 1 ,2,3-trιazole ring, M is N, and Q is N may be prepared as described in Chart Il Esters of the formula C4 obtained as described in Chart C are reacted with trialkylsilylacetylene (where R may be but not limited to methyl, ethyl, isopropyl) under Sonogashira coupling conditions (e g catalytic CuI, Ph3P, and (Ph3P)2PdCI2) to provide alkynes 111 , which are subsequently treated with lithium hydroxide to afford carboxylic acids of the formula II2 Cyclization of II2 with azides of the formula G-N3 in the presence of catalytic copper(ll) sulfate and sodium ascorbate provide 1 ,2,3-trιazoles of the formula II3 Treatment of 113 with a primary amine of the formula W-NH2 in the presence of O-(7-azabenzotrιazol-1 -yl)-N,N,N',N'-tetramethyluronιum hexafluorophosphate provides amides of the formula FF4
Azides of the formula G-N3 employed in Charts FF - Il may be prepared alcohols G-OH obtained commercially or prepared as described in Charts J - X For example, the alcohol G-OH may be converted to a sulfonate ester which is then subjected to substitution by a nucleophilic azide source (e g sodium azide) CHART JJ
JJ3 JJ4 JJ5 JJ6
Reagents of the formula G-X such as ((2S,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4- methylbenzenesulfonate (JJ6) may be prepared as described in Chart JJ /?-Epιchlorohydrιn, JJ 1 , was reacted with benzyl alcohol using boron trifluoride etherate as an acid catalyst to provide the alcohol of formula JJ2 The alcohol of formula JJ2 was reacted with the S-glycidol tosylate using boron trifluoride etherate as an acid catalyst to provide the alcohol of formula JJ3 The alcohol of formula JJ3 was cychzed under basic conditions (e g , aqueous sodium hydroxide) to provide the alcohol of formula JJ4 The alcohol of formula JJ4 was reacted with p-toluenesulfonyl chloride in the presence of an amine base (e g , pyridine) to provide the tosylate of formula JJ5 The benzyl ether of formula JJ5 was reacted with hydrogen gas in the presence of palladium on carbon to provide the alcohol of formula JJ6
CHART KK
FF3 KK1
Compounds of formula (I) in which L is an isoxazole ring, M is N, and Q is N may be prepared as described in Chart KK Alkynes of the formula FF3 described in Chart FF may be reacted with 2- chloro-2-(hydroxyιmιno)-derιvatιves of the formula G-C(NOH)-CI in the presence of an amine base (e g triethylamine) in toluene at temperatures from 20 - 1 10 0C The chloro-hydroxyimines are readily prepared from the corresponding aldehydes by reaction with hydroxylamme hydrochloride and sodium acetate followed by chlorination by Λ/-chlorosuccιnιmιde
CHART LL
Compounds of the general formula Y3 (wherein X is OH, J and K are independently CH2 or O) may be further elaborated as described in Chart LL Compounds of the formula Y3 (X = OH) may be reacted with an amine of the general formula HNR38R39 in the presence of 1 ,1 '-carbonyldιιmιdazole (or other suitable carboxylic acid activating agent) to afford amides of the general formula LL1
CHART MM
MM1 MM2 MM3
Compounds of the general formula MM1 (wherein R is an alkyl group) may be elaborated as described in Chart MM Esters of the formula MM1 may be reacted with an inorganic base (e g sodium hydroxide, lithium hydroxide) in a mixture of water and an organic solvent (e g tetrahydrofuran) to afford carboxylic acids of the formula MM2 Carboxylic acids of the formula MM2 may be reacted with an amine of the formula W-NH2 in the presence of a suitable carboxylic acid activating agent (e g 1 ,1 '-carbonyldιιmιdazole, 1 -hydroxybenzotπazole/1 -ethyl-3-(3'- dιmethylamιnopropyl)carbodιmιde hydrochloride) to afford amides of the formula MM3 Alternatively, esters of the formula MM1 (wherein R is methyl or ethyl) may be reacted with an amine of the formula W-NH2 at temperatures of 20 - 100 0C either neat or in a minimal amount of an organic solvent (e g methanol, tetrahydrofuran, and Λ/,Λ/-dιmethylformamιde) to provide amides of the formula MM3 directly
CHART NN
Compounds of the general formula NN 1 (wherein R is alkyl, J and K are independently CH2 or O) may be further elaborated as described in Chart NN Alcohols of the formula NN 1 (X = OH) may be reacted with p-toluenesulfonyl chloride in the presence of an amine base to afford compounds of the formula NN1 (Y = OTs) Subsequent reaction of NN1 (X = OTs) with the sodium salt of thioalkoxides of the formula HSR23 to afford compounds of the formula NN2 Sulfides of the formula NN2 may be oxidized by 3-chloroperbenzoιc acid to provide sulfones of the formula NN3 Compounds of formula NN2 and NN3 may be further elaborated as described in Chart MM to afford amides of Formula (I)
The compounds of Formula (I) may be prepared as single enantiomer or as a mixture of individual enantiomers which includes racemic mixtures Methods to obtain preferentially a single enantiomer from a mixture of individual enantiomers or a racemic mixture are well known to those ordinarily skilled in the art of organic chemistry Such methods include but are not limited to preferential crystallization of diastereomeric salts (e g tartrate or camphor sulfonate), covalent deπvatization by a chiral, non- racemic reagent followed by separation of the resulting diastereomers by common methods (e g crystallization, chromatographic separation, or distillation) and chemical reversion to scalemic compound, Simulated Moving Bed technology, or high/medium-pressure liquid chromatography or supercritical fluid chromatography employing a chiral stationary phase These techniques may be performed on the final compounds of Formula (I) or on any intermediates to compounds of Formula (I) which bear a stereogenic center Also, to facilitate separation by any of the methods described above, the compounds of Formula (I) or any intermediates to the compounds of Formula (I) which bear a stereogenic center may be transiently reacted with an achiral reagent, separated, and then reverted to scalemic compound by standard synthetic techniques
Detailed Preparative Methods
The detailed examples below illustrate preparation of compounds of this invention Other compounds of this invention may be prepared using the methods illustrated in these examples, either alone or in combination with techniques generally known in the art The following examples are merely illustrative, and not limiting to the remainder of this disclosure in any way
Example 1
/V-(4-Fluoro-3-methoxybenzyl)-6-(2-((frans-4-aminocyclohexyl)methyl)-2H-tetrazol-5- yl)pyrimidine-4-carboxamide
Step 1 Preparation of methyl θ-cvanopyrimidine^-carboxylate
Commercially available methyl 6-chloropyrιmιdιne-4-carboxylate (1 00 g, 5 80 mmol) was taken up in dichloromethane (20 mL) and then treated with tetraethyl ammonium cyanide (0 996 g, 6 37 mmol) and 1 ,4-dιazabιcyclo[2 2 2]octane (0 13 g, 1 2 mmol) The reaction was allowed to stir at room temperature for 0 5 h The reaction was diluted with diethyl ether (40 mL) then washed with water (1 x 25 mL) and brine (1 x 40 mL) The organics were poured onto a silica plug (20 g) and eluted with diethyl ether (200 mL) to afford the title compound as an orange oil (0 85 g, 90%) LC/MS (5%- 95% CH3CN/H2O, 6 mm) 0 267 mm, m/z 164 (M+Na) Step 2 Preparation of methyl 6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxylate
Methyl θ-cyanopyπmidine^-carboxylate (1 43 g, 8 77 mmol) was taken up in methanol (40 mL) and treated with sodium azide (598 mg, 9 20 mmol) and zinc (II) bromide (1 97 g, 8 77 mmol) The reaction was stirred at room temperature for 15 h and then was concentrated This residue was diluted with water (8 mL) and 1 N aqueous hydrochloric acid (40 mL) and stirred one hour The resulting slurry was filtered with the solids washed with water (10 mL) and dried in vacuo to afford the title compound as a yellow solid (1 37 g, 76%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 0 54 mm, m/z 207 (M+H) Step 3 Preparation of 4-fluoro-3-methoxybenzylamιne hydrochloride
A 2G Parr reactor (4842) was charged with 4-fluoro-3-methoxy-benzonιtrιle (133 0 g, 0 88 mol), ethano! (3550 mL), concentrated hydrochloric acid (396 ml, 4 75 mol) and 10% Pd/C with 50% water (13 3 g) The resulting mixture was stirred with heating at 30-33 0C under hydrogen pressure (40-50 psi, first 2 hours refill hydrogen every 20 mm) overnight The reaction mixture was cooled to room temperature, filtered through Celite™ and the filtrate concentrated The residue obtained was treated with acetonitrile (250 mL) and the white solid was filtered, washed with cold acetonitrile and vacuum dried to afford the title compound (140 g, 83%) MS (ES+) m/z 156 (M+H) Elemental analysis found C, 49 97, H, 6 13, N, 7 59 Step 4 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde
Methyl 6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxylate (0 75 g, 3 64 mmol) was taken up in dimethylacetamide (5 mL) and then treated with 4-fluoro-3-methoxybenzylamιne hydrochloride (1 57 g, 8 19 mmol) and triethylamine (1 5 g, 14 mmol) and left to stir for 15 hours at room temperature The mixture was diluted with 1 N aqueous NaOH (15 mL) and then washed with diethyl ether (2 x 10 mL) The mixture was then adjusted to pH 3 with concentrated Hydrochloric acid and stirred with ethyl acetate ( 10 mL) After 1 h, the organic layer was separated and concentrated to an oil that solidified affording the title compound as a beige solid (1 05 g, 88%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 2 26 mm, m/z 330 (M+H) Step 5 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-((frans-4-amιnocvclohexyl)methyl)-2/-/- tetrazol-5-yl)pyrimidine-4-carboxamide
Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (0 91 g, 2 8 mmol) and commercially available tert-butyl /rans-4-(hydroxymethyl)cyclohexylcarbamate (760 mg, 3 32 mmol) were taken up in tetrahydrofuran (20 mL) and treated with polymer supported triphenylphosphine (1 54 g, 3 32 mmol) After stirring for 30 mm at room temperature, di-tert-butyl azodicarboxylate (954 mg, 4 15 mmol) was added After 15 h at room temperature, the reaction was filtered to remove the resin The filtrate was concentrated to a crude oily residue The residue was purified via normal phase chromatography (silica, 0-75% ethyl acetate/heptane with a trace 1 % methanol ran through entire gradient) to afford the protected amine as a mixture of regioisomers ( 0 97 g, 65%, 1 80 mmol) which was subsequently dissolved in dichloromethane (5 mL) and treated with tπfluoroacetic acid (2 0 mL, 15 mmol) After the reaction was stirred at ambient temperature for 3 h, the mixture was diluted with dichloromethane (5 mL) and neutralized with 2 5 N aqueous NaOH to achieve pH 7-8 The organic layer was separated and washed with water (3 mL), dried over sodium sulfate, and concentrated to afford the title compound (0 87 g, 72%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 2 06 mm, m/z 441 (M+H)
Example 2
/V-(4-Fluoro-3-methoxybenzyl)-6-(2-(((rans-4-((methylsulfonyl)amino)cyclohexyl)methyl)-2H- tetrazol-5-yl)pyrimidine-4-carboxamide
Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-((frans-4-amιnocyclohexyl)methyl)-2H-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde (prepared as described in Example 1 ) (0 870 g, 1 98 mmol) was taken up in dichloromethane (5 mL) and treated with methane sulfonyl chloride ( 0 17 mL, 2 1 mmol) and tπethytamine (0 30 mL, 2 2 mmol) After 1 h at room temperature, the reaction was concentrated The residue was purified via reverse phase chromatography (4-60% acetonitrile/water over 45 minutes) with the first eluted compound was isolated to afford the title compound as a white solid (143 mg, 14%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 3 98 mm, m/z 519 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 1 04 - 1 25 (m, 4 H), 1 61 (br s , 2 H), 1 83 - 1 99 (m, 3 H), 2 83 (s, 3 H), 3 00 (br s , 1 H), 3 78 (s, 3 H), 4 46 (d, J=Q 0 Hz, 2 H), 4 66 (d, J=6 6 Hz, 2 H), 6 89 (d, J=I 3 Hz, 2 H), 7 03 - 7 21 (m, 2 H)1 8 56 (s, 1 H), 9 46 (s, 1 H), 9 61 (t, J=6 1 Hz, 1 H) Example 3
W-(3-Chloro-4-fluorobenzyl)-6-(2-((frans-4-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)pyrimidine-
4-carboxamide
Step 1 Preparation of Λ/-(3-chloro-4-fluorobenzyl)-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde
Methyl 6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxylate (prepared as described in step 2 of the synthesis of /V-(4-fluoro-3-methoxybenzyl)-6-(2-((frans-4-ammocyclohexyl)methyl)-2/-/-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde, Example 1 ) (0 72 g, 3 49 mmol) was taken up in dimethylacetamide (5 mL), treated with commercially available (4-fluoro-3-chlorophenyl)methanamιne (1 23 g, 7 68 mmol) and triethylamine (1 95 g, 14 mmol), and left to stir for 15 hours at room temperature The mixture was diluted with 1 N aqueous NaOH (15 mL) and then washed with diethyl ether (2 x 10 mL) The mixture was then adjusted to pH 3 with concentrated Hydrochloric acid, stirred with ethyl acetate (10 mL), and filtered to afford the title compound as a pale yellow solid (0 71 g, 61 %) LC/MS (5%-95% CH3CN/H2O, 6 mm) 2 19 mm, m/z 334 (M+H)
Step 2 Preparation of Ay-(3-chloro-4-fluorobenzyl)-6-(2-((frans-4-amιnocvclohexyl)methyl)-2/-/-tetrazol- 5-yl)pyrιmιdιne-4-carboxamιde
Λ/-(4-Fluoro-3-chlorobenzyl)-6-(2H-tetrazol-5-yl)pyπmιdιne-4-carboxamιde (0 71 g, 2 1 mmol) and commercially available tert-butyl frans-4-(hydroxymethyl)cyclohexylcarbamate (585 mg, 2 55 mmol) were taken up in tetrahydrofuran (20 mL) and treated with polymer supported triphenylphosphme (1 19 g, 2 55 mmol) After stirring for 30 mm at room temperature, di-tert-butyl azodicarboxylate (735 mg, 3 19 mmol) was added After 15 h at room temperature, the reaction was filtered to remove the resin The filtrate was concentrated to a crude oily residue The residue was purified via normal phase chromatography (silica, 0-75% ethyl acetate/heptane with a trace 1 % methanol ran through entire gradient) to afford the protected amine (1 08 g, 93%, 1 99 mmol) which was taken up in dichloromethane (5 mL) and treated with trifluoroacetic acid (2 0 mL, 15 mmol) After the reaction was stirred at ambient temperature for 3 h, the mixture was diluted with dichloromethane (5 mL) and neutralized with 2 5 N aqueous NaOH to achieve pH 7-8 The organic layer was separated, washed with water (3 mL), then dried over sodium sulfate, and concentrated to afford the title compound as an amber oil (0 87 g, 92%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 2 24 mm, m/z 445 (M+H)
Example 4
W-(3-Chloro-4-fluorobenzyl)-6-(2-(((rans-4-((methylsulfonyl)amino)cyclohexyl)methyl)-2H- tetrazol-5-yl)pyrimidine-4-carboxamide
Λ/-(3-Chloro-4-fluorobenzyl)-6-(2-((frans-4-ammocyclohexyl)methyl)-2/-/-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde (prepared as described in Example 3) (0 87 g, 2 0 mmol) was taken up in dichloromethane (5 mL) and treated with methane sulfonyl chloride (0 17 mL, 2 1 mmol) and triethylamine (0 30 mL, 2 2 mmol) After 1 h at room temperature, the reaction was concentrated to a crude residue The residue was purified via reverse phase chromatography (4-60% acetonitrile/water over 45 minutes) The first eluted compound was isolated to afford the title compound as a white solid (105 mg, 10%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 4 22 mm, m/z 523 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 04 - 1 27 (m, 4 H), 1 59 (d, J=10 8 Hz, 2 H), 1 80 - 1 98 (m, 3 H), 2 83 (s, 3 H), 3 01 (d, J=6 8 Hz, 1 H), 4 48 (d, J=6 2 Hz, 2 H), 4 66 (d, J=6 8 Hz, 2 H), 6 89 (d, J=7 3 Hz, 1 H), 7 25 - 7 36 (m, 2 H), 7 48 - 7 58 (m, 1 H), 8 55 (d, J=1 3 Hz, 1 H), 9 46 (d, J=1 1 Hz, 1 H), 9 71 (t, J=6 3 Hz1 1 H)
Example 5 W-(3-Methoxybenzyl)-6-(2-(((frans)-4-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrimidine-4-carboxamide
Step 1 Preparation of 6-chloro-2-methylpyrιmιdιn-4-ol
HCk ^^ ^CI
N^ . N
To a 0 0C solution of 13M sulfuric acid (1 2 L, 15 6 mol) was added portion-wise solid 4,6- dιchloro-2-methylpyrιmιdιne (475 g, 2 91 mol) The resulting mixture was allowed to warm to room temperature over 1 5 hours The solution was poured into a well stirred iced solution of 6N NaOH (3 6 L, 21 6 mol) The resulting solids were then collected by vacuum filtration and washed with warm water (3 x 1 L) High vacuum drying at 35 0C provided the title compound as a white solid (393 4 g, 93%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 0 95 mm, m/z 145 (M+H) 1H NMR (400 MHz, DMSO-^6) δ ppm 12 81 (br s, 1 H), 6 30 (s, 1 H), 2 26 (s, 3 H)
Step 2 Preparation of methyl 6-hvdroxy-2-methylpyrιmιdιne-4-carboxylate
6-Chloro-2-methylpyrιmtdιn-4-ol (36 7 g, 254 mmol), [1 ,1'-bιs(dιphenylphosphιno)ferrocene]- palladιum(ll) dichloride (10 4 g, 12 7 mmol), and dnsopropylethylamine (49 2 g, 381 mmol) were combined in methanol (254 mL) The reaction was heated to 85 0C in the presence of carbon monoxide (10 7 g, 381 mmol, 50 psi) for 24 hours The reaction was allowed to cool to room temperature and the resulting solids collected by vacuum filtration The solids were rinsed with methanol (100 mL) and diethyl ether (2 x 100 mL) Vacuum drying provided the title compound as a brown solid (38 7 g, 91 %) LC/MS (5%-95% CH3CN/H2O, 3 mm 0 29 mm, m/z 169 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 12 79 (br s, 1 H), 6 68 (s, 1 H), 3 79 (s, 3 H), 2 29 (s, 3 H)
Step 3 Preparation of methyl 6-chloro-2-methylpyrιmιdιne-4-carboxylate
Methyl 6-hydroxy-2-methylpyπmιdme-4-carboxylate (30 O g, 178 mmol) was dissolved in dichloromethane (446 mL) Oxalyl chloride (18 6 mL, 1 2 equiv) was added followed by addition of Λ/,Λ/-dιmethylacetamιde (3 5 mL, 0 25 equiv) The mixture was heated to reflux for 2 hours After cooling to room temperature, the insolubles were removed by filtration and the filtrate partially concentrated Purification by silica gel chromatography (35/65, ethyl acetate/heptane) provided the title compound as a white solid (26 6 g, 80%) LC/MS (5%-95% CH3CN/H2O, 4 mm 1 59 mm, m/z 187 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 7 90 (s, 1 H), 3 88 (s, 3 H), 2 65 (s, 3 H)
Step 4 Preparation of methyl 6-cyano-2-methylpyrιmιdιne-4-carboxylate
O
XN
O'
N •.\^ ^N'
Methyl 6-chloro-2-methylpyrimidine-4-carboxylate (30 O g, 161 mmol) was dissolved in dichloromethane (460 mL) Tetraethylammonium cyanide (27 6 g, 177 mmol) was added followed by 1 ,4-dιazabιcyclo[2 2 2]octane (3 60 g, 32 0 mmol) The reaction was stirred for 30 mm at room temperature The reaction mixture was washed with 1 N NaOH (3 x 100 mL), water (2 x 100 mL) and brine (200 mL) The organic layer was dried over sodium sulfate, filtered, and evaporated to give a dark brown solid Purification by silica gel chromatography (2/1 , ethyl acetate/heptane) provided the title compound as a white crystalline solid (24 4 g, 86%) LC/MS (5%-95% CH3CN/H2O, 4 mm 0 96 mm, m/z 178 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 8 38 (s, 1 H), 3 88 (s, 3 H), 2 75 (s, 3 H)
Step 5 Preparation of 6-cvano-Λ/-(3-methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde
3-Methoxybenyzlamιne (9 68 g, 70 6 mmol) and methyl 6-cyano-2-methylpyrιmιdιne-4- carboxylate (10 0 g, 56 4 mmol) were dissolved in Λ/,Λ/-dιmethylacetamιde (1 13 mL) Diisopropylethylamine (25 5 g, 198 mmol) was added and the mixture heated to 100 0C for 2 hours After cooling to room temperature, the mixture was diluted with water (250 mL) and extracted with ethyl acetate (3 x 250 mL) The combined organics were then washed with brine (250 mL) and dried over sodium sulfate, filtered, and evaporated to give a red oil Purification by silica gel chromatography (20/80, ethyl acetate/heptane) provided the title compound as a white solid (14 6 g, 92%) LC/MS (5%- 95% CH3CN/H2O, 4 mm 2 49 mm, m/z 283 (M+H) 1H NMR (400 MHz, DMSOd6) 6 ppm 9 55 (t, J=Q 2 Hz, 1 H), 8 31 (s, 1 H), 7 19 (t, J=8 1 Hz, 1 H), 6 74 - 6 89 (m, 3 H), 4 44 (d, J=6 3 Hz, 2 H), 3 69 (s, 3 H), 2 75 (s, 3 H)
Step 6 Preparation of Λ/-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-vDpyrιmιdιne-4-carboxamιde
6-Cyano-Λ/-(3-methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde (14 2 g, 50 3 mmol), sodium azide (3 60 g, 55 3 mmol), and zinc bromide (1 1 3 g, 50 3 mmol) were suspended in water (1 12 mL) The reaction was heated to reflux for 16 hours After cooling to room temperature, 6N hydrochloric acid (180 mL) was added and the mixture stirred vigorously for 1 hour The solids were collected by vacuum filtration and rinsed with 6N hydrochloric acid (3 x 100 mL) and water (2 x 100 mL) High vacuum drying at 55 0C provided the title compound as a white solid (15 0 g, 92%) LC/MS (5%-95% CH3CN/H2O, 4 mm 2 38 mm, m/z 326 (M+H) 1H NMR (400 MHz, DMSO-dδ) δ ppm 9 53 (t, J=Q 4 Hz, 1 H), 8 42 (s, 1 H), 7 21 (t, J=8 2 Hz, 1 H), 6 86 - 6 91 (m, 2 H), 6 76 - 6 82 (m, 1 H), 4 48 (d, J=Q 6 Hz, 2 H), 3 70 (s, 3 H), 2 82 (s, 3 H) Step 7 Preparation of (frans-4-((terf-butoxγcarbonyl)amιno)cvclohβxyl)methyl 4- methylbenzenesulfonate
p-Toluene sulfonyl chloride (1 68 g, 8 81 mmol) was added to a solution of tert-butyl trans-(4- hydroxymethyl)cyclohexylcarbamate (1 84 g, 8 02 mmol) in pyridine (10 mL) at 0 0C The reaction mixture was allowed to slowly warm to room temperature After 6 h, the mixture was cooled to 0 °C and treated with water (100 mL) The resulting precipitate was filtered, washed with cold water (2 x 20 mL), and dried in vacuo to afford the title compound as a white solid (2 91 g, 95%) 1H NMR (400 MHz, DMSOd6) δ ppm 7 78 (d, J=8 3 Hz, 2 H), 7 49 (d, J=8 2 Hz, 2 H), 6 69 (d, J=8 0 Hz, 1 H), 3 82 (d, J=6 2 Hz, 2 H), 3 04 - 3 14 (m, 1 H), 2 43 (s, 3 H), 1 69 - 1 76 (m, 2 H), 1 57 - 1 64 (m, 2 H), 1 42 - 1 53 (m, 1 H), 1 36 (s, 9 H), 1 01 - 1 12 (m, 2 H), 0 85 - 0 96 (m, 2 H)
Step 8 Preparation of tert-butyl frans-4-((5-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)- 2H-tetrazol-2-yl)methyl)cvclohexylcarbamate
Triethylamine (280 mg, 2 7 mmol) and (frans-4-((fert-butoxycarbonyl)amino)cyclohexyl)methyl 4-methylbenzenesulfonate (530 mg, 1 38 mmol) was added to a solution of Λ/-(3-methoxybenzyl)-2- methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (450 mg, 1 38 mmol) in anhydrous dimethylacetamide (0 5 mL) The reaction was stirred overnight at 85 0C in a capped vial The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitrile) to afford the title compound as a white solid (342 mg)
Step 9 Preparation of /V-(3-methoxybenzyl)-6-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)- 2-methylpyrιmιdtne-4-carboxamιde
4M Hydrochloric acid in dioxane (5 mL) was added to a solution of tert-butyl /rans-4-((5-(6-((3- methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexylcarbamate (342 mg) in acetonitrile (1 5 mL) The reaction was stirred overnight at room temperature The solvent was removed under vacuum and the residue was slurried 2x in ether (ether decanted off each time) and the resultant solid was dried under vacuum to afford the hydrochloride salt of the title compound as a white solid (418 mg)
Example 6
W-(3-Methoxybenzyl)-2-methyl-6-(2-(((frans-4-(methylsulfonamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)pyrimidine-4-carboxamide
Triethylamine (60 mg, 0 6 mmol) and methane sulfonyl chloride (34 mg, 0 3 mmol) were added to a solution of Λ/-(3-methoxybenzyl)-6-(2-(((frans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)- 2-methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 5) (100 mg, 0 19 mmol) in dichloromethane (1 mL) The reaction was stirred overnight at room temperature The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitπle) to afford the title compound as a white solid (41 mg) MS (ES+) m/z 515 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 49 (1 H, br s ), 8 41 (1 H, s), 7 56 (1 H, br s ), 7 22 - 7 30 (1 H, m), 6 93 (2 H, br s ), 6 84 (1 H, br s ), 4 70 (2 H, d, J=7 0 Hz), 4 51 (2 H, d, J=5 9 Hz), 3 74 (2 H, s), 3 05 (2 H, br s ), 2 86 (6 H, d, J=19 8 Hz), 1 90 (3 H, br s ), 1 64 (2 H, br s ), 1 20 (5 H, d, J=11 0 Hz)
Example 7
W-(3-Methoxybenzyl)-6-(2-((frans-4-acetamidocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrimidine-4-carboxamide
Triethylamine (60 mg, 0 6 mmol) and acetic anhydride (31 mg, 0 3 mmol) were added to a solution of N-(3-methoxybenzyl)-6-(2-(((frans)-4-aminocyclohexyl)methy!)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 5) (100 mg, 0 19 mmol) in dichloromethane (1 mL) The reaction was stirred overnight at room temperature The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitrile) and neutralized by passing through a small carbonate column to afford the title compound as a white solid (34 mg) MS (ES+) m/z 479 (M+H) 1H NMR (400 MHz, DMSO-d5) δ ppm 9 49 (1 H, br s ), 8 41 (1 H, s), 7 65 (1 H, d, J=7 7 Hz), 7 33 (1 H, br s ), 7 24 (1 H, s), 6 93 (1 H, br s ), 6 81 (1 H, br s ), 4 70 (2 H, d, J=6 6 Hz), 4 51 (2 H, d, J=6 6 Hz), 3 74 (3 H, s), 3 46 (1 H, br s ), 2 83 (3 H, s), 1 99 (1 H, br s ), 1 75 (5 H, s), 1 61 (2 H, br s ), 1 15 (5 H, d, J=10 2 Hz) Example 8
W-(3-Methoxybenzyl)-6-(2-((((rans)-4-(2-hydroxyacetamido)cyclohexyl)methyl)-2H-tetrazol-5-y!)-
2-methylpyrimidine-4-carboxamide
Λ/-(3-Methoxyben2yl)-6-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxannιde (prepared as described in Example 5) (146 mg, 0 287 mmol), triethylamine (102 mg, 1 OO mmol) and acetoxy acetyl chloride (47 mg, 0 344 mmol) were combined in dichloromethane (4 mL) After stirring for 10 mm, the mixture was concentrated and then treated with acetonitrile (2 mL) and 2 5 N sodium hydroxide (2 mL) After 1 h, the organics were removed under nitrogen stream and the aqueous was adjusted to pH 6 with 10% hydrogen chloride The mixture was extracted with ethyl acetate (2 x 5 mL) The combined organic layers were dried over magnesium sulfate, filtered, and concentrated to afford the title compound as a yellow solid (64 7 mg, 46%) LC/MS (10%-90% CH3CN/H2O, 6 mm) 4 44 mm m/z 495 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 47 (br, s, 1 H) 8 40 (s, 1 H), 7 37 (d, J = 8 05, 1 H), 7 17-7 30 (m, 1 H), 6 91 (br s, 2 H), 6 77 - 6 84 (m, 1 H), 5 38 (s, 1 H), 4 69 (d, J = 6 6 Hz, 2 H), 4 49 (d, J = 6 6 Hz, 2 H), 3 67 - 3 79 (m, 4 H), 3 56 (br s , 1 H), 2 81 (s, 3 H), 1 97 (br s , 1 H), 1 72 (br s , 2 H), 1 60 (d, J = 1 1 0 Hz, 2 H), 1 09 - 1 33 (m, 5 H)
Example 9
/V-(4-Fluoro-3-methoxybenzyl)-6-(2-(frans-4-aminocycIohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrimidine-4-carboxamide
Step 1 Preparation of 6-cvano-Λ/-(4-fluoro-3-methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde
4-Fluoro-3-methoxybenzylamιne hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-((frans-4-amιnocyclohexyl)methyl)-2H-tetrazol-5- y!)pyrιmιdιne-4-carboxamιde, Example 1 ) (13 5 g, 70 6 mmol) was dissolved in methanol (56 mL) Diisopropylethylamine (29 2 g, 226 mmol) was added and the mixture stirred for 15 minutes at room temperature Methyl 6-cyano-2-methylpyrιmιdιne-4-carboxylate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 5) (10 0 g, 56 4 mmol) was added and the reaction heated to 35 0C for 1 h The methanol was removed in vacuo and the crude material partitioned between ethyl acetate (500 mL) and 1 N hydrochloric acid (500 mL) The layers were separated and the aqueous layer extracted with ethyl acetate (2 x 250 mL) The combined organics were washed with saturated aqueous sodium bicarbonate (2 x 250 mL) and brine (250 mL) The organic layer was dried over sodium sulfate, filtered, and evaporated to give a brown solid Purification by silica gel chromatography (1/2, ethyl acetate/heptane) provided the title compound as a white solid (1 1 7 g, 69%) LC/MS (5%-95% CH3CN/H2O, 4 mm 2 67 mm, m/z 301 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 58 (t, J=6 2 Hz, 1 H), 8 32 (s, 1 H), 7 04 - 7 19 (m, 2 H), 6 79 - 6 90 (m, 1 H), 4 44 (d, J=6 2 Hz, 2 H), 3 78 (s, 3 H), 2 76 (s, 3 H)
Step 2 Preparation of /V-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4- carboxamide
6-Cyano-/V-(4-fluoro-3-methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde (4 8O g, 16 0 mmol), sodium azide (1 14 g, 17 6 mmol), and zinc bromide (3 6O g, 16 0 mmol) were suspended in water (36 mL) The reaction was heated to reflux for 16 h After cooling to room temperature, 6N hydrochloric acid (180 mL) was added and the mixture stirred vigorously for 1 hour The solids were collected by vacuum filtration and rinsed with 6N hydrochloric acid (3 x 100 mL) and water (2 x 100 mL) High vacuum drying at 55 0C provided the title compound as a white solid (5 45 g, 99%) LC/MS (5%-95% CH3CN/H2O, 4 mm 2 56 mm, m/z 344 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 55 (t, J=6 4 Hz, 1 H), 8 42 (s, 1 H), 7 06 - 7 20 (m, 2 H), 6 81 - 6 94 (m, 1 H), 4 47 (d, J=6 4 Hz, 2 H), 3 79 (s, 3 H), 2 82 (s, 3 H)
Step 3 Preparation of terf-butyl <rans-4-((5-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cvclohexylcarbamate
Triethylamine (176 mg, 1 7 mmol) and (/rans-4-((fe/t-butoxycarbonyl)amιno)cyclohexyl)methyl 4-methylbenzenesulfonate (prepared as described in step 7 of the synthesis of Λ/-(3-methoxybenzyl)- 6-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 5) (335 mg, 0 87 mmol) was added to a solution of Λ/-(4-f!uoro-3-methoxybenzyl)-2-methyl-6- (2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (300 mg, 0 87 mmol) in anhydrous Λ/,Λ/-dιmethylformamιde (0 6 mL) The reaction was stirred overnight at 85 °C in a capped vial The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitrile) to afford the title compound as a white solid (130 mg)
Step 4 Preparation of /V-(4-fluoro-3-methoxybenzyl)-6-(2-(frans-4-amιnocvclohexyl)methyl)-2/-/- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
A mixture of 4 M hydrochloric acid in dioxane (5 mL) and tert-butyl frans-4-((5-(6-((4-fluoro-3- methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexylcarbamate (130 mg) was stirred for 4 h at room temperature The solvent was removed under a stream of nitrogen The residue was slurried in ether (2x), decanting each time The resultant solid was dried under vacuum to afford the hydrochoride salt of the title compound as a white solid (135 mg)
Example 10
W-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2-((fraπs-4-(methylsulfonamido)cyclohexyl)methyl)-
2W-tetrazol-5-yl)pyrimidine-4-carboxamide
Triethylamine (60 mg, 0 6 mmol) and methane sulfonyl chloride (34 mg, 0 3 mmol) were added to a solution of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(frans-4-amιnocyclohexyl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 9) (70 mg, 0 14 mmol) in dichloromethane (1 mL) The reaction was stirred overnight at room temperature The product was isolated by reverse phase preparative HPLC (water/acetonitrile) to afford the title compound as a white solid (37 mg) MS (ES+) m/z 533 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 51 (1 H, t, J=6 0 Hz), 8 42 (1 H, s), 7 11 - 7 21 (1 H, m), 7 18 (1 H, d, J=9 2 Hz), 6 94 (2 H, d, J=7 3 Hz), 4 70 (2 H, d, J=7 0 Hz), 4 50 (2 H, d, J=5 9 Hz), 3 82 (3 H, s), 3 05 (1 H, br s ), 2 88 (3 H, s), 2 83 (3 H, s), 1 91 (3 H, d, J=10 2 Hz), 1 64 (2 H, br s ), 1 26 (1 H, br s ), 1 19 (3 H, d, J=10 6 Hz), 1 15 (1 H, br s )
Example 11
W^-Fluoro-S-methoxybenzyO-G^Z-^frans^-acetamidocyclohexyOmethyO^H-tetrazol-S-yl)^- methylpyrimidine-4-carboxamide
Triethylamine (60 mg, 0 6 mmol) and acetic anhydride (31 mg, O 3 mmol) were added to a solution of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(frans-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 9) (65 mg, 0 13 mmol) in dichloromethane (1 mL) The reaction was stirred overnight at room temperature The product was isolated by reverse phase preparative HPLC (water/acetonitrile) and neutralized by passing through a small carbonate column to afford the title compound as a white solid (51 mg) MS (ES+) m/z 497 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 51 (1 H, t, J=5 7 Hz), 8 42 (1 H, s), 7 66 (1 H, d, J=7 7 Hz), 7 11 - 7 21 (1 H, m), 7 18 (1 H, d, J=8 8 Hz), 6 90 (1 H, d, J=7 3 Hz), 4 70 (2 H, d, J=7 0 Hz), 4 50 (2 H, d, J=5 9 Hz), 3 82 (3 H, s), 3 46 (1 H, br s ), 2 83 (3 H, s), 1 99 (1 H, br s ), 1 75 (4 H, s), 1 80 (1 H, br s ), 1 61 (2 H, d, J=9 5 Hz), 1 25 (1 H, d, J=5 5 Hz), 1 15 (3 H, d, J=9 5 Hz), 1 10 - 1 21 (1 H, m)
Example 12
W-(4-Fluoro-3-methoxybenzyl)-6-(2-((((ra/7s)-4-(2-hydroxyacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(<rans-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 9) (108 mg, 0 238 mmol), triethylamine (84 2 mg, 0 832 mmol) and acetoxy acetyl chloride (38 9 mg, 0 285 mmol) were combined in dichloromethane (4 mL) and stirred for 10 mm The mixture was concentrated and then treated with acetonitrile (2 mL) and 2 5 N sodium hydroxide (2 mL) After 1 hour, the organics were removed under nitrogen stream and the aqueous solution was adjusted to pH 6 with 10% hydrogen chloride The mixture was extracted with ethyl acetate (2 x 5 mL) The combined organic layers were dried over magnesium sulfate, filtered and concentrated to afford the title compound as an white solid (76 mg, 62%) LC/MS (10%-90% CH3CN/H2O, 6 mm) 4 44 mm, m/z 495 (M+H) 1H NMR (400 MHz, DMSO-Cf6) 6 ppm 9 35 - 9 54 (m, 1 H), 8 40 (s, 1 H), 7 37 (d, J = 8 1 Hz, 1 H), 7 04-7 22 (m, 1 H), 6 89 (br s, 1 H), 5 34 (s, 1 H), 4 68 (d, J= 6 6 Hz, 2 H), 4 48 (d, J = 5 9 Hz, 2 H), 3 77 - 3 85 (m, 3 H), 3 73 (d, J = 5 9 Hz, 2 H), 3 53 (br s , 1 H), 2 81 (s, 3 H), 1 98 (br s , 1 H), 1 73 (d, J = 10 3 Hz, 2 H), 1 60 (d, J = 10 3 Hz, 2 H), 1 06 - 1 36 (m, 5 H)
Example 13 W-(3-(2-Hydroxyethoxy)benzyl)-6-(2-(((frans)-4-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrimidine-4-carboxamide
Step 1 Preparation of 2-(3-((benzylanr)ino)methyl)phenoxy)ethanol
A solution of 3-(2-hydroxyethoxy) benzaldehyde (10 00 g, 60 18 mmol) in anhydrous THF (230 mL) was treated at room temperature with benzyl amine (6 90 ml, 63 19 mmol) as a bolus and the resulting yellow solution was stirred at room temperature for 1 h Acetic acid (3 45 ml, 60 18 mmol) was added as a bolus followed by the portion-wise addition of sodium triacetoxyborohydride (19 1 g, 90 27 mmol) After 1 5 h, the reaction was quenched by the addition of 1 N NaOH (200 ml) The phases were separated and the aqueous layer was extracted with ethyl acetate (2 x 100 mL) The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated in vacuo to afford the title compound as an oil (13 20 g, 86 9 %) MS (ES+) m/z 258 (M+H)
Step 2 Preparation of 2-(3-(amιnomethyl)phenoxy)ethanol (3-((Benzylamιno)methyl)phenoxy)ethanol (13 2 g) was dissolved with heating in absolute ethanol (500 mL) and ammonium formate (40 9 g, 648 mmol) was added The mixture was sparged with N2 for a short period before 10% Pd/C (1 5 g, 13 9 mmol) was added The slurry was heated to reflux (55 0C to 66 0C) and stirred for 2 h Additional catalyst (1 5 g) was added and heating at reflux (74 7 0C) was continued for 30 mm The reaction was filtered and concentrated in vacuo The crude material was chromatographed on a normal phase column eluting with 95/5/0 5, dιchloromethane/methanol/NH4OH to afford the title compound (3 14 g)
Step 3 Preparation of Λ/-(3-(2-hvdroxyethoxy)benzyl)-6-cvano-2-methylpyrιmιdιne-4-carboxamιde
Methyl θ-cyano^-methylpyπmidine^-carboxylate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 5) (892 mg, 5 03 mmol), 2-(3-
(amιnomethyl)phenoxy)ethanol (894 mg, 5 35 mmol), and triethylamine (382 mg, 3 78 mmol) were combined in dimethylacetamide (6 mL) The mixture was stirred at 80 0C for 2 h The mixture was cooled and partitioned into ethyl acetate and water The aqueous layer was extracted with additional ethyl acetate (15 mL) The organic extracts were combined, dried over magnesium sulfate, filtered and concentrated The product was purified by silica gel chromatography (dichloromethane/methanol, 100/0 - 95/5) The pure fractions were combined and concentrated to afford the title compound as an oil (950 mg, 60%) LC/MS (10%-90% CH3CN H2O1 8 mm) 2 338 mm, m/z 313 (M+H)
Step 4 Preparation of Λ/-(3-(2-hvdroxyethoxy)benzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4- carboxamide
Λ/-(3-(2-Hydroxyethoxy)benzyl)-6-cyano-2-methylpyrιmιdιne-4-carboxamιde (687 mg, 2 20 mmol), sodium azide (214 mg, 3 30 mmol), and zιnc(ll) bromide (248 mg, 1 10 mmol) were combined in methanol (10 mL) The resulting mixture was stirred at 60 °C until homogeneous, then cooled to 25 0C and stirred for 18 h The methanol was removed, the solution acidified to pH 3 (3N hydrochloric acid) and extracted with ethyl acetate (3 x 10 mL) The organic extracts were combined, dried over magnesium sulfate, filtered and concentrated to afford the title compound as a yellow solid (782 mg, 100%) LC/MS (10%-90% CH3CN/H2O, 8 mm) 3 58 mm, m/z 356 (M+H) Step 5 Preparation of Λ/-(3-(2-hvdroxyethoxy)benzyl)-6-(2-(((<rans)-4-amιnocvclohexyl)methyl)-2/-/- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
Λ/-(3-(2-hydroxyethoxy)benzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (782 mg, 2 20 mmol), (frans-4-((/ert-butoxycarbonyl)amino)cyclohexyl)methyl 4-methylbenzenesulfonate (prepared as described in step 7 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((frans)-4- aminocyclohexyOmethyO^H-tetrazol-S-yO^-methylpyπmidine^-carboxamide, Example 5) (844 mg, 2 20 mmol), and triethylamine (267 mg, 2 64 mmol) were combined in dimethylacetamide (12 mL) The resulting mixture was stirred at 85 0C for 18 h The mixture was partitioned into water/ethyl acetate and extracted with additional ethyl acetate (5 mL) The organic extracts were combined, dried over magnesium sulfate, filtered and concentrated Purification was accomplished by reverse phase high-pressure liquid chromatography The pure fractions were combined, extracted with ethyl acetate (2 x 20 mL), dried over magnesium sulfate, and concentrated to an oil The intermediate was dissolved in methylene chloride (2 mL) and trifluoroacetic acid (2 mL) was added The mixture was stirred 10 mm , concentrated, and neutralized to pH 8 (NaOH) The mixture was extracted with ethyl acetate (2 x 15 mL), dried over magnesium sulfate, filtered and concentrated to afford the title compound as a clear oil (100 mg, 8%) LC/MS (10%-90% CH3CN/H2O, 6 mm) 5 92 mm, m/z 467 (M+H) Example 14
W-(3-(2-Hydroxyethoxy)benzyl)-6-(2-(((frans)-4-acetamidocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrimidine-4-carboxamide
Λ/-(3-(2-Hydroxyethoxy)benzyl)-6-(2-(((/rans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 13) (50 mg, 0 11 mmol), triethylamine (38 O mg, O 375 mmol) and acetyl chloride (10 1 mg, 0 129 mmol) were combined in dichloromethane (2 mL) After stirring for 18 h, the mixture was concentrated and then treated with acetonitrile (2 mL) and 2 5 N sodium hydroxide (2 mL) After 1 h, the organics were removed under a nitrogen stream and the aqueous layer was adjusted to pH 6 with 10% hydrogen chloride The mixture was extracted with ethyl acetate (2 x 5 mL) The combined organic layers were dried over magnesium sulfate, filtered and concentrated to afford the title compound as a white solid (6 mg, 1 1 %) LC/MS (10%-90% CH3CN/H2O, 4 mm) 2 45 mm, m/z 509 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 41 - 9 48 (m, 1 H), 8 39 (s, 1 H), 7 58-7 64 (m, 1 H), 7 14 - 7 24 (m, 1 H), 6 83 - 6 94 (m, 2 H), 6 77 - 6 84 (m, 1 H), 5 43 - 5 55 (m, 1 H), 4 64 - 4 71 (m, 1 H), 4 45 - 4 51 (m, 2 H), 3 97 (m, 1 H), 3 62 - 3 72 (m, 2 H), 3 37 - 3 48 (m, 1 H), 2 81 (s, 3 H), 1 88 - 2 03 (m, 2 H), 1 84 (m, 2 H), 1 72 (s, 3 H), 1 63 (m, 2 H), 0 95 - 1 26 (m, 5 H)
Example 15
/V-(3-(2-Hydroxyethoxy)benzyl)-2-methyl-6-(2-(((frans)-4- (methylsulfonamido)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)pyrimidine-4-carboxamide
A/-(3-(2-Hydroxyethoxy)benzyl)-6-(2-(((frans)-4-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 13) (184 mg, 0 409 mmol), triethylamine (200 μL) and methanesulfonyl chloride (46 9 mg, 0 409 mmol) were combined in dichloromethane (2 mL) After stirring for 18 h, the resulting mixture was stirred at 85 0C for 18 h The mixture was concentrated under a nitrogen stream Purification was accomplished by high-pressure liquid chromatography Pure fractions were combined and concentrated to afford the title compound as a white solid (6 5 mg, 2 9%) LC/MS (10%-90% CH3CN/H2O, 8 mm) 4 26 mm, m/z 545 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 48 (s, 1 H), 8 42 (s, 1 H), 7 23 (m, 1 H), 6 93 (m, 2 H), 6 83 (m, 1 H), 4 77 (m, 1 H), 4 70 (d, J = 6 6 Hz, 2 H), 4 51 (d, J = 6 22 Hz, 2 H), 3 96 (t, J = 4 9 Hz, 2 H), 3 69 (d, J = 5 1 Hz, 2 H), 3 06 (m, 1 H), 2 85 (s, 3 H), 2 83 (s, 3 H), 1 90 (m, 3 H), 1 64 (m, 2 H), 1 20 (m, 4 H), 0 06 (m, 1 H)
Example 16
W-(3-(2-Hydroxyethoxy)benzyl)-6-(2-(((frans)-4-(2-hydroxyacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Λ/-(3-(2-Hydroxyethoxy)benzyl)-6-(2-(((frans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 13) (184 mg, 0 409 mmol), triethylamine (200 μL) and acetoxy acetyl chloride (55 9 mg, 0 409 mmol) were combined in dichloromethane (4 mL) After stirring for 10 mm , the mixture was concentrated then treated with acetonitrile (2 mL) and 2 5 N sodium hydroxide (2 mL) After 1 h, the organics were removed under a nitrogen stream and the aqueous layer was adjusted to pH 6 with 10% hydrogen chloride The mixture was extracted with ethyl acetate (2 x 5 mL) The combined organic layers were dried over magnesium sulfate, filtered and concentrated to afford the title compound as a white solid (79 9 mg, 37%) LC/MS (10%-90% CH3CN/H2O, 6 mm) 4 00 mm, m/z 525 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 48 (s, 1 H), 8 31 (s, 1 H), 7 52 (s, 1 H), 7 38 - 6 94 (m, 4 H), 3 85 (s, 1 H), 3 72 (d, J = 1 1 4 Hz, 4 H), 3 47 (t, J = 1 1 0, 4 H), 2 60 (s, 3 H), 2 41 (d, J = 13 2, 4 H), 1 79 (m, 8 H), 0 06 (m, 1 H)
Example 17
/V-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((frans)-4-acetamidocyclohexyl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of methyl 2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxylate
Methyl 6-cyano-2-methylpyrιmιdιne-4-carboxylate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((<Λans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 5) (5 00 g, 28 2 mmol), sodium azide (1 93 g, 29 6 mmol), and zinc bromide (6 36 g, 28 2 mmol) were suspended in methanol (28 mL) The reaction was stirred at room temperature for 16 hours 1 N hydrochloric acid (75 mL) was added and the mixture was stirred vigorously for 1 hour The solids were collected by vacuum filtration and rinsed with 1 N hydrochloric acid (2 x 50 mL) and water (2 x 100 mL) High vacuum drying at 40 0C provided the title compound as a white solid (5 31 g, 85%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 2 24 mm, m/z 221 (M+H) 1H NMR (400 MHz, DMSO-dδ) δ ppm 8 38 (s, 1 H), 3 94 (s, 3 H), 2 80 (s, 3 H)
Step 2 Preparation of methyl 6-(2-(((/rans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxylate
Methyl 2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxylate (2 00 g, 9 0 mmol), tert-butyl
(frans)-4-(hydroxymethyl)cyclohexylcarbamate (2 29 g, 9 99 mmol), resin-bound tπphenylphosphine (4 84 g, 10 9 mmol) and di-tert-butyl azodicarboxylate (2 3 g, 9 99 mmol) were combined in tetrahydrofuran (30 mL) The mixture was stirred at 25 0C for 18 h The mixture was filtered and concentrated The residue was purified by reverse phase preparative high-pressure liquid chromatography Fractions containing methyl 6-(2-((trans-4-((tert- butoxycarbonyl)amιno)cyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxylate were combined, extracted with ethyl acetate (2 x 20 mL), dried over magnesium sulfate, and concentrated The residue was dissolved in methylene chloride (2 mL) and trifluoroacetic acid (2 mL) was added The mixture was stirred 10 mm, concentrated, and neutralized to pH 8 (NaOH) The organic layer was extracted with ethyl acetate (2 x 15 mL), dried with magnesium sulfate, filtered and concentrated to afford the title compound as a clear oil (400 mg, 7%) LC/MS (10%-90% CH3CN/H2O, 4 mm) 1 704 mm, m/z 332 (M+H)
Step 3 Preparation of 5-amιnomethyl-2-fluoro-phenol hydrobromide A mixture of 4-fluoro-3-methoxy-benzylamιne hydrochloride (133 g, 0 642 mol), 48% aqueous
HBr (1 L) and 30% HBr in acetic acid (1 L) was refluxed for 4 h and concentrated under vacuum Ethanol was added to the residue and evaporated to remove last remaining water The crystalline residue obtained was dissolved in a small amount of ethanol and ethyl ether was slowly added A heavy crystalline suspension formed and was filtered, washed with ethyl ether and dried in vacuum to afford the title compound (147 g, 95 4%) Step 4 Preparation of tert-butyl 4-fluoro-3-hvdroxybenzylcarbamate
Triethylamine (13 7 g, 0 135 mol) and di-tert-butyl dicarbonate (29 5 g, 0 135 mol) were added to a solution of 5-amιnomethyl-2-fluorophenol hydrobromide (30 g, 0 135 mol) in dichloromethane (200 mL) at ice bath temperature The reaction mixture was stirred overnight at room temperature, diluted with water and adjusted to pH-5 with acetic acid The organic layer was separated, washed with water and concentrated under vacuum to afford the title compound as a clear viscous oil (31 5 g, 96%)
Step 5 fert-butyl 4-fluoro-3-(2-hvdroxyethoxy)benzylcarbamate
To a mixture of /erf-butyl 4-fluoro-3-hydroxybenzylcarbamate (31 5 g, 0 13 mol) in dimethylsulfoxide (300 mL) was added KOH (15 75 g), Kl (0 3 g) and bromoethanol (19 6 g, 0 157 mol) The mixture was stirred for 5 days until no starting material remained The mixture was diluted with excess dichloromethane and washed with water The organic solution was concentrated and the crude product purified by silica gel column chromatography (0-80% ethyl acetate in hexane) to afford the desired tert-butyl 4-fluoro-3-(2-hydroxyethoxy)benzyIcarbamate as an oil (14 g, 40%)
Step 6 Preparation of 2-(5-amιnomethyl-2-fluorophenoxy)ethanol hydrochloride tert-Butyl 4-fluoro-3-(2-hydroxyethoxy)benzylcarbamate (14 g, 0 05 mol) was dissolved in excess of 4N hydrochloric acid in dioxane (125 ml) and stirred for 5 h at room temperature The resulting solid was diluted with an additional amount of dioxane and then filtered, washed with cold dioxane and dried in vacuo to afford the title compound as the hydrochloride salt (8 5 g, 78%) MS (ES+) m/z 186 (M+H) Elemental analysis found C, 48 25, H, 6 09, N, 6 45
Step 7 Preparation of Λ/-(4-fluoro-3-(2-hvdroxyethoxy)benzyl)-6-(2-((«rans)-4- acetamιdocvclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
Methyl 6-(2-(((frans)-4-aminocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrimidme-4- carboxylate (134 mg, 0 404 mmol), acetyl chloride (104 mg, 1 33 mmol) and triethylamine (200 μl_) were combined in dichloromethane (2 mL) The resulting mixture was stirred at 25 0C for 30 mm The dichloromethane was removed under nitrogen stream The residue was dissolved in dimethylacetamide (2 mL) and 2-(5-(amιnomethyl)-2-fluorophenoxy)ethanol hydrochloride (178 mg,
0 808 mmol) and triethylamine (200 μL) were added The mixture was stirred at 25 C for 18 h Purification was accomplished by reverse phase preparative high-pressure liquid chromatography (acetonitrile/water, 5 - 95%, 30 mm) The pure fractions were combined, extracted with ethyl acetate (2 x 20 mL), dried (magnesium sulfate), and concentrated to an oil that solidified under reduced pressure to afford the title compound as a white solid (48 5 mg, 23%) LC/MS (10%-90% CH3CN/H2O, 4 mm) 2 53 mm, m/z 527 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 47 (s, 1 H), 8 40 (s, 1 H), 7 61 (d, J = 8 05, 1 H), 7 18 (m, 2 H), 6 90 (m, 1 H), 4 81 (t, J = 5 68, 5 86, 1 H), 4 67 (d, J = 7 32, 2 H), 4 47 (d, J = 6 59, 2 H), 4 01 (m, 2 H), 3 71 (m, 2 H), 3 45 (m, 1 H), 2 81 (s, 3 H), 1 97 (m, 1 H),
1 78 (m, 2 H), 1 73 (s, 3 H), 1 58 (m, 2 H), 1 14 (m, 4 H)
Example 18
/V-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-2-methyl-6-(2-(((fraπs)-4- (methylsulfonamidoJcyclohexyOmethyO^H-tetrazol-S-yOpyrimidine^-carboxamide
Methyl 6-(2-(((frans)-4-aminocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpynmidine-4- carboxylate (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-(2- hydroxyethoxy)benzyl)-6-(2-(((frans)-4-acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 17) (134 mg, 0 404 mmol), methanesulfonyl chloride (152 mg, 1 33 mmol) and triethylamine (200 μL) were combined in dichloromethane (2 mL) The resulting mixture was stirred at 25 0C for 30 mm The dichloromethane was removed under nitrogen stream The residue was dissolved in dimethylacetamide (2 mL) and 2-(5-(amιnomethyl)-2- fluorophenoxy)ethanol (prepared as described in steps 3 - 6 of the synthesis of Λ/-(4-fluoro-3-(2- hydroxyethoxy)benzyl)-6-(2-(((frans)-4-acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 17) (178 mg, 0 808 mmol) and triethylamine (200 μL) were added The mixture was stirred at 25 0C for 18 h Purification was accomplished by reverse phase preparative high-pressure liquid chromatography (acetonitrile/water, 5 - 95%, 30 mm) The pure fractions were combined, extracted with ethyl acetate (2 x 20 mL), dried over magnesium sulfate, and concentrated to an oil that solidified under reduced pressure to afford the title compound as an white solid (45 3 mg, 20%) LC/MS (10%-90% CH3CN/H2O, 4 mm) 2 64 mm, m/z 563 (M+H) 1H NMR (400 MHz, DMSOd6) δ PPm 9 47 (m, 1 H), 8 40 (s, 1 H), 7 13 (m, 2 H), 6 90 (m, 2 H), 4 79 (m, 1 H), 4 68 (m, 2 H), 4 47 (m, 2 H), 4 03 (m, 2 H), 3 70 (m, 2 H), 3 05 (m, 1 H), 2 86 (s, 3 H), 2 81 (s, 3 H), 1 93 (m, 3 H), 1 61 (m, 2 H), 1 18 (m, 4 H) Example 19
W-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((frans)-4-(2- hydroxyacetamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Methyl 6-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxylate (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-(2- hydroxyethoxy)benzyl)-6-(2-(((frans)-4-acetamιdocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 17) (134 mg, 0 404 mmol), acetoxy acetyl chloride (181 mg, 1 33 mmol) and tπethylamine (200 μl_) were combined in dichloromethane (2mL) The resulting mixture was stirred at 25 °C for 30 mm The dichloromethane was removed under nitrogen stream The residue was dissolved in dimethylacetamide (2 mL) and (2-(5-(amιnomethyl)-2- fluorophenoxy)ethanol (prepared as described in steps 3 - 6 of the synthesis of Λ/-(4-fluoro-3-(2- hydroxyethoxy)benzyl)-6-(2-(((/rans)-4-acetamidocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 17) (178 mg, 0 808 mmol) and triethylamine (200 μL) were added The mixture was stirred at 25 0C for 18 h Purification was accomplished by reverse phase preparative high-pressure liquid chromatography (acetonitrile/water, 5 - 95%, 30 mm) The pure fractions were combined, extracted with ethyl acetate (2 x 20 mL), dried over magnesium sulfate, and concentrated The residue was dissolved in acetonitrile (4 5 mL) and treated with 2 5N NaOH (2 5 mL) The acetonitrile was removed in vacuo and the aqueous layer was adjusted to pH 6 with 10% hydrochloric acid The mixture was extracted with ethyl acetate (2 x 20 mL), dried over magnesium sulfate, and concentrated to an oil the solidified under reduced pressure to give the title compound as an white solid (52 2 mg, 24%) LC/MS (10%-90% CH3CN/H2O, 4 mm) 2 43 mm, m/z 543 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 47 (s, 1 H), 8 40 (s, 1 H), 7 35 (m, 1 H), 7 09 - 7 18 (m, 2 H), 6 90 (m, 1 H), 5 30 (m, 1 H), 4 81 (m, 1 H), 4 68 (d, J = 7 32, 2 H), 4 47 (d, J = 6 59, 2 H), 4 02 (m, 2 H), 3 70 (m, 4 H), 3 53 (m, 1 H), 2 81 (s, 3 H), 1 97 (m, 1 H), 1 72 (m, 2 H), 1 62 (m, 2 H), 1 15 - 1 28 (m, 4 H)
Example 20 fraπs-Methyl 4-((5-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexanecarboxylate
Step 1 Preparation of frans-methyl 4-((methylsulfonyloxy)methyl)cvclohexanecarboxylate
Triethylamine (6 46 g, 63 9 mmol) was added to a solution of frans-methyl 4- (hydroxymethyl)cyclohexanecarboxylate (10 0 g, 58 1 mmol) in dichloromethane (100 mL) Methane sulfonylchloride (7 98 g, 69 7 mmol) was added drop-wise and then the mixture was stirred at room temperature for 2 days The mixture was diluted with brine The organic layer was separated, dried over sodium sulfate, filtered, and concentrated The resulting oil crystallized upon addition of petroleum ether and was filtered to afford the title compound (14 0 g)
Step 2 Preparation of frans-methyl 4-((5-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn- 4-yl)-2H-tetrazol-2-yl)methyl)cvclohexanecarboxylate
frans-Methyl 4-((methylsulfonyloxy)methyl)cyclohexanecarboxylate (65 mg, 0 26 mmol) was added to a solution of Λ/-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide (60 mg, 0 17 mmol) and triethylamine (34 mg, 0 34 mmol) in anhydrous dimethylacetamide (0 3 mL) The mixture was stirred at 80 - 90 0C in a capped vial overnight The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitrile) to afford the title compound (43 mg)
Example 21
(rans-4-((5-(6-((4-Fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylic acid
Sodium hydroxide (2 pellets) were added to a mixture of frans-methyl 4-((5-(6-((4-fluoro-3- methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-2H-tetrazol-2-y!)methyl)cyclohexanecarboxylate (43 mg) in tetrahydrofuran (0 4 mL) and water (0 4 mL) The mixture was stirred at room temperature overnight The reaction mixture was acidified with trifluoroacetic acid and the product was purified by reverse phase preparative HPLC (water/acetonitrile) to afford the title compound as a white solid (28 mg) MS (ES+) m/z 484 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 51 (1 H, t, J=6 0 Hz), 8 42 (1 H, s), 7 1 1 - 7 22 (1 H, m), 6 92 (1 H, br s ), 4 70 (3 H, d, J=6 6 Hz), 4 51 (3 H, d, J=5 9 Hz), 3 82 (3 H, S), 2 83 (3 H, s), 2 14 (1 H, br s ), 1 99 (1 H, br s ), 1 90 (2 H, br s ), 1 64 (2 H, br s ), 1 30 (3 H, d, J=12 8 Hz), 1 08 - 1 19 (2 H, m)
Example 22
(fraπs)-Methyl 4-((5-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H-tetrazol-2- yOmethyOcyclohexanecarboxylate
frans-Methyl 4-((methylsulfonyloxy)methyl)cyclohexanecarboxylate (prepared as described in step 1 of the synthesis of /rans-methyl 4-((5-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)cyclohexanecarboxylate, Example 20) (56 mg, 0 22 mmol) was added to a solution of /V-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyπmιdιne-4- carboxamide (prepared as described in step 6 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((frans)- 4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 5) (50 mg, 0 15 mmol) and triethylamine (56 mg, 0 22 mmol) in anhydrous dimethylacetamide (0 3 mL) The mixture was stirred at 80 - 90 0C in a capped vial overnight The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitrile) to afford the title compound (37 mg)
Example 23
(<rans)-4-((5-(6-((3-Methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylic acid
Sodium hydroxide (2 pellets) was added to mixture of (fraπs)-methyl 4-((5-(6-((3- methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate (prepared as described in Example 22) in tetrahydrofuran (0 4 mL) and water (0 4 mL) The mixture was stirred at room temperature overnight The reaction mixture was acidified with trifluoroacetic acid and purified by reverse phase preparative HPLC (water/acetonitrile) The resulting residue was slurried and decanted from ethyl ether and dried in a vacuum desiccator to afford the title compound as an off-white solid (19 mg) MS (ES+) m/z 466 (M+H) 1H NMR (400 MHz, DMSO-Cy6) 6 ppm 9 49 (1 H, t, J=6 2 Hz), 8 41 (1 H,s), 7 24 (1 H, t, J=8 1 Hz), 6 93 (2 H, br s ), 6 83 (1 H, d, J=I 7 Hz), 4 70 (2 H, d, J=I 0 Hz), 4 51 (3 H, d, J=Q 2 Hz), 3 74 (3 H, s), 2 83 (3 H, s), 2 14 (1 H, br s ), 2 01 (1 H, br s ), 1 91 (2 H, d, J=12 1 Hz), 1 64 (2 H, br s ), 1 30 (3 H, d, J=12 4 Hz), 1 14 (2 H, t, J=1 1 3 Hz) Example 24
W-P-Methoxybenzyl^e-^-^frans^-cyanocyclohexyOmethyl^H-tetrazol-S-yO-Z- methylpyrimidine-4-carboxamide
Step 1 Preparation of 1 ,4-dιoxa-spιrof4 51decane-8-carbonitnle
tosyl-methyl-isocyanide (200 0 g, 1 024 mol) in DMF (2 2 L) and ethanol (85 mL), was added potassium f-butoxide (210 0 g, 1 87 mol) portion wise over a period of 2 h, and the temperature was maintained below -5 0C After complete addition, the mixture was brought to 0 0C and stirred another 1 h at 00C followed by room temperature for another 2 5 h The reaction mixture was diluted with ethyl acetate (3 5 L) and water (3 5 L) The mixture was stirred for 1 h The organic layer was separated and washed with water (3 x 1 5 L) followed by brine solution (1 5 L), dried over anhydrous sodium sulfate, and concentrated to afford the title compound as an oil (99 g, 75 %) Step 2 Preparation of 4-oxocvclohexanecarbonιtrιle
To a stirred solution of 1 ,4-dιoxa-spιro[4 5]decane-8-carbonιtrιle (100 g, 0 60 mol) in tetrahydrofuran (1 0 L) was added 2N hydrochloric acid (1 0 L) at room temperature and the mixture was stirred for 24 h The reaction mixture was diluted with ethyl acetate (1 0 L) The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 x 700 mL) The combined organic layer was washed with water (1 5 L) followed by brine (1 0 L), dried over anhydrous sodium sulfate, and concentrated The crude material was purified by flash column chromatography over silica gel (230-400 mesh) eluting with 20% ethyl acetate in hexane to afford the title compound (50 g, 67 %)
Step 3 Preparation of 4-(methoxymethylene)cvclohexanecarbonιtrιle
MeO / — v N — '
To a cold (-300C) suspension of methoxy methyl triphenylphosphonium chloride (84 g, 163 mmol) in dry tetrahydrofuran (300 mL) was added drop-wise 1 6 M n-butyllithium (153 mL, 243 6 mmol) maintaining the temperature at -250C to -300C After complete addition, the mixture was allowed to stir for 1 h at -200C A solution of 4-oxocyclohexanecarbonιtrιle (20 g, 162 4 mmol) in tetrahydrofuran (150 mL) was added drop-wise at -200C and allowed to stir for 2 h at the same temperature Hexane (200 mL) was added, and the mixture was filtered The filtrate was concentrated under reduced pressure and the crude material was purified by flash column chromatography over silica gel (230-400 mesh) eluting with 10% ethyl acetate in hexane to afford the title compound (9 g,
36%)
Step 4 Preparation of frans^-formylcvclohexanecarbomtrile
A mixture of 4-(methoxymethylene)cyclohexanecarbonιtrιle (9 g, 59 5 mmol) and tetrahydrofuran /2N hydrochloric acid (4 1 , 400 mL v/v) was heated to reflux for 30 minutes The reaction mixture was poured into water (300 mL) cold water and extracted with diethyl ether (3 x 300 mL) The combined organic layer was washed with water (400 mL), dried over anhydrous sodium sulfate and concentrated Recrystallization from hexane afforded the title compound (2 1 g, 25 %)
Step 5 Preparation of /rans^-divdroxymethvDcvclohexanecarbonitrile
A suspension of 600 mg (189 15 mmol) of sodium borohydride in methanol/diethyl ether (9 1 , 70 mL v/v) was treated drop-wise with a solution of frans-4-formylcyclohexanecarbonιtrιle (2 g, 14 6 mmol) in methanol/diethyl ether (9/1 , 30 mL v/v) within 10 minutes at 0 0C The reaction mixture was allowed to stir for 2 h at 10 °C, treated with 2N hydrochloric acid (35 mL) under ice-water cold condition, and extracted with dichloromethane (3 x 100 mL) The combined organic layers were dried over anhydrous sodium sulfate and concentrated to afford the title compound as an oil (1 45 g, 71 %) MS (ES+) m/z 162 (M+Na) Step 6 Preparation of «rans-4-cvanocvclohexyl)methyl 4-methylbenzenesulfonate
p-Toluene sulfonyl chloride (2 15 g, 1 1 3 mmol) was added portion-wise over 30 mm to a solution of <raπs-4-(hydroxymethyl)cyclohexanecarbonιtrιle (1 57 g, 11 3 mmol) in anhydrous pyridine (10 mL) at room temperature The reaction mixture was stirred for 4 h and then water (40 mL) was added drop-wise with ice bath cooling The mixture was extracted with dichloromethane The organic layer was washed with 3 M hydrochloric acid, dried over magnesium sulfate, and concentrated under vacuum to afford the title compound as a white solid (2 4 g) Step 7 Preparation of Λ/-(3-methoxybenzyl)-6-(2-(((frans-4-cvanocyclohexyl)methyl)-2H-tetrazol-5-yl)- 2-methylpyrιmιdιne-4-carboxamιde
(frans-4-Cyanocyclohexyl)methyl 4-methylbenzenesulfonate (232 mg, 0 79 mmol) was added to a solution of Λ/-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 6 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((frans)-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 5) (200 mg, 0 61 mmol) and triethylamine (186 mg, 1 8 mmol) in anhydrous dimethylacetamide (0 3 mL) The reaction was stirred overnight at 85 0C in a capped vial The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitπle) Fractions containing product were neutralized by passing through a small carbonate resin column and concentrated The residue was slurried and decanted from ethyl ether three times and dried in a vacuum desiccator to afford the title compound as a white solid (64 mg) MS (ES+) m/z 447 (M+H) 1H NMR (400 MHz, DMSO-d6) 6 ppm 9 48 (1 H, t, J=6 2 Hz), 8 41 (1 H, s), 7 24 (1 H, t, J=8 1 Hz), 6 93 (2 H, br s ), 6 83 (1 H, d, J=8 1 Hz), 4 71 (2 H, d, J=7 0 Hz), 4 51 (2 H, d, J=6 2 Hz), 3 74 (3 H, s), 2 83 (3 H, s), 2 63 (1 H, br s ), 2 08 (1 H, br s ), 2 02 (2 H, d, J=1 1 3 Hz), 1 65 (3 H, d, J=1 1 0 Hz), 1 51 (2 H, d, J=12 8 Hz), 1 15 (2 H, t, J=1 1 3 Hz)
Example 25
/V-(4-Fluoro-3-methoxybenzyl)-6-(2-(((<rans-4-cyanocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrimidine-4-carboxamide
(frans-4-Cyanocyclohexyl)methyl 4-methylbenzenesulfonate (prepared as described in step 6 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((frans-4-cyanocyclohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 24) (214 mg, 0 73 mmol) was added to a solution of /V-(4- fluoro-3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(/rans-4- aminocyclohexyOmethyl^H-tetrazol-S-yl^-methylpyπmidine^-carboxamide, Example 9) (170 mg, 0 495 mol) and triethylamine (148 mg, 1 4 mmol) in anhydrous dimethylacetamide (0 4 mL) The mixture was stirred overnight at 85 0C in a capped vial The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing product were neutralized by passing through a small carbonate resin column and concentrated The residue was slurried and decanted from ethyl ether three times and dried in a vacuum desiccator to afford the title compound as a white solid (65 mg) MS (ES+) m/z 465 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 50 (1 H, t, J=6 4 Hz), 8 42 (1 H, s), 7 19 (1 H, d, J=8 4 Hz), 7 14 (1 H, dd, J= 11 5, 8 6 Hz), 6 91 (1 H, br s ), 4 71 (2 H, d, J=7 0 Hz), 4 51 (2 H, d, J=6 2 Hz), 3 83 (3 H, s), 2 83 (3 H, s), 2 63 (1 H, br s ), 2 01 (3 H, br s ), 1 63 (3 H, br s ), 1 50 (2 H, br s ), 1 08 - 1 19 (2 H, m)
Example 26
W-(3-(2-Hydroxyethoxy)benzyl)-6-(2-(((frans)-4-cyanocyclohexyl)methyl)-2W-tetrazol-5-yl)-2- methylpyrimidine-4-carboxamide
Λ/-(3-(2-Hydroxyethoxy)benzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in steps 1 - 4 of the synthesis of Λ/-(3-(2-hydroxyethoxy)benzyl)-6-(2-(((/rans)- 4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyπmιdιne-4-carboxamιde, Example 13) (180 mg, 0 614 mmol), (fr-ans-4-cyanocyclohexyl)methyl 4-methylbenzenesulfonate (prepared as described in steps 1 - 6 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((fΛans-4-cyanocyclohexyl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 24) (150 mg, 0 423 mmol ), and triethylamine (400 μL) were combined in dimethylacetamide (100 μL) The resulting mixture was stirred at 85 0C for 18 h The mixture was concentrated under a nitrogen stream Purification was accomplished by reverse phase preparative high-pressure liquid chromatography Pure fractions were combined and concentrated to afford the title compound as a white solid (36 6 mg, 12%) MS (ES+) m/z 477 (M+H) 1H NMR (400 MHz, DMSOd6) ό ppm 9 48 (m, 1 H), 8 30 (s, 1 H), 7 24 (m, 1 H), 6 91 (m, 2 H), 6 79 (m, 1 H), 4 81 (m, 1 H), 4 71 (m , 2 H), 4 52 (m, 2 H), 3 96 (m, 2 H), 3 61 (m, 2 H), 2 80 (s, 3 H), 2 61 (m, 1 H), 2 40 (m, 1 H), 2 01 (m, 4 H), 1 62 (m, 2 H), 1 44 (m, 2 H), 1 05 (m, 2 H)
Example 27
/V-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((frans-4-cyanocyclohexyl)methyl)-2H-tetrazol-5- yl)-2 -methylpyrimidine-4-carboxamide
Step 1 Preparation of /V-(4-fluoro-3-(2-hvdroxyethoxy)benzyl)-6-cvano-2-methylpyrιmιdιne-4- carboxamide
Methyl δ-cyano-Σ-methylpynmidine^-carboxylate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzy!)-6-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 5) (5 20 g, 29 0 mmol), 2-(5-(amιnomethyl)-2- fluorophenoxy)ethanol hydrochloride (prepared as described in steps 3 - 6 of the synthesis of W-(4- fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((<rans)-4-acetamιdocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 17) (8 30 g, 32 3 mmol), and triethylamine (5 94 g, 58 7 mmol) were combined in dimethylacetamide (50 mL) The mixture was stirred at 80 0C for 2 h The mixture was cooled and poured into 1 N hydrochloric acid (50 mL) and was extracted with ethyl acetate (3 x 30 mL) The combined organic layers dried over magnesium sulfate, filtered and concentrated to a crude oil The product was triturated with ethyl acetate to afford the title compound as a solid (1 5 g, 15%) LC/MS (10%-90% CH3CN/H2O, 4 mm) 2 437 mm, m/z 331 (M+H) Step 2 Preparation of Λ/-(4-fluoro-3-(2-hvdroxyethoxy)benzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne- 4-carboxamιde
Λ/-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-cyano-2-methylpyrιmιdιne-4-carboxamιde (7 93 g, 24 0 mmol), sodium azide (2 34 g, 36 0 mmol), and zιnc(ll) bromide (2 70 g, 12 0 mmol) were combined in methanol (50 mL) The resulting mixture was stirred at 25 0C for 18 h The methanol was removed and the residue was acidified to pH 3 (3N hydrochloric acid) and extracted with ethyl acetate (2 x 50 mL) The combined organic layers were dried over magnesium sulfate, filtered and concentrated to afford the title compound as an off-white solid (4 25g, 47%) LC/MS (10%-90% CH3CN/H2O, 4 mm) 2 274 mm, m/z 374 (M+H)
Step 3 Preparation of Λ/-(4-fluoro-3-(2-hvdroxyethoxy)benzyl)-6-(2-(((<rans-4-cvanocvclohexyl)methyl)- 2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
(frans-4-cyanocyclohexyl)methyl 4-methylbenzenesulfonate (prepared as described in steps 1 - 6 of the synthesis of A/-(3-methoxybenzyl)-6-(2-(((frans-4-cyanocyclohexyl)methyl)-2/-/-tetrazol-5-yl)- 2-methylpyrιmιdιne-4-carboxamιde, Example 24) (1 14 mg, 0 389 mmol ) was added to a solution of N- (4-fluoro-3-(2-hydroxyethoxy)benzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (100 mg,
0 268 mmol) and triethylamine (162 mg, 1 6 mmol) in anhydrous dimethylacetamide (0 2 mL) The mixture was stirred overnight at 85 0C in a capped vial The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing product were neutralized by passing through a small carbonate resin column and concentrated The residue was slurried and decanted from ethyl ether three times and dried in a vacuum desiccator to afford the title compound as a white solid (46 mg) MS (ES+) m/z 495 (M+H) 1H NMR (400 MHz, DMSOd6) ό ppm 7 63 (1 H, s), 7 53 - 7 57 (1 H, m), 7 40 - 7 51 (3 H, m), 7 34 (2 H, d, J=Q 2 Hz), 7 25 (1 H, br s ), 7 14 (2 H, br s ), 7 03 (1 H, br s ), 3 96 (1 H, s), 3 85 (4 H, d, J= 1 1 7 Hz), 3 58 (4 H, t, J=10 8 Hz), 2 55 - 2 66 (3 H, m), 1 85 -
1 96 (3 H, m)
Example 28
W-(3-Methoxybenzyl)-6-(2-(((frans)-4-hydroxy-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-
5-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of 1 ,4-dιoxaspιro[4 51dec-8-ylmethyl 4-methylbenzenesulfonate
p-Toluene sulfonylchloπde (4 43 g, 23 24 mmol) was added portion-wise over 20 mm to a solution of 1 ,4-dιoxaspιro[4 5]dec-8-ylmethanol (Bioorg Med Chem 2005, 13, 6309-6323) (4 0 g, 23 0 mmol) in anhydrous pyridine (30 mL) The mixture was stirred at room temperature for 2 5 hours The reaction mixture was cooled to 0 0C and water (100 mL) was added drop-wise maintaining the temperature below 20 0C The mixture was extracted with dichloromethane The organic layer was washed with water (4x), dried over magnesium sulfate, and concentrated under vacuum to afford the title compound as a clear oil (5 7 g)
Step 2 Preparation of 6-(2-(1 ,4-dιoxaspιrof4 51dec-8-ylmethyl)-2H-tetrazol-5-yl)-Λ/-(3-methoxybenzyl)- 2-methylpyrιmιdιne-4-carboxamιde
1 ,4-Dιoxaspιro[4 5]dec-8-ylmethyl 4-methylbenzenesulfonate (552 mg, 1 69 mmol) was added to a solution of Λ/-(3-methoxybenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 6 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((frans)-4- aminocyclohexyOmethyO^H-tetrazol-δ-yO^-methylpyπmidine^-carboxamide, Example 5) (550 mg, 1 69 mmol) and triethylamine (171 mg, 1 7 mmol) in anhydrous dimethylacetamide (0 5 mL) The mixture was stirred overnight at 85 0C in a capped vial The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitrile) to afford the title compound (271 mg)
Step 3 Preparation of Λ/-(3-methoxybenzyl)-2-methyl-6-(2-((4-oxocvdohexyl)methyl)-2/-/-tetrazol-5- yl)pyrtmιdιne-4-carboxamιde
6-(2-(1 ,4-Dιoxaspιro[4 5]dec-8-ylmethyl)-2H-tetrazol-5-yl)-Λ/-(3-methoxybenzyl)-2- methylpyrιmιdιne-4-carboxamιde (271 mg) was dissolved in tetrahydrofuran (3 mL) and 96% formic acid (4 mL) was added The mixture was stirred at room temperature overnight The solvent was removed under a stream of nitrogen and the residue was dissolved in dichloromethane The mixture was washed with saturated aqueous sodium bicarbonate solution The organic layer was dried over magnesium sulfate, filtered, and concentrated under vacuum to afford the title compound (218 mg)
Step 4 Preparation of Λ/-(3-methoxybenzyl)-2-methyl-6-(2-(1-oxaspιro[2 51oct-6-ylmethyl)-2/-/-tetrazol- 5-yl)pyrιmιdιne-4-carboxamιde
A solution of Λ/-(3-methoxybenzyl)-2-methyl-6-(2-((4-oxocyclohexyl)methyl)-2H-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde (218 mg) in anhydrous dimethylsulfoxide (3 mL) was added to a solid mixture of trimethylsulfoxonium iodide (223 mg, 1 0 mmol) and potassium f-butoxιde(1 13 mg, 1 0 mmol) The mixture was stirred at room temperature for 40 mm Water (15 mL) was added and the resulting slurry was stirred an additional 20 mm The precipitate was filtered, washed with water, and dried under vacuum to afford the title compound (163 mg)
Step 5 Preparation of Λ/-(3-methoxybenzyl)-6-(2-(((frans)-4-hvdroxy-4- (hvdroxymethyl)cvclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
Perchloric acid (70%, 0 3 mL) was added to a solution of Λ/-(3-methoxybenzyl)-2-methyl-6-(2- (1 -oxaspιro[2 5]oct-6-ylmethyl)-2H-tetrazol-5-yl)pynmidine-4-carboxamide (163 mg) in a mixture of tetrahydrofuran (3 mL) and water (1 mL) The resulting slurry was warmed to afford a solution and the mixture was stirred at room temperature for 3 5 h The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing the first eluting product were neutralized by passing through a carbonate resin column and concentrated The residue was slurried and decanted from ethyl ether three times and dried in a vacuum desiccator to afford the title compound as a white solid (35 mg) MS (ES+) m/z 468 (M+H) 1H NMR (400 MHz, DMSO-d6) 6 ppm 9 48 (1 H, t, J=6 2 Hz), 8 42 (1 H, s), 7 24 (1 H, t, J=8 1 Hz), 6 90 - 6 95 (2 H, m), 6 83 (1 H, d, J=8 4 Hz), 4 75 (2 H, d, J=I 3 Hz), 4 51 (2 H, d, J=Q 2 Hz), 4 32 (1 H, t, J=5 9 Hz), 3 99 (1 H, s), 3 74 (3 H, s), 2 83 (3 H, s), 2 15 (1 H, br s ), 1 71 (2 H, d, J=10 2 Hz), 1 60 (2 H, d, J=10 2 Hz), 1 17 (3 H, d, J=9 9 Hz), 1 22 (3 H, d, J=12 8 Hz)
Example 29 W-(3-Methoxybenzyl)-6-(2-(((c/s)-4-hydroxy-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5- yl)-2-methylpyrimidine-4-carboxamide
Isolation of the second eluting product by reverse phase preparative HPLC from the reaction mixture described in Example 28 afforded the title compound as a white solid (19 mg) MS (ES+) m/z 468 (M+H) 1H NMR (400 MHz, DMSOd6) ό ppm 9 47 (1 H, t, J=Q 2 Hz), 8 41 (1 H, s), 7 24 (1 H, t, J=8 1 Hz), 6 90 - 6 95 (2 H, m), 6 83 (1 H, d, J=Q 1 Hz), 4 69 (2 H, d, J=I 0 Hz), 4 51 (2 H, d, J=6 6 Hz), 4 41 (1 H, t, J=5 7 Hz), 3 82 (1 H, s), 3 74 (3 H, s), 3 13 (2 H, d, J=5 9 Hz), 2 83 (3 H, s), 1 95 (1 H, br s ), 1 37 (3 H, d, J=9 2 Hz), 1 43 (5 H, t, J=13 0 Hz), 1 33 (1 H, br s ) Example 30
/V-(3-chloro-4-fluorobenzyl)-6-(2-((frans-4-hydroxy-4-(hydroxymethyl)cyclohexyl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of (4-oxocvclohexyl)methyl 4-methylbenzenesulfonate
Formic acid (8 mL) was added to a solution of 1 ,4-dιoxaspιro[4 5]dec-8-ylmethyl 4- methylbenzenesulfonate (prepared as described in step 1 of the synthesis of Λ/-(3-methoxybenzyl)-6- (2-(((frans)-4-hydroxy-4-(hydroxymethyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide, Example 28) (1 0 g, 3 0 mmol) in tetrahydrofuran (5 mL) The reaction was stirred at room temperature overnight, and then solvent was removed under a stream of nitrogen The residue was dissolved in dichloromethane The organic layer was washed with water (1 x), dried over magnesium sulfate, and concentrated under vacuum to afford the title compound as an oil (852 mg)
Step 2 Preparation of 1-oxaspιro[2 51oct-6-ylmethyl 4-methylbenzenesulfonate
A solution of (4-oxocyclohexyl)methyl 4-methylbenzenesulfonate (852 mg) in anhydrous dimethylsulfoxide (1 1 mL) was added in one portion to a mixture of trimethylsulfoxonium iodide (1 32 g, 6 0 mmol) and potassium f-butoxide (673 mg, 6 0 mmol) The mixture was stirred at room temperature for 1 h and then water (50 mL) was added The reaction mixture was extracted with ethyl ether (3x) The combined organic layers were washed with water (4x), dried over magnesium sulfate, and concentrated under vacuum to afford the title compound as an oil (621 mg) consisting of cis and trans isomers
Step 3 Preparation of (frans-4-hvdroxy-4-(hvdroxymethyl)cvclohexyl)methyl A- methylbenzenesulfonate
Perchloric acid (0 5 mL) was added to a solution of 1-oxaspιro[2 5]oct-6-ylmethyl 4- methylbenzenesulfonate (621 mg) in a mixture of tetrahydrofuran (4 mL) and water (2 mL) The mixture was stirred for 2 hours The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitπle) afforded the title compound as a clear oil (105 mg)
Step 4 Preparation of Λ/-(3-chloro-4-fluorobenzyl)-6-(2-((/rar7s-4-hydroxy-4- (hvdroxymethyl)cvclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
/rans-(4-Hydroxy-4-(hydroxymethyl)cyclohexyl)methyl 4-methylbenzenesulfonate (100 mg, 0 318 mmol) was added to a solution of Λ/-(3-chloro-4-fluorobenzyl)-2-methyl-6-(2/-/-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde (88 mg, 0 25 mmol) and triethylamine (140 mg, 1 38 mmol) in anhydrous dimethylacetamide (0 3 ml_) The mixture was stirred overnight at 85 0C in a capped vial The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing product were neutralized by passing through a carbonate resin column and concentrated The residue was slurried and decanted from ethyl ether three times and dried in a vacuum desiccator to afford the title compound as a white solid (35 mg) MS (ES+) m/z 490 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 61 (1 H, t, J=Q 2 Hz), 8 41 (1 H, s), 7 57 (1 H, d, J=I 0 Hz), 7 37 (2 H, d, J=I 7 Hz), 4 75 (2 H, d, J=I 7 Hz), 4 52 (2 H, d, J=6 2 Hz), 4 33 (1 H, t, «7=5 7 Hz), 4 00 (1 H, s), 3 30 (1 H, s), 2 83 (3 H, s), 2 15 (1 H, br s ), 1 71 (2 H, d, J=8 4 Hz), 1 60 (2 H, d, J= 10 2 Hz), 1 17 (2 H, d, J=9 5 Hz), 1 22 (3 H, d, J=12 8 Hz)
Example 31 rac-/V-(4-Fluoro-3-methoxybenzyl)-6-(2-(((1 S*,3R*)-3-aminocyclopentyl)methyl)-2H-tetrazol-5-yl)- 2-methylpyrimidine-4-carboxamide
Step 1 Preparation of tert-butyl rac-(1 f?*,3S*)-3-((5-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)cvclopentylcarbamate
In a 20 ml scintillation vial with a magnetic stir bar at room temperature, Λ/-(4-fluoro-3- methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(^ans-4-amιnocyclohexyl)methyl)-2/-/-tetrazol- 5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 9) (227 mg, 0 66 mmol) was combined with /erf- butyl rac-(1 S*,3R*)-3-(hydroxymethyl)cyclopentylcarbamate (193 mg, 0 90 mmol), polymer supported triphenylphosphine (247 mg, 0 531 mmol), and anhydrous tetrahydrofuran (15 ml) and stirred for 1 hour The mixture was cooled to -10 0C Di-fert-buty! azodicarboxylate (174 mg, 0 76 mmol) was added After 2 h, the reaction mixture was allowed to warm to room temperature and continue to stir for 14 hours The reaction mixture was concentrated, dissolved in acetonitrile and water and chromatographed by reversed phase preparative HPLC (Gilson, Delta Pak column, 30%-80% acetonitrile, 10 mm hold, 45 mm run, 10 mm hold) The desired product fractions were collected, combine and concentrated under vacuum to afford the title compound as a white solid (80 mg) 1H NMR (400 MHz, CDCI3) δ ppm 1 17 - 1 29 (m, 1 H), 1 41 (s, 9 H), 1 44 - 1 59 (m, 1 H), 1 61 (s, 3 H)1 1 70 (br s , 1 H), 2 01 (br s , 1 H), 2 16 (br s , 1 H), 2 59 (d, J=7 52 Hz, 1 H), 2 83 (s, 1 H), 3 88 (s, 3 H), 4 50 (br s , 1 H), 4 63 (d, J=6 18 Hz, 1 H), 4 97 (dd, J=7 52, 3 22 Hz, 2 H), 6 84 - 6 92 (m, 1 H), 6 98 (dd, J=Q 06, 1 88 Hz, 1 H), 7 05 (dd, J=U 01 , 8 32 Hz, 1 H), 8 18 - 8 30 (m, 1 H), 8 91 (s, 1 H) LC/MS (5%-95%, CH3CN/H2O,, 5 mm ) 3 428 mm, m/z 541 (M+H)
Step 2 Preparation of rac-Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(((1 S*,3f?*)-3-amιnocvclopentyl)methyl)- 2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
Trifluoroacetic acid (21 1 mg, 0 19 mmol) was added to a solution of tert-butyl rac-(1 R*,3S*)-3- ((5-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdm-4-yl)-2H-tetrazol-2- yl)methyl)cyclopentylcarbamate (80 mg, 0 15 mmol) in dichloromethane (10 mL) and the mixture was stirred at room temperature for 4 hours The reaction mixture was concentrated to afford the trifluoroacetic acid salt of the title compound (80 mg) LC/MS (5%-95%, CH3CN/H2O, 5 mm ) 2 383 mm, m/z 441 (M+H)
Example 32 rac-/V-(4-Fluoro-3-methoxybenzyl)-6-(2-(((1S*,3R*)-3-acetamidocyclopentyl)methyl)-2H-tetrazol-
5-yl)-2-methylpyrimidine-4-carboxamide
In a 2 dram vial with a magnetic stir bar at room temperature, rac-Λ/-(4-fluoro-3- methoxybenzyl)-6-(2-(((1 S*,3f?*)-3-amιnocyclopentyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide trifluoroacetic acid salt (prepared as described in Example 31 ) (40 mg, 0 7 mmol) was dissolved in Λ/,Λ/-dιmethyl formamide (2 0 ml) Acetic anhydrιde( 9 21 mg, 0 09 mmol) and N1N- dnsopropylethylamine (37 3 mg, 0 28 mmol) were added The reaction mixture was concentrated, dissolved in acetonitπle and water and chromatographed by reversed phase preparative HPLC (30% - 70% acetonitrile/water, 10 mm hold, 45 mm run, 10 mm hold) Fractions containing the desired product were collected and concentrated under vacuum to afford the title compound as a white solid (10 0 mg) 1H NMR (400 MHz, DMSOd6) S ppm 1 16 - 1 27 (m, 2 H), 1 43 - 1 55 (m, 2 H), 1 76 (s, 5 H), 2 01 (d, J=M 8 Hz, 1 H), 2 83 (s, 3 H), 3 82 (s, 3 H), 4 00 (d, J=I 3 Hz, 1 H), 4 51 (d, J=6 2 Hz, 2 H), 4 82 (br s , 1 H), 4 83 (d, J=2 2 Hz, 1 H), 6 92 (d, J=A 4 Hz, 1 H), 7 16 (td, J=M 0, 8 6 Hz, 2 H), 7 84 (br s , 1 H), 8 42 (s, 1 H), 9 48 - 9 54 (m, 1 H) LC/MS (5%-95%, CH3CN/H2O, 5 mm ) 2 842 mm, m/z 441 (M+H)
Example 33
(+)-N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((1 S*,3R*)-3-acetamidocyclopentyl)methyl)-2H-tetrazol-
5-yl)-2-methylpyrimidine-4-carboxamide
rac-Λ/-(4-Fluoro-3-methoxybenzy!)-6-(2-(((1 S\3R*)-3-acetamidocyclopentyl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 32) was separated by supercritical fluid chiral chromatography (Chiralcel AD-H column, 30 x 250 mm, 20% 2- propanol, 70 mL/min) Isolation of the first eluting isomer afforded the title compound (49 4 mg) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 2 813 mm , m/z 483 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 21 (br s , 1 H), 1 47 (d, J=5 49 Hz, 1 H), 1 70 (br s , 1 H), 1 76 (s, 3 H), 2 01 (br s , 1 H), 2 61 (br s , 1 H), 2 82 (s, 2 H), 3 37 (s, 9 H), 3 82 (s, 2 H), 4 00 (br s , 1 H), 4 50 (d, J=6 22 Hz, 1 H), 4 81 (dd, J=I 14, 2 01 Hz, 1 H), 6 90 (br s , 1 H), 7 16 (d, J=2 20 Hz, 1 H), 7 85 (br s , 1 H), 9 51 (s, 1 H) [σ]D 21'c = +3 7° (c = 0 7, dichloromethane)
Example 34 (-)-/V-(4-Fluoro-3-methoxybenzyl)-6-(2-(((1R*,3S*)-3-acetamidocyclopentyl)methyl)-2H-tetrazol-5- yl)-2-methylpyrimidine-4-carboxamide
rac-W-(4-Fluoro-3-methoxybenzyl)-6-(2-(((1 S*,3/:?*)-3-acetamιdocyclopentyl)methyl)-2/-/- tetrazol-5-yl)-2-rnethylpyπmιdιne-4-carboxamιde (prepared as described in Example 32) was separated by supercritical fluid chiral chromatography (Chiralcel AD-H column, 30 x 250 mm, 20% 2- propanol, 70 mL/min) Isolation of the second eluting isomer afforded the title compound (44 8 mg) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 2 813 mm , m/z 483 (M+H) 1H NMR (400 MHz, DMSOd6) 6 ppm 1 21 (br s , 1 H), 1 47 (d, J=5 89 Hz, 1 H), 1 70 (br s , 1 H), 1 76 (s, 3 H), 2 01 (br s , 1 H), 2 61 (br s , 1 H), 2 83 (s, 2 H), 3 37 (s, 9 H), 3 82 (s, 2 H), 4 10 (br s , 1 H), 4 51 (d, J=6 62 Hz, 1 H), 4 91 (dd, J=7 54, 2 01 Hz, 1 H), 6 90 (br s , 1 H), 7 18 (d, J=2 50 Hz, 1 H), 7 86 (br s , 1 H), 9 53 (s, 1 H) [σ]D 2rc = 4 6° (c = 0 7, dichloromethane)
Example 35 rac-W-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2-(((1S*,3R*)-3- (methylsulfonamido)cyclopentyl)methyl)-2H-tetrazol-5-yl)pyrimidine-4-carboxamide
In a 2 dram vial with a magnetic stir bar at room temperature, rac-Λ/-(4-fluoro-3- methoxybenzyl)-6-(2-(((1 S*,3R*)-3-ammocyclopentyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyπmιdιne-4- carboxamide trifluoroacetic acid salt (prepared as described in Example 31 ) (40 mg, 0 7 mmol) was dissolved in Λ/,Λ/-dιmethyl formamide (2 0 ml) Λ/,Λ/-Dιιsopropylethylamιne (28 0 mg, 0 216 mmol) and methane sulfonyl chloride (10 3 mg, 0 09 mmol) was added and the mixture was stirred for 1 h The reaction mixture was concentrated, dissolved in acetonitπle and water and chromatographed by reversed phase preparative HPLC (Gilson, Delta Pak column, 30%-70% acetonitrile, 10 mm hold, 45 mm run, 10 mm hold) Fractions containing the desired product were collect and concentrated under vacuum to afford the title compound as a white solid (10 4 mg) LC/MS (5%-95%, CH3CN/H2O, 5 mm ) 2 925 mm, m/z 519 (M+H) 1H NMR (400 MHz, DMSOd6) ό ppm 9 48 (t, J=6 2 Hz, 1 H), 8 40 (s, 1 H), 7 06 - 7 19 (m, 3 H), 6 86 - 6 91 (m, 1 H), 4 80 (d, J=7 3 Hz, 2 H), 4 48 (d, J=6 2 Hz, 2 H), 3 80 (s, 3 H), 3 59 - 3 69 (m, 1 H), 2 85 (s, 3 H), 2 81 (s, 3 H), 2 54 - 2 63 (m, 1 H), 2 02 - 2 1 1 (m, 1 H), 1 83 - 1 94 (m, 1 H), 1 62 - 1 73 (m, 1 H), 1 43 - 1 60 (m, 2 H), 1 25 - 1 36 (m, 1 H)
Example 36
(+)-Λ^4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2-(((1R*,3S*)-3- (methylsulfonamido)cyclopentyl)methyl)-2H-tetrazol-5-yl)pyrimidine-4-carboxamide
rac-Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2-(((1S\3R*)-3-
(methylsulfonamιdo)cyclopentyl)methyl)-2/-/-tetrazol-5-yl)pyπmιdιne-4-carboxamιde (prepared as described in Example 35) was separated by supercritical fluid chiral chromatography (Chiralcel OJ-H column, 30 x 250 mm, 25% methanol, 70 mUmin) Isolation of the first eluting isomer afforded the title compound (34 1 mg) MS (ES+) m/z 519 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 45 (t, J=Q 2 Hz, 1 H), 8 37 (s, 1 H), 7 03 - 7 16 (m, 3 H), 6 83 - 6 89 (m, 1 H), 4 77 (d, J=I 3 Hz, 2 H), 4 46 (d, J=6 2 Hz, 2 H), 3 78 (s, 3 H), 3 57 - 3 65 (m, 1 H), 2 83 (s, 3 H), 2 78 (s, 3 H), 2 51 - 2 60 (m, 1 H), 2 00 - 2 09 (m, 1 H), 1 82 - 1 91 (m, 1 H), 1 59 - 1 70 (m, 1 H), 1 41 - 1 58 (m, 2 H), 1 22 - 1 33 (m, 1 H) [O]D21 C = +2 9° (C = 0 7, dichloromethane)
Example 37
(.)-W-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2-(((1 S*,3fr)-3- (methylsulfonamido)cyclopentyl)methyl)-2H-tetrazol-5-yl)pyrimidine-4-carboxamide
rac-Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2-(((1 S*,3R*)-3- (methylsulfonamιdo)cyclopentyl)methyl)-2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in Example 35) was separated by supercritical fluid chiral chromatography (Chiralcel OJ-H column, 30 x 250 mm, 25% methanol, 70 mL/min) Isolation of the second eluting isomer afforded the title compound (36 9 mg) MS (ES+) m/z 519 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 50 (t, J=Q 2 Hz, 1 H), 8 42 (s, 1 H), 7 08 - 7 21 (m, 3 H), 6 88 - 6 94 (m, 1 H), 4 82 (d, J=I 3 Hz, 2 H), 4 51 (d, J=Q 2 Hz, 2 H), 3 82 (s, 3 H), 3 62 - 3 70 (m, 1 H), 2 87 (s, 3 H), 2 83 (s, 3 H), 2 55 - 2 65 (m, 1 H), 2 04 - 2 13 ((H1 1 H), 1 86 - 1 96 (m, 1 H), 1 65 - 1 74 (m, 1 H), 1 46 - 1 62 (m, 2 H), 1 27 - 1 37 (m, 1 H) [σ]D 21'C = -4 8° (c = 0 7, dichloromethane)
Example 38
/V-(3-Methoxybenzyl)-2-methyl-6-(2-((S)-morpholin-2-ylmethyl)-2H-tetrazol-5-yl)pyrimidine-4- carboxamide
Λ/-(3-Methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 6 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((/rans)-4-amιnocyclohexyl)methyl)- 2H-tetrazol-5-yl)-2-methylpynmidine-4-carboxamide, Example 5) (0 656 g, 2 02 mmol) and (S)-tert- butyl 2-(hydroxymethyl)morpholιne-4-carboxylate (438 mg, 2 02 mmol) were taken up in tetrahydrofuran (25 mL) and treated with polymer supported triphenylphosphine (1 34 g, 3 02 mmol) After stirring for 30 mm at room temperature, dι-/ert-butyl azodicarboxylate (557 mg, 2 42 mmol) was added After 36 h at room temperature, the reaction was filtered to remove the resin The filtrate was concentrated to a crude residue as a yellow oil The residue was purified via normal phase chromatography (silica, 0-75% ethyl acetate/heptane with a trace 1 % methanol ran through entire gradient) Fractions containing (2S)-ferf-butyl 2-((5-(6-((3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2H-tetrazol-2-yl)methyl)morpholιne-4-carboxylate were concentrated The residue was taken up in dichloromethane (5 mL) and stirred with trifluoroacetic acid (1 mL) After 3 h stirring at room temperature, additional dichloromethane (5 mL) was added and the reaction was neutralized with 2 5 N aqueous NaOH to pH 7-8 The organic layer was separated and washed with water, dried over sodium sulfate, and concentrated to afford a regioisomeric mixture of products (0 28 g) containing the title compound LC/MS (5%-95% CH3CN/H2O, 6 mm) 2 9 mm, m/z 525 (M+H)
Example 39
A/-(3-Methoxybenzyl)-6-(2-(((S)-4-acetylmorpholin-2-yl)methyl)-2H-tetrazol-5-yl)-2- methylpyrimidine-4-carboxamide
.
A regioisomeric mixture (0 13 g) containing Λ/-(3-methoxybenzyl)-2-methyl-6-(2-((S)- morpholιn-2-ylmethyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in Example 38) was taken up in dichloromethane (2 mL) and treated with triethylamine (0 047 mL, 0 38 mmol) and a solution of acetyl chloride (0 033 mL, 0 46 mmol) in dichloromethane (1 mL) After stirring for 2 h at room temperature, the mixture was concentrated and purified via reverse phase chromatography (40- 60% acetonitrile/water, 45 mm) Under these conditions, isolation of the first compound to elute afforded the title compound as a white solid (31 mg, 20%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 2 52 mm, m/z 467 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 2 01 (3 H, d, J=17 0 Hz), 2 56 - 2 74 (1 H, m), 2 81 (3 H, s), 3 40 (1 H, d, J=11 O Hz), 3 63 (1 H, d, J=1 1 0 Hz), 3 71 (3 H, s), 3 79 (1 H, d, J=7 9 Hz), 3 88 - 4 13 (2 H, m), 4 37 (1 H, d, J=14 3 Hz), 4 49 (2 H, d, J=6 2 Hz), 4 85 - 5 07 (2 H, m), 6 80 (1 H, d, J=7 9 Hz), 6 91 (2 H, br s ), 7 14 - 7 29 (1 H, m), 8 40 (1 H, s), 9 47 (1 H, s)
Example 40
/V-(3-Methoxybenzyl)-2-methyl-6-(2-(((/?)-4-(methylsulfonyl)morpholin-2-yl)methyl)-2H-tetrazol-5- yl)pyrimidine-4-carboxamide
A regioisomeric mixture (0 13 g) containing Λ/-(3-methoxybenzyl)-2-methyl-6-(2-((S)- morpholιn-2-ylmethyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in Example 38) was taken up in dichloromethane (2 mL) and treated with triethylamine (0 047 mL, 0 38 mmol) and a solution of methane sulfonyl chloride (0 026 mL, 0 32 mmol) in dichloromethane (1 mL) After stirring for 2 h at room temperature, the mixture was concentrated and purified via reverse phase chromatography (40-60% acetonitrile/water, 45 mm) Under these conditions, isolation of the first compound to elute afforded the title compound as a white solid (34 mg, 22%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 3 99 mm, m/z 503 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 2 68 - 2 88 (5 H, m), 2 91 (3 H, s), 3 34 (1 H1 br s ), 3 50 (1 H, t, J=10 8 Hz), 3 67 (1 H, d, J=11 7 Hz), 3 71 (3 H, s), 3 89 (1 H, d, J=1 1 0 Hz), 4 13 (1 H, t, J=9 0 Hz), 4 49 (2 H, d, J=6 4 Hz), 4 89 - 5 00 (1 H, m), 5 03 - 5 13 (1 H, m), 6 80 (1 H1 d, J=6 6 Hz), 6 91 (2 H, br s ), 7 22 (1 H, t, J=8 1 Hz), 8 40 (1 H, s), 9 47 (1 H, s)
Example 41
W-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2-((S)-morpholin-2-ylmethyl)-2H-tetrazol-5- yl)pyrimidine-4-carboxamide
Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyπmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(/rans-4- aminocyclohexy^methyl^H-tetrazol-S-yl^-methylpyπmidine^-carboxamide, Example 9) (1 00 g, 2 91 mmol) and (S)-tert-buty! 2-(hydroxymethyl)morpholιne-4-carboxylate (633 mg, 2 91 mmol) were taken up in tetrahydrofuran (50 mL) and treated with polymer supported tπphenylphosphine (1 94 g, 4 37 mmol) After stirring for 30 mm at room temperature, di-fert-butyl azodicarboxylate (895 mg, 3 50 mmol) was added After 15 h at room temperature, the reaction was filtered to remove the resin The filtrate was concentrated to a crude oily residue The residue was purified via normal phase chromatography (silica, 0-75% ethyl acetate/heptane with a trace 1% methanol ran through entire gradient) Fractions containing (2S)-tert-butyl 2-((5-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2H-tetrazol-2-yl)methyl)morpholιne-4-carboxylate were concentrated The residue was taken up in dichloromethane (10 mL) and stirred with trifluoroacetic acid (3 mL) After 3 h stirring at room temperature, additional dichloromethane (5 mL) was added and the reaction was neutralized with 2 5 N aqueous NaOH to pH 7-8 The organic layer was separated and washed with water (2 mL), dried over sodium sulfate, and concentrated to afford a regioisomeric mixture of products (0 57 g) containing the title compound LC/MS (5%-95% CH3CN/H2O, 6 mm) 2 33 mm, m/z 443 (M+H)
Example 42
N-(4-fluoro-3-methoxybenzyl)-6-(2-(((S)-4-acetylmorpholin-2-yl)methyl)-2H-tetrazol-5-yl)-2- methylpyrimidine-4-carboxamide
A regioisomeric mixture (0 065 g) containing Λ/-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2-((S)- morpholιn-2-ylmethyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in Example 41 ) was taken up in dichloromethane (2 mL) and treated with triethylamine (0 033 ml_, 0 24 mmol) and a solution of acetyl chloride (0 016 mL, 0 23 mmol) in dichloromethane (1 mL) After stirring for 2 h at room temperature, the mixture was concentrated and the crude residue was purified via reverse phase chromatography (40-60% acetonitrile/water, 45 mm) Under these conditions, isolation of the first peak to elute afforded the title compound as a white solid (35 mg, 49%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 3 75 mm, m/z 485 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 1 94 - 2 02 (3 H, m), 2 58 - 2 73 (1 H, m), 2 85 (3 H, s), 3 04 - 3 20 (1 H, m), 3 60 (1 H, d, J=13 2 Hz), 3 67 - 3 76 (1 H, m), 3 80 (3 H, s), 3 83 - 3 93 (1 H, m), 3 97 - 4 06 (1 H, m), 4 40 (1 H, d, J=13 2 Hz), 4 49 (2 H, d, J=6 4 Hz), 4 93 - 5 01 (1 H, m), 5 08 (1 H, d, J=9 7 Hz), 6 83 - 6 92 (1 H, m), 7 06 - 7 20 (2 H, m), 8 46 (1 H, s), 9 54 (1 H, t, J=6 0 Hz)
Example 43 Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2-(((/?)-4-(methylsulfonyl)morpholin-2-yl)methyl)-2H- tetrazol-5-yl)pyrimidine-4-carboxamide
A regioisomeric mixture (0 15 g) containing Λ/-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2-((S)- morpho!ιn-2-ylmethyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in Example 41 ) was taken up in dichloromethane (3 mL) and treated with triethylamine (0 052 mL, 0 37 mmol) and a solution of methane sulfonyl chloride ( 0 029 mL, 0 34 mmol) in dichloromethane (1 mL) After stirring for 2 h at room temperature, the mixture was concentrated and purified via reverse phase chromatography (40-60% acetonitrile/water, 55 mm) Under these conditions, isolation of the first eluted compound afforded the title compound as a white solid (68 mg, 39%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 3 94 mm m/z 521 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 2 73 - 2 88 (5 H, m), 2 91 (3 H, s), 3 32 (1 H, d, J=1 1 3 Hz), 3 44 - 3 55 (1 H, m), 3 65 (1 H, s), 3 80 (3 H, s), 3 89 (1 H, d, J=1 1 7 Hz), 4 06 - 4 16 (1 H, m), 4 48 (2 H, d, J=6 4 Hz), 4 89 - 4 99 (1 H, m), 5 01 - 5 12 (1 H, m), 6 89 (1 H, br s ), 7 06 - 7 21 (2 H, m), 8 40 (1 H, s), 9 49 (1 H, t, J=6 4 Hz)
Example 44 W-(3-Methoxybenzyl)-2-methyl-6-(2-((R)-morpholin-2-ylmethyl)-2H-tetrazol-5-yl)pyrimidine-4- carboxamide
Λ/-(3-Methoxybenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 6 of the synthesis of /V-(3-methoxybenzyl)-6-(2-(((frans)-4-amιnocyclohexyl)methyl)- 2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 5) (1 00 g, 3 07 mmol) and (R)-terf-butyl 2-(hydroxymethyl)morpholιne-4-carboxylate (801 mg, 3 69 mmol) were taken up in tetrahydrofuran (50 mL) and treated with polymer supported triphenylphosphine (2 05 g, 4 61 mmol) After stirring for 30 mm at room temperature, di-fert-butyl azodicarboxylate (849 mg, 3 69 mmol) was added After 15 h at room temperature, the reaction was filtered to remove the resin The filtrate was concentrated to a crude oily residue The residue was purified via normal phase chromatography (silica, 0-75% ethyl acetate/heptane with a trace 1 % methanol ran through entire gradient) Fractions containing (2R)-tert- butyl 2-((5-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-2H-tetrazol-2- yl)methyl)morpholιne-4-carboxylate were concentrated The residue was taken up in dichloromethane (10 mL) and stirred with trifluoroacetic acid (3 mL) After 3 h stirring at room temperature, additional dichloromethane (5 mL) was added and the reaction was neutralized with 2 5 N aqueous NaOH to pH 7-8 The organic layer was separated, washed with water, dried over sodium sulfate, and concentrated to afford a regioisomeπc mixture of products (0 85 g) containing the title compound LC/MS (5%-95% CH3CN/H2O, 6 mm) 2 69 mm, m/z 425 (M+H)
Example 45
^-(S-MethoxybenzyO-e^Z-i^RJ^-acetylmorpholin^-yOmethyO-ΣH-tetrazol-S-yl)^- methylpyrimidine-4-carboxamide
A regioisomeric mixture (0 42 g) containing Λ/-(3-methoxybenzyl)-2-methyl-6-(2-((R)- morpholιn-2-ylmethyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in Example 44) was taken up in dichloromethane (4 mL) and treated with tnethylamine (0 193 mL, 1 4 mmol) and a solution of acetyl chloride (0 077 mL, 0 1 1 mmol) in dichloromethane (1 mL) After stirring for 2 h at room temperature, the mixture was concentrated and purified via reverse phase chromatography (40- 60% acetonitπle/water, 60 mm) Under these conditions, isolation of the first compound to elute afforded the title compound as a white solid (67 mg, 15%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 3 66 mm, m/z 467 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 2 01 (3 H, d, J=17 0 Hz), 2 59 - 2 73 (1 H, m), 2 81 (3 H, s), 3 42 (1 H, t, J=1 1 0 Hz), 3 63 (1 H, d, J=13 0 Hz), 3 71 (3 H, s), 3 80 (1 H, d, J=9 7 Hz), 3 89 - 4 13 (2 H, m), 4 37 (1 H, d, J=13 0 Hz), 4 49 (2 H, d, J=6 4 Hz), 4 86 - 5 09 (2 H, m), 6 80 (1 H, d, J=7 7 Hz), 6 91 (2 H, br s ), 7 22 (1 H, t, J=8 1 Hz), 8 40 (1 H, s), 9 47 (1 H, t, J=6 4 Hz) Example 46
Λ/-(3-Methoxybenzyl)-2-methyl-6-(2-(((S)-4-(methylsulfonyl)morpholιn-2-vπmethyl)-2H-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde
A regioisomeric mixture (0 42 g) containing Λ/-(3-methoxybenzyl)-2-methyl-6-(2-((R)- morpholιn-2-ylmethyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in Example 44) was taken up in dichloromethane (5 mL) and treated with triethylamine (0 193 mL, 1 40 mmol) and a solution of methane sulfonyl chloride (0 087 mL, 1 1 mmol) in dichloromethane (1 mL) After stirring for 2 h at room temperature, the mixture was concentrated and purified via reverse phase chromatography (40-60% acetonitrile/water, 60 mm) Under these conditions, isolation of the first compound to elute afforded the title compound as a white solid (43 mg, 9%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 3 95 mm, m/z 503 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 2 71 - 2 88 (5 H, m), 2 91 (3 H, s), 3 32 (1 H, d, J=13 0 Hz), 3 42 - 3 54 (1 H, m), 3 67 (1 H, d, J=1 1 7 Hz), 3 71 (3 H, s), 3 89 (1 H, d, J=12 1 Hz), 4 13 (1 H, t, J=9 0 Hz), 4 49 (2 H, d, J=6 4 Hz), 4 85 - 5 01 (1 H, m), 5 01 - 5 12 (1 H, m), 6 80 (1 H, d, J=8 1 Hz), 6 91 (2 H, br s ), 7 22 (1 H, t, J=8 1 Hz), 8 40 (1 H, s), 9 47 (1 H, t, J=6 3 Hz)
Example 47
W-(3-Chloro-4-fluorobenzyl)-2-methyl-6-(2-((S)-morpholin-2-ylmethyl)-2H-tetrazol-5- yl)pyrimidine-4-carboxamide
Step 1 Preparation of Λ/-(3-chloro-4-fluorobenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4- carboxamide
Methyl 2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxylate (prepared as described in step 1 of the synthesis of Λ/-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((frans)-4- acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 17) (3 03 g, 13 8 mmol), 3-chloro-4-fluorobenzylamιne (2 31 g, 14 4 mmol) and triethylamine (2 78 g, 27 5 mmol) were combined in dimethylacetamide (30 mL) The resulting mixture was stirred at 25 0C for 18 h The solvent was removed and the product was slurried with 3N hydrochloric acid (100 mL) The precipitate was collected by suction filtration, washed with water (2 x 25 mL) and dried under vacuum to afford the title compound as a tan solid (2 08 mg, 44%) LC/MS (10%-90% CH3CN/H2O, 4 mm) 2 74 mm, m/z 348 (M+H)
Step 2 Preparation of (2SHert-butyl 2-((5-(6-((3-chloro-4-fluorobenzyl)carbamoyl)-2-methylpyrιmιdιn- 4-yl)-2/-/-tetrazol-2-yl)methyl)morpholιne-4-carboxylate
Λ/-(3-Chloro-4-fluorobenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyπmιdιne-4-carboxamιde (750 mg, 2 16 mmol) and (S)-tert-butyl 2-(hydroxymethyl)morpholιne-4-carboxylate (562 mg, 2 59 mmol) were taken up in tetrahydrofuran (40 mL) and treated with polymer supported triphenylphosphine (1 44 g, 3 24 mmol) After stirring for 30 mm at room temperature, di-tert-butyl azodicarboxylate (596 mg, 2 59 mmol) was added After 36 h at room temperature, the reaction was filtered to remove the resin The filtrate was concentrated and the residue was purified via normal phase chromatography (silica, 0-75% ethyl acetate/heptane with a trace 1 % methanol ran through entire gradient) The resulting regioisomeπc mixture was further purified by reverse phase chromatography (40-65%, acetonitπle/water, 60 minutes) Isolation of the first compound to elute afforded the title compound (0 10 g, 8%)
Step 3 Preparation of Λ/-(3-chloro-4-f1uorobenzyl)-2-methyl-6-(2-((S)-morpholιn-2-ylmethyl)-2/-/- tetrazol-5-yl)pyrιmιdιne-4-carboxamιde
(2S)-tert-Butyl 2-((5-(6-((3-chloro-4-fluorobenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-2H- tetrazol-2-yl)methyl)morpholme-4-carboxylate, (0 10 g, 0 18 mmol) was taken up in dichloromethane (1 mL) and stirred with trifluoroacetic acid (0 5 mL) After 3 h stirring at room temperature, additional dichloromethane (5 mL) was added and the reaction was neutralized with 2 5 N aqueous NaOH to pH 7-8 The organic layer was separated, washed with water, dried over sodium sulfate, and concentrated to afford the title compound as an oil (0 065 g, 7%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 2 30 mm, m/z 447 (M+H) Example 48
W-(3-Chloro-4-fluorobenzyl)-2-methyl-6-(2-(((R)-4-(methylsulfonyl)morpholin-2-yl)methyl)-2H- tetrazol-5-yl)pyrimidine-4-carboxamide
Λ/-(3-Chloro-4-fluorobenzyl)-2-methyl-6-(2-((S)-morpholιn-2-ylmethyl)-2/-/-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde (prepared as described in Example 47) (0 065 g, 0 15 mmol) was taken up in dichloromethane (2 mL) and treated with triethylamine (O 018 ml_, 0 1 1 mmol) and a solution of methane sulfonyl chloride (13 5 mg, 0 19 mmol) in dichloromethane (0 5 mL) After stirring for 2 h at room temperature, the mixture was concentrated The resulting residue was triturated with diethyl ether to afford the title compound as a beige solid (38 5 mg, 68%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 4 23 mm, 525 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 2 71 - 2 87 (5 H, m), 2 89 (3 H, s), 3 27 - 3 33 (1 H, m), 3 41 - 3 52 (1 H, m), 3 64 (1 H, d, J=1 1 5 Hz), 3 86 (1 H, d, J=9 2 Hz), 4 06 - 4 15 (1 H, m), 4 47 (2 H, d, J=6 2 Hz), 4 86 - 4 97 (1 H, m), 5 00 - 5 08 (1 H, m), 7 28 - 7 36 (2 H, m), 7 52 (1 H, d, J=7 9 Hz), 8 37 (1 H, s), 9 56 (1 H, t, J=6 2 Hz)
Example 49
Λ/-(3-Ethyl-4-fluorobenzyl)-2-methyl-6-(2-((S)-morpholιn-2-ylmethyl)-2/-/-tetrazol-5-yl)pγrιmιdιne-4- carboxamide
Step 1 Preparation of ethyl 3-bromo-4-fluorobenzoate
To a solution of 3-bromo-4-fluorobenzoιc acid (48 g, 219 18 mmol) in ethanol (250 mL) was added cone H2SO4 (15 mL) and the mixture was refluxed for 24 h The reaction mixture was concentrated under reduced pressure and the residue was extracted with dichloromethane (2 x 300 mL) The combined organic layers were washed with saturated NaHCO3 solution followed by brine solution, dried over sodium sulfate, and concentrated under reduced pressure to afford the title compound (50 5 g, 93 %) Step 2 Preparation of ethyl 3-ethyl-4-fluorobenzoate
Ethylmagnesium bromide (2 0 M in ether, 137 61 mL, 275 23 mmol) was added slowly to a solution of anhydrous ZnCI2 (37 43 g, 275 23 mmol) in dry tetrahydrofuran (200 mL) under argon atmosphere The resulting white slurry was stirred at 50 0C for 3 h In a separate flask, a solution of ethyl 3-bromo-4-fluorobenzoate (17 g, 68 80 mmol) in dry tetrahydrofuran (50 mL) was sequentially treated with PdCI2(dppf) (2 8 g, 3 44 mmol) and copper(l) iodide (0 78 g, 4 12 mmol) under an argon atmosphere and the mixture was stirred at room temperature for 30 mm The alkyl zinc slurry was added to the ester mixture at room temperature The resulting brown slurry was stirred in the dark at room temperature for 48 h The reaction mixture was concentrated under vacuum to give a dark brown residue which was taken up in ethyl acetate (75OmL) and washed sequentially with 1 N hydrochloric acid (300 mL) solution, sat NaHCO3 (200 mL) solution and brine (250 mL) solution The organic layer was concentrated in vacuo to obtain crude material which was purified by column chromatography over silica gel (100-200 mesh) using 5 % EtOAc in hexane as an eluent to afford the title compound (12 5 g, 93 %)
Step 3 Preparation of 3-ethyl-4-fluorobenzoιc acid
Ethyl 3-ethyl-4-fluorobenzoate (12 5 g, 63 7 mmol) and lithium hydroxide monohydrate were taken up in dioxane (250 mL) and water (1/1 ) and stirred overnight at room temperature The reaction mixture was concentrated under reduced pressure and the residue was acidified with 1 N hydrochloric acid under ice-water cold conditions The mixture was extracted with dichloromethane (2 x 150 mL) The combined organic layers were washed with brine solution, dried over sodium sulfate and concentrated to afford the title compound (10 g, 95 %)
Step 4 Preparation of 3-ethyl-4-fluorobenzamιde
3-Ethyl-4-fluorobenzoιc acid (10 3 g, 61 3 mmol) was taken up in SOCI2 (150 mL) and then refluxed for 4 h The SOCI2 was removed under reduced pressure and the residue was dissolved in dry acetonitrile (100 mL) Ammonia gas was passed through the solution at -78 °C for 10 mm and the reaction mixture was allowed to warm to room temperature very slowly and stirred overnight The reaction mixture was concentrated to a residue which was extracted with dichloromethane (2 x 100 mL) The combined organic layers were washed with sat NaHCO3 solution followed by brine solution, dried over sodium sulfate, and concentrated The residue was washed with hexane to afford the title compound (9 0 g, 88 % )
Step 5 Preparation of (3-ethyl-4-fluorophenyl)methanamιne Borane dimethylsulfide complex (94%, 22 mL, 215 49 mmol) was added slowly to a solution of
3-ethyl-4-fluorobenzamιde (9 0 g, 53 87 mmol) in dichloromethane (200 mL) under ice-cold condition After the addition, the reaction mixture was stirred for 1 h at room temperature and then it was refluxed for 24 h The reaction mixture was cooled to 00C and washed with NaHCO3 solution followed by brine The organic layer was concentrated to a crude material which was purified by column chromatography over silica gel (100-200 mesh) using 15 % dichloromethane in hexane as an eluent to afford (3-ethyl- 4-fluorophenyl)methanamιne as a solid (4 8 g, 58 %) MS (ES+) m/z 154 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 23 (t, 3 H) 1 76 (br s , 1 H) 2 67 (q, 2 H), 3 77 (br s , 1 H), 3 88 (s, 2 H), 7 01 -7 15 (m, 3 H)
Step 6 Preparation of Λ/-(3-ethyl-4-fluorobenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide
A solution of methyl 2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxylate (prepared as described in step 1 of the synthesis of Λ/-(4-fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((frans)-4- acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 17) (1 0 g, 4 54 mmol) in dimethylformamide (5 mL) was treated with (3-ethyl-4-fluorophenyl)methanamιne (2 09 g, 13 6 mmol) and heated to 65 0C for 3 days The mixture was cooled to room temperature Excess 2 5 N NaOH was added to the mixture The product mixture was washed with ethyl acetate (3 x 10 mL) Concentrated hydrochloric acid was added and the resulting precipitate was filtered, washed with water and dried in vacuo to afford the title compound (367 mg, 24%) Step 7 Preparation of (S)-tert-butyl 2-((tosyloxy)methyl)morpholιne-4-carboxylate
(S)-tert-Butyl 2-(hydroxymethyl)morpholιne-4-carboxylate (5 00 g, 23 0 mmol) was taken up in pyridine (10 mL) and then treated with p-toluene sulfonyl chloride (5 70 g, 29 9 mmo!) The reaction was allowed to stir at room temperature for 15 h The mixture was poured into cold water (50 mL) and extracted with ethyl acetate (2 * 50 mL) The organic layers were washed with water (3 * 40 mL) followed by brine (40 mL), dried over sodium sulfate, and concentrated The residue was purified on normal phase silica (50 g, 0-75% ethyl acetate/heptane) to afford the title compound as a white solid (7 3 g, 85%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 3 17 mm, m/z 394 (M+Na)
Step 8 Preparation of Λ/-(3-ethyl-4-fluorobenzyl)-2-methyl-6-(2-((S)-morpholιn-2-ylmethyl)-2/-/-tetrazol- 5-yl)pyrιmιdιne-4-carboxamιde
Λ/-(3-Ethyl-4-fluorobenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (430 mg, 1 26 mmol) and (S)-tert-butyl 2-((tosyloxy)methyl)morpholιne-4-carboxylate (515 mg, 1 39 mmol) were taken up in triethylamine (7 0 mL) and dimethylformamide (0 010 mL) The reaction was stirred at 80 0C for 15 h and was then concentrated This residue was purified on normal phase silica (20 g, 0-75% ethyl acetate/heptane with 1 % methanol trace running throughout gradient) Fractions containing (2S)- tert-butyl 2-((5-(6-((3-ethyl-4-fluorobenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-2H-tetrazol-2- yl)methyl)morpholιne-4-carboxylate were concentrated The residue was taken up in dichloromethane (4 mL) and stirred with trifluoroacetic acid (1 mL) for 2 h at room temperature Additional dichloromethane (5 mL) was added and the reaction was neutralized with 2 5 N aqueous NaOH to pH 7-8 The organic layer was separated, dried over sodium sulfate, and concentrated to afford a regioisomeric mixture of products (0 41 g) containing the title compound LC/MS (5%-95% CH3CN/H2O, 6 mm) 2 46 mm, m/z 441 (M+H)
Example 50
Λ/-(3-Ethyl-4-fluorobenzyl)-2-methyl-6-(2-(((f?)-4-(methylsulfonyl)morpholιn-2-yl)methyl)-2H-tetrazol-5- vl)pyrιmιdιne-4-carboxamιde
A regioisomeric mixture (0 40 g) containing Λ/-(3-ethyl-4-fluorobenzyl)-2-methyl-6-(2-((S)- morpholιn-2-ylmethyl)-2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in Example 49) (0 40 g, 0 91 mmol) was taken up in dichloromethane (2 mL) and treated with triethylamine (0 512 mL, 1 09 mmol) and a solution of methane sulfonyl chloride (114 mg, 1 00 mmol) in dichloromethane (0 5 mL) After stirring for 2 h at room temperature, the mixture was concentrated and purified via reverse phase chromatography (40-65% acetonitrile/water, 60 minutes) to afford the title compound as a white solid (36 mg, 8%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 4 41 mm, 519 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 06 - 1 16 (2 H, m), 1 21 (2 H, d, J=5 3 Hz), 2 55 (1 H, s), 2 70 - 2 83 (4 H, m), 2 89 (3 H, s), 3 21 - 3 35 (1 H, m), 3 40 - 3 52 (1 H, m), 3 59 - 3 71 (1 H, m), 3 86 (1 H, d, J=1 1 0 Hz), 4 01 - 4 14 (1 H, m), 4 44 (2 H, d), 4 87 - 4 97 (1 H, m), 4 99 - 5 07 (1 H, m), 6 95 - 7 04 (2 H, m), 7 16 (1 H, d, J=5 5 Hz), 7 22 - 7 29 (1 H, m), 8 38 (1 H, s), 9 46 (1 H, t, J=6 5 Hz)
Example 51 rac-6-(2-((1 ,4-Dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-/V-(3-methoxybenzyl)-2-methylpyrimidine-4- carboxamide
A mixture of /V-(3-methoxybenzyl)-2-me{hyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 6 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((/rans)-4- amιnocyclohexy!)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 5) (300 mg, 0 92 mmol), 2-ιodomethyl-1 ,4-dιoxane (421 mg, 1 84 mmol), triethylamine (0 51 mL, 3 69 mmol) and dimethylacetamide (0 5 mL) was stirred at 85 0C for 2 days The mixture was purified by reverse phase preparative HPLC Fractions containing the desired product were combined, isolated and concentrated to afford the title compound as a white solid (146 mg, 37%) LC/MS (5%-95% CH3CN/H2O, 4 mm , 95% CH3CN, 1 mm ) 2 75 mm, m/z 426 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 2 83 (s, 3 H), 3 38 - 3 59 (m, 3 H), 3 65 (d, J=10 6 Hz, 1 H), 3 73 - 3 75 (m, 4 H), 3 91 (dd, J= 11 5, 2 38 Hz, 1 H), 4 11 - 4 20 (m, 1 H), 4 51 (d, J=6 2 Hz, 2 H), 4 93 (d, J=6 2 Hz, 2 H), 6 89 - 6 96 (m, 2 H), 7 24 (t, J=8 05 Hz, 1 H), 8 42 (s, 1 H), 9 49 (t, J=6 4 Hz, 1 H)
Example 52 rac-6-(2-((1 ,4-Dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-/V-(4-fluoro-3-methoxybenzyl)-2- methylpyrimidine-4-carboxamide
A mixture of Λ/-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2- (/rans^-aminocyclohexyOmethyO^H-tetrazol-δ-yO^-methylpyrimidine^-carboxamide, Example 9) (300 mg, 0 87 mmol), 2-ιodomethyl-1 ,4-dιoxane (399 mg, 1 75 mmol), triethylamine (0 97 mL, 6 99 mmol) and dimethylacetamide (0 5 mL) was stirred at 85 0C for 2 days The mixture was purified by reverse phase preparative HPLC Fractions containing the desired product were combined, isolated and concentrated to afford the title compound as a white solid (147 mg, 38%) LC/MS (5%-95% CH3CN/H2O, 4 mm , 95% CH3CN, 1 mm ) 2 78 mm, m/z 444 (M+H) 1H NMR (400 MHz, DMSOd6) ό ppm 2 83 (s, 3 H), 3 38 - 3 59 (m, 3 H), 3 65 (d, J=10 6 Hz, 1 H), 3 73 (d, J= 1 1 0 Hz, 1 H), 3 83 (s, 3 H), 3 91 (dd, J= 11 5, 2 4 Hz, 1 H), 4 09 - 4 21 (m, 1 H), 4 51 (d, J=6 2 Hz, 2 H), 4 93 (d, J=6 2 Hz, 2 H), 6 87 - 6 95 (m, 1 H), 7 09 - 7 22 (m, 2 H), 8 42 (s, 1 H), 9 51 (t, J=6 2 Hz, 1 H)
Example 53
6-(2-(((R)-1 ,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-/V-(3-methoxybenzyl)-2-methylpyrimidine-4- carboxamide
Step 1 Preparation of (R)-(1 ,4-dιoxan-2-yl)methanol S-Epichlorohydrin (8 00 g, 86 5 mmol) was added drop wise to a stirred solution of chloro-2- ethanol (20 90 g, 259 0 mmol) and boron trifluoride diethyl etherate (0 12 mL, 1 3 mmol) at 45 0C After 1 5 hours, the reaction mixture was allowed to cool and was diluted with ethyl ether (50 mL) The mixture was washed with water (25 mL) The organic layer was dried over sodium sulfate and concentrated under reduced pressure with no heating to afford the intermediate, (S)-2-((2- chloroethoxy)methyl)oxιrane The oxirane was added drop wise to a stirred solution of sodium hydroxide (8 65 g, 216 mmol) in water (12 mL) The reaction mixture was stirred at room temperature for 2 hours and then was heated at 90 0C for 2 hours The reaction mixture was extracted with dichloromethane (3 x 30 mL) The combined organic layers were concentrated to afford the title compound (5 1 g) Step 2 Preparation of (S)-(1 ,4-dιoxan-2-yl)methyl 4-methγlbenzenesulfonate
p-Toluene sulfonyl chloride (8 75 g, 45 9 mmol) was added to a solution of (R)-(1 ,4-dιoxan-2- yl)methanol (5 1 g) in pyridine (50 mL) The mixture was stirred at room temperature for 15 hours The reaction mixture was poured into ice cold water and then extracted with dichloromethane (3 x 50 mL) The combined organic layers were washed with water (5 x 20 mL), dried over sodium sulfate and concentrated in vacuo to afford the title compound as an amber oil (6 1 g) LC/MS (5%-95% CH3CN/H2O, 6 mm) 2 50 mm, m/z 273 (M+H) Step 3 Preparation of 6-(2-(((ff)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-Λ/-(3-methoxybenzyl)-2- methylpyrιmιdιne-4-carboxamιde
A mixture of Λ/-(3-methoxybenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyπmιdιne-4-carboxamιde (prepared as described in step 6 of the synthesis of Λ/-(3-Methoxybenzyl)-6-(2-(((frans)-4- aminocyclohexyOmethyO^H-tetrazol-S-yO^-methylpyrimidine^-carboxamide, Example 5) (100 mg, O 307 mmol), (S)-(1 , 4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (167 mg, 0 615 mmol), tπethylamine (0 17 mL, 1 23 mmol) and dimethylacetamide (0 3 mL) was stirred at 85 0C for 18 hours The mixture was purified by reverse phase preparative HPLC Fractions containing the desired product were combined, isolated and concentrated to afford the title compound as a white solid (39 mg, 30%) LC/MS (5%-95% CH3CN/H2O, 4 mm , 95% CH3CN, 1 mm ) 2 75, m/z 426 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 2 83 (s, 3 H), 3 38 - 3 58 (m, 3 H), 3 64 (d, J=10 8 Hz, 1 H), 3 70 - 3 77 (m, 4 H), 3 92 (dd, J=1 1 4, 2 4 Hz, 1 H), 4 10 - 4 19 (m, 1 H), 4 51 (d, J=6 5 Hz, 2 H), 4 92 (d, J=1 6 Hz, 2 H), 6 83 (dd, J=9 0, 1 6 Hz, 1 H), 6 90 - 6 95 (m, 2 H), 7 24 (t, J=8 1 Hz, 1 H), 8 42 (s, 1 H), 9 54 (t, J=6 4 Hz, 1 H)
Example 54
6-(2-(((R)-1 ,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-/V-(4-fluoro-3-methoxybenzyl)-2- methylpyrimidine-4-carboxamide
A mixture of Λ/-(4-fluoro-3-methoxybenzyi)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2- (frans-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 9) (100 mg, 0 291 mmol), (S)-(1 , 4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 2 of the synthesis of 6-(2-(((R)-1 ,4-dιoxan-2-yl)methy!)-2H-tetrazol-5-yl)-Λ/-(3-methoxybenzyl)- 2-methylpyπmιdιne-4-carboxamιde, Example 53) (159 mg, 0 583 mmol), triethylamine (0 16 mL, 1 17 mmol) and dimethylacetamide (0 3 mL) was stirred at 85 0C for 18 hours The mixture was purified by reverse phase preparative HPLC Fractions containing the desired product were isolated and concentrated to afford the title compound as a white solid (51 mg, 39%) LC/MS (5%-95% CH3CN/H2O, 4 mm , 95% CH3CN, 1 mm ) 2 78 mm, m/z 444 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 2 83 (s, 3 H), 3 38 - 3 58 (m, 3 H), 3 65 (d, J=10 6 Hz, 1 H), 3 73 (d, J=11 4 Hz, 1 H), 3 83 (s, 3 H), 3 91 (dd, J= 1 1 5, 2 4 Hz, 1 H), 4 1 1 - 4 19 (m, 1 H), 4 51 (d, J=6 2 Hz, 2 H), 4 93 (d, J=6 2 Hz, 2 H), 6 88 - 6 94 (m, 1 H), 7 09 - 7 22 (m, 2 H), 8 42 (s, 1 H), 9 51 (t, J=6 4 Hz, 1 H) Example 55
6-(2-(((/?)-1 ,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-/V-(3-chloro-4-fluorobenzyl)-2- methylpyrimidine-4-carboxamide
Λ/-(3-Chloro-4-fluorobenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 1 of the synthesis of Λ/-(3-chloro-4-fluorobenzyl)-2-methyl-6-(2-((S)-morpholιn-2- ylmethyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 47) (150 mg, 0 43 mmol) and (S)-(1 , 4- dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 2 of the synthesis of 6- (2-(((f?)-1 ,4-dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-Λ/-(3-methoxybenzyl)-2-methylpyrιmιdιne-4- carboxamide, Example 53) (129 mg, 0 47 mmol) were taken up in triethylamine (2 00 mL) and dimethylformamide (0 033 mL) The reaction was heated at 90 0C while shaking on a reactor block for 15 h The mixture was concentrated and the residue was purified by reverse phase chromatography to afford the title compound as an oil (29 mg, 15%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 4 25 mm, m/z 448 (M+H) 1H NMR (400 MHz, DMSO-d6) ό ppm 2 81 (3 H, s), 3 35 - 3 57 (3 H, m), 3 62 (1 H, d, J=10 6 Hz), 3 71 (1 H, d, J=1 1 2 Hz), 3 89 (1 H, dd, J=11 53, 2 4 Hz), 4 06 - 4 20 (1 H, m), 4 49 (2 H, d, J=6 4 Hz), 4 90 (2 H, d, J=6 4 Hz), 7 35 (2 H, d, J=7 1 Hz), 7 54 (1 H, d, J=7 3 Hz), 8 39 (1 H, s), 9 59 (1 H, t, J=6 2 Hz)
Example 56
6-(2-(((/?)-1 ,4-Dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-W-(4-fluoro-3-(2-hydroxyethoxy)benzyl)-2- methylpyrimidine-4-carboxamide
Λ/-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-(2- hydroxyethoxy)benzyl)-6-(2-(((<rans-4-cyanocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrimidme-4- carboxamide, Example 27) (45 mg, 0 20 mmol) and (S)-(1 ,4-dιoxan-2-yl)methyl 4- methylbenzenesulfonate (prepared as described in step 2 of the synthesis of 6-(2-(((R)-1 ,4-dιoxan-2- yl)methyl)-2/-/-tetrazol-5-yl)-Λ/-(3-methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde, Example 53) (60 mg, 0 22 mmo!) were taken up in triethylamine (1 00 mL) and dimethylformamide (0 12 mL) The reaction was heated at 90 0C while shaking on a reactor block for 15 h The mixture was concentrated and the residue was purified by reverse phase chromatography to afford the title compound as an oil (17 mg, 18%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 3 43 mm, m/z 474 (M+H) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 2 81 (3 H, s), 3 35 - 3 57 (3 H, m), 3 62 (1 H, d, J=10 8 Hz), 3 67 - 3 75 (3 H, m), 3 89 (1 H, dd, J=11 6, 2 5 Hz), 4 02 (2 H, t, J=5 0 Hz), 4 06 - 4 18 (1 H, m), 4 47 (2 H, d, J=6 2 Hz),
4 81 (1 H, t, J=5 4 Hz)1 4 90 (2 H, d, J=6 6 Hz), 6 81 - 6 94 (1 H, m), 7 08 - 7 20 (2 H, m), 8 40 (1 H, s) 9 48 (1 H, t, J=6 3 Hz)
Example 57
6-(2-(((S)-1 ,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-W-(3-methoxybenzyl)-2-methylpyrimidine-4- carboxamide
Step 1 Preparation of (S)-(L 4-dιoxan-2-yl)methanol R-Epichlorohydrin (17 00 g, 180 mmol) was added drop wise to a stirred solution of chloro-2- ethanol (44 4 g, 551 mmol) and boron trifluoride diethyl etherate (1 05 g, 9 19 mmol) at 45 0C After 18 hours, the reaction was quenched by adding diethyl ether (100 mL) The organic layer was washed with water (100 mL), dried over magnesium sulfate, filtered and evaporated Purification was accomplished by vacuum distillation (10 torr) affording the desired intermediate as an oil (128-131 0C, 18 g, 57%) The intermediate was added drop-wise to a stirred solution of sodium hydroxide (10 4 g, 260 mmol) in water (15 mL) The reaction was stirred at room temperature for 1 h, diluted with water (15 mL) and heated at 90 0C for 2 h The reaction mixture was extracted with dichloromethane (3 x 30 mL) The organic extracts were combined, dried over magnesium sulfate, filtered and evaporated to afford the title compound as a clear oil (7 4 g, 35%) Step 2 Preparation of (ff)-(1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate
(S)-(1 ,4-Dιoxan-2-yl)methanol (2 52 g, 21 3 mmol) was taken up in pyridine (30 mL) and treated with p-toluene sulfonyl chloride (4 1 1 g, 21 5 mmol) and stirred at 25 °C for 18 hours The reaction mixture was dripped into ice water, extracted with dichloromethane (3 x 50 mL) and washed with water (5 x 20 mL) The organic extracts were combined, dried over magnesium sulfate, filtered and concentrated to afford the title compound as a clear oil (2 48 g, 43%) LC/MS (5%-95% CH3CN/H2O, 4 mm) 2 60 mm, m/z 273 (M+H) Step 3 Preparation of 6-(2-(((S)- 1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-Λ/-(3-methoxybenzyl)-2- methylpyrιmιdιne-4-carboxamιde
A mixture of Λ/-(3-methoxybenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 6 of the synthesis of Λ/-(3-Methoxybenzyl)-6-(2-(((<rans)-4- aminocyclohexyOmethyO^H-tetrazol-S-yO^-methylpyπmidine^-carboxamide, Example 5) (100 mg, O 307 mmol), (R)-(1 , 4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (167 mg, 0 615 mmol), triethylamine (0 17 mL, 1 23 mmol) and dimethylacetamide (0 3 mL) was stirred at 85 X for 18 h The mixture was purified by reverse phase preparative HPLC Fractions containing the desired product were isolated and concentrated to afford the title compound as a white solid (46 mg, 35%) LC/MS (5%-95% CH3CN/H2O, 4 mm , 95% CH3CN, 1 mm ) 2 75 mm, m/z 426 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 2 84 (s, 3 H), 3 38 - 3 59 (m, 3 H), 3 65 (d, J=10 8 Hz, 1 H), 3 70 - 3 76 (m, 4 H), 3 92 (dd, J=*\ 1 5, 2 5 Hz, 1 H), 4 1 1 - 4 20 (m, 1 H), 4 51 (d, J=Q 3 Hz, 2 H), 4 93 (d, J= 1 8 Hz, 2 H), 6 83 (dd, J=8 1 , 1 7 Hz, 1 H), 6 90 - 6 96 (m, 2 H), 7 25 (t, J=8 1 Hz, 1 H), 8 43 (s, 1 H), 9 54 (t, J=Q 5 Hz, 1 H)
Example 58
6-(2-(((S)-1 ,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-W-(4-fluoro-3-methoxybenzyl)-2- methylpyrimidine-4-carboxamide
A mixture of Λ/-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2- (frans^-aminocyclohexyOmethyO-ΣH-tetrazol-S-yO-Σ-methylpynmidine^-carboxamide, Example 9) (100 mg, 0 291 mmol), (R)-(1 ,4-dιoxan-2-yl)methy! 4-methylbenzenesulfonate (prepared as described in step 2 of the synthesis of 6-(2-(((S)- 1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-Λ/-(3-methoxybenzyl)- 2-methylpyrιmιdιne-4-carboxamιde, Example 57) (159 mg, 0 583 mmol), triethylamine (0 16 mL, 1 17 mmol) and dimethylacetamide (0 3 mL) was stirred at 85 0C for 18 hours The mixture was purified by reverse phase HPLC Fractions containing the desired product were concentrated to afford the title compound as a white solid (41 mg, 32%) LC/MS (5%-95% CH3CN/H2O, 4 mm , 95% CH3CN, 1 mm ) 2 78 mm, m/z 444 m/z (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 2 83 (s, 3 H) 3 38 - 3 59 (m, 3 H) 3 65 (d, J=10 6 Hz, 1 H) 3 73 (d, J=1 1 4 Hz, 1 H) 3 83 (s, 3 H) 3 91 (dd, J=1 1 5, 2 38 Hz, 1 H) 4 15 (q, J=Q 2 Hz, 1 H) 4 51 (d, J=Q 2 Hz, 2 H) 4 93 (d, J=5 5 Hz, 2 H) 6 88 - 6 95 (m, 1 H) 7 09 - 7 22 (m, 2 H) 8 42 (S, 1 H) 9 50 (t, J=Q 22 Hz, 1 H) Example 59
6-(2-(((S)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-W-(3-chloro-4-fluorobenzyl)-2- methylpyrimidine-4-carboxamide
Λ/-(3-Chloro-4-fluorobenzyl)-2-melhyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 1 of the synthesis of Λ/-(3-chloro-4-fluorobenzyl)-2-methyl-6-(2-((S)-morpholιn-2- ylmethyl)-2/-/-tetrazo!-5-yl)pyrιmιdιne-4-carboxamιde, Example 47) (100 mg, 0 288 mmol), (R)-(1 , 4- dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 2 of the synthesis of 6- (2-(((S)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-Λ/-(3-methoxybenzyl)-2-methylpyrιmιdιne-4- carboxamide, Example 57) (78 3 mg, 0 288 mmol), and triethylamine (400 μL) were combined in dimethylacetamide (100 μL) The resulting mixture was stirred at 90 0C for 18 h The mixture was concentrated The residue was purified by reverse phase high-pressure liquid chromatography The pure fractions were combined, extracted with ethyl acetate (2 x 20 ml_), dried over magnesium sulfate, and concentrated to afford the title compound as a solid (8 mg, 6%) MS (ES+) m/z 448 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 48 (m, 1 H), 8 40 (s, 1 H), 7 54(m, 1 H), 7 24 (m, 2 H), 4 91 (m, 2 H), 4 51 (m, 2 H), 4 18 (m, 1 H), 3 81 (m, 1 H), 3 42-3 72 (m, 5 H), 2 81 (s, 3 H)
Example 60
6-(2-(((S)-1 ,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-/V-(4-fluoro-3-(2-hydroxyethoxy)benzyl)-2- methylpyrimidine-4 -carboxamide
Λ/-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-(2- hydroxyethoxy)benzyl)-6-(2-(((/rans-4-cyanocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide, Example 27) (56 7 mg, 0 152 mmol), (R)-(1 , 4-dιoxan-2-yl)methyl 4- methylbenzenesulfonate (prepared as described in step 2 of the synthesis of 6-(2-(((S)-1 ,4-dιoxan-2- yl)methyl)-2/-/-tetrazol-5-yl)-Λ/-(3-methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde, Example 57) (400 μL) and triethylamine (30 7 mg, 0 304 mmol) were combined in dimethylacetamide (100 μL) After heating the reaction at 90 0C for 18 h, the mixture was concentrated The residue was purified by reverse phase high-pressure liquid chromatography The pure fractions were combined, extracted with ethyl acetate (2 x 20 mL), dried over magnesium sulfate, and concentrated to afford the title compound as an oil (12 1 mg, 17%) MS (ES+) m/z 474 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 48 (m, 1 H)1 8 41 (s, 1 H), 7 20 (m, 3 H), 6 84 (m, 1 H), 4 88 - 4 94 (m, 4 H), 4 81 (t, 1 H), 4 42 - 4 48 (m, 2 H), 4 10 - 4 16 (m, 1 H), 3 99 - 4 06 (m, 2 H), 3 84 - 3 93 (m, 2 H), 3 67 - 3 73 (m, 1 H), 3 57 - 3 65 (m, 1 H), 3 35 - 3 55 (m, 1 H), 2 81 (s, 3 H)
Example 61 rac-W-(3-Methoxybenzyl)-6-(2-(((2S*,5/?*)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-2H-tetrazol-
5-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of trans-2, 5-bιs(ιodomethyl)-1 ,4-dιoxane Yellow mercury oxide (700 g, 3 23 mol) was dissolved in concentrated nitric acid (70%, 443 mL, 6 53 mol) and water (295 mL) To the solution was added water (1180 mL) and it was cooled to 0 0C AIIyI alcohol (445 mL, 6 53 mol) was added in portions while the temperature was at 0-10 0C After addition, the mixture was stirred for 6 h The precipitate was collected by filtration and washed with water The solid was dissolved in 10% NaOH (1 94 L, 4 85 mol) and the solution was basic Concentrated potassium iodide (805 g, 4 85 mol) in water (560 mL) was added until precipitation of the mercury intermediate was complete The precipitate was collected and washed with water The wet solid was mixed with iodine (1041 g, 1 11 mol) and potassium iodide (1492 g, 8 99 mol) in water (3 7 L) The mixture was heated to reflux for 24 h A few mL of benzene was added to wash back iodine that sublimed on the condenser After 24 hr, the mixture was cooled to room temperature The precipitate was filtered, washed with dilute NaHSO3 and water to provide the title compound (598 g, 25%)
Step 2 Preparation of /rans-2,5-bιs-(acetoxymethyl)-1 ,4-dιoxane
A mixture of trans-2, 5-bιs(ιodomethyl)-1 ,4-dιoxane (523 g, 1 42 mol) and potassium acetate (956 g, 9 74 mol) in acetic acid (3 35 L) was heated to reflux The solution was seeded with 7 g of potassium iodide The resulting mixture was heated to gently reflux for nine days The dark mixture was cooled down and filtered to remove the solid The filtrate was concentrated to remove half of the solvent and then diluted with ethyl acetate (5 L), and filtered The filtrate was concentrated, and the residue was triturated with water (5 L) and cooled in an ice bath to provide the title compound as brown solid (140 5 g) Step 3 Preparation of trans-2, 5-bιs-(hydroxymethyl)-1 ,4-dιoxane
A mixture of trans-2, 5-bιs-(acetoxymethy1 )-1 ,4-dιoxane (213 g) in methanol (1065 mL) and 4N hydrochloric acid in dioxane (229 mL) was heated to reflux for 1 h About 30 g of decolorizing charcoal was added after cooling down The mixture was filtered through a pad of Celite™ The filtrate was concentrated, and the oily residue was dissolved in isopropyl alcohol/benzene (1/5, 600 mL) Crystals were obtained by filtration and washed with isopropyl alcohol/benzene (1/5) to provide the title compound as a solid (126 9)
Step 4 Preparation of rac-((2/?*,5f?*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4- methylbenzenesulfonate
<rans-2,5-bιs-(Hydroxymethyl)-1 ,4-dιoxane (342 9 g, 2 31 mol) and p-toluene sulfonylchloride (441 0 g, 2 31 mol), tπethylamine (471 5 g, 4 66 mol) and dichloromethane (3 L) were combined in a 5 L round-bottomed flask equipped with a mechanical stirrer under nitrogen The mixture was maintained at 35 0C for 30 mm with water bath cooling and than allowed to stir at room temperature overnight The mixture was diluted with 3 N hydrochloric acid (1 L), and the resulting solids were filtered The organic phase of the filtrate was separated, washed with 3 N hydrochloric acid (1 L) followed by saturated ammonium chloride solution (500 mL), dried over magnesium sulfate, and concentrated to afford the title compound (338 3 g) Step 5 Preparation of rac-ΛπS-MethoxybenzvO-θ-^-U^S'.SP'Vδ-fhvdroxymethyO-i ^-dioxan^- vOmethvO^H-tetrazol-δ-yO^-methylpyrimidine^-carboxamide
rac-((2R*,5R*)-5-(Hydroxymethy!)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (4 3 g, 14 0 mmol) was added to a solution of Λ/-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazo!-5-yl)pyrιmιdιne-4- carboxamide (prepared as described in step 6 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((frans)- 4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 5) (3 2 g, 9 8 mmol) and triethylamine (2 O g, 19 7 mmol) in anhydrous dimethylacetamide (4 mL) The reaction was stirred at 85 0C in a capped vial overnight The mixture was purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing product were neutralized by passing through a carbonate resin column and concentrated The resulting product was slurried with diethyl ether, decanted, and dried in vacuo to afford the title compound as a white solid (1 38 g) MS (ES+) m/z 456 (M+H) 1H NMR (400 MHz, DMSOd6) & PPm 9 44 - 9 52 (1 H, m), 8 42 (1 H, s), 7 24 (1 H, t, J=8 1 Hz), 6 89 - 6 95 (2 H, m), 6 83 (1 H, d, J=8 1 Hz), 4 93 (1 H, d, J=3 3 Hz), 4 88 (1 H, d, J=I 7 Hz), 4 51 (3 H, d, J=5 9 Hz), 4 08 (1 H, d, J=3 3 Hz), 3 99 (1 H, d, J= 1 1 3 Hz), 3 78 (1 H, d, J= 11 3 Hz), 3 74 (3 H, s), 3 36 - 3 48 (4 H, m), 3 31 (1 H, d, J=2 2 Hz), 2 83 (3 H, s)
Example 62
W-(3-Methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-
2-methylpyrimidine-4-carboxamide
Step 1 Preparation of ((2ff,5ff)-5-(hvdroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate
rac-((2R*,5R*)-5-(Hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 4 of the synthesis of rac-Λ/-(3-methoxybenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)- 1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 61 ) was chirally separated by supercritical fluid chromatography (AD-H, 30% methanol/dichloromethane, 10/1 , 200 mL/min) Isolation of the first eluting isomer afforded the title compound as a white solid Step 2 Preparation of Λ/-(3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hvdroxymethyl)-1 ,4-dιoxan-2-yl)methyl)- 2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
((2f?,5R)-5-(Hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (5 2 g, 17 2 mmol) was added to a solution of Λ/-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide (prepared as described in step 6 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((frans)- 4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 5) (4 0 g, 12 3 mmol) and triethylamine (3 1 g, 30 0 mmol) in anhydrous dimethylacetamide (4 ml.) The reaction was stirred at 85 0C in a capped vial overnight The mixture was purified by reverse phase preparative HPLC (water/acetonitrile), and fractions containing product were concentrated The residue was dissolved in dichloromethane and washed with dilute aqueous NaOH followed by water The organic layer was dried over magnesium sulfate, filtered, and concentrated under vacuum The crude product was further separated by supercritical fluid chromatography (OJ-H, 30 x 250 mm, 40% methanol, 70 mL/min) Fractions containing the desired product were concentrated and the resulting solid was recrystallized from isopropanol to afford the title compound as a white solid (986 mg) MS (ES+) m/z 456 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 52 (1 H, t, J=Q 4 Hz), 8 39 (1 H, s), 7 24 (1 H, t, J=8 1 Hz), 6 86-6 92 (2 H, m), 6 77-6 82 (1 H, m), 4 80-4 95 (2 H, m), 4 69 (1 H, t, J=5 5 Hz), 4 47 (2 H, d, J=6 2 Hz)1 3 93-4 09 (2 H, m), 3 71-3 77 (1 H1 m), 3 70 (3 H, s), 3 2-3 45 (5 H, m), 2 79 (3 H, s)
Example 63
W-(3-Methoxybenzyl)-6-(2-(((2R,5S)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-
2-methylpyrimidine-4-carboxamide
Step 1 Preparation of ((2S,5S)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate
rac-((2R*,5R*)-5-(Hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 4 of the synthesis of rac-Λ/-(3-methoxybenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)- 1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 61 ) was chirally separated by supercritical fluid chromatography (AD-H, 30% methanol/dichloromethane, 10/1 , 200 mL/min) Isolation of the second eluting isomer afforded the title compound as a white solid
Step 2 Preparation of Λ/-(3-Methoxybenzyl)-6-(2-(((2R,5S)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)- 2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
((2S,5S)-5-(Hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (5 2 g, 17 2 mmol) was added to a solution of Λ/-(3-methoxybenzyl)-2-methyl-6-(2/-y-tetrazol-5-yl)pyrιmιdιne-4- carboxamide (prepared as described in step 6 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((<rans)- 4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 5) (4 0 g, 12 3 mmol) and triethylamine (3 1 g, 30 0 mmol) in anhydrous dimethylacetamide (4 mL) The reaction was stirred at 85 0C in a capped vial overnight The mixture was purified by reverse phase preparative HPLC (water/acetonitπle), and fractions containing product were concentrated The residue was dissolved in dichloromethane and washed with dilute aqueous NaOH followed by water The organic layer was dried over magnesium sulfate, filtered, and concentrated under vacuum The crude product was further separated by supercritical fluid chromatography (OJ-H, 30 x 250 mm, 40% methanol, 70 mL/min) Fractions containing the desired product were concentrated and the resulting solid was recrystallized from isopropanol to afford the title compound as a white solid (576 mg) MS (ES+) m/z 456 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 52 (1 H, t, J=6 4 Hz), 8 39 (1 H, s), 7 24 (1 H, t, J=8 1 Hz), 6 86-6 92 (2 H, m), 6 77-6 82 (1 H, m), 4 80-4 95 (2 H, m), 4 69 (1 H, t, J=5 5 Hz), 4 47 (2 H, d, J=6 2 Hz), 3 93-4 09 (2 H, m), 3 71 -3 77 (1 H, m), 3 70 (3 H, s), 3 2-3 45 (5 H, m), 2 79 (3 H1 s)
Example 64 rac-N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)- 2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
rac-((2R*,5R*)-5-(Hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 4 of the synthesis of rac-Λ/-(3-methoxybenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)- 1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 61 ) (2 64 g, 8 7 mmol) was added to a solution of Λ/-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of Λ/-(4-Fluoro-3- methoxybenzyl)-6-(2-(ϊrans-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide, Example 9) (2 0 g, 5 8 mmol) and triethylamine (880 mg, 8 7 mmol) in anhydrous dimethylacetamide (2 mL) The reaction was stirred overnight at 85 °C in a capped vial The mixture was purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing product were neutralized by passing through a carbonate resin column and concentrated The resulting product was slurried with diethyl ether, decanted, and dried in vacuo to afford the title compound as a white solid (1 02 g) MS (ES+) m/z 474 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 50 (1 H, t, J=6 2 Hz), 8 42 (1 H, s), 7 15 (2 H, td, J=12 1 , 8 4 Hz), 6 92 (1 H, d, J=A 4 Hz), 4 93 (1 H, d, J=Z 7 Hz), 4 88 (1 H, d, J=I 7 Hz), 4 65 (1 H, t, J=5 5 Hz), 4 51 (3 H, d, J=6 2 Hz), 4 08 (1 H, d, J=2 9 Hz), 3 99 (1 H, dd, J=1 1 5, 2 0 Hz), 3 83 (3 H, s), 3 78 (1 H, d, J= 1 1 7 Hz), 3 36 - 3 48 (4 H, m), 3 31 (1 H, s), 2 83 (3 H, s)
Example 65
/V-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(frans-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 9) (10 0 g, 29 1 mmol) was dissolved in tπethylamine (7 04 g, 69 7 mmol) and Λ/,Λ/-dιmethylacetamιde (31 mL) ((2R,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 1 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((2S,5f?)-5-(hydroxymethyl)-1 ,4-dιoxan-2- yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 62) (12 4 g, 41 0 mmol) was added and the reaction heated to 85 0C for 16 hours After cooling to room temperature, the mixture was diluted with water (300 mL) and extracted with dichloromethane (3 x 200 mL) The combined organics were washed with 1 N NaOH (2 x 100 mL), 1 M hydrochloric acid (2 x 100 mL), water (100 mL), and brine (250 mL) The organic layer was dried over sodium sulfate, filtered and evaporated to give a yellow oil Purification by silica gel chromatography using heptane, ethyl acetate and methanol provided a mixture of regioisomers as an opaque oil The mixture was separated by supercritical fluid chromatography (OJ-H, 30 x 250 mm, 40% methanol, 70 mL/min) and the desired isomer was recrystallized from ethyl acetate (80 mL) and ethanol (1 mL) to provide the title compound as a white crystalline solid (3 5 g, 25%) LC/MS (5%-95% CH3CN/H2O, 4 mm) 3 39 mm, m/z 474 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 53 (t, J=6 3 Hz, 1 H), 8 39 (s, 1 H), 7 06 - 7 19 (m, 2 H), 6 83 - 6 91 (m, 1 H), 4 78 - 4 98 (m, 2 H), 4 68 (t, J=5 7 Hz, 1 H), 4 47 (d, J=6 4 Hz, 2 H), 3 99 - 4 10 (m, 1 H), 3 96 (dd, J=1 1 4, 2 4 Hz, 1 H), 3 79 (s, 3 H), 3 74 (dd, J=1 1 4, 2 2 Hz, 1 H), 3 19 - 3 47 (m, 5 H), 2 80 (s, 3 H)
Example 66
/V-(4-F!uoro-3-methoxybenzyl)-6-(2-(((2R,5S)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
((2S,5S)-5-(Hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 1 of the synthesis of Λ/-(3-Methoxybenzyl)-6-(2-(((2R,5S)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 63) (5 2 g, 17 2 mmol) was added to a solution of Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3- methoxybenzyl)-6-(2-(frans-4-amιnocyclohexyl)rnethyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide, Example 9) (4 22 g, 12 3 mmol) and triethylamine (3 1 g, 30 O mmol) in anhydrous dimethylacetamide (4 mL) The reaction was stirred at 85 0C in a capped vial overnight The mixture was purified by reverse phase preparative HPLC (water/acetonitrile), and fractions containing product were concentrated The residue was dissolved in dichloromethane and washed with dilute aqueous NaOH followed by water The organic layer was dried over magnesium sulfate, filtered, and concentrated under vacuum The crude product was further separated by supercritical fluid chromatography (OJ-H, 30 x 250 mm, 45% acetonitrile, 70 mL/min) Fractions containing the desired product were concentrated and the resulting solid was recrystallized from ethyl acetate (80 mL) to afford the title compound as a white solid (1 5 g) MS (ES+) m/z 474 (M+H) 1H NMR (400 MHz,
DMSO-CZ6) δ ppm 9 50 (1 H, t, J=Q 2 Hz), 8 42 (1 H, s), 7 08-7 17 (2 H, m), 6 85-6 9 (1 H, m), 4 80-4 95 (2 H, m), 4 69 (1 H, t, J=5 5 Hz), 4 47 (2 H, d, J=6 2 Hz), 3 93-4 09 (2 H, m), 3 79 (3 H, s), 3 71-3 77 (1 H, m), 3 2-3 45 (5 H, m), 2 79 (3 H, s)
Example 67 rac-W-(4-Fluoro-3-methylbenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H- tetrazol-5-y!)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of methyl rac-6-(2-(((2S*,5R*)-5-(hvdroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2/-/- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxylate
In a 30 mL scintillation vial with a magnetic stir bar at room temperature and standard pressure, methyl 2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxylate (prepared as described in step 1 of the synthesis of Λ/-(4-fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((frans)-4- acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 17) (1 57 g, 7 13 mmol) was dissolved in N,N-dιmethylformamιde (15ml) Λ/,Λ/-Dιιsopropylethylamιne (1 86 g, 14 40 mmol) was added and the mixture was stirred at room temperature for 30 mm rac-((2R* ,5R*)-5- (Hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 4 of the synthesis of rac-Λ/-(3-methoxybenzyl)-6-(2-(((2S*,5/?*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)- 2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 61 ) (4 41 g, 14 59 mmol) was added and the reaction mixture was heated to 80 0C with stirring for 14 hours The reaction mixture was concentrated, dissolved in acetonitrile and water, and chromatographed by reversed phase preparative HPLC (Gilson, Delta Pak, 20%-35% acetonitrile, 20 mm hold, 40 mm gradient, 8 mm hold) Fractions corresponding to the first eluting peak (27 34 mm) were concentrated under vacuum to afford the title compound as a solid (1 4 g) LC/MS (5%-95% CH3CN/H2O, 6 mm) 1 856 mm, m/z 351 (M+H) 1H NMR (400 MHz, DMSO-Cf6) rf ppm 1 16 - 1 27 (m, 2 H), 2 25 (s, 1 H), 2 79 (s, 3 H), 3 11 (dd, J=7 4, 4 2 Hz, 1 H), 3 18 - 3 29 (m, 2 H), 3 29 - 3 46 (m, 2 H), 3 59 (d, J=3 8 Hz, 1 H), 3 74 (dd, J= 1 1 6, 2 4 Hz, 1 H), 4 80 - 4 88 (m, 1 H), 4 89 - 4 97 (m, 1 H), 7 08 (d, J=7 8 Hz, 1 H), 7 44 (d, J=8 1 Hz, 1 H), 8 36 (s, 1 H)
Step 2 Preparation of rac-Λ/-(4-fluoro-3-methylbenzyl)-6-(2-(((2S*,5f?*)-5-(hvdroxymethyl)-1 ,4-dιoxan- 2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
A mixture of rac-methyl 6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxylate (100 mg, 0 285 mmol), 4-fluoro-3-methylbenzylamιne (1 19 mg, 0 856 mmol), and dimethylacetamide (1 mL) was heated to 85 0C for 18 hours The title compound was isolated as a solid by reverse phase preparative HPLC (73 mg, 56%) MS (ES+) m/z 458 m/z (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 2 22 (s, 3 H), 2 83 (s, 3 H), 3 34 - 3 55 (m, 5 H), 3 78 (dd, J= 1 1 5, 2 0 Hz, 1 H), 3 99 (dd, J= 1 1 5, 2 0 Hz, 1 H), 4 04 - 4 16 (m, 1 H), 4 48 (d, J=6 2 Hz, 2 H), 4 65 (t, J=5 7 Hz, 1 H), 4 80 - 5 00 (m, 2 H), 7 07 (t, J=9 2 Hz, 1 H), 7 16 - 7 24 (m, 1 H), 7 26 (d, J=7 3 Hz, 1 H), 8 42 (s, 1 H), 9 50 (t, J=6 2 Hz, 1 H)
Example 68
/V-(4-Fluoro-3-methylbenzyl)-6-(2-(((2S,5/:?)-5-(hydroxymethyl)-1l4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of Λ/-(4-fluoro-3-methylbenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide
A solution of methyl 2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxylate (prepared as described in step 1 of the synthesis of Λ/-(4-fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((rrans)-4- acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 17) (1 0 g, 4 54 mmol) in dimethylformamide (5 mL) was treated with 4-fluoro-3-methylbenzylamιne (1 9 g, 13 6 mmol) and heated to 65 0C for 3 days The mixture was cooled to room temperature Excess 2 5 N NaOH was added to the mixture The product mixture was washed with ethyl acetate (3 x 10 mL) Concentrated hydrochloric acid was added and the resulting precipitate was filtered, washed with water and dried in vacuo to afford the title compound (1 21 g, 75%)
Step 2 Preparation of N-(4-fluoro-3-methylbenzyl)-6-(2-(((2S,5f?)-5-(hvdroxymethyl)-1 ,4-dιoxan-2- yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
A mixture of Λ/-(4-fluoro-3-methylbenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyπmιdιne-4- carboxamide (96 mg, 0 293 mmol), ((2R,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4- methylbenzenesulfonate (prepared as described in step 1 of the synthesis of Λ/-(3-methoxybenzyl)-6- (2-(((2S,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide, Example 62) (106 mg, 0 352 mmol), and triethylamine (0 16 mL, 1 17 mmol) was heated in dimethylformamide at 85 0C overnight The mixture was chromatographed by reverse phase preparative HPLC Fractions containing the desired product were passed through a carbonate cartridge and concentrated to afford the title compound (39 mg, 28%) MS (ES+) m/z 458 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 1 83 (t, J=5 9 Hz, 1 H), 2 28 (d, J=2 0 Hz, 3 H), 2 89 (s, 3 H), 3 47 - 3 62 (m, 3 H), 3 62 - 3 71 (m, 2 H), 3 82 (dd, J= 1 1 6, 2 3 Hz, 1 H), 3 99 (dd, J= 1 1 6, 2 4 Hz, 1 H), 4 17 - 4 26 (m, 1 H), 4 64 (d, J=6 1 Hz, 2 H), 4 68 - 4 88 (m, 2 H), 6 96 - 7 03 (m, 1 H), 7 14 - 7 23 (m, 2 H), 8 27 - 8 34 (m, 1 H), 8 80 (s, 1 H)
Example 69
Λ/-(4-Fluoro-3-methylbenzyl)-6-(2-(((2R,5S)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
A mixture of A/-(4-fluoro-3-methylbenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide (prepared as described in step 1 in the synthesis of Λ/-(4-fluoro-3-methylbenzyl)-6-(2- (((2S,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide, Example 68) (96 mg, 0 293 mmol), ((2S,5S)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 1 of the synthesis of Λ/-(3-Methoxybenzyl)- 6-(2-(((2R,5S)-5-(hydroxymethyl)-1 ,4-dιoxan-2-y!)methyl)-2H-tetrazo!-5-yl)-2-methylpyrιmιdιne-4- carboxamide, Example 63) (106 mg, 0 352 mmol), and triethylamine (0 16 mL, 1 17 mmol) was heated in dimethylformamide at 85 0C overnight The mixture was chromatographed by reverse phase preparative HPLC Fractions containing the desired product were passed through a carbonate cartridge and concentrated to afford the title compound (21mg, 16%)
MS (ES+) m/z 458 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 2 26 (d, J= 1 4 Hz, 3 H), 2 87 (s, 3 H), 3 43 - 3 70 (m, 6 H), 3 79 (dd, J= 11 6, 2 1 Hz, 1 H), 3 96 (dd, J= 11 5, 2 5 Hz, 1 H), 4 14 - 4 25 (m, 1 H), 4 61 (d, J=6 3 Hz, 2 H), 4 66 - 4 86 (m, 2 H), 6 97 (t, J=8 9 Hz, 1 H), 7 10 - 7 21 (m, 2 H), 8 29 (t, J=5 8 Hz, 1 H), 8 77 (s, 1 H)
Example 70 rac-W-(4-Fluoro-3-(trifluoromethyl)benzyl)-6-(2-(((2S*,5/?*)-5-(hydroxymethyl)-1,4-dioxan-2- yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
A mixture of rac-methyl 6-(2-(((2S\5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxylate (prepared as described in step 1 of the synthesis of rac-Λ/-(4-fluoro-3-methylbenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyπmιdιne-4-carboxamιde, Example 67) (100 mg, 0 285 mmol), 4-fluoro-3- tπfluoromethylbenzylamine (165 mg, 0 856 mmol), and dimethylacetamide (1 mL) was heated to 85 0C for 18 hours The title compound was isolated as a solid by reverse phase preparative HPLC (52 mg, 36%) MS (ES+) m/z 512 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 2 84 (s, 3 H), 3 31 - 3 52 (m, 5 H), 3 78 (dd, J= 11 4, 1 8 Hz, 1 H), 3 99 (dd, J= 11 4, 2 2 Hz, 1 H), 4 03 - 4 14 (m, 1 H), 4 59 (d, J=6 2 Hz, 2 H), 4 65 (t, J=5 7 Hz, 1 H), 4 81 - 5 00 (m, 2 H), 7 41 - 7 53 (m, 1 H), 7 69 - 7 83 (m, 2 H), 8 41 (s, 1 H), 9 66 (t, J=6 04 Hz, 1 H) Example 71 rac-N-(3-Ethyl-4-fluorobenzyl)-6-(2-(((2S*,5f?*)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2W- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
A mixture of methyl rac-6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxylate (prepared as described in step 1 of the synthesis of rac-W-(4-fluoro-3-methylbenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 67) (100 mg, 0 285 mmol), (3-ethyl-4- fluorophenyl)methanamιne (prepared as described in steps 1 - 5 of the synthesis of Λ/-(3-ethyl-4- fluorobenzyl)-2-methyl-6-(2-((S)-morpholιn-2-ylmethyl)-2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 49) (131 mg, 0 856 mmol), and dimethylacetamide (1 mL) was heated to 85 0C for 18 hours The title compound was isolated as a solid by reverse phase preparative HPLC (57 mg, 42%) MS (ES+) m/z All (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 12 (t, J=7 7 Hz, 3 H), 2 57 (q, J=7 3 Hz, 2 H), 2 79 (s, 3 H), 3 26 - 3 47 (m, 5 H), 3 74 (dd, J= 11 0, 2 2 Hz, 1 H), 3 95 (dd, J= 1 1 0, 2 2 Hz, 1 H), 4 00 - 4 10 (m, 1 H), 4 46 (d, J=6 6 Hz, 2 H), 4 62 (t, J=5 9 Hz, 1 H), 4 77 - 4 96 (m, 2 H), 6 97 - 7 09 (m, 1 H), 7 13 - 7 21 (m, 1 H), 7 25 (d, J=9 5 Hz, 1 H), 8 38 (s, 1 H), 9 46 (t, J=6 2 Hz, 1 H)
Example 72
W-(3-Ethyl-4-fluorobenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-
5-yl)-2-methylpyrimidine-4-carboxamide
A mixture of /V-(3-ethyl-4-fluorobenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in steps 1 - 6 of the synthesis of Λ/-(3-ethyl-4-fluorobenzyl)-2-methyl-6-(2-((S)- morpholιn-2-ylmethyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 49) (100 mg, 0 293 mmol), ((2R,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methy! 4-methylbenzenesulfonate (prepared as described in step 1 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2- yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 62) (106 mg, 0 352 mmol), and triethylamine (0 16 mL, 1 17 mmol) was heated in dimethylformamide at 85 0C overnight The mixture was chromatographed by reverse phase preparative HPLC Fractions containing the desired product were passed through a carbonate cartridge and concentrated to afford the title compound (28 mg, 20%) MS (ES+) m/z 472 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 1 23 (t, J=7 5 Hz, 3 H), 1 80 (br s , 1 H), 2 67 (q, J=7 6 Hz, 2 H), 2 89 (s, 3 H), 3 41 - 3 73 (m, 5 H), 3 82 (dd, J=1 1 6, 2 3 Hz, 1 H), 3 99 (dd, J=1 1 5, 2 5 Hz, 1 H), 4 15 - 4 26 (m, 1 H), 4 65 (d, J=6 3 Hz, 2 H), 4 68 - 4 89 (m, 2 H), 7 00 (dd, J=9 7, 8 3 Hz, 1 H), 7 13 - 7 24 (m, 2 H), 8 32 (t, J=6 0 Hz, 1 H), 8 79 (s, 1 H)
Example 73
W-(3-Ethyl-4-fluorobenzyl)-6-(2-(((2/?,5S)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-
5-yl)-2-methylpyrimidine-4-carboxamide
A mixture of Λ/-(3-ethyl-4-fluorobenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in steps 1 - 6 of the synthesis of Λ/-(3-ethyl-4-fluorobenzyl)-2-methyl-6-(2-((S)- morpholιn-2-ylmethyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 49) (100 mg, 0 293 mmol), ((2S,5S)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 1 of the synthesis of Λ/-(3-Methoxybenzyl)-6-(2-(((2R,5S)-5-(hydroxymethyl)-1 ,4-dιoxan-2- yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 63} (106 mg, 0 352 mmol), and triethylamine (0 16 ml_, 1 17 mmol) was heated in dimethylformamide at 85 0C overnight The mixture was chromatographed by reverse phase preparative HPLC Fractions containing the desired product were passed through a carbonate cartridge and concentrated to afford the title compound (39 mg, 28%) MS (ES+) m/z All (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 1 23 (t, J=I 5 Hz, 3 H), 1 72 (br s , 1 H), 2 67 (q, J=I 5 Hz, 2 H), 2 89 (s, 3 H), 3 46 - 3 70 (m, 5 H), 3 82 (dd, J=1 1 6, 2 3 Hz, 1 H), 3 98 (dd, 4 65 (d, J=Q 1 Hz, 2 H), 4 68 - 4 88 (m, 2 H), 7 00 (dd, J=9 6, 8 4 Hz, 1 H), 7 14 - 7 24 (m, 2 H), 8 32 (t, J=6 0 Hz, 1 H), 8 79 (s, 1 H)
Example 74 rac-/V-(4-Fluoro-3-isopropylbenzyl)-6-(2-(((2S*,5/?*)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)- 2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of ethyl 4-fluoro-3-ιsopropylbenzoate
lsopropylmagnesium chloride (2 0 M in ether, 137 61 mL, 275 23 mmol) was added slowly to a solution of anhydrous ZnCI2 (37 43 g, 275 23 mmol) in dry tetrahydrofuran (200 mL) under an argon atmosphere The resulting white slurry was stirred at 50 0C for 3 h In a separate flask, a solution of ethyl 3-bromo-4-fluorobenzoate (prepared as described in step 1 of the synthesis of Λ/-(3-ethyl-4- fluorobenzyl)-2-methyl-6-(2-((S)-morpholιn-2-ylmethyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 49) (17 g, 68 80 mmol) in dry tetrahydrofuran (150 mL) was sequentially treated with PdCI2(dppf) (2 8 g, 3 44 mmol) and copper(l) iodide (0 78 g, 4 12 mmol) under an argon atmosphere The alkyl zinc slurry was added to the ester mixture at room temperature The resulting brown slurry was stirred in the dark at room temperature for 48 h The reaction mixture was concentrated under vacuum to give a dark brown residue, which was taken up in ethyl acetate (750 mL) and washed sequentially with 1 N hydrochloric acid (300 mL) solution, sat NaHCO3 solution, and brine The ethyl acetate layer was dried over anhydrous sodium sulfate and concentrated The crude product was purified by column chromatography over silica gel (100-200 mesh) using 5 % ethyl acetate in hexane as an eluent to afford the title compound (12 5 g, 89%)
Step 2 Preparation of 4-fluoro-3-ιsopropylbenzoιc acid
Ethyl 4-fluoro-3-ιsopropylbenzoate (12 5 g, 59 46 mmol) and lithium hydroxide monohydrate (7 49 g, 178 40 mmol) were taken up in a mixture of dioxane/water (1/1 , 250 mL) and stirred overnight at room temperature The reaction mixture was concentrated under reduced pressure and the residue was acidified with 1 N hydrochloric acid under ice-water cold condition The mixture was extracted with dichloromethane (2 x 150 mL) The combined organic layers were washed with brine solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford the title compound (10 g, 92 %)
Step 3 Preparation of 4-fluoro-3-ιsopropylbenzamιde
4-Fluoro-3-ιsopropylbenzoιc acid (10 3g, 54 94 mmol) was taken up in SOCI2 (150 mL) and then refluxed for 4 h The SOCI2 was removed under reduced pressure and the resulting residue was dissolved in dry acetonitrile (125 mL) Ammonia gas was passed through the solution at -78 0C for 10 mm The reaction mixture was allowed to warm to room temperature very slowly and stirred for overnight The reaction mixture was concentrated to a residue which was extracted with dichloromethane (2 x 100 mL) The combined dichloromethane layers were washed with sat NaHCO3 solution followed by brine, dried over sodium sulfate, and concentrated The resulting solid was washed with hexane (2 x 25 mL) to afford the title compound (9 g, 90%)
Step 4 Preparation of (4-fluoro-3-ιsopropylphenyl)methanamιne
Borane dimethylsulfide complex (94 %, 20 33 mL, 198 67 mmol) was added slowly to a solution of 4-fluoro-3-ιsopropylbenzamιde (9 g, 49 66 mmol) in dichloromethane (200 mL) at ice cold condition After the addition, the reaction mixture was stirred for 1 h at room temperature and then it was refluxed for 24 h The reaction mixture was cooled to 0 0C, washed with NaHCO3 solution followed by brine, and dried over sodium sulfate The organic layer was concentrated under reduced pressure The crude product was purified by column chromatography over silica gel (100-200 mesh) using 15 % CH2CI2 in hexane as an eluent to afford the title compound (4 8 g, 54%) MS (ES+) m/z 168 (M+H)
Step 5 Preparation of rac-Λy-(4-fluoro-3-ιsopropylbenzyl)-6-(2-(((2S*,5f?*)-5-(hvdroxymethyl)-1 A- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
A mixture of rac-methyl 6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxylate (prepared as described in step 1 of the synthesis of rac-Λ/-(4-fluoro-3-methylbenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 67) (100 mg, 0 285 mmol), (4-fluoro-3- ιsopropylphenyl)methanamιne (143 mg, 0 856 mmol), and dimethylacetamide (1 mL) was heated to 85 0C for 18 hours The title compound was isolated as a solid by reverse phase preparative HPLC (49 mg, 35%) MS (ES+) m/z 486 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 21 (d, J=I 0 Hz, 6 H), 2 83 (s, 3 H), 3 07 - 3 20 (m, 1 H), 3 31 - 3 52 (m, 5 H), 3 78 (dd, J=11 4, 1 8 Hz, 1 H), 3 99 (dd, J=1 1 4, 2 2 Hz, 1 H), 4 04 - 4 14 (m, 1 H), 4 51 (d, J=6 2 Hz, 2 H), 4 66 (t, J=5 7 Hz, 1 H), 4 79 - 5 02 (m, 2 H), 7 07 (dd, J=10 4, 8 6 Hz, 1 H), 7 15 - 7 25 (m, 1 H), 7 28 - 7 37 (m, 1 H), 8 42 (s, 1 H), 9 50 (t, J=6 2 Hz, 1 H)
Example 75 rac-W^S-CyclopropyM-fluorobenzyO-β^Z-^IZ^.S/^J-S^hydroxymethyO-i ^-dioxan-Z-y^methyl)- 2W-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of ethyl S-cyclopropyM-fluorobenzoate
Cyclopropylmagnesium bromide (2 O M in ether, 137 61 mL, 275 23 mmol) was added slowly to a solution of anhydrous ZnCI2 (37 43 g, 275 23 mmol) in dry tetrahydrofuran (200 mL) under an argon atmosphere The resulting white slurry was stirred at 50 0C for 3 h In a separate flask a solution of ethyl 3-bromo-4-fluorobenzoate (prepared as described in step 1 of the synthesis of Λ/-(3-ethyl-4- fluorobenzyl)-2-methyl-6-(2-((S)-morpholιn-2-ylmethyl)-2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 49) (17 g, 68 80 mmol) in dry tetrahydrofuran (150 mL) was sequentially treated with PdCI2(dppf) (2 8 g, 3 44 mmol) and copper(l) iodide (0 78 g, 4 12 mmol) under an argon atmosphere The alkyl zinc slurry was added to the ester mixture at room temperature The resulting brown slurry was stirred in the dark at room temperature for 48 h The reaction mixture was concentrated under vacuum to give a dark brown residue, which was taken up in ethyl acetate (750 mL) and washed sequentially with 1 N hydrochloric acid (300 mL) solution, sat NaHCO3 solution and brine The ethyl acetate layer was dried over anhydrous sodium sulfate and concentrated in vacuo to obtain a mixture of the desired product and bromo starting material (9 8 g of - 40/60 product/starting material ) The mixture was carried on to the next step without further purification
Step 2 Preparation of S-cyclopropyM-fluorobenzoic acid
A mixture containing ethyl 3-cyclopropyl-4-fluorobenzoate from step 1 (16 g) and lithium hydroxide monohydrate (9 68 g, 230 54 mmol) were taken up in a mixture of dioxane/water (1/1 , 300 mL) and stirred overnight at room temperature The reaction mixture was concentrated under reduced pressure and the residue was acidified with 1 N hydrochloric acid under ice-water cold condition The mixture was extracted with dichloromethane (2 x 150 mL) The combined organic layers were washed with brine solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford the title compound contaminated by 3-bromo-4-fluorobenzoιc acid (12 0 g) Step 3 Preparation of 3-cvclopropyl-4-fluorobenzamιde
A mixture containing S-cyclopropyM-fluorobenzoic acid from step 2 (10 5 g) was taken up in SOCI2 (150 mL) and then refluxed for 4 h The SOCI2 was removed under reduced pressure and the residue was dissolved in dry acetonitrile (125 mL) Ammonia gas was passed through solution at -78 0C for 10 mm The reaction mixture was allowed to warm at room temperature very slowly and stirred overnight The reaction mixture was concentrated to a residue and extracted with dichloromethane (2 x 100 mL) The combined dichloromethane layers were washed with sat NaHCO3 solution followed by brine, dried over sodium sulfate and concentrated The crude product was washed with hexane (2 x 25 mL) to afford a mixture of the title compound and 3-bromo-4-fluorobenzamιde and bromo impurity (9 5 g)
Step 4 Preparation of (S-cvclopropyM-fluorophenvDmethanamine
Borane dimethylsulfide complex (94%, 21 70 mL, 212 05 mmol) was added slowly to a solution of the mixture containing 3-cyclopropyl-4-fluorobenzamιde from step 3 (9 5 g) in dichloromethane (200 mL) under ice-cold condition After the addition, the reaction mixture was stirred for 1 h at room temperature and then it was refluxed for 24 h The reaction mixture was cooled to 0 0C1 washed with NaHCO3 solution followed by brine, and dried over sodium sulfate The organic layer was concentrated under reduced pressure The crude product was purified by column chromatography over silica gel (100-200 mesh) using 25 % CH2CI2 in hexane as an eluent to afford the title compound (1 8 g) MS (ES+) m/z 166 (M+H)
Step 5 Preparation of rac-Λ/-(3-cvclopropyl-4-fluorobenzyl)-6-(2-(((2S*,5R*)-5-(hvdroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
A mixture of rac-methyl 6-(2-(((2S*,5/?*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2/-/- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxylate (prepared as described in step 1 of the synthesis of rac-W-(4-fluoro-3-methylbenzyl)-6-(2-(((2S*,5/?*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methy!)-2H- tetrazol-5-yl)-2-methylpyπmιdιne-4-carboxamιde, Example 67) (100 mg, 0 285 mmol), (3-cyclopropyl- 4-fluoropheny!)methanamιne (141 mg, 0 856 mmol), and dimethylacetamide (1 mL) was heated to 85 0C for 18 hours The title compound was isolated as a solid by reverse phase preparative HPLC (58 mg, 42%) MS (ES+) m/z 484 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 0 60 - 0 75 (m, 2 H), 0 95 (d, J=10 3 Hz, 2 H), 1 91 - 2 07 (m, 1 H), 2 81 (s, 3 H), 3 18 - 3 46 (m, 5 H), 3 76 (d, J=1 1 4 Hz, 1 H), 3 97 (d, J=1 1 4 Hz, 1 H), 4 03 - 4 14 (m, 1 H), 4 45 (d, J=6 2 Hz, 2 H), 4 70 - 4 79 (m, 1 H), 4 78 - 4 97 (m, 2 H), 6 94 - 7 10 (m, 2 H), 7 10 - 7 20 (m, 1 H), 8 39 (s, 1 H), 9 47 (t, J=6 0 Hz, 1 H)
Example 76 rac-W-(3-Cyano-4-fluorobenzyl)-6-(2-(((2S*,5/?*)-5-(hydroxymethyl)-1 )4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of 2-fluoro-5-(hvdroxymethyl)benzonιtrιle
2-fluoro-5-formylbenzonιtrιle (7 0 g, 46 93 mmol) was dissolved in a mixture of methanol (30 mL) and dichloromethane (20 mL) Solid NaBH4 (1 8 g, 46 93 mmol) was added portion-wise, and the mixture was stirred at room temperature overnight The organic volatile was removed and the residue was dissolved in water (50 mL) and extracted with diethyl ether (2 x 50 mL) The combined organic layer was washed with saturated sodium bicarbonate solution followed by brine solution, dried over anhydrous sodium sulfate, and concentrated to afford the title compound (6 6 g, 93 %)
Step 2 Preparation of 5-(amιnomethyl)-2-fluorobenzonιtrιle 2-fluoro-5-(hydroxymethyl)benzonιtrιle (6 6 g, 43 66 mmol) was dissolved in dichloromethane (75 mL), and triethylamine (12 mL) was added Mesityl chloride (4 4 mL, 56 76 mmol) was added drop-wise under ice-cold condition and the reaction mixture was stirred for 2 h at room temperature The mixture was poured into cold water (50 mL) The organic layer was separated and was washed with saturated aqueous sodium bicarbonate solution, 1 % aqueous hydrochloric acid solution and brine solution The organic layer was dried over anhydrous sodium sulfate and concentrated The residue was dissolved in acetonitrile (50 mL), and aqueous NH4OH (30 mL) was added to it The reaction mixture was stirred at room temperature for 3 h and was then concentrated under reduced pressure The crude product was purified by washing with hexane and then with ethyl acetate to afford the title compound as a solid (6 8 g, quantitative) Step 3 Preparation of rac-Λ/-(3-cvano-4-fluorobenzyl)-6-(2-(((2S\5ff*)-5-(hvdroxymethyl)-1 ,4-dιoxan- 2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
A mixture of rac-methyl 6-(2-(((2S*,5f?*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxylate (prepared as described in step 1 of the synthesis of rac-Λ/-(4-fluoro-3-methylbenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 67) (100 mg, 0 285 mmol), 5- (amιnomethyl)-2-fluorobenzonιtrι!e (129 mg, 0 856 mmol), and dimethylacetamide (1 mL) was heated to 85 0C for 18 hours The title compound was isolated as a solid by reverse phase preparative HPLC 51 mg, 38%) MS (ES+) m/z 469 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 2 54 (s, 1 H), 2 84 (s, 3 H), 3 29 - 3 51 (m, 4 H), 3 78 (dd, J=1 1 7, 2 2 Hz, 1 H), 3 99 (dd, J=1 1 35, 2 56 Hz, 1 H), 4 03 - 4 14 (m, 1 H), 4 56 (d, J=6 6 Hz, 2 H), 4 65 (t, J=5 5 Hz, 1 H), 4 80 - 5 01 (m, 2 H), 7 49 (t, J=9 2 Hz, 1 H), 7 72 - 7 83 (m, 1 H), 7 88 (dd, J=5 9, 2 2 Hz, 1 H), 8 41 (s, 1 H), 9 63 (t, J=6 2 Hz, 1 H)
Example 77 rac-N-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((2S*,5/?*)-5-(hydroxymethyl)-1 ,4-dioxan-2- yl)methyl)-2tf-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Λ/-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-(2- hydroxyethoxy)benzyl)-6-(2-(((frans-4-cyanocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpynmidine-4- carboxamide, Example 27) (491 mg, 1 32 mmol), rac-((2f?*,5R*)-5-(Hydroxymethyl)-1 ,4-dιoxan-2- yl)methyl 4-methylbenzenesulfonate (prepared as described in step 4 of the synthesis of rac-Λ/-(3- methoxybenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 61 ) (398 mg, 1 32 mmol) and 1 ,8-dιazabιcyclo[5 4 OJundec- 7-ene (240 mg, 1 58 mmol) were combined in dimethylacetamide (5 mL) After heating the reaction at 90 0C for 18 h, the reaction mixture was purified by reverse phase preparative high-pressure liquid chromatography The pure fractions were combined, extracted with ethyl acetate (2 x 20 mL), dried over magnesium sulfate, and concentrated to an oil which solidified under reduced pressure to give the title compound as an white solid (70 mg, 1 1 %) MS (ES+) m/z 504 1H NMR (400 MHz, DMSOd6) δ ppm 9 48 (s, 1 H), 8 40 (s, 1 H), 7 14 (m, 2 H), 6 89 (m, 1 H), 4 74 (m, 2 H), 4 62 (m ,1 H), 4 41 (m , 2 H)1 4 15 (m, 1 H), 4 02 (m 2 H), 3 91 (m, 1 H), 3 78 - 3 95 (m, 2 H), 3 59 - 3 72 (m, 1 H), 3 72 (m, 1 H), 3 61 (m, 2 H), 3 65-3 79 (m, 4 H), 2 81 (s, 3 H)
Example 78 fac-W-(3-Chloro-4-fluorobenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
rac-((2R*,5R*)-5-(Hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 4 of the synthesis of rac-Λ/-(3-methoxybenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)- 1 ,4-dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 61 ) (224 mg, 0 741 mmol) was added to a mixture of Λ/-(3-chloro-4-fluorobenzyl)-2-methyl-6-(2H-tetrazol-5- yl)pyπmιdιne-4-carboxamιde (prepared as described in step 1 of the synthesis of Λ/-(3-chloro-4- fluorobenzyl)-2-methyl-6-(2-((S)-morpholιn-2-ylmethyl)-2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 47) (200 mg, 0 575 mmol) and triethylamine (349 mg, 3 4 mmol) in anhydrous dimethylacetamide (0 3 mL) The reaction was stirred overnight at 85 0C in a capped vial The mixture was purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing product were neutralized by passing through a carbonate resin column and concentrated The resulting product was slurried with diethyl ether, decanted, and dried in vacuo to afford the title compound as a white solid (95 mg) MS (ES+) m/z 478 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 60 (1 H, t, J=6 2 Hz), 8 41 (1 H,s), 7 57 (1 H, d, J=7 0 Hz), 7 37 (2 H, d, J=7 7 Hz), 4 93 (1 H, d, J=Z 7 Hz), 4 88 (1 H, d, J=8 1 Hz)1 4 66 (1 H, br s ), 4 52 (2 H, d, J=6 2 Hz), 4 08 (1 H, d, J=2 9 Hz), 3 99 (1 H, d,
J= 11 3 Hz), 3 78 (1 H, d, J=9 9 Hz), 3 36 - 3 48 (2 H, m), 3 45 (3 H, t, J=10 8 Hz), 3 30 - 3 34 (1 H, m), 2 84 (3 H, s)
Example 79
W-(3-Chloro-4-fluorobenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamιde
((2R,5R)-5-(Hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 1 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 62) (136 mg, 0 45 mmol) was added to a mixture of Λ/-(3-chloro-4-fluorobenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne- 4-carboxamιde (prepared as described in step 1 of the synthesis of Λ/-(3-chloro-4-fluorobenzyl)-2- methyl-6-(2-((S)-morpholιn-2-ylmethyl)-2/-/-tetrazol-5-yl)pyπmιdιne-4-carboxamιde, Example 47) (125 mg, 0 359 mmol) and triethylamine (153 mg, 1 5 mmol) in anhydrous dimethylacetamide (0 3 mL) The reaction was stirred overnight at 85 0C in a capped vial The mixture was purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing product were neutralized by passing through a carbonate resin column and concentrated The resulting product was slurried with diethyl ether, decanted, and dried in vacuo to afford the title compound as a white solid (49 mg) MS (ES+) m/z 478 (M+H) 1H NMR (400 MHz, DMSO-d6) ό ppm 9 60 (1 H, t, J=6 2 Hz), 8 41 (1 H,s), 7 57 (1 H, d, J=7 0 Hz), 7 37 (2 H, d, J=7 7 Hz), 4 93 (1 H, d, J=3 7 Hz), 4 88 (1 H, d, J=8 1 Hz), 4 66 (1 H, br s ), 4 52 (2 H, d, J=6 2 Hz), 4 08 (1 H, d, J=2 9 Hz), 3 99 (1 H, d, J=ϊ 1 3 Hz), 3 78 (1 H, d, J=9 9 Hz), 3 36 - 3 48 (2 H, m), 3 45 (3 H, t, J=10 8 Hz), 3 30 - 3 34 (1 H, m), 2 84 (3 H, s)
Example 80
W-(3-Bromo-4-fluorobenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of /V-(3-bromo-4-fluorobenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide
3-Bromo-4-fluorobenzylamιne (865 mg, 3 6 mmol) was added to a solution of methyl 2-methyl-
6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxylate (229 mg, 1 04 mmol) (prepared as described in step 1 of the synthesis of AV-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((frans)-4-acetamιdocyclohexyl)methyl)- 2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 17) and triethylamine (316 mg, 3 1 mmol) in anhydrous dimethylacetamide (2 0 mL) The mixture was stirred at 65 0C for 2 5 days After cooling to room temperature, the reaction mixture was diluted with excess 2 5 N NaOH solution and washed with ethyl acetate (2x) The aqueous layer was acidified with concentrated hydrochloric acid The resulting precipitate was filtered, washed with water, and dried to afford the title compound as a light yellow solid (300 mg) Step 2 Preparation of Λ/-(3-bromo-4-f1uorobenzyl)-6-(2-(((2S,5R)-5-(hvdroxymethyl)-1 ,4-dιoxan-2- yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
((2f?,5R)-5-(Hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 1 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 62) (136 mg, O 45 mmol) was added to a mixture of Λ/-(3-bromo-4-fluorobenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne- 4-carboxamιde (125 mg, 0 359 mmol) and triethylamine (153 mg, 1 5 mmol) in anhydrous dimethylacetamide (0 3 mL) The reaction was stirred overnight at 85 0C in a capped vial The mixture was purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing product were neutralized by passing through a carbonate resin column and concentrated The resulting product was slurried with diethyl ether, decanted, and dried in vacuo to afford the title compound as a white solid (61 mg) MS (ES+) m/z 522 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 60 (1 H, t, J=6 0 Hz), 8 41 (1 H, s), 7 69 (1 H, d, J=5 5 Hz), 7 41 (1 H, d, J= 1 8 Hz), 7 33 (1 H, t, J=8 8 Hz), 4 93 (1 H, d, J=3 7 Hz), 4 88 (1 H, d, J=8 1 Hz), 4 66 (1 H, br s ), 4 52 (2 H, d, J=6 2 Hz), 4 08 (1 H, d, J=2 9 Hz), 3 99 (1 H, d, J= 1 1 3 Hz), 3 78 (1 H, d, J=9 9 Hz), 3 36 - 3 48 (2 H, m), 3 45 (2 H, t, J=10 8 Hz), 3 31 (1 H, br s ), 2 84 (3 H, s)
Example 81
/V-(4-Fluoro-3-hydroxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5f?)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 65) (476 mg, 1 0 mmol) was dissolved in dichloromethane (20 mL) and the solution was cooled to -70 0C A solution of boron tribromide (4 0 mL, 1 0 M in dichloromethane, 4 0 mmol) was added After 30 mm, the mixture was allowed to warm to room temperature and was stirred for 2 hours The reaction mixture was poured into a mixture of ice and saturated aq sodium bicarbonate The mixture was extracted with dichloromethane (2 x 50 mL) The aqueous layer was acidified to pH 2 with 1 N hydrochloric acid and extracted with dichloromethane (50 mL) The combined organic layers were dried (sodium sulfate) and concentrated The residue was purified by silica gel column chromatography (dichloromethane/methanol, 100/2, 100/3, 100/4) to afford the title compound as a foaming white solid (1 14 mg, 25%) MS (ES+) m/z 460 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 72 (s, 1 H), 9 50 (t, J=Q 4 Hz, 1 H), 8 37 (s, 1 H), 7 00 (dd, J= 1 1 3, 8 4 Hz, 1 H), 6 89 (dd, J=B 6, 2 1 Hz, 1 H), 6 72 - 6 68 (m, 1 H), 4 89 (dd, J= 14 3, 3 7 Hz, 1 H), 4 84 - 4 77 (m, J= 14 3, 8 0 Hz, 1 H), 4 65 (t, J=5 7 Hz, 1 H), 4 37 (d, J=6 4 Hz, 2 H), 4 06 - 3 98 (m, 1 H), 3 93 (dd, J= 11 5, 2 3 Hz, 1 H), 3 72 (dd, J= 1 1 5, 2 5 Hz, 1 H), 3 42 - 3 18 (m, 5 H), 2 78 (s, 3 H)
Example 82
W-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2R,5R)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-2W- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of (2ff)-1 -(benzyloxy)-3-chloropropan-2-ol
To a flame-dried, three neck round bottomed flask was added dry 1 ,2-dιchloroethane (50 mL) and charged with f?-(-)-epιchlorohydrιn (3 8 mL, 49 mmol) and benzyl alcohol (10 mL, 100 mmol) The solution was cooled to 0 0C under nitrogen The stirring solution was then treated with boron tπfluoπde etherate (0 27 mL, 2 2 mmol) dropwise and allowed to warm to room temperature overnight The reaction mixture was then heated to reflux After about 2 hours, the mixture was cooled to room temperature The mixture was partitioned against 10% aqueous saturated sodium bicarbonate (25 mL) and the layers were separated The aqueous phase was extracted with dichloromethane (2 x 25 mL) The organic layers were combined and washed with brine (2 x 10 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a viscous oil The oil was adsorbed onto silica and purified by silica column chromatography eluting with 20-30% ethyl acetate in heptanes to provide the title compound as a viscous oil (5 6 g, 57%) LCMS (5%-100% CH3CN/H2O, 5 mm) 2 7 mm, m/z 223 (M+Na) 1H NMR (400 MHz, CDCI3) δ ppm 7 29 - 7 41 (m, 5 H), 4 58 (s, 2 H), 3 98 - 4 07 (m, 1 H), 3 58 - 3 71 (m, 4 H), 2 49 (d, J=5 8 Hz, 1 H) Step 2 Preparation of (2S)-3-((1 R)-2-(benzyloxy)-1 -(chloromethyl)ethoxy)-2-hvdroxypropyl 4- methylbenzenesulfonate
To a flask containing (2R)-1 -(benzyloxy)-3-chloropropan-2-ol (2 5 g, 12 5 mmol) was added S- glycidol tosylate (0 95 g, 0 33 mmol) and back-filled with nitrogen The flask was charged with dry 1 ,2- dichloroethane (50 mL) and the resulting stirring solution cooled to 0 0C The mixture was treated with boron trifluoride etherate (0 10 mL, 0 81 mmol) dropwise and the reaction mixture was allowed to slowly warm to room temperature overnight The mixture was diluted with dichloromethane (50 mL) and partitioned against 10% aqueous saturated sodium bicarbonate (100 mL) The layers were separated and the aqueous phase extracted with dichloromethane (2 x 50 mL) The organic layers were combined and washed with water (25 mL) and brine (25 mL) The organic layer was then dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a viscous oil The oil was adsorbed onto silica and purified by silica column chromatography eluting with 30-50% ethyl acetate in heptanes to provide the title compound as a viscous oil (0 80 gm, 45%) LCMS (5%-100% CH3CN/H2O, 5 mm) 4 0 mm, m/z 429 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 7 80 (d, «7=8 2 Hz, 2 H), 7 28 - 7 41 (m, 7 H), 4 54 (s, 2 H), 4 02 - 4 13 (m, 2 H), 3 69 - 3 76 (m, 2 H), 3 50 - 3 65 (m, 6 H), 2 95 (d, J=A 3 Hz, 1 H), 2 45 (s, 3 H)
Step 3 Preparation of ((2ff,5/?)-5-((benzyloxy)methyl)-1 ,4-dιoxan-2-yl)methanol To a flask containing (2S)-3-((1 R)-2-(benzyloxy)-1 -(chloromethyl)ethoxy)-2-hydroxypropyl 4- methylbenzenesulfonate (0 80 g, 1 9 mmol) was added 2 5 N aqueous sodium hydroxide solution (2 6 mL, 6 5 mmol) The resulting bi-phasic reaction mixture was vigorously stirred at room temperature After about 2 5 hours, the reaction mixture was heated to 90 0C After about 4 hours, the reaction mixture was cooled to room temperature and stirred overnight The mixture was then re-heated to 90 0C for about 2 hours and finally cooled to room temperature The reaction was neutralized with 1 N hydrochloric acid and solid sodium chloride was added to saturation The reaction mixture was partitioned against dichloromethane (10 mL) The aqueous layer was extracted with additional portions of dichloromethane (3 x 10 mL) The organic layers were combined and washed with saturated aqueous sodium bicarbonate, brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a viscous oil The oil was purified by silica column chromatography eluting with 1 -4% methanol in dichloromethane to provide the title compound as a viscous oil (0 20 gm, 45%) LCMS (5%-100% CH3CN/H2O, 5 mm) 2 6 mm, m/z 239 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 7 25 - 7 45 (m, 5 H), 4 59 (s, 2 H), 3 5 - 3 9 (m, 10 H), 2 3 (br S , 1 H) Step 4 Preparation of ((2S,5f?)-5-((benzyloxy)methyl)-1 ,4-dιoxan-2-yl)methyl 4- methylbenzenesulfonate
To a solution of ((2R,5/?)-5-((benzyloxy)methyl)-1 ,4-dιoxan-2-yl)methanol (0 20 g, 0 59 mmol) in pyridine (3 mL) was added p-toluenesulfonyl chloride (0 38 g, 3 4 mmol) and a small crystal of 4- dimethylaminopyπdine The reaction mixture was left to stir at room temperature overnight The mixture was then treated with additional p-toluenesulfonyl chloride (0 10 gm) and left to stir for about 8 hours The reaction mixture was treated with toluene (10 mL) and concentrated under reduced pressure using a cold bath The addition of toluene and concentration under reduced pressure was repeated (3x) The resulting residue was partitioned between water (20 mL) and ethyl acetate (20 mL) The layers were separated and the aqueous phase extracted with ethyl acetate (2 x 20 mL) The organic phases were combined and washed with saturated aqueous sodium bicarbonate solution, brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to give a viscous oil This oil was adsorbed onto silica and purified by silica column chromatography eluting with 30-40% ethyl acetate in heptanes to provide the title compound as a viscous oil (0 19 gm, 82%) LCMS (50%- 100% CH3CN/H2O, 5 mm) 2 6 mm, m/z 393 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 7 81 (d, J=B 2 Hz, 2 H), 7 28 - 7 41 (m, 7 H), 4 54 (s, 2 H), 4 30 (dd, J=10 4, 7 0 Hz, 1 H), 4 12 (dd, J=10 4, 5 6 Hz, 1 H), 3 52 - 3 86 (m, 7 H), 3 42 - 3 50 (m, 1 H), 2 45 (s, 3 H)
Step 5 Preparation of ((2S,5ff)-5-(hvdroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate
To a solution of ((2S,5/?)-5-((benzyloxy)methyl)-1 ,4-dιoxan-2-yl)methyl 4- methylbenzenesulfonate (0 19 g, 0 48 mmol) in ethanol (5 mL) under nitrogen was added palladium on carbon and back-filled with hydrogen gas The mixture was allowed to stir at room temperature overnight under a balloon of hydrogen gas The reaction mixture was filtered through Celite™ with ethanol washes The combined filtrates were concentrated under reduced pressure to give the title compound as a viscous oil (0 13 gm, 89%) LCMS (5%-100% CH3CN/H2O, 5 mm) 2 8 mm, m/z 303 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 7 80 (d, J=8 2 Hz, 2 H), 7 35 (d, J=Q 2 Hz, 2 H), 4 21 - 4 30 (m, 1 H), 4 1 1 - 4 19 (m, 1 H), 3 76 - 3 85 (m, 1 H), 3 52 - 3 75 (m, 7 H), 2 45 (s, 3 H) Step 6 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(((2R5R)-5-(hvdroxymethyl)-1.4-dιoxan-2- yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιclιne-4-carboxamιde
To a vial containing Λ/-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide (prepared as described in step 2 of the synthesis of N-(4-flυoro-3-methoxybenzyl)-6-(2- (fraπs-4-amιnocyclohexyl)methy!)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 9) (101 mg, 0 29 mmol) and ((2S,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4- methylbenzenesulfonate (1 15 mg, 0 38 mmol) was added Λ/,/V-dιmethylformamιde (0 3 mL) followed by triethylamine (1 0 mL) The vial was flushed with nitrogen, tightly capped and heated to 85 °C with stirring After about 2 days, the mixture was cooled to room temperature and concentrated under reduced pressure The resulting residue was diluted with dichloromethane (10 mL) and partitioned with water (10 mL) The layers were separated and the aqueous phase was extracted with dichloromethane (3 x 10 mL) The organic layers were combined and washed with 1 N hydrochloric acid solution (10 mL), water (10 mL), 1 N sodium hydroxide solution (10 mL), water (10 mL), brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure The residue was subjected to silica column chromatography eluting with 1 -3% methanol in ethyl acetate The crude product was further purified by reverse phase preparative HPLC (acetonitrile/water) to provide the title compound as a white solid (39 mg, 28%) LCMS (5%-100% CH3CN/H2O, 5 mm) 3 05 mm, m/z 474 (M+H) 1H NMR (400 MHz, DMSO-O6) δ ppm 9 58 (t, J=6 4 Hz, 1 H), 8 42 (s, 1 H), 7 09 - 7 24 (m, 2 H), 6 83 - 6 96 (m, 1 H), 5 35 (dd, J=14 2, 9 9 Hz, 1 H), 4 98 (dd, J=14 3, 4 0 Hz, 1 H), 4 70 - 4 82 (m, 1 H), 4 50 (d, J=Q 3 Hz, 2 H), 4 16 - 4 28 (m, 1 H), 3 82 (s, 3 H), 3 73 - 3 81 (m, 3 H), 3 43 - 3 58 (m, 4 H), 2 83 (s, 3 H)
Example 83
Λ/-(3-Chloro-4-fluorobenzyl)-6-(2-((5,5-bis(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5- yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of /rans-(5-formyl-1.4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate
To a -78 0C solution of oxalyl chloride (6 43 g, 49 6 mmol) in dichloromethane (30 mL) was slowly added dimethyl sulfoxide (7 29 g, 93 3 mmol) The reaction was stirred at -78 0C for 20 mm at which time a solution of rac-((2f?*,5/?*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4- methylbenzenesulfonate (prepared as described in step 4 of the synthesis of rac-Λ/-(3- methoxybenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 61 ) (6 0 g, 20 mmol) in dichloromethane (12 mL) was added drop-wise The resulting solution was stirred at -78 0C for 1 h and then quenched with triethylamine (1 1 O g, 109 mmol) forming a thick white precipitate The ice bath was removed and the reaction was slowly warmed to room temperature The mixture was diluted in dichloromethane (100 mL) and washed successively with 1 N hydrochloric acid (75 mL), sat sodium bicarbonate (75 mL), and brine (100 mL) The organic layer was dried over magnesium sulfate, filtered and evaporated to afford the title compound as a yellow oil (6 4 g, 100%) 1H NMR (400 MHz, DMSO-cfe) δ ppm 9 43 (s, 1 H), 7 75 (m, 2 H), 7 47 (m, 2 H), 3 63 - 4 08 (m, 5 H), 3 17 - 3 38 (m, 3 H), 2 39 (s, 3 H)
Step 2 Preparation of (5,5-bιs(hvdroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate
2 5 N Sodium hydroxide (17 0 mL, 1 70 g, 42 6 mmol) was added to a solution of trans-((5- formyl-1 ,4-dιoxan-2-y!)methyl 4-methylbenzenesulfonate (6 4 g, 21 0 mmol) in 2 1 tetrahydrofuran/water (30 mL) To this reaction was added a 37% solution of formaldehyde (3 69 mL, 3 80 g, 46 9 mmol) and the mixture was stirred at 25 0C for 18 hours The reaction mixture was neutralized with formic acid (2 mL) The reaction was concentrated, washed with ethyl acetate (150 mL) and filtered The filtrate was concentrated to afford the title compound as a yellow oil that solidified upon standing (5 4 g, 76%) LC/MS (5%-95% CH3CN H2O, 6 mm) 3 69 mm, m/z 333 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 7 75 (m, 2 H), 7 33 (m, 2 H), 4 75 (m, 2 H), 3 95 - 3 49 (m, 3 H), 3 45 - 3 75 (m, 9 H), 2 43 (s, 3 H) Step 3 Λ/-(3-chloro-4-fluQrobenzyl)-6-(2-((5,5-bιs(hvclroxymethyl)-1.4-clιoxan-2-yl)methyl)-2H-tetrazol- 5-yl)-2-methylpyrιmιdιne-4-carboxamιde
Λ/-(3-Chloro-4-fluorobenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 1 of the synthesis of /V-(3-chloro-4-fluorobenzyl)-2-methyl-6-(2-((S)-morpholιn-2- ylmethyl)-2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 47) (50 mg, 0 144 mmol), (5,5- bιs(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (47 8 mg, 0 144 mmol), and triethylamine (400 μL) were combined in dimethylacetamide (100 μl_) The resulting mixture was stirred at 90 0C for 18 h The mixture was concentrated The residue was purified by reverse phase high-pressure liquid chromatography The pure fractions were combined, extracted with ethyl acetate (2 x 20 mL), dried over magnesium sulfate, and concentrated to afford the title compound as a solid (12 mg, 16%) MS (ES+) m/z 508 (M+H) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 9 61 (t, J = 6 2 Hz, 1 H), 7 57 d, J = 7 0 Hz, 1 H), 7 37 (d, J = 7 7 Hz, 2 H), 4 97 (s, 1 H), 4 95 (d, J = 3 3 Hz, 1 H), 4 44 - 4 54 (m, 1 H), 4 52 (d, J = 6 2 Hz, 3 H), 3 73 (d, J = 3 3 Hz, 1 H), 3 60 (t, J = 5 5 Hz, 1 H), 3 66 (m, 2 H), 3 39 (d, J = 4 4 Hz, 1 H), 3 35 - 3 44 (m, 1 H), 3 23 (s, 1 H), 3 25 (d, J = 5 5 Hz, 2 H), 2 84 (s, 3 H), 2 74 (s, 1 H)
Example 84
/V-(3-Methoxybenzyl)-6-(2-((5,5-bis(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2- methylpyrimidine-4-carboxamide
Λ/-(3-Methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 6 of the synthesis of /V-(3-methoxybenzyl)-6-(2-(((/rans)-4-amιnocyclohexyl)methyl)- 2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 5) (47 mg, 0 144 mmol), (5,5- bιs(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 2 of the synthesis of Λ/-(3-chloro-4-fluorobenzyl)-6-(2-((5,5-bιs(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)- 2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 83) (48 mg, 0 144 mmol), and triethylamine (400 μL) were combined in dimethylacetamide (100 μL) The resulting mixture was stirred at 90 °C for 18 h The mixture was concentrated and the residue was purified by reverse phase high-pressure liquid chromatography The pure fractions were combined, extracted with ethyl acetate (2 x 20 mL), dried over magnesium sulfate, and concentrated to afford the title compound as a solid (12 mg, 16%) MS (ES+) m/z 486 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 49 (m, 1 H), 8 42 (s, 1 H), 7 24 (m, 1 H), 6 93 (m, 2 H), 6 81 (m, 2 H), 4 96 (m, 2 H), 4 53 (m, 3 H), 4 18 (m, 2 H), 3 74 (s, 3 H), 3 48 - 3 62 (m, 4 H), 3 42 (m, 2 H), 2 86 (s, 3 H)
Example 85 rac-(2S*,5S*)-Methyl 5-((5-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H-tetrazol- 2-yl)methyl)-1 ,4-dioxane-2-carboxylate
Step 1 Preparation of transΛ ,4-dιoxane-2,5-dιcarboxylιc acid
A solution of trans-2, 5-bιs-(hydroxymethyl)-1 ,4-dιoxane (prepared as described in step 3 of the synthesis of rac-Λ/-(3-methoxybenzyl)-6-(2-(((2S*,5f?*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 61 ) (88 17 g) in water (458 mL) and HNO3 (1238 mL) was heated to reflux for 100 mm and then cooled to 5 0C The resulting precipitate was collected by filtration, washed with cold water (500 mL), and dried in vacuo at 50 0C overnight to provide the title compound (100 75 g) Step 2 Preparation of frans-dimethyl 1.4-dιoxane-2.5-dιcarboxylate frans-1 , 4-Dιoxane-2,5-dιcarboxylιc acid (90 g) was dissolved in hot methanol (1380 mL) The solution was cooled to 15 0C and HCI gas (approximately 45 g) was bubbled through the solution until saturated The reaction mixture was stirred at room temperature for 24 hours, and then cooled to 5 0C The resulting precipitate was collected by filtration, washed methanol and cold saturated sodium bicarbonate solution (500 mL) The solid was further washed with cold water (500 mL) until the wash was neutral The product was dried in a vacuo at 50 0C overnight to afford the title compound (97 g)
Step 3 Preparation of rac-(2ff*,5S*)-5-(methoxycarbonyl)-1 ,4-dιoxane-2-carboxylιc acid A solution of /rans-dimethyl 1 ,4-dιoxane-2,5-dιcarboxylate (68 54 g, 336 mmol) in methanol
(3 2 L) and water (0 8 L) was slowly added to a solution of lithium hydroxide monohydrate (10 56 g, 252 mmol) in water (0 6 L) The reaction mixture was maintained at 20 0C during the addition by applying a water bath The resulting solution was stirred for 24 h and concentrated to remove most of the methanol in vacuo The remaining aqueous mixture was extracted with ethyl acetate (2 L) The aqueous layer was then acidified to pH 2 with 6 N hydrochloric acid and concentrated to a small volume (ca 400 mL) The mixture was cooled to 0-5 0C and filtered The solids were washed with cold water and dried in a vacuum oven at 50 0C for 24 h to afford the title compound (33 34 g)
Step 4 Preparation of rac-(2S*.5S*)-methyl 5-(hγdroxymethyl)-1 ,4-dιoxane-2-carboxylate rac-(2R\5S*)-5-(Methoxycarbonyl)-1 ,4-dιoxane-2-carboxylιc acid (19 34 g, 102 mmol) was dissolved in tetrahydrofuran (800 mL) A solution of borane dimethylsulfide (10 M, 12 2 mL) was slowly added to the solution The mixture was stirred at room temperature for 3 h and then quenched with water (50 mL) The mixture was concentrated under vacuum The residue was suspended in ethyl acetate and filtered The filtrate was concentrated The residue was again suspended in chloroform, filtered, and the filtrate concentrated The crude product was purified by silica gel chromatography (dichloromethane/methanol, 99 5/0 5 - 98/2) to afford the title compound
Step 5 Preparation of rac-(2S*.5ff*)-methyl 5-((tosyloxy)methyl)-1 ,4-dιoxane-2-carboxylate
p-Toluene sulfonylchloride (3 46 g, 18 15 mmol) was added portion-wise over 30 mm to a solution of rac-(2S*,5S*)-methyl 5-(hydroxymethyl)-1 ,4-dιoxane-2-carboxylate (3 2 g, 18 0 mmol) in anhydrous pyridine (24 mL) The mixture was stirred at room temperature for 3 5 h Water (100 mL) was added drop-wise at ice bath temperatures The resulting precipitate was filtered, washed with water, and dried to afford the title compound as a white solid (4 31 g)
Step 6 Preparation of rac-(2S*.5S*)-methyl 5-((5-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn- 4-yl)-2H-tetrazol-2-vDmethyl)-1 ,4-dιoxane-2-carboxylate
rac-(2S*,5R*)-Methyl 5-((tosyloxy)methyl)-1 ,4-dιoxane-2-carboxylate (2 19 g, 6 6 mmol) was added to a solution of A/-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrimidine-4-carboxamide (prepared as described in step 6 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((<rans)-4- amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 5) (2 16 g, 6 6 mmol) and triethylamine (1 33 g, 13 2 mmol) in anhydrous dimethylacetamide (4 mL) The mixture was stirred at 85 0C in a capped vial overnight The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitrile) to afford the title compound (54 mg) Example 86 rac-(2S*,5S*)-5-((5-(6-((3-Methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H-tetrazol-2- yl)methyl)-1 ,4-dioxane-2-carboxylic acid
Sodium hydroxide (10 pellets) was added to a mixture of rac-(2S*,5S*)-methyl 5-((5-(6-((3- methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-2H-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylate (54 mg) in tetrahydrofuran (3 mL) and water (3 mL) The mixture was stirred overnight at room temperature The reaction mixture was acidified with trifluoroacetic acid and purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing the product were concentrated The residue was slurried and decanted from ethyl ether and dried in a vacuum desiccator to afford the title compound as a white solid (736 mg) MS (ES+) m/z 470 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 48 (1 H, t, J=Q 2 Hz), 8 42 (1 H, s), 7 24 (1 H, t, J=8 1 Hz), 6 93 (2 H, br s ), 6 83 (1 H, d, J=I 3 Hz), 4 96 (1 H, d, J=3 3 Hz), 4 92 (1 H, d, J=I 7 Hz), 4 51 (2 H, d, J=Q 2 Hz), 4 09 (2 H, t, J=10 4 Hz), 4 12 (1 H, d, J=12 8 Hz), 3 95 (1 H, dd. J=1 1 7, 2 6 Hz), 3 74 (3 H, s), 3 49 (2 H, dt, J=16 4, 10 8 Hz), 2 83 (3 H, s), 2 43 (1 H, s)
Example 87 rac-(2S*,5S*)-methyl 5-((5-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H- tetrazol-2-yl)methyl)-1,4-dioxane-2-carboxylate
rac-(2S*,5f?*)-Methyl 5-((tosyloxy)methyl)-1 ,4-dιoxane-2-carboxylate (prepared as described in step 1 of the synthesis of rac-(2S*,5S*)-methyl 5-((5-(6-((3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2H-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylate, Example 85) (562 mg, 1 7 mmol) was added to a solution of Λ/-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3- methoxybenzyl)-6-(2-(fΛans-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide, Example 9) (400 mg, 1 17 mmol) and triethylamine (233 mg, 2 3 mmol) in anhydrous dimethylacetamide (1 0 mL) The mixture was stirred at 85 0C in a capped vial overnight The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitrile) to afford the title compound (210 mg) Example 88 rac-(2S*,5S*)-5-((5-(6-((4-Fluoro-3-methoxybenzyl)carbamoyl)-2-methy!pyrimidin-4-yl)-2H- tetrazol-2-yl)methyl)-1 ,4-dioxane-2-carboxylic acid
Sodium hydroxide (2 pellets) was added to a mixture of rac-(2S*,5S*)-methyl 5-((5-(6-((4- fluoro-S-methoxybenzyOcarbamoyO^-methylpyπmidin^-yO^H-tetrazol^-yOmethyO-i ^-dioxane-Z- carboxylate (prepared as described in Example 87) (34 mg, 0 068 mmol) in tetrahydrofuran (0 4 mL) and water (0 4 mL) The mixture was stirred overnight at room temperature The reaction mixture was acidified with tπfluoroacetic acid and purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing the product were concentrated The residue was slurried and decanted from ethyl ether and dried in a vacuum desiccator to afford the title compound as a white solid (31 mg) MS (ES+) m/z 488 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 46 - 9 56 (1 H, m), 8 42 (1 H, s), 7 17 (1 H, dd, J=12 8, 8 8 Hz), 6 92 (1 H, br s ), 4 89 - 5 00 (2 H, m), 4 50 (2 H, d, J=5 9 Hz), 4 06 (3 H, br s ), 3 95 (1 H, d, J=1 1 7 Hz), 3 82 (3 H, s), 3 48 (2 H, dd, J=10 4, 7 5 Hz), 3 22 (2 H, br s ), 2 83 (2 H, s), 1 25 (2 H, d, J=5 1 Hz)
Example 89
(2S,5S)-5-((5-(6-((4-Fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H-tetrazol-2- yl)methyl)-1 ,4-dioxane-2-carboxylic acid
A mixture of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2- yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 65) (238 mg, 0 5 mmol) and pyridinium dichromate (1 15 g, 3 0 mmol) in DMF (5 0 mL) was shaken for 24 hours at room temperature The reaction mixture was diluted with dichloromethane (50 mL) and washed with 1 N hydrochloric acid solution (2 x 50 mL) The organic layer was extracted with 1 N sodium hydroxide solution (2 x 40 mL) The combined aqueous layers were acidified with concentrated hydrochloric acid and extracted with dichloromethane (2 x 50 mL) The combined organic layers were dried (sodium sulfate) and concentrated The residue was triturated with diethyl ether and filtered to afford the title compound as a white solid (79 mg, 32%) MS (ES+) m/z 488 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 58 (t, J=Q 6 Hz, 1 H), 8 41 (s, 1 H), 7 17 (dd, J=8 4, 2 2 Hz, 1 H), 7 13 (dd, J=1 1 7, 8 4 Hz, 1 H), 6 89 (ddd, J=Q 3, 4 5, 2 2 Hz, 1 H), 4 97 (dd, J=14 3, 3 7 Hz1 1 H), 4 89 (dd, J=14 3, 7 7 Hz, 1 H), 4 49 (d, J=6 2 Hz, 2 H), 4 15 - 4 03 (m, 3 H), 3 93 (dd, J=1 1 5, 3 1 Hz, 1 H), 3 81 (s, 3 H), 3 53 - 3 41 (m, 2 H), 2 82 (s, 3 H)
Example 90
(2S,5S)-Methyl 5-((5-(6-((4-Fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyπmidin-4-yl)-2H- tetrazol-2-yl)methyl)-1 ,4-dioxane-2-carboxylate
A mixture of W-(4-fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2- yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 65) (952 mg, 2 0 mmol) and pyridinium dichromate (4 61 g, 12 0 mmol) in DMF (20 0 mL) was shaken for 36 h at room temperature The reaction mixture was poured into 1 N hydrochloric acid solution (100 mL) and extracted with ethyl acetate (4 x 50 mL) The combined organic layers were dried (sodium sulfate) and concentrated The residue was dissolved in methanol (50 mL) and a solution of hydrochloric acid (4M in dioxane, 25 mL) was added The mixture was allowed to stand for 18 h and was then concentrated The residue was mixed with dichloromethane (50 mL) and water (100 mL) The aqueous layer was further extracted with dichloromethane (2 x 50 mL) The combined organic layers were washed with brine (25 mL), dried (sodium sulfate), and concentrated The crude product was purified by silica gel column chromatography (dichloromethane/methanol, 100/1 , 100/2) to afford the title compound (711 mg, 71 %) MS (ES+) m/z 502 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 58 (t, J=6 2 Hz, 1 H), 8 41 (s, 1 H), 7 17 (dd, J=Q 1 , 2 2 Hz, 1 H), 7 13 ((Jd1 J=H 3, 8 1 Hz, 1 H)1 6 89 (ddd, J=8 3, 4 5, 1 8 Hz, 1 H), 4 98 (dd, J=14 3, 3 7 Hz1 1 H)1 4 90 (dd, J=14 3, 7 7 Hz1 1 H)1 4 48 (d, J=6 6 Hz, 2 H)1 4 24 (dd, J=10 2, 2 9 Hz1 1 H)1 4 17 - 4 10 (m, 1 H)1 4 08 (dd, J= 1 1 5, 2 7 Hz, 1 H), 3 99 - 3 91 (m, 1 H)1 3 81 (s, 3 H)1 3 63 (s, 3 H)1 3 56 - 3 44 (m, 2 H)1 2 82 (s, 3 H)
Example 91
W-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5S)-5-(2-hydroxypropan-2-yl)-1,4-dioxan-2-yl)methyl)- 2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
(2S,5S)-Methyl 5-((5-(6-((4-Fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-2/-/- tetrazo!-2-yl)methyl)-1 ,4-dιoxane-2-carboxylate (prepared as in Example 90) (251 mg, 0 5 mmol) was dissolved in anhydrous tetrahydrofuran (5 mL) and the solution was cooled to -70 °C A solution of methylmagnesium bromide (3 M in ethyl ether, 666 μl, 2 O mmol) was added and the mixture was allowed to warm to room temperature After 2 h, the reaction mixture was quenched with 1 N hydrochloric acid (5 mL) The mixture was poured into water (50 mL) and extracted with ethyl acetate (2 x 50 mL) The combined organic layers were dried (sodium sulfate) and concentrated The crude product was purified by silica gel column chromatography (dichloromethane/methanol, 100/1 , 100/2) to afford the title compound (51 7 mg, 21%) MS (ES+) m/z 502 (M+H) 1H NMR (400 MHz, DMSO- d6) δ ppm 9 57 (t, J=6 6 Hz, 1 H), 8 41 (s, 1 H), 7 20 - 7 10 (m, 2 H), 6 89 (ddd, J=Q 4, 4 4, 2 2 Hz, 1 H), 4 93 (dd, J=13 9, 3 7 Hz, 1 H), 4 88 - 4 82 (m, J=14 3, 7 7 Hz, 1 H), 4 49 (d, J=6 6 Hz, 2 H), 4 46 (S, 1 H), 4 07 - 3 98 (m, 2 H), 3 85 - 3 77 (m, 4 H), 3 39 (dt, J=16 8, 11 3 Hz, 2 H), 3 19 - 3 13 (m, J=10 2, 2 2 Hz, 1 H), 2 82 (s, 3 H), 1 06 (s, 3 H), 0 99 (s, 3 H)
Example 92 rac-(2S*,5S*)-Methyl 5-((5-(6-((3-chloro-4-fluorobenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H- tetrazot-2-yl)methyl)-1 ,4-dioxane-2-carboxylate
rac-(2S*,5/?*)-Methyl 5-((tosyloxy)methyl)-1 ,4-dιoxane-2-carboxylate (prepared as described in step 1 of the synthesis of rac-(2S*,5S*)-methyl 5-((5-(6-((3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylate, Example 85) (244 mg, 0 74 mmol) was added to a solution of Λ/-(3-chloro-4-fluorobenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyπmιdιne- 4-carboxamιde (prepared as described in step 1 of the synthesis of Λ/-(3-chloro-4-fluorobenzyl)-2- methyl-6-(2-((S)-morpholιn-2-ylmethyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 47) (200 mg, 0 575 mmol) and triethylamine (349 mg, 3 4 mmol) in anhydrous dimethylacetamide (0 3 mL) The mixture was stirred at 85 0C in a capped vial overnight The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitrile) to afford the title compound (103 mg)
Example 93 rac-(2S*,5S*)-5-((5-(6-((3-Chloro-4-fluorobenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H-tetrazol-
2-yl)methyl)-1 ,4-dioxane-2-carboxylic acid
Sodium hydroxide (3 pellets) was added to a mixture of rac-(2S*,5S*)-methy! 5-((5-(6-((3- chloro^-fluorobenzyOcarbamoyl^-methylpynmidin^-yl^H-tetrazol^-yl^ethyl^i ^-dioxane^- carboxylate (prepared as described in Example 92) (103 mg) in tetrahydrofuran (0 4 mL) and water (0 4 mL) The mixture was stirred overnight at room temperature The reaction mixture was acidified with trifluoroacetic acid with ice bath cooling and purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing the product were concentrated The residue was slurried and decanted from ethyl ether and dried in a vacuum desiccator to afford the title compound as a white solid (88 mg) MS (ES+) m/z 492 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 55 - 9 64 (1 H, m), 8 42 (1 H, s), 7 57 (1 H, d, J=7 3 Hz), 7 37 (2 H, d, J=I 0 Hz), 4 91 (1 H, br s ), 4 95 (1 H, d, J=12 8 Hz), 4 52 (2 H, d, J=5 9 Hz), 4 1 1 (3 H, d, J=12 8 Hz), 4 06 (1 H, br s ), 3 95 (1 H, d, J=11 7 Hz), 3 48 (1 H, t, J=1 1 0 Hz), 3 44 - 3 55 (1 H, m), 2 84 (3 H, s)
Example 94 rac-(2S*,5S*)-Methyl 5-((5-(6-((3-bromo-4-fluorobenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H- tetrazol-2-yl)methyl)-1 ,4-dioxane-2-carboxylate
rac-(2S*,5R*)-Methyl 5-((tosyloxy)methyl)-1 ,4-dιoxane-2-carboxylate (prepared as described in step 1 of the synthesis of rac-(2S*,5S*)-methyl 5-((5-(6-((3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-y!)-2H-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylate, Example 85) (150 mg, 0 454 mmol) was added to a solution of Λ/-(3-bromo-4-fluorobenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne- 4-carboxamιde (prepared as described in step 1 of the synthesis of Λ/-(3-bromo-4-fluorobenzyl)-6-(2- (((2S,5f?)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide, Example 80) (150 mg, 0 382 mmol) and triethylamine (153 mg, 1 5 mmol) in anhydrous dimethylacetamide (0 3 mL) The mixture was stirred at 85 0C in a capped vial overnight The reaction mixture was purified by reverse phase preparative HPLC (water/acetonitrile) to afford the title compound (70 mg)
Example 95 rac-(2S*,5S*)-5-((5-(6-((3-Bromo-4-fluorobenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H-tetrazol-
2-yl)methyl)-1 ,4-dioxane-2-carboxylic acid
Sodium hydroxide (3 pellets) was added to a mixture of rac-(2S*,5S*)-methyl 5-((5-(6-((3- bromo-4-fluorobenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2- carboxylate (prepared as described in Example 94) (70 mg) in tetrahydrofuran (0 4 mL) and water (0 4 mL) The mixture was stirred overnight at room temperature The reaction mixture was acidified with trifluoroacetic acid with ice bath cooling and purified by reverse phase preparative HPLC
(water/acetonitrile) Fractions containing the product were concentrated The residue was slurried and decanted from ethyl ether and dried in a vacuum desiccator to afford the title compound as a white solid (18 mg) MS (ES+) m/z 536 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 61 (1 H, t, J=6 2 Hz), 8 42 (1 H, s), 7 69 (1 H, d, J=7 0 Hz), 7 41 (1 H, t, J=5 7 Hz), 7 33 (1 H, t, J=8 6 Hz), 4 90 - 5 00 (2 H, m), 4 52 (3 H, d, J=6 2 Hz), 4 05 - 4 17 (3 H, m), 3 95 (1 H, dd, J=Ϊ 1 9, 2 7 Hz), 3 50 (2 H, dt, J=16 3, 11 1 Hz), 2 84 (3 H, s)
Example 96 rac-rV-(3-Methoxybenzyl)-6-(2-(((2S*,5R*)-5-(aminomethyl)-1,4-dioxan-2-yl)methyl)-2H-tβtrazol-5- yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of rac-((2S*,5S*)-5-((5-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyπmιdιn-4-yl)- 2H-tetrazol-2-yl)methyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate
In a 40 mL scintillation vial with a magnetic stir bar at room temperature and standard pressure, /V-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyπmιdιne-4-carboxamιde (prepared as described in step 6 of the synthesis of /V-(3-methoxybenzyl)-6-(2-(((frans)-4-amιnocyclohexyl)methyl)- 2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 5) (520 mg, 1 60 mmol) was combined with rac-((2R*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 4 of the synthesis of rac-Λ/-(3-methoxybenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)- 1 ,4-dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 61 ) (604 mg, 2 00 mmol), polymer supported triphenylphosphine (1490 mg, 3 20 mmol), and anhydrous tetrahydrofuran (15 ml) The reaction mixture was cooled to 0 0C and di-tert-butyl azodicarboxylate (736 mg, 3 20 mmol) was added The mixture was stirred at 0 0C for 2 hours and then was allowed to warm to room temperature for 12 hours The reaction mixture was filtered and concentrated to oil The oil was dissolved in acetonitrile and water and chromatographed by reversed phased preparative HPLC (Gilson prep, Delta Pak column, 30 to 40% acetonitrile, 10 mm hold, 40 mm run, 10 mm hold) Fractions containing the desired were combined and concentrated under vacuum to afford the title compound as a white solid (136 5 mg) 1H NMR (400 MHz, methanol-d4) 6 ppm 2 84 - 2 86 (m, 3 H), 3 03 (dd, J=13 3, 2 8 Hz, 1 H), 3 37 (dd, J=11 6, 10 2 Hz, 1 H), 3 60 (dd, .7=1 1 6, 10 5 Hz, 1 H), 3 74 - 3 77 (m, 3 H), 4 12 (dd, J=λ 1 7, 2 6 Hz, 1 H), 4 20 - 4 28 (m, 1 H), 4 57 - 4 62 (m, 2 H), 4 87 - 4 90 (m, 2 H), 6 81 (dd, J=7 9, 2 0 Hz, 1 H), 6 90 - 6 95 (m, 2 H), 7 22 (t, 1 H), 8 57 (s, 1 H), 9 50 (t, 1 H) LC/MS (5%-95% CH3CN/H2O, 8 mm) 6 47 mm, m/z 610 (M+H) Step 2 Preparation of rac-Λ/-(3-methoxybenzyl)-6-(2-(((2S\5ff*)-5-(amιnomethyl)-1 ,4-dιoxan-2- yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
In a 20 ml scintillation vial with a magnetic stir bar at room temperature and standard pressure, rac-((2S*,5S*)-5-((5-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-2H-tetrazol-2- yl)methyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (130 mg) was dissolved in dimethyl sulfoxide (5 mL) and ammonium hydroxide (31 5 mg, 0 898 mmol) was added The mixture was stirred at room temperature for 2 hours and then heated to 80 0C for 12 hours The reaction mixture was concentrated, dissolved in acetonitrile and water, acidified with acetic acid, and chromatographed by reversed phase preparative HPLC (Gilson, Delta Pak column, 30-60% acetonitrile, 5 mm hold, 30 mm run, 5 mm hold) Fractions containing the desired product were collected and concentrated under vacuum to afford the trifluoroacetic acid salt of the title compound as a clear oil (81 6 mg) 1H NMR (400 MHz, methanol-d,) δ ppm 2 85 (s, 3 H)1 3 03 (dd, J=13 3, 2 8 Hz, 1 H), 3 37 (dd, J=11 4, 10 3 Hz, 1 H), 3 60 (dd, J=11 6, 10 5 Hz, 1 H), 3 76 (s, 3 H), 3 81 (dd, J=1 1 6, 2 4 Hz, 1 H), 4 12 (dd, J=11 7, 2 6 Hz, 1 H), 4 20 - 4 28 (m, 1 H), 4 58 - 4 61 (m, 2 H), 4 87 - 4 90 (m, 2 H), 6 79 - 6 83 (m, 1 H), 6 91 - 6 95 (m, 2 H), 7 22 (t, J=8 1 Hz, 1 H), 8 57 (s, 1 H), 9 50 (t, J=6 58 Hz, 1 H) LC/MS (5%-95% CH3CN/H2O, 5 mm) 2 241 mm, m/z 455 (M+H)
Example 97 rac-N-(3-Methoxybenzyl)-6-(2-(((2S*,5/?*)-5-(acetamidomethyl)-1,4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
In a 20 mL scintillation vial with a magnetic stir bar at room temperature and standard pressure, rac-Λ/-(3-methoxybenzyl)-6-(2-(((2S*,5R*)-5-(amιnomethyl)-1 ,4-dιoxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde trifluoroacetate (prepared as described in Example 96) (40 mg, 0 70 mmol) was combined with Λ/,Λ/-dιmethylformamιde (5 mL) and N,N- diisopropylethylamme (59 2 mg, 0 458 mmol) Acetic anhydride (19 1 mg, 0 187 mmol) was added and the mixture was stirred overnight The reaction mixture was concentrated, re-dissolved in acetonitrile and water, and chromatographed by reversed phase preparative HPLC (Gilson, Delta Pak column, 20- 60% acetonitrile, 10 mm hold, 20 mm run, 10 mm hold) Fractions containing the desired product were collected and concentrated to afford the title compound as a white solid (21 3 mg) 1H NMR (400 MHz, methanol-d4) 6 ppm 1 32 - 1 37 (m, 2 H), 1 91 (s, 3 H), 2 85 (s, 3 H)1 3 09 - 3 16 (m, 1 H), 3 18 - 3 24 (m, 1 H), 3 49 - 3 60 (m, 1 H), 3 76 (s, 3 H), 4 01 (dd, J= 11 6, 2 4 Hz, 1 H), 4 14 - 4 22 (m, 1 H), 4 58 - 4 62 (m, 1 H), 6 81 (dd, J=8 1 , 1 9 Hz, 1 H), 6 92 - 6 95 (m, 2 H), 7 23 (t, J=8 1 Hz, 1 H), 8 58 (s, 1 H), 9 49 (t, J=6 6 Hz, 1 H) LC/MS (5%-95% CH3CN/H2O, 5 mm) 2 59 mm, m/z 497 (M+H)
Example 98 rac-W-(3-Methoxybenzyl)-6-(2-(((2S*,5/?*)-5-(acetamidomethyl)-1,4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
In a 20 mL scintillation vial with a magnetic stir bar at room temperature and standard pressure, rac-Λ/-(3-methoxybenzyl)-6-(2-(((2S*,5/?*)-5-(amιnomethyl)-1 ,4-dιoxan-2-yl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde trifluoroacetate (prepared as described in Example 96) (115 mg, 0 253 mmol) was combined with Λ/,Λ/-dιmethylformamιde (5 mL) and N, N- dnsopropylethylamine (98 1 mg, 0 759 mmol) at room temperature After 30 mm, methane sulfonyl chloride was added and the reaction mixture was stirred for 12 hours The reaction mixture was concentrated, dissolved in acetonitrile and water, and chromatographed by reversed phased preparative HPLC (Gilson, Delta Pak column, 30-60% acetonitrile, 10 mm hold, 30 mm run, 5 mm hold) Fractions containing the desired product were collected and concentrated to afford the title compound as a white solid (10 mg) 1H NMR (400 MHz, methanol-d,) δ ppm 2 68 (s, 3 H), 2 84 (dd, J= 13 2, 9 4 Hz, 1 H), 3 03 (dd, J=13 3, 2 6 Hz, 1 H), 3 37 (dd, J= 1 1 6, 10 5 Hz, 1 H), 3 56 - 3 63 (m, 1 H), 3 76 (s, 3 H), 3 82 (dd, J= 11 4, 2 6 Hz, 1 H), 4 11 (dd, J=11 6, 2 4 Hz, 1 H), 4 18 - 4 26 (m, 1 H), 4 60 (s, 2 H), 6 81 (dd, J=9 0, 2 3 Hz, 1 H), 6 91 - 6 96 (m, 2 H), 7 23 (t, J=8 1 Hz, 1 H), 8 1 1 (d, J= 1 1 Hz, 1 H), 8 57 (s, 1 H) LC/MS (5%-95% CH3CN/H2O, 5 mm) 2 695 mm, m/z 533 (M+H)
Example 99
C->W-(4-Fuoro-3-methoxybenzyl)-6-(2-(((2/?*,5R*)-5-(hydroxymethyl)-tetrahydro-2H-pyran-2- yl)methyl)-2W-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of diethyl 2-(but-3-enyl)malonate
Small pieces of sodium (13 g, 565 mmol) were added to absolute ethanol (300 mL) slowly After complete consumption, diethylmalonate (100 g, 625 mmol) was added drop wise The reaction mixture was heated to 50 0C for 30 mm and then cooled to room temperature 1 -Bromo-3-butene (76 g, 565 mmol) was added and the mixture was refluxed overnight The ethanol was evaporated and the residue was diluted with water (500 mL) The mixture was extracted with ethyl acetate (3 x 500 mL) The combined ethyl acetate extract was dried over anhydrous sodium sulfate and concentrated under reduced pressure The crude material was purified by vacuum (0 1mm) distillation (bath temp 125-135 0C and vapor temp 82-85 0C) to afford the title compound (110 g, 82%)
Step 2 Preparation of 2-(but-3-enyl)propane-1.3-dιol
To a suspension of lithium aluminum hydride (56 g, 1 47 mol) in tetrahydrofuran (800 mL) was added diethyl 2-(but-3-enyl)malonate (80 O g1 O 373 mol) dissolved in tetrahydrofuran (400 mL) drop- wise under ice-water cold condition Lithium bromide (3 2 g, 37 3 mmol) was added and the mixture was stirred at room temperature overnight under nitrogen atmosphere The mixture was cooled in an ice water bath and the reaction was cautiously quenched by the drop-wise addition of water (56 mL), then with 15% aqueous NaOH solution (168 mL) and finally with water (56 mL) The mixture was stirred for another 1 h and filtered The solid residue was thoroughly washed with tetrahydrofuran (3 x 500 mL) The combined filtrate was dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford the title compound (41 5 g, 85 %)
Step 3 Preparation of (6-(ιodomethyl)-tetrahydro-2H-pyran-3-yl)methanol
To a suspension of iodine (98 g, 386 mmol) and NaHCO3 (32 6 g, 388 56 mmol) in ether (430 mL) and water (205 mL) was added a solution of 2-(bυt-3-enyl)propane-1 ,3-dιol (33 5 g, 257 33 mmol) in ether (250 mL) at 0 °C The mixture was stirred at room temperature for 8-10 h and then was quenched by the addition of saturated aqueous Na2S2O3 at 0 0C The organic layer was separated and the aqueous layer was extracted with ether (2 x 350 mL) The combined organic layers were dried over anhydrous sodium sulfate and concentrated The crude material was purified by flash column chromatography over silica gel (230-400 mesh) using 40% ethyl acetate in hexane as an eluent to afford the title compound as an oil consisting of a mixture of cis/trans isomers (53 0 g, 80 5%) MS (ES+) m/z 256 (M+H) Step 4 Preparation of Λ)-((3f?*,6ff*)-6-(ιodome(hyl)-tetrahvdro-2/-/-pyran-3-yl)methanol (Peak 1 )
An isomeric mixture of (6-(ιodomethyl)-tetrahydro-2H-pyran-3-yl)methanol (4 0 g) in ethanol (50 mL) was separated by supercritical-fluid chromatography (AD-H 30 x 250 mm, 15% ethanol, 70 mL/min, 0 5 mL/injection) The first eluting isomer was isolation and concentrated under vacuum to afford the title compound as a colorless oil (920 mg) 1H NMR (500 MHz, DMSOd6) δ ppm 1 07 - 1 28 (m, 2 H), 1 50 - 1 64 (m, 1 H), 1 67 - 1 80 (m, 2 H), 2 99 - 3 36 (m, 6 H), 3 89 - 4 00 (m, 1 H), 4 42 (t, J=5 1 Hz, 1 H) SFC (AD-H, 20% ethanol) 3 01 mm LC/MS (5% to 95%, CH3CN/H2O, 12 mm) 4 197 mm, m/z 257 (M+H) Ia]224 0 D = -0 380 (acetonitrile, 6 76) Step 5 Preparation of ^)-Λy-(4-Fuoro-3-methoxybenzvO-6-(2-(((2ff\5f?*)-5-(hvdroxymethyl)-tetrahvdro- 2/-/-pyran-2-yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
In a 20 ml scintillation vial with a magnetic stir bar at room temperature and standard pressure, Λ/-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(/rans-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 9) (600 mg, 1 75 mmol) was dissolved in Λ/,Λ/-dιmethyl acetamide (3 mL) A/,Λ/-Dιιsopropylethylamιne (226 mg, 1 75 mmol) was added, and the mixture was stirred at room temperature for 30 mm A solution of (-)- ((3R*,6R*)-6-(ιodomethyl)-tetrahydro-2H-pyran-3-yl)methanol (Peak 1 ) (895 mg, 3 50 mmol) in N, N- dimethyl acetamide (2 mL) was added, and the mixture was warmed to 80 0C for 14 hours After cooling, the reaction mixture was concentrated, dissolved in acetonitrile and water, and chromatographed by reversed phase preparative HPLC (Gilson, Delta Pak column, 20-60% acetonitrile, 10 minute hold, 60 minutes run, 5 minute hold) The first eluting peak (49 mm) was isolated and concentrated under vacuum to afford the title compound as a clear, colorless oil (373 mg) 1H NMR (500 MHz, DMSO-d6) δ ppm 1 14 - 1 25 (m, 1 H), 1 29 - 1 40 (m, 1 H), 1 54 - 1 65 (m, 1 H), 1 78 (d, J=9 9 Hz, 2 H), 2 06 (s, 3 H), 2 82 (s, 3 H), 3 00 (t, J=1 1 1 Hz, 1 H), 3 14 (dd, J=10 8, 7 20 Hz, 1 H), 3 23 (dd, J=10 7, 5 6 Hz, 1 H), 3 81 (s, 3 H), 3 86 (dd, J=11 1 , 3 9 Hz1 2 H), 4 49 (d, J=6 3 Hz, 2 H), 4 80 - 4 92 (m, 2 H), 6 87 - 6 92 (m, 1 H), 7 10 - 7 20 (m, 2 H), 8 41 (s, 1 H), 9 53 (t, J=6 5 Hz, 1 H) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 2 748 mm, m/z 472 (M+H) HPLC (5%-95% CH3CN/H2O, 40 mm) 19 509 mm [σ]22 4 C D = -0 193 (acetonitrile, 0 27) Example 100
(+/)-W-(4-Fuoro-3-methoxybenzyl)-6-(2-(((2/?*,5/?*)-5-(hydroxymethyl)-tetrahydro-2H-pyran-2- yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of /'•<-)-((3/:?*.6/?>)-6-(ιodomethyl)-tetrahvdro-2/-/-pyran-3-yl)fnethanol (Peak 2)
The second eluting isomer from the separation described in step 3 of Example 99 was isolated and concentrated under vacuum to afford the title compound as a clear, colorless oil (1 0 g) 1H NMR (500 MHz, DMSOd6) δ ppm 1 07 - 1 28 (m, 2 H), 1 50 - 1 64 (m, 1 H), 1 67 - 1 80 (m, 2 H), 2 99 - 3 36 (m, 6 H), 3 89 - 4 00 (m, 1 H), 4 42 (t, J=5 1 Hz, 1 H) SFC (AD-H, 20% ethanol) 3 18 mm LC/MS (5% -95%, CH3CN/H2O, 12 mm ) 4 210 mm, m/z 257(M+H) [O]22 4 0 D = 0 289 (acetonitrile, 2 56)
Step 2 Preparation of ^)-Λy-(4-Fuoro-3-methoxybenzyl)-6-(2-(((2/:?*,5Rt)-5-(hvdroxymethyl)- tetrahvdro-2H-pγran-2-yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
In a 20 ml scintillation vial with a magnetic stir bar at room temperature and standard pressure, Λ/-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of /V-(4-flυoro-3-methoxybenzyl)-6-(2-(/rans-4- amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 9) (680 mg, 1 98 mmol) was dissolved in Λ/,A/-dιmethyl acetamide (3 mL) Λ/,/V-Dιιsopropylethylamιne (256 mg, 1 98 mmol) was added, and the mixture was stirred at room temperature for 30 mm A solution of (+)- ((3/?*,6/?*)-6-(ιodomethyl)-tetrahydro-2/-/-pyran-3-yl)methanol (Peak 2) (1010 mg, 3 96 mmol) in N1N- dimethyl acetamide (2 mL) was added, and the mixture was warmed to 80 0C for 14 hours After cooling, the reaction mixture was concentrated, dissolved in acetonitrile and water, and chromatographed by reversed phase preparative HPLC (Gilson, Delta Pak column, 20-60% acetonitrile, 10 minute hold, 60 minutes run, 5 minute hold) The first eluting peak (49 mm) was isolated and concentrated under vacuum to afford the title compound as a clear, colorless oil (344 mg) 1H NMR (500 MHz, DMSOd6) δ ppm 1 14 - 1 25 (m, 1 H), 1 29 - 1 40 (m, 1 H), 1 54 - 1 65 (m, 1 H), 1 78 (d, J=9 9 Hz, 2 H), 2 06 (s, 3 H), 2 82 (s, 3 H), 3 00 (t, J=11 1 Hz, 1 H), 3 14 (dd, J=IO 8, 7 2 Hz, 1 H), 3 23 (dd, J=10 7, 5 3 Hz, 1 H), 3 81 (s, 3 H), 3 86 (dd, J=11 1 , 3 9 Hz, 2 H), 4 49 (d, J=6 3 Hz, 2 H), 4 80 - 4 92 (m, 2 H), 6 87 - 6 92 (m, 1 H), 7 10 - 7 20 (m, 2 H), 8 41 (s, 1 H), 9 53 (t, J=6 5 Hz, 1 H) LC/MS (5%-95% CH3CN/H2O, 5 mm) 2 752 mm, m/z 472 (M+H) HPLC (5%-95% CH3CN/H2O, 40 mm) 19 501 mm [O]22 4 0 D = 0 200 (acetonitrile, 0 09)
Example 101
('->W-(4-Fuoro-3-methoxybenzyl)-6-(2-(((2S*,5/?*)-5-(hydroxymethyl)-tetrahydro-2H-pyran-2- yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of ("-)-((3ff*,6S*)-6-(ιodomethyl)-tetrahydro-2H-Dyran-3-yl)methanol (Peak 3)
The third eluting isomer from the separation described in step 3 of Example 99 was isolated and concentrated under vacuum to afford the title compound as a clear, colorless oil (440 mg) 1H NMR (500 MHz, DMSOd6) 6 ppm 1 07 - 1 27 (m, 2 H), 1 50 - 1 62 (m, 1 H), 1 66 - 1 80 (m, 2 H), 3 02 - 3 35 (m, 6 H), 3 89 - 4 00 (m, 1 H), 4 42 (t, J=5 1 Hz, 1 H) SFC (AD-H, 20% ethanol) 3 48 mm LC/MS (5% -95%, CH3CN/H2O, 12 mm ) 4 154 mm, m/z 257 (M+H) [σ]22 4 C D = -1 469 (acetonitrile, 2 37)
Step 2 Preparation of ('-)-/V-(4-fluoro-3-methoxybenzyl)-6-(2-(((2S*,5/?*)-5-(hvdroxymethyl)-tetrahvdro- 2/-/-pyran-2-yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
In a 20 ml scintillation vial with a magnetic stir bar at room temperature and standard pressure, Λ/-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(frans-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 9) (296 mg, 0 862 mmol) was dissolved in Λ/,Λ/-dιmethyl acetamide (3 mL) Λ/,Λ/-Dιιsopropylethylamιne (1 1 1 mg, 0 862 mmol) was added, and the mixture was stirred at room temperature for 30 mm A solution of (-J- ((3R*,6S*)-6-(ιodomethyl)-tetrahydro-2H-pyran-3-yl)methanol (Peak 3) (442 mg, 1 72 mmol) in N1N- dimethyl acetamide (2 ml.) was added, and the mixture was warmed to 80 0C for 14 hours After cooling, the reaction mixture was concentrated, dissolved in acetonitrile and water, and chromatographed by reversed phase preparative HPLC (Giison, Delta Pak column, 20-50% acetonitrile, 10 minute hold, 60 minutes run, 5 minute hold) The first eluting peak (47 mm) was isolated and concentrated under vacuum to afford the title compound as a clear, colorless oil (206 mg) 1H NMR (500 MHz, DMSOd6) δ ppm 1 41 - 1 71 (m, 3 H), 1 71 - 1 85 (m, 1 H), 2 47 - 2 52 (m, 1 H), 2 81 (s, 3 H), 3 34 - 3 43 (m, 1 H), 3 45 - 3 53 (m, 1 H), 3 69 - 3 77 (m, 1 H), 3 81 (s, 3 H), 3 92 - 4 06 (m, 1 H), 4 43 - 4 54 (m, 2 H), 4 77 - 4 97 (m, 2 H), 6 86 - 6 93 (m, 1 H), 7 13 (dd, J= 11 4, 8 4 Hz,
1 H), 7 17 (dd, J=8 5, 1 8 Hz, 1 H), 8 41 (s, 1 H), 9 52 (t, J=6 4 Hz, 1 H) LC/MS (5%-95% CH3CN/H2O, 5 mm) 2 753 mm m/z 472 (M+H) HPLC (5%-95% CH3CN/H2O, 40 mm) 19 582 mm [σ]22 4 C D = -0 154 (acetonitrile, 0 39)
Example 102
C+j.Λ/.(4.fluoro-3-methoxyberzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)-tetrahydro-2H-pyran-2- yl)methyl)-2»4-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
F
Step 1 Preparation of (+)-((3R*.6S*)-6-(ιodomethyl)-tetrahvdro-2/-/-pyran-3-yl)methanol (Peak 4)
The fourth eluting isomer from the separation described in step 3 of Example 99 was isolated and concentrated under vacuum to afford the title compound as a clear, colorless oil (390 mg) 1H NMR (500 MHz, DMSO-Cf6) δ ppm 1 07 - 1 27 (m, 2 H), 1 50 - 1 62 (m, 1 H), 1 66 - 1 80 (m, 2 H), 3 02 - 3 35 (m, 6 H), 3 89 - 4 00 (m, 1 H), 4 42 (t, J=5 12 Hz, 1 H) SFC (AD-H, 20% ethanol) 3 402 mm LC/MS (5%-95%, CH3CN/H2O, 12 mm ) 4 153 mm, m/z 257 (M+H) (σ)22 4 C D = 0 194 (acetonitrile, 1 99) Step 2 Preparation of ^)-Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(((2S*,5ff*)-5-(hvdroxymethyl)- tetrahvdro-2H-pyran-2-yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde
In a 20 ml scintillation vial with a magnetic stir bar at room temperature and standard pressure, Λ/-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(frans-4- aminocyclohexyOmethyl^H-tetrazol-S-ylJ^-methylpyπmidine^-carboxamide, Example 9) (275 mg, 0 801 mmol) was dissolved in Λ/,W-dιmethyl acetamide (3 mL) Λ/,Λ/-Dιιsopropylethylamιne (104 mg,
0 801 mmol) was added, and the mixture was stirred at room temperature for 30 mm A solution of (+)- ((3R*,6S*)-6-(ιodomethyl)-tetrahydro-2H-pyran-3-yl)methanol (Peak 4) (410 mg, 1 60 mmol) in N1N- dimethyl acetamide (2 mL) was added, and the mixture was warmed to 80 0C for 14 hours After cooling, the reaction mixture was concentrated, dissolved in acetonitrile and water, and chromatographed by reversed phase preparative HPLC (Gilson, Delta Pak column, 30-50% acetonitrile, 10 minute hold, 60 minutes run, 5 minute hold) The first eluting peak (39 mm) was isolated and concentrated under vacuum to afford the title compound as a clear, colorless oil (130 mg) 1H NMR (500 MHz, DMSOd6) δ ppm 1 41 - 1 71 (m, 3 H), 1 71 - 1 85 (m, 1 H), 2 47 - 2 52 (m, 1 H), 2 81 (s, 3 H), 3 34 - 3 43 (m, 1 H), 3 45 - 3 53 (m, 1 H), 3 69 - 3 77 (m, 1 H), 3 81 (s, 3 H), 3 92 - 4 06 (m, 1 H), 4 43 - 4 54 (m, 2 H), 4 77 - 4 97 (m, 2 H), 6 86 - 6 93 (m, 1 H), 7 13 (dd, J=I ^l 4, 8 4 Hz,
1 H)1 7 17 (dd, J=8 5, 1 8 Hz, 1 H)1 8 41 (s, 1 H), 9 52 (t, J=6 4 Hz, 1 H) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 2 751 mm, m/z 472 (M+H) HPLC (5%-95% CH3CN/H2O, 40 mm ) 19 586 mm [O)224 0 D = 0 267 (acetonitrile, 0 45)
Example 103
W-(3-Methoxybenzyl)-6-(2-(((2R*,5S*)-5-hydroxy-tetrahydro-2H-pyran-2-yl)methyl)-2H-tetrazol-5- yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of rac-(3.4-dιhvdro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate
A mixture of (3,4-dιhydro-2H-pyran-2-yl)methanol (10 g, 87 6 mmol), p-toluenesulfonyl chloride (16 7 g, 87 6 mmol), and pyridine (20 mL) was stirred at room temperature overnight The reaction was cooled in an ice bath and water (50 mL) was added slowly while keeping the mixture cold The mixture was then extracted with dichloromethane (3 x 20 mL) The combined organic layers were washed with 3N hydrochloric acid, dried over magnesium sulfate, and concentrated to afford the title compound as an oil (20 2 g, 86%)
Step 2 Preparation of rac-((2ff*.5S*)-5-hvdroxy-tetrahvdro-2H-pyran-2-yl)methyl 4- methyl benzenesulfonate
To a solution of rac-(3,4-dιhydro-2/-/-pyran-2-yl)methyl 4-methylbenzenesulfonate (1 5 g, 5 6 mmol) in dry tetrahydrofuran (10 mL) cooled to 0 0C was added a 1 M BH3TTHF solution (16 8 mL, 16 8 mmol) drop-wise After complete addition, the reaction was brought to room temperature and stirred overnight The reaction was treated with 2 5 N NaOH (13 4 mL) by careful drop-wise addition followed by H2O2 (4 6 mL), and then the mixture was heated to 55 °C for 1 h The mixture was cooled in an ice bath and K2CO3 was added until the aqueous layer was saturated (-7 g) The resulting mixture was stirred for 30 mm and then was extracted with ethyl acetate (3 x 20 mL) The combined organic layers were dried over magnesium sulfate, filtered, and concentrated to an oil The crude product mixture was purified by reverse phase preparative HPLC to afford the title compound as an oil (3 69 g, 97%) LC/MS (5%-95% CH3CN/H2O, 4 mm , 95% CH3CN, 1 mm ) 2 37 mm, m/z 287 (M+H)
Step 3 Preparation of Λ/-(3-methoxybenzyl)-6-(2-(((2fr.5S»)-5-hvdroxy-tetrahvdro-2H-pyran-2- yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxarnιde
A mixture of Λ/-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde
(prepared as described in step 6 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((fra/7S)-4- amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 5) (400 mg, 1 23 mmol), rac-((2R\5S*)-5-hydroxy-tetrahydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate (704 mg, 2 46 mmol), triethylamine (1 37 mL, 9 84 mmol), and dimethylacetamide (2 mL) was stirred at 85 0C for 3 days The reaction mixture was purified by reverse phase preparative HPLC and the peak containing the desired regioisomer was isolated Further separation by supercritical fluid chromatography (Chiralcel AS-H, 30 x 250 mm, 12% methanol, 70 mL/min) and isolation of the first eluting enantiomer afforded the title compound (40 mg) MS (ES+) m/z 439 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 1 39 (d, J=10 3 Hz, 1 H), 1 78 - 1 90 (m, 1 H), 1 99 (d, J=8 4 Hz, 1 H), 2 83 (s, 3 H), 2 91 (t, J= 10 4 Hz, 1 H), 3 34 - 3 49 (m, 1 H), 3 68 - 3 78 (m, 4 H), 3 80 - 3 93 (m, 2 H), 4 51 (d, J=Q 6 Hz, 2 H), 4 77 (d, J=A 8 Hz, 1 H), 4 81 - 4 95 (m, 2 H)1 6 83 (d, J=B 1 Hz, 1 H), 6 88 - 6 97 (m, 2 H), 7 24 (t, J=8 1 Hz, 1 H), 8 42 (s, 1 H), 9 48 (t, J=6 4 Hz, 1 H)
Example 104
Λ/-(3-Methoxybenzyl)-6-(2-(((2R*,5S*)-5-hydroxy-tetrahydro-2H-pyran-2-yl)methyl)-2H-tetrazol-5- yl)-2-methylpyrimidine-4-carboxamide
Isolation of the second eluting enantiomer from the product mixture described in Example 103 afforded the title compound (40 mg) MS (ES+) m/z 439 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 25 - 1 52 (m, 2 H), 1 76 - 1 90 (m, 1 H), 1 99 (d, J=11 0 Hz, 1 H), 2 83 (s, 3 H)1 2 85 - 2 96 (m, 1 H), 3 36 - 3 49 (m, 1 H), 3 68 - 3 79 (m, 4 H)1 3 84 - 3 95 (m, 1 H), 4 52 (d, J=6 6 Hz, 2 H)1 4 72 - 4 95 (m, 3 H)1 6 84 (d, J=1 5 Hz, 1 H), 6 89 - 6 97 (m, 2 H), 7 24 (t, J=8 1 Hz, 1 H), 8 42 (s, 1 H), 9 48 (t, J=6 2 Hz, 1 H)
Example 105
(+)-W-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2/?*,5S*)-5-hydroxy-tetrahydro-2H-pyran-2-yl)methyl)- 2W-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
A mixture of Λ/-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2- (/rans-4-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide, Example 9) (461 mg, 1 34 mmol), rac-((2ff,5S*)-5-hydroxy-tetrahydro-2H-pyran-2-yl)methyl A- methylbenzenesulfonate (prepared as described in step 2 of the synthesis of Λ/-(3-methoxybenzyl)-6- (2-(((2/?*,5S*)-5-hydroxy-tetrahydro-2H-pyran-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide, Example 103) (500 mg, 1 75 mmol), and triethylamine (1 50 mL, 10 7 mmol) was heated in Λ/,W-dιmethylacetamιde (15 mL) at 85 0C for 18 hours The mixture was purified by reverse phase preparative HPLC The racemate was further separated by supercritical fluid chiral chromatography (Chiralcel AD-H column, 30 x 250 mm, 50% 2-propanol, 70 mL/min) and the first eluting isomer was isolated to afford the title compound (25 mg, 4%) MS (ES+) m/z 458 (M+H) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 1 26 - 1 48 (m, 2 H), 1 77 - 1 88 (m, 1 H), 1 91 - 2 03 (m, 1 H), 2 74 - 2 95 (m, 4 H), 3 38 - 3 46 (m, 1 H), 3 64 - 3 75 (m, 1 H), 3 76 - 3 92 (m, 4 H), 4 49 (d, J=6 59 Hz, 2 H), 4 74 - 4 98 (m, 3 H), 6 81 - 6 96 (m, 1 H), 7 06 - 7 23 (m, 2 H), 8 40 (s, 1 H), 9 50 - 9 64 (m, 1 H) [σ]D 21'c = +9 1 ° (c = 0 7, dichloromethane)
Example 106
(-)-Λ/-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S*,5/?*)-5-hydroxy-tetrahydro-2W-pyran-2-yl)methyl)- 2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamidβ
Isolation of the second eluting isomer by supercritical fluid chiral chromatography (Chiralcel
AD-H column, 30 x 250 mm, 50% 2-propanol, 70 mL/min) of the racemic mixture provided in Example 105 afforded the title compound (21 mg, 3%) 1H NMR (400 MHz1 DMSO-d6) δ ppm 1 27 - 1 48 (m, 2 H)1 1 78 - 1 89 (m, 1 H)1 1 92 - 2 03 (m, 1 H), 2 77 - 2 93 (m, 4 H)1 3 38 - 3 48 (m, 1 H), 3 67 - 3 75 (m, 1 H), 3 77 - 3 93 (m, 4 H), 4 49 (d, J=6 59 Hz, 2 H), 4 74 - 4 96 (m, 3 H), 6 83 - 6 95 (m, 1 H), 7 08 - 7 23 (m, 2 H)1 8 40 (s, 1 H), 9 50 - 9 64 (m, 1 H)
Example 107 rac-W-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2/?*,5S*)-5-hydroxy-5-(hydroxymethyl)-tetrahydro-2H- pyran-2-yl)methyl)-2W-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of (5-oxo-tetrahvdro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate
A solution of dichloromethane (40 mL) and dimethylsulfoxide (1 37 ml_, 19 3 mmol) was cooled to -78 0C and oxalyl chloride (0 84 mL, 9 64 mmol) was added drop-wise rac-((2R*,5S*)-5- hydroxy-tetrahydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 2 of the synthesis of rac-Λ/-(3-Methoxybenzyl)-6-(2-(((2f?*,5S*)-5-hydroxy-tetrahydro-2H-pyran-2- yl)methyl)-2/-/-tetrazol-5-y!)-2-methylpyrιmιdιne-4-carboxamιcle, Example 103) (2 51 g, 8 77 mmol) in dichloromethane (20 mL) was then added via pipette The mixture was stirred at -78 0C for 15 mm and then triethylamine (6 1 1 mL, 43 8 mmol) was added drop-wise After 5 mm, the dry ice bath was removed and the mixture allowed to warm to room temperature over 30 minutes The mixture was washed with sat NaHCO3 (2 x 20 mL), brine (2 x 20 mL), and water (20 mL) The organic layer was dried over magnesium sulfate, filtered, and concentrated to an oil The crude product was purified by reverse phase preparative HPLC to afford the title compound as an oil (2 43 g, 97%) MS (ES+) m/z 285 (M+H)
Step 2 Preparation of 1 ,5-dιoxaspιro[2 51oct-6-ylmethyl 4-methylbenzenesulfonate
5-Oxo-tetrahydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate (2 4 g, 8 4 mmol) in dimethylsulfoxide (25 mL) was added to a dry mixture of tπmethylsulfoxoniυm iodide (3 72 g, 16 9 mmol) and potassium f-butoxide (1 89 g, 16 9 mmol) The resulting mixture was stirred at room temperature for 3 hours The solution was poured into water (200 mL) and stirred for 30 mm Ethyl acetate and brine were added and the mixture extracted with ethyl acetate (3 x 20 mL) The organic extracts were combined, dried over magnesium sulfate and concentrated to afford the title compound as an oil (1 32 g) LC/MS (5%-95% CH3CN/H2O, 4 mm , 95% CH3CN, 1 mm ) 2 72 mm, m/z 321 (M+Na)
Step 3 Preparation of (5-hvdroxy-5-(hvdroxymethyl)-tetrahvdro-2/-/-pyran-2-yl)methyl 4- methylbenzenesulfonate
1 ,5-dιoxaspιro[2 5]oct-6-ylmethyl 4-methylbenzenesulfonate (1 3 g, 4 4 mmol) was taken up in tetrahydrofuran (6 mL) and water (3 mL) The resulting solution was treated with perchloric acid (1 mL) and the reaction stirred at room temperature for 3 hours The product mixture was purified by reverse phase preparative HPLC to afford the title compound LC/MS (5%-95% CH3CN/H2O, 4 mm , 95% CH3CN, 1 mm ) 2 23 mm, m/z 317 (M+H) Step 4 Preparation of rac-Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(((2/?*,5S*)-5-hvdroxy-5- (hvdroxymethylVtetrahvdro^H-pyran-Σ-vOmethvO^H-tetrazol-δ-vπ^-methylpyrimidine^-carboxamide
A mixture of Λ/-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4- carboxamide (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2- (frans-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 9) (116 mg, O 337 mmol), (5-hydroxy-5-(hydroxymethyl)-tetrahydro-2H-pyran-2-yl)methyl 4- methylbenzenesulfonate (160 mg, 0 506 mmol), tπethylamine (0 38 mL, 2 70 mmol), and dimethylacetamide (1 mL) was stirred at 85 °C overnight The reaction mixture was purified by reverse phase preparative HPLC to provide a mixture of isomers which was further separated by supercritical fluid chromatography (Pegasus, 30 x 250 mm, 20% n-butanol, 70 mUmm) / (Diol, 30 x 250 mm, 25% n-butanol, 70 mL/min) to afford the title compound (20 mg, 12%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 2 545 mm, m/z 488 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 40 - 1 50 (m, 2 H), 1 74 (d, J=9 2 Hz, 1 H), 1 84 - 1 98 (m, 1 H), 2 83 (s, 3 H), 2 97 (d, J= 1 1 0 Hz, 1 H), 3 33 - 3 38 (m, 1 H), 3 40 - 3 46 (m, 1 H), 3 56 (d, J=11 0 Hz, 1 H), 3 82 (s, 3 H), 3 93 (d, J=5 9 Hz, 1 H), 4 51 (d, J=6 2 Hz, 3 H), 4 89 (d, J=5 5 Hz, 2 H), 6 87 - 6 94 (m, 1 H), 7 15 (td, J=12 2, 8 2 Hz, 2 H), 8 14 (s, 1 H), 8 42 (s, 1 H), 9 50 (t, J=6 4 Hz, 1 H)
Example 108 rac-W-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2/?*,5/?*)-5-hydroxy-5-(hydroxymethyl)-tetrahydro-2H- pyran-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Isolation of a second eluting isomer from the product mixture described in Example 107 afforded the title compound (30 mg, 18%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 2 531 mm, m/z 488 (M+H) 1H NMR (400 MHz, DMSOd6) S ppm 1 24 (br s , 1 H), 1 44 - 1 84 (m, 6 H), 2 83 (s, 3 H), 3 14 (d, J= 1 8 Hz, 2 H), 3 41 - 3 53 (m, 1 H), 3 84 (s, 3 H)1 3 85 - 3 94 (m, 1 H), 4 51 (d, J=6 2 Hz, 2 H), 4 82 - 4 93 (m, 2 H), 6 84 - 6 95 (m, 1 H), 7 15 (td, J= 12 0, 8 2 Hz, 2 H)1 8 42 (s, 1 H), 9 50 (t, J=6 2 Hz, 1 H) Example 109 rac-/V-(3-Methoxybenzyl)-6-(1 -(((2/?*,5S*)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-1 H-1 ,2,4- triazol-3-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of dimethyl 2-methylpyrιmιdιne-4,6-dιcarboxylate
4,6-Dιchloro-2-methylpyrιmιdιne (24 g, 147 mmol), Pd(Ph3P)2CI2 (1 03 g, 1 47 mmol), triethylamine (45 1 mL, 324 mmol), and methanol (400 mL) were added to a 1 L high-pressure vessel The vessel was pressurized to 500 psi with carbon monoxide and heated to 100 0C for 10 h The mixture was filtered and the filtrate concentrated The residue was suspended in a mixture of ethyl acetate/tetrahydrofuran (2/1 ) and the mixture was refluxed for 30 mm After cooling to below 40 0C, the mixture was filtered and the filtrate was concentrated The crude product was purified by silica gel chromatography eluting with ethyl acetate Fractions containing product were concentrated The residue was slurried in a mixture of acetone/hexanes (2/1 ), filtered and dried in vacuo at 45 0C to afford the title compound as a light yellow solid
Step 2 Preparation of Λ/-(3-methoxybenzyl)-2-methylpyrιmιdιne-4,6-dιcarboxamιde
Dimethyl 2-methylpyrιmιdιne-4,6-dιcarboxylate (5 0 g, 23 8 mmol), 3-methoxybenzylamιne (3 59 g, 26 2 mmol), and 2-methyltetrahydrofuran (31 7 mL) were combined in an 50 mL microwave reaction tube and heated to 90 0C for 15 mm The reaction mixture was filtered through a plug of silica gel, and the filtrate was concentrated The residue was suspended in methanol (25 mL) and a solution of ammonia in methanol (7 N, 3 0 mL) was added The mixture was stirred at room temperature overnight and then concentrated The crude product was purified by silica gel chromatography (ethyl acetate/heptane/methanol, 65/34/1 ) to afford the title compound as a white solid (2 2 g) MS (ES+) m/z 301 (M+H) 1H NMR (400 MHz, DMSOd6) d ppm 9 46 (t, J=6 3 Hz, 1 H), 8 27 (br s , 1 H), 8 22 (s, 1 H), 7 98 (br s , 1 H), 7 20 (t, J=B 1 Hz, 1 H), 6 85 - 6 90 (m, 2 H), 6 79 (dd, J=8 3, 2 1 Hz, 1 H), 4 45 (d, J=6 2 Hz, 2 H), 3 70 (s, 3 H), 2 77 (s, 3 H) Step 3 Preparation of Λ/-(3-methoxybenzyl)-2-methyl-6-(1H-1 ,2,4-trιazol-3-yl)pyrιmιdιne-4- carboxamide
Λ/-(3-Methoxybenzyl)-2-methylpyrιmιdιne-4,6-dιcarboxamιde (1 49 g, 4 96 mmol) was treated with dimethylformamide dimethylacetal (50 mL, 380 mmol) followed by heating at 101 0C for 2h A short path distillation was utilized to collect the generated methanol The solvent was then removed in vacuo to afford a crude residue The residue was dissolved in glacial acetic acid (20 ml ) and treated with monohydrazine hydrate (0 75 mL, 14 9 mmol) The mixture was heated at 90 0C for 2 hours and then allowed to cool to room temperature The mixture was poured into H2O (75 mL) and left to stand at room temperature overnight The resulting solids were filtered and dried to afford the title compound (1 1 1 g, 69 %) LC/MS (5%-95% CH3CN/H2O, 6 mm) 3 95 mm, m/z 325 (M+H)
Step 4 Preparation of rac-Λ/-(3-methoxybenzyl)-6-(1-(((2/?*,5S*)-5-(hvdroxymethyl)-1 ,4-dιoxan-2- yl)methyl)-1/-/-1 ,2,4-trιazol-3-yl)-2-methylpyrιmιdιne-4-carboxamιde
W-(3-Methoxybenzyl)-2-methyl-6-(1/-/-1 ,2,4-trιazol-3-yl)pyrιmιdιne-4-carboxamιde (0 070 g,
0 22 mmol) was treated with rac-((2/?*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4- methylbenzenesulfonate (prepared as described in step 4 of the synthesis of rac-Λ/-(3- methoxybenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 61 ) (0 085 g, 0 28 mmol) and 1 ,8- dιazabιcyclo[5 4 0]undec-7-ene (0 082 g, 0 54 mmol) in acetonitrile (5 mL) After the reaction was stirred for 12 h at 75 °C, the mixture was concentrated to a crude residue that was purified via reverse phase chromatography (40-60% acetonitrile/water, 55 mm) to afford the title compound as a white solid (30 mg, 31 %) LC/MS (5%-95% CH3CN/H2O, 6 mm) 3 83 mm, m/z 455 (M+H) 1 H NMR (400 MHz, DMSO-Of6) δ ppm 2 78 (3 H, s), 3 30 - 3 38 (4 H, m), 3 42 (1 H, d, J=5 9 Hz)1 3 74 (3 H, s), 3 79 (1 H, br s ), 3 90 (2 H, d, J=9 2 Hz), 4 29 - 4 36 (1 H, m), 4 38 - 4 46 (1 H, m), 4 50 (2 H, d, J=6 2 Hz), 4 60 - 4 69 (1 H, m), 6 82 (1 H, d, J=7 7 Hz), 6 93 (2 H, br s ), 7 24 (1 H, t, J=8 1 Hz), 8 36 (1 H, s), 8 69 (1 H, s), 9 39 (1 H, t, J=6 2 Hz)
Example 110
/V^S-MethoxybenzyO-e^i-^frans^-aminocyclohexyOmethyO-IH-i^^-triazol-S-yl)^- methylpyrimidine-4-carboxamide
Step 1 Preparation of (/raπs-4-((tert-butoxycarbonyDamιno)cvclohexyl)methyl 4-nιtrobenzenesulfonate
The commercially available tert-butyl (<raπs)-4-(hydroxymethyl)cyclohexylcarbamate (0 30 g, 1 3 mmol) was taken up in dichloromethane (7 mL) and treated with pyridine (0 16 mL, 2 0 mmol) before dripping in a solution of 4-nιtrobenzene-1 -sulfonyl chloride (0 43 g, 1 96 mmol) in dichloromethane (3 0 mL) The reaction was allowed to stir at room temperature for 15 h The mixture was washed with water (5 mL), 5% aqueous hydrochloric acid (3 mL), followed by water ( 5 mL) before drying over sodium sulfate The organic layer was concentrated to a crude oily residue that crystallized to afford the title compound as a beige solid (0 44 g, 81%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 5 48 mm, m/z 439 (M+Na)
Step 2 Preparation of terf-butyl (frans)-4-((3-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)- 1 H- 1.2,4-trιazol-1 -vDmethvDcvclohexylcarbamate
(/rans-4-((/ert-Butoxycarbonyl)amιno)cyclohexyl)methyl 4-nιtrobenzenesulfonate (0 096 g,
0 23 mmol) and Λ/-(3-methoxybenzyl)-2-methyl-6-(1H-1 ,2,4-trιazol-3-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of rac-Λ/-(3-methoxybenzyl)-6-(1-(((2R*,5S*)-5- (hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-1/-/-1 ,2,4-trιazol-3-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 109) (0 050 g, 0 15 mmol) were treated with 1 ,8-dιazabιcyclo[5 4 0]undec-7-ene (0 022 mL, 0 15 mmol) in acetonitrile ( 5mL) at 75 °C for 12 h The mixture was concentrated and the residue was purified via reverse phase chromatography (10-90% acetonitrile/water, 30 mm) to afford the title compound as a tan oil (0 057 mg, 69%) LC/MS (5%-95% CH3CN/H2O, 5 mm) 3 10 mm, m/z 536 (M+H) Step 3 Preparation of Λ/-(3-methoxybenzyl)-6-(1-(((/rans)-4-amιnocyclohexyl)methyl)-1 H-1 ,2,4-trιazol- 3-yl)-2-methylpyrιmιdιne-4-carboxamιde
terf-Butyl (frans)-4-((3-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyrimidm-4-yl)-1 H- 1 ,2,4- trιazol-1 -yl)methyl)cyclohexylcarbamate (0 057 g, 0 1 1 mmol) was taken up in dichloromethane (2 mL) and treated with trifluoroacetic acid (1 0 mL, 7 7 mmol) The reaction was stirred at ambient temperature for 3 h, diluted with dichloromethane (5 mL), and then neutralized with 2 5 N aqueous NaOH to achieve pH 7-8 The organic layer was separated, washed with water (3 mL), dried over sodium sulfate, and concentrated to afford the title compound (0 037 g, 51%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 3 78 mm, m/z 436 (M+H)
Example 111
/V-(3-Methoxybenzyl)-6-(1 -(((frans)-4-acetamidocyclohexyl)methyl)-1 W- 1 ,2,4-triazol-3-yl)-2- methylpyrimidine-4-carboxamide
Λ/-(3-Methoxybenzyl)-6-(1-(((<rans)-4-amιnocyclohexyl)methyl)-1 /-/-1 ,2,4-trιazol-3-yl)-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 110) (0 034 g, 0 078 mmol) was taken up in dichloromethane (2 mL) and treated with acetyl chloride (0 006 mL, 0 086 mmol) and triethylamine (0 012 mL, 0 086 mmol) After 1 h, the reaction was concentrated, and the residue was purified via reverse phase chromatography (10-95% acetonitrile/water over 30 minutes) to afford the title compound as a clear oil (11 7 mg, 31%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 4 07 mm, m/z 477 m/e 1 H NMR (400 MHz, DMSO-d6) d ppm 1 09 (4 H, br s ) 1 22 - 1 33 (1 H, m) 1 60 (2 H, br s ) 1 73 - 1 84 (2 H, m) 1 75 (3 H, s) 2 78 (3 H, s) 3 46 (1 H, br s ) 3 74 (3 H, s) 4 16 (2 H, d, J=6 95 Hz) 4 50 (2 H, d, J=6 22 Hz) 6 82 (1 H, d, J=8 05 Hz) 6 92 (2 H, br s ) 7 24 (1 H, t, J=8 05 Hz) 7 64 (1 H, d, J=7 69 Hz) 8 36 (1 H, s) 8 72 (1 H, s) 9 39 (1 H, t, J=6 04 Hz)
Example 112
Λ/-(3-Methoxybenzyl)-2-methyl-6-(1 -(((frans)-4-{methylsulfonamido)cyclohexyl)methyl)-1 H-1 ,2,4- triazol-3-yl)pyrimidine-4-carboxamide
/V-(3-Methoxybenzyl)-6-(1-(((?rans)-4-amιnocyclohexyl)methyl)-1/-/-1 ,2,4-trιazol-3-yl)-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 1 10) (0 050 g, 0 115 mmol) was taken up in dichloromethane (1 mL) and treated with methane sulfonyl chloride (0 009 mL, 0 1 15 mmol) and triethylamine (0 018 mL, 0 126 mmol) After 1 h, the reaction was concentrated to a crude residue The residue was purified via reverse phase chromatography (10-95% acetonitrile/water over 25 minutes) to afford the title compound as a clear oil (38 1 mg, 64%) LC/MS (5%-95% CH3CN/H2O,
6 mm) 2 57 mm, m/z 514 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 1 00 - 1 26 (5 H1 m), 1 58 (2 H, d), 1 79 (1 H, br s ), 1 88 (2 H, d, J=9 9 Hz)1 2 76 (3 H, s), 2 86 (3 H, s), 3 02 (1 H, br s ), 3 71 (3 H, s), 4 14 (2 H, d, J=7 0 Hz), 4 48 (2 H, d, J=6 2 Hz), 6 80 (1 H, d, J=7 9 Hz), 6 90 (2 H1 br s ), 7 15 -
7 29 (1 H1 m), 8 33 (1 H, s), 8 70 (1 H, s), 9 37 (1 H, br s )
Example 113
2-((fraπs)-4-((3-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-1 H-Λ ,2,4-triazol-1 - yl)methyl)cyclohexylamino)-2-oxoethyl acetate
Λ/-(3-Methoxybenzyl)-6-(1-(((/rans)-4-amιnocyclohexyl)methyl)-1 /-/-1 ,2l4-trιazol-3-yl)-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 1 10) (0 085 g, 0 195 mmol) was taken up in dichloromethane (2 mL) and treated with acetoxy acetyl chloride (0 025 mL, 0 234 mmol) and triethylamine (0 041 mL, 0 293 mmol) After stirring 2 hours at room temperature, the reaction was concentrated and the residue was purified via reverse phase chromatography (10-95% acetonitrile/water over 25 minutes) to afford the title compound (0 095 g, 91 %)
Example 114
^-(S-MethoxybenzyO-e^i^^^ransJ^^Z-hydroxyacetamidoJcyclohexyOmethyO-IH-i ^^-triazol-S- yl)-2-methylpyrimidine-4-carboxamide
2-((<rans)-4-((3-(6-((3-Methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-1 /-/-1 ,2,4-trιazol-1 - yl)methyl)cyclohexylamιno)-2-oxoethyl acetate (prepared as described in Example 1 13) (0 095g, 0 18 mmol) was taken up in acetonitrile (3 mL) and stirred with 2 5 N aqueous NaOH (2 O mL) for 2 hours at room temperature The acetonitrile was removed in vacuo and the aqueous solution was acidified to pH 5 via 10% aqueous hydrochloric acid to afford a solid The solid was filtered, washed with water (2 x 3 mL), and dried to afford the title compound as a beige solid (11 1 mg, 11 3%) LC/MS (5%-95% CH3CN/H2O, 6 mm) 3 45 mm, m/z 494 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 1 00 - 1 16 (2 H, m), 1 16 - 1 30 (2 H, m), 1 58 (2 H, d, J=13 2 Hz), 1 73 (2 H, d, J=9 5 Hz), 2 52 (2 H, s), 2 76 (3 H, s), 3 42 - 3 59 (1 H, m), 3 66 - 3 78 (4 H, m), 4 15 (2 H, d, J=6 6 Hz), 4 48 (2 H, d, J=6 2 Hz), 5 30 (1 H, t, J=5 5 Hz), 6 80 (1 H, d, J=10 6 Hz), 6 86 - 6 95 (2 H, m), 7 16 - 7 26 (1 H, m), 7 35 (1 H, d, J=8 4 Hz), 8 34 (1 H, s), 8 71 (1 H, s), 9 29 - 9 40 (1 H, m)
Example 115 rac-W-(4-Fluoro-3-methoxybenzyl)-6-(1-(((2R*,5S*)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)- 1 W-1 ,2,4-triazol-3-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of methyl 6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιne-4- carboxylate
Dimethyl 2-methylpyπmιdιne-4,6-dιcarboxylate (prepared as described in step 1 of the synthesis of rac-Λ/-(3-Methoxybenzyl)-6-(1-(((2f?*,5S*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-1 H- 1 ,2,4-trιazol-3-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 109) (4 50 g, 21 4 mmol), 4-fluoro-3- methoxybenzylamine (prepared as described in step 3 of the synthesis of W-(4-fluoro-3- methoxybenzyl)-6-(2-((/rans-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 1 ) (3 65 g, 23 6 mmol), and 2-methyltetrahydrofuran (21 4 mL) were combined in an 80 mL microwave reaction tube and heated to 110 0C for 30 mm The reaction mixture was filtered through a plug of silica gel eluting with 65/35, ethyl acetate/heptane The filtrate was concentrated and purified by silica gel chromatography (heptane/acetone, 4/1 ) to afford the title compound as a white solid (1 95 g) MS (ES+) m/z 334 (M+H) 1H NMR (400 MHz, DMSO-d6) 9 53 (t, J=6 3 Hz, 1 H), 8 20 (s, 1 H), 7 14 (dd, J=7 8, 1 9 Hz, 1 H), 7 07 - 7 13 (m, J=11 5, 8 2 Hz, 1 H), 6 85 (ddd, J=Q 3, 4 4, 1 9 Hz, 1 H), 4 45 (d, J=6 4 Hz, 2 H), 3 91 (s, 3 H), 3 78 (s, 3 H), 2 77 (s, 3 H) Step 2 Preparation of /V-4-(4-fluoro-3-methoxybenzyl)-2-methylpyrιmιdιne-4.6-dιcarboxamιde
Methyl 6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyπmιdιne-4-carboxylate (1 945 g, 5 84 mmol) was dissolved in a mixture of methanol (80 mL) and dichloromethane (15 mL) A solution of ammonia in methanol (7 N, 16 7 mL, 117 mmol) was added and the mixture was stirred at room temperature for 18 h The mixture was concentrated to minimal volume The resulting precipitate was filtered and washed with ethyl ether to afford the title compound as a white solid (1 785 g) MS (ES+) m/z 319 (M+H) 1H NMR (400 MHz, DMSO-cfe) 9 48 (t, J=6 4 Hz, 1 H), 8 27 (s, 1 H), 8 22 (s, 1 H), 7 98 (s, 1 H), 7 14 (dd, J=I 9, 1 7 Hz, 1 H), 7 1 1 (dd, J=1 1 5, 8 3 Hz, 1 H), 6 86 (ddd, J=8 2, 4 4, 1 9 Hz, 1 H), 4 45 (d, J=6 3 Hz, 2 H), 3 78 (s, 3 H), 2 77 (s, 3 H)
Step 3 Preparation of Λ/-(4-fluoro-3-methoxybenzγl)-2-methyl-6-(1H-1 ,2,4-trιazol-3-yl)pyrιmιdιne-4- carboxamide
Λ/-4-(4-Fluoro-3-methoxybenzyl)-2-methylpyrιmιdιne-4,6-dιcarboxamιde (1 O g, 3 1 mmol) was dissolved in dimethylformamide dimethylacetal (25 mL), and the reaction was refluxed for approximately 2 h The reaction was concentrated under reduced pressure, and the residue was dissolved in acetic acid (20 mL) Hydrazine hydrate (1 0 mL) was added and the reaction mixture was heated at 90 0C for 1 h The reaction mixture was poured into water and left to sit overnight The resulting precipitate was collected by suction filtration and washed with water and diethyl ether to afford the title compound (702 mg, 65%) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 4 60 mm, m/z 343 (M+H)
Step 4 Preparation of /•ac-Λ/-(4-fluoro-3-methoxybenzyl)-6-(1-(((2ff*,5S*)-5-(hvdroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-1 H-1 ,2,4-trιazol-3-yl)-2-methylpyrιmιdιne-4-carboxamιde
Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(1 H-\ ,2,4-trιazol-3-yl)pyrιmιdιne-4-carboxamιde
(1 10 mg, 0 321 mmol) and rac-((2/?*,5f?*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4- methylbenzenesulfonate (prepared as described in step 4 of the synthesis of rac-Λ/-(3- methoxybenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 61 ) (126 mg, 0 418 mmol) were stirred in acetonitrile (5 mL), and 1 ,8-dιazobιcyclo[5 4 0]υndec-7ene (73 4 mg, 0 482 mmol) was subsequently added The reaction was heated at 75 °C overnight before cooling to room temperature and concentrating under reduced pressure The residue was dissolved in acetonitrile (2 mL)/water (1 mL) and was purified by reverse phase HPLC (20-mιnute hold at 20% B followed by a 30 minute gradient from 20% B to 80% B (A = 0 1 % TFA / water and B = 0 1 % TFA / acetonitrile)) The combined fractions were lyophilized to afford the title compound (4 5 mg, 2 4%) as the TFA salt LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 4 73 mm, m/z 473 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 48 (t, 1 H), 8 71 (s, 1 H), 8 33 (s, 1 H)1 7 04 - 7 23 (m, 2 H), 6 87 (s, 1 H) 4 19 - 4 53 (m, 5 H), 3 56 - 4 05 (m, 6 H), 3 78 (s, 3 H), 3 19 - 3 49 (m, 2 H), 2 75 (s, 3 H)
Example 116
Λ/-(4-Fluoro-3-methoxybenzyl)-6-(1-((<rans-4-aminocyclohexyl)methyl)-1H-1,2,4-triazol-3-yl)-2- methylpyrimidine-4-carboxamide
Step 1 Preparation of terf-butyl <rans-4-((3-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-
Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(1/-/-1 ,2,4-trιazol-3-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of rac-/V-(4-fluoro-3-methoxybenzyl)-6-(1 -(((2R*,5S*)- 5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-1H-1 ,2,4-tnazol-3-yl)-2-methylpyrimidine-4-carboxamide, Example 115) (702 mg, 2 05 mmol) and (/rans-4-((/ert-butoxycarbonyl)amιno)cyclohexyl)methyl 4- methylbenzenesulfonate (prepared as described in step 7 of the synthesis of Λ/-(3-methoxybenzyl)-6- (2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 5) (786 mg, 2 05 mmol) were stirred in acetonitrile (40 mL), and 1 ,8-dιazobιcyclo[5 4 0]undec-7ene (480 mg, 3 15 mmol) was subsequently added The reaction was heated at 75 0C overnight before cooling to room temperature and concentrating under reduced pressure The residue was purified by reverse phase HPLC using a 40% B to 60% B, 30 minutes (A = 0 1% TFA / water and B = 0 1% TFA / acetonitrile) to afford the title compound (230 mg, 20%) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN1 2 mm ) 6 28 mm, m/z 554 (M+H) Step 2 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1-((/rans-4-amιnocvclohexyl)methyl)-1 H-1 ,2,4- trιazol-3-yl)-2-methylpyrιmιdιne-4-carboxamιcle
tert-Butyl /rans-4-((3-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-1 H- 1 ,2,4-trιazol-1 -yl)methyl)cyclohexylcarbamate (230 mg, 0 415 mmol) was dissolved in 1 1 TFA / dichloromethane (2 mL each), and the reaction was stirred at room temperature for an hour The reaction was then concentrated under reduced pressure, and the residue was dissolved in water The pH was adjusted to 8, and the product was extracted into ethyl acetate The organic layer was washed with water and saturated sodium chloride before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound (120 mg, 64% yield) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 4 28 mm, m/z 454 (M+H)
Example 117
/V-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(1-((<rans-4-(methylsulfonamido)cyclohexyl)methyl)-
1 HA ,2,4-triazol-3-yl)pyrimidine-4-carboxamιde
Λ/-(4-Fluoro-3-methoxybenzyl)-6-(1-((/rans-4-amιnocyclohexyl)methyl)-1 H-1 ,2,4-tπazol-3-yl)-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 1 16) (60 mg, 0 13 mmol) was dissolved in dichloromethane (2 mL) Triethylamine (26 8 mg, 0 265 mmol) and methanesulfonyl chloride (18 2 mg, 0 159 mmol) were subsequently added, and the reaction was continued overnight at room temperature The solvent was then removed under reduced pressure, and the residue was dissolved in ethyl acetate The organic layer was washed with water (3x), 1 N hydrochloric acid (2x), and saturated sodium chloride before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound as an off-white solid (60 mg, 85% yield) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 5 19 mm, m/z 532 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 38 (t, 1 H), 8 69 (s, 1 H), 8 31 (s, 1 H), 7 03 - 7 20 (m, 2 H), 6 83 - 7 00 (m, 2 H), 4 40 - 4 52 (m, 2 H), 4 09 - 4 23 (m, 2 H), 3 80 (s, 3 H), 2 94 - 3 12 (m, 1 H), 2 86 (s, 3 H), 2 75 (s, 3 H), 1 68 - 1 99 (m, 3 H), 1 50 - 1 66 (m, 2 H), 0 90 - 1 29 (m, 4 H)
Example 118
W-(4-fluoro-3-methoxybenzyl)-6-(1-((ffans-4-acetamidocyclohexyl)methyl)-1H-1 ,2,4-tπazol-3-yl)- 2-methylpyrimidine-4-carboxamide
Λ/-(4-Fluoro-3-methoxybenzyl)-6-(1-((/raπs-4-amιnocyclohexyl)methyl)-1 /-/-1 ,2,4-trιazol-3-yl)-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 1 16) (60 mg, 0 13 mmol) was dissolved in dichloromethane (2 mL) Triethylamine (26 8 mg, 0 265 mmol) and acetyl chloride (12 5 mg, 0 159 mmol) were subsequently added, and the reaction was continued overnight at room temperature The solvent was then removed under reduced pressure, and the residue was dissolved in ethyl acetate The organic layer was washed with water (3x), 1 N hydrochloric acid (2x), and saturated sodium chloride before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded a crude solid which was dissolved in acetonitrile (1 mL), water (0 5 mL), and DMF (0 5 mL) and purified by reverse phase HPLC using a 30 - 60% B, 30 minutes (A = 0 1 % TFA / water and B = 0 1% TFA / acetonitrile) The product-containing fractions were combined and concentrated under reduced pressure to afford the title compound as a white solid (14 mg, 17% yield) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 5 16 mm, 496 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 37 (t, 1 H), 8 66 (s, 1 H), 8 33 (s, 1 H), 7 54 - 7 68 (m, 1 H), 7 04 - 7 22 (m, 2 H), 6 76 - 6 97 (m, 1 H), 4 41 - 4 53 (m, 2 H), 4 04 - 4 18 (m, 2 H), 3 78 (s, 3 H), 3 38 - 3 53 (m, 1 H), 2 76 (s, 3 H), 1 73 - 1 89 (m, 3 H), 1 73 (s, 3 H), 1 40 - 1 63 (m, 2 H), 0 95 - 1 17 (m, 4 H)
Example 119
/V-(4-Fluoro-3-methoxybenzyl)-6-(1 -(((rans-4-(2-hydroxyacetamido)cyclohexyl)methyl)-1 W-1 ,2,4- triazol-3-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of 2-(frans-4-((3-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4- yl)-1/-/-1 ,2,4-trιazol-1-yl)methyl)cvclohexylamιno)-2-oxoethyl acetate
Λ/-(4-Fluoro- -methoxybenzyl)-6-(1 -((frans-X4-amιnocyclohexNyrl)methΛyl)-1 H- 1 ,2,4-trιazol-3-yl)-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 116) (60 mg, 0 13 mmol) was dissolved in dichloromethane (2 mL) Triethylamine (26 8 mg, 0 265 mmol) and acetoxyacetyl chloride (21 7 mg, 0 159 mmol) were subsequently added, and the reaction was continued overnight at room temperature The solvent was then removed under reduced pressure, and the residue was dissolved in ethyl acetate The organic layer was washed with water (3x), 1 N hydrochloric acid (2x), and saturated sodium chloride before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound (56 mg, 76%) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 5 26 mm, m/z 554 (M+H)
Step 2 Preparation of /V-(4-fluoro-3-methoxybenzyl)-6-(1-((frans-4-(2- hvdroxyacetamιdo)cvclohexyl)methyl)-1/-/-1 ,2,4-trιazol-3-yl)-2-methylpyrιmιdιne-4-carboxamιde
2-(frans-4-((3-(6-((4-Fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-1 /-/-1 ,2,4- trιazol-1-yl)methyl)cyclohexylamιno)-2-oxoethy! acetate (56 mg, 0 10 mmol) was dissolved in acetonitrile (3 mL), and 2 5 N NaOH (1 5 mL) was added The reaction was continued overnight at room temperature The pH was adjusted with concentrated hydrochloric acid, and the product was extracted into ethyl acetate (2x) The organic layer was washed with water and saturated sodium chloride before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound as a solid (26 mg, 50% yield) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 4 82 mm, m/z 512 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 36 (t, 1 H)1 8 72 (s, 1 H), 8 31 (s, 1 H), 7 29 - 7 41 (m, 1 H), 6 97 - 7 25 (m, 2 H), 6 79 - 7 00 (m, 1 H), 5 21 - 5 40 (m, 1 H), 4 40 - 4 55 (m, 2 H), 4 06 - 4 23 (m, 2 H), 3 80 (s, 3 H), 3 65 - 3 75 (m, 2 H), 3 40 - 3 60 (m, 1 H), 2 77 (s, 3 H), 1 66 - 1 85 (m, 3 H), 1 52 - 1 63 (m, 2 H), 0 99 - 1 31 (m, 4 H)
Example 120
W-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-2-methyl-6-(1 -((<rans-4- (methylsulfonamido)cyclohexyl)methyl)-1/-/-1,2,4-triazol-3-yl)pyrιmidιne-4-carboxamide
Step 1 Preparation of Λ/-(3-(2-(fert-butyldιphenylsιlyloxytethoxy)-4-fluorobenzyl)-6-cvano-2- methvlpvrιmιdιne-4-carboxamιde
A/-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-cyano-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in step 1 of the synthesis of Λ/-(4-fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((frans-4- cyanocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 27) (2 2 g, 6 7 mmol) and imidazole (453 mg, 6 7 mmol) were dissolved in dry DMF (36 mL) After cooling to 0 0C, tert-butyldiphenylsilyl chloride (2 2 g, 8 0 mmol) was added The reaction was permitted to warm to room temperature with stirring for 2 days The reaction was then diluted with ethyl acetate and washed with water (3x) and saturated sodium chloride (1X) before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound as an oil (3 g, 79%) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 8 48 mm, 591 (M+Na)
Step 2 Preparation of Λ/-(3-(2-(ferf-butyldιphenylsιlyloxy)ethoxy)-4-fluorobenzyl)-2-methylpyrιmιdιne- 4,6-dιcarboxamιde
To a solution of Λ/-(3-(2-(tert-butyldιphenylsιlyloxy)ethoxy)-4-fluorobenzyl)-6-cyano-2- methylpyrιmιdιne-4-carboxamιde (3 g, 5 mmol) in acetone (21 mL) was added 2 5 N sodium hydroxide (1 1 mL) followed by 30% hydrogen peroxide (3 15 mL) The reaction was stirred at room temperature for 1 h The reaction mixture was diluted with ethyl acetate, and the organic layer was washed with water and saturated sodium chloride before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound as an oil (2 95 g, 100%) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 8 00 mm, m/z 609 (M+Na) Step 3 Preparation of /V-(3-(2-(terf-butyldιphenylsιlyloxy)ethoxy)-4-fluorobenzyl)-2-methyl-6-(1 /-/-1 ,2,4- trιazol-3-yl)pyrιmιdιne-4-carboxamιde
Λ/-(3-(2-(fert-butyldιphenylsιlyloxy)ethoxy)-4-fluorobenzyl)-2-methylpyrιmιdιne-4,6- dicarboxamide (2 95 g, 5 0 mmol) was dissolved in dimethylformamide dimethylacetal (45 mL), and the mixture was refluxed for approximately 2 h The reaction was concentrated under reduced pressure, and the residue was dissolved in acetic acid (30 mL) Hydrazine hydrate (1 5 mL) was then added and the mixture was heated at 90 0C for 1 h After cooling to room temperature, the reaction was poured into water The pH was adjusted to 7, and the product was extracted into ethyl acetate The organic layer was washed with water and saturated sodium chloride before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound (1 7 g) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 7 88 mm, m/z 611 (M+H)
Step 4 Preparation of terf-butyl trans-4-((3-(6-((3-(2-(tert-butyldιphenylsιlyloxy)ethoxy)-4- fluorobenzyl Carbamoyl )-2-methylpyrιmιdιn-4-yl)-1 H-1.2,4-trιazol-1 -yl)methyl)cyclohexylcarbamate
Λ/-(3-(2-(<ert-Butyldιphenylsιlyloxy)ethoxy)-4-fluorobenzyl)-2-methyl-6-(1 H-1 ,2,4-trιa2θl-3- yl)pyrιmιdιne-4-carboxamιde (1 73 g, 2 83 mmol) and (trans-4-((tert- butoxycarbonyl)amιno)cyclohexyl)methyl 4-methylbenzenesulfonate (prepared as described in step 7 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((/rans)-4-amιnocydohexyl)methyl)-2H-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 5) (1 19 g, 3 12 mmol) were stirred in acetonitrile (50 mL), and 1 ,8-dιazobιcyclo[5 4 0]undec-7ene (647 mg, 4 25 mmol) was subsequently added The reaction was heated at 75 0C overnight before cooling to room temperature and concentrating under reduced pressure The residue was purified by reverse phase HPLC using a 40% B to 60% B, 30 minutes (A = 0 1 % TFA / water and B = 0 1 % TFA / acetonitrile) to afford the title compound (300 mg, 13%) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 9 04 mm, 822 (M+H) Step 5 Preparation of /V-(3-(2-(te^butyldιphenylsιlyloxy)ethoxy)-4-fluorobenzyl)-6-(1 -((frans-4- amιnocvclohexyl)methyl)-1 H-1.2,4-trιazol-3-yl)-2-methylpyrιmιclιne-4-carboxamιcle
tert-Butyl /rans-4-((3-(6-((3-(2-(tert-butyldιphenylsιlyloxy)ethoxy)-4-fluorobenzyl)carbamoyl)-2- (300 mg, O 365 mmol) was dissolved in 1 1 TFA / dichloromethane (3 mL each), and the reaction was stirred at room temperature for 1 h The reaction was concentrated under reduced pressure, and the residue was dissolved in water The pH was adjusted to 8, and the product was extracted into ethyl acetate The organic layer was washed with water followed by saturated sodium chloride and concentrated to afford title compound (60 mg, 23%) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 7 07 mm, 722 (M+H)
Step 6 Preparation of /V-(3-(2-(teft-butyldιphenylsιlyloxy)ethoxy)-4-fluorobenzyl)-2-methyl-6-(1 -((frans- 4-(methylsulfonamιdo)cvclohexyl)methyl)-1H-1 ,2,4-trιazol-3-yl)pyrιmιdιne-4-carboxamιde
Λ/-(3-(2-(tert-Butyldιphenylsιlyloxy)ethoxy)-4-flυorobenzyl)-6-(1 -((trans-4- amιnocyclohexyl)methyl)-1 /-/-1 ,2,4-trιazol-3-yl)-2-methylpyrιmιdιne-4-carboxamιde (60 mg, 0 0 83 mmol) was dissolved in dichloromethane (3 mL) Triethylamine (16 8 mg, 0 166 mmol) and methanesulfonyl chloride (1 1 4 mg, 0 0997 mmol) were subsequently added, and the reaction was continued overnight at room temperature The solvent was then removed under reduced pressure, and the residue was dissolved in ethyl acetate The organic layer was washed with water (3X) and saturated sodium chloride (1X) before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound as a solid (60 mg, 90%) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 7 97 mm, 800 (M+H) Step 7 Preparation of /V-(4-fluoro-3-(2-hvdroxyethoxy)benzyl)-2-methyl-6-(1-((frans-4- (methylsulfonamιdo)cvdohexyl)methyl)-1H-1.2,4-trιazol-3-yl)pyrιmιdιne-4-carboxamιde
Λ/-(3-(2-(/ert-Butyldιphenylsιlyloxy)ethoxy)-4-fluorobenzyl)-2-methyl-6-(1-((fraπs-4- (methylsulfonamιdo)cyclohexyl)methyl)-1/-/-1 ,2,4-trιazol-3-yl)pyrιmιdιne-4-carboxanrιιde (60 mg, 075 mmol) was dissolved in THF (2 mL) Tetrabutylammonium fluoride in THF (1 M) (19 6 mg, 0 075 mmol) was subsequently added and the mixture stirred for a couple of hours The reaction mixture was purified by reverse phase chromatography using an acetonitrile gradient in water (10% - 85% over 30 minutes) The product-containing fractions were combined and neutralized with 2 5 N sodium hydroxide The product was extracted into ethyl acetate, and the organic layer was washed with saturated sodium chloride before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure The residue was redissolved in ethyl acetate and washed with saturated ammonium chloride and saturated sodium chloride before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound as a solid (5 mg, 10%) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 4 57 mm, 562
(M+H) 1H NMR (400 MHz, DMSO-d6) 6 ppm 9 40 (t, 1 H), 8 70 (s, 1 H), 8 33 (s, 1 H), 7 58 - 7 76 (m,1 H), 7 05 - 7 23 (m, 2 H), 6 83 - 6 98 (m, 1 H), 4 82 (t, 1 H), 4 41 - 4 53 (m, 2 H), 4 08 - 4 21 (m, 2 H), 3 98 - 4 08 (m, 2 H), 3 61 - 3 78 (m, 2 H), 3 02 - 3 12 (m, 1 H), 2 87 (s, 3 H), 2 76 (s, 3 H), 1 77 - 1 92 (m, 3 H), 1 51 - 1 65 (m, 2 H), 0 98 - 1 33 (m, 4 H)
Example 121
W-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-(1-((frans-4-acetamidocyclohexyl)methyl)-1H-1 ,2,4- triazol-3-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of Λ/-(4-fluoro-3-(2-hvdroxyethoxy)benzyl)-6-(carbamιmιdoyl)-2-methylpyrιmιdιne- 4-carboxamιde
Λ/-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-cyano-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in step 1 of the synthesis of Λ/-(4-fluoro-3-(2-hydroxyethoxy)benzyl)-6-(2-(((frans-4- cyanocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 27) (700 mg, 2 12 mmol) was dissolved in absolute ethanol (20 mL) Hydrazine hydrate (2 33 g, 46 6 mmol) was added, and the reaction was refluxed for 3 h The reaction mixture was allowed to cool to room temperature The reaction was diluted with ethyl acetate and washed with water (3X) and saturated sodium chloride (1X) before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound as an oil (300 mg, 39%) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 3 19 mm , m/z 363 (M+H)
Step 2 Preparation of Λ/-(4-fluoro-3-(2-hydroxyethoxy)benzyl)-2-methyl-6-(1 H-1.2,4-trιazol-3- yl)pyπmιdιne-4-carboxamιde
Λ/-(4-Fluoro-3-(2-hydroxyethoxy)benzyl)-6-(carbamιmιdoyl)-2-methylpyrιmιdιne-4-carboxamιde
(300 mg, 0 83 mmol) was dissolved in formic acid (3 mL), and the reaction was refluxed overnight The reaction was then cooled and concentrated under reduced pressure The residue was partitioned between saturated sodium bicarbonate and ethyl acetate The layers were separated, and the organic layer was washed with saturated sodium bicarbonate and saturated sodium chloride before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound as an oil (80 mg, 26%) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 4 77 mm, m/z 373 (M+H)
Step 3 Preparation of (fraπs-4-amιnocyclohexyl)methyl 4-methylbenzenesulfonate
(frans-4-((^ert-Butoxycarbonyl)amιno)cyclohexyl)methyl 4-methylbenzenesυlfonate (prepared as described in step 7 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((frans)-4- aminocyclohexyOmethyl^H-tetrazol-S-yl^-methylpyrimidine^-carboxamide, Example 5) (1 0 g, 2 6 mmol) was dissolved in 1 1 TFA / dichloromethane (5 mL each), and the reaction was stirred at room temperature for an hour The reaction was then concentrated under reduced pressure, and the residue was dissolved in water The pH was adjusted to 8, and the product was extracted into ethyl acetate The organic layer was washed with water followed by saturated sodium chloride, dried over anhydrous sodium sulfate, filtration and concentrated to afforded the title compound (450 mg, 61 % yield) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 3 99 mm , m/z 284 (M+H)
Step 4 Preparation of (/rans^-acetamidocvclohexyOmethyl 4-methylbenzenesulfonate
(/rans-4-Amιnocyclohexyl)methyl 4-methylbenzenesulfonate (450 mg, 1 59 mmol) was dissolved in dichloromethane (10 mL) Triethylamine (321 mg, 3 18 mmol) and acetyl chloride (150 mg, 1 91 mmol) were subsequently added, and the reaction was continued overnight at room temperature The solvent was then removed under reduced pressure, and the residue was dissolved in ethyl acetate The organic layer was washed with water (3x), 1 N hydrochloric acid (2x), and saturated sodium chloride solution before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound as an oil (450 mg) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 5 23 mm, m/z 326 (M+H)
Step 5 Preparation of Λ/-(4-fluoro-3-(2-hvdroxyethoxy)benzyl)-6-(1-((frans-4- acetamιdocvclohexyl)methyl)-1 /-/-1 ,2,4-trιazol-3-yl)-2-methylpyrιmιdιne-4-carboxamιde
Λ/-(4-F!uoro-3-(2-hydroxyethoxy)benzyl)-2-methyl-6-(1 H-1 ,2,4-trιazol-3-yl)pyrιmιdιne-4- carboxamide (80 mg, 0 21 mmol) and ((?rans-4-acetamιdocyclohexyl)methyl 4- methylbenzenesulfonate (76 9 mg, 0 236 mmol) were stirred in acetonitrile (5 mL), and 1 ,8- dιazobιcyclo[5 4 0]undec-7ene (DBU) (49 1 mg, 0 322 mmol) was subsequently added The reaction was heated at 75 0C overnight before cooling to room temperature and diluting with ethyl acetate The organic layer was washed with water (3X) and saturated sodium chloride (1X) before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded an oil which was purified by reverse phase HPLC using a 20% B to 60% B, 40 minutes (A = 0 1 % TFA / water and B = 0 1% TFA / acetonitrile) The product-containing fractions were combined, and the pH was made basic with 2 5 N sodium hydroxide The product was extracted into ethyl acetate, and the combined organic layer was washed with saturated sodium chloride before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound (3 9 mg, 3 5%) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 4 56 mm, m/z 326 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 39 (t, 1 H), 8 73 (s, 1 H)1 8 32 (s, 1 H), 7 54 - 7 72 (m,1 H), 7 04 - 7 26 (m, 2 H), 6 84 - 6 96 (m, 1 H), 4 80 (t, 1 H), 4 41 - 4 54 (m, 2 H), 4 11 - 4 22 (m, 2 H), 3 96 - 4 09 (m, 2 H), 3 63 - 3 80 (m, 2 H), 3 33 - 3 52 (m, 1 H), 2 76 (s, 3 H), 1 78 - 2 05 (m, 3 H), 1 71 (s, 3 H), 1 48 - 1 65 (m, 2 H), 1 09 - 1 34 (m, 4 H)
Example 122
/V-(4-Fluoro-3-methoxybenzyl)-6-(5-((<rans-4-aminocyclohexyl)methyl)-1 ,2,4-oxadiazol-3-yl)-2- methylpyrimidine-4-carboxamide
Step 1 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-cvano-2-methylpyrιmιdιne-4-carboxamιde
A mixture of methyl 6-cyano-2-methylpyrιmιdιne-4-carboxylate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((<rans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 5) (10 0 g, 56 4 mmol), 4-fluoro-3-methoxybenzylamιne hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2- ((^ans^-aminocyclohexyOmethyl^H-tetrazol-S-yOpyπmidine^-carboxamide, Example 1 ) (13 5 g, 70 6 mmol), /V,Λ/-dιιsopropylethylamιne (39 3 mL, 226 mmol), and methanol (56 4 mL) was heated to 35 °C for 1 h The mixture was concentrated and the residue was partitioned between ethyl acetate (500 mL) and 1 N hydrochloric acid (500 mL) The aqueous layer was extracted with ethyl acetate (2 x 250 mL) The combined organic layers were washed with saturated sodium bicarbonate solution (2 x 250 mL) followed by brine, dried over sodium sulfate, and concentrated The crude product was purified by silica gel chromatography (2/1 , heptane/ethyl acetate) to afford the title compound as a white solid (1 1 7 g) MS (ES+) m/z 301 (M+H)
Step 2 Preparation of Λ/-(4-f1uoro-3-methoxybenzyl)-6-(carbamιmιdovO-2-methylpyrιmιdιne-4- carboxamide
Λ/-(4-Fluoro-3-methoxybenzyl)-6-cyano-2-methylpyrιmιdιne-4-carboxamιde (1 0 g, 3 3 mmol) was dissolved in ethanol / water (20 mL / 5 mL) Hydroxylamine hydrochloride (255 mg, 3 66 mmol) and sodium hydroxide (213 mg, 3 66 mmol) were subsequently added, and the reaction was heated at 75 0C for 2 hours After cooling to room temperature, the reaction was diluted with ethyl acetate and washed with water and saturated sodium chloride before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound as an off- white solid (1 0 g, 90% yield) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 4 65 mm, m/z 334 (M+H)
Step 3 Preparation of tert-butyl (4-(2-((((1Z)-amino(6-(((4-fluoro-3-methoxybenzyl)amιno)carbonyl)-2- methylpyrιmιdιn-4-yl)methylene)amιno)oxy)-2-oxoeth yl )cvclohexyl Carbamate
Λ/^-fluoro-S-methoxybenzyO-θ^carbamimidoyO^-methylpynmidine^-carboxamide (500 mg,
1 50 mmol), 2-(/rans-4-(tert-butoxycarbonyl)cyclohexyl)acetιc acid (386 mg, 1 50 mmol), N- hydroxybenzotnazole (230 mg, 1 50 mmol), and dnsopropyethylamine (582 mg, 4 50 mmol) were dissolved in acetonitrile (20 mL) and dimethylacetamide (2 mL) PS-carbodiimide resin (3 49 g, 4 50 mmol) was subsequently added, and the reaction was agitated at 40 °C overnight The reaction was filtered to remove the resin, and the resin was washed with dimethylformamide The filtrate was diluted with ethyl acetate, and the organic layer was washed with water and saturated sodium chloride before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound as a white solid (700 mg, 82%) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 6 23 mm, m/z 517 (M+H-f-butyl) Step 4 Preparation of fert-butyl (frans)-4-((3-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-
tert-Butyl (4-(2-((((12)-amιno(6-(((4-fluoro-3-methoxybenzyl)amιno)carbonyl)-2- methylpyrιmιdιn-4-yl)methylene)amιno}oxy)-2-oxoethyl)cyclohexyl)carbamate (400 mg, 0 70 mmol) was dissolved in acetonitrile (8 mL) and dimethylacetamide (4 mL) MP-carbonate resin (732 mg, 2 1 mmol) was added, and the reaction was microwaved for 15 mm at 120 0C at 200W The reaction was filtered to remove the resin, and the filtrate was diluted with ethyl acetate The organic layer was washed with water (3X) and saturated sodium chloride (1X) before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound as a solid (388 mg, 95%) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 6 76 mm, m/z 577 (M+Na)
Step 5 Preparation of /V-(4-fluoro-3-methoxybenzyl)-6-(5-((frans-4-aminocvclohexy0methyl)-1 ,2,4- oxadiazol-3-yl)-2-methylpyrimidine-4-carboxarnide
fert-Bυtyl (frans)-4-((3-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-1 ,2,4- oxadιazol-5-yl)methyl)cyclohexylcarbamate (370 mg, 0 67 mmol) was dissolved in a mixture of tnfluoroacetic acid (5 mL) and dtchloromethane (5 mL) The reaction mixture was stirred at room temperature for several hours before being concentrated under reduced pressure The residue was treated with saturated sodium bicarbonate, and the product was extracted into ethyl acetate The organic layer was washed with saturated sodium bicarbonate and saturated sodium chloride before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound LC/MS (5%-95% CH3CN/H2O, 8 mm, 2 mm) 4 53 mm, m/z 455 (M+H)
Example 123
/V-(4-fluoro-3-methoxybenzyl)-6-(5-((frans-4-acetamidocyclohexyl)methyl)-1,2,4-oxadiazol-3-yl)-
2-methylpyrimidine-4-carboxamide
/V-(4-Fluoro-3-methoxybenzyl)-6-(5-((/rans-4-amιnocyclohexyl)methyl)-1 ,2,4-oxadιazol-3-yl)-2- methylpyπmιdιne-4-carboxamιde (prepared as described in Example 122) (10 mg, 0 022 mmol) was dissolved in dichloromethane (2 mL) Triethylamine (4 45 mg, 0 0440 mmol) and acetyl chloride (1 90 mg, 0 0242 mmol) were subsequently added, and the reaction was continued overnight at room temperature The solvent was then removed under reduced pressure, and the residue was dissolved in ethyl acetate The organic layer was washed with water (3x), 1 N hydrochloric acid (3x), and saturated sodium chloride solution before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound (9 mg, 83% yield) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 5 61 mm, m/z 497 (M+H) 1H NMR (400 MHz, DMSO-de) δ ppm 9 46 (t, 1 H), 8 28 (s, 1 H), 8 08 (s, 1 H), 7 49 - 7 67 (m,1 H), 7 02 - 7 19 (m, 1 H), 6 81 - 6 94 (m, 1 H), 4 39 - 4 52 (m, 2 H), 3 76 (s, 3 H), 3 31 - 3 50 (m, 1 H), 2 89 - 2 99 (m, 2 H), 2 78 (s, 3 H), 1 70 - 1 91 (m, 2 H), 1 71 (s, 3 H), 1 10- 1 28 (m, 7 H) Example 124
W-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(5-((fraπs-4-(methylsulfonamido)cyclohexyl)methyl)-
1 ,2,4-oxadιazol-3-yl)pyrimidine-4-carboxamide
Λ/-(4-Fluoro-3-methoxybenzyl)-6-(5-((fraπs-4-amιnocyclohexyl)methyl)-1 ,2,4-oxadιazol-3-yl)-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 122) (15 mg, 0 033 mmol) was dissolved in dichloromethane (2 mL) Triethylamine (6 69 mg, 0 0661 mmol) and methanesulfonyl chloride (4 55 mg, 0 0397 mmol) were subsequently added, and the reaction was continued overnight at room temperature The solvent was then removed under reduced pressure, and the residue was dissolved in ethyl acetate The organic layer was washed with water (3x), 1 N hydrochloric acid (3x), and saturated sodium chloride solution before drying over anhydrous sodium sulfate Filtration and evaporation of the solvent under reduced pressure afforded the title compound (6 5 mg, 37% yield) LC/MS (5%-95% CH3CN/H2O, 8 mm , 95% CH3CN, 2 mm ) 5 70 mm, m/z 534 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 47 (t, 1 H), 8 28 (s, 1 H), 7 55 - 7 72 (m,1 H), 7 02 - 7 21 (m, 2 H), 6 81 - 6 97 (m, 1 H), 4 40 - 4 52 (m, 2 H), 3 76 (s, 3 H), 2 99 - 3 08 (m, 1 H), 2 89 - 2 99 (m, 2 H), 2 85 (s, 3 H), 2 75 (s, 3 H), 1 62 - 2 02 (m, 2 H), 1 1 1 - 1 31 (m, 7 H)
Example 125
W-(4-Fluoro-3-methoxybenzyl)-6-(2-(3-hydroxypropyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4- carboxamide
Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(frans-4- aminocyclohexyOmethyO^H-tetrazol-S-yO^-methylpyπmidine^-carboxamide, Example 9) (355 mg, 1 03 mmol), 2-bromoethanol (194 mg, 1 55 mmol), triethylamine (400 μL) and dimethylacetamide (400 μL) were combined The resulting mixture was stirred at 130 °C for 2 h The mixture was cooled and purification was accomplished by reverse phase preparative high-pressure liquid chromatography The pure fractions were combined, extracted with ethyl acetate (2 x 20 mL), dried over magnesium sulfate, and concentrate to afford a residue that upon methanol trituration provided the title compound as a white solid (25 mg, 6 2%) LC/MS (10%-90% CH3CN/H2O, 8 mm) 4 94 mm, m/z 388 (M+H) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 9 54 (m, 1 H), 8 42 (s, 1 H), 7 15 (td, J = 12 3, 8 4 Hz, 2 H), 6 92 (br s, 1 H), 4 87 (t, J = 6 8 Hz, 2 H), 4 69 (br s , 1 H), 4 51 (d, J = 5 9 Hz, 2 H), 3 82 (s, 3 H), 3 49 (d, J = 5 1 Hz, 2 H), 2 83 (s, 3 H), 2 1 1 (m, 2 H) Example 126
W-(4-Fluoro-3-methoxybenzyl)-6-(2-((S)-3-hydroxy-2-methylpropyl)-2H-tetrazol-5-yl)-2- methylpyrimidine-4-carboxamide
Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde
(prepared as described in step 2 of the synthesis of A/-(4-fluoro-3-methoxybenzyl)-6-(2-(frans-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 9) (104 mg, 0 303 mmol), (R)-3-bromo-2-methylpropan-1 -ol (46 4 mg, 0 303 mmol), triethylamine (400 μL) and dimethylacetamide (100 μL) were combined The resulting mixture was stirred at 130 0C for 2 h The mixture was cooled and purification was accomplished by reverse phase preparative high-pressure liquid chromatography The pure fractions were combined, extracted with ethyl acetate (2 x 20 mL), dried over magnesium sulfate, and concentrated to afford a residue that upon methanol trituration provided the title compound as a white solid (10 mg, 7 9%) MS (ES+) m/z 416 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 50 (s, 1 H), 8 42 (s, 1 H), 7 18 (dd, J = 8 4, 1 8 Hz, 1 H), 7 14 (dd, J = 1 1 7, 8 4 Hz, 1 H), 6 91 (br s, 1 H), 4 87 (dd, J = 13 5, 5 9 Hz, 1 H), 4 77 (t, J = 5 1 Hz1 1 H), 4 65 (dd, J = 13 5, 8 1 , 1 H), 4 50 (d, J = 6 2 Hz, 2 H), 3 82 (s, 3 H), 3 38 (dt, J = 10 0, 5 1 Hz, 2 H), 2 83 (s, 3 H), 2 33 (s, 1 H), 0 86 (d, J = 7 0 Hz, 3H)
Example 127
/V-(4-Fluoro-3-methoxybenzyl)-6-(2-((/?)-3-hydroxy-2-methylpropyl)-2H-tetrazol-5-yl)-2- methylpyrimidine-4-carboxamide
Λ/-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-(frans-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 9) (104 mg, 0 303 mmol), (S)-3-bromo-2-methylpropan-1-ol (46 4 mg, 0 303 mmol), triethylamine (400 μL) and dimethylacetamide (100 μL) were combined The resulting mixture was stirred at 130 0C for 2 h The mixture was cooled and purification was accomplished by reverse phase preparative high-pressure liquid chromatography The pure fractions were combined, extracted with ethyl acetate (2 x 20 mL), dried over magnesium sulfate, and concentrated to afford a residue that upon methanol trituration provided the title compound as a white solid (10 mg, 7 9%) MS (ES+) m/z 416 (M+H) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 9 51 (s, 1 H), 8 42 (s, 1 H), 7 15 (td, J = 1 1 7, 8 4, Hz, 2 H), 6 91 (br s, 1 H), 4 87 (dd, J = 13 5, 5 9 Hz, 1 H), 4 77 (t, J = 5 1 Hz, 1 H), 4 65 (dd, J = 13 5, 8 1 , 1 H), 4 50 (d, J = 6 2 Hz, 2 H), 3 82 (s, 3 H)1 3 38 (dt, J = 10 0, 5 1 Hz, 2 H), 2 83 (s, 3 H), 2 33 (s, 1 H), 0 86 (d, J = 7 0 Hz, 3H)
Example 128
W-(4-Fluoro-3-methoxyben2yl)-6-(1-(((2S,5f?)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-1H- 1 ,2,3-triazol-4-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-hvdroxy-2-methylpyrιmιdιne-4-carboxamιde
Methyl 6-hydroxy-2-methylpyrιmιdιne-4-carboxy!ate (prepared as described in step 2 of the synthesis of Λ/-(3-methoxybenzy1 )-6-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-y1 )-2- methylpyrιmιdιne-4-carboxamιde, Example 5) (10 0 g, 59 5 mmol), 4-fluoro-3-methoxybenzylamιne hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3- methoxybenzy1 )-6-(2- ((frans-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-y1 )pyrιmιdιne-4-carboxamιde, Example 1 ) (13 7 g, 71 4 mmol, 1 20 equiv ), and Λ/,/V-dιιsopropylethylamιne (26 mL, 149 mmol, 2 50 equiv ) were combined in methanol (120 mL) After stirring for 2 hours at reflux, the mixture was cooled to room temperature, and diluted with 1 0 N aqueous hydrochloric acid (150 mL) and water (100 mL) The resulting solid was collected by suction filtration, and the filter cake was washed with water (2 x 100 mL) and air dried for 1 h The solid was dried under vacuum at 40 0C to provide the title compound as a tan solid (13 9 g, 80%) MS (ES+) m/z 292 (M+H) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 12 75 (1 H, br s ), 9 09 (1 H, t, J=6 2 Hz), 7 04 - 7 21 (2 H, m), 6 78 - 6 90 (1 H1 m), 6 67 (1 H1 s), 4 40 (2 H, d, J=6 2 Hz)1 3 81 (3 H, s), 2 35 (3 H, s)
Step 2 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-chloro-2-methylpyrιmιdιne-4-carboxamιde
Λ/-(4-Fluoro-3-methoxybenzyl)-6-hydroxy-2-methylpyrιmιdιne-4-carboxamιde (10 0 g, 34 3 mmol) and W,Λ/-dιmethylformamιde (0 66 mL, 8 58 mmol, 0 25 equiv ) were combined in tetrahydrofuran (137 mL) and the mixture was heated to 60 0C To the mixture was added dropwise oxalyl chloride (5 1 mL, 58 4 mmol, 1 70 equiv ) After stirring for 1 hour at 60 0C, the mixture was cooled to room temperature, water (25 mL) was added dropwise, the mixture was filtered through Celite™, the filter cake was washed with tetrahydrofuran (100 mL), and the filtrate was evaporated to one-third the original volume Water (150 mL) was added and the mixture was concentrated under reduced pressure to induce precipitation of the product The solid was collected by suction filtration, the filter cake was washed with water (3 x 100 mL), and the solid was air dried for 15 hours to provide the title compound as a red solid (9 50 g, 89%) MS (ES+) m/z 310 (M+H) 1H NMR (400 MHz,
DMSO-d6) δ ppm 9 50 ( 1 H, t, J=6 2 Hz), 7 88 (1 H, s), 7 07 - 7 19 (2 H, m), 6 82 - 6 92 (1 H, m), 4 45 (2 H1 d, J=6 4 Hz), 3 81 (3 H, s), 2 71 (3 H, s)
Step 3 Preparation of /V-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2-(trιmethylsιlyl)ethvnyl)pyrιmιdιne-4- carboxamide
A solution of tetrahydrofuran (10 0 mL) and triethylamine (15 0 mL) was sparged with nitrogen gas for 5 minutes To this solution was added sequentially Λ/-(4-fluoro-3-methoxybenzyl)-6-chloro-2- methylpyrιmιdιne-4-carboxamιde (3 00 g, 9 69 mmol), dιchlorobιs(trιphenylphosphιne)palladιum(ll) (68 mg, 97 μmol, 0 01 equiv ), triphenylphosphine (51 mg, 0 19 mmol, 0 02 equiv ), copper (I) iodide (37 mg, 0 19 mmol, 0 02 equiv ), and trimethylsilylacetylene (2 2 mL, 15 5 mmol, 1 60 equiv ) After stirring for 3 hours at 50 0C, the mixture was cooled to room temperature, diluted with ethyl acetate (100 mL), filtered, and concentrated under reduced pressure to give a red oil Purification by silica gel chromatography (gradient 5 1 heptane/EtOAc to 2 1 heptane/EtOAc) provided the title compound as a viscous, yellow oil (2 60 g, 72%) LC/MS (5%-100% CH3CN/H2O, 5 mm) 4 12 mm, m/z 372 (M+H) Step 4 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-ethvnyl-2-methylpyrιmιdιne-4-carboxamιde
To a solution of /V-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2-(trιmethylsιlyl)ethynyl)pyrιmιdιne- 4-carboxamιde (2 60 g, 7 00 mmol) in tetrahydrofuran (20 mL) and water (10 mL) was added potassium fluoride (447 mg, 7 70 mmol, 1 10 equiv ) After stirring for 2 hours at room temperature, the mixture was concentrated under reduced pressure to remove the tetrahydrofuran, diluted with ethyl acetate (50 mL), and washed with pH 7 0 aqueous phosphate buffer The layers were separated and the aqueous layer was washed with ethyl acetate (1x) The organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound as a brown solid (2 06 g, >95%) LC/MS (5%-100% CH3CN/H2O, 5 mm) 3 24 mm, m/z 300 (M+H) Step 5 Preparation of ((2S,5ff)-5-((trιfluoromethylsulfonyloxy)methyl)-1 ,4-dιoxan-2-yl)methγl 4- methylbenzenesulfonate
((2S,5S)-5-(Hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 1 of the synthesis of Λ/-(3-methoxybenzy1 )-6-(2-(((2S,5f?)-5-(hydroxymethyl)-1 ,4- dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 62) (5 0 g, 16 5 mmol) and pyridine (1 4 mL, 17 3, 1 05 equiv ) were combined in 70 mL dichloromethane, the resulting solution was cooled in a methanol/ice bath, and a solution of trifluoromethanesulfonic anhydride (2 9 mL, 17 3 mmol, 1 05 equiv ) in dichloromethane (10 mL) was added dropwise via cannula After warming to room temperature, the mixture was diluted with dichloromethane (150 mL) and treated with 1 0 N aqueous hydrochloric acid (40 mL) The layers were separated and the aqueous layer was washed with dichloromethane (3 x 10 mL) The organic layers were combined, washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound as a light yellow solid (6 89 g, >95%) Step 6 Preparation of ((2S,5S)-5-((4-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4- yl)-1 /-/-1.2,3-triazol-1 -yl)methyl)-1.4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate
((2S,5f?)-5-((Trιfluoromethylsulfonyloxy)methyl)-1 ,4-dιoxan-2-yl)methyl 4- methylbenzenesulfonate (100 mg, 0 23 mmol) and sodium azide (16 mg, 0 24 mmol, 1 05 equiv ) were combined in tetrahydrofuran (0 8 mL), tert-butano! (0 4 mL), and water (0 4 mL) After stirring for 1 hour at room temperature, the reaction vessel was charged sequentially with Λ/-(4-fluoro-3- methoxybenzyl)-6-ethynyl-2-methylpyrιmιdιne-4-carboxamιde (69 mg, 0 23 mmol, 1 00 equiv ), 1 0 M aqueous sodium ascorbate (23 μL, 0 023 mmol, 0 10 equiv ), and 0 30 M aqueous copper (II) sulfate (17 μL, 0 005 mmol, 0 02 equiv ) After stirring for 15 hours at room temperature, the mixture was diluted with ethyl acetate and washed with 50% aqueous sodium chloride The layers were separated and the aqueous layer was washed with ethyl acetate (3x) The organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure to give a dark, orange oil Purification by silica gel chromatography (gradient 1 1 heptane/EtOAc to 100% EtOAc) provided the title compound as a white solid (142 mg, >95%) LC/MS (10%-90% CH3CN/H2O, 5 mm) 3 07 mm, m/z 627 (M+H) Step 7 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1 -(((2S.5R)-5-(hvdroxymethyl)-1 ,4-dιoxan-2- v0methyl)-1 /-/-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde
((2S,5S)-5-((4-(6-((4-Fluoro-3-methoxybenzyl Carbamoyl )-2-methylpyrιmιdιn-4-yl)-1 H-1 , 2, 3- trιazol-1 -yl)methyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (75 mg, 0 12 mmol) and tetrabutylammonium acetate (40 mg, 0 13 mmol, 1 10 equiv ) were combined in dimethylformamide (1 0 mL) After stirring for 1 hour at 65 0C, the mixture was cooled to room temperature, and the reaction vessel was charged sequentially with water (250 //L) and 1 0 N aqueous sodium hydroxide (144 μL, 0 144 mmol, 1 20 equiv ) After stirring for 20 minutes at room temperature, the mixture was diluted with ethyl acetate (10 mL) and washed with 50% aqueous sodium chloride (2 x 3 mL) The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give an orange oil Purification by silica gel chromatography (gradient 100% EtOAc to 5% MeOH/EtOAc) provided the title compound as a white solid (40 mg, 71 %) LC/MS (10%-90% CH3CN/H2O, 5 mm) 2 01 mm, m/z 473 (M+H) 1H NMR (400 MHz, CD3OD) 6 ppm 8 65 (1 H, s), 8 47 (1 H, s), 7 13 (1 H, dd, J=8 3, 1 8 Hz), 7 03 (1 H, dd, J= 1 1 4, 8 3 Hz), 6 86 - 6 97 (1 H, m), 4 60 - 4 70 (1 H, m), 4 58 (3 H, s), 4 45 - 4 55 (1 H, m), 3 92 - 4 01 (2 H, m), 3 88 (1 H, d, J=11 1 Hz)1 3 86 (3 H, s), 3 51 - 3 59 (1 H, m), 3 47 - 3 51 (2 H, m), 3 41 - 3 48 (1 H, m), 3 33 - 3 41 (1 H, m), 2 77 (3 H, s)
Example 129
/V-(4-Fluoro-3-methoxybenzyl)-6-(1-(((S)-4-acetylmorpholin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)-2- methylpyrimidine-4-carboxamide
Step 1 Preparation of methyl 2-methyl-6-(2-(trιmethylsιlyl)ethvnyl)pyrιmιdιne-4-carboxylate
The title compound was prepared in a similar manner to Λ/-(4-fluoro-3-methoxybenzyl)-2- methyl-6-(2-(trιmethylsιlyl)ethynyl)pyrιmιdιne-4-carboxamιde (step 3, Example 128) by reaction of methyl 6-chloro-2-methylpyrιmιdιne-4-carboxylate (prepared as described in step 3 of the synthesis of Λ/-(3-methoxybenzy1 )-6-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-y1 )-2-methylpyrιmιdιne- 4-carboxamιde, Example 5) (1 00 g, 5 36 mmol), dιchlorobιs(trιphenylphosphιne)palladιum(!l) (38 mg, 54 μmol, 0 01 equiv ), triphenylphosphine (28 mg, 0 1 1 mmol, 0 02 equiv ), copper (I) iodide (20 mg, 0 11 mmol, 0 02 equiv ), and tπmethylsilylacetylene (1 2 mL, 8 50 mmol, 1 60 equiv ) Purification by silica gel chromatography (gradient 3 1 heptane/EtOAc to 2 1 heptane/EtOAc) provided the title compound as a tan solid (1 15 g, 86%) LC/MS (10%-90% CH3CN/H2O, 5 mm) 2 91 mm, m/z 249 (M+H)
Step 2 Preparation of methyl 6-ethvnyl-2-methylpyrιmιdιne-4-carboxylate
The title compound was prepared in a similar manner to Λ/-(4-fluoro-3-methoxybenzyl)-6- ethynyl-2-methylpyrιmιdιne-4-carboxamιde (step 4, Example 128) by reaction of methyl 2-methyl-6-(2- (trιmethylsιlyl)ethynyl)pyrιmιdιne-4-carboxylate (100 mg, 0 40 mmol) and potassium fluoride (26 mg, 0 44 mmol, 1 10 equiv ) to afford the title compound as an orangish-brown solid (70 mg, >95%) LC/MS (10%-90% CH3CN/H2O, 5 mm) 1 20 mm, m/z 177 (M+H)
Step 3 Preparation of (9H-fluoren-9-yl)methyl (S)-2-(hvdroxymethyl)morpholιne-4-carboxylate
terf-Butyl (S)-2-(hydroxymethyl)morpholιne-4-carboxylate (1 0 g, 4 60 mmol) and 4 0 M hydrochloric acid in 1 ,4-dιoxane (50 mL, 20 0 mmol, 4 35 equiv ) were combined and the solution was stirred at room temperature for 30 minutes The solvent was evaporated and to the crude residue was added sequentially tetrahydrofuran (10 mL), water (5 0 mL), sodium bicarbonate (1 16 g, 13 8 mmol, 3 0 equiv ), and 9-fluorenylmethyl chloroformate (1 19 g, 4 60 mmol, 1 00 equiv ) After stirring for 15 h at room temperature, the tetrahydrofuran was evaporated under reduced pressure and the mixture was diluted with ethyl acetate (25 mL) The layers were separated and the aqueous layer was washed with ethyl acetate (3x) The organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound as a white solid (1 56 g, >95%) Step 4 Preparation of (9H-fluoren-9-yl)methyl (S)-2-((trιfluoromethylsulfonyloxy)methyl)morpholιne-4- carboxylate
The title compound was prepared in a similar manner to ((2S,5R)-5- ((trιfluoromethylsulfonyloxy)methyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (step 5,
Example 128) by reaction of (9H-fluoren-9-yl)methyl (S)-2-(hydroxymethyl)morpholιne-4-carboxylate (1 25 g, 3 68 mmol), pyridine (313 μL, 3 87 mmol, 1 05 equiv ), and trifluoromethanesulfonic anhydride (0 65 mL, 3 87 mmol, 1 05 equiv ) to afford the title compound as a light tan solid (1 68 g, >95%)
Step 5 Preparation of methyl 6-(1-(((S)-4-(((9/-/-fluoren-9-yl)methoxy)carbonyl)morpholιn-2-yl)methyl)- 1 H- 1.2.3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxylate
The title compound was prepared in a similar manner to ((2S,5S)-5-((4-(6-((4-fluoro-3- methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-1 H-1 ,2,3-triazol-1-yl)methyl)-1 ,4-dioxan-2-yl)methyl 4-methylbenzenesulfonate (step 6, Example 128) by reaction of (9H-fluoren-9-y!)methyl (S)-2- ((tπfluoromethylsulfonyloxy)methyl)morpholιne-4-carboxylate (140 mg, 0 30 mmol), sodium azide (20 mg, 0 31 mmol, 1 05 equiv ), methyl 6-ethynyl-2-methylpyrιmιdιne-4-carboxylate (52 mg, 0 30 mmol, 1 00 equiv ), 1 0 M aqueous sodium ascorbate (30 μL, 0 030 mmol, 0 10 equiv ), and 0 30 M aqueous copper (II) sulfate (20 μL, 0 006 mmol, 0 02 equiv ) Purification by silica gel chromatography (gradient 1 1 heptane/EtOAc to 100% EtOAc) provided the title compound as a tan solid (1 13 mg, 71 %) LC/MS (10%-90% CH3CN/H2O, 5 mm) 2 99 mm, m/z 541 (M+H)
Step 6 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1-(((S)-4-acetylmorpholιn-2-yl)methyl)-1 H- 1.2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde
Methyl 6-(1-(((S)-4-(((9/-/-fluoren-9-yl)methoxy)carbonyl)morpholιn-2-yl)methyl)-1 H-1 , 2,3- trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxylate (49 mg, 91 μmol), 4-fluoro-3-methoxybenzylamιne hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3- methoxybenzy1 )-6-(2- ((/raπs^-aminocyclohexyOmethyO^H-tetrazol-S-y^pyπmidine^-carboxamide, Example 1 ) (52 mg, 0 27 mmol, 3 00 equiv ), and triethylamine (51 μL, O 36 mmol, 4 OO equiv ) were combined in N1N- dimethylacetamide (1 O mL) After stirring for 1 hour at 65 0C, the mixture was cooled to room temperature, and to the mixture was added sequentially dichloromethane (1 0 mL), triethylamine (76 μL, 0 54 mmol, 6 00 equiv ), and acetyl chloride (32 μL, 0 45 mmol, 5 00 equiv ) After stirring for 1 hour at room temperature, the mixture was concentrated under reduced pressure, diluted with ethyl acetate {5 mL), and washed with pH 7 0 aqueous phosphate buffer (2 mL) The layers were separated and the aqueous layer was washed with ethyl acetate (3 x 1 mL) The organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure Partial purification by silica gel chromatography (gradient 1 2 heptane/EtOAc to 100% EtOAc to 5% MeOH/EtOAc) provided an oily residue, which was further purified by reverse-phase HPLC to afford the title compound as a white solid (7 mg, 16%) MS (ES+) m/z 484 (M+H) 1H NMR (400 MHz, DMSO-CZ6) δ 9 39 (1 H, t, J=5 9 Hz), 8 80 (1 H, d, J=11 9 Hz), 8 34 (1 H, s), 7 17 - 7 21 (1 H, m), 7 14 (1 H, dd, J= 1 1 7, 8 6 Hz), 6 81 - 6 98 (1 H, m), 4 63 - 4 77 (1 H, m), 4 54 - 4 63 (1 H, m), 4 49 (2 H, d, J=6 2 Hz), 4 21 (1 H, dd, J=86 2, 13 0 Hz), 3 85 - 3 98 (2 H1 m), 3 82 (3 H, s), 3 39 - 3 71 (1 H, m), 2 92 - 3 23 (1 H, m), 2 75 (3 H, s), 2 52 - 2 73 (1 H, m), 2 02 (3 H, d, J= 1 1 3 Hz)
Example 130
^-(a-MethoxybenzyO^-methyl-e^i-IISJ-morpholin^-ylmethyO-IW-i ^.a-triazoM-yOpyrimidine^- carboxamide
Step 1 Preparation of 6-(1-(((S)-4-(((9/-/-fluoren-9-yl)methoxy)carbonyl)morpholιn-2-yl)methyl)-1 H- 1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxylιc acid
Methyl 2-methy!-6-(2-(trιmethylsιlyl)ethynyl)pyrιmιdιne-4-carboxylate (prepared as described in step 4 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1-(((S)-4-acetylmorpholιn-2-yl)methyl)-1H- 1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 129) (200 mg, 0 81 mmol) was dissolved in tetrahydrofuran (0 90 mL), tert-bυtanol (0 90 mL), and water (0 90 mL), and to this mixture was added 2 0 N aqueous lithium hydroxide (423 μL, 0 85 mmol, 1 05 equiv ) In a separate reaction vessel, (9/-/-fluoren-9-yl)methyl (S)-2-((trιfluoromethylsulfonyloxy)methyl)morpholιne-4-carboxylate (prepared as described in step 4 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1 -(((S)-4- acetylmorpholιn-2-yl)methyl)-1/-M ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 129) (380 mg, 0 81 mmol, 1 00 equiv ) and sodium azide (55 mg, 0 85 mmol, 1 05 equiv ) were combined in tetrahydrofuran (0 90 mL), tert-butanol (0 90 mL), and water (0 90 mL) After stirring for 2 hours at room temperature, both crude reaction mixtures were combined into a single reaction vessel To this mixture was added sequentially 1 0 M aqueous sodium ascorbate (81 μL, 0 081 mmol, 0 10 equiv ), and 0 30 M aqueous copper (II) sulfate (54 μL, 0 016 mmol, 0 02 equiv ) After stirring for 15 hours at room temperature, the mixture was diluted with ethyl acetate (4 mL) and washed with 2 0 N aqueous sodium hydroxide (0 5 mL) The layers were separated, the aqueous layer was acidified with 1 0 N aqueous hydrochloric acid (1 2 mL), and extracted with ethyl acetate (3 x 2 mL) and dichloromethane (3 x 2 mL) The organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure to provide the crude title compound as a purple solid (424 mg) that was used in subsequent reactions without further purification LC/MS (10%-90% CH3CN/H2O, 5 mm) 2 60 mm, m/z 527 (M+H)
Step 2 Preparation of (2S)-(9/-/-fluoren-9-yl)methyl 2-((4-(6-((3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-1 /-/-1 ,2,3-trιazol-1-yl)methyl)morpholιne-4-carboxylate
6-(1-(((S)-4-(((9H-Fluoren-9-yl)methoxy)carbonyl)morpholιn-2-yl)methyl)-1 H-1 ,2,3-trιazol-4-yl)- 2-methylpyrιmιdιne-4-carboxylιc acid (200 mg, 0 38 mmol), 3-methoxybenzylamιne (54 μL, 0 42 mmol, 1 10 equiv ), /V,W-diisopropylethylamine (79 μL, 0 42 mmol, 1 20 equiv ), and O-(7-azabenzotπazol-1- yl)-Λ/,Λ/,/\r,Λ/'-tetramethyluronιum hexafluorophosphate (188 mg, 0 49 mmol, 1 30 equiv ) were combined in Λ/,Λ/-dιmethylformamιde (2 5 mL) After stirring for 15 hours at room temperature, the mixture was diluted with ethyl acetate (10 mL), and washed with pH 7 0 aqueous phosphate buffer (3 mL) The layers were separated and the aqueous layer was washed with ethyl acetate (3 x 2 mL) The organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure to give an oily residue Purification by silica gel chromatography (gradient 1 1 heptane/EtOAc to 100% EtOAc) provided the title compound as a white solid (192 mg, 78%) LC/MS (10%-90% CH3CN/H2O, 5 mm) 3 43 mm, m/z 646 (M+H)
Step 3 Preparation of /V-(3-methoxybenzyl)-2-methyl-6-(1-((S)-morpholιn-2-ylmethyl)-1 H-1 ,2,3-trιazol- 4-vQpyrιmιdιne-4-carboxamtde
(2SH9H-Fluoren-9-yl)methyl 2-((4-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)- 1 H-1 ,2,3-trιazol-1 -y!)methyl)morpholιne-4-carboxylate (192 mg, 0 30 mmol) and piperidine (60 μL, 0 60 mmol, 2 0 equiv ) were combined in Λ/,Λ/-dιmethylformamιde (1 2 mL) After stirring for 5 minutes at room temperature, the mixture was concentrated under reduced pressure to afford the crude title compound as an oil that was used in subsequent reactions without further purification LC/MS (10%- 90% CH3CN/H2O, 5 mm) 1 62 mm, m/z 424 (M+H)
Example 131
W-(3-Methoxybenzyl)-6-(1 -(((S)-4-acetylmorpholin-2-yl)methyl)-1 H-1 ,2,3-triazol-4-yl)-2- methylpyrJmidine-4-carboxamide
Λ/-(3-Methoxybenzyl)-2-methyl-6-(1-((S)-morpholιn-2-ylmethyl)-1 H-1 ,2,3-trιazol-4- yl)pyrιmιdιne-4-carboxamιde (prepared as described in Example 130) (63 mg, 0 15 mmol), triethylamine (83 μL, 0 60 mmol, 4 00 equiv ), and acetyl chloride (32 μL, 0 45 mmol, 3 00 equiv ) were combined in dichloromethane (1 5 mL) After stirring for 1 hour at room temperature, methanol (0 5 mL) was added and the mixture was concentrated under reduced pressure to give a salty slurry Purification by silica gel chromatography (gradient 100% EtOAc to 10% MeOH/EtOAc) provided the title compound as an off-white foam (41 mg, 60%) MS (ES+) m/z 466 (M+H) 1H NMR (400 MHz, DMSO-dβ) (J 9 38 (1 H, t, J=6 3 Hz), 8 80 (1 H, d, J=M 3 Hz), 8 34 (1 H1 s), 7 24 (1 H, t, J=Q 1 Hz), 6 89 - 6 98 (2 H, m), 6 82 (1 H, dd, J=B 3, 1 9 Hz), 4 65 - 4 79 (1 H, m), 4 52 - 4 64 (1 H, m), 4 50 (2 H, d, J=Q 2 Hz), 4 21 (1 H, dd, J=86 1 , 12 7 Hz), 3 77 - 3 99 (3 H, m), 3 74 (3 H, s), 3 65 (1 H, d, J=14 3 Hz), 3 33 - 3 51 (1 H, m), 2 94 - 3 21 (1 H1 m), 2 75 (3 H, s), 2 02 (3 H, d, J=1 1 5 Hz)
Example 132
N-(3-Methoxybenzyl)-2-methyl-6-(1 -(((R)-4-(methylsulfonyl)morpholin-2-yl)methyl)-1 H-1 ,2,3- triazol-4-y!)pyrιmidine-4-carboxamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-6-(1-(((S)-4- acetylmorpholιn-2-yl)methyl)-1 H-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde (Example 131 ) by reaction of Λ/-(3-methoxybenzyl)-2-methyl-6-(1-((S)-morpholιn-2-ylmethyl)-1 H-1 ,2, 3-trιazol-4- yl)pyπmιdιne-4-carboxamιde (prepared as described in Example 130) (63 mg, 0 15 mmol), triethylamine (83 μL, 0 60 mmol, 4 00 equiv ), and methanesulfonyl chloride (34 μL, 0 45 mmol, 3 00 equiv ) to afford the title compound as an off-white foam (48 mg, 65%) MS (ES+) m/z 502 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ 9 38 (1 H, t, J=6 4 Hz), 8 84 (1 H, s), 8 34 (1 H, s), 7 24 (1 H, t, J=8 1 Hz), 6 88 - 6 98 (2 H, m), 6 82 (1 H, dd, J=Q 2, 2 0 Hz), 4 68 - 4 76 (1 H, m), 4 55 - 4 65 (1 H, m), 4 50 (2 H, d, J=6 2 Hz), 3 98 - 4 08 (1 H1 m), 3 95 (1 H, d, J=11 0 Hz), 3 74 (3 H, s), 3 48 - 3 63 (2 H, m), 3 32 - 3 40 (1 H, m), 2 92 (3 H, s), 2 80 - 2 90 (1 H, m), 2 75 (3 H, s), 2 68 (1 H, dd, .7=1 1 4, 10 2 Hz)
Example 133
W-(3-Methoxybenzyl)-6-(1 -(((2S,5R)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-1 W-1 ,2,3-triazol-4- yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of methyl 2-methyl-6-(1-(((2S.5S)-5-((tosyloxy)methyl)-1 ,4-dιoxan-2-yl)methyl)-1 H- 1.2.3-trιazol-4-yl)pyrιmιdιne-4-carboxylate
Methyl 2-methyl-6-(2-(trιmethylsιlyl)ethynyl)pyrιmιdιne-4-carboxylate (prepared as described in step 4 of the synthesis of /V-(4-fluoro-3-methoxybenzyl)-6-(1-(((S)-4-acetylmorpholin-2-yl)methyl)-1 H- 1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 129) (30 mg, 0 12 mmol) was dissolved in tetrahydrofuran (0 20 mL), terf-butanol (0 20 mL), and water (0 20 mL), and to this mixture was added potassium fluoride (7 mg, 0 12 mmol, 1 00 equiv ) In a separate reaction vessel, ((2S,5f?)-5- ((trιfluoromethy!sulfonyloxy)methyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 5 of the synthesis of /V-(4-fluoro-3-methoxybenzyl)-6-(1 -(((2S,5R)-5-(hydroxymethyl)- 1 ,4-dιoxan-2-yl)methyl)-1 H- 1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 128) (50 mg, 0 12 mmol, 1 00 equiv ) and sodium azide (8 mg, 0 12 mmol, 1 00 equiv ) were combined in tetrahydrofuran (0 2 mL), tert-butanol (0 2 mL), and water (0 2 mL) After stirring for 1 hour at room temperature, both crude reaction mixtures were combined into a single reaction vessel To this mixture was added sequentially 1 0 M aqueous sodium ascorbate (12 μt, 0 012 mmol, 0 10 equiv ), and 0 30 M aqueous copper (II) sulfate (8 μL, 0 002 mmol, 0 02 equiv ) After stirring for 15 hours at room temperature, the mixture was diluted with ethyl acetate (4 mL) and washed with saturated aqueous sodium chloride (1 mL) The layers were separated and the aqueous layer was washed with ethyl acetate (2 mL) The organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure to provide an orange oil Purification by silica gel chromatography (gradient 1 1 heptane/EtOAc to 100% EtOAc) provided the title compound as a yellow solid (59 mg, >95%) LC/MS (10%-90% CH3CN/H2O, 5 mm) 2 50 mm, m/z 504 (M+H) Step 2 Preparation of 2-methyl-6-(1-(((2S,5S)-5-(((osyloxy)methyl)-1 ,4-dιoxan-2-yl)methyl)-1H-1 , 2, 3- triazol^-vDpyrimidine^-carboxylic acid
Methyl 2-methyl-6-(1-(((2S,5S)-5-((tosyloxy)methyl)-1 ,4-dιoxan-2-yl)methy!)-1 H-1 ,2,3-trιazol-4- yl)pyrιmιdιne-4-carboxy!ate (59 mg, 0 12 mmol) was dissolved in tetrahydrofuran (0 80 mL), and water (0 40 mL), and to this mixture was added 2 0 N aqueous lithium hydroxide (65 μL, 0 13 mmol, 1 08 equiv ) After stirring for 5 minutes at room temperature, the solution was neutralized with 1 0 N aqueous hydrochloric acid (130 μL, 0 13 mmol, 1 08 equiv ) The mixture was concentrated under reduced pressure, the residue was dissolved in ethyl acetate (4 mL) and methanol (2 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to afford the crude title compound as an orange solid (57 mg) that was used in subsequent reactions without further purification LC/MS (10%-90% CH3CN/H2O, 5 mm) 2 13 mm, m/z 490 (M+H)
Step 3 Preparation of ((2S,5S)-5-((4-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-1 /-/- 1 ,2,3-trιazol-1 -yl)methyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate
2-Methyl-6-(1 -(((2S,5S)-5-((tosyloxy)methyl)-1 ,4-dιoxan-2-yl)methyl)-1 H-1 ,2,3-trιazol-4- yl)pyrιmιdιne-4-carboxylιc acid (108 mg, 0 22 mmol), 3-methoxybenzylamιne (30 μL, 0 23 mmol, 1 05 equiv ), Λ/,Λ/-dιιsopropylethylamιne (40 μL, 0 23 mmol, 1 05 equiv ), and O-(7-azabenzotrιazol-1-yl)- Λ/,Λ/,Λ/',/V-tetramethyluronιum hexafluorophosphate (88 mg, 0 23 mmol, 1 05 equiv ) were combined in Λ/,Λ/-dιmethylformamιde (1 5 mL) After stirring for 15 hours at room temperature, the mixture was diluted with ethyl acetate (10 mL) and washed with 10% aqueous sodium bisulfate (3 mL) The layers were separated and the aqueous layer was washed with ethyl acetate (3 x 2 mL) The organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure to give an oily residue Purification by silica gel chromatography (gradient 1 2 heptane/EtOAc to 100% EtOAc to 10% MeOH/EtOAc) provided the title compound as a white solid (131 mg, >95%) LC/MS (10%- 90% CH3CN/H2O, 5 mm) 3 02 mm, m/z 609 (M+H) Step 4 Preparation of A7-(3-methoxybenzyl)-6-(1 -(((2S,5ff)-5-(hvdroxymethyl)-1.4-dιoxan-2-yl)methyl)- 1 H- 1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde
The title compound was prepared in a similar manner to Λ/-(4-fluoro-3-methoxybenzyl)-6-(1 - (((2S,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-1 H-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4- carboxamide (step 7, Example 128) by reaction of ((2S,5S)-5-((4-(6-((3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-1 H-1 ,2,3-tπazol-1-yl)methyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (131 g, 0 22 mmol), tetrabutylammonium acetate (71 mg, 0 24 mmol, 1 10 equiv ), and 1 0 N aqueous sodium hydroxide (260 μL, 0 26 mmol, 1 20 equiv ) Purification by silica gel chromatography (gradient 100% EtOAc to 10% MeOH/EtOAc) provided the title compound as a white solid (50 mg, 51 %) MS (ES+) m/z 455 (M+H) 1H NMR (400 MHz, DMSOd6) δ 9 38 (1 H, t, J=6 4 Hz), 8 80 (1 H1 s), 8 33 (1 H, s), 7 24 (1 H, t, J=S 1 Hz), 6 88 - 6 99 (2 H, m), 6 82 (1 H, dd, J=8 1 , 2 0 Hz), 4 67 (1 H, t, J=5 6 Hz), 4 55 - 4 63 (1 H, m), 4 43 - 4 54 (3 H1 m), 3 87 - 4 01 (2 H, m), 3 77 - 3 85 (1 H, m), 3 74 (3 H1 s), 3 32 - 3 47 (4 H, m), 2 75 (3 H1 s)
Example 134
W^-Fluoro-S-methoxybenzylJ-e^i^^fransJ^-aminocyclohβxyOmethyO-I H-I .Σ.S-triazol^-yO-Σ- methylpyrimidine-4-carboxamide
Step 1 Preparation of ((fransM-ftert-butoxycarbonvOcvclohexyQmethyl 2.2.2-trιfluoroethanesulfonate
Commercially available tert-butyl fraπs-4-(hydroxymethyl)cyclohexylcarbamate (2 00 g, 8 72 mmol), 2,2,2-trιfluoroethanesulfonyl chloride (1 2 mL, 11 0 mmol, 1 20 equiv ), and N1N- dnsopropylethylamine (2 0 mL, 11 0 mmol, 1 20 equiv ) were combined in dichloromethane (35 mL) After stirring for 1 hour at 0 0C, the mixture was concentrated under reduced pressure, and the salty residue was partitioned between ethyl acetate (100 mL) and 1 0 N aqueous hydrochloric acid (20 mL) The layers were separated and the organic layer was washed with 1 0 N aqueous hydrochloric acid (10 mL), saturated aqueous sodium bicarbonate (20 mL), and brine (20 mL) The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure Purification by recrystallization (1 2 heptane/EtOAc) provided the title compound as a white needles (2 29 g, 70%) 1H NMR (400 MHz, CDCI3) δ 4 40 (1 H, br s ), 4 15 (2 H, d, J=6 5 Hz), 3 89 (2 H, q, J=S 7 Hz), 3 40 (1 H, br s ), 1 98 - 2 16 (2 H, m), 1 80 - 1 93 (2 H, m), 1 66 - 1 79 (1 H, m), 1 44 (9 H, s), 1 05 - 1 20 (4 H, m)
Step 2 Preparation of /ert-butyl (fransM-((4-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-1/-/-1 ,2,3-trιazol-1 -yl)methyl)cvclohexylcarbamate
((/raπs)-4-(fert-Butoxycarbonyl)cyclohexyl)methyl 2,2,2-trιfluoroethanesulfonate (450 mg, 1 20 mmol) and sodium azide (80 mg, 1 22 mmol, 1 02 equiv ) were combined in Λ/,Λ/-dιmethylformamιde (1 0 mL) After stirring for 18 hours at room temperature, the reaction vessel was charged sequentially with Λ/,/V-dιmethylformamιde (3 0 mL), water (1 0 mL), Λ/-(4-fluoro-3-methoxybenzyl)-6-ethynyl-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in step 4 of the synthesis of /V-(4-fluoro-3- methoxybenzyl)-6-(1-(((2S,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-1 H-1 ,2,3-trιazol-4-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 128) (305 mg, 1 20 mmol, 1 00 equiv ), 1 0 M aqueous sodium ascorbate (120 μl, 0 12 mmol, 0 10 equiv ), and 0 30 M aqueous copper (II) sulfate (80 μL, 0 024 mmol, 0 02 equiv ) After stirring for 23 hours at room temperature, to the reaction mixture was added sequentially Λ/,Λ/-dιmethylformamιde (2 0 mL), 1 0 M aqueous sodium ascorbate (120 μL, 0 12 mmol, 0 10 equiv ), and 0 30 M aqueous copper (II) sulfate (80 μl, 0 024 mmol, 0 02 equiv ) After stirring for 6 hours at room temperature, the mixture was poured with vigorous stirring into ice-cold water (150 mL) The precipitate was collected by suction filtration, washed with water (3x), dissolved in ethyl acetate, dried over sodium sulfate, filtered, and concentrated under reduced pressure The reddish-orange amorphous solid was dissolved in 5% methanol/ethyl acetate, filtered through a short pad of silica, and concentrated under reduced pressure Purification by recrystallization (2 3 heptane/EtOAc) provided the title compound as a pale orange solid (504 mg, 76%) LC/MS (5%- 100% CH3CN/H2O, 5 mm) 3 71 mm, m/z 554 (M+H) Step 3 Preparation of /V-(4-f1uoro-3-methoxybenzyl)-6-(1 -(((frans)-4-aminocvclohexyl)methyl)-1 /-/- 1.2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde
tert-Butyl (<rans)-4-((4-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpynmidin-4-yl)-1 H- 1 ,2,3-tnazol-1 -yl)methyl)cyclohexylcarbamate (497 mg, 0 90 mmol) and 4 0 N hydrochloric acid in 1 ,4- dioxane (3 6 mL, 14 4 mmol, 16 0 equiv ) were combined in 1 ,4-dιoxane (4 0 mL) After stirring for 18 hours at room temperature, the mixture was concentrated under reduced pressure The residue was dissolved in methanol, concentrated under reduced pressure, and dried under high vacuum to afford the hydrochloride salt form of title compound as a white solid (440 mg, >95%) that was used in subsequent reactions without further purification LC/MS (5%-100% CH3CN/H2O, 5 mm) 2 74 mm, m/z 454 (M+H)
Example 135
W-(4-Fluoro-3-methoxybenzyl)-6-(1 -((((ransJ^-acetamidocyclohexylJmethyO-i H-1 ,2,3-triazol-4- yl)-2-methylpyrimidine-4-carboxamide
The hydrochloride salt form of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1-(((frar?s)-4-amιnocyclohexyl)- methyl)-1H-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 134) (440 mg, 0 90 mmol), triethylamine (376 μl, 2 70 mmol, 3 00 equiv ), and acetyl chloride (77 μL, 1 08 mmol, 1 20 equiv ) were combined in dichloromethane (5 0 mL) After stirring for 1 hour at room temperature, methanol (2 mL) was added and the mixture was diluted with dichloromethane (20 mL) and water (5 mL) The layers were separated and the organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure Purification by silica gel chromatography (gradient 100% EtOAc to 20% MeOH/EtOAc) provided the title compound as a white solid (353 mg, 79%) LC/MS (5%-100% CH3CN/H2O, 5 mm) 3 17 mm, m/z 496 (M+H) 1H NMR (400 MHz, DMSO-d6) δ 9 46 (1 H, t, J=Q 4 Hz), 8 90 (1 H, s), 8 33 (1 H, s), 7 71 (1 H, d, J=I 9 Hz), 7 10 - 7 23 (2 H, m), 6 84 - 6 95 (1 H, m), 4 49 (2 H, d, J=Q 3 Hz), 4 33 (2 H, d, J=I 2 Hz), 3 82 (3 H, s), 2 75 (3 H, s), 1 82 - 1 94 (1 H, m), 1 75 - 1 82 (2 H1 m), 1 75 (3 H, s), 1 47 - 1 63 (2 H, m), 1 00 - 1 18 (4 H, m)
Example 136
/V-(4-Fluoro-3-methoxybenzyl)-6-(1 -(((frans)-4-(2-hydroxyacetamido)cyclohexyl)methyl)-1 H- 1 ,2,3-triazol-4-yl)-2-methylpyrimidine-4-carboxamide
The hydrochloride salt form of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1 -(((frans)-4-amιnocyclohexyl)- methyl)-1H-1 ,2,3-tπazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde (prepared as described Example 134) (224 mg, 0 46 mmol), triethylamine (160 μL, 1 14 mmol, 2 50 equiv ), and 2-acetoxyacetyl chloride (59 μL, 0 55 mmol, 1 20 equiv ) were combined in dichloromethane (10 mL) After stirring for 1 hour at room temperature, the mixture was concentrated under reduced pressure To the salty residue were added sequentially tetrahydrofuran (4 0 mL) and 2 0 N aqueous lithium hydroxide (2 0 mL, 4 00 mmol, 8 70 equiv ) After stirring for 1 hour at room temperature, the mixture was diluted with ethyl acetate (20 mL) and water (5 mL) The layers were separated and the organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure Purification by silica gel chromatography (gradient 100% EtOAc to 10% MeOH/EtOAc) provided the title compound as a white solid (185 mg, 81 %) MS (ES+) m/z 512 (M+H) 1H NMR (400 MHz, DMSO-d6) δ 9 47 (1 H, t, J=6 3 Hz), 8 90 (1 H, s), 8 33 (1 H, s), 7 47 (1 H, d, J=8 2 Hz), 7 1 1 - 7 21 (2 H, m), 6 90 (1 H, ddd), 5 41 (1 H, t, J=5 8 Hz), 4 49 (2 H, d, J=6 4 Hz), 4 34 (2 H, d, J=I 1 Hz), 3 82 (3 H, s), 3 75 (2 H, d, J=5 7 Hz), 3 48 - 3 64 (1 H, m), 2 74 (3 H, s), 1 80 - 1 98 (1 H, m), 1 73 (2 H, d, J= 11 2 Hz), 1 56 (2 H, d, J= 1 1 9 Hz), 1 19 - 1 36 (2 H, m), 1 00 - 1 19 (2 H, m)
Example 137
N-(4-Fluoro-3-methoxybenzyl)-6-(1 -(((1 R,3S)-3-aminocyclopentyl)methyl)-1 H-1 ,2,3-triazol-4-yl)-2- methylpyrimidine-4-carboxamide
Step 1 Preparation of ((1 f?,3S)-3-(/eff-butoxycarbonyl)cvclopentyl)methyl 2,2,2- tnfluoroethanesulfonate terf-Butyl (1 S,3f?)-3-(hydroxymethyl)cyclopentylcarbamate (prepared from commercially available 1-(R)-( — )-2-azabιcyclo[2 2 1]hept-5-en-3-one according to the method described by Shuto and coworkers, see Kudoh, T et al J Am Chem Soc 2005, 127, 8846-8855) (150 mg, 0 70 mmol), 2,2,2-trιfluoroethanesulfonyl chloride (82 μL, 0 73 mmol, 1 05 equiv ), and Λ/,/V-dιιsopropylethylamιne (140 μL, 0 80 mmol, 1 15 equiv ) were combined in dichloromethane (3 0 mL) After stirring for 30 minutes at 0 0C, the mixture was diluted with dichloromethane (15 mL) and 10% aqueous sodium bisulfate (5 mL) The layers were separated and the aqueous layer was washed with dichloromethane (1 x) The organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure Purification by silica gel chromatography (gradient 4 1 heptane/EtOAc to 2 1 heptane/EtOAc) provided the title compound as a white solid (206 mg, 82%) 1H NMR (400 MHz, CDCI3) δ 4 50 (1 H, br s ), 4 28 (2 H, d, J=6 4 Hz), 3 97 (1 H, br s ), 3 90 (2 H, q, J=8 8 Hz), 2 33 - 2 46 (1 H, m), 2 20 - 2 32 (1 H, m), 1 95 - 2 09 (1 H, m), 1 77 - 1 91 (1 H, m), 1 46 - 1 58 (2 H, m), 1 45 (9 H, s), 1 10 - 1 23 (1 H, m)
Step 2 Preparation of terf-butyl (1 S,3ff)-3-(azιdomethyl)cvclopentylcarbamate ((1 R,3S)-3-(fert-Butoxycarbonyl)cyclopentyl)methyl 2,2,2-trιfluoroethanesulfonate (125 mg,
0 35 mmol) and sodium azide (35 mg, 0 54 mmol, 1 54 equiv ) were combined in N1N- dimethylformamide (0 90 mL) After stirring for 1 hour at 60 0C, the mixture was cooled to room temperature and diluted with ethyl acetate (10 mL) and 50% aqueous sodium chloride (2 mL) The layers were separated and the aqueous layer was washed with ethyl acetate (3 x 1 mL) The organic layers were combined, dried over sodium sulfate, filtered, and concentrated under reduced pressure Purification by silica gel chromatography (gradient 4 1 heptane/EtOAc to 2 1 heptane/EtOAc) provided the title compound as a colorless oil (83 mg, >95%)
Step 3 Preparation of tert-butyl (1 S,3R)-3-((4-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-
tert-Butyl (I S.S^-S^azidomethyOcyclopentylcarbamate (75 mg, 0 31 mmol), Λ/-(4-fluoro-3- methoxybenzyl)-6-ethynyl-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in step 4 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1-(((2S,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)- 1 H-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 128) (93 mg, 0 31 mmol, 1 00 equiv ), 1 0 M aqueous sodium ascorbate (31 μL, 0 031 mmol, 0 10 equiv ), and 0 30 M aqueous copper (II) sulfate (20 μL, 0 006 mmol, 0 02 equiv ) were combined in tetrahydrofuran (0 50 mL), tert- butanol (0 50 mL), and water (0 50 mL) After stirring for 15 hours at room temperature, the mixture was diluted with ethyl acetate (10 mL) and saturated aqueous sodium chloride (2 mL) The layers were separated and the aqueous layer was washed with ethyl acetate (3 x 1 mL) The organic layers were combined, dried over sodium sulfate, filtered, and concentrated under reduced pressure Purification by silica gel chromatography (gradient 4 1 heptane/EtOAc to 100% EtOAc) provided the title compound as an off-white solid (136 mg, 81%) LC/MS (5%-100% CH3CN/H2O, 5 mm) 3 78 mm, m/z 484 (M - 2-Me-propene + H)
Step 4 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1 -(((1 ff,3S)-3-amιnocvclopentyl)methyl)-1 H- 1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde
tert-Butyl (1 S,3R)-3-((4-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-1 H- 1 ,2,3-triazol-1 -yl)methyl)cyclopentylcarbamate (136 mg, 0 25 mmol) was dissolved in 4 0 N hydrochloric acid in methanol (1 5 mL, 6 00 mmol, 24 2 equiv ) After stirring for 18 hours at room temperature, the mixture was concentrated under reduced pressure The residue was dissolved in methanol, concentrated under reduced pressure, and dried under high vacuum to afford the hydrochloride salt form of title compound as a white solid (1 18 mg, >95%) that was used in subsequent reactions without further purification LC/MS (5%-100% CH3CN/H2O, 5 mm) 2 73 mm, m/z 440 (M+H)
Example 138
N-(4-Fluoro-3-methoxybenzyl)-6-(1-(((1R,3S)-3-acetamidocyclopentyl)methyl)-1H-1 ,2,3-triazol-4- yl)-2-methylpyrimidine-4-carboxamide
The title compound was prepared in a similar manner to /V-(3-methoxybenzyl)-6-(1 -(((S)-4- acetylmorpholιn-2-yl)methyl)-1 H- 1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde (Example 131 ) by reaction of the hydrochloride salt form of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1-(((1f?,3S)-3- (prepared as described in Example 137) (39 mg, 0 089 mmol), triethylamine (35 μl, 0 25 mmol, 2 80 equiv ), and acetyl chloride (15 μL, 0 21 mmol, 2 40 equiv ) Purification by silica gel chromatography (gradient 100% EtOAc to 10% MeOH/EtOAc) provided the title compound as a light yellow foam (27 mg, 63%) MS (ES+) m/z 482 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ 9 39 (1 H, t, J=Q 2 Hz), 8 89 (1 H, s), 8 34 (1 H, s), 7 81 (1 H, d, J=I 3 Hz), 7 18 (1 H, dd, J=8 6, 1 6 Hz), 7 14 (1 H, dd, .7=12 0, 8 5 Hz), 6 85 - 6 96 (1 H, m), 4 50 (2 H, d, J=Q 2 Hz), 4 46 (2 H, d, J=I 3 Hz), 3 92 - 4 05 (1 H, m), 3 83 (3 H, s), 2 75 (3 H, s), 1 91 - 2 01 (1 H, m), 1 78 - 1 88 (1 H, m), 1 76 (3 H, s), 1 57 - 1 70 (1 H, m), 1 37 - 1 54 (2 H, m), 1 07 - 1 22 (1 H, m)
Example 139 W-(4-fluoro-3-methoxybenzyl)-6-(1 -(((1 /?,3S)-3-(2-hydroxyacetamido)cyclopentyl)methyl)-1 H-
1 ,2,3-triazol-4-yl)-2-methylpyrimidine-4-carboxamide
The title compound was prepared in a similar manner to /V-(4-fluoro-3-methoxybenzyl)-6-(1 - (((/rans)-4-(2-hydroxyacetamιdo)cyclohexyl)methyl)-1 /-/-1 ,2,3-trιazol-4-yl)-2-methylpyπmιdιne-4- carboxamide (Example 136) by reaction of the hydrochloride salt form of Λ/-(4-fluoro-3- methoxybenzyl)-6-(1-(((1 R,3S)-3-amιnocyclopentyl)methyl)-1 /-/-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne- 4-carboxamιde (prepared as described in Example 137) (39 mg, 0 089 mmol), triethylamine (35 μL, 0 25 mmol, 2 80 equiv ), 2-acetoxyacetyl chloride (20 μL, 0 19 mmol, 2 10 equiv ), and 2 0 N aqueous lithium hydroxide (0 45 mL, 0 89 mmol, 10 0 equiv ) Purification by silica gel chromatography (gradient 100% EtOAc to 10% MeOH/EtOAc) provided the title compound as a light yellow foam (25 mg, 56%) MS (ES+) m/z 498 (M+H) 1H NMR (400 MHz, DMSO-d6) δ 9 39 (1 H, t, J=Q 2 Hz), 8 89 (1 H, s), 8 34 (1 H, s), 7 61 (1 H, d, J=I 5 Hz), 7 18 (1 H, dd, J=Q 6, 1 5 Hz), 7 14 (1 H, dd, J=1 1 6, 8 3 Hz), 6 82 - 6 96 (1 H, m), 5 31 (1 H, t, J=5 9 Hz), 4 50 (2 H, d, J=Q 4 Hz), 4 46 (2 H, dd, J=I 0, 2 1 Hz), 4 02 - 4 16 (1 H, m), 3 82 (3 H, s), 3 77 (2 H, d, J=5 9 Hz), 2 75 (3 H, s), 1 90 - 2 01 (1 H, m), 1 75 - 1 90 (1 H, m), 1 42 - 1 70 (4 H, m), 1 21 - 1 35 (1 H, m)
Example 140
W-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(1 -(((1 f?,3S)-3- (methylsulfonamidoJcyclopentyOmethyO-IH-i ^jS-triazoM-yOpyrimidine^-carboxamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-6-(1 -(((S)-4- acetylmorpholιn-2-yl)methyl)-1 /-/-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde (Example 131 ) by reaction of the hydrochloride salt form of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1 -(((1 R,3S)-3- amιnocyclopentyl)methyl)-1 H- 1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 137) (39 mg, 0 089 mmol), triethylamine (35 μL, 0 25 mmol, 2 80 equiv ), and methanesulfonyl chloride (15 μL, 0 19 mmol, 2 10 equiv ) Purification by silica gel chromatography (gradient 100% EtOAc to 10% MeOH/EtOAc) provided the title compound as a light yellow foam (33 mg, 72%) MS (ES+) m/z 518 (M+H) 1H NMR (400 MHz, DMSO-d6) δ 9 39 (1 H, t, J=Q 5 Hz), 8 89 (1 H, s), 8 34 (1 H, s), 7 18 (1 H, dd, J=Q 6, 1 6 Hz), 7 1 1 - 7 17 (1 H, m), 7 09 (1 H, d, J=I 3 Hz), 6 83 - 6 96 (1 H, m), 4 50 (2 H, d, J=Q 2 Hz), 4 45 (2 H, d, J=I 3 Hz), 3 82 (3 H, s), 3 51 - 3 71 (1 H, m), 2 88 (3 H, s), 2 75 (3 H, s), 1 97 - 2 09 (1 H, m), 1 82 - 1 96 (1 H, m), 1 35 - 1 72 (4 H, m), 1 19 - 1 34 (1 H, m)
Example 141
/V-(4-Fluoro-3-methoxybenzyl)-6-(1 -(((1 S,3R)-3-aminocyclopentyl)methyl)-1 H-1 ,2,3-triazol-4-yl)-2- methylpyrimidine-4-carboxamide
Step 1 Preparation of ((I S.Sffϊ-S-^ert-butoxycarbonvOcyclopentvDmethyl methanesulfonate tert-Butyl (1 R,3S)-3-(hydroxymethyl)cyclopentylcarbamate (prepared from commercially available 1 -(S)-(+)-2-azabιcyclo[2 2 1]hept-5-en-3-one according to the method described by Shuto and coworkers, see Kudoh, T et al J Am Chem. Soc 2005, 127, 8846-8855) (250 mg, 1 16 mmol), methanesulfonyl chloride (108 μL, 1 39 mmol, 1 20 equiv ), and Λ/,Λ/-dιιsopropylethylamιne (263 μL, 1 51 mmol, 1 30 equiv ) were combined in dichloromethane (5 0 mL) After stirring for 30 minutes at 0 0C, the mixture was diluted with dichloromethane (15 mL) and 10% aqueous sodium bisulfate (5 mL) The layers were separated and the aqueous layer was washed with dichloromethane (3 x 2 mL) The organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure to afford the title compound as an off-white solid (341 mg, >95%)
Step 2 Preparation of terf-butyl (1 R,3S)-3-(azιdomethyl)cvclopentylcarbamate ((1 S,3R)-3-(^erf-Butoxycarbonyl)cyclopentyl)methyl methanesulfonate (100 mg, 0 34 mmol) and sodium azide (69 mg, 1 07 mmol, 3 15 equiv ) were combined in Λ/,Λ/-dιmethylformamιde (0 60 mL) After stirring for 15 hours at 50 0C, the mixture was cooled to room temperature, diluted with ethyl acetate (10 mL), and washed with water (3 x 2 mL) The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure Purification by silica gel chromatography (gradient 4 1 heptane/EtOAc to 2 1 heptane/EtOAc) provided the crude title compound as a pale orange oil (82 mg, >95%) that was used in subsequent reactions without further purification
Step 3 Preparation of tert-butyl (1 f?,3S)-3-((4-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-1 /-/-1 ,2,3-trιazol-1 -yl)methyl)cvclopentylcarbamate
The title compound was prepared in a similar manner to tert-butyl (1 S,3R)-3-((4-(6-((4-fluoro-
3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-1 /-M ,2,3-trιazol-1 - yl)methyl)cyclopentylcarbamate (step 3, Example 137) by the reaction of tert-butyl (1 R,3S)-3- (azιdomethyl)cyclopentylcarbamate (82 mg, 0 34 mmol), /V-(4-fluoro-3-methoxybenzyl)-6-ethynyl-2- methylpyrιmιdιne-4-carboxamιde (prepared as described in step 4 of the synthesis of Λ/-(4-fluoro-3- methoxybenzy!)-6-(1 -(((2S,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-1 H-1 ,2,3-trιazol-4-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 128) (102 mg, 0 34 mmol, 1 00 equiv ), 1 0 M aqueous sodium ascorbate (34 μL, 0 034 mmol, 0 10 equiv ), and 0 30 M aqueous copper (II) sulfate (23 μL, 0 007 mmol, 0 02 equiv ) to afford title compound as a light yellow foam (128 mg, 70%) LC/MS (5%- 100% CH3CN/H2O, 5 mm) 3 78 mm, m/z 484 (M - 2-Me-propene + H) Step 4 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1 -(((1 S.3f?)-3-amιnocvclopentyl)methyl)-1 /-/- 1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde
The title compound was prepared in a similar manner to /V-(4-fluoro-3-methoxybenzyl)-6-(1 - (((1 R,3S)-3-amιnocyclopentyl)methyl)-1 H-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde (step 4, Example 137) by the reaction of tert-butyl (1 R,3S)-3-((4-(6-((4-fluoro-3-methoxybenzyl Carbamoyl )-2- methylpyπmιdιn-4-yl)-1 H-1 ,2,3-trιazol-1-yl)methyl)cyclopentylcarbamate (128 mg, 0 24 mmol) and 4 0 N hydrochloric acid in methanol (1 5 mL, 6 00 mmol, 25 Oequiv ) to afford the hydrochloride salt form of title compound as a white solid (1 14 mg, >95%) that was used in subsequent reactions without further purification LC/MS (5%-100% CH3CN/H2O, 5 mm) 2 73 mm, m/z 440 (M+H)
Example 142
/V-(4-Fluoro-3-methoxybenzyl)-6-(1 -(((1 S,3/?)-3-acetamidocyclopentyl)methyl)-1 H-1 ,2,3-triazol-4- yl)-2-methylpyrimidine-4-carboxamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-6-(1-(((S)-4- acetylmorpholιn-2-yl)methyl)-1 H- 1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde (Example 131 ) by reaction of the hydrochloride salt form of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1 -(((1 S,3/?)-3- aminocyclopentyOmethyO-I H-I .Σ.S-tπazoM-yl^-methylpyπmidine^-carboxamide (prepared as described in Example 141 ) (38 mg, 0 079 mmol), triethylamine (35 μL, 0 25 mmol, 3 16 equiv ), and acetyl chloride (1 1 μL, 0 16 mmol, 2 02 equiv ) Purification by reverse phase HPLC provided the title compound as a white solid (15 mg, 39%) MS (ES+) m/z 482 (M+H) 1H NMR (400 MHz, DMSO-Cy6) δ 9 39 (1 H, t, J=Q 2 Hz), 8 89 (1 H, s), 8 34 (1 H, s), 7 81 (1 H, d, J=I 0 Hz), 7 18 (1 H, dd, J=Q 5, 1 6 Hz), 7 14 (1 H, dd, J= 1 1 6, 8 3 Hz), 6 84 - 6 95 (1 H, m), 4 50 (2 H, d, J=Q 4 Hz), 4 45 (2 H, d, J=I 1 Hz), 3 91 - 4 05 (1 H, m), 3 82 (3 H, s), 2 75 (3 H, s), 1 90 - 2 02 (1 H, m), 1 78 - 1 88 (1 H, m), 1 76 (3 H, s), 1 57 - 1 70 (1 H, m), 1 37 - 1 53 (2 H, m), 1 09 - 1 21 (1 H, m)
Example 143
/V-(4-Fluoro-3-methoxybenzyl)-6-(1 -(((1 S,3R)-3-(2-hydroxyacetamido)cyclopentyl)methyl)-1 H- 1 ,2,3-triazol-4-yl)-2-methylpyrimidine-4-carboxamide
The title compound was prepared in a similar manner to Λ/-(4-fluoro-3-methoxybenzyl)-6-(1- (((/Λans)-4-(2-hydroxyacetamιdo)cyclohexyl)methyl)-1 /-/-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4- carboxamide (Example 136) by reaction of the hydrochloride salt form of Λ/-(4-fluoro-3- methoxybenzyl)-6-(1 -(((1 S,3R)-3-amιnocyc!opentyl)methyl)-1 H-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne- 4-carboxamιde (prepared as described in Example 141 ) (38 mg, 0 079 mmol), triethylamine (35 μL,
0 25 mmol, 3 16 equiv ), 2-acetoxyacetyl chloride (17 μL, 0 16 mmol, 2 02 equiv ), and 2 0 N aqueous lithium hydroxide (0 40 mL, 0 80 mmol, 10 1 equiv ) Purification by reverse phase HPLC provided the title compound as a white solid (16 mg, 41 %) MS (ES+) m/z 498 (M+H) 1H NMR (400 MHz, DMSO- dβ) δ 9 39 (1 H, t, J=Q 4 Hz), 8 89 (1 H, s), 8 34 (1 H, s), 7 61 (1 H, d, J=I 7 Hz), 7 18 (1 H, dd, J=8 5,
19 Hz), 714(1 H, dd, J=116, 83 Hz), 687 - 696 (1 H, m), 532 (1 H, t, J=57 Hz), 450 (2 H, d, J=Q 2 Hz), 439 - 448 (2 H, m), 404 - 416 (1 H, m), 382 (3 H, s), 377 (2 H, d, J=59 Hz), 275 (3 H, s), 190 - 203 (1 H, m), 177 - 190 (1 H, m), 141 - 170 (4 H, m), 121 - 135 (1 H, m)
Example 144 N-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(1-(((1S,3f?)-3-
(methylsulfonamido)cyclopentyl)methyl)-1H-1,2,3-triazol-4-yl)pyrimidine-4-carboxamide
The title compound was prepared in a similar manner to /V-(3-methoxybenzyl)-6-(1 -(((S)-4- acetylmorpholιn-2-yl)methyl)-1 /-/-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde (Example 131 ) by reaction of the hydrochloride salt form of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1 -(((1 S,3R)-3- amιnocyclopentyl)methyl)-1 H- 1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 141 ) (38 mg, 0 079 mmol), triethylamine (35 μL, 0 25 mmol, 3 16 equiv ), and methanesulfonyl chloride (12 μL, 0 16 mmol, 2 02 equiv ) Purification by reverse phase HPLC provided the title compound as a white solid (12 mg, 29%) MS (ES+) m/z 518 (M+H) 1H NMR (400 MHz, DMSO-ds) δ 9 38 (1 H, t, J=Q 3 Hz), 8 89 (1 H, s), 8 33 (1 H, s), 7 18 (1 H, dd, J=Q 4, 1 8 Hz), 7 13 (1 H, dd, J=1 1 7, 8 4 Hz), 7 09 (1 H, d, J=I 1 Hz), 6 86 - 6 95 (1 H, m), 4 49 (2 H, d, J=Q 2 Hz), 4 45 (2 H, d, J=I 3 Hz), 3 82 (3 H, s), 3 56 - 3 70 (1 H, m), 2 87 (3 H, s), 2 74 (3 H, s), 1 97 - 2 09 (1 H, m), 1 83 - 1 95 (1 H, m), 1 39 - 1 69 (3 H, m), 1 20 - 1 33 (1 H, m)
Example 145 6-(1 -(((S)-1 ,4-Dioxan-2-yl)methyl)-1 H-1 ,2,3-triazol-4-yl)-/V-(4-f luoro-3-methoxybenzyl)-2- methylpyrimidine-4-carboxamide
Step 1 Preparation of (R)-C\ ,4-dιoxan-2-vl)methvl tπfluoromethanesulfonate
The title compound was prepared in a similar manner to ((2S,5R)-5- ((trιfluoromethylsulfonyloxy)methyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (step 5, Example 128) by reaction of (S)-(1 , 4-dιoxan-2-y!)methanol (prepared as described in step 1 of the synthesis of 6-(2-(((S)- 1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-Λ/-(3-methoxybenzyl)-2- methylpyrιmιdιne-4-carboxamιde, Example 57) (100 mg, 0 85 mmol), pyridine (72 μL, 0 89 mmol, 1 05 equiv ), and trifluoromethanesulfonic anhydride (150 μL, 0 89 mmol, 1 05 equiv ) to afford the title compound as a tan oil (185 mg, 87%) 1H NMR (400 MHz, CDCI3) δ 4 40 - 4 54 (2 H, m), 3 90 - 3 97 (1 H, m), 3 72 - 3 90 (4 H, m), 3 59 - 3 70 (1 H, m), 3 48 (1 H, dd, J=11 4, 10 0 Hz)
Step 2 Preparation of 6-(1 -(((S)-1 ,4-dιoxan-2-yl)methyl)-1 /-/-1 ,2,3-trιazol-4-yl)-Λ/-(4-fluoro-3- methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde
The title compound was prepared in a similar manner to ((2S,5S)-5-((4-(6-((4-fluoro-3- methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-1 H-1 ,2,3-trιazol-1-yl)methyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (step 6, Example 128) by reaction of (R)-(1 ,4-dιoxan-2-yl)methyl trifluoromethanesulfonate (175 mg, 0 70 mmol, 1 20 equiv ), sodium azide (38 mg, 0 58 mmol, 1 00 equiv ), Λ/-(4-fluoro-3-methoxybenzyl)-6-ethynyl-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in step 4 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1-(((2S,5R)-5-(hydroxymethyl)- 1 ,4-dιoxan-2-yl)methyl)-1 H-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 128) (174 mg, 0 58 mmol), 1 0 M aqueous sodium ascorbate (58 μL, 0 058 mmol, 0 10 equiv ), and 0 30 M aqueous copper (II) sulfate (40 μL, 0 012 mmol, 0 02 equiv ) Purification by silica gel chromatography (gradient 1 2 heptane/EtOAc to 100% EtOAc) provided the title compound as a white solid (258 mg, >95%) MS (ES+) m/z 443 (M+H) 1H NMR (400 MHz, DMSOd6) δ 9 47 (1 H, t, J=6 4 Hz), 8 82 (1 H, s), 8 33 (1 H, s), 7 10 - 7 24 (2 H, m), 6 90 (1 H, ddd, J=8 1 , 4 3, 1 8 Hz), 4 50 - 4 65 (2 H, m), 4 49 (2 H, d, J=6 8 Hz), 3 94 - 4 06 (1 H, m), 3 80 - 3 87 (4 H, m), 3 75 (1 H, d, J=11 3 Hz), 3 64 (1 H, d, J=1 1 0 Hz), 3 51 - 3 59 (1 H, m), 3 40 - 3 50 (1 H, m), 3 24 - 3 33 (1 H, m), 2 75 (3 H, s) Example 146
6-(1 -(((R)-1 ,4-Dioxan-2-yl)methyl)-1 H-1 ,2,3-triazol-4-yl)-N-(4-f luoro-3-methoxybenzyl)-2- methylpyrimidine-4-carboxamide
Step 1 Preparation of (S)-(1 ,4-dιoxan-2-yl)methyl trifluoromethanesulfonate
The title compound was prepared in a similar manner to ((2S,5R)-5-
((trιfluoromethylsulfonyloxy)methyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (step 5, Example 128) by reaction of (f?)-(1 ,4-dιoxan-2-yl)methanol (prepared as described in step 1 of the synthesis of 6-(2-(((f?)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-y1 )-Λ/-(3-methoxybenzyl)-2- methylpyrιmιdιne-4-carboxamιde, Example 53) (54 mg, 0 46 mmol), pyridine (41 μL, 0 50 mmol, 1 10 equiv ), and tπfluoromethanesulfonic anhydride (85 μL, 0 50 mmol, 1 10 equiv ) to afford the title compound as a tan oil (96 mg, 84%)
Step 2 Preparation of 6-(1 -(((/?)-1 ,4-dιoxan-2-yl)methyl)-1 /-/-1 ,2,3-trιazol-4-yl)-Λ/-(4-fluoro-3- methoxybenzyl)-2-methylpyrιrnιdιne-4-carboxamιde
The title compound was prepared in a similar manner to ((2S,5S)-5-((4-(6-((4-fluoro-3- methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-1 H-1 ,2,3-trιazol-1 -yl)methyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (step 6, Example 128) by reaction of (S)-(1 , 4-dιoxan-2-yl)methyl trifluoromethanesulfonate (96 mg, 0 38 mmol, 1 30 equiv ), sodium azide (20 mg, 0 31 mmol, 1 05 equiv ), Λ/-(4-fluoro-3-methoxybenzyl)-6-ethynyl-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in step 4 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1-(((2S,5R)-5-(hydroxymethyl)- 1 ,4-dιoxan-2-yl)methyl)-1 H-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 128) (88 mg, 0 30 mmol), 1 0 M aqueous sodium ascorbate (30 μL, 0 030 mmol, 0 10 equiv ), and 0 30 M aqueous copper (II) sulfate (20 μL, 0 006 mmol, 0 02 equiv ) Purification by silica gel chromatography (gradient 1 2 heptane/EtOAc to 100% EtOAc) provided the title compound as a white solid (95 mg, 73%) MS (ES+) m/z 443 (M+H) 1H NMR (400 MHz, DMSOd6) δ 9 47 (1 H, t, J=Q 2 Hz), 8 82 (1 H, s), 8 33 (1 H, s), 7 1 1 - 7 22 (2 H, m), 6 85 - 6 94 (1 H, m), 4 51 - 4 63 (2 H, m), 4 49 (2 H, d, J=6 6 Hz), 3 96 - 4 05 (1 H, m), 3 79 - 3 87 (4 H, m), 3 75 (1 H, d, J=1 1 5 Hz), 3 64 (1 H, d, J= 1 1 2 Hz), 3 51 - 3 59 (1 H, m), 3 41 - 3 49 (1 H, m), 3 25 - 3 32 (1 H, m), 2 75 (3 H, s)
Example 147
W-(4-Fluoro-3-methoxybenzyl)-6-(1-(((2S,5/?)-5-amιno-tetrahydro-2W-pyran-2-yl)methyl)-1H-1 ,2,3- trιazol-4-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of ((2S,5f?)-5-(terf-butoxycarbonyl)-tetrahvdro-2/-/-pyran-2-yl)methyl 2,2,2- trifluoroethanesulfonate
terf-Butyl (3f?,6S)-6-(hydroxymethyl)-tetrahydro-2/-/-pyran-3-ylcarbamate (prepared from commercially available tri-O-acetyl-D-glucal according to the method described by Overkleeft and coworkers, see Kπek, N M A J et al Eur J Org Chem 2003, 2418-2427) (75 mg, 0 32 mmol), 2,2,2-trιfluoroethanesulfonyl chloride (43 μl, 0 39 mmol, 1 20 equiv ), and triethylamine (59 μL, 0 42 mmol, 1 30 equiv ) were combined in dichloromethane (2 0 mL) After stirring for 2 hours at 0 0C, the mixture was diluted with dichloromethane (10 mL) and 10% aqueous sodium bisulfate (3 mL) The layers were separated and the aqueous layer was washed with dichloromethane (3 x 1 mL) The organics were combined, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a faint yellow residue Purification by silica gel chromatography (gradient 2 1 heptane/EtOAc to 100% EtOAc) provided the title compound as a white solid (1 11 mg, 91 %) 1H NMR (400 MHz, CDCI3) δ 4 33 (2 H, d, J=4 8 Hz), 4 27 (1 H, br s ), 3 88 - 4 19 (3 H, m), 3 48 - 3 70 (2 H, m), 3 03 (1 H, t, J=10 8 Hz), 2 06 - 2 25 (1 H, m), 1 65 - 1 79 (1 H, m), 1 46 - 1 58 (1 H, m), 1 45 (9 H, s), 1 24 - 1 40 (1 H, m)
Step 2 Preparation of tert-butyl (3R6S)-6-((4-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-1 /-/-1 ,2,3-trιazol-1 -yl)methyl)-tetrahvdro-2/-/-pyran-3-ylcarbamate
((2S,5f?)-5-(fer -Butoxycarbonyl)-tetrahydro-2H u-pyraon-2-yl)methyl 2,2,2- tπfluoroethanesulfonate (97 mg, 0 26 mmol) and sodium azide (18 mg, 0 28 mmol, 1 10 equiv ) were combined in Λ/,Λ/-dιmethylformamιde (0 50 mL) After stirring for 18 hours at room temperature, the reaction vessel was charged sequentially with Λ/,Λ/-dιmethylformamιde (1 0 mL), water (0 50 mL), N- (4-fluoro-3-methoxybenzyl)-6-ethynyl-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in step 4 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1-(((2S,5/?)-5-(hydroxymethyl)-1 ,4-dιoxan- 2-yl)methyl)-1 /-/-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 128) (77 mg, 0 26 mmol, 1 00 equiv ), 1 0 M aqueous sodium ascorbate (26 μl_, 0 026 mmol, 0 10 equiv ), and 0 30 M aqueous copper (II) sulfate (17 μl_, 0 005 mmol, 0 02 equiv ) After stirring for 15 hours at room temperature, water (15 mL) was added, the precipitate was collected by suction filtration, and the filter cake was washed with water (3x) The solid was dissolved in ethyl acetate, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a solid residue Purification by silica gel chromatography (gradient 1 1 heptane/EtOAc to 100% EtOAc) provided the title compound as a pale yellow solid (95 mg, 66%) LC/MS (5%-100% CH3CN H2O, 5 mm) 3 61 mm, m/z 556 (M+H)
Step 3 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1 -(((2S,5ff)-5-amιno-tetrahvdro-2/-/-pyran-2- yl)methylH H-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde
tert-Butyl (3R,6S)-6-((4-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-1 H-
1 ,2,3-trιazol-1 -yl)methyl)-tetrahydro-2H-pyran-3-ylcarbamate (95 mg, 0 17 mmol) was dissolved in 4 0 N hydrochloric acid in 1 ,4-dιoxane (1 0 mL, 4 00 mmol, 23 5 equiv ) After stirring for 2 hours at room temperature, the mixture was concentrated under reduced pressure The residue was dissolved in methanol, concentrated under reduced pressure, and dried under high vacuum to afford the title compound as the hydrochloride salt (84 mg, >95%)
Example 148
W-(4-Fluoro-3-methoxybenzyl)-6-(1-(((2S,5/?)-5-acetamido-tetrahydro-2W-pyran-2-yl)methyl)-1 H- 1 ,2,3-triazol-4-yl)-2-methylpyrimidine-4-carboxamide
The hydrochloride salt of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1 -(((2S,5R)-5-amιno-tetrahydro-2/-/- pyran-2-yl)methyl)-1 /-/-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde (prepared as described in Example 147) (84 mg), triethylamine (71 μL, 0 51 mmol, 3 00 equiv ), and acetyl chloride (24 μL, 0 34 mmol, 2 00 equiv ) were combined in dichloromethane (1 2 mL) After stirring for 15 hours at room temperature, methanol (2 mL) was added and the mixture concentrated under reduced pressure to give a salty residue Purification by silica gel chromatography (gradient 100% EtOAc to 10%
MeOH/EtOAc) provided the title compound as a white solid (60 mg, 71 %) MS (ES+) m/z 498 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ 9 47 (1 H, t, J=Q 3 Hz), 8 77 (1 H, s), 8 33 (1 H, s), 7 74 (1 H, d, J=7 1 Hz), 7 08 - 7 24 (2 H, m), 6 82 - 6 96 (1 H, m), 4 55 - 4 64 (1 H, m), 4 43 - 4 54 (3 H, m), 3 70 - 3 86 (5 H, m), 3 52 - 3 67 (1 H, m), 2 92 (1 H, t, J=10 6 Hz), 2 75 (3 H, s), 1 83 - 1 95 (1 H, m), 1 68 - 1 82 (4 H, m), 1 20 - 1 50 (2 H, m)
Example 149
/V-(4-Fluoro-3-methoxybenzyl)-6-(5-(((2S,5/?)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-1,2,4- oxadiazol-3-yl)-2-methylpyrimidine-4-carboxamide
Step 1 Preparation of ((2S,5S)-5-(cvanomethyl)-1 ,4-dioxan-2-yl)methyl 4-methylbenzenesulfonate
Potassium cyanide (580 mg, 8 91 mmol) was added to a solution of ((2S,5R)-5-
((tπfluoromethylsulfonyloxy)methyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 5 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1 -(((2S,5/:?)-5-(hydroxymethyl)- 1 ,4-dιoxan-2-yl)methyl)-1 /-/-1 ,2,3-tπazol-4-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 128) (3 87 g, 8 91 mmol) in acetonitrile (30 ml_) and water (3 ml) The mixture was stirred for 2 hours at room temperature and then was concentrated The residue washed with water and dried to afford the title compound as a solid (2 17 g, 78%)
Step 2 Preparation of ((2S,5S)-5-(2-oxoethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate
A diisobutylaluminum hydride solution (1 M in dichloromethane, 17 4 mL, 17 4 mmol) was added to a solution of ((2S,5S)-5-(cyanomethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (2 17 g, 6 97 mmol) in dichloromethane (60 mL) cooled in a dry ice/acetone bath The mixture was stirred at -78 0C for 1 hour 1 N Hydrochloric acid solution (25 mL) was added and the mixture was allowed to warm to room temperature The mixture was poured into water (100 mL) and extracted with ethyl acetate (3x) The combined organic layers were dried over magnesium sulfate and concentrated The residue was purified by reverse phase preparative HPLC to afford the title compound (553 mg, 25%) 1H NMR (400 MHz, CDCI3) δ ppm 2 32 - 2 42 (m, 1 H), 2 44 (s, 3 H), 2 47 - 2 58 (m, 1 H), 3 25 - 3 48 (m, 2 H), 3 67 - 3 83 (m, 3 H), 3 89 - 4 03 (m, 3 H), 7 34 (d, J=8 01 Hz, 2 H), 7 77 (d, J=8 40 Hz, 2 H), 9 57 - 9 80 (m, 1 H)
Step 3 Preparation of ((2S,5S)-5-((((4-methylphenyl)sulfonyl)oxy)methv0-1 ,4-dioxan-2-yl)acetic acid
((2S,5S)-5-(2-oxoethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (390 mg, 1 24 mmol) was dissolved in f-butanol (20 mL) A 2M solution of 2-methyl-2-butene (12 4 mL, 24 8 mmol) was added to the stirring mixture followed by a solution of sodium chlorite (1 12 g, 10 mmol) and mono-sodium phosphate (monobasic) monohydrate (2 23 g, 13 0 mmol) in water (10 mL) The mixture was stirred at room temperature for 18 hours The reaction mixture was diluted with dichloromethane and saturated aqueous ammonium chloride The layers were separated and the aqueous layer was extracted with dichloromethane (3x) The combined organic layers were dried over magnesium sulfate and concentrated to afford the title compound as an oil which crystallized upon standing (515 mg) MS (ES+) m/z 331 (M+H)
Step 5 Preparation of ((2S,5S)-5-(2-(((6-(((4-fluoro-3-methoxybenzyl)amιno)carbonyl)-2- methylpyrιmιdιn-4-yl)(hγdroxyιmιno)methyl)amιno)-2-oxoethyl)-1 ,4-dιoxan-2-yl)methyl 4- methylbenzenesulfonate
A mixture of Λ/-(4-fluoro-3-methoxybenzyl)-6-(carbamιmιdoyl)-2-methylpyrιmιdιne-4- carboxamide (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(5- ((/rans-4-ammocyclohexyl)methyl)-1 ,2,4-oxadiazol-3-yl)-2-methylpyrimidine-4-carboxamide, Example 122) (353 mg, 1 06 mmol), ((2S,5S)-5-((((4-methylphenyl)sulfonyl)oxy)methyl)-1 ,4-dιoxan-2-yl)acetιc acid (350 mg, 1 06 mmol), 1 -hydroxybenzotrιazole ( 143 mg, 1 06 mmol), dnsopropylethylamine (0 55 mL, 3 18 mmol), and polymer supported-carbodiimide resin (2 86 g, 3 18 mmol) in acetonitrile (10 mL) was stirred at 40 0C for 42 hours The reaction mixture was filtered and the resin was washed with acetonitrile The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound as a solid (155 mg, 23%) Step 6 Preparation of ΛΛ(4-fluoro-3-methoxybenzyl)-6-(5-(((2S,5R)-5-(hvdroxymethyl)-1 ,4-dιoxan-2- yl)methyl)-1 ,2,4-oxadιazol-3-yl)-2-methylpyrιmιdιne-4-carboxamιde
A solution of ((2S,5S)-5-(2-(((6-(((4-fluoro-3-methoxybenzyl)amιno)carbonyl)-2- methylpyrιmιdιn-4-yl)(hydroxyιmιno)methyl)amιno)-2-oxoethyl)-1 ,4-dιoxan-2-yl)methyl A- methylbenzenesulfonate (134 mg, 0 209 mmol) in acetonitrile (5 mL) was treated with MP-carbonate resin and heated to 65 0C for 18 hours The resin was filtered and washed with acetonitrile The filtrate was concentrated to a volume of 5 mL Tetrabutyl ammonium acetate (126 mg, 0 418 mmol) was added and the mixture was heated to 65 0C for 5 hours The mixture was then treated with a 2 5 M sodium hydroxide solution (1 mL) and the solution was stirred at room temperature for 18 hours After reaction mixture was purified by reverse phase preparative HPLC The crude product was dissolved in ethyl acetate and washed several times with a saturated solution of ammonium chloride The organic layer was dried over magnesium sulfate and concentrated to afford the title compound as an oil (22 mg, 11 %) MS (ES+) m/z 474 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 25 (d, J=5 49 Hz, 2 H), 2 83 (s, 3 H), 3 07 - 3 22 (m, 2 H), 3 31 - 3 54 (m, 4 H), 3 74 - 3 87 (m, 4 H), 4 50 (d, J=Q 22 Hz, 2 H), 4 60 - 4 72 (m, 1 H), 5 28 (dd, 1 H), 6 80 - 6 98 (m, 1 H), 7 06 - 7 25 (m, 2 H), 8 33 (s, 1 H), 9 43 - 9 60 (m, 1 H)
Example 150
6-(5-((2R)-1 ,4-Dioxan-2-ylmethyl)-1,2,4-oxadiazol-3-yl)-/V-(4-fluoro-3-methoxybenzyl)-2- methylpyrimidine-4-carboxamide
Step 1 Preparation of (2R)- 1 ,4-dιoxan-2-ylacetonιtrιle
Potassium cyanide (2 27 g) was added to (S)-(1 , 4-dιoxan-2-yl)methyl tπfluoromethanesulfonate (prepared as describe in step 1 of the synthesis of 6-(1 -(((R)-1 ,4-dιoxan-2- yl)methyl)-1H-1 ,2,3-trιazol-4-yl)-Λ/-(4-fluoro-3-methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde, Example 146) (7 3 g, 29 0 mmol) in a mixture of acetonitrile (60 mL) and water (6 mL) The mixture was stirred at room temperature for 18 hours and was then concentrated The residue was taken up in ethyl acetate and washed with water (2x) The organic layer was dried over sodium sulfate to afford the title compound as an oil (3 23 g, 87%) MS (ES+) m/z 128 (M+H)
Step 2 Preparation of methyl (2/?)-1 ,4-dιoxan-2-ylacetate (2R)-1 ,4-dιoxan-2-ylacetonιtrιle (3 2 g, 25 0 mmol) was dissolved in methanol (10 mL) and HCI gas was bubbled through the mixture for several minutes The resulting solution was stirred at room temperature for 1 hour Water (2 mL) was added and most of the solvent was removed in vacuo The residue was taken up in ethyl acetate and washed with a saturated sodium bicarbonate solution The organic layer was dried over magnesium sulfate, and concentrated to afford the title compound as an oil MS (ES+) m/z 161 (M+H)
Step 3 Preparation of (2ff)-1 ,4-dιoxan-2-ylacetιc acid
A mixture of methyl (2/?)-1 ,4-dιoxan-2-ylacetate (300 mg, 1 87 mmol), tetrahydrofuran (5 mL), water (1 mL), and lithium hydroxide (359 mg, 15 0 mmol) was stirred at room temperature for 18 hours The mixture was acidified with the addition of 3N hydrochloric acid and then passed through a Chem Elute extraction column eluting with ethyl acetate The eluant was concentrated to afford the title compound as a solid (262 mg, 96%) MS (ES+) m/z 147 (M+H)
Step 4 Preparation of 6-(5-((2R)- 1 ,4-dιoxan-2-ylmethyl)-1 ,2,4-oxadιazol-3-yl)-Λ/-(4-fluoro-3- methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde
A mixture of Λ/-(4-fluoro-3-methoxybenzyl)-6-(carbamιmιdoyl)-2-methylpyrιmιdιne-4- carboxamide (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(5- ((/rans^-aminocyclohexyOmethylJ-i ^^-oxadiazol-S-yO^-methylpyπmidine^-carboxamide, Example 122) (100 mg, 0 30 mmol), (2R)-1 ,4-dιoxan-2-ylmethanol (87 mg, 0 60 mmol), 1 -hydroxybenzotrιazole (61 mg, 0 45 mmol), polymer supported-carbodiimide resin (81 1 mg, 0 90 mmol), and diisopropylamine (0 16 mL, 0 90 mmol) in acetonitrile (5 mL) was heated to 40 °C for 3 days The reaction mixture was filtered and the resin was washed with a minimal amount of acetonitrile The filtrate was then treated with MP-carbonate resin (523 mg, 1 5 mmol) and heated to 65 0C for 18 hours The mixture was filtered and the resin was washed with acetonitrile The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound as a solid (16 mg, 12%) MS (ES+) m/z 444 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 2 82 (s, 3 H), 3 13 - 3 20 (m, 1 H), 3 22 - 3 31 (m, 2 H), 3 42 - 3 50 (m, 1 H), 3 54 - 3 66 (m, 2 H), 3 68 - 3 73 (m, 1 H), 3 77 - 3 89 (m, 4 H), 4 00 - 4 08 (m, 1 H), 4 48 (d, J=6 22 Hz, 2 H), 6 88 (ddd, J=& 33, 4 30, 2 01 Hz, 1 H), 7 09 - 7 19 (m, 2 H), 8 32 (s, 1 H), 9 55 - 9 62 (m, 1 H)
Example 151
6-(5-((2S)-1 ,4-Dioxan-2-ylmethyl)-1 ,2,4-oxadiazol-3-yl)-/V-(4-fluoro-3-methoxybenzyl)-2- methylpyrimidine-4-carboxamide
The title compound was prepared in a similar manner to 6-(5-((2R)-1 ,4-dιoxan-2-ylmethyl)- 1 ,2,4-oxadιazol-3-yl)-Λ/-(4-fluoro-3-methoxybenzyl)-2-methylpyrιmιdιne-4-carboxamιde (Example 150) starting from (S)- 1 ,4-dιoxan-2-ylmethanol (prepared as described in step 1 of the synthesis of 6-(2- (((S)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol5-yl)-/V-(3-methyoxybenzyl)-2-methylpyrιmιdιne-4- carboxamide, Example 57) to afford 75 mg (56%) MS (ES+) m/z 444 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 2 82 (s, 3 H), 3 12 - 3 21 (m, 1 H), 3 22 - 3 30 (m, 1 H), 3 42 - 3 50 (m, 1 H), 3 55 (d, J=2 56 Hz, 1 H), 3 57 - 3 66 (m, 2 H), 3 68 - 3 73 (m, 1 H), 3 77 - 3 90 (m, 4 H), 4 00 - 4 08 (m, 1 H), 4 48 (d, J=Q 22 Hz, 2 H), 6 88 (ddd, J=8 33, 4 30, 2 01 Hz, 1 H), 7 09 - 7 19 (m, 2 H), 8 32 (s, 1 H), 9 55 - 9 62 (m, 1 H)
Example 152
W-(4-Fluoro-3-methoxybenzyl)-6-(3-(((frans)-4-acetamidocyclohexyl)methyl)isoxazol-5-yl)-2- methylpyrimidine-4-carboxamide
Step 1 Preparation of tert-butyl (frans)-4-((E)-2-(hvdroxyimino)ethyl)cyclohexylcarbamate
tert-Butyl (frans)-4-(2-oxoethyl)cyclohexylcarbamate (403 mg, 1 67 mmol) was dissolved in a mixture of ethanol (12 ml) and water (8 mL) Sodium acetate (407 mg, 4 96 mmol) was added and the mixture was stirred for 30 mm at room temperature Hydroxylamine hydrochloride (363 mg, 5 01 mmol) was added and the mixture was heated to 60 0C for 1 5 hours The reaction mixture was concentrated to obtain the title compound as a white solid (70 mg) Step 2 Preparation of tert-butyl (fraπs)-4-((Z)-2-chloro-2-mvdroxyιmιno)ethyl)cycloheχylcarbamate
/V-Chlorosuccinimide (51 5 mg, 0 38 mmol) was added to a solution of tert-butyl (trans)-4-((E)- 2-(hydroxyιmιno)ethyl)cyclohexylcarbamate (99 mg, 0 38 mmol) in acetonιtrιle( 5 mL) and the mixture was stirred at room temperature for 18 hours Additional Λ/-chlorosuccιnιmιde was added (25 7 mg,
0 19 mmol) After 4 hours, the reaction mixture was concentrated The residue was suspended in dichloromethane and filtered The filtrate was concentrated to afford the title compound as a white solid (177 mg) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 2 621 mm , m/z 338 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 1 09 (d, J= 10 16 Hz, 2 H), 1 43 (s, 9 H), 1 77 (d, J=10 94 Hz, 2 H), 2 77 (s, 5 H), 2 92 (s, 1 H), 5 30 (s, 1 H)
Step 3 Preparation of /erf-butyl (fraπs)-4-((5-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2- methylpyrimidin^-vDisoxazol-S-yQmethvDcyclohexylcarbamate
tert-Butyl (/rans)-4-((Z)-2-chloro-2-(hydroxyιmιno)ethyl)cyclohexylcarbamate (48 6 mg, 0 16 mmol) was added to a mixture of Λ/-(4-fluoro-3-methoxybenzyl)-6-ethynyl-2-methylpyrιmιdιne-4- carboxamide (prepared as described in step 4 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(1 - (((2S,5R)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-1 H-1 ,2,3-trιazol-4-yl)-2-methylpyrιmιdιne-4- carboxamide, Example 128) (50 1 mg, 0 16 mmol) and tπethylamine (0 023 mL, 0 16 mmol) in toluene (5 mL) The mixture was stirred at room temperature for 2 hours, then heated to 1 10 0C for 2 hours, and finally allowed to stir at room temperature for 18 hours The reaction mixture was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound as an orange solid (51 7 mg, 46%) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 3 72 mm , m/z 498 (M-C4H9) 1H NMR (400 MHz, CDCI3) δ ppm 1 02 - 1 20 (m, 4 H), 1 22 - 1 27 (m, 1 H), 1 36 - 1 51 (m, 9 H), 1 58 -
1 72 (m, 1 H), 1 80 (d, J=10 55 Hz, 2 H), 1 94 - 2 06 (m, 2 H), 2 64 (d, J=7 04 Hz, 2 H), 2 74 - 2 82 (m, 3 H), 3 36 (br s , 1 H), 3 84 - 3 91 (m, 3 H), 4 62 (d, J=5 86 Hz, 2 H), 5 28 (s, 1 H), 6 83 - 6 91 (m, 1
H), 6 92 - 6 99 (m, 2 H), 6 99 - 7 07 (m, 1 H), 8 29 - 8 37 (m, 1 H), 8 38 (s, 1 H) Step 4 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-(3-(((frar?s)-4- acetamιdocvclohexvl)methvl)ιsoxazol-5-vl)-2-methvlpvrιmιdιne-4-carboxamιde
Trifluoroacetic acid (1 mL) was added to a solution of fert-butyl (frans)-4-((5-(6-((4-fluoro-3- methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)ιsoxazol-3-yl)methyl)cyclohexylcarbamate (51 mg, 0 076 mmol) in dichloromethane (40 mL) and the mixture was stirred at room temperature for 6 hours The reaction mixture was concentrated and the residue was dissolved in Λ/,Λ/-dιmethylformamιde (10 mL) Diisopropylethylamine (0 05 mL, 0 30 mmol) and acetic anhydride (0 015 mL, 0 152 mmol) were added and the mixture was stirred at room temperature under nitrogen for 16 hours The reaction mixture was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound as a white solid (32 3 mg) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 3 062 mm , m/z 496 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 03 - 1 15 (m, 4 H), 1 17 (d, J=O 73 Hz, 1 H), 1 69 (d, J=1 1 71 Hz, 3 H), 1 73 - 1 79 (m, 5 H), 2 61 (d, J=6 95 Hz, 2 H), 2 79 (s, 3 H), 3 31 (br s , 1 H), 3 44 (dt, J=I 05, 3 61 Hz, 1 H), 3 81 (s, 3 H), 4 48 (d, J=6 59 Hz, 2 H), 6 89 (ddd, J=Q 33, 4 30, 2 01 Hz, 1 H), 7 09 - 7 20 (m, 2 H), 7 41 (s, 1 H), 7 71 (d, J=I 69 Hz, 1 H), 8 20 (s, 1 H), 9 50 - 9 57 (m, 1 H)
Example 153
/V-(3-Methoxybenzyl)-4-(2-(((fraπs)-4-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Step 1 Preparation of Λ/-terf-butyl-2-chloro-6-methylιsonιcotιnamιde
Oxalyl chloride (95 mL, 1 10 mol) was added to 2-chloro-6-methylιsonιcotιnιc acid (95 g, 0 55 mol) in dichloromethane (950 mL, anhydrous) The mixture was cooled in an ice/water bath and DMF (2 0 mL) was slowly added When gas evolution subsided, the ice/water bath was removed and the mixture was allowed to reach ambient temp and stir for 15 hours The solution was then concentrated in vacuo and azeotroped with toluene (2 x 200 mL) The residue was taken into dichloromethane (800 mL, anhydrous), cooled in an ice/water bath, and a solution of tert-butylamine (175 mL, 1 7 mol) in dichloromethane (300 mL, anhydrous) was added drop wise The mixture was allowed to reach ambient temp and stir for 15 hours Water (250 mL) was added The organic layer was washed with water (200 mL) followed by brine (200 mL), dried over magnesium sulfate, filtered, and concentrated to afford the title compound as a beige solid (12O g, 96%) 1H NMR (400 MHz, DMSO-d6) δ ppm 7 39 (s, 1 H), 7 38 (s, 1 H), 6 05 (s, 1 H), 2 59 (s, 3 H), 1 5 (s, 9 H)
Step 2 Preparation of 2-chloro-6-methylιsonιcotιnonιtrιle
To AZ-tert-butyl^-chloro-β-methylisonicotinamide (120 g, 0 53 mol) in toluene (2 5 L, anhydrous) was added POCI3 (572 mL, 6 26 mol) The resulting mixture was refluxed 15 h, cooled to ambient temperature, and concentrated in vacuo The residue was dissolved in dichloromethane (1 0 L) and aqueous saturated sodium bicarbonate (500 mL) was carefully added Solid sodium bicarbonate was then added portion wise until the aqueous layer was basic The organic layer was washed with brine (300 mL), dried (magnesium sulfate), filtered, and concentrated to afford the title compound as a pale tan solid (76 g, 94%) 1H NMR (400 MHz, DMSO-d6) δ ppm 7 41 (s, 1 H), 7 37 (s, 1 H), 2 61 (s, 3 H)
Step 3 Preparation of 2-chloro-6-methyl-4-(2/-/-tetrazol-5-yl)pyrιdιne hydrochloride
Triethylamine hydrochloride (72 g, 0 52 mol) and sodium azide (34 g, 0 52 mol) were added to a solution of 2-chloro-6-methylιsonιcotιnonιtrιle (76 g, 0 50 mol) in toluene (1 2 L, anhydrous) The mixture was refluxed for 4 hours behind a blast shield After cooling to ambient temperature, water (1 5 L) was added and the layers were separated The toluene layer was washed with water (500 mL) and the combined aqueous layers were acidified with 6N hydrochloric acid (100 mL) The resulting precipitate was filtered and dried in vacuo (60 0C) to afford the title compound (105 g) 1H NMR (400 MHz, DMSO-d6) δ ppm 7 92 (s, 1 H), 7 89 (s, 1 H), 2 79 (s, 3 H) Step 4 Preparation of methyl 6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnate
Triethylamine (120 mL), 1 ,1 '-bιs(dιphenylphosphιno)ferrocene (8 0 g, 14 mmol), and Pd(OAc)2 (9 2 g, 40 mmol) were added to a solution of 2-chloro-6-methyl-4-(2H-tetrazol-5-yl)pyndine hydrochloride (88 g, 380 mmol) in methanol (1 5 L, anhydrous) in a pressure reactor The reactor was evacuated and purged with carbon monoxide gas twice and finally pressurized to 120 PSI and heated to 100 0C for 24 hr (190 PSI reached) An aliquot was taken and analyzed by HPLC revealing consumption of the starting material After cooling to ambient temp, the mixture was filtered through Celite™ and concentrated in vacuo Water (700 mL) and aq saturated NaHCO3 (200 mL) were added to provide an almost clear solution 3N hydrochloric acid was added until a pH of 2 was reached The resulting solid was filtered and dried in vacuo (50 0C) until constant weight (78 g, 94%) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 8 48 (s, 1 H), 8 15 (s, 1 H), 3 95 (s, 3 H), 2 67 (s, 3 H)
Step 5 Preparation of /V-(3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde
A mixture of methyl 6-methyl-4-(2H-tetrazo!-5-yl)pιcolιnate (3 29 g, 15 0 mmol) and 3- methoxybenzylamine (6 17 g, 45 0 mmol) was heated at 100 0C with removal of methanol in a stream of nitrogen for 1 hour A solution of 1 N hydrochloric acid (50 mL) was added The resulting precipitate was filtered and washed with ethyl ether The solid was suspended in a solution of 2 5 N sodium hydroxide (30 mL)/water (50 mL) and extracted with ethyl acetate ( 2 x 50 mL) The aqueous layer was cooled in an ice bath and acidified to pH 1 with concentrated hydrochloric acid The resulting precipitate was filtered and dried to afford the title compound as a white solid (4 69 g, 96%) MS (ES+) m/z 325 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 28 (t, J=Q 3 Hz, 1 H), 8 49 (d, J= 0 8 Hz, 1 H), 8 13 (d, J=1 2 Hz, 1 H), 7 24 (t, J=8 1 Hz, 1 H), 6 94-6 90 (m, 2 H), 6 82 (dd, J=Q 0, 2 1 Hz, 1 H), 4 51 (d, J=& 3 Hz, 2 H), 3 73 (s, 3 H), 2 68 (s, 3 H)
Step 6 Preparation of terf-butyl (frans)-4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)- 2/-/-tetrazol-2-yl)methyl)cvclohexylcarbamate
Λ/-(3-Methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (1 62 g, 5 0 mmol), polymer supported tπphenylphosphine (3 49 g, 7 5 mmol), and terf-butyl trans-{4- hydroxymethyl)cyclohexylcarbamate (1 38 g, 6 0 mmol) were suspended in tetrahydrofuran (100 mL) Di-tert-butyl azodicarboxylate (1 73 g, 7 5 mmol) was added The mixture was allowed to stir for 18 hours The reaction mixture was filtered and the resin washed with THF (100 mL) The filtrate was concentrated The crude product was purified by silica column chromatography (CH2CI2/methanol, 100/1 , 100/2) Combined fractions were concentrated onto silica and repurified by silica column chromatography (heptane/EtOAc, 2/1 , 1/1 ) Combined fractions were concentrated The resulting solid was slurried in heptane and filtered to afford the title compound as a white solid (1 824 g, 68%) MS (ES+) m/z 536 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 23 (t, J=Q 3 Hz, 1 H), 8 40 (d, J=O 8 Hz, 1 H), 8 05 (d, J=1 1 Hz, 1 H), 7 21 (t, J=8 1 Hz, 1 H), 6 86 - 6 90 (m, 2 H), 6 79 (dd, J=Q 2, 1 9 Hz, 1 H), 6 68 (d, J=I 8 Hz, 1 H), 4 63 (d, J=I 0 Hz, 2 H), 4 48 (d, J=6 3 Hz, 2 H), 3 70 (s, 3 H), 3 13 (br s , 1 H), 2 64 (s, 3 H), 1 90 (br s , 1 H), 1 71 - 1 77 (m, 2 H), 1 53 - 1 59 (m, 2 H), 1 33 (s, 9 H), 1 06 - 1 14 (m, 4 H)
Step 7 Preparation of Λ/-(3-methoxybenzyl)-4-(2-(((/rans)-4-amιnocvdohexyl)methyl)-2H-tetrazol-5-yl)- 6-methylpιcolιnamιde
terf-Butyl (frans)-4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2- yOmethyOcyclohexylcarbamate (1 82 g, 3 40 mmol) was dissolved in dichloromethane (20 mL) and trifluoroacetic acid (5 05 mL, 68 0 mmol) was added The mixture was allowed to stand for 2 hours and was then concentrated The residue was dissolved in dichloromethane (150 mL) and washed with 1 N NaOH solution (2 x 40 mL) The organic layer was dried over sodium sulfate and concentrated The residue was triturated with heptane and filtered to afford the title compound as a white solid (1 407 g, 95%) MS (ES+) m/z 436 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 23 (t, J=6 3 Hz, 1 H), 8 39 (d, J=O 8 Hz, 1 H), 8 05 (d, J= 1 2 Hz, 1 H), 7 21 (t, J=8 1 Hz, 1 H), 6 90 - 6 86 (m, 2 H), 6 79 (dd, J=8 2, 1 9 Hz, 1 H), 4 62 (d, J=7 1 Hz, 2 H), 4 48 (d, J=6 3 Hz, 2 H), 3 70 (s, 3 H), 2 64 (s, 3 H), 2 45 - 2 37 (m, 1 H), 1 96 - 1 84 (m, 1 H), 1 71 (d, J=12 0 Hz, 2 H), 1 53 (d, J=12 2 Hz, 2 H), 1 37 (br s , 2 H), 1 07 (q, J=12 8 Hz, 2 H), 1 01 - 0 88 (m, J=10 6, 10 6, 10 6 Hz, 2 H)
Example 154 N^S-MethoxybenzyO-e-methyM^Z^^fraπsJ^^methylsulfonamidoJcyclohexyOmethyO^H- tetrazol-5-yl)picolinamide
Triethylamine (0 096 mL, 0 690 mmol) and methane sulfonyl chloride (0 021 mL, 0 276 mmol) were added to a solution of /V-(3-methoxybenzy!)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)-2H-tetrazol- 5-yl)-6-methylpιcolιnamιde (prepared as described in Example 153) (100 0 mg, 0 230 mmol) in dichloromethane (2 mL) The mixture was stirred for 2 hours at room temperature Volatiles were removed under a nitrogen stream The residue was purified by reverse phase preparative HPLC (5%- 95% CH3CN/H2O, 8 mm) to afford the title compound as a solid (28 2 mg, 24%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 148 mm , m/z 514 (M+H) 1H NMR (400 MHz, DMSO- dβ) δ ppm 0 95 - 1 32 (m, 4 H), 1 49 - 1 69 (m, 2 H), 1 78 - 2 04 (m, 3 H), 2 65 (s, 3 H), 2 86 (s, 3 H), 3 71 (s, 3 H), 4 49 (d, J=5 9 Hz, 2 H), 4 64 (d, J=I 3 Hz, 2 H), 6 77 - 6 82 (m, 1 H), 6 90 (m, 2 H), 6 93 (s, 1 H), 7 12 - 7 29 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 04 - 9 31 (m, 1 H)
Example 155
W-(3-Methoxybenzyl)-4-(2-(((frans)-4-(ethylsulfonamido)cyclohexyl)methyl)-2W-tetrazol-5-yl)-6- methylpicolinamide
Triethylamine (0 096 mL, 0 690 mmol) and ethane sulfonyl chloride (44 3 mg, 0 344 mmol) were added to a solution of Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol- 5-yl)-6-methylpιcolιnamιde (prepared as described in Example 153) (100 0 mg, 0 230 mmol) in tetrahydrofuran (2 mL) The mixture was stirred overnight at room temperature Volatiles were removed under a nitrogen stream The residue was purified by reverse phase preparative HPLC (5%- 95% CH3CN/H2O, 8 mm) to afford the title compound as a solid (9 9 mg, 8%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 252 mm , m/z 528 (M+H) 1H NMR (400 MHz, DMSO- d6) δ ppm 0 96 - 1 36 (m, 7 H), 1 52 - 1 70 (m, 2 H), 1 78 - 1 90 (m, 2 H), 1 89 - 2 10 (m, 1 H), 2 65 (s, 3 H), 2 94 - 3 09 (m, 1 H), 3 71 (s, 3 H), 4 49 (d, J=6 6 Hz, 2 H), 4 63 (d, J=6 6 Hz, 2 H), 6 73 - 6 84 (m, 1 H), 6 86 - 6 92 (m, 2 H), 6 92 - 7 01 (m, 1 H), 7 15 - 7 27 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 10 - 9 25 (m, 1 H)
Example 156
W-(3-Methoxybenzyl)-4-(2-(((frans)-4-(cyclopropanesulfonamido)cyclohexyl)methyl)-2H-tetrazol- 5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4- (ethylsulfonamidoJcyclohexyOmethyO^H-tetrazol-S-yO-θ-methylpicolinamide (Example 155) by reaction with cyclopropane sulfonyl chloride and afforded 22 3 mg (18%) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 310 mm , m/z 540 (M+H) 1H NMR (400 MHz, DMSO- d6) δ ppm 0 80 - 0 95 (m, 4 H), 1 04 - 1 33 (m, 4 H), 1 51 - 1 68 (m, 2 H), 1 83 - 2 01 (m, 2 H), 2 41 - 2 55 (m, 1 H), 2 65 (s, 3 H), 2 96 - 3 14 (m, 1 H), 3 71 (s, 3 H), 4 49 (d, J=5 9 Hz, 2 H), 4 64 (d, J=6 6 Hz, 2 H), 6 73 - 6 84 (m, 1 H), 6 86 - 6 93 (m, 2 H), 6 93 - 7 02 (m, 1 H), 7 13 - 7 29 (m, 1 H), 8 05 (s, 1 H), 8 40 (S, 1 H), 9 11 - 9 27 (m, 1 H) Example 157
W-(3-Methoxybenzyl)-4-(2-(((frans)-4-(butylsulfonamido)cyclohexyl)methyl)-2W-tetrazol-5-yl)-6- methytpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4-
(ethylsulfonamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolmamide (Example 155) by reaction with butane sulfonyl chloride and afforded 45 6 mg (36%) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm, 95% CH3CN, 1 5 mm ) 3 574 mm , 556 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 0 77 - 0 91 (m) 1 07 - 1 47 (m) 1 48 - 1 91 (m) 1 91 - 2 05 (m, 1 H), 2 65 (s, 3 H), 2 83 - 3 01 (m) 3 48 - 3 65 (m, 1 H), 3 71 (s, 3 H), 4 49 (d, J=Q 59 Hz, 2 H), 4 66 (d, J=I 32 Hz, 2 H), 6 76 - 6 82 (m, 1 H), 6 87 - 6 97 (m) 7 17 - 7 26 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 15 - 9 25 (m)
Example 158
^-(S-MethoxybenzylM-^-Mfrans^-acetamidocyclohexylJmethyl^H-tetrazol-S-yO-β- methylpicolinamide
Acetic anhydride (0 033 mL, 0 344 mmol) and silica-bound 4-(dιmethylamιno)pyrιdιne (833 0 mg, 0 575 mmol, 0 69 mmol/g loading) were added to a solution of Λ/-(3-methoxybenzyl)-4-(2-(((frans)- 4-ammocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 153) (50 1 mg, 0 1 15 mmol) in dichloromethane (2 mL) The reaction mixture was agitated overnight at room temperature, filtered, and washed with Λ/,Λ/-dιmethylformamιde The filtrate was concentrated under a stream of nitrogen The residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound (22 4 mg, 41 %) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 994 mm , m/z 478 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 0 99 - 1 28 (m, 4 H), 1 60 (m, 2 H), 1 73 (s, 3 H), 1 74 - 1 81 (m, 3 H), 1 89 - 2 06 (m, 1 H), 2 65 (s, 3 H), 3 71 (s, 3 H), 4 49 (d, J=5 9 Hz, 2 H), 4 64 (d, J=I 3 Hz, 2 H), 6 75 - 6 83 (m, 1 H), 6 86 - 6 98 (m, 2 H), 7 13 - 7 30 (m, 1 H), 7 63 (s, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 06 - 9 25 (m, 1 H)
Example 159
W-(3-Methoxybenzyl)-4-(2-(((frans)-4-isobutyramidocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-Methoxybenzyl)-4-(2-(((/rans)-4- acetamιdocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 158) by reaction with isobutyric anhydride and afforded 22 6 mg (39%) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 325 mm , m/z 506 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 0 93 (s, 3 H), 0 94 (s, 3 H), 1 02 - 1 26 (m, 4 H), 1 54 - 1 66 (m, 2 H), 1 69 - 1 81 (m, 2 H), 1 86 - 2 04 (m, 1 H), 2 18 - 2 36 (m, 1 H)1 2 65 (s, 3 H), 3 71 (s, 3 H), 4 49 (d, J=5 9 Hz, 2 H), 4 65 (d, J=7 3 Hz, 1 H), 6 71 - 6 83 (m, 1 H), 6 86 - 6 98 (m, 2 H), 7 13 - 7 30 (m, 1 H), 7 38 - 7 55 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 12 - 9 26 (m, 1 H)
Example 160
2-((<rans)-4-((5-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2-yl)methyl)- cyclohexylamino)-2-oxoethyl acetate
Triethylamine (651 μL, 6 43 mmol), 4-(dιmethylamιno)pyrιdιne (78 5 mg, 0 64 mmol), and acetoxyacetyl chloride (415 μL, 3 86 mmol) were added to a solution of Λ/-(3-methoxybenzyl)-4-(2- ((((rans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 153) (1 400 g, 3 21 mmol) in dichloromethane (60 mL) The mixture was allowed to stir at room temperature for 1 hour The reaction mixture was diluted with dichloromethane (150 mL) and washed with saturated aq sodium bicarbonate solution (2 x 40 mL) The organic layer was dried over sodium sulfate and concentrated The crude product was purified by silica column chromatography (CH2CI2/methanol, 100/1 , 100/2) Fractions were concentrated and the oily residue was partially concentrated from a mixture of dichloromethane/heptane/ethyl ether The resulting slurry was filtered to afford the title compound as a white solid (1 513 g, 88%) MS (ES+) m/z 536 (M+H) 1H NMR (400 MHz, DMSOd6) 6 ppm 9 24 (t, J=6 4 Hz, 1 H), 8 40 (d, J=O 8 Hz, 1 H), 8 06 (d, J= 1 2 Hz, 1 H), 7 82 (d, J=7 9 Hz, 1 H), 7 21 (t, J=8 1 Hz, 1 H), 6 90 - 6 86 (m, 2 H), 6 79 (dd, J=7 9, 2 0 Hz, 1 H), 4 65 (d, J=7 0 Hz, 2 H), 4 48 (d, J=6 4 Hz, 2 H), 4 35 (s, 2 H), 3 70 (s, 3 H), 3 49 (br s , 1 H), 2 65 (s, 3 H), 2 03 (s, 3 H), 1 95 (br s , 1 H), 1 78 - 1 71 (m, 2 H), 1 63 - 1 56 (m, 2 H), 1 21 - 1 1 1 (m, 4 H)
Example 161
N-(3-Methoxybenzyl)-4-(2-((((rans)-4-(2-hydroxyacetamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)- 6-methylpicolinamide
2-((frans)-4-((5-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyπdιn-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexylamιno)-2-oxoethyl acetate (prepared as described in Example 160) (1 50 g, 2 80 mmol) was dissolved in tetrahydrofuran (100 mL) Lithium hydroxide (201 mg, 8 40 mmol) followed by water (35 mL) were added The mixture was stirred for 1 hour and then the tetrahydrofuran was removed in vacuo The residue was added to dichloromethane (100 mL) and washed with water (2 x 20 mL) The organic layer was dried over sodium sulfate and concentrated to afford a foaming solid The residue was dissolved in methanol (10 mL) and seeded The resulting slurry was filtered to afford the title compound as a white crystalline solid (1 233 g, 89%) MS (ES+) m/z 494 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 23 (t, J=6 4 Hz, 1 H), 8 40 (s, 1 H), 8 06 (d, J= 1 2 Hz, 1 H), 7 41 (d, «7=8 3 Hz, 1 H), 7 21 (t, J=8 1 Hz, 1 H), 6 90 - 6 86 (m, 2 H), 6 79 (dd, J=8 2, 1 9 Hz, 1 H), 5 36 (t, J=5 8 Hz, 1 H), 4 65 (d, J=7 0 Hz, 2 H), 4 48 (d, J=6 4 Hz, 2 H), 3 72 (d, J=5 8 Hz, 2 H), 3 70 (s, 3 H), 3 59 - 3 48 (m, 1 H), 2 65 (s, 3 H), 2 00 - 1 89 (m, 1 H), 1 71 (d, J= 10 6 Hz, 2 H), 1 59 (d, J=13 6 Hz, 2 H), 1 32 - 1 09 (m, 4 H)
Example 162
W-(3-Methoxybenzyl)-4-(2-((((rans)-4-(2-hydroxy-2-methylpropanamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
A mixture of 2-hydroxy isobutyric acid (10 mg, 0 10 mmol) and 1 -hydroxybenzatrιazole (15 mg, 0 1 1 mmol) in 2- methyl tetrahydrofuran (2 mL) for was stirred for 5 minutes Λ/-(3-
Methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 153) (0 050 g, 0 09 mmol), tπethylamine (0 015 mL, 0 11 mmol), and polymer supported carbodiimide (0 1 1 g, 0 14 mmol) were added The mixture was stirred for 18 hours at room temperature and was then filtered The filtrate was washed with water (3 x 5 mL) followed by brine (5 mL), dried over anhydrous sodium sulfate, and concentrated The residue was purified by reverse phase preparative HPLC to afford the title compound (21 mg, 45%) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 19 (t, J=6 2 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 22 (t, J=8 1 Hz, 2 H), 6 90 (br s , 2 H), 6 80 (d, J=8 8 Hz, 1 H), 4 65 (d, J=6 6 Hz, 2 H), 4 49 (d, J=5 9 Hz, 2 H), 3 71 (s, 3 H), 3 21 - 3 35 (m, 1 H), 2 65 (s, 3 H), 1 91 - 2 05 (m, 1 H), 1 72 (d, J= 1 1 7 Hz, 2 H), 1 60 (d, J= 1 1 7 Hz, 2 H), 1 06 - 1 33 (m, 10 H) Example 163
/V-(3-Methoxybenzyl)-4-(2-(((<rans)-4-((S)-2-hydroxypropanamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
A mixture of (S)-2-acetoxypropanoιc acid (13 mg, 0 10 mmol) and 1-hydroxybenzatrιazole (16 mg, 0 12 mmol) in 2-methyl tetrahydrofuran (2 ml_) was stirred for 5 minutes A/-(3-Methoxybenzyl)-4- (2-(((/raπs)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 153) (0 055 g, 0 10 mmol), tπethylamme (0 017 mL, 0 12 mmol), and polymer supported carbodiimide (0 12 g, 0 15 mmol) were added The mixture was stirred for 18 hours at room temperature and was then filtered The filtrate was concentrated, and the residue was dissolved in acetonitrile (5 mL) Aqueous sodium hydroxide solution (2 5 N, 1 0 mL) was added and the mixture was stirred for 18 hours at room temperature The acetonitrile was removed in vacuo and the aqueous phase was acidified to pH 6 with an aqueous 10% solution of hydrochloric acid The mixture was extracted with ethyl acetate (3 x 5 mL) The combined organic layers were washed with water (2 x 5 mL) followed by brine (5 mL), dried over anhydrous sodium sulfate, and concentrated The residue was purified by reverse phase preparative HPLC to afford the title compound (23 mg, 45%) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 19 (t, J=6 2 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 31 (d, J=8 1 Hz, 1 H), 7 22 (t, J=8 1 Hz, 1 H), 6 90 (br s , 2 H), 6 80 (d, J=I 3 Hz, 1 H), 5 32 (d, J=5 1 Hz, 1 H), 4 65 (d, J=Q 6 Hz, 2 H), 4 49 (d, J=Q 6 Hz, 2 H), 3 83 - 3 96 (m, 1 H), 3 71 (s, 3 H), 3 42 - 3 55 (m, 1 H), 2 65 (s, 3 H), 1 97 (d, J=2 9 Hz, 1 H), 1 72 (d, J=Q Q Hz, 2 H), 1 61 (d, J=12 4 Hz, 2 H), 0 97 - 1 34 (m, 7 H)
Example 164
/V-(3-Methoxybenzyl)-4-(2-(((frans)-4-(3-aminopropanamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)-
6-methylpicolinamide
A solution of 1 -hydroxybenzotrιazole (3 2 mg, 0 024 mmol) in Λ/,/V-dιmethylformamιde (2 mL) was added to 3-(tert-butoxycarbonyl)propanoιc acid (27 2 mg, 0 144 mmol) Carbodiimide resin (138 mg, 0 18 mmol, 1 30 mmol/g loading), dichloromethane (2 mL), Λ/-(3-methoxybenzyl)-4-(2-(((/rans)-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 153) (52 3 mg, 0 120 mmol), and /V-methylmorpholine (0 066 mL, 0 60 mmol) were added The mixture was agitated at room temperature overnight The reaction mixture was filtered washing with Λ/,Λ/-dιmethylformamιde followed by dichloromethane, and volatiles were removed under a stream of nitrogen The residue was purified by reverse phase preparative HPLC (5%-95% CH3CNZH2O, 8 mm) After concentration, the resulting intermediate was dissolved in a mixture of tnfluoroacetic acid/dichloromethane (1/1 ) and stirred for 1 hour The reaction mixture was filtered and concentrated The residue was suspended in dichloromethane and neutralized using MP-carbonate resin to afford the title compound (10 mg, 16%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 642 mm , m/z 507 (M+H)
Example 165
/V-(3-Methoxybenzyl)-4-(2-(((ffans)-4-(2-methoxyacetamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)- 6-methylpicolinamide
The title compound was prepared in a similar manner to /V-(3-methoxybenzyl)-4-(2-(((<rans)-4- (3-amιnopropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 164) by reaction with 2-methoxyacetιc acid to afford 25 6 mg (42%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 162 mm , m/z 508 (M+H)
Example 166
/V-(3-Methoxybenzyl)-4-(2-(((frans)-4-(3-methoxypropanamido)cyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to A/-(3-methoxybenzyl)-4-(2-(((frans)-4-
(3-amιnopropanamιdo)cyclohexyl)methy!)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 164) by reaction with 3-methoxypropanoιc acid to afford 24 3 mg (39%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 087 mm , m/z 522 (M+H)
Example 167 /V-(3-Methoxybenzyl)-4-(2-((((rans)-4-(2-aminoacetamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4- (S-aminopropanamidoJcyclohexy^methyO-ZH-tetrazol-δ-yO-θ-methylpicolinamide (Example 164) by reaction with 2-(tert-butoxycarbonyl)acetιc acid to afford 10 0 mg (17%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 631 mm , m/z 493 (M+H)
Example 168
/V-(3-Methoxybenzyl)-4-(2-((((raπs)-4-(3-hydroxypropanamido)cyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpicolinamide
Step 1 Preparation of methyl 4-(2-(((/rans)-4-amιnocvclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinate
A mixture of methyl 6-methyl-4-(2H-tetrazol-5-yl)picolinate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((/rans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide, Example 153) (1 5 g, 6 8 mmol), fert-butyl trans-(4- hydroxymethyl)cyclohexylcarbamate (3 14 g, 13 7 mmol), and polymer supported triphenylphosphine resin (6 37 g, 13 7 mmol, 2 15 mmol/g loading) in tetrahydrofuran (75 mL) was cooled in an ice bath Di-fert-butylazodicarboxylate (3 15 g, 13 7 mmol) was added and the mixture was stirred with cooling for 30 minutes The mixture was then allowed to warm to room temperature and stir for 18 hours The reaction mixture was filtered and the resin was washed with tetrahydrofuran and methanol The filtrate was concentrated The residue was dissolved in methanol (25 mL) and treated with 4N hydrochloric acid in dioxane (10 2 mL, 40 8 mmol) for 18 hours at room temperature The reaction mixture was concentrated and the residue washed with ethanol to afford the hydrochloride salt of the product as a solid (2 09 g, 84%) MS (ES+) m/z 331 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 18 (s, 2 H), 1 26 - 1 42 (m, 2 H), 1 65 (d, J= 1 1 28 Hz, 2 H), 1 97 (s, J=9 94 Hz, 3 H), 2 64 (s, 3 H), 2 89 (br s , 1 H), 3 91 (s, 3 H), 4 67 (d, J=6 71 Hz, 2 H), 8 1 1 (s, J= 1 34 Hz, 1 H), 8 25 (br s , 2 H), 8 39 (s, 1 H) Step 2 Preparation of 4-(2-(((frans)-4-(3-hvdroxypropanamιdo)cvclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinic acid
2-(1 /-/-Benzotrιazole-1 -yl)-1 ,1 ,3,3-tetramethyluronιum hexafluorophosphate (775 mg, 2 04 mmol) was added to a solution of methyl 4-(2-(((frans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinate (500 mg, 1 36 mmol), 3-hydroxypropanoιc acid (147 mg, 1 63 mmol), and tπethylamine (0 23 mL, 1 63 mmol) in Λ/,Λ/-dιmethylformamιde (20 mL) The reaction mixture was allowed to stir at room temperature for 2 days and was then treated with lithium hydroxide (326 mg, 13 6 mmol) The mixture was stirred for 18 hours The reaction mixture was acidified with the addition of 3 N hydrochloric acid and then extracted with ethyl acetate The organic layer was dried over magnesium sulfate and concentrated to afford the title compound as a solid
Step 3 Preparation of Λ/-(3-methoxybenzyl)-4-(2-(((/rans)-4-(3- hvdroxypropanamιdo)cvclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
2-(1 H-Benzotπazole-1 -yl)-1 ,1 ,3,3-tetramethyluronιum hexafluorophosphate (109 mg, 0 289 mmol) was added to a solution of 4-(2-(((/rans)-4-(3-hydroxypropanamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnιc acid (50 mg, 0 13 mmol), 3-methoxyphenylmethanamιne (50 mg, 0 36 mmol), and triethylamine (0 07 mL, 0 48 mmol) in Λ/,Λ/-dιmethylformamιde (1 mL), and the mixture was stirred at room temperature for 18 hours The reaction mixture was purified by reverse phase preparative HPLC Fractions containing the product were passed through a carbonate cartridge eluting with methanol and then concentrated to afford the title compound as a white solid (16 mg, 24%) MS (ES+) m/z 508 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 0 99 - 1 23 (m, 4 H), 1 53 -
1 64 (m, 2 H), 1 68 - 1 81 (m, 2 H), 1 86 - 2 03 (m, 2 H), 2 15 (t, J=6 59 Hz, 2 H), 2 44 - 2 48 (m, 1 H),
2 64 (s, 3 H), 3 54 (t, J=Q 22 Hz, 2 H), 3 70 (s, 3 H), 4 48 (d, J=Q 59 Hz, 2 H), 4 63 (d, J=Q 59 Hz, 2 H), 6 78 (d, J=8 05 Hz, 1 H), 6 85 - 6 91 (m, 1 H), 7 12 - 7 25 (m, 2 H), 7 58 (d, J=Q 05 Hz, 1 H), 8 04 (s, 1
H), 8 39 (s, 1 H), 9 18 (t, J=Q 22 Hz, 1 H)
Example 169
1 -(((rans)-4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexyl)-3-methylurea
Methyl isocyanate (1 mL, 4M solution in dichloromethane) and silica-bound 4- (dιmethylamιno)pyrιdιne (833 0 mg, 0 575 mmol, 0 69 mmol/g loading) were added to a solution of Λ/- (3-rnethoxybenzyl)-4-(2-(((/rans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 153) (50 0 mg, 0 115 mmol) in dichloromethane (1 mL) The mixture was agitated overnight at room temperature and was then filtered washing with N, N- dimethylformamide The filtrate was concentrated under a stream of nitrogen The residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound as a solid (22 8 mg, 40%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 963 mm , m/z 493 (M+H) 1H NMR (400 MHz, DMSOd6) ό ppm 0 87 - 1 30 (m, 4 H), 1 48 - 1 68 (m, 2 H), 1 71 -
1 85 (m, 2 H), 1 95 (s, 1 H), 2 38 - 2 53 (m, 3 H), 2 65 (s, 3 H), 3 71 (s, 3 H), 4 49 (d, J=6 6 Hz, 2 H),
464 (d, J=73 Hz, 2 H), 542 - 555 (m, 1 H), 558 - 572 (m, 1 H), 671 - 684 (m, 1 H), 686 - 695 (m,
2 H), 714 - 732 (m, 1 H), 805 (s, 1 H), 840 (s, 1 H), 919 (s, 1 H)
Example 170 W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-aminocyclohexyl)methyl)-2W-tetrazol-5-yl)-6- methylpicolinamide
Step 1 Preparation of 6-methyl-4-(2/-/-tetrazol-5-γl)pιcolιnιc acid
A solution of lithium hydroxide monohydrate (4 1 g, 100 mmol) in water (100 mL) was added to a suspension of methyl 6-methyl-4-(2H-tetrazol-5-yl)picolinate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolmamide, Example 153) in tetrahydrofuran (300 mL) The mixture was heated to reflux overnight, concentrated in vacuo, and dissolved in water The mixture was cooled in an ice/water bath and acidified with 1 N hydrochloric acid The resulting precipitate was filtered, washed with water, and air dried to afford the title compound as an odd-white solid (10 35 g, 100%) MS (ES+) m/z 206 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 8 41 (d, J=O 8 Hz, 1 H), 8 06 (d, J= 1 1 Hz, 1 H), 2 62 (s, 3 H)
Step 2 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolι namide
A mixture of 6-methyl-4-(2H-tetrazol-5-yl)pιcolιnιc acid (27 g, 0 132 mol), 4-fluoro-3- methoxybenzylamine hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3- methoxybenzyl)-6-(2-(((rans-4-arnιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 1 ) (26 5 g, 0 138 mol), tetrahydrofuran (445 mL), and 1 -hydroxybenzotrιazole (18 6 g, 0 138 mmol) was cooled in an ice bath Λ/-Methylmorpholιne (43 5 mL, 0 396 mmol) followed by dimethylsulfoxide (335 mL) and 1-ethyl-3-(3'-dιmethylamιnopropyl)carbodιιmιde hydrochloride (26 5 g, 0 138 mmol) were added The mixture was allowed to warm to room temperature overnight Dimethylsulfoxide (100 mL) was added followed by 1 N hydrochloric acid (400 mL) with ice bath cooling After stirring for 45 mm, the precipitate was filtered The resulting solid was slurried in ethyl acetate, filtered, and dried in vacuo to afford the title compound (31 98 g) MS (ES+) m/z 343 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 30 (t, J=6 4 Hz, 1 H), 8 47 (d, J= 1 1 Hz, 1 H), 8 09 (d, J= 1 2 Hz, 1 H), 7 18 (dd, J=8 5, 1 9 Hz, 1 H), 7 14 (dd, J= 1 1 7, 8 3 Hz, 1 H), 6 90 (ddd, J=8 2, 4 4, 2 0 Hz, 1 H), 4 50 (d, J=6 3 Hz, 2 H), 3 82 (s, 3 H), 2 68 (s, 3 H)
Step 3 Preparation of tert-butyl (frans)-4-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6- methylpyridin^-vO^H-tetrazol^-vQmethvDcvclohexylcarbamate
Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (1 71 g, 5 0 mmol), polymer supported triphenylphosphine (3 49 g, 7 5 mmol), and tert-butyl trans-(4- hydroxymethyl)cyclohexylcarbamate (1 38 g, 6 0 mmol) were suspended in tetrahydrofuran (100 mL) Di-terf-butyl azodicarboxylate (1 73 g, 7 5 mmol) was added The mixture was allowed to stir for 18 hours The reaction mixture was filtered and the resin washed with tetrahydrofuran (100 mL) The filtrate was concentrated The crude product was purified by silica column chromatography (CH2C!2/methanol, 100/1 , 100/2) Combined fractions were concentrated onto silica and repurified by silica column chromatography (heptane/EtOAc, 2/1 , 1/1 ) Combined fractions were concentrated and triturated with heptane to afford the title compound as a white solid (1 903 g, 69%) MS (ES+) m/z 554 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 26 (t, J=6 4 Hz, 1 H), 8 40 (d, J=O 8 Hz, 1 H), 8 05 (d, J= 1 2 Hz, 1 H), 7 15 (dd, J=8 7, 1 9 Hz, 1 H), 7 11 (dd, J=11 7, 8 3 Hz, 1 H), 6 87 (ddd, J=8 3, 4 3, 2 0 Hz, 1 H), 6 68 (d, J=I 7 Hz, 1 H), 4 63 (d, J=7 0 Hz, 2 H), 4 47 (d, J=6 4 Hz, 2 H), 3 79 (s, 3 H), 3 14 (br s , 1 H), 2 64 (s, 3 H), 1 89 (br s , 1 H), 1 78 - 1 70 (m, 2 H), 1 59 - 1 53 (m, 2 H), 1 33 (s, 9 H)1 1 16 - 1 04 (m, 4 H)
Step 3 Preparation of A/-(4-fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-amιnocvclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
terf-Butyl (frans)-4-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexylcarbamate (1 90 g, 3 43 mmol) was dissolved in dichloromethane (20 mL) and tπfluoroacetic acid (5 1 mL, 68 6 mmol) was added The mixture was allowed to stand for 2 hours and was then concentrated The residue was dissolved in dichloromethane (150 mL) and washed with 1 N NaOH solution (2 x 40 mL) The organic layer was dried over sodium sulfate and concentrated to afford the title compound as a glass (1 541 g, 98%) MS (ES+) m/z 454 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 25 (t, J=Q 4 Hz, 1 H), 8 39 (s, 1 H), 8 05 (d, J=1 1 Hz, 1 H), 7 15 (dd, J=Q 5, 1 9 Hz, 1 H), 7 1 1 (dd, J= 1 1 7, 8 3 Hz, 1 H), 6 87 (ddd, J=Q 3, 4 4, 2 0 Hz, 1 H), 4 62 (d, J=I 0 Hz, 2 H), 4 47 (d, J=6 4 Hz, 2 H), 3 79 (s, 3 H), 2 64 (s, 3 H), 2 42 (tt, J= 10 9, 3 4 Hz, 1 H), 1 95 - 1 84 (m, 1 H), 1 71 (d, J= 1 1 1 Hz, 2 H), 1 53 (d, J=12 5 Hz, 2 H), 1 37 (br s , 2 H), 1 07 (q, J=12 1 Hz, 2 H), 0 94 (q, J=1 1 5 Hz, 2 H)
Example 171
/V^-Fluoro-S-methoxybenzyO^^Z-l^fransJ^-acetamidocyclohexyOmethyO^H-tetrazol-S-yO-e- methylpicolinamide
Triethylamine (944 μl, 6 77 mmol), 4-(dιmethylamιno)pyrιdιne (83 mg, 0 68 mmol), and acetyl chloride (289 μL, 4 06 mmol) was added to a solution of N-(4-fluoro-3-methoxybenzyl)-4-(2-(((?rans)-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 170) (1 535 g, 3 39 mmol) in dichloromethane (60 mL) The mixture was allowed to stir at room temperature for 1 hour The reaction mixture was diluted with dichloromethane (150 mL) and washed with saturated aq sodium bicarbonate solution (2 x 40 mL) The organic layer was dried over sodium sulfate and concentrated The crude product was purified by silica column chromatography (CH2CI2/methanol, 100/1 , 100/2, 100/4) Fractions were concentrated The resulting solid was triturated with ethyl ether and filtered to afford the title compound as a white solid (1 370 g, 82%) MS (ES+) m/z 496 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 26 (t, J=6 4 Hz, 1 H), 8 40 (d, J=O 8 Hz, 1 H), 8 05 (d, J=1 2 Hz, 1 H), 7 67 (d, J=I 8 Hz, 1 H), 7 15 (dd, J=8 5, 1 9 Hz, 1 H), 7 1 1 (dd, J=1 1 6, 8 4 Hz, 1 H), 6 87 (ddd, J=Q 3, 4 4, 2 0 Hz, 1 H), 4 64 (d, J=7 1 Hz, 2 H), 4 47 (d, J=6 3 Hz, 2 H), 3 79 (s, 3 H), 3 47 - 3 38 (m, 1 H), 2 65 (s, 3 H), 1 98 - 1 90 (m, 1 H), 1 78 - 1 72 (m, 2 H), 1 72 (s, 3 H), 1 62 - 1 55 (m, 2 H), 1 19 - 1 03 (m, 4 H)
Example 172
W^-Fluoro-S-methoxybenzyO^-IZ^^fransJ^-IS-aminopropanamidoJcyclohexyOmethyO^H- tetrazol-5-yl)-6-methylpicolinamide
O-(7-Azabenzotrιazole-1-yl)-Λ/,W,ΛfΛT-tetramethyluronιum hexafluorophosphate (75 0 mg, 0 198 mmol), 3-(tert-butoxycarbonyl)propanoιc acid (31 2 mg, 0 165 mmol), and dnsopropylethylamine (0 057 mL, 0 330 mmol) were added to a solution of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((fraπs)-4- aminocyclohexyOmethyl^H-tetrazol-S-yO-θ-methylpicolmamide (prepared as described in Example 170) (74 8 mg, 0 165 mmol) in Λ/,Λ/-dιmethylformamιde (2 mL) The mixture was stirred overnight at room temperature Volatiles were removed under a stream of nitrogen The residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound (30 5mg, 35%) LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 3 69 mm , m/z 525 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 0 96 - 1 28 (m), 1 50 - 1 84 (m), 1 88 - 2 05 (m), 2 10 (t, J=6 6 Hz, 2 H), 2 65 (s, 3 H), 2 69 (t, J=Q 6 Hz, 2 H), 3 27 (br s ), 3 46 (br s ), 3 80 (s, 3 H), 4 48 (d, J=5 9 Hz, 2 H), 4 65 (d,
J=66 Hz, 2 H), 678 - 695 (m), 704 - 721 (m), 766 - 775 (m, 1 H), 805 (s, 1 H), 840 (s, 1 H), 914 - 927(m, 1 H)
Example 173
W-(4-Fluoro-3-methoxybenzyl)-4-(2-((((rans)-4-(2-methoxyacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to /V-(4-fluoro-3-methoxybenzyl)-4-(2- (((frans)-4-(3-ammopropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 172) by reaction with 2-methoxyacetιc acid to afford 41 5 mg (48%) LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 4 71 min , m/z 526 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 1 07 - 1 35 (m, 4 H), 1 55 - 1 80 (m, 4 H), 1 87 - 2 03 (m, 1 H), 2 65 (s, 3 H), 3 44 - 3 63 (m, 1 H), 3 72 (s, 3 H), 3 80 (s, 3 H), 4 48 (d, J=6 6 Hz, 2 H), 4 65 (d, J=6 6 Hz, 2 H), 6 84 - 6 92 (m, 1 H), 7 06 - 7 20 (m, 2 H), 7 42 - 7 50 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 1 1 - 9 27 (m, 1 H)
Example 174
W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-(3-methoxypropanamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(4-fluoro-3-methoxybenzyl)-4-(2- (((fransH^S-aminopropanamidoJcyclohexyOmethyO^H-tetrazol-S-yO-θ-methylpicolinamide (Example 172) by reaction with 3-methoxypropanoιc acid to afford 52 7 mg (59%) LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 4 61 mm , m/z 540 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 1 02 - 1 25 (m, 4 H), 1 56 - 1 83 (m, 4 H), 1 90 - 2 02 (m, 1 H), 2 23 (t, J=6 2 Hz, 2 H), 2 65 (s, 3 H), 3 28 (s), 3 47 (t, J=6 6 Hz, 2 H), 3 80 (s, 3 H), 4 48 (d, J=6 6 Hz, 2 H), 4 65 (d, J=6 6 Hz, 2 H), 6 84 - 6 92 (m, 1 H), 7 05 - 7 20 (m, 2 H), 7 61 - 7 68 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 18 - 9 26 (m, 1 H)
Example 175 W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((fraπs)-4-(2-aminoacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
NH2 The title compound was prepared in a similar manner to /V-(4-fluoro-3-methoxybenzyl)-4-(2-
(((frans)-4-(3-amιnopropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 172) by reaction with 2-(tert-butoxycarbony!)acetιc acid to afford 34 5 mg (41%) LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 3 66 mm , m/z 511 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 07 - 1 27 (m, 4 H), 1 53 - 1 84 (m, 4 H), 1 91 - 2 03 (m, 1 H), 2 65 (s, 3 H), 3 01 (s, 2 H), 3 28 (br s ), 3 41 - 3 58 (m, 1 H), 3 80 (s, 3 H), 4 48 (d, J=δ 6 Hz, 2 H), 4 65 (d, J=6 6 Hz, 2 H), 6 85 - 6 91 (m, 1 H), 7 06 - 7 20 (m, 2 H), 7 53 - 7 61 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 16 - 9 27 (m, 1 H) Example 176
2-((<rans)-4-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexylamino)-2-oxoethyl acetate
The title compound was prepared in a similar manner to Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-
(((frans)-4-(3-ammopropanamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide (Example 172) by reaction with 2-acetoxyacetιc acid to afford 48 0 mg (53%) LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 4 76 mm , m/z 554 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 1 07 - 1 26 (m, 4 H), 1 56 - 1 81 (m, 4 H), 1 90 - 2 02 (m, 1 H), 2 04 (s, 3 H), 2 65 (s, 3 H), 3 42 - 3 56 (m, 1 H), 3 80 (s, 3 H), 4 36 (s, 2 H), 4 48 (d, J=5 9 Hz, 2 H), 4 65 (d, J=6 6 Hz, 2 H), 6 84 - 6 93 (m, 1 H), 7 06 - 7 20 (m, 2 H), 7 74 - 7 82 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 17 - 9 25 (m, 1 H)
Example 177
/V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-(2-hydroxyacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(4-fluoro-3-methoxybenzyl)-4-(2- (((frans)-4-(3-amιnopropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 172) by reaction with 2-hydroxyacetιc acid to afford 41 0 mg (49%) LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 4 41 mm , m/z 512 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 1 07 - 1 39 (m, 4 H), 1 53 - 1 79 (m, 4 H), 1 88 - 2 05 (m, 1 H), 2 65 (s, 3 H), 3 48 - 3 61 (m, 1 H), 3 73 (s, 3 H), 3 80 (s, 2 H), 4 48 (d, J=6 6 Hz, 2 H), 4 65 (d, J=I 3 Hz, 2 H), 6 85 - 6 92 (m, 1 H), 7 06 - 7 19 (m, 2 H), 7 33 - 7 40 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 17 - 9 26 (m, 1 H)
Example 178
/V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-(3-hydroxypropanamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4- (S-hydroxypropanamidoJcyclohexyOmethyO^H-tetrazol-δ-yO-θ-methylpicolinamide (Example 168) by reaction with 4-fluoro-3-methoxybenzylamιne hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-((/rans-4-amιnocyclohexyl)methyl)-2H-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde, Example 1 ) to afford 25 mg (37%) of a white solid MS (ES+) m/z 526 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 1 05 - 1 25 (m, 4 H), 1 57 - 1 68 (m, 2 H), 1 73 - 1 84 (m,
2 H), 1 92 - 2 04 (m, 1 H), 2 19 (t, J=6 59 Hz, 2 H), 2 54 (s, 2 H), 2 67 (s, 3 H), 3 53 - 3 62 (m, 2 H),
382 (s, 3 H), 451 (d, J=586 Hz, 2 H), 467 (d, J=I 32 Hz, 2 H), 686 - 695 (m, 1 H), 706 - 725 (m, 2 H), 762 (d, J=I 32 Hz, 1 H), 807 (s, 1 H), 843 (s, 1 H), 924 (t, J=622 Hz, 1 H)
Example 179
/V-(4-Fluoro-3-methoxybenzyl)-4-(2-((((rans)-4-(2-hydroxy-2- methylpropanamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide
Step 1 Preparation of methyl 4-(2-(((frans)-4-(2-hydroxy-2-methylpropanamιdo)cyclohexyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcohnate
A mixture of 2-hydroxy isobutyric acid (25 mg, 0 24 mmol) and 1 -hydroxybenzatrιazole (37 mg, 0 27 mmol) in 2- methyl tetrahydrofuran (2 mL) was stirred for 5 minutes 4-(2-(((frans)-4- Amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnate (prepared as described in step 1 of the synthesis of /V-(3-methoxybenzyl)-4-(2-(((frans)-4-(3-hydroxypropanamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde, Example 168) (0 10 g, 0 23 mmol), triethylamine (0 038 mL, 0 27 mmol), and polymer supported carbodiimide (0 27 g, 0 34 mmol) were added The mixture was stirred for 18 hours at room temperature The reaction mixture was filtered The filtrate was washed with water (3 x 5 mL) followed by brine (5 mL), dried over anhydrous sodium sulfate, and concentrated The residue was purified by silica column chromatography (0-50% ethyl acetate/heptane) to afford the title compound (65 mg, 69%)
Step 2 Preparation of 4-(2-(((/rans)-4-(2-hvdroxy-2-methylpropanamιdo)cvclohexyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnιc acid
Aqueous sodium hydroxide (2 5 N, 1 0 mL) was added to a solution of methyl 4-{2-(((trans)-4- (2-hydroxy-2-methylpropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnate (65 mg, 0 16 mmol) in acetonitrile (2 mL), and the mixture was stirred for 1 hour at room temperature The acetonitπle was removed in a stream of nitrogen Water (1 mL) was added to the residue and the mixture was acidified to pH 6 with 10% aqueous hydrochloric acid The resulting solid was collected by filtration, washed with water (2 x 2 mL), and dried to afford the title compound (53 mg, 84%) MS (ES+) m/z 403 (M+H)
Step 3 Preparation of Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((fraπs)-4-(2-hydroxy-2- methylpropanamido^vclohexyDmethvD^H-tetrazol-δ-vD-e-methylpicolinamide
A mixture of 4-(2-(((frans)-4-(2-hydroxy-2-methylpropanamιdo)cyclohexyl)methyl)-2H-tetrazol-
5-yl)-6-methylpιcolιnιc acid (0 040 g, 0 10 mmol) and 1 -hydroxybenzatrιazole (21 mg, 0 12 mmol) in Λ/,Λ/-dιmethylformamιde was stirred for 15 minutes 4-Fluoro-3-methoxybenzy!amιne hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-((frans-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)pyπmιdιne-4-carboxamιde, Example 1 ) (27 mg, 0 16 mmol) was then added followed by polymer supported carbodiimide (0 135 g, 0 15 mmol) The mixture was stirred for 18 hours at room temperature The reaction mixture was filtered, and the filtrate was extracted by ethyl acetate (3 x 5 mL) The combined organic layers were washed with water (2 x 5 mL) followed by brine (5 mL), dried over anhydrous sodium sulfate, and concentrated The residue was purified by reverse phase preparative HPLC to afford the title compound (8 3 mg, 15%) 1H NMR (400 MHz, DMSO-cfe) δ ppm 9 21 (s, 1 H), 8 41 (br s , 1 H), 8 06 (br s , 1 H), 7 06 - 7 28 (m, 2 H), 6 88 (d, J=8 8 Hz, 1 H), 6 43 (br s , 1 H), 5 25 (br s , 1 H), 4 67 (d, J=3 7 Hz, 2 H), 4 48 (d, J=5 9 Hz, 2 H), 3 80 (s, 3 H), 3 60 (d, J=9 5 Hz, 1 H), 2 66 (s, 3 H), 2 05 (s, 1 H), 1 72 (d, J= 1 1 7 Hz, 2 H), 1 60 (d, J=7 3 Hz, 2 H), 1 10 - 1 34 (m, 9 H) Example 180
/V^S-EthoxybenzylJ-e-methyl^^Z^^fransJ^^methylsulfonamidoJcyclohexyOmethyO-ΣH- tetrazol-5-yl)picolinamide
Step 1 Preparation of 6-methyl-4-(2-(((/rans)-4-(methylsulfonamιdo)cvclohexyl)methyl)-2H-tetrazol-5- vDpicolinic acid
Diisopropylethylamine (O 59 mL, 3 4 mmol) and methanesulfonyl chloride (0 16 mL, 2 1 mmol) were added to a solution of methyl 4-(2-(((<rans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinate (prepared as described in step 1 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2- (((frans)-4-(3-hydroxypropanamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 168) (125 mg, 0 34 mmol) in Λ/,Λ/-dιmethylformamιde (1 mL) The mixture was allowed to stir at room temperature overnight The reaction mixture was concentrated and the residue was dissolved in tetrahydrofuran (8 mL) A 4N aqueous solution of lithium hydroxide (2 mL) was added and the mixture was allowed to stir for 4 hours The reaction mixture was concentrated and purified by reverse phase preparative HPLC (20-60% acetonitrile/water) to afford the title compound (42 mg, 25%)
Step 2 Preparation of (3-ethoxyphenyl)methanamιne
Lithium aluminum hydride (59 5 g) was added to anhydrous ethyl ether (900 mL) cooled to 10 0C A solution of 3-ethoxybenzonιtrιle (35 5 g) in anhydrous ethyl ether (100 mL) was added over 1 25 hours, and the mixture was stirred for 4 5 hours The reaction mixture was quenched with water (60 mL) and was stirred for 1 25 hours A 15% aqueous solution of sodium hydroxide (60 mL) was added followed by ether (500 mL) and water (180 mL) The slurry was filtered The filtrate was dried over sodium sulfate and concentrated to afford the title compound as an oil (35 3 g) MS (ES+) m/z 152 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 7 20 (t J=8 1 , 1 H), 6 87-6 72 (m, 3 H), 4 00 (q, J=6 9, 2 H), 3 78 (s, 2 H), 1 38 (t, J=7 2, 3 H) Step 3 Preparation of Λ/-(3-ethoxybenzyl)-6-methyl-4-(2-(((frans)-4- (methylsulfonamιdo)cvclohexyl)methyl)-2/-/-tetrazol-5-yl)pιcolιnamιde
In a 2 dram vial with a magnetic stir bar, 6-methyl-4-(2-(((frans)-4- (methylsulfonamido)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)picolinic acid (70 mg, 0 177 mmol) was dissolved in Λ/,Λ/-dιmethylformamιde (2 mL) Dnsopropylethylamine (0 19 mL, 1 06 mmol) and (3- ethoxyphenyl)methanamιne (33 4 mg, 0 221 mmol) were added and the mixture was stirred for 30 minutes O-(1 H-Benzotrιazol-1 -yl)-Λ/,W,Λ/\ Λ/Metramethyluronium tetrafluoroborate (128 mg, 0 398 mmol) was added and stirring continued at room temperature overnight The reaction mixture was purified by reverse phase preparative HPLC to afford the title compound (27 2 mg) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 3 54 mm, m/z 514 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 06 - 1 33 (m, 8 H), 1 54 - 1 65 (m, 3 H), 1 82 - 1 98 (m, 3 H), 2 45 - 2 50 (m, 1 H), 2 50 - 2 53 (m, 1 H), 2 61 - 2 68 (m, 3 H), 2 80 - 2 88 (m, 3 H), 2 97 - 3 08 (m, 1 H), 3 94 - 3 98 (m, 2 H), 4 43 - 4 52 (m, 2 H), 4 58 - 4 69 (m, 2 H), 6 73 - 6 80 (m, 1 H), 6 83 - 6 97 (m, 2 H), 7 15 - 7 26 (m, 1 H), 8 02 - 8 07 (m, 1 H), 8 38 - 8 43 (m, 1 H), 9 14 - 9 23 (m, 1 H)
Example 181
W-(4-Fluoro-3-(hydroxymethyl)benzyl)-6-methyl-4-(2-((((rans)-4- (methylsulfonamidoJcyclohexyOmethyO-ZH-tetrazol-S-yOpicolinamide
Step 1 Preparation of (5-(amιnomethyl)-2-fluorophenyl)methanol
In a 250 round bottomed flask with a magnetic stir bar, 4-fluoro-3-formylbenzonιtrιle (1 50 g, 10 06 mmol) was dissolved in tetrahydrofuran (30 mL) The mixture was cooled in an ice bath to 0 0C and lithium aluminum hydride (573 mg, 15 1 mmol) was added The reaction mixture was stirred at 0 0C for 3 hours and then was allowed to warm to room temperature and stir overnight The mixture was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound as a white solid (478 mg, 30%) MS (ES+) m/z 156 (M+H) 1H NMR (400 MHz, methanol- d4) δ ppm 4 09 (s, 2 H), 4 68 (s, 2 H), 7 13 (dd, J=9 67, 8 59 Hz, 1 H), 7 31 - 7 44 (m, 1 H), 7 56 (dd, J=6 85, 2 28 Hz, 1 H) Step 2 Preparation of Λ/-(4-fluoro-3-(hvdroxymethyl)benzyl)-6-methyl-4-(2-(((frans)-4- (methylsulfonamidotovclohexyOmethvO^H-tetrazol-δ-vQpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-ethoxybenzyl)-6-methyl-4-(2-(((frans)-4- (methylsulfonamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde (Example 180) by reaction with (5-(amιnomethyl)-2-fluorophenyl)methanol to afford 14 1 mg 1H NMR (400 MHz, CD3OD) δ ppm 1 28 (d, ./=1 1 6 Hz, 4 H), 1 34 (d, 1 H), 1 73 (s, 2 H), 2 67 (s, 3 H), 3 12 - 3 22 (m, 1 H), 4 59 - 4 64 (m, 6 H), 7 02 (s, 1 H), 7 26 - 7 34 (m, 1 H), 7 45 - 7 51 (m, 1 H), 8 09 (d, J=1 1 Hz, 1 H)
Example 182 /V^-Fluoro-S-methoxybenzyO-e-methyM-l∑-^lfransJ^^methylsulfonamidoJcyclohexyOmethyl)-
2H-tetrazol-5-yl)picolinamide
The title compound was prepared in a similar manner to /V-(3-ethoxybenzyl)-6-methyl-4-(2- (((frans)-4-(methylsulfonamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)picolinamide (Example 180) by reaction with 4-fluoro-3-methoxybenzylamιne hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-((frans-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde, Example 1 ) to afford 15 9 mg 1H NMR (400 MHz, DMSO-Cf6) δ ppm
1 07 - 1 27 (m, 5 H), 1 61 (d, J=10 3 Hz, 2 H), 1 89 (d, J=10 3 Hz, 2 H), 2 51 (s, 1 H), 2 65 (s, 3 H),
286 (s, 3 H), 296 - 311 (m, 2 H), 327 (s, 1 H), 380 (s, 3 H), 448 (d, J=59 Hz, 2 H), 464 (d, J=66 Hz, 2 H), 685 - 695 (m, 2 H), 705 - 719 (m, 2 H), 803 - 807 (m, 1 H), 837 - 843 (m, 1 H), 915 -
925(m, 1 H)
Example 183
/V-(3-(Hydroxymethyl)benzyl)-6-methyl-4-(2-(((frans)-4-(methylsulfonamido)cyclohexyl)methyl)-
2H-tetrazol-5-yl)picolinamide
Step 1 Preparation of (3-(amιnomethyl)phenyl)methanol
To a refluxing (33 8 0C) suspension of lithium aluminum hydride (20 0 g) in anhydrous ethyl ether (300 mL) under nitrogen was added portionwise of 3-cyanobenzaldehyde (10 51 g) over a 2 mm period The resulting slurry was heated at reflux for 10 hours The reaction mixture was cooled in an ice bath and water (20 mL) was added in 1 mL increments while keeping the temperature < 20 0C A 15 % sodium hydroxide solution (20 mL) was added in a similar fashion, followed by water (60 mL) The resulting solids were filtered off and washed The filtrate was concentrated in vacuo The residue was dissolved in a mixture of dichloromethane/methanol/ammonium hydroxide (95/5/0 5, 10 mL), filtered, and purified by silica column chromatography eluting with the same to afford the title compound as a light yellow oil (4 25 g)
Step 2 Preparation of Λ/-(3-(hvdroxymethyl)benzyl)-6-methyl-4-(2-(((frans)-4- (methylsulfonamido)cvclohexyl)methyl)-2H-tetrazol-5-yl)picolinamide
The title compound was prepared in a similar manner to Λ/-(3-ethoxybenzyl)-6-methyl-4-(2-
(((<rans)-4-(methylsulfonamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)pιcolιnamιde (Example 180) by reaction with (3-(amιnomethyl)phenyl)methanol to afford 27 2 mg 1H NMR (400 MHz, DMSO-d6) δ ppm 1 07 - 1 28 (m, 5 H), 1 61 (d, J=10 3 Hz, 3 H), 1 89 (d, J= 1 1 0 Hz, 2 H), 2 65 (s, 3 H), 2 85 (s, 3 H), 2 97 - 3 08 (m, 1 H), 3 32 (s, 1 H), 4 45 (d, J=5 1 Hz, 2 H), 4 51 (d, J=6 6 Hz, 2 H), 4 64 (d, J=7 3 Hz, 2 H), 6 92 (d, J=I 3 Hz, 1 H), 7 13 - 7 21 (m, 1 H), 7 22 - 7 30 (m, 2 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 20 (t, _/=6 2 Hz, 1 H)
Example 184
/V-(3-(2-Hydroxyethoxy)benzyl)-6-methyl-4-(2-(((frans)-4- (methylsulfonamido)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)picolinamide
The title compound was prepared in a similar manner to Λ/-(3-ethoxybenzyl)-6-methyl-4-(2- (((frans)-4-(methylsulfonamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde (Example 180) by reaction with 2-(3-(amιnomethyl)phenoxy)ethanol (prepared as described in step 2 of the synthesis of Λ/-(3-(2-hydroxyethoxy)benzy!)-6-(2-(((<rans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-2- methylpyrιmιdιne-4-carboxamιde, Example 13) to afford 10 6 mg 1H NMR (400 MHz, DMS0-c/6) δ ppm 1 08 - 1 27 (m, 5 H), 1 61 (d, J=10 3 Hz, 2 H), 1 89 (d, J=9 5 Hz, 2 H), 2 51 (s, 1 H), 2 65 (s, 3 H), 2 86 (s, 3 H), 3 03 (s, 1 H), 3 67 (t, J=4 8 Hz, 2 H), 3 93 (t, J=5 1 Hz, 2 H), 4 49 (d, J=6 6 Hz, 2 H), 4 64 (d, J=7 3 Hz, 2 H), 6 79 (d, J=7 3 Hz, 1 H), 6 86 - 6 95 (m, 3 H), 7 20 (t, J=8 1 Hz, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 19 (t, J=6 2 Hz, 1 H)
Example 185
/V-(4-Fluoro-3-methylbenzyl)-4-(2-(((frans)-4-aminocyclohexyl)methyl)-2W-tetrazol-5-yl)-6- methylpicolinamide
Step 1 Preparation of Λ/-(4-fluoro-3-methylbenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde
Tetrahydrofuran (2 mL) and 4-fluoro-3-methy!benzylamιne (3 5 g) was added to methyl 6- methyl-4-(2/-/-tetrazol-5-yl)pιcolιnate (prepared as described in step 4 of the synthesis of Λ/-(3- methoxybenzyl)-4-(2-(((/rans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (2 69 g) The resultant slurry was treated with Λ/,/V-dιmethylacetamιde (2 mL) and heated to 90 0C After 3 h, the mixture was allowed to cool to room temperature, treated with 1 N hydrochloric acid, diluted with water and filtered The crude product was triturated with methanol, (50 mL) to provided the title compound as a solid (2 06 g, 51 %) MS(ES+) m/z 327 (M+H), 1H NMR (400 MHz, DMSOd6) δ ppm 2 18 (d, J=1 6 Hz, 3 H), 2 65 (s, 3 H), 4 45 (d, J=6 2 Hz, 2 H), 7 05 (t, 1 H), 7 13 - 7 20 (m, 1 H), 7 22 (d, J=7 5 Hz, 1 H), 8 06 (d, J=1 3 Hz, 1 H), 8 45 (d, J=1 1 Hz, 1 H), 9 27 (t, J=6 3 Hz, 1 H)
Step 2 Preparation of tert-butyl (frans)-4-((5-(2-((4-fluoro-3-methylbenzyl)carbamoyl)-6-methylpyridm- 4-yl)-2H-tetrazol-2-yl)methyl)cvclohexylcarbamate
To Λ/-(4-fluoro-3-methylbenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (1 95 g) was added fert-butyl-frans-(4-hydroxymethyl)cyclohexylcarbamate (1 65 g), polymer supported triphenylphosphine (7 00 g, Argonaut, 2 15 mmol/g) and anhydrous THF (60 mL) The stirred mixture was cooled in an ice-water bath and treated with di-tert-butyl azodicarboxylate (2 76 g) The mixture was concentrated in vacuo and the residue was purified by silica column chromatography (40% ethyl acetate/hexanes) to afford the title compound as a white, crystalline solid (2 00 g, 62%) MS(ES+) 538 (M+H), 1H NMR (400 MHz, CDCI3) δ ppm 1 02 - 1 30 (m, 4 H), 1 42 (s, 9 H), 1 56 - 1 65 (m, 1 H), 1 71 (d, J=13 2 Hz, 2 H), 2 00 - 2 12 (m, 3 H), 2 26 (d, J= 1 9 Hz, 3 H), 2 63 (s, 3 H), 4 37 (s, 1 H), 4 52 (d, J=7 3 Hz, 2 H), 4 61 (d, J=6 2 Hz, 2 H), 6 96 (t, 1 H), 7 1 1 - 7 23 (m, 2 H), 8 04 (d, J= 1 1 Hz, 1 H), 8 40 (t, 1 H), 8 71 (s, 1 H)
Step 3 Preparation of Λ/-(4-fluoro-3-methylbenzyl)-4-(2-(((trans)-4-amιnocvdohexyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnamιde
Tπfluoroacetic acid (5 mL) was added to a solution of tert-butyl (frans)-4-((5-(2-((4-fluoro-3- methylbenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexylcarbamate (849 5 mg, 1 58 mmol) in dichloromethane (5 mL), and the mixture was stirred for 30 minutes The reaction mixture was concentrated under a stream of nitrogen The residue was dissolved in dichloromethane and neutralized with MP-carbonate resin The mixture was filtered, washed with dichloromethane followed by methanol, and concentrated under a stream of nitrogen to afford the title compound (781 mg) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 625 mm , m/z 438 (M+H)
Example 186 N-(4-fluoro-3-methylbenzyl)-6-methyl-4-(2-(((<rans)-4-(methylsulfonamido)cyclohexyl)methyl)-
2H-tetrazol-5-yl)picolinamide
Triethylamine (0 071 mL, 0 513 mmol) and methane sυlfonyl chloride (0 020 mL, 0 257 mmo!) was added to a solution of Λ/-(4-fluoro-3-methylbenzyl)-4-(2-(((<rans)-4-amιnocydohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 185) (75 0 mg, 0 171 mmol) in tetrahydrofυran (2 mL) The mixture was stirred for approximately 30 mm at room temperature and was then concentrated under a stream of nitrogen The residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound as a solid (29 mg, 33%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 365 mm , m/z 516 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 0 91 - 1 35 (m, 4 H), 1 49 - 1 68 (m, 2 H), 1 75 - 2 02 (m, 3 H), 2 19 (s, 3 H), 2 65 (s, 3 H), 2 85 (s, 3 H), 2 94 - 3 13 (m, 1 H), 4 45 (d, J=6 6 Hz, 2 H), 4 64 (d, J=7 3 Hz, 2 H), 6 88 - 6 97 (m, 1 H), 6 99 - 7 09 (m, 1 H), 7 12 - 7 21 (m, 1 H), 7 21 - 7 27 (m, 1 H), 8 00 - 8 08 (m, 1 H), 8 35 - 8 45 (m, 1 H), 9 14 - 9 25 (m, 1 H)
Example 187
/V-(4-Fluoro-3-methylbenzyl)-4-(2-(((fraπs)-4-acetamidocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Acetic anhydride (0 065 mL, 0 687 mmol) and 4-(dιmethylamιno)pyrιdιne Si bound (1 659 g, 1 145 mmol, 0 69 mmol/g loading) was added to a solution of Λ/-(4-fluoro-3-methylbenzyl)-4-(2- (((fraπs)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 185) (100 0 mg, 0 229 mmol) in dichloromethane (2 mL) The mixture was agitated overnight at room temperature, filtered, and Λ/,Λ/-dιmethylformamιde The filtrate was concentrated under a stream of nitrogen The residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound as a solid (33 mg, 30%) LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 4 82 mm , m/z 480 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 0 95 - 1 29 (m), 1 53 - 1 82 (m), 1 90 - 2 04 (m, 1 H), 2 19 (s, 3 H), 3 35 - 3 52 (m, 1 H), 4 46 (d, J=5 9 Hz, 2 H), 4 64 (d, J=6 6 Hz, 2 H), 6 99 - 7 08 (m, 1 H), 7 13 - 7 21 (m, 1 H), 7 21 - 7 28 (m, 1 H), 7 59 - 7 67 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 16 - 9 24 (m, 1 H) Example 188
W-(4-Fluoro-3-methylbenzyl)-4-(2-((((rans)-4-(3-aminopropanamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
O-(7-Azabenzotrιazole-1-yl)-Λ/,Λ/,Λ/Α/'-tetramethyluronιum hexafluorophosphate (78 0 mg,
0 205 mmol), 3-(tert-butoxycarbonyl)propanoιc acid (32 4 mg, 0 171 mmol), and dnsopropylethylamine (0 060 mL, 0 342 mmol) was added to a solution of Λ/-(4-fluoro-3-methylbenzyl)-4-(2-(((/rans)-4- aminocyclohexyOmethyO^H-tetrazol-S-ylJ-β-methylpicolinamide (prepared as described in Example 185) (100 0 mg, 0 229 mmol) (75 0 mg, 0 171 mmol) in Λ/,Λ/-dιmethylformamιde (2 mL) The mixture was stirred overnight at room temperature and was then concentrated under a stream of nitrogen The residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) The resulting intermediate was dissolved in dichloromethane and trifluoroacetic acid was added The mixture was stirred for approximately 30 mm and then concentrated under a stream of nitrogen The residue was dissolved in dichloromethane and stirred with MP-carbonate resin for approximately 30 minutes The mixture was filtered and washed with dichloromethane followed by methanol The filtrate was concentrated under a stream of nitrogen to afford the title compound as a solid (15 mg, 17%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 833 mm , m/z 509 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 0 98 - 1 20 (m, 4 H), 1 49 - 1 65 (m, 2 H), 1 67 - 1 82 (m, 2 H), 1 94 (s, 3 H), 2 06 - 2 14 (m, 2 H), 2 17 (s, 3 H), 2 49 - 2 56 (m, 2 H), 2 60 (s, 3 H), 4 43 (d, J=6 6, Hz, 2 H), 4 59 (d, J=6 6 Hz, 2 H), 6 95 - 7 07 (m, 1 H), 7 10 - 7 19 (m), 7 21 (m, 1 H), 7 70 (m, 1 H), 7 96 (s, 1 H), 8 34 (s, 1 H), 9 08 - 9 18 (m, 1 H)
Example 189
W-(4-Fluoro-3-methylbenzyl)-4-(2-(((frans)-4-(2-methoxyacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(4-fluoro-3-methylbenzyl)-4-(2- (((fΛansH^S-aminopropanamido^yclohexyOmethyO^H-tetrazol-S-yO-θ-methylpicolmamide (Example 188) by reaction with 2-methoxyacetιc acid to afford 42 2 mg (48%) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm, 95% CH3CN, 1 5 mm ) 3 356 mm , m/z 510 (M+H) 1H NMR (400 MHz, DMSO- Of6) ό ppm 0 99 - 1 39 (m, 4 H), 1 51 - 1 81 (m, 4 H), 1 83 - 2 07 (m, 2 H), 2 19 (s, 3 H), 2 65 (s, 3 H), 3 43 - 3 63 (m, 2 H), 3 72 (s, 3 H), 4 45 (d, J=Q 6 Hz, 2 H), 4 65 (d, J=I 3 Hz, 2 H), 6 96 - 7 10 (m, 1 H), 7 12 - 7 21 (m, 1 H), 7 20 - 7 29 (m, 1 H), 7 39 - 7 50 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 13 - 9 26 (m, 1 H)
Example 190
2-((fraπs)-4-((5-(2-((4-Fluoro-3-methylbenzyl)carbamoyl)-6-methylpyridin-4-yl)-2W-tetrazol-2- yl)methyl)cyclohexylamino)-2-oxoethyl acetate
The title compound was prepared in a similar manner to /V-(4-fluoro-3-methylbenzyl)-4-(2- (((fransH^S-ammopropanamidoJcyclohexyOmethyO^H-tetrazol-S-yO-e-methylpicolinamide (Example 188) by reaction with 2-acetoxyacetιc acid to afford 49 2 mg (54%) as a solid LC/MS (5%-95%
CH3CN/H2O, 4 5 mm, 95% CH3CN, 1 5 mm ) 3 353 mm 538 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 00 - 1 31 (m, 4 H), 1 49 - 1 84 (m, 4 H), 1 87 - 2 01 (m, 1 H), 2 03 (s, 3 H), 2 19 (s, 3 H), 2 65 (s, 3 H), 3 39 - 3 61 (m, 1 H), 4 36 (s, 2 H), 4 45 (d, J=5 9 Hz, 2 H), 4 65 (d, J=I 3 Hz, 2 H), 6 96 - 7 10 (m, 1 H)1 7 12 - 7 21 (m, 1 H), 7 21 - 7 28 (m, 1 H), 7 71 - 7 84 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 16 - 9 25 (m, 1 H)
Example 191
W-(4-Fluoro-3-methylbenzyl)-4-(2-(((frans)-4-(2-hydroxyacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(4-fluoro-3-methylbenzyl)-4-(2-
(((^Λaπs^^S-aminopropanamido^yclohexy^methylJ^H-tetrazol-δ-yO-θ-methylpicolinamide (Example 188) by reaction with 2-hydroxyacetιc acid to afford 37 5 mg (44%) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 080 mm , m/z 496 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 1 04 - 1 42 (m, 4 H), 1 50 - 1 83 (m, 4 H), 1 85 - 2 07 (m, 1 H), 2 19 (s, 3 H), 2 65 (s, 3 H), 3 41 - 3 64 (m, 1 H), 3 73 (s, 2 H), 4 45 (d, J=Q 6 Hz, 2 H), 4 65 (d, J=I 3 Hz, 2 H), 6 97 - 7 11 (m, 1 H), 7 13 - 7 21 (m, 1 H), 7 21 - 7 27 (m, 1 H), 7 32 - 7 43 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 13 - 9 26 (m, 1 H) Example 192
/V-(4-Fluoro-3-methylbenzyl)-4-(2-((((rans)-4-(3-methoxypropanamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(4-fluoro-3-methylbenzyl)-4-(2-
(((/rans)-4-(3-amιnopropanamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 188) by reaction with 3-methoxypropanoιc acid to afford 39 7 mg (44%) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 298 mm , m/z 524 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 00 - 1 22 (m, 4 H), 1 52 - 1 82 (m, 4 H), 1 87 - 2 03 (m, 1 H), 2 19 (s, 3 H), 2 23 (t, J=6 6 Hz, 2 H), 2 65 (br s , 6 H), 3 35 - 3 54 (m, 3 H), 4 45 (d, J=6 6 Hz, 2 H), 4 64 (d, J=I 3 Hz, 2 H)1 6 96 - 7 09 (m, 1 H), 7 1 1 - 7 20 (m, 1 H), 7 20 - 7 27 (m, 1 H), 7 55 - 7 75 (m, 1 H), 7 97 - 8 09 (m, 1 H), 8 35 - 8 46 (m, 1 H), 9 15 - 9 27 (m, 1 H)
Example 193
N-(4-fluoro-3-methylbenzyl)-4-(2-((((rans)-4-(2-aminoacetamido)cyclohexyl)methyl)-2H-tetrazol- 5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(4-fluoro-3-methylbenzyl)-4-(2- (((/rans)-4-(3-amιnopropanamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 188) by reaction with 2-(tert-butoxycarbonyl)acetιc acid to afford 33 7 mg (40%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 790 mm , m/z 495 (M+H) 1H NMR (400 MHz,
DMSO-d6) 6 ppm 1 08 - 1 28 (m, 4 H), 1 52 - 1 83 (m, 4 H), 1 89 - 2 04 (m, 1 H), 2 19 (s, 3 H), 2 65 (s, 3 H), 3 01 (s, 2 H), 3 38 - 3 57 (m, 1 H), 4 45 (d, J=5 9 Hz, 1 H), 4 65 (d, J=I 3 Hz, 1 H), 7 00 - 7 09 (m, 1 H), 7 1 1 - 7 19 (m, 1 H), 7 21 - 7 28 (m, 1 H), 7 51 - 7 62 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 17 - 9 26 (m, 1 H)
Example 194
/V-(3-Chloro-4-fluorobenzyl)-4-(2-((((rans)-4-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Step 1 Preparation of Λ/-(3-chloro-4-fluorobenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde
4-Fluoro-3-chlorobenzylamιne (3 52 g) was added to a solution of methyl 6-methyl-4-(2H- tetrazol-5-yl)pιcolιnate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2- (((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (2 20 g) in Λ/,Λ/-dιmethylacetamιde (4 mL) The mixture was heated to 90 0C for 2 hours The reaction mixture was allowed to cool, treated with water and filtered The solids were triturated with methanol (50 mL) overnight to afford the title compound as an off-white solid (2 00 g, 47%) MS(ES+) m/z 347 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 2 66 (s, 3 H), 4 49 (d, J=Q 4 Hz, 2 H), 7 30 - 7 39 (m, 1 H), 7 53 (d,
J=I 8 Hz, 1 H), 8 07 (d, J=1 1 Hz, 1 H), 8 44 (s, 1 H), 9 40 (t, J=G 4 Hz, 1 H) 19 F NMR (376 MHz, DMSO-c/6) δ ppm -1 19 66 (q)
Step 2 Preparation of tert-butyl (^ans)-4-((5-(2-((3-chloro-4-fluorobenzyl)carbamoyl)-6-methylpyrιdιn- 4-yl)-2/-/-tetrazol-2-yl)methyl)cvclohexylcarbamate
fert-Butyl-trans-(4-hydroxymethyl)cyclohexylcarbamate (1 46 g), polymer supported triphenylphosphine (Argonaut, 2 15 mmol/g, 6 17 g), and anhydrous tetrahydrofuran (55 mL) were added to Λ/-(3-chloro-4-fluorobenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (1 84 g) The stirred mixture was cooled in an ice-water bath and treated with di-tert-butyl azodicarboxylate (2 45 g) After 30 mm, the ice bath was removed and the mixture allowed to stir overnight at room temperature The mixture was concentrated in vacuo and the residue was purified by silica column chromatography (40% ethyl acetate/hexanes) to afford the title compound as a yellow, crystalline solid (0 83 g, 28%) MS(ES+) m/z 558 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 1 02 - 1 29 (m, 4 H), 1 42 (s, 9 H), 1 71 (d, J=12 6 Hz, 2 H), 2 00 - 2 14 (m, 3 H), 2 62 - 2 68 (m, 3 H), 3 31 - 3 50 (m, 1 H), 4 34 - 4 45 (m, 1 H), 4 52 (d, J=I 3 Hz, 2 H), 4 63 (d, J=6 4 Hz, 2 H), 7 10 (t, J=B 6 Hz, 1 H), 7 21 - 7 29 (m, 1 H), 7 42 (dd, J=I 0, 2 2 Hz, 1 H), 8 06 (d, J=1 1 Hz, 1 H), 8 51 (t, J=6 2 Hz, 1 H), 8 71 (d, J= 1 1 Hz, 1 H) 19F NMR (376 MHz, CDCI3) δ ppm -1 17 85 (br s)
Step 3 Preparation of Λ/-(3-chloro-4-fluorobenzyl)-4-(2-(((frans)-4-amιnocvdohexyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnamιde
Trifluoroacetic acid (5 mL) was added to a solution of tert-butyl (frans)-4-((5-(2-((3-chloro-4- fluorobenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexylcarbamate (199 8 mg, 0 358 mmol) in dichloromethane (5 mL), and the mixture was stirred for 30 mm at room temperature The reaction mixture was concentrated under a stream of nitrogen The residue was dissolved in dichloromethane and neutralized for approximately 30 mm with MP-carbonate resin The mixture was filtered and washed with dichloromethane and methanol The filtrate was concentrated under a stream of nitrogen for a quantitative yield LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 687 mm , m/z 458 (M+H)
Example 195 /^-(S-Chloro^-fluorobenzyO-β-methyM^Z^^fransJ^^methylsulfonamidoJcyclohexyOmethyl)-
2H-tetrazol-5-yl)picolinamide
Triethylamine (0 068 mL, 0 492 mmol) and methane sulfonyl chloride (0 019 mL, 0 246 mmol) were added to a solution of Λ/-(3-chloro-4-fluorobenzyl)-4-(2-(((/rans)-4-amιnocyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 194) (75 1 mg, 0 164 mmol) in tetrahydrofuran (5 mL), and the mixture was stirred for 30 mm at room temperature The reaction mixture was concentrated and the residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound as a solid (45 6 mg, 52%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 384 mm , m/z 536 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 0 98 - 1 31 (m, 4 H), 1 53 - 1 67 (m, 2 H), 1 78 - 2 03 (m, 3 H), 2 66 (s, 3 H), 2 85 (s, 3 H), 2 95 - 3 12 (m, 1 H), 4 49 (d, J=6 6 Hz, 2 H), 4 64 (d, J=6 6 Hz, 2 H), 6 86 - 6 96 (m, 1 H), 7 26 - 7 39 (m, 2 H), 7 49 - 7 56 (m, 1 H), 8 02 - 8 10 (m, 1 H), 8 36 - 8 42 (m, 1 H), 9 29 - 9 38 (m, 1 H) Example 196
W-(3-Chloro-4-fluorobenzyl)-4-(2-(((frans)-4-acetamidocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Acetic anhydride (0 037 mL, 0 393 mmol) and 4-(dιmethylamιno)pyrιdιne Si bound (949 0 mg,
0 655 mmol, 0 69 mmol/g loading) were added to a solution of N-(3-chloro-4-fluorobenzyl)-4-(2- (((/rans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 194) (60 0 mg, 0 131 mmol) in dichloromethane (2 mL), and the mixture was agitated overnight at room temperature The reaction mixture was filtered and washed with N1N- dimethylformamide The filtrate was concentrated under a stream of nitrogen and purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound as a solid (23 mg, 35%) LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 4 93 mm , m/z 500 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 0 94 - 1 27 (m), 1 54 - 1 83 (m), 1 89 - 2 04 (m, 1 H), 2 66 (s, 3 H), 3 28 (s), 3 35 - 3 52 (m, 1 H), 4 49 (d, J=5 9 Hz, 2 H), 4 64 (d, J=I 3 Hz, 2 H), 7 26 - 7 38 (m, 2 H), 7 46 - 7 57 (m, 1 H), 7 59 - 7 67 (m, 1 H), 8 06 (s, 1 H), 8 40 (s, 1 H), 9 30 - 9 39 (m, 1 H)
Example 197
W-(3-Chloro-4-fluorobenzyl)-4-(2-(((frans)-4-(3-aminopropanamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
O-(7-Azabenzotrιazole-1-yl)-Λ/,Λ/,Λ/\Λ/'-tetramethyluronιum hexafluorophosphate (65 0 mg,
0 170 mmol), 3-(tert-butoxycarbonyl)propanoιc acid (26 9 mg, 0 142 mmol), and dnsopropylethylamine (0 049 mL, 0 284 mmol) were added to a solution of Λ/-(3-chloro-4-fluorobenzyl)-4-(2-(((frans)-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 194) (65 0 mg, 0 142 mmol) in Λ/,Λ/-dιmethylformamιde (2 mL), and the mixture was overnight at room temperature The reaction mixture was concentrated, treated with trifluoroacetic acid, and purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound as a solid (24 0 mg, 32%) LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 3 86 mm , m/z 529 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 05 - 1 23 (m, 4 H), 1 53 - 1 81 (m, 4 H), 1 90 - 2 03 (m, 1 H), 2 10 (t, J=6 6 Hz, 2 H), 2 66 (s, 3 H), 2 69 (t, J=6 6 Hz, 2 H), 3 28 (br s ), 3 40 - 3 53 (m, 1 H), 4 49 (d, J=5 9 Hz, 2 H), 4 65 (d, J=6 6 Hz, 2 H), 7 23 - 7 38 (m, 2 H), 7 48 - 7 57 (m, 1 H), 7 66 - 7 75 (m, 1 H), 8 06 (s, 1 H), 8 40 (s, 1 H), 9 30 - 9 39 (m, 1 H)
Example 198
/V-(3-Chloro-4-fluorobenzyl)-4-(2-(((frans)-4-(2-methoxyacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-Chloro-4-fluorobenzyl)-4-(2- (((/rans)-4-(3-amιnopropanamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 197) by reaction with 2-methoxyacetιc acid to afford 35 mg (46%) as a solid LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 5 13 mm , m/z 530 (M+H) 1H NMR (400 MHz, DMSOd6) ό ppm 1 06 - 1 34 (m, 4 H), 1 54 - 1 78 (m, 4 H), 1 86 - 2 05 (m, 1 H), 2 66 (s), 3 23 - 3 33 (m), 3 45 - 3 62 (m, 1 H), 3 72 (S, 3 H), 4 49 (d, J=5 9 Hz, 2 H), 4 65 (d, J=7 3 Hz, 2 H), 7 29 - 7 39 (m, 2 H), 7 43 - 7 49 (m, 1 H), 7 50 - 7 58 (m, 1 H), 8 06 (s, 1 H), 8 40 (s, 1 H), 9 30 - 9 37 (m, 1 H)
Example 199 2-((frans)-4-((5-(2-((3-Chloro-4-fluorobenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexylamino)-2-oxoethyl acetate
The title compound was prepared in a similar manner to A/-(3-Chloro-4-fluorobenzyl)-4-(2- (((frans)-4-(3-amιnopropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 197) by reaction with 2-acetoxyacetιc acid to afford 31 2 mg (39%) as a solid LC/MS (5%-100%
CH3CN/H2O, 10 0 mm ) 5 06 mm , m/z 558 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 1 06 - 1 29 (m, 4 H), 1 55 - 1 84 (m, 4 H), 1 89 - 2 01 (m, 1 H), 2 04 (s, 3 H), 2 66 (s, 3 H), 3 41 - 3 59 (m, 1 H), 4 36 (s, 2 H), 4 49 (d, J=5 9 Hz, 2 H), 4 65 (d, J-I 3 Hz, 2 H), 7 30 - 7 38 (m, 2 H), 7 50 - 7 55 (m, 1 H), 7 75 - 7 82 (m, 1 H), 8 06 (s, 1 H), 8 40 (s, 1 H), 9 30 - 9 38 (m, 1 H)
Example 200
W-(3-Chloro-4-fluorobenzyl)-4-(2-((((rans)-4-(2-hydroxyacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-Chloro-4-fluorobenzyl)-4-(2- (((frans)-4-(3-amιnopropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 197) by reaction with 2-hydroxyacetιc acid to afford 48 2 mg (66%) as a solid LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 4 74 mm , m/z 516 (M+H) 1H NMR (400 MHz, DMSOd6) ό ppm 1 05 - 1 35 (m, 4 H), 1 55 - 1 79 (m, 4 H), 1 88 - 2 03 (m, 1 H), 2 66 (s, 3 H), 3 28 (br s ), 3 47 - 3 61 (m, 1 H), 3 73 (s, 2 H), 4 49 (d, J=Q 6 Hz, 2 H), 4 65 (d, J=Q 6 Hz, 2 H), 7 24 - 7 44 (m, 3 H), 7 48 - 7 58 (m, 1 H), 8 06 (s, 1 H), 8 40 (s, 1 H), 9 27 - 9 41 (m, 1 H)
Example 201
W-(3-Chloro-4-fluorobenzyl)-4-(2-((((rans)-4-(3-methoxypropanamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-Chloro-4-fluorobenzyl)-4-(2- (((frans)-4-(3-aminopropanamido)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpicolinamide (Example 197) by reaction with 3-methoxypropanoιc acid to afford 49 1 mg (64%) as a solid LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 5 01 mm , m/z 544 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 01 - 1 25 (m, 4 H), 1 50 - 1 81 (m, 4 H), 1 86 - 2 05 (m, 1 H), 2 23 (t, J=Q 6 Hz, 2 H), 2 66 (s, 3 H), 3 24 - 3 32 (m), 3 47 (t, J=Q 2 Hz, 2 H), 4 49 (d, J=5 9 Hz, 2 H), 4 64 (d, J=Q 6 Hz, 2 H), 7 29 - 7 39 (m, 2 H), 7 49 - 7 55 (m, 1 H), 7 60 - 7 68 (m, 1 H), 8 06 (s, 1 H), 8 40 (s, 1 H), 9 30 - 9 38 (m, 1 H)
Example 202
/V-(3-Chloro-4-fluorobenzyl)-4-(2-(((frans)-4-(2-aminoacetamido)cyclohexyl)methyl)-2H-tetrazol-
5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-Chloro-4-fluorobenzyl)-4-(2- (((frans)-4-(3-aminopropanamido)cyclohexyl)methyl)-2/-y-tetrazol-5-yl)-6-methylpicolinamide (Example 197) by reaction with 2-(tert-butoxycarbonyl)acetιc acid to afford 45 6 mg (62%) as a solid LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 3 81 mm , m/z 515 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 1 03 - 1 27 (m, 4 H), 1 50 - 1 84 (m, 4 H), 1 89 - 2 05 (m, 1 H), 2 66 (s, 3 H), 3 04 (s), 3 27 (br s ), 3 41 - 3 57 (m, 1 H), 4 49 (d, J=5 9 Hz, 2 H), 4 65 (d, J=I 3 Hz, 2 H), 7 26 - 7 39 (m, 2 H), 7 50 - 7 55 (m, 1 H), 7 58 - 7 65 (m, 1 H), 8 06 (s, 1 H), 8 40 (s, 1 H), 9 30 - 9 38 (m, 1 H)
Example 203 W-(4-Fluoro-3-((2-hydroxyethoxy)methyl)benzyl)-6-methyl-4-(2-(((frans)-4-(methylsulfonamido)- cyclohexyl)methyl)-2H-tetrazol-5-yl)picolinamide
Λ/-(4-Fluoro-3-(hydroxymethyl)benzyl)-6-methyl-4-(2-(((frans)-4- (methylsulfonamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 181 ) (38 mg, 0 059 mmol), potassium carbonate (8 13 mg, 0 59 mmol), and ethanol (5 mL) were combined in a 20 mL scintillation vial with a magnetic stir bar and reflux for 2 hours The reaction mixture was cooled in an ice bath and ethylene oxide (7 13 mg, 0 162 mmol) was added The mixture was slowly warmed to room temperature and stirred for 36 hours The reaction mixture was concentrated and purified by preparative reverse phase preparative HPLC to afford the title compound as a white solid (30 8 mg, 76%) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 2 71 mm , m/z 576 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 25 (t, J=6 22 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 44 (d, J=7 32 Hz, 1 H), 7 19 - 7 28 (m, J=6 59 Hz, 1 H), 7 06 (t, 1 H), 6 92 (d, J=7 32 Hz, 1 H), 5 20 (t, J=5 49 Hz, 1 H), 4 64 (d, J=6 59 Hz, 2 H), 4 50 (d, J=5 12 Hz, 3 H), 3 28 (d, J=5 12 Hz, 1 H), 2 97 - 3 1 1 (m, J=6 59 Hz, 1 H), 2 79 - 2 91 (m, 2 H), 2 65 (s, 2 H), 2 43 - 2 53 (m, 1 H), 1 75 (dd, J=1 11 63, 10 61 Hz, 4 H), 1 05 - 1 28 (m, 3 H)
Example 204
4-(2-(((fra/7s)-4-Acetamidocyclohexyl)methyl)-2H-tetrazol-5-yl)-W-((6-hydroxypyridin-2- yl)methyl)-6-methylpicolinamide
Step 1 Preparation of 4-(2-((4-acetamιdocvclohexyl)methyl)-2/-/-tetrazol-5-v0-6-methylpιcolιnιc acid
Tπethylamine (0 95 mL, 6 81 mmol) and acetic anhydride (0 52 ml_, 5 45 mmol) were added to a solution of methyl 4-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnate (prepared as described in step 1 of the synthesis of N-(3-methoxybenzyl)-4-(2-(((frans)-4-(3- hydroxypropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 168) (500 mg, 1 36 mmol) in dichloromethane (20 mL) and the mixture was stirred at room temperature for two days The reaction mixture was filtered and washed with dichloromethane The filtrate was concentrated and the residue was dissolved in a mixture of tetrahydrofuran/water (12 mL, 5/1 ) Lithium hydroxide (131 mg, 5 45 mmol) was added and the mixture was stirred at room temperature for 18 hours The reaction mixture was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound as a white solid (165 mg, 34%) MS (ES+) m/z 359 (M+H) Step 2 Preparation 4-(2-(((rrans)-4-acetamιdocvclohexyl)rnethyl)-2H-tetrazol-5-yl)-N-((6- hvdroxypyrιdιn-2-yl)methyl)-6-methylpιcolιnamιde
Λ/,Λ/,Λ/',Λ/'-Tetramethyl-O-(1 H-benzotrιazol-1 -yl)uronιum hexafluorophosphate (254 mg, 0 67 mmol) was added to a mixture of 4-(2-((4-acetamιdocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinic acid (160 mg, 0 446 mmol), 6-(amιnomethyl)pyrιdιn-2(1 H)-one (Bronn, W R US 4,555,573, 1985) (191 mg, 0 67 mmol), and triethylamine (0 22 mL, 1 56 mmol) in W1N- dimethylformamide (2 mL) The mixture was stirred at room temperature for 18 hours The reaction mixture was purified by reverse phase preparative HPLC to afford the title compound as a solid (106 mg, 51%) MS (ES+) m/z 465 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 0 99 - 1 21 , (m, 4 H), 1 58 (s, J=9 52 Hz, 2 H), 1 67 - 1 81 (m, 5 H), 1 87 - 2 00 (m, 2 H), 2 66 (s, 3 H), 3 36 - 3 48 (m, 1 H), 4 33 (d, J=5 86 Hz, 2 H), 4 63 (d, J=7 32 Hz, 2 H), 5 98 - 6 10 (m, 1 H), 6 17 (d, J=9 52 Hz, 1 H), 7 24 - 7 37 (m, 1 H), 7 61 (d, J=8 05 Hz, 1 H), 8 07 (s, 1 H), 8 38 (s, 1 H), 9 24 (t, J=B 95 Hz, 1 H) Example 205
W-(3-(Hydroxymethyl)benzyl)-4-(2-(((frans)-4-acetamidocyclohexyl)methyl)-2W-tetrazol-5-yl)-6- methylpicolinamide
Λ/,Λ/,Λ/',Λ/'-Tetramethyl-O-(1/-/-benzotrιazol-1-yl)uronιum hexafluorophosphate (159 mg, 0 42 mmol) was added to a mixture of 4-(2-((4-acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinic acid (prepared as described in step 1 of the synthesis of 4-(2-(((frans)-4- acetamιdocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-Λ/-((6-hydroxypyrιdιn-2-yl)methyl)-6-methylpιcolιnamιde, Example 204) (50 mg, 0 14 mmol), (3-(amιnomethyl)pheny!)methanol (prepared as described in step 1 of the synthesis of Λ/-(3-(hydroxymethyl)benzyl)-6-methyl-4-(2-(((/rans)-4-
(methylsulfonamιdo)cydohexyl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde, Example 183) (29 mg, 0 21 mmol), and triethylamine (0 03 mL, 0 21 mmol) in Λ/,Λ/-dιmethylformamιde (2 mL) The mixture was stirred at room temperature for 18 hours The reaction mixture was purified by reverse phase preparative HPLC Fractions containing desired product were combined and concentrated The resulting residue was taken up in methanol and passed through a carbonate cartridge The filtrate was concentrated to afford the title compound as a solid (22 mg, 33%) MS (ES+) m/z 478 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 04 - 1 26 (m, 6 H), 1 56 - 1 67 (m, 2 H), 1 71 - 1 85 (m, 5 H), 1 91 - 2 03 (m, 1 H), 2 67 (s, 3 H), 3 25 - 3 35 (m, 1 H), 4 48 (s, 2 H), 4 54 (d, J=6 59 Hz, 2 H), 4 67 (d, J=I 32 Hz, 2 H), 7 14 - 7 34 (m, 3 H), 7 66 (d, J=I 32 Hz, 1 H), 8 08 (s, 1 H), 8 44 (s, 1 H), 9 22 (t, J=5 86 Hz, 1 H)
Example 206
/V-(3-(2-Hydroxyethoxy)benzyl)-4-(2-((((rans)-4-acetamidocyclohexyl)methyl)-2W-tetrazol-5-yl)-6- methylpicolinamide
Ay,Λ/,/V',Λ/'-Tetramethyl-O-(1H-benzotrιazol-1-yl)uronιum hexafluorophosphate (159 mg, 0 42 mmol) was added to a mixture of 4-(2-((4-acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinic acid (prepared as described in step 1 of the synthesis of 4-(2-(((/rans)-4- acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-/V-((6-hydroxypyrιdιn-2-yl)methyl)-6-methylpιcolιnamιde, Example 204) (50 mg, 0 14 mmol), 2-(3-(amιnomethyl)phenoxy)ethanol (prepared as described in step 2 of the synthesis of Λ/-(3-(2-hydroxyethoxy)benzyl)-6-(2-(((frans)-4-amιnocyclohexyl)methyl)-2H- tetrazol-5-yl)-2-methylpyπmιdιne-4-carboxamιde, Example 13) (35 mg, 0 21 mmol), and triethylamine (0 03 mL, 0 21 mmol) in Λ/,Λ/-dιmethylformamιde (2 mL) The mixture was stirred at room temperature for 18 hours The reaction mixture was purified by reverse phase preparative HPLC Fractions containing desired product were combined and concentrated The resulting residue was taken up in methanol and passed through a carbonate cartridge The filtrate was concentrated to afford the title compound as a solid (26 mg, 37%) MS (ES+) m/z 508 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 04 - 1 24 (m, 5 H), 1 58 - 1 68 (m, 2 H), 1 72 - 1 84 (m, 5 H), 1 92 - 2 05 (m, 2 H), 2 68 (s, 3 H), 3 69 (t, J=5 12 Hz, 2 H), 3 96 (t, J=5 12 Hz, 2 H), 4 51 (d, J=5 86 Hz, 2 H), 4 67 (d, J=I 32 Hz, 2 H), 6 82 (d, J=I 32 Hz, 1 H), 6 88 - 6 96 (m, 1 H), 7 23 (t, J=Q 05 Hz, 1 H), 7 66 (d, J=I 32 Hz, 1 H), 8 08 (s, 1 H), 8 43 (s, 1 H), 9 22 (t, J=6 59 Hz, 1 H)
Example 207
W-(4-Fluoro-3-(hydroxymethyl)benzyl)-4-(2-((((rans)-4-acetamidocyclohexyl)methyl)-2H-tetrazol-
5-yl)-6-methylpicolinamide
Λ/,Λ/,Λ/',Λ/'-Tetramethyl-0-(1 /-/-benzotrιazol-1 -yl)uronιum hexafluorophosphate (476 mg, 1 26 mmol) was added to a mixture of 4-(2-((4-acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolimc acid (prepared as described in step 1 of the synthesis of 4-(2-(((trans)-4- acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-Λ/-((6-hydroxypyrιdιn-2-yl)methyl)-6-methylpιcolιnamιde, Example 204) (150 mg, 0 42 mmol), (5-(amιnomethyl)-2-fluorophenyl)methanol (prepared as described in step 1 of the synthesis of Λ/-(4-fluoro-3-(hydroxymethyl)benzyl)-6-methyl-4-(2-(((/raπs)-4- (methylsulfonamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)picolinamide, Example 181 ) (120 mg, 0 63 mmol), and tπethylamine (0 15 mL, 1 05 mmol) in Λ/,Λ/-dιmethylformamιde (6 mL) The mixture was stirred at room temperature for 18 hours The reaction mixture was purified by reverse phase preparative HPLC Fractions containing desired product were combined and concentrated The resulting residue was taken up in methanol and passed through a carbonate cartridge The filtrate was concentrated to afford the title compound as a solid (1 12 mg, 54%) MS (ES+) m/z 496 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 04 - 1 27 (m, 4 H), 1 55 - 1 68 (m, Hz, 2 H), 1 71 - 1 84 (m, 5 H), 1 91 - 2 06 (m, 2 H), 2 67 (s, 3 H), 3 82 (s, 3 H), 4 51 (d, J=5 86 Hz, 2 H), 4 67 (d, J=I 32 Hz, 2 H), 6 82 - 6 96 (m, 1 H), 7 05 - 7 26 (m, 2 H), 7 65 (d, J=I 32 Hz, 1 H), 8 07 (s, 1 H), 8 43 (s, 1 H), 9 24 (t, J=Q 22 Hz, 1 H)
Example 208
/V-(3-Ethoxybenzyl)-4-(2-(((frans)-4-acetamidocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Λ/,Λ/,Λ/',Λ/'-Tetramethyl-O-(1 /-/-benzotrιazol-1 -yl)uronιum hexafluorophosphate (159 mg, 0 42 mmol) was added to a mixture of 4-(2-((4-acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinic acid (prepared as described in step 1 of the synthesis of 4-(2-(((frans)-4- acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-Λ/-((6-hydroxypyrιdιn-2-yl)methyl)-6-methylpιcolιnamιde, Example 204) (50 mg, 0 14 mmol), (3-ethoxyphenyl)methanamιne (prepared as described in step 2 of the synthesis of Λ/-(3-ethoxybenzyl)-6-methyl-4-(2-(((frans)-4-(methylsulfonamιdo)cyclohexyl)methyl)- 2/-/-tetrazo!-5-yl)pιcolιnamιde, Example 180) (31 mg, 0 21 mmol), and tπethylamine (0 03 mL, 0 21 mmol) in Λ/,Λ/-dιmethylformamιde (2 mL) The mixture was stirred at room temperature for 18 hours The reaction mixture was purified by reverse phase preparative HPLC Fractions containing desired product were combined and concentrated The resulting residue was taken up in methanol and passed through a carbonate cartridge The filtrate was concentrated to afford the title compound as a solid (39 mg, 57%) MS (ES+) m/z 492 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 02 - 1 25 (m, 4 H), 1 30 (t, J=6 95 Hz, 3 H), 1 53-1 68(m, 2H), 1 72 - 1 85 (m, 5 H), 1 98 (m, 2 H), 2 68 (s, 3 H), 4 00 (q, J=6 83 Hz, 2 H), 4 50 (d, J=6 59 Hz, 2 H), 4 67 (d, J=6 59 Hz, 2 H), 6 77 - 6 83 (m, 1 H), 6 87 - 6 94 (m, 2 H), 7 17 - 7 26 (m, 8 05 Hz, 1 H), 7 60 - 7 70 (m, 1 H), 8 08 (s, 1 H), 8 43 (s, 1 H), 9 21 (t, J=6 22 Hz, 1 H)
Example 209
W-(3-Methoxybenzyl)-4-(2-(((c/s)-4-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Step 1 Preparation of tert-butyl (c/s)-4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2/-/- tetrazol-2-yl)methyl)cvclohexylcarbamate
A mixture of Λ/-(3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((/rans)-4-amιnocyclohexyl)methyl)- 2H-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (1 0 g, 3 08 mmol), tert-butyl cιs-(4- hydroxymethyl)cyclohexyl carbamate (1 41 g, 6 17 mmol), and polymer supported-triphenylphosphine (3 580 g, 7 07 mmol) in anhydrous tetrahydrofuran (60 mL) was cooled to 0 0C in an ice bath and then di-tert-butyl azodicarboxylate (1 42 g, 3 08 mmol) was added The reaction was allowed to warm to room temperature while stirring over 15 hours The reaction mixture was filtered and the filtrate was concentrated The residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O) to afford the title compound
Step 2 Preparation of Λ/-(3-methoxybenzyl)-4-(2-(((c<5)-4-amιnocvclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide
Trifluoroacetic acid was added to a solution of tert-butyl (c;s)-4-((5-(2-((3-methoxybenzyl)- carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexylcarbamate in dichloromethane and the mixture was allowed to stir for 30 mm at room temperature The reaction mixture was concentrated The residue was dissolved in dichloromethane and MP-carbonate resin was added The mixture was agitated for 1 h, filtered, and washed with dichloromethane and methanol The filtrate was concentrated to afford the title compound as a solid (1 091 g, 81 %) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 479 mm , m/z 436 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 1 33 - 1 86 (m, 8 H), 2 17 - 2 31 (m, 1 H), 2 65 (s, 3 H), 3 18 - 3 28 (m, 1 H), 3 70 (s, 3 H), 4 48 (d, J=6 4 Hz, 2 H), 4 72 (d, J=7 3 Hz, 2 H), 6 76 - 6 84 (m, 1 H), 6 85 - 6 93 (m, 2 H), 7 17 - 7 27 (m, 1 H), 7 93 (br s , 2 H), 8 03 - 8 09 (m, 1 H), 8 41 (s, 1 H), 9 19 - 9 28 (m, 1 H)
Example 210
W-(3-Methoxybenzyl)-6-methyl-4-(2-(((c/s)-4-(methylsulfonamido)cyclohexyl)methyl)-2H-tetrazol-
5-yl)picolinamide
Triethylamine (0 048 mL, 0 345 mmol) and methane sulfonyl chloride (0 013 mL, 0 173 mmol) were added to a solution of Λ/-(3-methoxybenzyl)-4-(2-(((c/s)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methy!pιcolιnamιde (prepared as described in (Example 209) (50 1 mg, 0 1 15 mmol) in tetrahydrofuran (1 5 mL) and the mixture was stirred 2 hours at room temperature The reaction mixture was concentrated and purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O) to afford the title compound as a solid (33 7 mg, 57%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 188 mm , m/z 514 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 1 29 - 1 79 (m), 1 99 - 2 22 (m), 2 65 (s, 3 H), 2 87 (s, 3 H), 3 36 - 3 48 (m), 3 71 (s, 3 H), 4 49 (d, J=6 6 Hz, 2 H), 4 67 (d, _/=6 6 Hz, 2 H), 6 73 - 6 84 (m, 1 H), 6 84 - 6 97 (m, 3 H), 7 13 - 7 28 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 12 - 9 25 (m, 1 H)
Example 211
W-(3-Methoxybenzyl)-4-(2-(((c/s)-4-acetamidocyclohexyl)methyl)-2W-tetrazol-5-yl)-6- methylpicolinamide
Acetic anhydride (0 033 mL, 0 345 mmol) and 4-(dιmethylamιno)pyrιdιne Si bound (833 0 mg, 0 575 mmol, 0 69 mmol/g loading) were added to a solution of Λ/-(3-methoxybenzyl)-4-(2-(((c/s)-4- amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 209) (50 0 mg, 0 1 15 mmol) in dichloromethane (2 mL) and the mixture was agitated overnight at room temperature The reaction mixture was filtered, washed with Λ/,Λ/-dιmethylformamιde, and concentrated The residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O) to afford the title compound as a solid (27 1 mg, 49%) LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 4 64 mm , m/z 478 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 31 - 1 66 (m), 1 80 (s, 3 H), 2 07 - 2 21 (m, 1 H), 2 62 - 2 69 (m, 3 H), 3 23 - 3 31 (m), 3 71 (s, 3 H), 3 74 - 3 82 (m, 1 H), 4 49 (d, J=6 6 Hz, 2 H), 4 68 (d, J= 7 3 Hz, 2 H), 6 76 - 6 82 (m, 1 H), 6 86 - 6 94 (m, 2 H), 7 17 - 7 25 (m, 1 H), 7 60 - 7 68 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 14 - 9 23 (m, 1 H)
Example 212
W-(3-Methoxybenzyl)-4-(2-(((c/s)-4-(3-aminopropanamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
O-(7-Azabenzotrιazole-1 -yl)-N,N,/V,/V-tetramethyluronιum hexafluorophosphate (52 0 mg, 0 138 mmol), 3-(tert-butoxycarbonyl)propanoιc acid (21 6 mg, 0 1 15 mmol), and dnsopropylethylamine (0 040 mL, 0 230 mmol) were added to a solution of Λ/-(3-methoxybenzyl)-4-(2-(((c/s)-4- aminocyclohexyOmethyO^H-tetrazol-S-yO-e-methylpicolinamide (prepared as described in Example 209) (50 1 mg, 0 1 15 mmol) in Λ/,Λ/-dιmethylformamιde (2 mL) and the mixture was stirred overnight at room temperature The reaction mixture was concentrated, treated with trifluoroacetic acid, and the residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O) to afford the title compound as a solid (16 3 mg, 28%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 665 mm , m/z 507 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 27 - 1 69 (m), 2 14 (t, J=6 6 Hz, 2 H), 2 18 - 2 27 (m, 1 H), 2 65 (s, 3 H), 2 70 (t, J=6 6 Hz, 2 H), 3 71 (s, 3 H), 3 80 (br s), 4 49 (d, J=6 6 Hz, 2 H), 4 68 (d, J=I 3 Hz, 2 H), 6 74 - 6 82 (m, 1 H), 6 84 - 6 93 (m, 2 H), 7 14 - 7 25 (m, 1 H), 7 80 - 7 87 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 13 - 9 23 (m, 1 H)
Example 213 /V-(3-Methoxybenzyl)-4-(2-(((c/s)-4-(2-methoxyacetamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-4-(2-(((c/s)-4-(3- amιnopropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 212) by reaction with 2-methoxyacetιc acid and afforded 26 8 mg (46%) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 151 mm , m/z 508 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 1 22 - 1 75 (m), 2 13 - 2 28 (m), 2 52 (s), 2 65 (s, 3 H), 3 71 (s, 3 H), 3 77 (s), 3 78 - 3 86 (m), 4 49 (d, J=6 6 Hz, 2 H), 4 76 (d, J=I 3 Hz, 2 H), 6 75 - 6 83 (m, 1 H), 6 86 - 6 94 (m, 2 H), 7 17 - 7 25 (m, 1 H), 7 38 - 7 45 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 15 - 9 24 (m, 1 H)
Example 214
2-((c/s)-4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2-yl)methyl)- cyclohexylamino)-2-oxoethyl acetate
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-4-(2-(((c/s)-4-(3- amιnopropanamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 212) by reaction with 2-acetoxyacetιc acid and afforded 20 9 mg (34%) as a solid LC/MS (5%-95% ^ CH3CNZH2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 163 mm , m/z 536 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 1 27 - 1 71 (m), 2 04 (s, 3 H), 2 1 1 - 2 26 (m, 1 H), 2 65 (s, 3 H), 3 71 (s, 3 H), 3 74 - 3 84 (m, 1 H), 4 43 (s, 2 H), 4 49 (d, J=Q 6 Hz, 2 H), 4 70 (d, J=I 3 Hz, 2 H), 6 74 - 6 83 (m, 1 H), 6 85 - 6 98 (m, 2 H), 7 15 - 7 27 (m, 1 H), 7 70 - 7 82 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 12 - 9 24 (m, 1 H)
Example 215
W-(3-Methoxybenzyl)-4-(2-(((c/s)-4-(2-hydroxyacetamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-4-(2-(((c/s)-4-(3- amιnopropanamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 212) by reaction with 2-hydroxyacetιc acid and afforded 27 4 mg (48%) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 897 mm , m/z 494 (M+H) 1H NMR (400 MHz,
DMSO-dg) δ ppm 1 26 - 1 76 (m), 2 14 - 2 29 (m), 2 65 (s, 3 H), 3 71 (s, 3 H), 3 78 (s), 3 80 - 3 90 (m, 1 H), 4 49 (d, J=5 9 Hz, 2 H), 4 76 (d, J=I 3 Hz, 2 H), 6 74 - 6 84 (m, 1 H), 6 84 - 6 97 (m, 2 H), 7 16 - 7 28 (m, 1 H), 7 34 - 7 46 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 12 - 9 25 (m, 1 H)
Example 216
W-(3-Methoxybenzyl)-4-(2-(((c/s)-4-(3-methoxypropanamido)cyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-4-(2-(((c/s)-4-(3- ammopropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 212) by reaction with 3-methoxypropanoιc acid and afforded 23 7 mg (40%) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 1 1 1 mm , m/z 522 (M+H) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 1 28 - 1 71 (m), 2 06 - 2 21 (m, 1 H), 2 31 (t, J=6 2 Hz, 2 H), 2 65 (s), 3 49 (t, J=6 6 Hz, 2 H), 3 71 (s), 3 75 - 3 83 (m, 1 H), 4 49 (d, J=6 6 Hz, 2 H), 4 68 (d, J=I 3 Hz, 2 H), 6 74 - 6 84 (m, 1 H), 6 84 - 6 96 (m, 2 H), 7 13 - 7 30 (m, 1 H), 7 56 - 7 68 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 12 - 9 25 (m, 1 H)
Example 217
W-(3-Methoxybenzyl)-4-(2-(((c/s)-4-(2-aminoacetamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-4-(2-(((c/s)-4-(3- aminopropanamido^yclohexyOmethyO^H-tetrazol-S-yO-θ-methylpicolinamide (Example 212) by reaction with 2-(tert-butoxycarbonyl)acetιc acid and afforded 13 6 mg (24%) as a solid LC/MS (5%- 95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 628 mm , m/z 493 (M+H) 1H NMR (400 MHz, DMSO-d6) ό ppm 1 19 - 1 73 (m), 2 10 - 2 25 (m, 1 H), 2 60 - 2 66 (m), 2 65 (s, 3 H), 3 05 (s), 3 28 (s) 3 71 (s, 3 H), 3 76 - 3 88 (m, 1 H), 4 49 (d, J=Q 6 Hz, 2 H), 4 72 (d, J=I 3 Hz, 2 H), 6 73 - 6 84 (m, 1 H), 6 85 - 6 95 (m, 2 H), 7 14 - 7 26 (m, 1 H), 7 62 - 7 70 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 13 - 9 23 (m, 1 H)
Example 218
/V-(3-Methoxybenzyl)-4-(2-(((c/s)-4-(2-hydroxy-2-methylpropanamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
A mixture of 2-hydroxy isobutyric acid (19 mg, 0 19 mmol) and 1 -hydroxybenzatrιazole (25 mg, 0 19 mmol) in 2- methyl tetrahydrofuran (2 mL) was stirred for 5 minutes Λ/-(3-Methoxybenzyl)-4- (2-(((c/s)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 209) (0 085 g, 0 15 mmol), triethylamine (0 026 mL, 0 19 mmol), and polymer supported carbodiimide (0 18 g, 0 23 mmo!) were then added The mixture was allowed to stir for 18 hours at room temperature and then filtered The filtrate was washed with water (3 x 5 mL) followed by brine (5 mL), dried over anhydrous sodium sulfate, and concentrated The residue was purified by reverse phase preparative HPLC to afford the title compound (20 mg, 25%) 1H NMR (400 MHz, DMSO-d5) δ ppm 9 19 (t, J=6 6 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 29 (d, J=8 05 Hz, 1 H), 7 22 (t, J=8 1 Hz, 1 H), 6 90 (br s , 2 H), 6 80 (d, J=8 1 Hz, 1 H), 5 35 (s, 1 H), 4 77 (d, J=I 3 Hz, 2 H), 4 49 (d, J=6 6 Hz, 2 H), 3 71 (s, 3 H), 2 65 (s, 3 H), 2 17 - 2 30 (m, 1 H), 1 61 - 1 74 (m, 2 H), 1 42 - 1 55 (m, 4 H), 1 30 - 1 41 (m, 2 H), 1 22 (s, 6 H)
Example 219
W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((c/s)-4-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolJnamide
Step 1 Preparation of methyl 4-(2-(((c<s)-4-(tert-butoxycarbonyl)cvclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinate
A mixture of methyl 6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((<rans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide, Example 153) (0 23 g, 1 1 mmol), tert-butyl c/s-(4-hydroxymethyl)cyclohexyl carbamate (0 24 g, 1 1 mmol), and polymer supported-tπphenylphosphine (0 70 g, 1 6 mmol) in anhydrous tetrahydrofuran (15 mL) was cooled to 0 0C in an ice bath for 15 mm and then di-tert-butyl azodicarboxylate (0 29 g, 1 3 mmol) was added The reaction was allowed to warm to room temperature while stirring over 15 hours The reaction mixture was filtered and the filtrate was concentrated to afford the title compound
Step 2 Preparation of 4-(2-(((c;s)-4-(tert-butoxycarbonyl)cvclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolimc acid
An aqueous solution of sodium hydroxide (2 5 N, 1 0 mL) was added to a mixture of 4-(2-
(((c/s)-4-(tert-butoxycarbonyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnate in acetonitπle (3 mL), and the mixture was stirred 2 hours The acetonitrile was removed in vacuo and the aqueous residue was acidified to pH 6 with a 10% aqueous solution of hydrochloric acid This mixture was extracted with ethyl acetate (3 x 5 mL) The combined organic layers were washed with water (2 x 5mL) followed by brine (5 mL), dried over sodium sulfate, and concentrated to afford the title compound
Step 3 Preparation of tert-butyl (c/s)-4-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn- 4-yl)-2/-/-tetrazol-2-yl)methγl)cyclohexylcarbamate
A mixture of 4-(2-(((c/s)-4-(tert-butoxycarbonyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinic acid and 1 -hydroxybenzatπazole (97 mg, 0 72 mmol) in Λ/,Λ/-dιmethylformamιde (2 mL) was stirred for 5 minutes 4-Fluoro-3-methoxybenzylamιne hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-((^ans-4-amιnocyclohexyl)methyl)-2/-/- tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 1 ) (0 13g, 0 66 mmol), triethylamine (O 10 mL, O 72 mmol), and polymer supported carbodiimide (0 88 g, 0 98 mmol) were added The mixture was stirred for 18 hours at room temperature and then was filtered The filtrate was washed with water (3 x 5 mL) followed by brine (5 mL), dried over anhydrous sodium sulfate, and concentrated The residue was purified by silica column chromatography (0-50%, ethyl acetate/heptane) to afford the title compound as a beige oil
Step 4 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((c<s)-4-amιnocyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
Trifluoroacetic acid (1 0 mL) was added to a solution of tert-butyl (c/s)-4-((5-(2-((4-fluoro-3- methoxybenzyl^arbamoyO-θ-methylpyπdin^-ylJ^H-tetrazol-Σ-yOmethyOcyclohexylcarbamate in dichloromethane (5 mL), and the mixture was stirred for 3 hours at room temperature The reaction mixture was concentrated and then triturated with diethyl ether to afford the title compound as a trifluoroacetate salt (0 12 g) LC/MS (5-100% CH3CN/H2O, 6 mm) 5 33 mm, m/z 454 (M+H)
Example 220
/V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-(2-hydroxy-2- methylpropanamido)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide
A mixture of 2-hydroxy isobutyric acid (10 mg, 0 09 mmol) and 1 -hydroxybenzatrιazole (1 1 mg, 0 08 mmol) in 2- methyl tetrahydrofuran (2 mL) was stirred for 5 minutes Λ/-(4-Fluoro-3- methoxybenzy!)-4-(2-(((c/s)-4-amιnocyc!ohexy!)methyl)-2H-tetrazol-5-yl)-6-methylpιco!ιnamιde (prepared as described in Example 219) (0 040 g, 0 07 mmol), triethylamine (0 012 mL, 0 085 mmol), and polymer supported carbodiimide (0 082 g, 0 1 1 mmol) were added The mixture was stirred for 18 hours at room temperature and was then filtered The filtrate was washed with water (3 x 5 mL) followed by brine (5 mL), dried over anhydrous sodium sulfate, and concentrated The residue was purified by reverse phase preparative HPLC to afford the title compound (10 mg, 29%) 1H NMR (400 MHz, DMSOd6) δ ppm 9 21 (t, J=6 2 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 29 (d, J=7 3 Hz, 1 H), 7 05 - 7 20 (m, 2 H), 6 89 (d, J=3 7 Hz, 1 H), 5 35 (s, 1 H), 4 77 (d, J=Q 1 Hz, 2 H), 4 48 (d, J=5 9 Hz, 2 H), 3 80 (s, 3 H), 3 71 (br s , 1 H), 2 61 - 2 70 (m, 3 H), 2 21 (d, J=3 7 Hz, 1 H), 1 61 - 1 74 (m, 2 H), 1 48 (dd, J=W 3, 3 7 Hz, 3 H), 1 27 - 1 40 (m, 2 H), 1 14 - 1 28 (m, 6 H)
Example 221
/V-(4-Fuoro-3-methoxybenzyl)-4-(2-(((c/s)-4-(2-hydroxyacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
A mixture of 2-acetoxyacetιc acid (1 1 mg, 0 092 mmol) and 1 -hydroxybenzatrιazole (1 1 mg, 0 08 mmol) in 2- methyl tetrahydrofuran (2 mL) was stirred for 5 minutes Λ/-(4-Fluoro-3- methoxybenzyl)-4-(2-(((c/s)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 219) (0 040 g, 0 07 mmol), triethylamine (0 012 mL, 0 085 mmol), and polymer supported carbodiimide (0 082 g, 0 11 mmol) were added The mixture was stirred for 18 hours at room temperature and was then filtered The filtrate was washed with water (3 x 5 mL) followed by brine (5 mL), dried over anhydrous sodium sulfate, and concentrated The residue was dissolved in tetrahydrofuran (2 mL) and stirred with an aqueous solution of sodium hydroxide (2 5 N, 0 5 mL) for 2 hours at room temperature The tetrahydrofuran was removed in vacuo and the aqueous residue was acidified with a 10% aqueous solution of hydrochloric acid The mixture was extracted with ethyl acetate (3 x 5 mL) The combined organic layers were washed with water (5 mL) followed by brine (5 mL), dried over anhydrous sodium sulfate, and concentrated The residue that was purified by reverse phase preparative HPLC to afford the title compound (7 3 mg, 20%) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 22 (t, J=Q 22 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 39 (d, J=Q 8 Hz1 1 H), 7 04 - 7 23 (m, 2 H), 6 89 (d, J=Q Q Hz, 1 H), 5 35 (t, J=5 9 Hz, 1 H), 4 76 (d, J=I 3 Hz, 2 H), 4 48 (d, J=5 9 Hz, 2 H), 3 69 - 3 93 (m, 5 H), 2 65 (s, 3 H), 2 21 (br s , 1 H), 1 65 (br s , 2 H), 1 41 - 1 55 (m, 4 H), 1 36 (d, J=8 8 Hz, 2 H)
Example 222 W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((c/s)-4-acetamidocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Triethylamine (0 012 mL, 0 085 mmol) and a solution of acetyl chloride (6 3 mg in 0 5 mL dichloromethane) were added to a solution of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((c/s)-4- aminocyclohexyOmethyO^H-tetrazol-S-yO-θ-methylpicolinamide (prepared as described in Example 219) (O 040 g, O 07 mmol) in 2-methyltetrahydrofuran (2 mL) The reaction mixture was stirred for 1 hour at room temperature and was then concentrated The residue was purified by reverse phase preparative HPLC (10-90 % acetonitrile/water) to afford the title compound (1 1 mg, 31 %) 1H NMR (400 MHz, DMSO-cfe) δ ppm 9 22 (t, J=6 2 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 63 (d, J= 7 3 Hz, 1 H), 7 03 - 7 25 (m, 2 H), 6 75 - 6 95 (m, 1 H), 4 68 (d, J=I 3 Hz, 2 H), 4 48 (d, J=5 9 Hz, 2 H), 3 80 (s, 4 H), 2 65 (s, 3 H), 2 06 - 2 24 (m, 1 H), 1 79 (s, 3 H), 1 52 - 1 62 (m, 2 H), 1 31 - 1 52 (m, 6 H)
Example 223 rac-W-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Step 1 Preparation of rac-terf-butyl (1 /?*,3S*)-3-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyπdιn- 4-yl)-2H-tetrazol-2-yl)methyl)cvclohexylcarbamate
A solution of Λ/-(3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((/rans)-4-amιnocyclohexyl)methyl)- 2H-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (500 0 mg, 1 54 mmol) in anhydrous tetrahydrofuran (30 mL) and triphenylphosphine resin (1 790 g, 3 85 mmol, 2 15 mmol/g loading) was added to a vial containing rac-tert-butyl (1 R\3S*)-3-(hydroxymethyl)cyclohexylcarbamate (707 0 mg, 3 08 mmol) The mixture was cooled in an ice bath and di-tert-butylazodicarboxylate (710 0 mg, 3 08 mmol) was added The reaction mixture was agitated overnight at room temperature and then concentrated The residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound Step 2 Preparation of rac-/V-(3-methoxybenzyl)-4-(2-(((1 S\3ff*)-3-amιnocyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde
rac-tert-butyl (1f?*,3S*)-3-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/- tetrazol-2-yl)methyl)cyclohexylcarbamate obtained in step 1 was dissolved in dichloromethane and trifluoroacetic acid and stirred for approximately 30 minutes The mixture was concentrated and the residue was dissolved in dichloromethane MP-carbonate resin was added to the solution and the mixture was agitated for approximately 1 hour The mixture was filtered and the resin was washed with dichloromethane and methanol The filtrate was concentrated under a stream of nitrogen and dried under high vacuum overnight to afford the title compound as a solid (456 mg, 68%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 531 mm , m/z 436 (M+H) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 0 86 - 1 99 (m, 8 H), 2 04 - 2 24 (m, 1 H), 2 66 (s, 3 H), 2 91 - 3 11 (m, 1 H), 3 71 (s, 3 H), 4 48 (d, J=Q 44 Hz, 2 H), 4 65 - 4 88 (m, 2 H), 6 74 - 6 83 (m, 1 H), 6 86 - 6 93 (m, 2 H), 7 17 - 7 26 (m, 1 H), 7 86 (br s , 2 H), 8 00 - 8 1 1 (m, 1 H), 8 41 (s, 1 H), 9 19 - 9 30 (m, 1 H)
Example 224 rac-W-(3-Methoxybenzyl)-4-(2-(((1 S*,3/?*)-3-(3-aminopropanamido)cyclohexyl)methyl)-2W- tetrazol-5-yl)-6-methylpicolinamide
O-(7-Azabenzotrιazo!e-1 -yl)-/V,Λ/,Λ/,/V-tetramethyluronιum hexafluorophosphate (52 0 mg, 0 138 mmol), 3-(terf-butoxycarbonyl)propanoιc acid (21 6 mg, 0 115 mmol), and dnsopropylethylamine (0 040 mL, 0 230 mmol) were added to a solution of rac-Λ/-(3-methoxybenzyl)-4-(2-(((1 S*,3R*)-3- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 223) (50 1 mg, 0 1 15 mmol) in dimethylformamide (2 mL) The mixture was stirred overnight at room temperature The reaction mixture was concentrated and the residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) The resulting intermediate was added to a mixture of dichloromethane and trifluoroacetic acid and stirred approximately 30 minutes The mixture was concentrated and the residue was dissolved in dichloromethane MP-carbonate resin was added and the mixture was agitated for approximately 30 minutes The mixture was filtered and the resin was washed with dichloromethane and methanol The filtrate was concentrated and dried overnight under high vacuum to afford the title compound as a solid (19 1 mg, 33%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 669 mm , m/z 507 (M+H) 1H NMR (400 MHz, DMSO-c/β) δ ppm 0 83 - 1 79 (m), 2 01 - 2 19 (m), 2 65 (s, 3 H), 3 51 (s), 3 71 (s, 3 H), 4 49 (d, J=6 59 Hz, 2 H), 4 68 (m, 2 H), 6 76 - 6 83 (m, 1 H), 6 86 - 6 94 (m, 2 H), 7 18 - 7 26 (m, 1 H), 7 69 - 7 77 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 13 - 9 24 (m, 1 H)
Example 225 rac-W-(3-Methoxybenzyl)-4-(2-(((1 S*,3/?*)-3-acetamidocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Acetic anhydride (0 033 mL, 0 345 mmol) and 4-(dιmethylamιno)pyrιdιne Si bound (833 0 mg, 0 575 mmol, 0 69 mmol/g loading) were added to a solution of rac-Λ/-(3-methoxybenzyl)-4-(2- (((1 S'.SR^-S-aminocyclohexyOmethyO^H-tetrazol-δ-yO-θ-methylpicolinamide (prepared as described in Example 223) (50 0 mg, 0 1 15 mmol) in dichloromethane (2 mL) The mixture was agitated overnight at room temperature The reaction mixture was filtered, and the resin was washed with dimethylformamide The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound as a solid (28 0 mg, 51 %) LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 4 61 mm , m/z 478 (M+H) 1H NMR (400 MHz, DMSO-Of6) δ ppm 0 83 - 1 82 (m), 2 01 - 2 18 (m, 1 H), 3 40 - 3 61 (m, 1 H), 3 71 (s, 3 H), 4 49 (d, J=5 9 Hz, 2 H), 4 61 - 4 75 (m), 6 76 - 6 83 (m, 1 H), 6 86 - 6 93 (m, 2 H), 7 17 - 7 26 (m, 1 H), 7 63 - 7 71 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 14 - 9 23 (m, 1 H)
Example 226
W-(3-Methoxybenzyl)-4-(2-(((1 S*,3f?*)-3-acetamidocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
rac-W-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide (prepared as described in Example 225) was resolved by chiral supercritical-fluid chromatography (OJ-H, 30 x 250 mm, 15% methanol, 70 mL/min) The first eluting enantiomer was isolated to provide 22 mg (8%) of the title compound 1H NMR (400 MHz, DMSOd6) δ ppm 9 20 (t, J=Q 6 Hz, 1 H), 8 42 (s, 1 H), 8 07 (s, 1 H), 7 68 (d, J=I 3 Hz, 1 H), 7 23 (t, J=Q 1 Hz, 1 H), 6 92 (br s , 2 H), 6 81 (d, J=8 8 Hz, 1 H), 4 62 - 4 78 (m, 2 H), 4 51 (d, J=5 9 Hz, 2 H), 3 73 (s, 3 H), 3 42 - 3 57 (m, 1 H), 2 67 (s, 3 H), 2 53 (s, 1 H), 2 1 1 (br s , 1 H), 1 64 - 1 80 (m, 5 H), 1 59 (d, J=\ 1 7 Hz, 1 H), 1 20 - 1 34 (m, 1 H), 0 82 - 1 09 (m, 3 H) Example 227
A/-(3-Methoxybenzyl)-4-(2-(((1R*,3S*)-3-acetamidocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
rac-Λ/-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-acetamιdocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide (prepared as described in Example 225) was resolved by chiral supercritical-fluid chromatography (OJ-H, 30 x 250 mm, 15% methanol, 70 mL/min) The second eluting enantiomer was isolated to provide 23 mg (9%) of the title compound 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 18 (t, J=6 6 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 66 (d, J=I 3 Hz, 1 H), 7 22 (t, J=& 1 Hz, 1 H), 6 90 (br s , 2 H), 6 80 (d, J=7 3 Hz, 1 H), 4 62 - 4 77 (m, 2 H), 4 49 (d, J=6 6 Hz, 2 H), 3 71 (s, 3 H), 3 41 - 3 55 (m, 1 H), 2 60 - 2 73 (m, 3 H), 2 51 (s, 1 H), 2 07 (d, J=19 76 Hz, 1 H), 1 64 - 1 81 (m, 5 H), 1 55 (br s , 1 H), 1 19 - 1 36 (m, 2 H), 0 80 - 1 08 (m, 2 H)
Example 228 rac-W-(3-Methoxybenzyl)-4-(2-(((1 S*,3/?*)-3-(2-methoxyacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to rac-Λ/-(3-methoxybenzyl)-4-(2- (((1 S*,3f?*)-3-(3-amιnopropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 224) by reaction with 2-methoxyacetιc acid and afforded 33 9 mg (58%) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 169 mm , m/z 508 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 0 81 - 1 80 (m), 2 03 - 2 20 (m), 2 65 (s, 3 H), 3 50 - 3 66 (m, 1 H), 3 71 (s, 3 H), 4 49 (d, J=6 6 Hz, 2 H), 4 59 - 4 77 (m, 2 H), 6 74 - 6 83 (m, 1 H), 6 86 - 6 94 (m, 2 H), 7 17 - 7 25 (m, 1 H), 7 51 - 7 58 (m, 1 H), 8 06 (s, 1 H), 8 41 (s, 1 H), 9 13 - 9 26 (m, 1 H)
Example 229 rac-2-((1/?*)3S*)-3-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexylamino)-2-oxoethyl acetate
The title compound was prepared in a similar manner to rac-/V-(3-methoxybenzyl)-4-(2- (((1 S*,3/?*)-3-(3-amιnopropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 224) by reaction with 2-acetoxyacetιc acid and afforded 32 7 mg (53%) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 174 mm , m/z 536 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 0 85 - 1 80 (m), 2 03 (s, 3 H), 2 06 - 2 24 (m, 1 H), 2 65 (s, 3 H), 3 46 - 3 64 (m, 1 H), 3 71 (s, 3 H), 4 34 (s, 2 H), 4 49 (d, J=6 6 Hz, 2 H), 4 69 (d, J=5 9 Hz, 2 H), 6 74 - 6 84 (m, 1 H), 6 86 - 6 93 (m, 2 H), 7 17 - 7 26 (m, 1 H), 7 76 - 7 85 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 14 - 9 25 (m, 1 H)
Example 230 rac-W-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-(2-hydroxyacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to rac-/V-(3-methoxybenzyl)-4-(2- (((I S'.SR^-S^S-aminopropanamido^yclohexyOmethy^^H-tetrazol-S-yO-θ-methylpicolmamide (Example 224) by reaction with 2-hydroxyacetιc acid and afforded 32 1 mg (57%) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 902 mm , m/z 493 (M+H) 1H NMR (400 MHz, DMSO-d6) 6 ppm 0 82 - 1 77 (m), 1 99 - 2 20 (m, 1 H), 2 52 (s), 2 65 (s, 3 H), 3 27 - 3 39 (m), 3 71 (s, 3 H), 4 49 (d, J=5 9 Hz, 2 H), 4 57 - 4 77 (m, 2 H), 5 23 - 5 37 (m), 6 74 - 6 82 (m, 1 H), 6 86 - 6 94 (m, 2 H), 7 17 - 7 25 (m, 1 H), 7 39 - 7 48 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 11 - 9 24 (m, 1 H)
Example 231
W-(3-Methoxybenzyl)-4-(2-(((1/?*,3S*)-3-(2-hydroxyacetamido)cyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpicolinamide
rac-Λ/-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-(2-hydroxyacetamιdo)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 230) was resolved by chiral supercritical-fluid chromatography (OJ-H, 30 x 250 mm, 15% methanol, 70 mL/min) The first eluting enantiomer was isolated to provide 23 mg (10%) of the title compound 1H NMR (400 MHz, DMSOd6) δ ppm 9 18 (t, J=6 2 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 43 (d, J=8 1 Hz, 1 H), 7 22 (t, J=B 1 Hz, 1 H), 6 90 (br s , 2 H), 6 80 (d, J=I 3 Hz, 1 H), 5 28 (t, J=5 5 Hz, 1 H), 4 68 (dd, J=6 2, 3 3 Hz, 2 H), 4 49 (d, J=Q 6 Hz, 2 H), 3 71 (s, 3 H), 3 59 (d, >13 9 Hz, 1 H), 2 65 (s, 3 H), 2 51 (s, 1 H), 2 1 1 (br s 1 H), 1 63 (dd, J=34 8, 20 1 Hz, 4 H), 0 90 - 1 35 (m, 5 H)
Example 232
W-(3-Methoxybenzyl)-4-(2-(((1S*,3/?*)-3-(2-hydroxyacetamido)cyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpicolinamide
rac-A/-(3-Methoxybenzyl)-4-(2-(((1 S*,3f?*)-3-(2-hydroxyacetamido)cyclohexyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 230) was resolved by chiral supercritical-fluid chromatography (OJ-H, 30 x 250 mm, 15% methanol, 70 mL/min) The second eluting enantiomer was isolated to provide 21 mg (10%) of the title compound 1H NMR (400 MHz, DMSO-cfe) δ ppm 9 18 (t, J=6 6 Hz1 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 43 (d, J=8 1 Hz, 1 H), 7 22 (t, J=8 1 Hz, 1 H), 6 90 (br s , 2 H), 6 80 (d, J=8 1 Hz, 1 H), 5 28 (t, J=5 9 Hz, 1 H), 4 63 - 4 76 (m, 2 H), 4 49 (d, J=6 6 Hz, 2 H), 3 71 (s, 3 H), 3 60 (d, J= 1 1 0 Hz, 1 H), 2 65 (s, 3 H), 2 51 (s, 1 H), 2 1 1 (br s , 1 H), 1 54 - 1 78 (m, 4 H), 0 84 - 1 37 (m, 5 H)
Example 233 rac-W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((1 S*,3R*)-3-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-
6-methylpicolinamide
Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((/rans)-4- amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 170) (1 00 g, 2 64 mmol), t- butyl cιs-(3-hydroxymethyl)cyclohexylcarbamate (0 73 g, 3 2 mmol), and polymer supported- tπphenylphosphine (1 76 g, 4 0 mmol) were suspended in anhydrous tetrahydrofuran (50 mL) The mixture was cooled to 0 0C in an ice bath for 15 mm and then di-tert-butyl azodicarboxylate (0 73 g, 3 2 mmol) was added The reaction mixture was allowed to warm to room temperature while stirring over 15 hours The mixture was filtered and the filtrate was concentrated The crude residue was purified on silica (20 g, 0-2% methanol/dichloromethane) to afford the protected amine The intermediate was dissolved in dichloromethane (5 mL) and trifluoroacetic acid (2 mL) was added After 2 hours at room temperature, the reaction mixture was diluted with dichloromethane (10 mL) and neutralized with an aqueous solution of sodium hydroxide (2 5 N) for pH 7 The organic layer was separated, dried over anhydrous sodium sulfate, filtered and concentrated to afford the title compound as a beige oil (689 mg, 58%) LC/MS (5-100% CH3CN/H2O, 8 mm) 3 90-4 15 mm, m/z 454 (M+H)
Example 234 rac-2-((1/?*,3S*)-3-((5-(2-((4-Fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexylamino)-2-oxoethyl acetate
rac-A/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((1 S*,3/?*)-3-aminocyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpιcolιnamιde (prepared as described in Example 233) (1 00 g, 2 20 mmol) was dissolved in dichloromethane (10 mL) Triethylamine (0 19 mL, 2 6 mmol) and a solution of acetoxy acetyl chloride (336 mg) in dichloromethane (1 0 mL) was added The mixture was stirred for 4 hours at room temperature and was then concentrated The residue was purified by reverse phase preparative HPLC (10-90 % acetonitrile/water) to afford the title compound (190 mg)
Example 235 rac-/V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((1S*,3R*)-3-(2-hydroxyacetamido)cyclohexyl)methyl)- 2W-tetrazol-5-yl)-6-methylpicolinamide
rac-2-((1 f?*,3S*)-3-((5-(2-((4-Fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexylamιno)-2-oxoethyl acetate (190 mg) was dissolved in acetonitrile ( 10 mL) An aqueous solution of sodium hydroxide (2 5 N, 4 0 mL) was added and the mixture was stirred for 2 hours The reaction mixture was concentrated and the aqueous residue was acidified to pH 7 with a 10% solution of hydrochloric acid in water The neutralized mixture was extracted with ethyl acetate (3 x 1 OmL) The combined organics were washed with brine (2 x 10 mL), dried over anhydrous sodium sulfate, and filtered, and concentrated The residue was purified by reverse phase preparative HPLC to afford the title compound (150 mg) MS (ES+) m/z 512 (M+H)
Example 236
W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((1S*,3/?*)-3-(2-hydroxyacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide rac-Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((1 S\3/?*)-3-(2- hydroxyacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 235) was resolved by chiral supercritical-fluid chromatography (OJ-H, 30 x 250 mm, 15% methanol, 70 ml_/mιn) The first eluting enantiomer was isolated to provide 120 mg (21 %) of the title compound 1H NMR (400 MHz, DMSO-d6) δ ppm 9 20 (t, J=6 6 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H)1 7 42 (d, J=Q 1 Hz, 1 H), 7 05 - 7 20 (m, 2 H), 6 88 (d, J=8 1 Hz, 1 H), 5 27 (t, J=5 9 Hz, 1 H), 4 59 - 4 72 (m, 2 H), 4 48 (d, J=5 9 Hz, 2 H), 3 77 - 3 84 (m, 3 H), 3 71 (d, J=5 1 Hz, 2 H), 3 53 - 3 64 (m, 1 H), 2 65 (s, 3 H), 2 51 (s, 1 H), 2 06 - 2 19 (m, 1 H), 1 49 - 1 75 (m, 3 H), 0 88 - 1 33 (m, 4 H)
Example 237
/V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((1/?*,3S*)-3-(2-hydroxyacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
rac-Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((1 S*,3/?*)-3-(2- hydroxyacetamido^yclohexyOmethyl^H-tetrazol-δ-yO-θ-methylpicolinamide (prepared as described in Example 235) was resolved by chiral supercritical-fluid chromatography (OJ-H, 30 x 250 mm, 15% methanol, 70 mL/min) The second eluting enantiomer was isolated to provide 107 mg (19%) of the title compound 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 20 (t, J=5 9 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 42 (d, J=8 8 Hz, 1 H), 7 05 - 7 22 (m, 2 H), 6 89 (br s , 1 H), 5 27 (t, J=5 9 Hz, 1 H), 4 68 (d, J=2 9 Hz, 2 H), 4 48 (d, J=5 9 Hz, 2 H), 3 80 (s, 3 H), 3 71 (d, J=5 1 Hz, 2 H), 3 60 (d, J=1 1 7 Hz, 1 H), 2 65 (s, 3 H), 2 51 (s, 1 H), 2 1 1 (br s , 1 H), 1 59 (d, J=20 5 Hz, 3 H), 0 84 - 1 36 (m, 4 H)
Example 238 rac-A/-(3-Methoxybenzyl)-4-(2-(((1S*,3/?*)-3-(3-methoxypropanamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to rac-Λ/-(3-methoxybenzyl)-4-(2- (((1 S*,3R*)-3-(3-amιnopropanamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 224) by reaction with 3-methoxypropanoιc acid and afforded 35 2 mg (59%) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 1 15 mm , m/z 522 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 0 84 - 1 79 (m), 2 01 - 2 17 (m, 1 H), 2 22 (t, J=6 6 Hz, 2 H), 2 65 (s, 3 H), 3 37 - 3 60 (m), 3 71 (s, 3 H), 4 49 (d, J=5 9 Hz, 2 H), 4 61 - 4 77 (m, 2 H), 6 76 - 6 83 (m, 1 H), 6 87 - 6 93 (m, 2 H), 7 18 - 7 25 (m, 1 H), 7 64 - 7 72 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 14 - 9 22 (m, 1 H)
Example 239 rac-A/-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-(2-aminoacetamido)cyclohexyl)methyl)-2W-tetrazol-5- yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to rac-Λ/-(3-methoxybenzyl)-4-(2-
(((I S'.SR^-S^S-aminopropanamidoJcyclohexyl^ethyO^H-tetrazol-δ-yO-e-methylpicolinamide (Example 224) by reaction with 2-(tert-bυtoxycarbonyl)acetιc acid and afforded 23 0 mg (41 %) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 634mιn , m/z 493 (M+H) 1H NMR (400 MHz, DMSO-tf6) δ ppm 0 80 - 1 83 (m), 2 02 - 2 21 (m), 2 65 (s, 3 H), 2 98 (s, 1 H), 3 45 - 3 61 (m, 1 H), 3 71 (s, 3 H), 4 49 (d, J=6 6 Hz, 2 H), 4 61 - 4 73 (m, 2 H), 6 75 - 6 83 (m, 1 H), 6 86 - 6 94 (m, 2 H), 7 17 - 7 26 (m, 1 H), 7 54 - 7 62 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 13 - 9 25 (m, 1 H)
Example 240 rac-W-(3-Methoxybenzyl)-6-methyl-4-(2-(((1S*,3/?*)-3-(methylsulfonamido)cyclohexyl)methyl)-
2W-tetrazol-5-yl)picolinamide
Triethylamine (0 048 mL, 0 345 mmol) and methane sulfonyl chloride (0 013 mL, 0 173 mmol) were added to a solution of rac-Λ/-(3-methoxybenzyl)-4-(2-(((1 S*,3f?*)-3-amιnocyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 223) (50 1 mg, 0 1 15 mmol) in tetrahydrofuran (1 5 mL) The mixture was stirred for 2 hours at room temperature The reaction mixture was concentrated and the residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound as a solid (26 0 mg, 44%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 188 mm , m/z 514 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 12 - 9 24 (m, 1 H), 8 41 (s, 1 H),8 05 (s, 1 H), 7 16 - 7 26 (m, 1 H), 6 95 - 7 03 (m, 1 H), 6 86 - 6 93 (m, 2 H), 6 75 - 6 83 (m, 1 H), 4 68 (d, J=6 6 Hz, 2 H), 4 49 (d, J=5 9 Hz, 2 H), 3 71 (s, 3 H), 2 85 (s, 3 H), 2 65 (s, 3 H), 2 03 - 2 20 (m), 1 81 - 1 92 (m), 1 63 - 1 74 (m), 1 43 - 1 58 (m), 0 82 - 1 37 (m)
Example 241 rac-/V-(3-Methoxybenzyl)-4-(2-(((1R*,3/?*)-3-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Step 1 Preparation of rac-tert-butyl (1 R>,3P*)-3-((5-(2-((3-methoxybenzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)cvclohexylcarbamate
A solution of Λ/-(3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)- 2H-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (500 0 mg, 1 54 mmol) in anhydrous tetrahydrofuran (30 mL) and triphenylphosphine resin (1 790 g, 3 85 mmol, 2 15 mmol/g loading) was added to a vial containing rac-tert-butyl (IR'^fO-S^hydroxymethyOcyclohexylcarbamate (707 0 mg, 3 08 mmol) The mixture was cooled in an ice bath and di-tert-butylazodicarboxylate (710 0 mg, 3 08 mmol) was added The reaction mixture was agitated overnight at room temperature and then concentrated The residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound
Step 2 Preparation of rac-/V-(3-methoxybenzyl)-4-(2-(((1 f?*,3ff*)-3-amιnocvclohexyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnamιde
rac-tert-bυtyl (1 f?*,3R*)-3-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexylcarbamate obtained in step 1 was dissolved in dichloromethane and trifluoroacetic acid and stirred for approximately 30 minutes The mixture was concentrated and the residue was dissolved in dichloromethane MP-carbonate resin was added to the solution and the mixture was agitated for approximately 1 hour The mixture was filtered and the resin was washed with dichloromethane and methanol The filtrate was concentrated under a stream of nitrogen and dried under high vacuum overnight to afford the title compound as a solid (460 mg, 68%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 514 mm , m/z 436 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 21 - 9 29 (m, 1 H), 8 41 (s, 1 H), 8 05 - 8 08 (m, 1 H), 7 93 (br s , 2 H), 7 17 - 7 26 (m, 1 H), 6 85 - 6 94 (m, 2 H), 6 75 - 6 83 (m, 1 H), 4 68 - 4 86 (m, 2 H), 4 48 (d, J=6 4 Hz, 2 H), 3 70 (s, 3 H), 3 37 - 3 49 (m, 1 H), 2 66 (s, 3 H), 2 45 - 2 56 (m, 1 H), 1 12 - 1 78 (m)
Example 242 rac-W-(3-Methoxybenzyl)-4-(2-(((1/?*,3/?*)-3-(2-methoxyacetamido)cyclohexyl)methyl)-2W- tetrazol-5-yl)-6-methylpicolinamide
O-(7-Azabenzotrιazole-1 -yl)-Λ/,Λ/,Λ/\/V-tetramethyluronιum hexafluorophosphate (52 0 mg, 0 138 mmol), 2-methoxyacetιc acid (10 4 mg, 0 115 mmol), and dnsopropylethylamine (0 040 mL,
0 230 mmol) were added to a solution of rac-Λ/-(3-methoxybenzyl)-4-(2-(((1 R*,3R*)-3- amιnocyclohexyl)methyl)-2/-V-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 241 ) (50 1 mg, 0 115 mmol) in Λ/,Λ/-dιmethylformamιde (2 mL) The mixture was allowed to stir at room temperature overnight and was then concentrated The residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound as a solid (31 9 mg, 55%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 196 mm , m/z 508 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 05 - 9 24 (m, 1 H), 8 40 (s, 1 H), 8 05 (s, 1 H), 7 41 - 7 50 (m, 1 H), 7 16 - 7 26 (m, 1 H), 6 86 - 6 93 (m, 2 H), 6 76 - 6 84 (m, 1 H), 4 70 (d, J=I 32 Hz, 2 H), 4 49 (d, J=5 86 Hz, 2 H), 4 01 (br s ), 3 76 (s, 3 H), 3 71 (s, 3 H), 2 62 - 2 70 (s, 3 H), 2 32 - 2 45 (m, 1 H),
1 04 - 1 74 (m)
Example 243 rac-W-(3-Methoxybenzyl)-4-(2-(((1R*,3f?*)-3-acetamidocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Acetic anhydride (0 033 mL, 0 345 mmol) and 4-(dιmethylamιno)pyπdιne Si bound (833 0 mg, 0 575 mmol, 0 69 mmol/g loading) were added to a solution of rac-Λ/-(3-methoxybenzyl)-4-(2- (((IR'.SR'J-S-aminocyclohexyOmethylJ^H-tetrazol-S-yO-β-methylpicolinamide (prepared as described in Example 241 ) (50 0 mg, 0 1 15 mmol) in dichloromethane (2 mL) The mixture was agitated overnight and then filtered The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound (30 0 mg, 55%) LC/MS (5%-100% CH3CN/H2O, 10 0 mm ) 4 57 mm , m/z 478 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 14 - 9 23 (m, 1 H), 8 41 (s, 1 H), 8 06 (s, 1 H), 7 65 - 7 73 (m, 1 H), 7 18 - 7 26 (m, 1 H), 6 86 - 6 94 (m, 2 H), 6 75 - 6 83 (m, 1 H), 4 66 (d, J=I 32 Hz, 2 H), 4 49 (d, J=5 86 Hz, 2 H), 3 92 - 4 02 (m, 1 H), 3 71 (s, 3 H), 2 65 (s, 3 H), 3 28 (s), 2 32 - 2 45 (m, 1 H), 1 78 (s, 3 H), 0 95 - 1 70 (m)
Example 244 rac-2-((1/?*,3/?*)-3-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexylamino)-2-oxoethyl acetate
The title compound was prepared in a similar manner to rac-Λ/-(3-methoxybenzyl)-4-(2-
(((1/?*,3/?*)-3-(2-methoxyacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 242) by reaction with 2-acetoxyacetιc acid to afford 23 7 mg (38%) as a solid LC/MS (5%- 95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 188 mm , m/z 536 (M+H) 1H NMR (400 MHz, DMSO-Cf6) ό ppm 0 99 - 1 73 (m) 2 01 (s, 3 H), 2 26 - 2 46 (m, 1 H), 2 65 (s, 3 H)1 3 71 (s, 3 H), 3 99 (br s ) 4 41 (s, 2 H), 4 49 (d, J=6 59 Hz, 1 H), 4 68 (d, J=I 32 Hz, 2 H), 6 74 - 6 83 (m, 1 H), 6 86 - 6 95 (m, 2 H), 7 16 - 7 25 (m, 1 H), 7 79 - 7 87 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 14 - 9 23 (m, 1 H)
Example 245 rac-W-(3-Methoxybenzyl)-4-(2-(((1R*,3R*)-3-(2-hydroxyacetamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to rac-Λ/-(3-methoxybenzyl)-4-(2- (((1 R*,3R*)-3-(2-methoxyacetamιdo)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 242) by reaction with 2-hydroxyacetιc acid to afford 26 1 mg (46%) as a solid LC/MS (5%- 95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 927 mm , m/z 494 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 1 02 - 1 75 (m) 2 27 - 2 43 (m, 1 H), 2 52 (s, 3 H), 2 65 (s, 3 H), 3 71 (s, 3 H), 3 77 (br s ) 4 01 (br s ) 4 49 (d, J=5 86 Hz, 2 H), 4 70 (d, J=I 32 Hz, 2 H), 6 72 - 6 83 (m, 1 H), 6 86 - 6 93 (m, 2 H), 7 17 - 7 26 (m, 1 H), 7 32 - 7 39 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 15 - 9 24 (m, 1 H) Example 246 fac-W-(3-Methoxybenzyl)-4-(2-(((1/?*,3/7*)-3-(3-methoxypropanamido)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to rac-Λ/-(3-methoxybenzyl)-4-(2-
(((I R'.SR^-S^Z-methoxyacetamido^yclohexyOmethyO^H-tetrazol-δ-yO-β-methylpicolinamide (Example 242) by reaction with 3-methoxypropanoιc acid to afford 33 O mg (55%) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 152 mm , m/z 522 (M+H) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 0 98 - 1 70 (m) 2 30 (t, J=6 22 Hz, 2 H), 2 39 (br s ) 2 65 (s, 3 H), 3 46 (t, J=6 59 Hz, 2 H), 3 71 (s, 3 H), 3 97 (br s ) 4 49 (d, J=6 59 Hz, 2 H), 4 66 (d, J=I 32 Hz, 2 H), 6 76 - 6 83 (m, 1 H), 6 85 - 6 93 (m, 2 H), 7 18 - 7 26 (m, 1 H), 7 65 - 7 73 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 14 - 9 24 (m, 1 H)
Example 247 rac-/V-(3-Methoxybenzyl)-4-(2-(((1R*,3R*)-3-(2-aminoacetamido)cyclohexyl)methyl)-2H-tetrazol- 5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to rac-Λ/-(3-methoxybenzyl)-4-(2- (((1 f?*,3/:?*)-3-(2-methoxyacetamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 242) by reaction with 2-(tert-butoxycarbonyl)acetιc acid to afford 19 8 mg (41 %) as a solid LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 653 mm , m/z 493 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 0 97 - 1 69 (m) 2 34 (br s ) 2 65 (s, 3 H), 3 27 (br s ) 3 71 (s, 3 H), 3 99 (br s ) 4 49 (d, J=5 86 Hz, 2 H), 4 57 - 4 77 (m, 2 H), 6 72 - 6 84 (m, 1 H), 6 85 - 6 94 (m, 2 H), 7 13 - 7 27 (m, 1 H), 7 63 - 7 72 (m, 1 H), 8 04 - 8 08 (m, 1 H), 8 39 - 8 47 (m, 1 H), 9 13 - 9 23 (m, 1 H)
Example 248 rac-W-(3-Methoxybenzyl)-6-methyl-4-(2-(((1/?*,3R*)-3-(methylsulfonamido)cyclohexyl)methyl)-
2H-tetrazol-5-yl)picolinamide
Triethylamine (0 048 mL, 0 345 mmol) and methane sulfonyl chloride (0 013 mL, 0 173 mmol) were added to a solution of rac-Λ/-(3-methoxybenzyl)-4-(2-(((1 R*,3R*)-3-amιnocyclohexyl)methyl)-2/-y- tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 241 ) (50 1 mg, 0 1 15 mmol) in tetrahydrofuran (1 5 mL) The mixture was stirred for 2 hours at room temperature and was then concentrated The residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm) to afford the title compound as a solid (29 2 mg, 49%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 198 mm , m/z 514 (M +H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 09 - 9 25 (m, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 15 - 7 28 (m, 1 H), 6 92 - 6 99 (m, 1 H), 6 86 - 6 93 (m, 2 H), 6 73 - 6 83 (m), 4 68 (d, J=7 3 Hz, 2 H), 4 49 (d, J=6 6 Hz, 2 H), 3 71 (s, 3 H), 3 52 - 3 63 (m), 2 84 (s, 3 H), 2 65 (s, 3 H), 2 32 - 2 46 (m), 1 30 - 1 75 (m), 0 86 - 1 21 (m)
Example 249 rac-W-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-aminocyclopentyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Step 1 Preparation of (erf-butyl rac-(1 /?*,3S*)-3-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn- 4-yl)-2/-/-tetrazol-2-yl)methyl)cvclopentylcarbamate
tert-Butyl (c7s)-3-(hydroxymethyl)cyclopentylcarbamate (1 66 g, 6 166 mmol) and polymer supported-triphenylphosphine (5 74 g, 12 3 mmol) was added to a solution of /V-(3-methoxybenzyl)-6- methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3- methoxybenzyl)-4-(2-((((rans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) in THF (25 mL) cooled to -20 0C Di-tert-butylazodicarboxylate (2 84 g, 12 3 mmol) was added and the mixture was stirred at -20 0C for 2 hours The reaction mixture was allowed to warm and stir overnight The mixture was filtered and the resin was washed with tetrahydrofuran The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound (1 759 g) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 3 647 mm , m/z 522 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 1 17 - 1 29 (m, 1 H), 1 37 - 1 46 (m, 9 H), 1 46 - 1 62 (m, 1 H), 1 75 - 1 86 (m, 1 H), 1 86 - 1 96 (m, 1 H), 1 97 - 2 09 (m, 1 H), 2 17 - 2 30 (m, 1 H), 2 57 - 2 73 (m, 3 H), 3 75 - 3 84 (m, 3 H), 3 96 (br s , 1 H), 4 54 (d, J=5 6 Hz, 1 H), 4 65 (t, J=7 3 Hz, 3 H), 6 82 (dd, J=8 2, 2 3 Hz, 1 H), 6 88 - 7 01 (m, 1 H), 7 20 - 7 34 (m, 1 H), 8 03 (s, 1 H), 8 42 (t, J=5 8 Hz, 1 H), 8 70 (s, 1 H)
Step 2 Preparation of rac-Λ/-(3-methoxybenzyl)-4-(2-(((1 S*,3f?*)-3-amιnocvclopentyl)nnethyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnamιde
Trifluoroacetic acid (0 73 mL, 9 84 mmol) was added to a solution of /ert-butyl rac-(1 R*,3S*)-3- ((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2- yl)methyl)cyclopentylcarbamate (1 475 g, 1 968 mmol) in dichloromethane (25 mL) The mixture was allowed to stir at room temperature overnight and was then concentrated to afford the title compound as a clear, yellow oil (1 59 g, 100% yield) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 2 484 mm , m/z 422 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 1 62 - 1 75 (m, 2 H), 1 79 - 1 95 (m, 2 H), 2 02 - 2 13 (m, 1 H), 2 21 - 2 32 (m, 1 H), 2 70 (s, 3 H), 3 50 (br s , 1 H), 3 76 (s, 3 H), 4 62 (d, J=5 9 Hz, 2 H), 4 64 - 4 81 (m, 2 H), 5 28 (s, 2 H), 6 78 - 6 92 (m, 2 H), 6 95 (br s , 2 H), 7 23 - 7 27 (m, 1 H), 7 72 (br s , 1 H), 8 15 (s, 1 H), 8 63 (s, 1 H)
Example 250 rac-/V-(3-Methoxybenzyl)-6-methyl-4-(2-(((1 S*,3/?*)-3-(methylsulfonamido)cyclopentyl)methyl)-
2/-/-tetrazol-5-yl)picolinamide
Diisopropylethylamine (0 64 ml, 13 4 mmol) was added to a solution of rac-/V-(3- methoxybenzyl)-4-(2-(((1 S*,3R*)-3-amιnocyclopentyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 249) (1 16 mg, 0 275 mmol) in DMF (5 0 mL) After 20 minutes, methanesulfonyl chloride (158 mg, 1 38 mmol) was added and the mixture was allowed to stir overnight The reaction mixture was concentrated and the residue was purified by preparative reverse phase preparative HPLC to afford the title compound as an oil (62 8 mg, 49%) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 3 156 mm , m/z 500 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm9 19 (t, J=6 22 Hz, 1 H), 8 41 (br s , 1 H), 8 06 (s, 1 H), 7 22 (t, J=8 05 Hz, 1 H), 7 09 (d, J=7 32 Hz, 1 H), 6 90 (br s , 2 H), 6 80 (d, J=8 05 Hz, 1 H), 4 77 (d, J=7 32 Hz, 2 H), 4 49 (d, J=5 86 Hz, 2 H), 3 71 (s, 3 H), 2 85 (s, 3 H), 2 65 (s, 3 H), 2 01 - 2 13 (m, 2 H), 1 82 - 1 96 (m, 2 H), 1 69 (br s , 2 H), 1 44 - 1 60 (m, 2 H), 1 23 - 1 37 (m, 2 H) Example 251 rac-W-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-(ethylsulfonamido)cyclopentyl)methyl)-2H-tetrazol-5- yl)-6-methylpicolinamide
Diisopropylethylamine (0 23 ml_, 1 31 mmol) was added to a solution of rac-Λ/-(3- methoxybenzyl)-4-(2-(((1 S*,3R*)-3-amιnocyclopentyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 249) (100 rng, 0 131 mmol) in DMF (5 0 mL) After 20 minutes, ethanesulfonyl chloride (101 mg, 0 786 mmol) was added and the mixture was allowed to stir overnight The reaction mixture was concentrated and the residue was purified by preparative reverse phase preparative HPLC to afford the title compound as an oil (25 3 mg, 26%) MS (ES+) m/z 514 (M+H) 1H NMR (400 MHz, methanol-d4) δ ppm 1 28 (t, J=7 38 Hz, 3 H), 1 34 - 1 45 (m, 1 H), 1 55 - 1 69 (m, 1 H), 1 79 (d, J=6 71 Hz, 1 H), 1 96 - 2 07 (m, 1 H), 2 14 - 2 24 (m, 1 H), 2 67 (s, 3 H), 3 01 (q, J=7 25 Hz, 2 H), 3 76 (s, 3 H), 4 59 (s, 2 H), 4 74 (d, J=I 52 Hz, 2 H), 6 80 (dd, J=8 06, 2 42 Hz, 1 H), 6 90 - 6 96 (m, 1 H), 7 22 (t, J=Q 19 Hz, 1 H), 8 10 (d, J= 1 07 Hz, 1 H), 8 57 (s, 1 H)
Example 252 rac-W-(3-Methoxybenzyl)-4-(2-(((1 S*,3R*)-3-acetamidocyclopentyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Diisopropylethylamine (128 mg, 1 00 mmol) was added to a solution of rac-Λ/-(3- methoxybenzyl)-4-(2-(((1 S*,3R*)-3-amιnocyclopentyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 249) (100 mg, 0 131 mmol) in dichloromethane (5 mL) After 20 minutes, acetic anhydride (40 mg, 0 40 mmol) was added The mixture was allowed to stir at room temperature overnight The reaction mixture was concentrated and the residue was purified by preparative reverse phase preparative HPLC to afford the title compound (58 3 mg, 43%) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 3 071 mm , m/z 464 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 20 (t, J=6 22 Hz, 1 H), 8 40 (s, 1 H), 8 05 (s, 1 H), 7 82 (d, J=5 86 Hz, 1 H), 7 21 (t, J=8 05 Hz, 1 H), 6 90 (br s , 1 H), 6 79 (d, J=7 32 Hz, 2 H), 4 76 (d, J=6 59 Hz, 2 H), 4 49 (d, J=5 86 Hz, 2 H), 3 98 (dd, J=14 64, 7 32 Hz, 1 H), 3 71 (s, 3 H), 2 65 (s, 3 H), 2 50 - 2 60 (m, 1 H), 2 48 (br s , 1 H), 1 94 - 2 07 (m, 1 H)1 61 - 1 87 (m, 4 H), 1 37 - 1 56 (m, 2 H), 1 13 - 1 26 (m, 1 H) Example 253 rac-A/-(3-Methoxybenzyl)-4-(2-(((1S*,3/?*)-3-(2-hydroxyacetamido)cyclopentyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
Diisopropylethylamine (118 mg, 0 917 mmol) and glycolic acid (19 9 mg, 0 262 mmol) were added to a solution of rac-Λ/-(3-methoxybenzyl)-4-(2-(((1 S*,3f?*)-3-amιnocyclopentyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 249) (100 mg, 0 131 mmol) in Λ/,Λ/-dιmethylformamιde (5 mL) After 20 mm, O-(1 H-benzotrιazol-1-yl)-Λ/,Λ/,A/',Λ/"-tetramethyluronιum tetrafluoroborate (116 mg, 0 360 mmol) was added and the mixture was allowed to stir for 72 hours The reaction mixture was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound (30 5 mg, 33%) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 2 958 mm , m/z 480 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 19 (t, J=6 22 Hz, 1 H), 8 41 (br s , 1 H), 8 06 (s, 1 H), 7 22 (t, J=8 05 Hz, 1 H), 6 90 (br s , 1 H), 6 80 (d, J=8 05 Hz, 1 H), 5 29 (br s , 1 H), 4 49 (d, J=5 86 Hz, 2 H), 4 03 - 4 18 (m, 1 H), 3 67 - 3 80 (m, 3 H), 2 65 (s, 3 H), 2 50 - 2 62 (m, 1 H), 2 48 (br s , 1 H), 1 76 - 1 88 (m, 1 H), 1 61 - 1 73 (m, 1 H), 1 53 (d, J=6 59 Hz, 2 H), 1 22 - 1 39 (m, 1 H)
Example 254 rac-/V-(3-Methoxybenzyl)-4-(2-(((1S*,3/?*)-3-(3-hydroxypropanamido)cyclopentyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
Diisopropylethylamine (130 mg, 1 01 mmol) and 3-hydroxypropιonιc acid (26 mg, 0 288 mmol) were added to a solution of rac-Λ/-(3-methoxybenzyl)-4-(2-(((1 S*,3R*)-3-amιnocyclopentyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 249) (1 10 mg, 0 144 mmol) in Λ/,Λ/-dιmethylformamιde (5 mL) After 20 mm, O-(1 H-benzotrιazol-1-yl)-Λ/,Λ/,Λ/',Λ/"-tetramethyluronιum tetrafluoroborate (127 mg, 0 396 mmol) was added and the mixture was allowed to stir for 72 hours The reaction mixture was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound (16 1 mg, 15%) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 2 936 mm , m/z 494 (M+H) 1H NMR (400 MHz, CD3OD) ό ppm 9 20 (s, 1 H), 8 55 (s, 1 H), 8 10 (s, 1 H), 7 23 (t, J=Q 19 Hz, 1 H), 6 91 - 6 96 (m, 2 H), 6 78 - 6 83 (m, 1 H), 4 73 - 4 81 (m, 2 H), 4 59 (s, 2 H), 3 74 - 3 79 (m, 3 H), 2 66 - 2 70 (m, 3 H), 2 35 (t, J=6 31 Hz, 1 H), 2 13 - 2 22 (m, 1 H), 1 99 (d, J=6 18 Hz, 1 H), 1 81 (s, 1 H), 1 51 - 1 67 (m, 2 H), 1 28 - 1 38 (m, 1 H) Example 255
(frans)-Methyl 4-((5-(2-((4-fluorobenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate
Step 1 Preparation of Λ/-(4-fluorobenzγl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde
A solution of trimethyl aluminum (2M in toluene, 91 25 ml_, 0 183 mol) was added to a solution of 4-fluorobenzylamιne (22 84 g, 0 183 mol) in anhydrous tetrahydrofuran (400 mL) The reaction mixture was stirred at room temperature for 4 h, at which time the solution was cannulated into a suspension of methyl 6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((fraπs)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide, Example 153) (20 0 g, 0 0913 mol) in anhydrous tetrahydrofuran (400 mL) The reaction mixture was then stirred overnight The mixture was quenched slowly with methanol and was poured into a 2 L Erlenmeyer containing methanol (500 mL) The mixture was filtered through Celite™ and concentrated in vacuo The crude product was purified by silica column chromatography
(CH2CI2/tetrahydrofuran, 9/1 ) The desired fractions were combined and concentrated to afford the title compound (25 4 g, 89%) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 9 33 (t, J= 6 34, 1 H), 8 43 (s, 1 H), 8 05 (s, 1 H), 7 34 (dd, J= 8 5, 2 H)1 7 1 1 (dd, J= 8 9, 2 H), 4 48 (d, J= 6 6, 2 H), 2 64 (s, 3 H)
Step 2 Preparation of (frans)-methyl 4-((5-(2-((4-fluorobenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol^-vDmethvQcvclohexanecarboxylate
Triethylamine (9 12 g, 0 09 mol)was added to a suspension of the Λ/-(4-fluorobenzyl)-6- methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (12 8 g, 0 04 mol) in acetonitrile (400 mL, anhydrous) trans- methyl 4-((methylsulfonyloxy)methyl)cyclohexanecarboxylate (prepared as described in step 1 of the synthesis of frans-methyl 4-((5-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrιmιdιn-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexanecarboxylate, Example 20) (10 77 g, 0 04 mol) was then added and the reaction mixture was stirred over night at 60 0C The mixture was concentrated under reduced pressure and the crude product was purified by silica column chromatography (CH2CI2/tetrahydrofuran, 9/1 ) The desired fractions were combined and concentrated to afford the title compound (1 1 g, 58%) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 29 (t, J= 6 34, 1 H), 8 39 (s, 1 H)1 8 04 (s, 1 H), 7 36 (m, 2H), 7 1 1 (m, 2H), 4 64 (d, J= 7 1 , 2H), 4 49 (d, J= 6 6, 2H), 3 30 (s, 3H), 2 64 (s, 3H), 2 1 (m, 1 H), 1 96 (m, 1 H), 1 89 (m, 2H), 1 64 (m, 2H), 1 26 (m, 2H), 1 09 (m, 2H)
Example 256
(fra/7s)-4-((5-(2-((4-Fluorobenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylic acid
To a solution of (frans)-methyl 4-((5-(2-((4-fluorobenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexanecarboxylate (prepared as described in Example 255) (10 g, 0 021 mol) in tetrahydrofuran (300 mL) was added water (300 mL) and then sodium hydroxide (4 3 g, 0 107 mol) The mixture was stirred vigorously overnight The tetrahydrofuran was removed under reduced pressure and the resulting alkaline solution was acidified drop wise with 1 M hydrochloric acid until the solution reached pH 5 The mixture was left sitting in a refrigerator overnight The resulting precipitate was isolated by filtration and washed with water (pH 5) The solid was dried in a vacuum oven overnight to afford the title compound (7 5 g, 77%) Mp 122-124 0C, 1H NMR (400 MHz, DMSO-d6) δ ppm 1 1 96 (s, 1 H), 9 27 (t, J= 6 4, 1 H), 8 36 (s, 1 H), 8 02 (s, 1 H), 7 33 (dd, J= 8 5, 2H), 7 09 (dd, J= 9 0, 2H), 4 61 (d, J= 6 8, 2H), 4 45 (d, J= 6 3, 2H), 2 61 (s, 3H), 2 07 (m, 1 H), 1 93 (m, 1 H), 1 85 (d, J= 11 , 2H), 1 58 (d, J= 10 8, 2H), 1 25 (m, 2H), 1 07 (m, 2H)
Example 257
/V-(4-Fluorobenzyl)-6-methyl-4-(2-(((frans)-4-(methylsulfonylcarbamoyl)cyclohexyl)methyl)-2H- tetrazol-5-yl)picolinamide
4-(Dιmethylamιno)pyrιdιne (5 4mg, 0 041 mmol) was added to a mixture of (/rans)-4-((5-(2-((4- fluorobenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylιc acid
(prepared as described in Example 256) (0 20 g, 0 442 mmol), dι-(Λ/,/V-succιnιmιdyl)carbonate (0 14g, 0 53 mmol), and triethylamine (0 092 mL, 0 66 mmol) in Λ/,N-dιmethylacetamιde (2 mL) After 5 minutes, methanesulfonamide (51 mg, 0 53 mmol) was added The reaction mixture was allowed to stir at room temperature for 24 hours and then purified by reverse phase preparative HPLC to afford the title compound as a solid (0 040 g, 17%) 1H NMR (400 MHz, DMSOd6) δ ppm 9 29 (t, J=6 31 Hz, 1 H), 8 39 (s, 1 H), 8 05 (s, 1 H), 7 26 - 7 44 (m, 2 H), 7 02 - 7 18 (m, 2 H), 4 66 (d, J=6 99 Hz, 2 H), 4 48 (d, J=6 45 Hz, 2 H), 3 31 (br s , 1 H), 2 76 (s, 3 H), 2 61 - 2 69 (m, 4 H), 1 92 - 2 13 (m, 3 H), 1 68 (d, J= 12 90 Hz, 2 H), 1 33 - 1 50 (m, 2 H), 1 10 - 1 29 (m, 2 H)
Example 258
A/-(4-Fluorobenzyl)-4-(2-(((fraπs)-4-(2-hydroxyacetyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Oxalyl chloride (3 mL) was added to a solution of (/rans)-4-((5-(2-((4-fluorobenzyl)carbamoyl)- 6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylιc acid (prepared as described in Example 256) (380 mg, 0 84 mmol) in dichloromethane (2 mL) and the mixture was stirred at room temperature for 18 hours The reaction mixture was concentrated and the residue was treated with trιs(trιmethylsιloxy)ethylene (541 mg, 1 85 mmol) The mixture was heated to 90 °C for 3 hours and then was stirred at room temperature for 2 days The mixture was treated with several drops of 4 N hydrochloric acid until gas stopped evolving The reaction mixture was purified by reverse phase preparative HPLC The crude product was taken up in methanol and passed through a carbonate cartridge The filtrate was concentrated to afford the title compound as a white solid (79 mg, 20%) LCMS (ES+) m/z 467(M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 02 - 1 40 (m, 4 H), 1 61 - 1 73 (m, J=10 98 Hz, 2 H), 1 91 (s, J= 10 98 Hz, 2 H), 1 96 - 2 08 (m, 1 H), 2 20 - 2 32 (m, 1 H), 2 67 (s, 3 H), 3 26 - 3 33 (m, J=2 20 Hz, 1 H), 3 57 (s, 2 H), 4 52 (d, J=5 86 Hz, 2 H), 4 58 - 4 72 (m, 3 H), 7 14 (s, J=8 78, 8 78 Hz, 1 H), 7 39 (dd, J=Q 05, 5 86 Hz, 2 H), 8 07 (s, 1 H), 8 42 (s, 1 H), 9 28 (t, J=6 59 Hz, 1 H)
Example 259
(frans)-Methyl 4-((5-(2-((3-(hydroxymethyl)benzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol- 2-yl)methyl)cyclohexanecarboxylate
Step 1 Preparation of (frans)-methyl 4-((3-nιtrophenylsulfonyloxy)methyl)cvclohexanecarboxylate
A mixture of /rans-methyl 4-(hydroxymethyl)cyclohexanecarboxylate (22 O g, 128 mmol) and 3-nιtrobenzene-1 -sulfonyl chloride (35 7 g, 161 mmol) in dichloromethane (130 mL) was cooled in an ice bath and triethylamine (23 7 mL, 170 mmol) was added by addition funnel maintaining the temperature below 7°C The mixture was stirred at this temperature for 1 hour and then quenched with water (1 mL) The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane The organic layer was dried over magnesium sulfate, filtered, and concentrated The residue was slurried in methanol, filtered, and dried in a vacuum oven to afford the title compound as a white solid (40 66 g, 89%)
Step 2 Preparation of methyl 4-(2-(((frans)-4-(methoxycarbonyl)cvclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinate
Diisopropylethylamine (20 7 mL, 1 18 6 mmol) was added by addition funnel to a mixture of (frans)-methyl 4-((3-nιtrophenylsulfonyloxy)methyl)cyclohexanecarboxylate (35 9 g, 100 4 mmol) and methyl 6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnate (prepared as described in step 4 of the synthesis of /V- (3-methoxybenzyl)-4-(2-(((/rans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (20 g, 91 2 mmol) in acetonitrile (120 mL) The mixture was heated at reflux for 7 hours and then was concentrated in vacuo The residue was suspended in dichloromethane and washed with 1 N aqueous sodium hydroxide solution The organic layer was dried over magnesium sulfate, filtered, and concentrated The crude product was purified by silica gel column chromatography (heptane/ethyl acetate, 65/35, 50/50) to afford the title compound as a white solid (27 g, 79%)
Step 3 Preparation of (frans)-methyl 4-((5-(2-((3-(hvdroxymethyl)benzyl)carbamoyl)-6-methylpyrιdιn-4- vO-2H-tetrazol-2-yl)methyl)cvclohexanecarboxvlate
(3-(Amιnomethyl)phenyl)methanol (prepared as described in step 1 of the synthesis of Λ/-(3- (hydroxymethyl)benzyl)-6-methyl-4-(2-(((frans)-4-(methylsulfonamido)cyclohexyl)methyl)-2H-tetrazol- 5-yl)pιcolιnamιde, Example 183) (1 15 mg, 0 838 mmol) was added to a solution of methyl 4-(2- (((trans )-4-(methoxycarbonyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnate (75 mg, 0 201 mmol) in Λ/,Λ/-dιmethylformamιde (6 mL) and the mixture was heated at 60 0C for 3 days The reaction mixture was purified by reverse-phase preparative HPLC to afford the title compound as a solid (50 mg, 65%) LC/MS (0%-25% CH3CN/H2O, 5 mm ) 3 010 mm , m/z 479 (M+H) 1H NMR (400 MHz, methanol-^) δ ppm 1 10 - 1 24 (m, 2 H), 1 34 - 1 49 (m, 2 H), 1 74 (dd, ,7=13 7, 3 0 Hz, 2 H), 1 99 (dd, .7=13 8, 3 1 Hz, 2 H), 2 03 - 2 16 (m, 1 H), 2 23 - 2 35 (m, 1 H), 2 65 - 2 71 (m, 3 H), 3 62 (s, 3 H), 3 96 (s, 1 H), 4 62 (d, J=7 0 Hz, 2 H), 4 74 (s, 2 H), 7 77 (d, J=8 1 Hz, 1 H), 8 03 (dd, .7=8 2, 1 5 Hz, 1 H), 8 09 (d, J= 1 1 Hz, 1 H), 8 54 (s, 1 H), 8 72 (d, J= 1 6 Hz, 1 H)
Example 260
((rans)-4-((5-(2-((3-(Hydroxymethyl)benzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylic acid
(fraπs)-Methyl 4-((5-(2-((3-(hydroxymethyl)benzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexanecarboxylate (50 mg, 0 13 mmol) was dissolved in tetrahydrofuran (1 0 mL) and a 4 N aqueous solution of lithium hydroxide (1 0 mL) was added The mixture was allowed to stir at room temperature overnight The reaction mixture was concentrated to afford the title compound (16 7 mg, 18%) 1H NMR (400 MHz, CD3OD) δ ppm 1 12 - 1 25 (m, 2 H), 1 35 - 1 48 (m, 2 H), 1 70 - 1 78 (m, 2 H), 1 95 - 2 03 (m, 2 H), 2 05 - 2 14 (m, 1 H), 2 25 - 2 35 (m, 1 H), 2 67 (s, 3 H), 3 33 (s, 1 H), 3 62 (s, 3 H), 3 85 (s, 3 H), 4 62 (d, J=7 25 Hz, 2 H), 4 67 (s, 2 H), 6 90 - 6 97 (m, 1 H), 6 97 - 7 08 (m, 2 H), 8 09 (s, 1 H), 8 55 (s, 1 H)
Example 261
(frans)-Methyl 4-((5-(2-((3-hydroxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate
A mixture of 3-(amιnomethyl)phenol (1 01 g, 8 21 mmol) and methyl 4-(2-(((trans)-4- (methoxycarbonyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnate (prepared as described in step 2 of the synthesis of (frans)-methyl 4-((5-(2-((3-(hydroxymethyl)benzyl)carbamoyl)-6- methylpyridm-4-yl)-2/-/-tetrazol-2-yl)methyl)cyclohexanecarboxylate, Example 260) (1 0 g, 2 05 mmol) in methanol (25 mL) was heated at 60 0C for 4 days The reaction mixture was allowed to cool to room temperature and filtered The resulting solids were washed with methanol to afford the title compound (770 mg, 80%) MS (ES+) m/z 465 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 06 - 1 22 (m, 2 H), 1 24 - 1 41 (m, 2 H), 1 58 - 1 71 (m, 2 H), 1 85 - 1 95 (m, 2 H), 1 96 - 2 08 (m, 1 H), 2 20 - 2 32 (m, 1 H), 2 67 (s, 3 H), 3 57 (s, 3 H), 4 45 (d, J=6 44 Hz, 2 H), 4 67 (d, J=6 98 Hz, 2 H), 6 62 (d, 1 H), 6 72 - 6 80 (m, 2 H), 7 10 (t, J=I 92 Hz, 1 H), 8 08 (d, J= 1 34 Hz, 1 H), 8 43 (s, 1 H), 9 22 (t, J=6 31 Hz, 1 H), 9 32 (s, 1 H)
Example 262
((rans)-4-((5-(2-((3-Hydroxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2W-tetrazol-2-yl)methyl)- cyclohexanecarboxylic acid
A mixture of (frans)-methyl 4-((5-(2-((3-hydroxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexanecarboxylate (prepared as described in Example 261 ) (50 mg, 0 1 1 mmol) and lithium hydroxide (15 mg, 0 65 mmol) in a mixture of tetrahydrofuran/water (5/1 , 3 mL) was stirred at room temperature for 3 days The reaction mixture was concentrated and the aqueous residue was treated dropwise with 3N hydrochloric acid until a precipitate formed The precipitate was taken up in a mixture of dichloromethane and methanol and then passed through an lsolute SPE 103 cartridge eluting with dichloromethane/methanol (9/1 ) The filtrate was concentrated The residue was washed with water and dried to afford the title compound as a white solid (38 mg, 76%) MS (ES+) m/z 451 (M+H) 1H NMR (400 MHz, DMSOd6) 6 ppm 1 04 - 1 20 (m, 2 H), 1 21 - 1 38 (m, 2 H), 1 65 (d, J=10 74 Hz, 2 H), 1 90 (d, J= 1 1 01 Hz, 2 H), 1 99 (s, J=7 12, 3 89 Hz, 1 H), 2 08 - 2 20 (m, 1 H), 2 68 (s, 3 H), 4 46 (d, J=6 18 Hz, 2 H), 4 67 (d, J=6 98 Hz, 2 H), 6 58 - 6 66 (m, 1 H), 6 71 - 6 79 (m, 1 H), 7 10 (t, J=8 06 Hz, 1 H), 8 08 (d, J= 1 34 Hz, 1 H), 8 43 (s, 1 H), 9 15 - 9 27 (m, 1 H), 9 30 (s, 1 H), 12 03 (s, 1 H)
Example 263
(fraπs)-Methyl 4-((5-(2-((3-(3-methoxypropoxy)benzyl)carbamoyl)-6-methylpyrϊdin-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexanecarboxylate
A mixture of (/ra/7s)-methyl 4-((5-(2-((3-hydroxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazo!-2-yl)methyl)cyclohexanecarboxylate (prepared as described in Example 261 ) (50 mg, 0 11 mmol), 1 -bromo-3-methoxypropane (33 mg, 0 22 mmol), potassium carbonate (37 mg, 0 27 mmol), and tetrabutylammonium iodide (4 mg, 0 01 mmol) in Λ/,Λ/-dιmethylformamιde (2 mL) was heated at 60 0C for 18 hours Additional potassium carbonate (30 mg) was added and heating was continued for 18 hours The reaction mixture was purified by reverse phase preparative HPLC to afford the title compound as an oil (26 mg, 45%) MS (ES+) m/z 537 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 1 08 - 1 24 (m, 2 H), 1 37 - 1 55 (m, 2 H), 1 74 - 1 85 (m, 2 H), 1 96 - 2 21 (m, 5 H), 2 22 - 2 35 (m, 1 H), 2 67 (s, 3 H), 3 35 (d, J= 1 61 Hz, 3 H), 3 55 (t, J=5 91 Hz, 2 H), 3 67 (s, 3 H), 4 06 (t, J=6 31 Hz, 2 H)1 4 56 (d, J=6 71 Hz, 2 H), 4 68 (d, J=6 18 Hz, 2 H), 6 77 - 6 89 (m, J=& 32 Hz, 1 H), 6 91 - 7 03 (m, 2 H), 7 21 - 7 33 (m, 1 H), 8 08 (s, 1 H), 8 46 - 8 60 (m, 1 H), 8 76 (s, 1 H)
Example 264
((raπs)-4-((5-(2-((3-(3-Methoxypropoxy)benzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylic acid
A mixture of (Zrans)-methyl 4-((5-(2-((3-(3-methoxypropoxy)benzyl)carbamoyl)-6- methylpyπdin^-yl^H-tetrazol^-yOmethyOcyclohexanecarboxylate (prepared as described in Example 263) (25 mg, 0 05 mmol) and lithium hydroxide (5 mg, 0 2 mmol) in a mixture of tetrahydrofuran/water (5/1 , 3 mL) was stirred at room temperature for 18 hours The reaction mixture was acidified with a few drops of 4N hydrochloric acid and purified by reverse phase preparative HPLC to afford the title compound (17 mg, 57%) MS (ES+) m/z 523 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 1 1 1 - 1 25 (m, 2 H), 1 41 - 1 55 (m, 2 H), 1 77-1 86 (m, 2 H), 2 00 - 2 19 (m, 6 H), 2 26 ■ 2 37 (m, 1 H), 2 65 (s, 3 H), 3 35 (s, 3 H), 3 46-3 56 (m, 1 H), 3 56 (t, J=6 18 Hz, 2 H), 4 06 (t, J=6 18 Hz, 2 H), 4 56 (d, J=Q 98 Hz, 2 H), 4 68 (d, J=5 91 Hz, 2 H), 6 85 (t, J=8 19, 2 28 Hz, 1 H), 6 91 - 7 00 (m, 2 H), 8 06 (d, J= 1 07 Hz, 1 H), 8 46 (t, J=6 04 Hz, 1 H), 8 74 (s, 1 H)
Example 265
(fraπs)-Methyl 4-((5-(2-((3,4-difluorobenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate
A mixture of (3,4-dιfluorophenyl)methanamιne (153 mg, 1 07 mmol) and 4-(2-(((frans)-4-
(methoxycarbonyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnate (prepared as described in step 2 of the synthesis of (Zrans)-methyl 4-((5-(2-((3-(hydroxymethyl)benzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate, Example 260) (100 mg, 0 27 mmol) in tetrahydrofuran (0 5 mL) was heated at 60 0C for 3 days The reaction mixture was purified by reverse phase preparative HPLC The fractions containing the desired product were combined and concentrated The residue was taken up in methanol and passed through a carbonate cartridge The filtrate was concentrated to afford the title compound as a white solid (87 mg, 61 %) MS (ES+) m/z 485 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 1 08 - 1 25 (m, 2 H), 1 38 - 1 53 (m, 2 H), 1 79 (dd, J= 13 70, 2 95 Hz, 2 H), 1 99 - 2 19 (m, 3 H), 2 22 - 2 35 (m, 1 H), 2 66 (s, 3 H), 3 67 (s, 3 H), 4 56 (d, J=6 98 Hz, 2 H), 4 66 (d, J=6 44 Hz, 2 H), 7 07 - 7 26 (m, 3 H), 8 08 (d, J=1 07 Hz, 1 H), 8 43 - 8 54 (m, 1 H), 8 73 (s, 1 H)
Example 266
((rans)-4-((5-(2-((3,4-Difluorobenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2-yl)methyl)- cyclohexanecarboxylic acid
A mixture of (Zrans)-methyl 4-((5-(2-((3,4-dιfluorobenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol-2-y!)methyl)cyc!ohexanecarboxylate (prepared as described in Example 265) (50 mg, 0 1 1 mmol),and lithium hydroxide (8 mg, 0 33 mmol) in a mixture of tetrahydrofuran/water (5/1 , 6 mL) was stirred at room temperature for 18 hours The reaction mixture was purified by reverse phase preparative HPLC The fractions containing the desired product were combined and concentrated The residue was taken up in dichloromethane and saturated sodium chloride solution (2 mL) and passed through a Vaπan ChemElute column eluting with dichloromethane The filtrate was concentrated to afford the title compound as a white solid (35 mg, 72%) _MS (ES+) m/z 471 (M+H) 1H NMR (400 MHz, CDCI3) ό ppm 1 11 - 1 29 (m, 2 H), 1 40 - 1 56 (m, 2 H), 1 74 - 1 86 (m, 2 H), 2 02 - 2 22 (m, 3 H), 2 25 - 2 38 (m, 2 H), 2 67 (s, 3 H), 4 56 (d, J=6 98 Hz, 2 H), 4 66 (d, J=6 18 Hz, 2 H), 7 07 - 7 26 (m, 3 H), 8 09 (s, 1 H), 8 44 - 8 63 (m, 1 H), 8 73 (s, 1 H)
Example 267
(frans)-Methyl 4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate
A mixture of Λ/-(3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)- 2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (2 0 g, 6 17 mmol), (frans)-methyl 4- (hydroxymethyl)cyclohexanecarboxylate (2 12 g, 12 33 mmol), and polymer supported triphenylphosphine resin (7 18 g, 15 43 mmol, 2 15 mmol/g loading) m tetrahydrofuran (100 mL) was cooled in an ice bath and di-tert-butylazodicarbxylate (2 84 g, 12 33 mmol) was added The mixture was stirred for 10 minutes in the ice bath, allowed to warm to room temperature, and stirred an additional 2 hours The reaction mixture was filtered and the resin was washed with tetrahydrofuran and methanol The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound as a white solid (1 58 g, 54%) MS (ES+) m/z 479
(M+H) 1H NMR (400 MHz, DMSO-c/6) 6 ppm 1 06 - 1 21 (m, 2 H), 1 25 - 1 39 (m, 2 H), 1 58 - 1 70 (m, 2 H), 1 84 - 1 95 (m, 2 H), 1 95 - 2 08 (m, 1 H), 2 19 - 2 31 (m, 1 H), 2 67 (s, 3 H), 3 57 (s, 3 H), 3 73 (s, 3 H), 4 51 (d, J=6 18 Hz, 2 H), 4 67 (d, J=6 98 Hz, 2 H), 6 77 - 6 86 (m, 1 H), 6 88 - 6 97 (m, 2 H), 7 24 (t, J=8 19 Hz, 1 H), 8 07 (s, 1 H), 8 42 (s, 1 H), 9 26 (t, J=6 44 Hz, 1 H)
Example 268
((rans)-4-((5-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2-yl)methyl)- cyclohexanecarboxylic acid
A mixture of (frans)-methyl 4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexanecarboxylate (prepared as described in Example 267) (2 729 g, 5 697 mmol), aqueous 2 5 N sodium hydroxide solution (28 515 mmol, 5 equiv ), water (114 ml_), and tetrahydrofuran (1 14 ml_) was stirred overnight at room temperature The reaction mixture was concentrated and the aqueous residue was acidified The precipitate was filtered, washed with water, and dried under high vacuum to afford the title compound as a solid (2 598 g, 98%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 217 mm , m/z 465 (M+H) 1H NMR (400 MHz, acetone-d6) δ ppm 1 15 - 1 32 (m, 2 H), 1 33 - 1 50 (m, 2 H), 1 72 - 1 83 (m, 2 H), 1 99 - 2 02 (m, J=3 22 Hz, 2 H), 2 07 - 2 18 (m, 1 H), 2 20 - 2 33 (m, 1 H), 2 64 (s, 3 H), 3 77 (s, 3 H), 4 64 (d, J=6 44 Hz, 2 H), 4 68 (d, J=6 98 Hz, 2 H), 6 82 (dd, J=Q 32, 1 61 Hz, 1 H), 6 93 - 7 02 (m, 2 H), 7 24 (t, J=I 92 Hz, 1 H), 8 06 (d, J=1 07 Hz, 1 H), 8 61 (s, 1 H), 8 88 (s, 1 H)
Example 269
/V^S-MethoxybenzyO-β-methyM^Z-l^fransJ^^piperidine-i-carbonyOcyclohexyOmethyO^H- tetrazol-5-yl)picolinamide
To a vial containing piperidine, (13 79 mg, 0 162 mmol) added a solution of (/rans)-4-((5-(2-((3- methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxy!ιc acid (prepared as described in Example 268) (51 0 mg, 0 108 mmol) and 1-hydroxybenzotπazole (2 9 mg,
0 022 mmol) in Λ/,Λ/-dιmethylformamιde (2 ml_), followed by carbodiimide resin (125 mg, 0 162 mmol,
1 30 mmol/g loading), dichloromethane (2 ml_), and Λ/-methylmorpholιne (54 54 mg, 0 54 mmol) The mixture was agitated on an orbital shaker overnight at room temperature The mixture was filtered and the resin was washed with Λ/,Λ/-dιmethylformamιde and dichloromethane The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm ) to afford the title compound (34 5 mg, 60%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 705 mm , m/z 532 (M+H)
Example 270 4-(2-(((frans)-4-((2-Methoxyethyl)carbamoyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-W-(3- methoxybenzyl)-6-methylpicolinamide
The title compound (34 1 mg, 61 %) was prepared in a similar manner to Λ/-(3-methoxybenzyl)- 6-methyl-4-(2-(((/rans)-4-(pιperιdιne-1 -carbonyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)pιcolιnamιde (Example 269) by reaction with 2-methoxyethanamιne LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 183 mm , m/z 522 (M+H)
Example 271
/V-(3-Methoxybenzyl)-6-methyl-4-(2-(((frans)-4-(morpholine-4-carbonyl)cyclohexyl)methyl)-2W- tetrazol-5-yl)picolinamide
The title compound (32 9 mg, 57%) was prepared in a similar manner to Λ/-(3-methoxybenzyl)- 6-methyl-4-(2-(((frans)-4-(pιperιdιne-1-carbonyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde (Example 269) by reaction with morpholine LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 259 mm , m/z 534 (M+H)
Example 272
/V-(3-Methoxybenzyl)-4-(2-((((rans)-4-(dimethylcarbamoyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
The title compound (37 O mg, 70%) was prepared in a similar manner to Λ/-(3-methoxybenzyl)- 6-methyl-4-(2-(((frans)-4-(pipendine-1-carbonyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)picolinamide (Example 269) by reaction with dimethylamine LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 295 mm , m/z 492 (M+H)
Example 273
W-(3-Methoxybenzyl)-4-(2-(((frans)-4-(isopropylcarbamoyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-
6-methylpicolinamide
The title compound (16 6 mg, 30%) was prepared in a similar manner to Λ/-(3-methoxybenzyl)-
6-methyl-4-(2-(((frans)-4-(piperidine-1-carbonyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)picolmamide (Example 269) by reaction with propan-2-amιne LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 422 mm , m/z 506 (M+H)
Example 274
4-(2-(((frans)-4-((2-Amino-2-oxoethyl)carbamoyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-W-(3- methoxybenzyl)-6-methylpicolinamide
The title compound (29 9 mg, 53%) was prepared in a similar manner to Λ/-(3-methoxybenzyl)- 6-methyl-4-(2-(((/rans)-4-(pιperιdιne-1 -carbonyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)pιcolιnamιde (Example 269) by reaction with 2-amιnoacetamιde LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 861 mm , m/z 521 (M+H)
Example 275
/V-(3-Methoxybenzyl)-6-methyl-4-(2-(((frans)-4-(methylcarbamoyl)cyclohexyl)methyl)-2H- tetrazol-5-yl)picolinamide
O-(7-Azabenzotrιazole-1-yl)-Λ/,Λ/,ΛPΛ/'-tetramethyluronιurn hexafluorophosphate (49 0 mg, 0 130 mmol), methylamine (0 054 ml_ of a 2M solution in tetrahydrofuran, 0 108 mmol), and diisopropylethylamine (0 038 mL, 0 216 mmol) was added to a solution of (/rans)-4-((5-(2-((3- methoxybenzyl)carbamoyl)-6-methylpyπdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)cyclohexanecarboxylιc acid (prepared as described in Example 268) (50 0 mg, 0 108 mmol) in Λ/,Λ/-dιmethylformamιde (1 mL), and the mixture was stirred overnight at room temperature The reaction mixture was concentrated and the residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm ) to afford the title compound as a solid (47 4 mg, 92%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 996 mm , m/z 478 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 0 95 - 1 18 (m, 2 H), 1 21 - 1 43 (m, 2 H), 1 53 - 1 80 (m, 4 H), 1 87 - 2 13 (m, 1 H), 2 51 (d, J=A 39 Hz, 3 H), 2 65 (s, 3 H), 3 71 (s, 3 H), 4 49 (d, J=6 59 Hz, 2 H), 4 65 (d, J=I 32 Hz, 2 H), 6 74 - 6 83 (m, 1 H), 6 90 (m, 2 H), 7 15 - 7 29 (m, 1 H), 7 48 - 7 64 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 1 1 - 9 29 (m, 1 H)
Example 276 W-(3-Methoxybenzyl)-4-(2-(((frans)-4-(ethylcarbamoyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
The title compound (45 2 mg, 85%) was prepared in a similar manner to Λ/-(3-methoxybenzyl)- 6-methyl-4-(2-(((frans)-4-(methylcarbamoyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde (Example 275) by reaction with ethylamine LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 163 mm , m/z 492 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 0 95 (t, J=I 32 Hz, 3 H), 1 00 - 1 15 (m, 2 H), 1 22 - 1 41 (m, 2 H), 1 52 - 1 82 (m, 4 H), 1 87 - 2 13 (m, 1 H), 2 65 (s, 3 H), 2 89 - 3 09 (m, 2 H), 3 71 (s, 3 H), 4 49 (d, J=6 59 Hz, 2 H), 4 65 (d, J=6 59 Hz, 2 H), 6 74 - 6 85 (m, 1 H), 6 90 (m, 2 H), 7 13 - 7 29 (m, 1 H), 7 51 - 7 68 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 08 - 9 26 (m, 1 H)
Example 277
4-(2-(((frans)-4-((2-Hydroxyethyl)carbamoyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-N-(3- methoxybenzyl)-6-methylpicolinamide
The title compound (45 2 mg, 85%) was prepared in a similar manner to /V-(3-methoxybenzyl)- 6-methyl-4-(2-(((/rans)-4-(methylcarbamoyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde (Example 275) by reaction with 2-amιnoethanol LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 835 mm 508 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 0 96 - 1 19 (m, 2 H), 1 21 - 1 44 (m, 2 H), 1 54 - 1 80 (m, 4 H), 1 88 - 2 16 (m, 3 H), 2 65 (s, 3 H), 2 96 - 3 14 (m, 2 H), 3 71 (s, 3 H), 4 49 (d, J=5 86 Hz, 2 H), 4 65 (d, J=6 59 Hz, 2 H), 6 73 - 6 85 (m, 1 H), 6 90 (m, 2 H), 7 10 - 7 33 (m, 1 H), 7 50 - 7 68 (m, 1 H), 8 06 (s, 1 H), 8 41 (s, 1 H)
Example 278 /V-(3-Methoxybenzyl)-4-(2-(((frans)-4-carbamoylcyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Formamide (120 mg) was added to a solution of (Zrans)-methyl 4-((5-(2-((3-methoxybenzyl)- carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate (prepared as described in Example 267) (100 mg, 0 2 mmol) in anhydrous tetrahydrofuran (1 mL) and the mixture was heated to reflux A 25% sodium methoxide solution in methanol (120 mg) was added and the reaction was stirred at reflux for 2 hours The reaction mixture was allowed to cool to room temperature and then diluted with methanol (2 mL) The resulting precipitate was filtered, washed with a small amount of methanol and the solid was dried in a vacuum desiccator to afford the title compound as a white solid (77 5 mg) MS (ES+) m/z 464 (M+H)
Example 279
W-(3-Methoxybenzyl)-4-(2-((((rans)-4-cyanocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Polymer supported triphenylphosphine (Argonaut, 2 15 mmol/g, 500 mg) was added to Λ/-(3- methoxybenzyl)-4-(2-((((rans)-4-carbamoylcyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 278) (77 5 mg, 0 16 mmol) in a mixture of carbon tetrachloride (0 5 mL) and dichloroethane (4 5 mL) and the mixture was heated at 80 0C for 2 hours The reaction mixture was filtered and the resin was washed with dichloroethane The filtrate was concentrated and the residue was recrystallized from methanol to afford the title compound as a white solid (33 6 mg) MS (ES+) m/z 446 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 29 (t, J=6 6 Hz, 1 H), 8 43 (s, 1 H), 8 09 (s, 1 H), 7 25 (t, J=8 0 Hz, 1 H), 6 90 - 6 94 (m, 2 H), 6 83 (dd, J=& 1 , 2 3 Hz, 1 H), 4 69 (d, J=6 8 Hz, 2 H), 4 51 (d, J=S 5 Hz, 2 H), 3 74 (s, 3 H), 2 68 (s, 3 H), 2 59 - 2 67 (m, 1 H), 1 98 - 2 13 (m, 3 H), 1 65 (d, J=13 1 Hz, 2 H), 1 45 - 1 56 (m, 2 H), 1 07 - 1 19 (m, 2 H)
Example 280 W-(3-Methoxybenzyl)-4-(2-(((<rans)-4-(2-hydroxyacetyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Oxalyl chloride (10 mL) was added to a solution of (trans)-4-((5-{2-((3- methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)cyclohexanecarboxylιc acid (prepared as described in Example 268) (1 4 g, 3 0 mmol) in dichloromethane (10 mL) and the mixture was stirred at room temperate for 3 hours The reaction mixture was concentrated The residue was taken up in dioxane (15 mL) and treated with trιs(trιmethylsιloxy)ethylene (1 94 g, 6 63 mmol) The mixture was heated to 90 0C for 3 hours and then stirred at room temperate for 18 hours The mixture was treated with several drops of 4 N hydrochloric acid until gas stopped evolving The reaction mixture was purified by reverse phase preparative HPLC The crude product was taken up in methanol and passed through a carbonate cartridge The filtrate was concentrated to afford the title compound as a white solid (24 mg, 2%) LCMS (ES+) m/z 479 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 1 06 - 1 41 (m, 4 H), 1 60 - 1 71 (m, J=10 98 Hz, 2 H), 1 85 - 1 96 (m, J=10 98 Hz, 2 H), 1 96 - 2 07 (m, 1 H), 2 20 - 2 31 (m, J=12 08, 12 08 Hz, 1 H), 2 67 (s, 3 H), 3 28 - 3 34 (m, 1 H), 3 57 (s, 2 H), 3 73 (s, 3 H), 4 51 (d, J=5 86 Hz, 2 H), 4 67 (d, J=Q 59 Hz, 2 H), 6 82 (d, J=Q 05 Hz, 1 H), 6 88 - 6 98 (m, 2 H), 7 24 (t, J=& 05 Hz, 1 H), 8 07 (s, 1 H), 8 43 (s, 1 H), 9 21 (t, J=Q 22 Hz, 1 H)
Example 281
(frans)-Methyl 4-((5-(2-((3-(Difluoromethoxy)benzyl)carbamoyl)-6-methylpyridin-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexanecarboxylate
A mixture of (3-(dιfluoromethoxy)phenyl)methanamιne (380 mg, 2 2 mmol) and 4-(2-(((fraπs)- 4-(methoxycarbonyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnate (prepared as described in step 2 of the synthesis of (frans)-methyl 4-((5-(2-((3-(hydroxymethyl)benzyl)carbamoyl)-6- methylpyridin^-yl^H-tetrazol^-y^methyOcyclohexanecarboxylate, Example 260) (205 mg, 0 54 mmol) in Λ/,Λ/-dιmethylacetamιde (0 5 ml.) was allowed to stir at room temperature for 3 days The reaction mixture was purified by reverse phase preparative HPLC The product containing fractions were passed through a carbonate resin column and concentrated The residue was slurried with ethyl ether, decanted, and the solid was dried to afford the title compound (135 mg) MS (ES+) m/z 515 (M+H)
Example 282
(ffans)-4-((5-(2-((3-(Difluoromethoxy)benzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylic acid
Sodium hydroxide (1 pellet) was added to a solution of (frans)-methyl 4-((5-(2-((3-
(dιfluoromethoxy)benzyl)carbamoyl)-6-methylpyπdιn-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate (prepared as described in Example 281 ) (40 mg, 0 077 mmol) in a mixture of tetrahydrofuran/water (0 6 mL, 1/1 ) and the mixture was stirred at room temperature overnight The reaction mixture was acidified with trifluoroacetic acid and purified by reverse phase preparative HPLC The crude product was slurried in ethyl ether, decanted, and the solid was dried to afford the title compound as a white solid (29 mg) MS (ES+) m/z 502 (M+H)
Example 283
^-(S-IDifluoromethoxyJbenzyO^^Z^^fransJ^^hydroxymethylJcyclohexyOmethyO^H-tetrazol-S- yl)-6-methylpicolinamide
Lithium aluminum hydride (50 mg) was added to a solution of (frans)-methyl 4-((5-(2-((3- (dιfluoromethoxy)benzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2- yl)methyl)cyclohexanecarboxylate (prepared as described in Example 281 ) (53 mg, 0 1 mmol) in anhydrous tetrahydrofuran (1 mL) cooled in an ice bath The mixture was stirred at room temperature for 1 hour Water (1 mL) was slowly added followed by acetonitrile (1 mL) The reaction mixture was filtered and the filtrate was concentrated The residue was purified by reverse phase preparative HPLC Fractions containing the product were passed through a carbonate resin column The crude product was slurried and decanted from ethyl ether several times, and dried in a vacuum desiccator to afford the title compound as a white solid (28 mg) MS (ES+) m/z 487 (M+H) 1H NMR (400 MHz, DMSOd6) 6 ppm 9 39 (t, J=6 4 Hz, 1 H), 8 43 (s, 1 H), 8 10 (s, 1 H), 7 36 - 7 41 (m, 1 H), 7 21 - 7 24 (m, 1 H), 7 16 (s, 1 H), 7 03 - 7 09 (m, 2 H), 4 67 (d, J=7 0 Hz, 2 H), 4 55 (d, J=6 3 Hz, 2 H), 4 37 (t, J=5 2 Hz, 1 H), 3 19 (t, J=5 8 Hz, 2 H), 2 69 (s, 3 H), 1 91 - 2 03 (m, 1 H), 1 74 (d, J= 1 1 4 Hz, 2 H), 1 62 (d, J=10 9 Hz, 2 H), 1 25 - 1 36 (m, 1 H), 1 02 - 1 15 (m, 2 H), 0 81 - 0 94 (m, 2 H)
Example 284
(frans)-Methyl 4-((5-(2-((4-Fluoro-3-methylbenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate
The title compound was prepared in a similar manner to (frans)-methyl 4-((5-(2-((3- (dιfluoromethoxy)benzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate (Example 281 ) by reaction with 4-fluoro-3-methylbenzylamιne to afford 172 mg as a solid MS (ES+) m/z 481 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 30 (t, J=6 4 Hz, 1 H), 8 43 (s, 1 H), 8 09 (d, J=O 9 Hz, 1 H), 7 26 (d, J=I 9 Hz, 1 H), 7 17 - 7 22 (m, 1 H), 7 05 - 7 1 1 (m, 1 H), 4 68 (d, J=Q 8 Hz, 2 H), 4 48 (d, J=6 5 Hz, 2 H), 3 58 (s, 3 H), 2 68 (s, 3 H), 2 22 2 31 (m, 1 H), 2 21 (d, J= 1 5 Hz, 3 H), 1 95 - 2 07 (m, 1 H), 1 91 (d, J=1 1 1 Hz, 2 H), 1 66 (d, J=13 0 Hz, 2 H), 1 26 - 1 39 (m, 2 H), 1 07 - 1 21 (m, 2 H)
Example 285
(frans)-4-((5-(2-((4-Fluoro-3-methylbenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylic acid
Sodium hydroxide (1 pellet) was added to a solution of (frans)-methyl 4-((5-(2-((4-fluoro-3- methylbenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate (prepared as described in Example 284) (81 mg, 0 168 mmol) in a mixture of tetrahydrofuran/water (0 6 mL, 1/1 ) and the mixture was stirred at room temperature overnight The reaction mixture was acidified with trifluoroacetic acid and purified by reverse phase preparative HPLC The crude product was slurried in ethyl ether, decanted, and the solid was dried to afford the title compound as a white solid (71 mg) MS (ES+) m/z 467 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 12 12 (br s , 1 H), 9 30 (t, J=6 4 Hz, 1 H), 8 43 (s, 1 H), 8 09 (s, 1 H), 7 26 (d, J=7 7 Hz, 1 H), 7 17 - 7 22 (m, 1 H), 7 08 (t, J=9 6 Hz, 1 H), 4 68 (d, J=I 0 Hz, 2 H), 4 48 (d, J=6 3 Hz, 2 H), 2 68 (s, 3 H), 2 21 (d, J= 1 4 Hz, 3 H), 2 08 - 2 17 (m, 1 H), 1 94 - 2 05 (m, 1 H), 1 90 (d, J=10 8 Hz, 2 H), 1 65 (d, J=12 5 Hz, 2 H), 1 22 - 1 36 (m, 2 H), 1 06 - 1 18 (m, 2 H)
Example 286
W-(4-Fluoro-3-methylbenzyl)-4-(2-(((frans)-4-carbamoylcyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Formamide (60 mg) was added to a solution of (frans)-methyl 4-((5-(2-((4-fluoro-3- methylbenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate (prepared as described in Example 284) (50 mg, 0 1 mmol) in anhydrous tetrahydrofuran (0 6 mL) and the mixture was heated to reflux A 25% sodium methoxide solution in methanol (60 mg) was added and the reaction was stirred at reflux for 2 hours The reaction mixture was allowed to cool to room temperature, diluted with excess methanol, and then concentrated Methanol (2 mL) was added to the residue The resulting precipitate was filtered, washed with a small amount of methanol and the solid was dried in a vacuum desiccator to afford the title compound as a white solid (25 4 mg) MS (ES+) m/z 466 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 30 (t, J=6 4 Hz, 1 H), 8 43 (s, 1 H), 8 09 (s, 1 H), 7 26 (d, J=7 7 Hz, 1 H), 7 16 - 7 22 (m, 2 H), 7 08 (t, J=9 1 Hz, 1 H), 6 67 (br s , 1 H), 4 68 (d, J=6 8 Hz, 2 H), 4 48 (d, J=6 3 Hz, 2 H), 2 68 (s, 3 H), 2 22 (d, J= 1 0 Hz, 3 H), 2 02 (t, J=12 0 Hz, 2 H), 1 76 (d, J=10 9 Hz, 2 H), 1 65 (d, J=1 1 8 Hz, 2 H), 1 25 - 1 37 (m, 2 H), 1 03 - 1 15 (m, 2 H) Example 287
W-(4-Fluoro-3-methylbenzyl)-4-(2-(((fraπs)-4-cyanocyclohexyl)methyl)-2W-tetrazol-5-yl)-6- methylpicolinamide
Polymer supported triphenylphosphine (Argonaut, 2 15 mmol/g) was added to Λ/-(4-fluoro-3- methylbenzyl)-4-(2-(((^rans)-4-carbamoylcyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpicolinamide (Example 286) (20 mg, 0 043 mmol) in a mixture of carbon tetrachloride (0 16 mL) and dichloroethane (1 5 mL) and the mixture was heated at 80 0C for 2 hours The reaction mixture was filtered and the resin was washed with dichloroethane The filtrate was concentrated to afford the title compound as a white solid (9 7 mg) MS (ES+) m/z 448 (M+H) 1H NMR (400 MHz, DMSOd6) <$ PPm 9 30 (t, J=6 3 Hz, 1 H), 8 43 (s, 1 H), 8 09 (d, J=O 9 Hz, 1 H), 7 26 (d, J=7 3 Hz, 1 H), 7 17 - 7 22 (m, 1 H), 7 08 (t, J=9 1 Hz, 1 H), 4 69 (d, J=7 0 Hz, 2 H), 4 48 (d, J=6 3 Hz, 2 H), 2 68 (s, 3 H), 2 59 - 2 67 (m, 1 H), 2 22 (d, J= 1 4 Hz, 3 H), 1 98 - 2 11 (m, 3 H), 1 65 (d, J=13 3 Hz, 2 H), 1 44 - 1 58 (m, 2 H), 1 05 - 1 19 (m, 2 H)
Example 288
(frans)-Methyl 4-((5-(2-((3-Ethylbenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate
The title compound was prepared in a similar manner to (frans)-methyl 4-((5-(2-((3- (dιfluoromethoxy)benzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate (Example 281 ) by reaction with 3-ethylbenzylamιne to afford 155 mg MS (ES+) m/z 477 (M+H)
Example 289
(<rans)-4-((5-(2-((3-Ethylbenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylic acid
The title compound was prepared in a similar manner to (/rans)-4-((5-(2-((3-(dιfluoromethoxy)- benzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)cyclohexanecarboxylιc acid (Example 282) by reaction wιth(frans)-methyl 4-((5-(2-((3-ethylbenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol^-ylJmethyOcyclohexanecarboxylate (Example 288) to afford 45 mg as a white solid MS (ES+) m/z 463 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 12 1 1 (br s , 1 H), 9 27 (t, J=6 5 Hz, 1 H)1 8 44 (s, 1 H), 8 09 (s, 1 H), 7 08 - 7 26 (m, 4 H), 4 68 (d, J=Q 8 Hz, 2 H), 4 52 (d, J=6 3 Hz, 2 H), 2 68 (s, 3 H), 2 59 (q, J=7 6 Hz, 2 H), 2 09 - 2 17 (m, 1 H), 1 95 - 2 05 (m, 1 H), 1 90 (d, J= 1 1 1 Hz, 2 H), 1 65 (d, J=10 6 Hz, 2 H), 1 23 - 1 36 (m, 2 H), 1 06 - 1 19 (m, 5 H)
Example 290
/V-(3-Ethylbenzyl)-4-(2-(((fraπs)-4-carbamoylcyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Formamide (120 mg) was added to a solution of (frans)-methyl 4-((5-(2-((3- ethylbenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate
(prepared as described in Example 288) (80 mg, 0 16 mmol) in anhydrous tetrahydrofυran (1 mL) and the mixture was heated to reflux A 25% sodium methoxide solution in methanol (120 mg) was added and the reaction was stirred at reflux for 2 hours The reaction mixture was allowed to cool to room temperature and was diluted with methanol (2 mL) The mixture was stirred for 15 minutes and then the resulting precipitate was filtered, washed with a small amount of methanol and dried in a vacuum desiccator to afford the title compound as a white solid (41 mg) MS (ES+) m/z 462 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 17 (t, J=Q 2 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 03 - 7 25 (m, 5 H), 6 58 (br s , 1 H), 4 65 (d, J=I 0 Hz, 2 H), 4 50 (d, J=Q 2 Hz, 2 H), 2 65 (s, 3 H), 2 56 (q, J=7 4 Hz, 2 H), 1 90 - 2 05 (m, 2 H), 1 74 (d, J= 1 1 3 Hz, 2 H), 1 63 (d, J= 11 0 Hz, 2 H), 1 22 - 1 36 (m, 2 H), 1 01 - 1 18 (m, 5 H)
Example 291
(frans)-Methyl 4-((5-(2-((3-Cyanobenzyl)carbamoyl)-6-methylpyridin-4-yl)-2W-tetrazol-2- yl)methyl)cyclohexanecarboxylate
The title compound was prepared in a similar manner to (frans)-methyl 4-((5-(2-((3- (dιfluoromethoxy)benzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate (Example 281 ) by reaction with 3-(amιnomethyl)benzonιtrιle to afford 157 mg as a white solid MS (ES+) m/z 474 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 47 (t, J=6 3 Hz, 1 H), 8 43 (s, 1 H), 8 10 (s, 1 H), 7 79 (s, 1 H), 7 74 (d, J=7 7 Hz, 1 H), 7 70 (d, J=I 9 Hz, 1 H), 7 56 (t, J=I 8 Hz, 1 H), 4 68 (d, J=6 8 Hz, 2 H), 4 58 (d, J=Q 1 Hz, 2 H), 3 58 (s, 3 H), 2 69 (s, 3 H), 2 22 - 2 31 (m, 1 H), 1 96 - 2 06 (m, 1 H), 1 91 (d, J=1 1 1 Hz, 2 H), 1 65 (d, J=*\0 8 Hz, 2 H), 1 33 (q, J=12 6 Hz, 2 H), 1 07 - 1 21 (m, 2 H)
Example 292
(frans)-4-((5-(2-((3-Cyanobenzyl)carbamoyl)-6-methylpyridin-4-yl)-2W-tetrazol-2- yl)methyl)cyclohexanecarboxylic acid
Sodium hydroxide (1 pellet) was added to a solution of (frans)-methyl 4-((5-(2-((3- cyanobenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate
(prepared as described in Example 291 ) (81 mg, 0 17 mmol) in a mixture of tetrahydrofuran/water (0 6 mL, 1/1 ) and the mixture was stirred at room temperature overnight The reaction mixture was acidified with trifluoroacetic acid and purified by reverse phase preparative HPLC The crude product was slurried in ethyl ether, decanted, and the solid was dried to afford the title compound as a white solid (45 mg) MS (ES+) m/z 460 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 46 (t, J=6 4 Hz, 1 H), 8 43 (S, 1 H), 8 10 (d, J=O 9 Hz, 1 H), 7 79 (s, 1 H), 7 67 - 7 76 (m, 2 H), 7 56 (t, J=I 7 Hz, 1 H), 4 66 (d, J=7 0 Hz, 2 H), 4 58 (d, J=6 5 Hz, 2 H), 2 69 (s, 3 H), 1 92 - 2 02 (m, 2 H), 1 87 (d, J=10 9 Hz, 2 H), 1 61 (d, J=10 8 Hz, 2 H), 1 18 - 1 31 (m, 2 H)1 1 01 - 1 15 (m, 2 H)
Example 293 (frans)-Methyl 4-((5-(2-((3-Ethoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate
The title compound was prepared in a similar manner to (/rans)-methyl 4-((5-(2-((3- (dιfluoromethoxy)benzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2- yl)methyl)cyclohexanecarboxylate (Example 281 ) by reaction with (3-ethoxyphenyl)methanamιne (prepared as described in step 2 of the synthesis of Λ/-(3-ethoxybenzyl)-6-methyl-4-(2-(((/rans)-4- (methylsulfonamιdo)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)pιcolιnamιde, Example 180) to afford 182 mg as a white solid MS (ES+) m/z 493 (M+H) 1H NMR (400 MHz, DMS0-d6) δ ppm 9 28 (t, J=6 4 Hz, 1 H), 8 43 (s, 1 H), 8 09 (d, J=O 9 Hz, 1 H), 7 23 (t, J=8 0 Hz, 1 H), 6 89 - 6 92 (m, 2 H), 6 80 (dd, J=Q 0, 1 9 Hz, 1 H), 4 68 (d, J=I 0 Hz, 2 H), 4 50 (d, J=6 5 Hz, 2 H), 4 00 (q, J=Q 9 Hz, 2 H), 3 58 (s, 3 H), 2 68 (s, 3 H), 2 21 - 2 31 (m, 1 H), 1 97 - 2 07 (m, 1 H), 1 91 (d, J=10 6 Hz, 2 H), 1 66 (d, J=10 6 Hz, 2 H), 1 27 - 1 39 (m, 5 H), 1 09 - 1 21 (m, 2 H)
Example 294
((rans)-4-((5-(2-((3-Ethoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylic acid
Sodium hydroxide (1 pellet) was added to a solution of (trans )-methyl 4-((5-(2-((3- ethoxybenzyl)carbamoyl)-6-methylpyπdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate (prepared as described in Example 293) (78 mg, 0 15 mmol) in a mixture of tetrahydrofuran/water (0 6 mL, 1/1 ) and the mixture was stirred at room temperature overnight The reaction mixture was acidified with tπfluoroacetic acid and purified by reverse phase preparative HPLC The crude product was slurried in ethyl ether, decanted, and the solid was dried to afford the title compound as a white solid (7 mg) MS (ES+) m/z 479 (M+H)
Example 295
N-(3-Ethoxybenzyl)-4-(2-(((frans)-4-carbamoylcyclohexyl)methyl)-2H-tetra2ol-5-yl)-6- methylpicolinamide
Formamide (120 mg) was added to a solution of (frans)-methyl 4-((5-(2-((3- ethoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate (prepared as described in Example 293) (85 mg, 0 17 mmol) in anhydrous tetrahydrofuran (1 mL) and the mixture was heated to reflux A 25% sodium methoxide solution in methanol (120 mg) was added and the reaction was stirred at reflux for 2 hours The reaction mixture was allowed to cool to room temperature, diluted with excess methanol, and was concentrated Methanol (2 mL) was added to the residue The resulting precipitate was filtered, washed with a small amount of methanol and the solid was dried in a vacuum desiccator to afford the title compound as a white solid (33 mg) MS (ES+) m/z 478 (M+H)
Example 296
/V-P-EthoxybenzylM-^-^fransM-cyanocyclohexyOmethyO-aH-tetrazol-S-yO-e- methylpicolinamide
Polymer supported tπphenylphosphine (Argonaut, 2 15 mmol/g, 200 mg) was added to Λ/-(3- ethoxybenzyl)-4-(2-(((/rans)-4-carbamoylcyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 295) (30 mg, 0 062 mmol) in a mixture of carbon tetrachloride (0 25 mL) and dichloroethane (2 25 mL) and the mixture was heated at 80 0C for 2 hours The reaction mixture was filtered and the resin was washed with dichloroethane The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC Fractions containing product were passed through a carbonate resin column and were concentrated The product was slurried and decanted several times from ether and the solid was dried in a vacuum desiccator to afford the title compound as a white solid (18 3 mg) MS (ES+) m/z 460 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 18 (t, J=6 2 Hz, 1 H), 8 40 (s, 1 H), 8 05 (s, 1 H), 7 20 (t, J=8 1 Hz, 1 H), 6 85 - 6 90 (m, 2 H), 6 78 (d, J=8 8 Hz, 1 H), 4 65 (d, J=I 3 Hz, 2 H), 4 48 (d, J=5 9 Hz, 2 H), 3 97 (q, J=7 3 Hz, 2 H), 2 65 (s, 3 H), 2 56 - 2 64 (m, 1 H), 1 95 - 2 1 1 (m, 3 H), 1 63 (d, J=1 1 O Hz, 2 H), 1 49 (q, J= 12 7 Hz, 2 H), 1 28 (t, J=7 0 Hz, 3 H), 1 05 - 1 17 (m, 2 H)
Example 297
(frans)-Methyl 4-((5-(2-((4-Fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyridιn-4-yl)-2H-tetrazol-
2-yl)methyl)cyclohexanecarboxylate
The title compound was prepared in a similar manner to (frans)-methyl 4-((5-(2-((3- (dιfluoromethoxy)benzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate (Example 281 ) by reaction with 4-fluoro-3-methoxybenzylamιne (prepared as described in step 3 of the synthesis of A/-(4-fluoro-3-methoxybenzyl)-6-(2-((frans-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 1 ) to afford 121 mg as a white solid MS (ES+) m/z 497 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 31 (t, J=6 3 Hz, 1 H), 8 43 (s, 1 H), 8 09 (d, J=O 9 Hz, 1 H), 7 19 (dd, J=8 5, 1 9 Hz, 1 H), 7 15 (dd, J=1 1 6, 8 4 Hz, 1 H), 6 87 - 6 93 (m, 1 H), 4 68 (d, J=7 0 Hz, 2 H), 4 50 (d, J=6 5 Hz, 2 H), 3 82 (s, 3 H), 3 58 (s, 3 H), 2 68 (s, 3 H), 2 21 - 2 31 (m, 1 H), 1 98 (br s , 1 H), 1 92 (d, J=13 3 Hz, 2 H), 1 65 (d, J=10 6 Hz, 2 H), 1 26 - 1 39 (m, 2 H), 1 09 - 1 20 (m, 2 H)
Example 298
(frans)-4-((5-(2-((4-Fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylic acid
Sodium hydroxide (1 pellet) was added to a solution of (frans)-methyl 4-((5-(2-((4-fluoro-3- methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate (prepared as described in Example 297) (63 mg, 0 13 mmol) in a mixture of tetrahydrofuran/water (0 6 mL, 1/1 ) and the mixture was stirred at room temperature overnight The reaction mixture was acidified with trifluoroacetic acid and purified by reverse phase preparative HPLC The crude product was slurried in ethyl ether, decanted, and the solid was dried to afford the title compound as a white solid (30 mg) MS (ES+) m/z 483 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 30 (t, J=6 3 Hz, 1 H), 8 43 (s, 1 H), 8 09 (s, 1 H), 7 19 (dd, J=9 0, 2 1 Hz, 1 H), 7 15 (dd, J=11 6, 8 4 Hz, 1 H), 6 88 - 6 93 (m, 1 H), 4 67 (d, J=6 8 Hz, 2 H), 4 50 (d, J=Q 3 Hz, 2 H), 3 82 (s, 3 H), 2 68 (s, 3 H), 1 93 - 2 12 (m, 2 H), 1 89 (d, J=10 9 Hz, 2 H), 1 63 (d, J=10 9 Hz, 2 H), 1 28 (q, J=12 5 Hz, 2 H), 1 05 - 1 18 (m, 2 H)
Example 299
W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-carbamoylcyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Formamide (720 mg) was added to a solution of (frans)-methyl 4-((5-(2-((4-fIuoro-3- methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate (prepared as described in Example 297) (476 mg (0 95 mmol) in anhydrous tetrahydrofuran (6 mL) and the mixture was heated to reflux A 25% sodium methoxide solution in methanol (720 mg) was added and the reaction was stirred at reflux for 2 hours The reaction mixture was allowed to cool to room temperature, diluted with methanol (6 mL), and then concentrated Methanol (3 mL) was added to the residue The resulting precipitate was filtered, washed with methanol and the solid was dried in a vacuum desiccator to afford the title compound as a white solid (262 mg) MS (ES+) m/z 482 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 31 (t, J=Q 4 Hz, 1 H), 8 43 (s, 1 H), 8 09 (s, 1 H), 7 12 - 7 23 (m, 3 H), 6 91 (dd, J=Q 1 , 3 9 Hz, 1 H), 6 67 (br s , 1 H), 4 68 (d, J=I 0 Hz, 2 H), 4 51 (d, J=Q 1 Hz, 2 H), 3 83 (s, 3 H), 2 68 (s, 3 H), 1 94 - 2 07 (m, 2 H), 1 76 (d, J=12 1 Hz, 2 H), 1 65 (d, J=M 1 Hz, 2 H), 1 24 - 1 38 (m, 2 H), 1 03 - 1 16 (m, 2 H)
Example 300 /V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-cyanocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Polymer supported triphenylphosphine (Argonaut, 2 15 mmol/g, 1 g) was added to Λ/-(4-fluoro- 3-methoxybenzyl)-4-(2-(((frans)-4-carbamoylcyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 299) (223 mg, 0 46 mmol) in a mixture of carbon tetrachloride (1 5 mL) and dichloroethane (13 5 mL) and the mixture was heated at 80 0C for 2 hours The reaction mixture was filtered and the resin was washed with dichloroethane The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC The product was slurried and decanted several times from ether and the solid was dried in a vacuum desiccator to afford the title compound as a white solid (139 mg) MS (ES+) m/z 464 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 31 (t, J=Q 4 Hz, 1 H), 8 43 (s, 1 H), 8 09 (d, J=O 9 Hz, 1 H), 7 19 (dd, J=Q 5, 1 7 Hz, 1 H), 7 15 (dd, J=11 1 6, 8 2 Hz, 1 H), 6 87 - 6 93 (m, 1 H), 4 69 (d, J=Q 8 Hz, 2 H), 4 50 (d, J=Q 3 Hz, 2 H), 3 83 (s, 3 H), 2 68 (s, 3 H), 2 58 - 2 67 (m, 1 H), 1 98 - 2 12 (m, 3 H), 1 65 (dd, J=13 2, 2 6 Hz, 2 H), 1 44 - 1 57 (m, 2 H), 1 07 - 1 19 (m, 2 H) Example 301
(frans)-Methyl 4-((5-(2-((3-Chloro-4-fluorobenzyl)carbamoyl)-6-methylpyridin-4-yl)-2W-tetrazol-2- yl)methyl)cyclohexanecarboxylate
The title compound was prepared in a similar manner to (frans)-methyl 4-((5-(2-((3-
(dιfluoromethoxy)benzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-y-tetrazol-2- yl)methyl)cyclohexanecarboxylate (Example 281 ) by reaction with 3-chloro-4-fluorobenzylamιne to afford 123 mg as a white solid MS (ES+) m/z 501 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 43 (t, J=6 4 Hz, 1 H), 8 42 (s, 1 H), 8 10 (d, J=O 7 Hz, 1 H), 7 56 (d, J=7 9 Hz, 1 H), 7 35 - 7 40 (m, 2 H), 4 68 (d, J=I 0 Hz, 2 H), 4 51 (d, J=Q 3 Hz, 2 H), 3 58 (s, 3 H), 2 69 (s, 3 H), 2 21 - 2 31 (m, 1 H), 1 96 - 2 07 (m, 1 H), 1 91 (d, J= 1 1 1 Hz, 2 H), 1 65 (d, J=10 8 Hz, 2 H)1 1 27 - 1 38 (m, 2 H), 1 09 - 1 21 (m, 2 H)
Example 302
(frans)-4-((5-(2-((3-Chloro-4-fluorobenzyl)carbamoyl)-6-methylpyridin-4-yl)-2W-tetrazol-2- yl)methyl)cyclohexanecarboxylic acid
Sodium hydroxide (1 pellet) was added to a solution of (frans)-methyl 4-((5-(2-((3-chloro-4- fluorobenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)cyclohexanecarboxylate (prepared as described in Example 301 ) (65 mg, 0 13 mmol) in a mixture of tetrahydrofuran/water (0 6 mL, 1/1 ) and the mixture was stirred at room temperature overnight The reaction mixture was acidified with trifluoroacetic acid and purified by reverse phase preparative HPLC The crude product was slurried in ethyl ether, decanted, and the solid was dried to afford the title compound as a white solid (41 mg) MS (ES+) m/z 487 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 49 (t, J=6 2 Hz, 1 H), 8 42 (s, 1 H), 8 10 (s, 1 H), 7 78 (d, J=7 0 Hz, 1 H), 7 71 - 7 75 (m, 1 H), 7 45 - 7 52 (m, 1 H), 4 68 (d, J=6 8 Hz, 2 H), 4 58 (d, J=6 3 Hz, 2 H), 3 58 (s, 3 H), 2 69 (s, 3 H), 2 20 - 2 30 (m, 1 H), 1 96 - 2 04 (m, 1 H), 1 91 (d, J=13 0 Hz, 2 H), 1 66 (d, J=12 8 Hz, 2 H), 1 26 - 1 39 (m, 2 H), 1 08 - 1 20 (m, 2 H)
Example 303
W-(3-Chloro-4-fluorobenzyl)-4-(2-(((frans)-4-carbamoylcyclohexyl)methyl)-2W-tetrazol-5-yl)-6- methylpicolinamide
Formamide (720 mg) was added to a solution of (frans)-methyl 4-((5-(2-((3-chloro-4- fluorobenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate (prepared as described in Example 301 ) (268 mg, 0 53 mmol) in anhydrous tetrahydrofuran (6 mL) and the mixture was heated to reflux A 25% sodium methoxide solution in methanol (720 mg) was added and the reaction was stirred at reflux for 2 hours The reaction mixture was allowed to cool to room temperature, diluted with methanol (6 mL), and then concentrated Methanol (3 mL) was added to the residue The resulting precipitate was filtered, washed with a small amount of methanol and the solid was dried in a vacuum desiccator to afford the title compound as a white solid (135 mg) MS (ES+) m/z 486 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 43 (t, J=6 4 Hz, 1 H), 8 42 (s, 1 H), 8 10 (s, 1 H), 7 56 (d, J=7 0 Hz, 1 H), 7 37 (d, J=7 9 Hz, 2 H), 7 17 (br s , 1 H), 6 67 (br s , 1 H), 4 68 (d, J=Q 8 Hz, 2 H), 4 51 (d, J=6 5 Hz, 2 H), 2 69 (s, 3 H), 1 92 - 2 07 (m, 2 H), 1 76 (d, J= 1 1 1 Hz, 2 H), 1 64 (d, J=10 8 Hz, 2 H), 1 25 - 1 38 (m, 2 H), 1 03 - 1 15 (m, 2 H)
Example 304
W-(3-Chloro-4-fluorobenzyl)-4-(2-((((rans)-4-cyanocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Polymer supported triphenylphosphine (Argonaut, 2 15 mmol/g, 1 g) was added to Λ/-(3- chloro-4-fluorobenzyl)-4-(2-(((frans)-4-carbamoylcyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide (Example 303) (100 mg, 0 2 mmol) in a mixture of carbon tetrachloride (1 5 mL) and dichloroethane (13 5 mL) and the mixture was heated at 80 0C for 2 hours The reaction mixture was filtered and the resin was washed with methanol The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC Fractions containing product were passed through a carbonate resin column and then concentrated The product was slurried and decanted several times from ether and the solid was dried in a vacuum desiccator to afford the title compound as a white solid (33 9 mg) MS (ES+) m/z 468 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 43 (t, J=6 4 Hz, 1 H), 8 42 (s, 1 H), 8 09 (d, J= 1 0 Hz, 1 H), 7 53 - 7 59 (m, 1 H), 7 35 - 7 41 (m, 2 H), 4 69 (d, J=6 8 Hz, 2 H), 4 51 (d, J=6 3 Hz, 2 H), 2 69 (s, 3 H), 2 58 - 2 67 (m, 1 H), 1 98 - 2 13 (m, 3 H), 1 60 - 1 69 (m, 2 H), 1 45 - 1 57 (m, 2 H), 1 07 - 1 19 (m, 2 H) Example 305
(fraπs)-Methyl 4-((5-(2-((4-Fluoro-3-(trifluoromethyl)benzyl)carbamoyl)-6-methylpyridin-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexanecarboxylate
The title compound was prepared in a similar manner to (frans)-methyl 4-((5-(2-((3-
(dιfluoromethoxy)benzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2- yl)methyl)cyclohexanecarboxylate (Example 281 ) by reaction with (4-fluoro-3- (trιfluoromethyl)phenyl)methanamιne to afford 143 mg as a white solid MS (ES+) m/z 535 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 49 (t, J=6 2 Hz, 1 H), 8 42 (s, 1 H), 8 10 (s, 1 H), 7 76 - 7 79 (m, 1 H), 7 71 - 7 76 (m, 1 H), 7 48 (dd, J=10 5, 8 5 Hz, 1 H), 4 68 (d, J=6 8 Hz, 2 H), 4 58 (d, J=6 3 Hz, 2 H), 3 58 (s, 3 H), 2 69 (s, 3 H), 2 20 - 2 31 (m, 1 H), 1 91 (d, J= 1 1 9 Hz, 2 H), 1 65 (d, J=U 7 Hz, 2 H), 1 26 - 1 39 (m, 2 H), 1 08 - 1 21 (m, 2 H)
Example 306
((rans)-4-((5-(2-((4-Fluoro-3-(trifluoromethyl)benzyl)carbamoyl)-6-methylpyridin-4-yl)-2H- tetrazol-2-yl)methyl)cyclohexanecarboxylic acid
Sodium hydroxide (1 pellet) was added to a solution of (rans)-methyl 4-((5-(2-((4-fluoro-3- (trιfluoromethyl)benzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2- yl)methyl)cyclohexanecarboxylate (prepared as described in Example 305) (68 mg, 0 13 mmol) in a mixture of tetrahydrofuran/water (0 6 mL, 1/1 ) and the mixture was stirred at room temperature overnight The reaction mixture was acidified with tπfluoroacetic acid and purified by reverse phase preparative HPLC The crude product was slurried in ethyl ether, decanted, and the solid was dried to afford the title compound as a white solid (46 mg) MS (ES+) m/z 521 (M+H) 1H NMR (400 MHz, DMSO-c/6) ό ppm 9 49 (t, J=6 3 Hz, 1 H), 8 42 (s, 1 H), 8 10 (s, 1 H), 7 76 - 7 80 (m, 1 H), 7 71 - 7 75 (m, 1 H), 7 48 (dd, J=10 7, 8 8 Hz, 1 H), 4 67 (d, J=6 8 Hz, 2 H), 4 58 (d, J=6 3 Hz, 2 H), 2 69 (s, 3 H), 2 06 - 2 15 (m, 1 H), 1 94 - 2 03 (m, 1 H), 1 86 - 1 93 (m, 2 H), 1 64 (d, J=12 5 Hz, 2 H), 1 22 - 1 35 (m, 2 H), 1 05 - 1 18 (m, 2 H)
Example 307
/V-((2,3-Dihydrobenzofuran-5-yl)methyl)-4-(2-((((rans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
Step 1 Preparation of methyl 4-(2-(((frans)-4-(hvdroxymethyl)cvclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinate
Methyl 6-methyl-4-(2H-tetrazol-5-yl)pιcolιnate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide, Example 153) (2 19 g, 10 0 mmol), polymer supported triphenylphosphine (9 3 g, 20 0 mmol), and trans-cyclohexane-1 ,4-dιmethanol (2 88 g, 20 0 mmol) were suspended in tetrahydrofuran (200 mL) The mixture was cooled to 0 0C Di-tert-butyl azodicarboxylate (4 6 g, 20 0 mmol) was added The mixture was allowed to warm to room temperature and stir for 18 hours The reaction mixture was filtered and the resin washed with tetrahydrofuran (100 mL) The filtrate was concentrated The residue was dissolved in ethyl acetate (200 mL) and washed with water (50 mL) The organic layer was dried over sodium sulfate and concentrated The crude product was purified by silica column chromatography (C^C^/methanol, 100/1 , 100/2, 100/4) to afford the title compound as an oil (2 3 g, 67%) MS (ES+) m/z 346 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 8 40 (d, J=O 8 Hz, 1 H), 8 12 (d, J= 1 1 Hz, 1 H), 4 67 (d, J=7 0 Hz, 2 H), 4 35 (t, J=5 3 Hz, 1 H), 3 93 (s, 3 H), 3 19 (t, J=5 8 Hz, 2 H), 2 66 (s, 3 H), 2 04 - 1 90 (m, 1 H), 1 74 (d, J=10 6 Hz, 2 H), 1 61 (d, J=10 6 Hz, 2 H), 1 37 - 1 23 (m, 1 H), 1 08 (dq, J=12 6, 2 7 Hz, 2 H), 0 87 (dq, J=12 8, 3 1 Hz, 2 H)
Step 2 Preparation of 4-(2-(((<rans)-4-(hvdroxymethyl)cvclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinic acid
Methyl 4-(2-(((/rans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnate (2 3 g, 6 68 mmol) was dissolved in a mixture of tetrahydrofuran/water (40 mL, 1/1 ) Lithium hydroxide (479 mg, 20 0 mmol) was added and the mixture was stirred at room temperature for 3 hours The solvent was removed in vacuo and the residue was diluted with water (20 mL) The solution was made acidic with 1 N hydrochloric acid solution (20 mL) and the resulting precipitate was filtered to afford the title compound as a white solid (1 03 g, 47%) MS (ES+) m/z 332 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 13 36 (br, 1 H), 8 40 (d, J=O 8 Hz, 1 H), 8 09 (d, J=1 1 Hz, 1 H), 4 66 (d, J=7 1 Hz, 2 H), 4 35 (br, 1 H), 3 19 (d, J=6 2 Hz, 2 H), 2 65 (s, 3 H), 2 03 - 1 90 (m, 1 H), 1 74 (d, J= 10 5 Hz, 2 H), 1 61 (d, J=10 9, 2 H), 1 35 - 1 25 (m, 1 H), 1 08 (dg, J=12 6, 2 8 Hz, 2 H), 0 87 (dg, J=12 8, 3 2 Hz, 2 H)
Step 3 Preparation of /V-((2,3-dιhvdrobenzofuran-5-yl)methyl)-4-(2-(((ffans)-4- (hvdroxymethvDcvclohexyDmethvD^H-tetrazol-δ-vD-S-methylpicolinamide
A mixture of 4-(2-(((/rans)-4-(hydroxymethyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinic acid (33 mg, 0 10 mmol) and 1-hydroxybenzotπazole (18 9 mg, 0 14 mmol) in N, N- dimethylformamide (0 5 mL) was shaken for 15 minutes Λ/-Methylmorpholιne (44 μL, 0 40 mmol) was added followed by (2,3-dιhydrobenzofuran-5-yl)methanamιne (17 9 mg, 0 12 mmol) in N1N- dimethylformamide (0 5 mL) 1-Ethyl-3-(3'-dιmethylamιnopropyl)carbodιιmιde hydrochloride (26 8 mg, 0 14 mmol) was then added and the mixture was shaken for 18 hours The reaction mixtures were purified by preparative reverse phase preparative HPLC to afford the title compound (33 mg) MS (ES+) m/z 463 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 10 48 (s, 0 5 H), 9 1 1 (t, J=6 2 Hz, 1 H), 8 37 (s, 1 H), 8 02 (s, 1 H), 7 18 (s, 1 H), 7 03 (d, J=7 7 Hz, 1 H), 6 64 (d, J=8 1 Hz, 1 H), 4 61 (d, J=7 0 Hz, 2 H), 4 44 (t, J=8 8 Hz, 2 H), 4 39 (d, J=6 6 Hz, 2 H), 4 32 (t, J=5 1 Hz, 1 H), 3 14 (t, J=5 5 Hz, 2 H), 3 09 (t, J=8 8 Hz, 2 H), 2 61 (s, 3 H), 1 99 - 1 84 (m, 1 H), 1 69 (d, J=12 8 Hz, 2 H), 1 56 (d, J= 1 1 7 Hz, 2 H), 1 30 - 1 19 (m, 1 H), 1 03 (q, J=1 1 7 Hz, 2 H), 0 82 (q, J=12 2 Hz, 2 H)
Example 308 Λ/-(3-(Trifluoromethyl)benzyl)-4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpicolinamide
3-Trιfluoromethylbenzylamιne was reacted according to procedures described in Example 307 to afford the title compound (37 mg) MS (ES+) m/z 489 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 43 (t, J=6 2 Hz, 1 H), 8 37 (s, 1 H), 8 04 (s, 1 H), 7 69 - 7 48 (m, 4 H), 4 61 (d, J=7 0 Hz, 2 H), 4 56 (d, J=6 2 Hz, 2 H), 4 31 (t, J=5 1 Hz, 1 H), 3 13 (t, J=5 7 Hz, 2 H), 2 63 (s, 3 H), 1 98 - 1 85 (m, 1 H), 1 68 (d, J= 1 1 7 Hz, 2 H), 1 56 (d, J= 1 1 3 Hz, 2 H), 1 31 - 1 19 (m, 1 H), 1 02 (q, J=12 8 Hz, 2 H), 0 82 (q, J=12 4 Hz, 2 H) Example 309
/V-(3-(Trifluoromethoxy)benzyl)-4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-
5-yl)-6-methylpicolinamide
3-Trιfluoromethoxybenzylamιne was reacted according to procedures described in Example
307 to afford the title compound (31 mg) MS (ES+) m/z 527 (M+H) 1H NMR (400 MHz, DMSO-d6) 6 ppm 9 40 (t, J=6 4 Hz, 1 H), 8 38 (s, 1 H), 8 05 (s, 1 H), 7 43 (t, J= 7 9 Hz, 1 H), 7 34 (d, J=I 7 Hz, 1 H), 7 29 (s, 1 H), 7 21 (d, J=Q 1 Hz, 1 H), 4 62 (d, J=I 0 Hz, 2 H), 4 53 (d, J=Q 2 Hz, 2 H), 4 32 (t, J=5 3 Hz, 1 H), 3 14 (t, J=5 7 Hz, 2 H), 2 64 (s, 3 H), 1 97 - 1 87 (m, 1 H)1 1 70 (d, J=12 4 Hz, 2 H), 1 57 (d, J= 1 1 7 Hz, 2 H), 1 31 - 1 20 (m, 1 H), 1 03 (q, J= 13 2 Hz, 2 H), 0 83 (q, J=12 8 Hz, 2 H)
Example 310
W-(3-Chlorobenzyl)-4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2W-tetrazol-5-yl)-6- methylpicolinamide
3-Chlorobenzylamιne was reacted according to procedures described in Example 307 to afford the title compound (16 mg) MS (ES+) m/z 455 (M+H) 1H NMR (400 MHz, DMSO-Cf6) 6 ppm 9 37 (t, J=6 4 Hz, 1 H), 8 38 (s, 1 H), 8 05 (s, 1 H), 7 26 - 7 37 (m, 4 H), 4 62 (d, J=7 0 Hz, 2 H), 4 49 (d, J=6 6 Hz, 2 H), 4 33 (t, J=5 3 Hz, 1 H), 3 14 (t, J=5 7 Hz, 2 H), 2 64 (s, 3 H), 1 97 - 1 87 (m, 1 H), 1 70 (d, J=10 6 Hz, 2 H), 1 57 (d, J= 1 1 3 Hz, 2 H), 1 31 - 1 21 (m, 1 H), 1 03 (q, J=12 4 Hz, 2 H), 0 83 (q, J=12 4 Hz, 2 H)
Example 311
/V-(3-Methylbenzyl)-4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
3-Methylbenzylamιne was reacted according to procedures described in Example 307 to afford the title compound (33 mg) MS (ES+) m/z 435 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 21 (t, J=6 4 Hz, 1 H), 8 39 (s, 1 H), 8 04 (s, 1 H), 7 17 (t, J=I 5 Hz, 1 H), 7 07 - 7 13 (m, 2 H), 7 02 (d, J=7 3 Hz, 1 H), 4 62 (d, J=I 0 Hz, 2 H), 4 46 (d, J=Q 2 Hz, 2 H), 4 32 (t, J=5 1 Hz, 1 H), 3 14 (t, J=5 9 Hz, 2 H), 2 63 (s, 3 H), 2 24 (s, 3 H), 1 97 - 1 87 (m, 1 H), 1 70 (d, J=1 1 0 Hz, 2 H), 1 57 (d, J=\ 1 3 Hz, 2 H), 1 30 - 1 20 (m, 1 H), 1 04 (q, J=13 2 Hz, 2 H), 0 83 (q, J=12 2 Hz, 2 H)
Example 312
W-(3-Ethylbenzyl)-4-(2-(((rrans)-4-(hydroxymethyl)cyclohexyl)methyl)-2W-tetrazol-5-yl)-6- methylpicolinamide
3-Ethylbenzylamιne was reacted according to procedures described in Example 307 to afford the title compound (32 mg) MS (ES+) m/z 449 (M+H) 1H NMR (400 MHz, DMSO-d6) ό ppm 9 21 (t, J=6 2 Hz, 1 H), 8 38 (s, 1 H), 8 03 (s, 1 H), 7 21 - 7 02 (m, 4 H), 4 61 (d, J=I 0 Hz, 2 H), 4 46 (d, J=6 6 Hz, 2 H), 4 32 (t, J=5 3 Hz, 1 H), 3 14 (t, J=5 7 Hz, 2 H), 2 62 (s, 3 H), 2 53 (q, J=7 6 Hz, 2 H), 1 97 - 1 87 (m, 1 H), 1 69 (d, J=\ 1 0 Hz, 2 H), 1 56 (d, J=10 2 Hz, 2 H), 1 30 - 1 20 (m, 1 H), 1 1 1 (t, J=I 7 Hz, 3 H), 1 03 (q, J=12 4 Hz, 2 H), 0 82 (q, J=12 1 Hz, 2 H)
Example 313
/V-(3-lsopropoxybenzyl)-4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
3-lsopropoxybenzylamιne was reacted according to procedures described in Example 307 to afford the title compound (37 mg) MS (ES+) m/z 479 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 22 (t, J=6 2 Hz, 1 H), 8 38 (s, 1 H), 8 04 (s, 1 H), 7 16 (t, J=8 1 Hz, 1 H), 6 87 - 6 72 (m, 3 H), 4 61 (d, J=7 0 Hz, 2 H), 4 52 (qq, J=5 9 Hz, 1 H), 4 44 (d, J=6 2 Hz, 2 H), 4 31 (t, J=5 1 Hz, 1 H), 3 14 (t, J=5 7 Hz, 2 H), 2 63 (s, 3 H), 1 98 - 1 86 (m, 1 H), 1 69 (d, J= 1 1 3 Hz, 2 H), 1 56 (d, J= 1 1 0 Hz, 2 H), 1 30 - 1 19 (m, 1 H), 1 19 (d, J=5 9 Hz, 6 H), 1 03 (q, J=12 8 Hz, 2 H), 0 82 (q, J= 12 4 Hz, 2 H)
Example 314
W-(3-Ethoxybenzyl)-4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
(3-Ethoxyphenyl)methanamιne (prepared as described in step 2 of the synthesis of Λ/-(3- ethoxybenzyl)-6-methy!-4-(2-(((frans)-4-(methylsulfonamιdo)cyclohexyl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde, Example 180) was reacted according to procedures described in Example 307 to afford the title compound (36 mg) MS (ES+) m/z 465 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 22 (t, J=6 2 Hz, 1 H), 8 38 (s, 1 H), 8 04 (s, 1 H), 7 18 (t, J=8 1 Hz, 1 H), 6 88 - 6 83 (m, 2 H), 6 76 (d, J=8 4 Hz, 1 H), 4 62 (d, J=7 0 Hz, 2 H), 4 46 (d, J=6 2 Hz, 2 H), 4 33 (t, J=5 3 Hz, 1 H), 3 95 (q, J=7 0 Hz, 2 H), 3 14 (t, J=5 7 Hz, 2 H), 2 63 (s, 3 H), 1 97 - 1 87 (m, 1 H), 1 69 (d, J=12 4 Hz, 2 H), 1 57 (d, J=12 4 Hz, 2 H), 1 26 (t, J=7 0 Hz, 3 H), 1 28 - 1 20 (m, 1 H), 1 04 (q, J=12 4 Hz, 2 H), 0 83 (q, J=1 1 3 Hz, 2 H)
Example 315 rV-(3,4-Difluorobenzyl)-4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
3,4-Dιfluorobenzylamιne was reacted according to procedures described in Example 307 to afford the title compound (33 mg) MS (ES+) m/z 457 (M+H) 1H NMR (400 MHz, DMSOd6) ό ppm 9 36 (t, J=6 4 Hz, 1 H), 8 38 (s, 1 H), 8 05 (s, 1 H), 7 39 - 7 30 (m, J=8 5, 8 5, 8 5 Hz, 2 H), 7 13 - 7 18 (m, 1 H), 4 62 (d, J=7 0 Hz, 2 H), 4 47 (d, J=6 6 Hz, 2 H), 4 32 (t, J=5 3 Hz, 1 H), 3 14 (t, J=5 9 Hz, 2 H), 2 64 (s, 3 H), 1 97 - 1 87 (m, 1 H), 1 70 (d, J= 1 1 0 Hz, 2 H), 1 57 (d, J=12 1 Hz, 2 H), 1 30 - 1 18 (m, 1 H), 1 03 (q, J=12 8 Hz, 2 H), 0 83 (q, J= 1 1 3 Hz, 2 H)
Example 316
/V-(4-Fluoro-3-methylbenzyl)-4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpicolinamide
4-Fluoro-3-methylbenzylamιne was reacted according to procedures described in Example 307 to afford the title compound (35 mg) MS (ES+) m/z 453 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 25 (t, J=6 2 Hz, 1 H), 8 38 (s, 1 H), 8 04 (s, 1 H), 7 21 (d, J=7 3 Hz, 1 H), 7 17 - 7 13 (m, 1 H), 7 03 (t, J=9 2 Hz, 1 H), 4 62 (d, J=7 0 Hz, 2 H), 4 43 (d, J=6 2 Hz, 2 H), 4 32 (t, J=5 1 Hz, 1 H), 3 14 (t, J=5 7 Hz, 2 H), 2 63 (s, 3 H), 2 17 (s, 3 H), 1 97 - 1 87 (m, 1 H), 1 70 (d, J= 1 1 0 Hz, 2 H), 1 57 (d, J=13 2 Hz, 2 H), 1 30 - 1 20 (m, 1 H), 1 03 (q, J=10 6 Hz, 2 H), 0 83 (q, J=M 4 Hz, 2 H)
Example 317
/V-(4-Fluoro-3-(trifluoromethyl)benzyl)-4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
4-Fluoro-3-trιfluorobenzylamιne was reacted according to procedures described in Example 307 to afford the title compound (30 mg) MS (ES+) m/z 507 (M+H) 1H NMR (400 MHz, DMSOd6) S ppm 9 43 (t, J=Q 2 Hz, 1 H), 8 37 (s, 1 H), 8 05 (s, 1 H), 7 73 (d, J=6 2 Hz, 1 H), 7 71 - 7 66 (m, 1 H), 7 47 - 7 40 (m, 1 H), 4 62 (d, J=I 0 Hz, 2 H), 4 53 (d, J=6 2 Hz, 2 H), 4 32 (t, J=5 3 Hz, 1 H), 3 14 (t, J=5 5 Hz, 2 H), 2 64 (s, 3 H), 1 97 - 1 87 (m, 1 H), 1 69 (d, .7=10 6 Hz, 2 H), 1 57 (d, J= 1 1 3 Hz, 2 H), 1 30 - 1 20 (m, 1 H), 1 03 (q, J=12 8 Hz, 2 H), 0 83 (q, J=12 4 Hz, 2 H)
Example 318
/V-(3-(Hydroxymethyl)benzyl)-4-(2-((((rans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpicolinamide
(3-(Amιnomethyl)phenyl)methanol was reacted according to procedures described in Example 307 to afford the title compound (34 mg) MS (ES+) m/z 451 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 24 (t, J=6 4 Hz, 1 H), 8 39 (s, 1 H), 8 04 (s, 1 H), 7 12 - 7 29 (m, 4 H), 5 13 (t, J=5 7 Hz, 1 H), 4 62 (d, J=7 0 Hz, 2 H), 4 49 (d, J=6 2 Hz, 2 H), 4 43 (d, J=5 5 Hz, 2 H), 4 33 (t, J=5 1 Hz, 1 H), 3 14 (t, J=5 7 Hz, 2 H), 2 63 (s, 3 H), 1 97 - 1 87 (m, 1 H), 1 70 (d, J=11 0 Hz, 2 H), 1 57 (d, J=λ 1 0 Hz, 2 H), 1 30 - 1 20 (m, 1 H), 1 03 (q, J=M 1 Hz, 2 H), 0 83 (q, J=12 1 Hz, 2 H)
Example 319
^-(S-HydroxybenzyO^^Z^^fransJ^^hydroxymethyOcyclohexyOmethyO^W-tetrazol-S-yO-e- methylpicolinamide
3-Hydroxybenzylamιne was reacted according to procedures described in Example 307 to afford the title compound (34 mg) MS (ES+) m/z 437 (M+H) 1H NMR (400 MHz, DMSO-d6) ό ppm 9 27 (s, 1 H), 9 18 (t, J=6 0 Hz, 1 H), 8 38 (s, 1 H), 8 04 (s, 1 H), 7 06 (t, J=7 9 Hz, 1 H), 6 73 - 6 67 (m, 2 H), 6 57 (d, J=8 8 Hz, 1 H), 4 62 (d, J=I 0 Hz, 2 H), 4 40 (d, J=Q 2 Hz, 2 H), 4 32 (t, J=5 1 Hz, 1 H), 3 14 (t, J=5 5 Hz, 2 H), 2 63 (s, 3 H), 1 98 - 1 86 (m, 1 H), 1 69 (d, J=1 1 3 Hz, 2 H), 1 56 (d, J=1 1 0 Hz, 2 H), 1 31 - 1 20 (m, 1 H), 1 03 (q, J=12 8 Hz, 2 H), 0 82 (q, J=12 8 Hz, 2 H)
Example 320
/V-(3-Fluoro-5-methoxybenzyl)-4-(2-((((rans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpicolinamide
Step 1 Preparation of (3-fluoro-5-methoxyphenyl)methanamιne
To a suspension of lithium aluminum hydride ( 3 3 mL, 2 0 M in tetrahydrofuran) was added dropwise a solution of 3-fluoro-5-methoxybenzonιtrιle (0 20 g, 1 34 mmol) in tetrahydrofuran (5 0 mL) at 00C After 2 h, a saturated solution of sodium sulfate (2-3 mL) was added dropwise until hydrogen gas evolution ceased The precipitate was filtered off and the filtrate was diluted with ethyl acetate ( 10 mL) The organic layer was separated, washed with water (2 x 5 mL), brine (5 mL), dried over sodium sulfate, and concentrated to afford the title compound (0 14 g, 69%) 1H NMR (400 MHz, DMSO-Cf6) ό ppm 6 68 - 6 74 (m, 2 H), 6 54 - 6 61 (m, 1 H), 3 72 (s, 3 H), 3 64 (s, 2 H), 1 68 - 1 87 (m, 2 H) Step 2 Preparation of Λ/-(3-fluoro-5-methoxybenzyl)-4-(2-(((frans)-4- (hvdroxymethyl)cvclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide
(3-Fluoro-5-methoxyphenyl)methanamιne was reacted according to procedures described in Example 307 to afford the title compound (22 mg) 1H NMR (400 MHz, DMSOd6) δ ppm 9 27 (t, J=6 2 Hz, 1 H), 8 40 (s, 1 H), 8 06 (s, 1 H), 6 55 - 6 84 (m, 3 H), 4 63 (d, J=7 3 Hz, 2 H), 4 48 (d, J=6 6 Hz, 2 H), 4 29 (t, J=5 1 Hz, 1 H), 3 60 - 3 80 (m, 3 H), 2 66 (s, 3 H), 2 40 - 2 54 (m, 1 H), 1 88 - 2 06 (m, 1 H), 1 72 (d, J=1 1 0 Hz, 2 H), 1 60 (d, J=1 1 0 Hz, 2 H), 1 27 (d, J=1 1 7 Hz, 1 H), 0 96 - 1 14 (m, 2 H), 0 74 - 0 98 (m, 2 H)
Example 321
W-((2,3-Dιhydrobenzofuran-6-yl)methyl)-4-(2-(((rrans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
Step 1 Preparation of (2, 3-dιhydrobenzofuran-5-yl)methanamιne
To a suspension of lithium aluminum hydride (0 38 mL, 2 0 M in tetrahydrofuran) was added dropwise a solution of 2,3-dιhydrobenzofuran-6-carbonιtrιle (0 10 g, 0 61 mmol) in tetrahydrofuran (2 0 mL) at 0 0C The reaction was allowed to warm to room temperature and then was heated at 70 0C for 3 hours A saturated solution of sodium sulfate (1-2 mL) was added dropwise until hydrogen gas evolution ceased The precipitate was filtered off and the filtrate was diluted with ethyl acetate (10 mL) The organic layer was separated, washed with water (2 x 5 mL) followed by brine (5 mL), dried over sodium sulfate, and concentrated The residue was taken up in acetonitrile and filtered through a Celite™ pad The filtrate was concentrated to afford the title compound as an oil (65 mg, 61%) LC/MS (5-100% CH3CN/H2O, 5 mm) 0 73 mm, m/z 150 (M+H) Step 2 Preparation of Λ/-((2,3-dιhydrobenzofuran-6-yl)methyl)-4-(2-(((frans)-4- (hvdroxymethyl)cvclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
(2,3-Dιhydrobenzofuran-5-yl)methanamιne was reacted according to procedures described in Example 307 to afford the title compound (33 mg) 1H NMR (400 MHz, DMSOd6) δ ppm 9 13 (t, J=6 6 Hz, 1 H)1 8 39 (s, 1 H), 8 04 (s, 1 H), 7 13 (d, J=7 3 Hz, 1 H), 6 61 - 6 84 (m, 3 H), 4 63 (d, J=7 3 Hz1 2 H)1 4 37 - 4 56 (m, 4 H)1 4 29 (t, J=5 1 Hz, 1 H)1 3 00 - 3 19 (m, 1 H), 2 64 (s, 3 H), 2 46 - 2 58 (m, 2 H)1 1 84 - 2 04 (m, 1 H), 1 72 (d, J=10 3 Hz, 2 H), 1 60 (d, J=1 1 0 Hz, 2 H)1 1 29 (d, J=5 9 Hz, 1 H), 0 93 - 1 18 (m, 2 H), 0 72 - 0 97 (m, 2 H)
Example 322
Λ/-(3-Methoxybenzyl)-4-(2-((((rans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
(3-Methoxyphenyl)methanamιne was reacted according to procedures described in Example 307 to afford the title compound (46 mg) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 261 mm , m/z 451 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 23 (m, 1 H), 8 39 (s, 1 H), 8 05 (s, 1 H), 7 12 - 7 28 (m, 1 H), 6 94 - 6 84 (m, 2 H), 6 82 - 6 72 (m, 1 H), 4 63 (d, J=7 0 Hz1 2 H), 4 47 (d, J=6 4 Hz1 2 H), 3 70 (s, 3 H), 3 21 - 3 08 (m, 2 H)1 2 64 (s, 3 H), 2 04 - 1 81 (m, 1 H), 1 78 - 1 50 (m, 4 H), 1 43 - 1 16 (m), 1 15 - 0 71 (m, 4 H)
Example 323
/V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2W-tetrazol-5- yl)-6-methylpicolinamide
4-Fluoro-3-methoxybenzylamιne hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-((/rans-4-amιnocyclohexyl)methyl)-2H-tetrazol-5- yl)pyπmιdιne-4-carboxamιde, Example 1 ) (133 mg, 0 857 mmol) and dnsopropylethylamine (0 5 ml_, 0 308 mmol) was added to a solution of 4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnιc acid (prepared as described in step 2 of the synthesis of Λ/-((2,3- dihydrobenzofuran-5-yl)methyl)-4-(2-(((/rans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide, Example 307) (102 mg, 0 308 mmol) in DMF (10 mL), and the mixture was stirred at room temperature for 10 minutes (Benzotrιazol-1 -yloxy)- dιmethylamιnomethylene]dιmethylammonιum tetrafluoroborate (254 mg, 0 79 mmol) was added and stirring continued for 30 minutes The reaction mixture was concentrated and purified by reverse phase preparative HPLC followed by neutralization using a carbonate column to afford the title compound (50 mg, 28%) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 3 331 mm , m/z 469 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 0 91 - 1 04 (m, 2 H), 1 05 - 1 19 (m, 2 H), 1 39 - 1 54 (m, 1 H), 1 66 - 1 90 (m, 4 H), 2 00 - 2 14 (m, 1 H), 2 61 (s, 3 H), 3 38 - 3 48 (m, 3 H), 3 86 (s, 3 H), 4 52 (d, J=I 0 Hz, 2 H), 4 62 (d, J=6 4 Hz, 2 H), 6 85 - 6 92 (m, 1 H), 6 94 - 7 06 (m, 2 H), 8 03 (d, J=1 3 Hz, 1 H), 8 42 (t, J=6 2 Hz, 1 H), 8 70 (s, 1 H)
Example 324
/V-(3-Bromobenzyl)-4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Triethylamine (0 16 mL, 1 18 mmol) and 3-bromobenzylamιne hydrochloride (55 mg, 0 245 mmol) were added to a solution of 4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpιcolιnιc acid (prepared as described in step 2 of the synthesis of Λ/-((2,3- dιhydrobenzofuran-5-yl)methyl)-4-(2-(((/rans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide, Example 307) (65 mg, 0 196 mmol) in Λ/,Λ/-dιmethylformamιde (2 mL), and the mixture was stirred for 30 minutes O-(1 H-Benzotrιazol-1 -yl)-/V,/V,W,Λf-tetramethyluronιum hexafluorophosphate (186 mg, 0 49 mmol) was added and stirring continued overnight The reaction mixture was purified by reverse phase preparative HPLC to afford the title compound (1 5 mg, 1 5%) 1H NMR (400 MHz, CDCI3) δ ppm 1 13 - 1 31 (m, 4 H), 1 74 - 1 98 (m, 3 H), 2 01 - 2 23 (m, 3 H), 2 64 (s, 2 H), 4 35 (d, J=6 7 Hz, 2 H1) 4 56 (d, J=I 0 Hz, 2 H), 4 66 (d, J=6 2 Hz, 2 H), 7 14 - 7 27 (m, 1 H), 7 30 (d, J=I 8 Hz, 1 H), 7 34 - 7 44 (m, 2 H), 7 44 - 7 57 (m, 2 H), 8 02 (d, J=β 6 Hz, 1 H), 8 07 (d, J=1 1 Hz, 1 H), 8 52 (t, J=6 2 Hz, 1 H), 8 71 (s, 1 H)
Example 325
W-(3-(2-Hydroxyethoxy)benzyl)-4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-
5-yl)-6-methylpicolinamide
2-(1 H-Benzotrιazole-1-yl)-1 ,1 ,3,3-tetramethyluronιum hexafluorophosphate (137 mg, 0 362 mmol) was added to a mixture of 4-(2-(((frans)-4-(hydroxymethyl)cydohexyl)methyl)-2/-/-tetrazol-5-yl)- 6-methylpιcolιnιc acid (prepared as described in step 2 of the synthesis of Λ/-((2,3-dιhydrobenzofuran- 5-yl)methyl)-4-(2-(((frans)-4-(hydroxyrnethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 307) (100 mg, 0 302 mmol), 2-(3-(amιnomethyl)phenoxy)ethanol (prepared as described in step 2 of the synthesis of Λ/-(3-(2-hydroxyethoxy)benzyl)-6-(2-(((frans)-4-amιnocyclohexyl)methyl)-2H- tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 13) (60 55 mg, 0 362 mmol), and triethylamine (0 09 mL, 0 664 mmol) in tetrahydrofuran (1 mL) The mixture was stirred at room temperature for 18 hours and then purified by reverse phase preparative HPLC Fractions containing the desired product were combined, passed through a carbonate cartridge to neutralize, and concentrated to afford the title compound as a white solid (32 mg, 22%) MS (ES+) m/z 481 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 0 89 - 1 32 (m, 4 H), 1 40 - 1 58 (m, 1 H), 1 65 - 2 01 (m, 6 H), 1 99 - 2 19 (m, 1 H), 2 64 (s, 3 H), 3 47 (d, J=6 18 Hz, 2 H), 3 89 - 4 01 (m, 2 H), 4 03 - 4 15 (m, 2 H), 4 54 (d, J=6 98 Hz, 2 H), 4 67 (d, J=6 18 Hz, 2 H), 6 79 - 6 89 (m, 1 H), 6 91 - 7 04 (m, 2 H), 7 21 - 7 34 (m, 1 H), 8 06 (s, 1 H), 8 48 (t, J=5 77 Hz, 1 H), 8 73 (s, 1 H)
Example 326
W-(3-Propoxybenzyl)-4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2W-tetrazol-5-yl)-6- methylpicolinamide
Step 1 Preparation of 3-propoxybenzonιtrιle
A mixture of potassium hydroxide (18 8 g, 85 %, crushed) in dimethylsulfoxide (80 mL) was stirred for 5 minutes at ambient temperature To this white slurry was added 3-cyanophenol (10 0 g) and iodopropane (28 5 g) The mixture was stirred for 2 5 hours at room temperature The reaction mixture was poured into 1 L of ice water and then extracted with dichloromethane (5 x 300 mL) The combined organic layers were washed with water (5 x 500 mL) and dried over anhydrous sodium sulfate Filtration and concentration in vacuo afforded the title compound (13 23 g, 97 8%) Step 2 Preparation of (3-propoxyphenyl)methanamιne
3-Propoxybenzonιtrιle (13 2 g) was dissolved in absolute ethanol (100 mL) and the solution was sparged with nitrogen gas Palladium on carbon catalyst (4 0 g) was added and the mixture was shaken under hydrogen gas for 2 hours The mixture was sparged, filtered, and concentrated in vacuo The residue was purified by silica gel chromatography (dιchloromethane/methanol/NH4OH, 97/3/0 3, 94/6/0 6, 90/10/1 ) to afford the title compound (8 47 g)
Step 3 Preparation of Λ/-(3-propoxybenzyl)-4-(2-(((frans)-4-(hvdroxymethyl)cvclohexyl)methyl)-2/-y- tetrazol-5-yl)-6-methylpιcolιnamιde
(3-Propoxyphenyl)methanamιne (59 8 mg, 0 362 mmol) was reacted according to procedures described in Example 325 to afford the title compound as a solid (44mg, 30%) MS (ES+) m/z 479 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 0 91 - 1 06 (m, 5 H), 1 08 - 1 25 (m, 3 H), 1 43 - 1 56 (m, 1 H), 1 71 - 1 91 (m, 6 H), 2 04 - 2 18 (m, 1 H), 2 66 (s, 3 H), 3 43 - 3 50 (m, 2 H), 3 93 (t, J=6 58 Hz, 2 H), 4 55 (d, J=I 25 Hz, 2 H), 4 68 (d, J=Q 18 Hz, 2 H), 6 84 (dd, J=Q 19, 2 28 Hz, 1 H), 6 91 - 7 01 (m, 2 H), 7 22 - 7 32 (m, 1 H), 8 07 (d, J=λ 34 Hz, 1 H), 8 49 (t, J=5 91 Hz, 1 H), 8 75 (s, 1 H)
Example 327
W-((2,3-Dihydrobenzo[b][1 ,4]dioxin-6-yl)methyl)-4-(2-(((trans)-4- (hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide
(2,3-Dιhydrobenzo[b][1 ,4]dιoxιn-6-yl)methanamιne (37 4 mg, 0 226 mmol) was reacted according to procedures described in Example 325 to afford the title compound as a solid (3 2 mg, 9%) MS (ES+) m/z 479 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 0 92 - 1 32 (m, 8 H), 1 71 - 1 93 (m, 4 H), 2 02 - 2 17 (m, 1 H), 2 70 (s, 2 H), 3 48 (d, J=6 18 Hz, 2 H), 4 26 (s, 3 H), 4 58 (dd, J=17 19, 6 44 Hz, 4 H), 6 80 - 6 95 (m, 3 H), 8 10 (d, J= 1 34 Hz, 1 H), 8 62 (br s , 1 H), 8 77 (s, 1 H) Example 328
4-(2-((((rans)-4-(Hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-W-((2-methoxypyridin-4- yl)methyl)-6-methylpicolinamide
(2-Methoxypyrιdιn-4-yl)methanamιne (39 5 mg, 0 226 mmol) was reacted according to procedures described in Example 325 to afford the title compound as a solid (5 4 mg, 7%) MS (ES+) m/z 452 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 0 93 - 1 30 (m, 5 H), 1 41 - 1 56 (m, 1 H), 1 76 (d, J=12 89 Hz, 2 H), 1 87 (d, J=10 47 Hz, 2 H), 2 04 - 2 17 (m, 1 H), 2 68 (s, 3 H), 3 48 (d, J=Q 18 Hz, 2 H), 3 96 (S, 3 H), 4 55 (d, J=6 98 Hz, 2 H), 4 69 (d, J=Q 18 Hz, 2 H), 6 77 (s, 1 H), 6 92 (d, J=5 10 Hz, 1 H), 8 10 (s, 1 H), 8 15 (d, J=5 37 Hz, 1 H), 8 54 (t, J=Q 31 Hz, 1 H), 8 73 (s, 1 H)
Example 329
/V-(4-Fluorobenzyl)-4-(2-(((frans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
A mixture of Λ/-(4-fluorobenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 1 of the synthesis of (frans)-Methyl 4-((5-(2-((4-fluorobenzyl)carbamoyl)-6- methylpyridm-4-yl)-2/-/-tetrazol-2-yl)methyl)cyclohexanecarboxylate, Example 255) (50 mg, 0 16 mmol), polymer supported triphenylphosphine (186 mg, 0 4 mmol), and rrans-cyclohexane-1 ,4- dimethanol (46 mg, 0 32 mmol) in tetrahydrofuran (3 mL) was cooled in an ice bath and di-fert-butyl azodicarboxylate (74 mg, 0 32 mmol) was added The mixture was allowed to warm to room temperature and stir for 2 hours The reaction mixture was acidified with trifluoroacetic acid and filtered The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC The product was dissolved in dichloromethane and passed through a carbonate resin column The filtrate was concentrated to afford the title compound as a white solid (36 7 mg) MS (ES+) m/z 439 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 35 (t, J=Q 4 Hz, 1 H), 8 43 (s, 1 H), 8 09 (s, 1 H), 7 39 (dd, J=8 4, 5 7 Hz, 2 H), 7 16 (t, J=Q 9 Hz, 2 H), 4 67 (d, J=I 0 Hz, 2 H), 4 52 (d, J=Q 3 Hz, 2 H), 4 37 (t, J=5 3 Hz, 1 H), 3 19 (t, J=5 7 Hz, 2 H), 2 68 (s, 3 H), 1 91 - 2 02 (m, 1 H), 1 71 - 1 78 (m, 2 H), 1 58 - 1 64 (m, 2 H), 1 24 - 1 37 (m, 1 H), 1 02 - 1 14 (m, 2 H), 0 81 - 0 94 (m, 2 H) Example 330
W-(3-Methoxybenzyl)-4-(2-(((c/s)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Λ/-(3-Methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step
5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((/rans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide, Example 153) (100 mg, 0 31 mmol), polymer supported tπphenylphosphine (287 mg, 0 62mmol), and cis-cyclohexane-i ^-dimethanol (89 mg, 0 62 mmol) (Kuroda, C , Murase, A , Suzuki, hours , Endo, T , Anzai, S Bull Chem Soc Jpn 1998, 71 , 1639-1647 ) were suspended in tetrahydrofuran (10 mL) The mixture was cooled to 0 0C Di-tert-butyl azodicarboxylate (142 mg, 0 62 mmol) was added The mixture was allowed to warm to room temperature and stir for 36 hours The reaction mixture was filtered and the resin washed with tetrahydrofuran (20 mL) The filtrate was concentrated The crude product was purified by silica column chromatography (CH2CI2/methanol, 100/1 , 100/2) to afford the title compound as an oil (62 mg, 45%) MS (ES+) m/z 351 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 26 (t, J=6 4 Hz, 1 H), 8 42 (d, J=O 9 Hz, 1 H), 8 08 (d, J= 1 1 Hz, 1 H), 7 24 (t, J=B 1 Hz, 1 H), 6 93 - 6 90 (m, 2 H), 6 82 (ddd, J=8 2, 2 5, 0 9 Hz, 1 H), 4 76 (d, J=7 7 Hz, 2 H), 4 51 (d, J=6 4 Hz, 2 H), 4 37 (t, J=5 4 Hz, 1 H), 3 73 (s, 3 H), 3 33 (dd, J=6 4, 5 5 Hz, 2 H), 2 68 (s, 3 H), 2 31 - 2 21 (m, 1 H), 1 65 - 1 27 (m, 9 H)
Example 331 W-(3-Methoxybenzyl)-4-(2-(((frans)-4-(2-hydroxypropan-2-yl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-
6-methylpicolinamide
A mixture of /V-(3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)- 2H-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (105 mg), 2-((trans)-4-
(hydroxymethyl)cyclohexyl)propan-2-ol (Aust J Chem 1993, 46, 1869-1879) (98 7 mg), and polymer supported triphenylphosphine (740 mg) in anhydrous tetrahydrofuran (10 mL) was cooled in an ice bath Di-tert-butyl azodicarboxylate (126 mg) was added and the mixture was placed in an ultrasonic bath for 30 minutes The reaction mixture was filtered and the resin was washed with tetrahydrofuran and methanol The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC (acetonitrile/water, 50/50 - 80/20) The fractions containing product were concentrated The aqueous residue was made basic with 5% aqueous sodium bicarbonate (3 mL) and extracted with dichloromethane (3 x 10 mL) The combined organic layers were dried over magnesium sulfate, filtered and concentrated to afford the title compound (1 18 mg) MS (ES+) m/z 479 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 21 (t, J=6 2 Hz, 1 H), 8 42 (s, 1 H), 8 07 (s, 1 H), 7 24 (t, J=Q 1 Hz, 1 H), 6 90 - 6 94 (m, 2 H), 6 82 (d, J=I 7 Hz, 1 H), 4 65 (d, J=I 0 Hz, 2 H), 4 51 (d, J=6 6 Hz, 2 H), 3 94 (s, 1 H), 3 73 (s, 3 H), 2 67 (s, 3 H), 1 95 (s, 1 H), 1 80 (d, J=12 1 Hz, 2 H), 1 65 (d, J= 1 1 3 Hz, 2 H), 1 13 (d, J=8 1 Hz, 1 H), 0 97 - 1 07 (m, 10 H)
Example 332
/V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-(2-hydroxypropan-2-yl)cyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4- (2-hydroxypropan-2-yl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 331 ) by reaction with Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnamιde, Example 170) and afforded 53 8 mg as an oil MS (ES+) m/z 497 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 21 (t, J=6 2 Hz, 1 H), 8 40 (s, 1 H), 8 05 (s, 1 H), 7 16 (d, J=8 4 Hz, 1 H), 7 1 1 (dd, J= 11 5, 8 2 Hz, 1 H), 6 85 - 6 92 (m, 1 H), 4 62 (d, J=6 6 Hz, 2 H), 4 48 (d, J=6 2 Hz, 2 H), 3 92 (s, 1 H), 3 80 (s, 3 H), 2 65 (s, 3 H), 1 87 - 1 98 (m, 1 H), 1 78 (d, J=11 7 Hz, 2 H), 1 63 (d, J= 1 1 3 Hz, 2 H), 0 90 - 1 23 (m, 11 H)
Example 333
W-(3-Methoxybenzyl)-4-(2-(((frans)-4-hydroxycyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Step 1 Preparation of 4-(hydroxymethyl)cyclohexanol
A solution of 2M lithium aluminum hydride in tetrahydrofuran (70 mL) was added to diethyl ether (100 mL) in a mechanically stirred 2L flask A solution of ethyl 4- hydroxycyclohexanecarboxylate (24 92 g) in diethyl ether (100 mL) was added dropwise over 50 minutes The mixture was heated at reflux for 1 hour and then stirred overnight at room temperature Ethyl acetate (5 mL) was carefully added and the mixture was acidified with 12 N hydrochloric acid (50 mL) with ice bath cooling The organic layer was decanted and the aqueous layer was extracted with a mixture of tetrahydrofuran (150 mL) and ether (100 mL) The aqueous layer was neutralized with sodium bicarbonate (75 g) and extracted with ethyl acetate (4 x 400 mL) The combined organic layers were dried over magnesium sulfate, filtered and concentrated The resulting oil was distilled under reduced pressure to afford the title compound as a colorless oil (15 07 g)
Step 2 Preparation of A/-(3-methoxybenzyl)-4-(2-(((fraf7S)-4-hvdroxycvclohexyl)methyl)-2/-/-tetrazol-5- yl)-6-methylpιcolιnamιde
A mixture of Λ/-(3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((/rans)-4-amιnocyclohexyl)methyl)- 2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (986 mg), 4-(hydroxymethyl)cyclohexanol (614 mg), and polymer supported triphenylphosphine (3 55 g, 7 5 mmol) in tetrahydrofuran (60 mL) was cooled in an ice bath Di-terf-butylazodicarboxylate (1 046 g) was added and the mixture was placed in an ultrasonic bath for 50 minutes The mixture was filtered and the resin was washed with tetrahydrofuran The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC (acetonitrile/water, 35/65 - 55/45) Fractions containing the first eluting isomer were combined and concentrated The residue was dissolved in dichloromethane and washed with 5% aqueous sodium bicarbonate (3 mL) The organic layer was dried over magnesium sulfate, filtered, and concentrated to afford the title compound (298 mg) MS (ES+) m/z 437 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 19 (t, J=Q 4 Hz, 1 H), 8 40 (s, 1 H), 8 05 (s, 1 H), 7 22 (t, J=Q 1 Hz, 1 H), 6 87 - 6 92 (m, 2 H), 6 77 - 6 82 (m, 1 H), 4 63 (d, J=I 0 Hz, 2 H), 4 49 (d, J=Q 2 Hz, 2 H), 3 71 (s, 3 H), 2 65 (s, 3 H), 2 52 (s, 1 H), 1 89 - 1 98 (m, 1 H), 1 77 - 1 85 (m, 2 H), 1 53 - 1 61 (m, 2 H), 1 37 (d, J=I 3 Hz, 2 H), 1 03 - 1 17 (m, 2 H)
Example 334
W-(3-Methoxybenzyl)-4-(2-(((c/s)-4-hydroxycyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Isolation of the second eluting isomer by reverse phase preparative HPLC from the reaction mixture described in Example 333 afforded the title compound (520 mg) MS (ES+) m/z 437 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 19 (t, J=6 4 Hz, 1 H), 8 40 (s, 1 H), 8 05 (s, 1 H), 7 21 (t, J=8 1 Hz, 1 H), 6 87 - 6 92 (m, 2 H), 6 79 (dd, J=8 4, 1 5 Hz, 1 H), 4 65 (d, J=I 0 Hz, 2 H), 4 48 (d, J=6 6 Hz, 2 H), 4 30 (br s , 1 H), 3 73 (br s , 1 H), 3 71 (s, 3 H), 2 65 (s, 3 H), 2 52 (s, 1 H), 2 04 (br s , 1 H), 1 54 - 1 63 (m, 2 H), 1 27 - 1 48 (m, 5 H)
Example 335
W-(4-Fluoro-3-methylbenzyl)-4-(2-(((<rans)-4-hydroxycyclohexyl)methyl)-2W-tetrazol-5-yl)-6- methylpicolinamide
Step 1 Preparation of methyl 4-(2-(((frans)-4-hvdroxycvclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinate
A mixture of methyl 6-methyl-4-(2H-tetrazol-5-yl)pιcolιnate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((/rans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide, Example 153) (5 0 g, 28 8 mmol), 4-(hydroxymethyl)cyclohexanol (prepared as described in step 1 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4- hydroxycyclohexyOmethyO^H-tetrazol-δ-yO-θ-methylpicolinamide, Example 333) (3 71 g, 28 5 mmol), and polymer supported-triphenylphosphine (21 2 g, 45 6 mmol) in tetrahydrofuran (100 mL) was cool to 0 0C in an ice bath Di-tert-butyl azodicarboxylate (10 5 g, 45 6 mmol) was added and stirring was continued for 60 minutes in an ice bath The mixture was allowed to warm to room temperature and stir overnight The reaction mixture was filtered and the resin was washed with tetrahydrofuran The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC Isolation of the first eluting isomer afforded the title compound as a clear, light yellow colored oil (1 48 g) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 3 22 mm , m/z 332 (M+H) 1H NMR (500 MHz, DMSOd6) δ ppm 1 04 - 1 16 (m, 3 H), 1 57 (d, J=I 07 Hz, 2 H), 1 78 - 1 84 (m, 2 H), 1 89 - 1 97 (m, 1 H), 2 63 (s, 3 H), 3 29 - 3 36 (m, 1 H), 3 91 (s, 3 H), 4 63 (d, J=I 07 Hz, 2 H), 4 70 (d, J=7 07 Hz, 1 H), 8 08 (d, J=λ 63 Hz, 1 H), 8 36 (d, J=1 36 Hz, 1 H)
Step 2 Preparation of A/-(4-fluoro-3-methylbenzyl)-4-(2-(((frans)-4-hvdroxycvclohexyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcohnamιde
Diisopropylethylamine (77 9 mg, 0 603 mmol) and (4-fluoro-3-methylphenyl)methanamιne (125 9 mg, 0 905 mmol) were added to a solution of methyl 4-(2-(((<rans)-4-hydroxycyclohexyl)methyl)- 2H-tetrazol-5-yl)-6-methylpιcolιnate (100 mg, 0 301 mmol) in Λ/,Λ/-dιmethylformamιde (2 ml_) The mixture was stirred for 30 minutes and then heated to 60 0C overnight The reaction mixture was purified by reverse-phase preparative HPLC to afford the title compound (18 5 mg, 12%) 1H NMR (400 MHz, DMSO-cfe) δ ppm 1 09 (t, J= 10 25 Hz, 3 H), 1 57 (s, 2 H), 1 79 (s, 2 H), 1 93 (s, 1 H), 2 19 (s, 2 H), 2 65 (s, 2 H), 4 46 (d, J=6 59 Hz, 2 H), 4 63 (d, J=6 59 Hz, 2 H), 6 99 - 7 09 (m, 1 H), 7 12 - 7 28 (m, 2 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 21 (t, J=Q 59 Hz, 1 H)
Example 336 /V-(4-Fluoro-3-methylbenzyl)-4-(2-(((c/s)-4-hydroxycyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Step 1 Preparation of methyl 4-(2-(((c<s)-4-hvdroxycvclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinate
Isolation of the second eluting isomer from reverse phase preparative HPLC of the reaction mixture obtained in step 1 of the synthesis of Λ/-(4-fluoro-3-methylbenzyl)-4-(2-((((Λans)-4- hydroxycyclohexyOmethyO^H-tetrazol-S-yO-θ-methylpicolmamide (Example 335) afforded the title compound as a clear, light yellow colored oil (2 41 g) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 3 34 mm , m/z 332 (M+H) 1H NMR (500 MHz, DMSO-cfe) δ ppm 1 29 - 1 35 (m, 2 H), 1 37 - 1 47 (m, 3 H), 1 60 (dd, J=9 65, 3 67 Hz, 2 H), 1 89 - 2 10 (m, 1 H), 2 64 (s, 3 H), 3 75 (br s , 1 H), 3 91 (s, 3 H), 4 67 (d, J=I 07 Hz, 2 H), 4 74 (d, J=I 07 Hz, 1 H), 8 1 1 (s, 1 H), 8 39 (s, 1 H) Step 2 Preparation of Λ/-(4-fluoro-3-methylbenzyl)-4-(2-(((c/s)-4-hvdroxycvclohexyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnamιde
Diisopropylethylamine (0 5 mL, 0 287 mmol) and (4-fluoro-3-methylphenyl)methanamιne (41 7 mg, 0 30 mmol) were added to a solution of methyl 4-(2-(((c/s)-4-hydroxycyclohexyl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnate (25 mg, 0 075 mmol) in /V,N-dιmethylacetamιde (2 mL) The mixture was stirred for 30 minutes and then heated to 60 0C overnight The reaction mixture was purified by reverse-phase preparative HPLC to afford the title compound (21 5 mg, 65%) 1H NMR (400 MHz, DMSO-Cy6) δ ppm 1 09 (t, J=10 25 Hz, 4 H), 1 57 (s, 2 H), 1 79 (s, 2 H), 1 93 (s, 2 H), 2 19 (s, 3 H), 2 65 (s, 3 H), 3 27 (s, 1 H), 4 43 - 4 49 (m, 2 H), 7 01 - 7 08 (m, 1 H), 7 14 - 7 21 (m, 1 H), 7 23 (d, J=6 59 Hz1 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 21 (t, J=Q 22 Hz, 1 H)
Example 337
/V-(3-Chloro-4-fluorobenzyl)-4-(2-(((frans)-4-hydroxycyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
The title compound (18 7 mg, 13%) was prepared in a similar manner to Λ/-(4-fluoro-3- methylbenzyl)-4-(2-(((frans)-4-hydroxycyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 335) by reaction with (3-chloro-4-fluorophenyl)methanamιne 1H NMR (400 MHz, DMSO-d6) δ ppm 1 09 (t, J=9 88 Hz, 5 H), 1 57 (s, 2 H), 1 79 (s, 2 H), 1 91 (d, J=13 91 Hz, 2 H), 2 66 (s, 3 H), 4 43 - 4 53 (m, 3 H), 4 63 (d, J=Q 59 Hz, 2 H), 7 34 (d, J=I 32 Hz, 2 H), 7 53 (d, J=7 32 Hz, 1 H), 8 05 (S, 1 H), 8 39 (s, 1 H), 9 34 (t, J=Q 22 Hz, 1 H)
Example 338
/V-(3-Chloro-4-fluorobenzyl)-4-(2-(((c/s)-4-hydroxycyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
The title compound (18 8 mg, 55%) was prepared in a similar manner to Λ/-(4-fluoro-3- methylbenzyl)-4-(2-(((c/s)-4-hydroxycyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 336) by reaction with (3-chloro-4-fluorophenyl)methanamιne 1H NMR (400 MHz, DMSOd6) δ ppm 1 01 - 1 18 (m, 4 H), 1 57 (s, 3 H), 1 79 (s, 2 H), 1 91 (d, J=13 91 Hz, 1 H), 2 66 (s, 3 H), 4 43 - 4 54 (m, 3 H), 4 63 (d, J=6 59 Hz, 2 H), 7 34 (d, J= 7 32 Hz, 2 H), 7 53 (d, J=8 05 Hz, 1 H), 8 05 (s, 1 H), 8 39 (s, 1 H), 9 34 (t, J=6 22 Hz, 1 H)
Example 339
W-(3-Ethoxybenzyl)-4-(2-((((rans)-4-hydroxycyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
The title compound (18 5 mg, 13%) was prepared in a similar manner to Λ/-(4-fluoro-3- methylbenzyl)-4-(2-(((<rans)-4-hydroxycyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde
(Example 335) by reaction with (3-ethoxyphenyl)methanamιne (prepared as described in step 2 of the synthesis of Λ/-(3-ethoxybenzyl)-6-methyl-4-(2-(((frans)-4-(methylsulfonamιdo)cyclohexyl)methyl)-2H- tetrazol-5-yl)pιcohnamιde, Example 180) 1H NMR (400 MHz, DMSOd6) δ ppm 1 09 (t, J=9 88 Hz, 5 H), 1 28 (t, J=6 95 Hz, 3 H), 1 57 (s, 2 H), 1 79 (s, 2 H), 1 93 (s, 1 H), 2 65 (s, 3 H), 3 27 (s, 1 H), 3 97 (q, J=6 59 Hz, 2 H), 4 41 - 4 53 (m, 2 H), 4 63 (d, J=6 59 Hz, 2 H), 6 78 (d, J=8 05 Hz, 1 H), 6 87 (s, 2 H), 7 20 (t, J=8 05 Hz, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 18 (t, J=6 59 Hz, 1 H)
Example 340
W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-hydroxycyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
The title compound (20 9 mg, 15%) was prepared in a similar manner to Λ/-(4-fluoro-3- methylbenzyl)-4-(2-(((/rans)-4-hydroxycyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 335) by reaction with 4-fluoro-3-methoxybenzylamιne hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-((frans-4-amιnocyclohexyl)methyl)-2/-/- tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 1 ) 1H NMR (400 MHz, DMSOd6) δ ppm 1 31 (d, J=Q 78 Hz, 2 H), 1 43 (t, J=10 25 Hz, 3 H), 1 59 (dd, J=10 25, 4 39 Hz, 2 H), 2 05 (s, 1 H), 2 51 (s, 1 H), 2 65 (s, 3 H), 3 72 (d, J= 10 25 Hz, 1 H), 3 80 (s, 3 H), 4 27 (d, J=2 93 Hz, 1 H), 4 48 (d, J=6 59 Hz, 2 H), 4 65 (d, J=7 32 Hz, 2 H), 6 89 (s, 1 H), 7 07 - 7 13 (m, 1 H), 7 13 - 7 19 (m, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 17 - 9 25 (m, 1 H) Example 341 rac-/V-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((3-oxocyclopentyl)methyl)-2H-tetrazol-5- yl)picolinamide
Step 1 Preparation of (3, 3-dιmethoxycvclopentyl)methanol
/ O
O
A solution of methyl S.S-dimethoxycyclopentanecarboxylate (Tetrahedron 1977, 33, 1 1 13) (6 22 g) in anhydrous tetrahydrofuran (60 mL) was added dropwise to a solution of 2 M lithium aluminum hydride (20 mL) in anhydrous tetrahydrofuran (240 mL) and the mixture was heated at 40 0C for 18 hours The reaction mixture was cooled in an ice bath and water (7 mL) was added slowly, followed by 10% aqueous sodium hydroxide (2 0 mL) The mixture was heated to 40 0C for an hour The mixture was filtered through a pad of neutral alumina and rinsed with tetrahydrofuran The filtrate was concentrated to afford the title compound as an oil (4 77 g) 1H NMR (400 MHz, CDCI3) ό ppm 3 47 - 3 56 (m, 2 H), 3 18 (s, 3 H), 3 18 (s, 3 H), 2 19 - 2 29 (m, 1 H), 1 97 (dd, J=13 2, 8 9 Hz, 1 H), 1 92 (s, 1 H), 1 72 - 1 84 (m, 3 H), 1 51 - 1 58 (m, 1 H), 1 36 - 1 47 (m, 1 H)
Step 2 Preparation of rac-Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((3-oxocvclopentyl)methyl)-2/-/- tetrazol-5-yl)pιcolιnamιde
A mixture of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((/rans)-4- amιnocyclohexyl)methy!)-2/-/-tetra2θl-5-yl)-6-methylpιcolιnamιde, Example 170) (500 mg), (3,3- dιmethoxycyclopentyl)methanol (350 mg), polymer support triphenylphosphine (1 388 g, 3 0 mmol) in anhydrous tetrahydrofuran (50 mL) was cooled in an ice bath Di-tert-butylazodicarboxylate (403 mg) was added and the mixture was placed in an ultrasonic bath for one hour After standing overnight, the mixture was filtered and the resin was washed with tetrahydrofuran and methanol The filtrate was acidified with tπfluoroacetic acid and concentrated The residue was purified by reverse phase preparative HPLC (acetonitrile/water, 50/50 - 75/25) The product containing fractions were concentrated The aqueous residue was made basic with 5% aqueous sodium bicarbonate and extracted with dichloromethane (3 x 5 mL) The combined organic layers were dried over magnesium sulfate, filtered and concentrated to afford the title compound (435 mg) MS (ES+) m/z 439 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 24 (t, J=Q 2 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H), 7 09 - 7 21 (m, 2 H), 6 90 (s, 1 H), 4 91 (d, J=I 3 Hz, 2 H), 4 50 (d, J=6 2 Hz, 2 H), 3 82 (s, 3 H), 2 88 - 2 97 (m, 1 H), 2 68 (s, 3 H), 2 27 - 2 37 (m, 1 H), 2 18 - 2 24 (m, 2 H), 1 99 - 2 17 (m, 2 H), 1 67 - 1 77 (m, 1 H)
Example 342 rac-/V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((1/?*,3/?*)-3-hydroxycyclopentyl)methyl)-2H-tetrazol-5- yl)-6-methylpicolinamide
A 2 M solution of lithium aluminum hydride in tetrahydrofuran (0 20 ml_) was added to a cooled solution (ice/acetone bath) of rac-Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((3- oxocyclopentyOmethyO^H-tetrazol-δ-yOpicolinamide (prepared as described in Example 341 ) (272 mg) in anhydrous tetrahydrofuran (5 0 mL) under nitrogen The mixture was allowed to stir for 5 minutes and was then quenched with methanol (1 mL) The reaction mixture was concentrated and the residue was purified by reverse phase preparative HPLC (acetonitrile/water, 40/60 - 60/40) Fractions containing the first eluting isomer were combined and concentrated The aqueous residue was extracted with dichloromethane (3 x 5 mL) The organic layer was dried over magnesium sulfate, filtered, and concentrated to afford the title compound (83 mg) MS (ES+) m/z 441 (M+H) 1H NMR (400 MHz, DMSO-Cy6) δ ppm 9 23 (t, J=5 9 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H), 7 15 - 7 20 (m, 1 H), 7 09 - 7 15 (m, 1 H), 6 86 - 6 93 (m, 1 H), 4 73 (d, J=I 3 Hz, 2 H), 4 50 (d, J=Q 2 Hz, 2 H), 4 43 (s, 1 H), 4 16 (s, 1 H), 3 82 (s, 3 H), 2 75 - 2 83 (m, 1 H), 2 67 (s, 3 H), 1 77 - 1 86 (m, 2 H), 1 62 (d, J=Q 6 Hz, 1 H), 1 43 - 1 52 (m, 2 H), 1 28 - 1 38 (m, 1 H)
Example 343 rac-W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((1/?*,3S*)-3-hydroxycyclopentyl)methyl)-2W-tetrazol-5- yl)-6-methylpicotinamide
Isolation of the second eluting isomer by reverse phase preparative HPLC from the reaction mixture described in Example 342 afforded the title compound as a white solid (122 mg) MS(ES+) m/z 441 (M+H) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 9 23 (t, J=Q 2 Hz, 1 H), 8 43 (s, 1 H), 8 07 (s, 1 H), 7 15 - 7 20 (m, 1 H), 7 10 - 7 15 (m, 1 H), 6 87 - 6 93 (m, 1 H), 4 78 (d, J=I 3 Hz, 2 H), 4 56 (d, J=3 7 Hz, 1 H), 4 50 (d, J=Q 2 Hz, 2 H), 4 10 - 4 16 (m, 1 H), 3 82 (s, 3 H), 2 67 (s, 3 H), 2 55 - 2 62 (m, 1 H), 1 86 - 1 94 (m, 1 H), 1 62 - 1 70 (m, 2 H), 1 52 - 1 62 (m, 2 H), 1 31 - 1 38 (m, 1 H) Example 344
A/-(3-Methoxybenzyl)-4-(2-(((c/s)-4-hydroxy-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpicolinamide
Step 1 Preparation of 4-(2-(1 ,4-dιoxaspιro[4 51dec-8-ylmethyl)-2H-tetrazol-5-yl)-Λ/-(3-methoxybenzyl)- 6-methylpyrιdιne-2-carboxamιde
1 ,4-Dιoxaspιro[4 5]dec-8-ylmethyl 4-methylbenzenesulfonate (prepared as described in step 1 of the synthesis of Λ/-(3-methoxybenzyl)-6-(2-(((<rans)-4-hydroxy-4-(hydroxymethyl)cyclohexyl)methyl)- 2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 28) (1 4 g, 4 3 mmol) is added to a mixture of /V-(3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyc!ohexyl)methyl)-2/-/-tetrazol-5- yl)-6-methylpιcolιnamιde, Example 153) (1 39 g, 4 3 mmol) and triethylamine (434 mg) in anhydrous /V,Λ/-dιmethylacetamιde (2 mL) The mixture was stirred at 85 0C for 64 hours The reaction mixture is purified by reverse phase preparative HPLC to afford the title compound as an oil (1 7 g)
Step 2 Preparation of Λ/-(3-methoxybenzyl)-6-methyl-4-(2-((4-oxocvclohexyl)methyl)-2H-tetrazol-5- vQpicolinamide
Formic acid (96%, 20 mL) was added to a solution of 4-(2-(1 ,4-dιoxaspιro[4 5]dec-8-ylmethyl)- 2/-/-tetrazol-5-yl)-Λ/-(3-methoxybenzyl)-6-methylpyrιdιne-2-carboxamιde (1 6 g, 3 3 mmol) in tetrahydrofuran (13 mL) and the mixture is stirred overnight at room temperature The reaction mixture is concentrated and the residue is dissolved in dichloromethane The mixture was washed with saturated aqueous sodium bicarbonate solution The organic layer was dried over magnesium sulfate and concentrated to afford the title compound as a white solid (1 6 g) Step 3 Preparation of Λ/-(3-methoxybenzyl)-6-methyl-4-(2-(1-oxaspιrof2 51oct-6-ylmethyl)-2H-tetrazol- 5-yl)pyrιdιne-2-carboxamιde
A solution of Λ/-(3-methoxybenzyl)-6-methyl-4-(2-((4-oxocyclohexyl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde (445 mg, 1 0 mmol) in anhydrous dimethylsulfoxide (4 mL) was added to a solid mixture of trimethylsulfoxonium iodide (445 mg, 2 0 mmol) and potassium t-butoxide (225 mg, 2 0 mmol) The mixture was allowed to stir at room temperature for 30 minutes Water (25 mL) was then added and the slurry was stirred at room temperature for 20 minutes The resulting precipitate was filtered, washed with water and dried under vacuum to afford the title compound (266 mg) Step 4 Preparation of Λ/-(3-methoxybenzyl)-4-(2-(((c<s)-4-hvdroxy-4-
(hvdroxymethyl)cvclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde
Perchloric acid (70%, 0 4 mL) was added to Λ/-(3-methoxybenzyl)-6-methyl-4-(2-(1 - oxaspιro[2 5]oct-6-ylmethyl)-2H-tetrazol-5-yl)pyrιdιne-2-carboxamιde (260 mg, 0 58 mmol) in a mixture of tetrahydrofuran (4 ml) and water (1 2 mL) The mixture was allowed to stir at room temperature for 3 5 hours The reaction mixture was purified by reverse phase preparative HPLC followed by elution through a carbonate resin column The resulting mixture of isomers were separated by supercritical fluid chiral chromatography (OJ-H column, 30 x 250 mm, 20% 2-propanol, 70 mL/min) and the first eluting isomer was isolated to afford the title compound as a white solid (32 mg) MS (ES+) m/z 467 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 19 (t, J=6 4 Hz, 1 H), 8 41 (s, 1 H), 8 06 (s, 1 H), 7 22 (t, J=& 1 Hz, 1 H), 6 88 - 6 92 (m, 2 H), 6 80 (d, J=& 8 Hz, 1 H), 4 64 (d, J=I 0 Hz, 2 H), 4 49 (d, J=Q 2 Hz, 2 H), 4 39 (t, J=5 3 Hz, 1 H), 3 80 (s, 1 H), 3 71 (s, 3 H), 3 10 (d, J=5 5 Hz, 2 H), 2 65 (s, 3 H), 1 87 - 1 97 (m, 1 H), 1 25 - 1 49 (m, 8 H)
Example 345 W-(3-Methoxybenzyl)-4-(2-((((rans)-4-hydroxy-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-
5-yl)-6-methylpicolinamide
Isolation of the second eluting isomer by supercritical fluid chiral chromatography (OJ-H column, 30 x 250 mm, 20% 2-propanol, 70 mUmin) from the reaction mixture described in Example 344 afforded the title compound as a white solid (54 mg) MS (ES+) m/z 467 (M+H)
Example 346
W-(3-(2-Hydroxyethoxy)benzyl)-6-methyl-4-(2-(((frans)-4- (methylsulfonylmethyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)picolinamide
Step 1 Preparation of ((frans)-4-(hvdroxymethyl)cvclohexyl)methyl 4-methylbenzenesulfonate
4-Methylbenzenesulfonyl chloride (19 O g, 100 mmol) was added to a solution of fraπs- 1 ,4- cyclohexane dimethanol (14 4 g, 100 mmol) in anhydrous pyridine (50 mL) cooled in an ice bath The mixture was allowed to warm to room temperature and was stirred for 18 hours The reaction mixture was diluted with ether (300 mL), poured into water (400 mL), and filtered The separated aqueous layer was further extracted with ether (2 x 200 mL) The combined organic layers were washed with water (200 mL), 1 N hydrochloric acid (2 x 200 mL), water (200 mL), and saturated aqueous sodium bicarbonate solution (200 mL) The organic layer was dried over magnesium sulfate and concentrated to afford the title compound as an oil (14 8 g)
Step 2 Preparation of methyl 6-methyl-4-(2-(((frans)-4-((tosyloxy)methyl)cvclohexyl)methyl)-2/-/- tetrazol-5-yl)pιcolιnate
In a 100 ml round-bottomed flask under nitrogen at room temperature, methyl 6-methyl-4-(2H- tetrazol-5-yl)pιcolιnate (prepared as described in step 4 of the synthesis of /V-(3-methoxybenzy!)-4-(2- (((<raπs)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (0 835 mg, 3 81 mmol) was combined with ((fra/7s)-4-(hydroxymethyl)cyclohexyl)methyl 4- methylbenzenesulfonate (1 25 g, 4 19 mmol), polymer supported-tπphenylphosphine (4 87 g, 10 5 mmol) and tetrahydrofuran (30 mL) The mixture was cool to 0 0C in a dry ice bath for 20 minutes and di-terf-butyl azodicarboxylate (1 75 g, 7 62 mmol) was added The mixture was stirred in a dry ice bath for 1 hour and then allowed to warm to room temperature and stir overnight The reaction mixture was filtered and the resin was washed with tetrahydrofuran The residue was purified by reverse phase preparative HPLC to afford the title compound (1 295 g) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 3 565 mm , m/z 500 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 0 88 - 1 18 (m, 3 H), 1 55 - 1 82 (m, 4 H), 1 95 - 2 12 (m, 1 H), 2 38 - 2 46 (m, 3 H), 2 91 (s, 3 H), 3 79 (d, J=6 18 Hz, 2 H), 4 04 (s, 3 H), 4 56 (d, J=I 25 Hz, 2 H), 7 31 (d, J=8 06 Hz, 2 H), 7 67 - 7 79 (m, 2 H), 8 44 (s, 1 H), 8 85 (s, 1 H), 13 80 (s, 2 H)
Step 3 Preparation of methyl 6-methyl-4-(2-(((frans)-4-(methylthιomethyl)cvclohexyl)methyl)-2/-/- tetrazol-5-yl)pιcolιnate
Sodium thiomethoxide (0 363 g, 5 18 mmol) was added to a solution of methyl 6-methyl-4-(2-
(((<rans)-4-((tosyloxy)methyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)pιcolιnate (1 295 g, 2 592 mmol) in dimethylsulfoxide (20 mL) and the mixture was heated at 50 0C for 2 hours The reaction mixture was passed through a silica plug, eluted with ethyl acetate, and concentrated The residue was purified by reverse phase preparative HPLC to afford the title compound as a clear, light yellow colored oil (0 973 g) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 3 536 mm , m/z 376 (M+H)
Step 4 Preparation of methyl 6-methyl-4-(2-((((rans)-4-(methylsulfonylmethyl)cvclohexyl)methyl)-2H- tetrazol-5-yl)pιcolιnate
3-Chloroperoxybenzoιc acid (772 mg, 4 47 mmol) was added to a solution of methyl 6-methyl- 4-(2-(((frans)-4-(methylthιomethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)pιcolιnate (381 4 mg, 1 016 mmol) in dichloromethane (10 mL) and the mixture was allowed to stir overnight A saturated aqueous sodium bicarbonate solution (5 mL) was added The organic layer was separated, dried over magnesium sulfate, filtered, and concentrated to afford the title compound as a clear, colorless oil (415 mg) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 2 626 mm , m/z 408 (M+H) Step 5 Preparation of 6-methyl-4-(2-(((/rans)-4-(methylsulfonylmethyl)cvclohexyl)methyl)-2H-tetrazol- 5-yl)pιcolιnιc acid
A solution of lithium hydroxide (1 M, 1 ml, 1 0 mmol) was added to a solution of methyl 6- methyl-4-(2-(((^ans)-4-(methylsulfonylmethyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)pιcolιnate (414 mg, 1 02 mmol) in tetrahydrofuran (10 mL) The mixture was allowed to stir at room temperature overnight and was then concentrated to afford the title compound LC/MS (5%-95% CH3CN/H2O, 5 mm ) 2 090 mm , m/z 394 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 1 08 - 1 29 (m, 4 H), 1 99 (s, 1 H), 2 00 - 2 17 (m, 4 H), 2 86 - 3 00 (m, 8 H), 4 60 (d, J=6 98 Hz, 2 H), 8 48 (s, 1 H), 8 87 (s, 1 H), 12 53 (br s , 2 H) Step 6 Preparation of Λ/-(3-(2-hvdroxyethoxy)benzyl)-6-methyl-4-(2-((((rans)-4-(methylsulfonylmethyl)- cvclohexyl)methyl)-2/-/-tetrazol-5-yl)pιcolιnamιde
A mixture of 6-methyl-4-(2-(((frans)-4-(methylsulfonylmethyl)cyclohexyl)methyl)-2/-/-tetrazol-5- yl)pιcolιnιc acid (50 0 mg, 0 130 mmol), dnsopropylethylamine (150 mg, 1 10 mmol), and 2-(3- (amιnomethyl)phenoxy)ethanol (prepared as described in step 2 of the synthesis of Λ/-(3-(2- hydroxyethoxy)benzyl)-6-(2-(((/rans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne- 4-carboxamιde, Example 13) (42 0 mg, 0 250 mmol) in Λ/,Λ/-dιmethylformamιde (2 0 mL) was stirred for 20 minutes O-(1 H-Benzotrιazol-1-yl)-W,W,/V,W-tetramethyluronιum tetrafluoroborate (102 mg,
0 318 mmol) was added and the mixture was stirred for 3 hours The reaction mixture was purified by reverse phase preparative HPLC to afford the title compound as the trifluoroacetate salt (38 0 mg,
55% yield) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 05 - 1 16 (m, 14 H), 1 61 (d, J= 10 25 Hz, 9 H),
1 90 (d, J=10 98 Hz, 11 H), 2 65 (s, 9 H), 2 90 - 2 96 (m, 10 H), 2 99 (d, J=6 59 Hz, 7 H), 3 67 (d, J=A 39 Hz, 7 H), 3 93 (t, J=5 12 Hz, 8 H), 4 49 (d, J=6 59 Hz, 9 H), 4 64 (d, J=I 32 Hz, 8 H), 6 85 - 6 93 (m, 6 H)
Example 347
/V^S-HydroxybenzyO-β-methyM^Z^^ffansJ^^methylsulfonylmethyOcyclohexyOmethyO^H- tetrazol-5-yl)picolinamide
The title compound (49 O mg, 77%) was prepared in a similar manner to Λ/-(3-(2- hydroxyethoxy)benzyl)-6-methyl-4-(2-(((^rans)-4-(methylsulfonylmethyl)cyclohexyl)methyl)-2/-y-tetrazol- 5-yl)pιcolιnamιde (Example 346) by reaction with 3-(amιnomethyl)phenol 1H NMR (400 MHz, DMSO- d6) <5 ppm 1 05 - 1 16 (m, 17 H), 1 61 (d, J=10 98 Hz, 1 1 H), 1 82 - 1 93 (m, 14 H), 2 65 (s, 12 H), 2 90 - 2 97 (m, 12 H), 2 99 (d, J=5 86 Hz, 8 H), 4 44 (d, J=6 59 Hz, 10 H), 4 64 (d, J=6 59 Hz, 9 H), 6 70 - 6 77 (m, 7 H)
Example 348
^-(S-Chloro^-fluorobenzylJ-β-methyM-IZ^^fransJ^^methylsulfonylmethyOcyclohexyOmethyl)- 2H-tetrazol-5-yl)picolinamide
The title compound (48 0 mg, 58%) was prepared in a similar manner to Λ/-(3-(2- hydroxyethoxy)benzyl)-6-methyl-4-(2-(((frans)-4-(methylsulfonylmethyl)cyclohexyl)methyl)-2H-tetrazol- 5-yl)pιcolιnamιde (Example 346) by reaction with (3-chloro-4-fluorophenyl)methanamιne 1H NMR (400 MHz, DMSO-Cf6) δ ppm 1 04 - 1 15 (m, 18 H), 1 61 (d, J=1 1 71 Hz, 12 H), 1 81 - 1 93 (m, 16 H), 2 66 (s, 13 H), 2 89 - 2 95 (m, 12 H), 2 99 (d, J=5 86 Hz, 9 H), 4 49 (d, J=5 86 Hz, 10 H), 4 64 (d, J=6 59 Hz, 10 H)
Example 349
W-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-(((frans)-4- (methylsulfonylmethy^cyclohexylJmethyl^H-tetrazol-S-yOpicolinamide
The title compound (76 5 0 mg, 56%) was prepared in a similar manner to Λ/-(3-(2- hydroxyethoxy)benzyl)-6-methyl-4-(2-(((frans)-4-(methylsulfonylmethyl)cyclohexyl)methyl)-2H-tetrazol- 5-yl)pιcolιnamιde (Example 346) by reaction with 4-fluoro-3-methoxybenzylamιne hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-((frans-4- amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 1 ) 1H NMR (400 MHz, DMSO-(Z6) S PPm 1 08 - 1 16 (m, 12 H), 1 61 (d, J=10 26 Hz, 10 H), 1 82 - 1 93 (m, 12 H), 1 97 (s, 7 H), 2 65 (s, 9 H), 2 92 (s, 9 H), 2 99 (d, J=5 86 Hz, 8 H), 3 80 (s, 8 H), 4 48 (d, J=5 86 Hz, 9 H), 4 64 (d, J=5 86 Hz, 8 H), 7 06 - 7 18 (m, 7 H)
Example 350
N-(3-(Hydroxymethyl)benzyl)-6-methyl-4-(2-(((frans)-4- (methylsulfonylmethyOcyclohexyOmethyO-ΣH-tetrazol-δ-yOpicolinamide
The title compound (45 O mg, 69%) was prepared in a similar manner to Λ/-(3-(2- hydroxyethoxy)benzyl)-6-methyl-4-(2-(((frans)-4-(methylsulfonylmethyl)cyclohexyl)methyl)-2H-tetrazol- 5-yl)pιcolιnamιde (Example 346) by reaction with (3-(amιnomethyl)phenyl)methanol 1H NMR (400 MHz, DMSO-d6) δ ppm 1 04 - 1 16 (m, 17 H), 1 61 (d, J=11 71 Hz, 11 H), 1 81 - 1 93 (m, 14 H), 2 65 (s, 12 H), 2 89 - 2 95 (m, 12 H), 2 99 (d, J=5 86 Hz, 8 H), 4 45 (s, 7 H), 4 48 - 4 56 (m, 10 H), 4 64 (d, J=I 32 Hz, 9 H)
Example 351
W-(3-Methoxybenzyl)-4-(2-(((frans)-4-(aminomethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Step 1 Preparation of terf-butyl ((fransM-ihydroxymethvDcyclohexyDrnethylcarbarnate
A solution of trans 4-(fert-butyloxycarbonylamιno)methylcyclohexanecarboxylιc acid (5 O g, 19 mmol) in a mixture of 1 ,4-dιoxane/tetrahydrofuran (1 /1 , 20 mL) was added drop wise to a cooled suspension of lithium aluminum hydride (2 1 g, 57 mmol) and the resulting mixture was stirred at room temperature for 15 hours The excess of lithium aluminum hydride was destroyed by drop wise addition of water (2 mL) The suspension was filtered and the filter cake was washed with tetrahydrofuran (10 mL) and methanol (2 x 10 mL) The filtrate was concentrated in vacuo and extracted with ethyl acetate ( 3 x 15 mL) The combined organic layers were dried with sodium sulfate and concentrated to afford the title compound as a light amber oil which solidified on standing (3 7 g, 80%) LC/MS (5-100% CH3CN/H2O, 8 mm) 4 79 mm, m/z 266 (M+Na) Step 2 Preparation of Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4-(amιnomethyl)cvclohexyl)methyl)-2H- tetrazol-δ-vP-β-methylpicolinamide
A mixture of tert-butyl ((/ransH^hydroxymethyOcyclohexyOmethylcarbamate (O 75 g, 3 1 mmol), /V-(3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((<Λans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide, Example 153) (0 50 g, 1 5 mmol), and polymer supported-tπphenylphosphine (1 85 g, 2 65 mmol) in tetrahydrofuran (25 0 mL) was cooled to 0 0C in an ice bath for 15 minutes Di- fert-butyl azodicarboxylate (755 mg, 3 08 mmol) was added and the mixture was allowed to warm to room temperature and stir for 48 hours The reaction mixture was filtered and the filtrate was concentrated The residue was dissolved in dichloromethane (4 mL) and tπfluoroacetic acid (2 mL) was added The mixture was stirred for 30 minutes at room temperature and then concentrated in vacuo The residue was triturated with diethyl ether and further purified by reverse phase preparative HPLC (10-90% acetonitrile/water) to afford the title compound as a white solid (0 24 g, 52%) LC/MS (5-100% CH3CN/H2O, 8 mm) 4 59 mm, m/z 450 (M+H)
Example 352
W-(3-Methoxybenzyl)-4-(2-(((frans)-4-(acetamidomethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Triethylamine (0 031 ml) and acetyl chloride (0 010 mL) was added to a solution of Λ/-(3- methoxybenzyl)- 4-(2-(((frans)-4-(amιnomethyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicohnamide (prepared as described in Example 351 ) (0 050 g, 0 010 mmol) in Λ/,Λ/- dimethylformamide (1 mL) and the mixture was stirred at room temperature for 4 hours The reaction mixture was diluted with water (2 mL) and extracted with ethyl acetate (2 x 5 mL) The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated The residue was purified by reverse phase preparative HPLC to afford the title compound as a solid (19 mg, 39%) 1H NMR (400 MHz, DMSOd6) δ ppm 9 13 - 9 25 (m, 1 H), 8 40 (s, 1 H), 8 05 (s, 1 H), 7 69 (s, 1 H), 7 17 - 7 26 (m, 1 H), 6 90 (s, 2 H), 6 80 (d, J=Q 05 Hz, 1 H), 4 64 (d, J=6 59 Hz, 2 H), 4 49 (d, J=6 59 Hz, 2 H), 3 71 (s, 3 H), 2 84 (t, J=5 86 Hz, 2 H), 2 65 (s, 3 H), 1 96 (d, J=2 93 Hz, 1 H), 1 76 (s, 3 H), 1 68 (d, J=11 71 Hz, 2 H), 1 60 (d, J=M 45 Hz, 2 H), 1 30 (s, 1 H), 0 98 - 1 12 (m, 2 H), 0 79 - 0 94 (m, 2 H) Example 353
/V-(3-Methoxybenzyl)-6-methyl-4-(2-(((frans)-4-(methylsulfonamidomethyl)cyclohexyl)methyl)-
2H-tetrazol-5-yl)picolinamide
Triethylamine (0 031 ml) and methane sulfonylchloπde (0 010 mL) was added to a solution of
Λ/-(3-methoxybenzyl)- 4-(2-(((/rans)-4-(amιnomethyl)cyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide (prepared as described in Example 351 ) (0 050 g, 0 010 mmol) in N, N- dimethylformamide (1 mL) and the mixture was stirred at room temperature for 4 hours The reaction mixture was diluted with water (2 mL) and extracted with ethyl acetate (2 x 5 mL) The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated The residue was purified by reverse phase preparative HPLC to afford the title compound as a solid (15 mg, 28%) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 14 - 9 25 (m, 1 H), 8 41 (s, 1 H), 8 06 (s, 2 H), 7 16 - 7 27 (m, 1 H), 6 87 - 6 96 (m, 2 H), 6 80 (d, J=I 32 Hz, 1 H), 4 64 (d, J=I 32 Hz, 2 H), 4 49 (d, J=Q 59 Hz, 2 H), 3 71 (s, 3 H), 2 82 (s, 3 H), 2 74 (t, J=Q 59 Hz, 2 H), 2 65 (s, 3 H), 1 97 (s, 1 H), 1 75 (d, J=13 18 Hz, 2 H), 1 61 (d, J=1 1 71 Hz, 2 H), 1 34 (s, 1 H), 0 98 - 1 17 (m, 2 H), 0 79 - 0 95 (m, 2 H)
Example 354
/V-(4-Fluoro-3-methoxybenzyl)-4-(2-((((rans)-4-(aminomethyl)cyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpicolinamide
Step 1 Preparation of methyl 4-(2-(((frans)-4-((feft-butoxycarbonyl)methyl)cvclohexyl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnate
A mixture of methyl 6-methyl-4-(2H-tetrazol-5-yl)pιcolιnate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((^rans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolmamide, Example 153) (1 5Og, 6 85 mmol), te/t-butyl ((trans)-4-
(hydroxymethyl)cyclohexyl)methylcarbamate (prepared as described in step 1 of the synthesis of Λ/-(3- methoxybenzyl)-4-(2-(((frans)-4-(amιnomethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide, Example 351 ) (3 00 g, 12 3 mmol), and polymer supported-triphenylphosphine (7 78 g, 17 1 mmol) in tetrahydrofuran (150 mL) was cooled to 0 0C in an ice bath for 15 minutes Di- tert-butyl azodicarboxylate (3 15 g, 13 7 mmol) was added and the mixture was allowed to warm to room temperature and stir for 15 hours The reaction mixture was filtered and the filtrate was concentrated The residue was purified by silica gel chromatography (0-50% ethyl acetate/heptane) to afford the title compound as an beige solid (2 15 g, 71 %) LC/MS (5-100% CH3CN/H2O, 8 mm) 5 84 mm, m/z 445 (M+H)
Step 2 Preparation of 4-(2-(((frans)-4-((tert-butoxycarbonyl)methyl)cvclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpιcolιnιc acid
An aqueous solution of sodium hydroxide (2 5 N, 5 0 mL) was added to a solution of methyl 4- (2-(((frans)-4-((/ert-butoxycarbonyl)methyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnate (0 50 g, 1 1 mmol) in tetrahydrofuran (5 mL) and water (2 mL) and the mixture was stirred at room temperature for 15 hours The tetrahydrofuran was removed in vacuo and the aqueous residue was acidified with aqueous hydrochloric acid to pH 7 The resulting white solid was filtered and dried to afford the title compound (0 45g, 92%) LC/MS (5-100% CH3CN/H2O, 8 mm) 5 10 mm, m/z 431 (M+H)
Step 3 Preparation of tert-butyl ((frans)-4-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)cvclohexyl)methylcarbamate
A mixture of 4-(2-(((<rans)-4-((fert-butoxycarbonyl)methyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)- 6-methylpιcolιnιc acid ( 0 080 g, 0 19 mmol) and 1-hydroxybenzatrιazole (30 mg, 0 22 mmol) in N1N- dimethylacetamide (2 mL) was stirred for 5 minutes Triethylamine (0 028 g, 0 28 mmol), 4-fluoro-3- methoxybenzylamine hydrochloride (prepared as described in step 3 of the synthesis of /V-(4-fluoro-3- methoxybenzyl)-6-(2-((frans-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)pyrιmιdιne-4-carboxamιde, Example 1 ) (35 mg, 0 22 mmol), and 1-(3-dιmethylamιnopropyl)-3-ethylcarbodιιmιde hydrochloride (53 mg, 0 28 mmol) were added, and the mixture was stirred at room temperature for 18 hours The reaction mixture was purified by reverse phase preparative HPLC to afford the title compound as solid (100 mg, 95%) LC/MS (5-100% CH3CN/H2O, 8 mm) 5 72 mm, m/z 568 (M+H) Step 4 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((/rans)-4-(amιnomethyl)cvclohexyl)methyl)- 2H-tetrazol-5-yl)-6-methylpιcolιnamιde hydrochloride
A solution of hydrochloric acid in dioxane (4 N, 6 0 mL) was added to a solution of tert-butyl ((<rans)-4-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yOmethylJcyclohexyOmethylcarbamate (105 mg, 0 185 mmol) in dichloromethane (2 mL) and the mixture was stirred for 1 5 hours The reaction mixture was concentrated and the residue was triturated with diethyl ether to afford the title compound as the hydrochloride salt (41 mg, 44%) 1H NMR (400 MHz, DMSOd6) 6 ppm 9 26 (br s , 1 H), 8 40 (br s , 1 H), 8 05 (br s , 1 H), 7 97 (br s , 1 H), 7 04 - 7 19 (m, 1 H), 6 87 (br s , 1 H), 4 65 (br s , 2 H), 4 47 (br s , 2 H), 3 79 (br s , 2 H), 3 54 (s, 3 H), 3 35 (br s , 1 H), 2 65 (br s , 3 H), 2 59 (br s , 1 H), 1 98 (br s , 1 H), 1 77 (d, J=9 94 Hz, 2 H), 1 61 (d, J=10 47 Hz, 2 H), 1 50 (br s , 1 H), 1 06 (br s , 2 H), 0 92 (d, J=Q 32 Hz, 2 H)
Example 355 fac-N^S-MethoxybenzyO^^Z-i^i/r.aS^J-a-lhydroxymethyOcyclopentyOmethyO^H-tetrazol-S- yl)-6-methylpicolinamide
A mixture of Λ/-(3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((/rans)-4-amιnocyclohexyl)methyl)- 2H-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (325 mg), c/s-cyclopentane-1 ,3-dιmethanol (Bioorg Med Chem Lett 2005, 15, 2685-2688) (203 mg), and polymer supported triphenylphosphine (1 27 g) in anhydrous tetrahydrofuran (15 mL) was cooled in an ice bath Dι-fert-butyl azodicarboxylate (345 mg) was added and the mixture was placed in an ultrasonic bath for 30 minutes The mixture was filtered and the resin was washed with tetrahydrofuran The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC (acetonitπle/water, 40/60 - 70/30) The product was dissolved in dichloromethane (20 mL) and stirred with Argonaut MP- CO3H resin (2 62 mmol/g, 0 9 g) and eluting through a Stratosphere MP-CO3H SPE column The eluent was concentrated to afford the title compound as an oil (245 mg) MS (ES+) m/z 437 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 19 (t, J=6 2 Hz, 1 H), 8 40 (s, 1 H), 8 05 (s, 1 H), 7 22 (t, J=8 2 Hz, 1 H), 6 87 - 6 92 (m, 2 H), 6 79 (dd, J=8 1 , 1 5 Hz, 1 H), 4 67 - 4 77 (m, 2 H), 4 49 (d, J=6 6 Hz, 2 H), 4 41 (t, J=5 1 Hz, 1 H), 3 71 (s, 3 H), 3 23 - 3 32 (m, 2 H), 2 65 (s, 3 H), 2 50 - 2 59 (m, 1 H), 1 96 - 2 07 (m, 1 H), 1 74 - 1 84 (m, 1 H), 1 57 - 1 71 (m, 2 H), 1 31 - 1 42 (m, 2 H), 0 96 - 1 06 (m, 1 H) Example 356 rac-W-(3-Methoxybenzyl)-4-(2-(((1/?*)3S*)-3-(aminomethyl)cyclopentyl)methyl)-2H-tetrazol-5-yl)-
6-methylpicolinamide
Step 1 Preparation of rac-((1 S*.3/?*)-3-((5-(2-((3-methoxybenzyl)carbannoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol-2-yl)methvDcvclopentyl)methyl methanesulfonate
Methanesulfonyl chloride (0 160 mL) was added to a solution of rac-Λ/-(3-methoxybenzyl)-4- (2-(((1 /?*,3S*)-3-(hydroxymethyl)cyclopentyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 355) (742 mg) in pyridine (15 mL) cooled in an ice bath The mixture was allowed to warm to room temperature and was stirred for 3 hours The reaction mixture was concentrated and the residue was purified by reverse phase preparative HPLC (acetonitrile/water, 50/50 - 80/20) The combined fractions were made basic with 5% aqueous sodium bicarbonate (3 mL) and extracted with dichloromethane (3 x 10 mL) The combined organic layers were dried over magnesium sulfate, filtered, and concentrated to afford the title compound (752 mg) MS (ES+) m/z 515 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 19 (t, J=Q 4 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 22 (t, J=Q 1 Hz, 1 H), 6 87 - 6 92 (m, 2 H), 6 80 (d, J=8 1 Hz, 1 H), 4 76 (d, J=I 3 Hz, 2 H), 4 49 (d, J=6 2 Hz, 2 H), 4 05 - 4 14 (m, 2 H), 3 71 (s, 3 H), 2 65 (s, 3 H), 2 56 - 2 64 (m, 1 H), 2 52 (s, 3 H), 2 25 - 2 36 (m, 1 H), 1 85 - 1 94 (m, 1 H), 1 67 - 1 77 (m, 2 H), 1 38 - 1 48 (m, 2 H), 1 04 - 1 15 (m, 1 H)
Step 2 Preparation of rac-Λ/-(3-methoxybenzyl)-4-(2-(((1 ff*,3S*)-3-(amιnomethyl)cvclopentyl)methyl)- 2H-tetrazol-5-yl)-6-methylpιcolιnamιde
Ammonium hydroxide (2 mL) was added to a solution of rac-((1 S*,3R*)-3-((5-(2-((3- methoxybenzyOcarbamoyO-θ-methylpyπdin^-yO^H-tetrazol-Σ-yOmethyOcyclopentyOmethyl methanesulfonate (227 mg) in DMSO (2 mL) and the mixture was heated to 70 °C overnight The mixture was poured into water (10 mL) and extracted with dichloromethane (2 x 5 mL) The combined organic layers were washed with water (5 mL), dried over magnesium sulfate, filtered and concentrated The residue was purified by reverse phase preparative HPLC (acetonitrile/water, 30/70
- 60/40) The product containing fractions were concentrated The aqueous residue was made basic with 5% aqueous sodium bicarbonate and extracted with dichloromethane (5 x 10 mL) The combined organic layers were dried over magnesium sulfate, filtered and concentrated to afford the title compound as an oil (1 10 mg) MS (ES+) m/z 436 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 19 (t, J=Q 2 Hz, 1 H), 8 40 (s, 1 H), 8 05 (s, 1 H), 7 22 (t, J=8 1 Hz, 1 H), 6 90 (br s , 2 H), 6 80 (d, J=Q 1 Hz, 1 H), 4 72 (d, J=I 3 Hz, 2 H), 4 49 (d, J=Q 2 Hz, 2 H), 3 71 (s, 3 H), 2 65 (s, 3 H), 2 50 - 2 59 (m, 1 H), 1 78 - 1 94 (m, 2 H), 1 62 - 1 72 (m, 2 H), 1 23 - 1 44 (m, 2 H), 0 90 - 1 02 (m, 1 H)
Example 357 rac-N-(3-Methoxybenzyl)-6-methyl-4-(2-(((1 /?\3S*)-3-
(methylsulfonamidomethyOcyclopentylJmethyO-ZH-tetrazol-S-yOpicolinamide
Methanesulfonyl chloride (1 1 4 μL) was added to a mixture of rac-Λ/-(3-methoxybenzyl)-4-(2- (((1 R*,3S*)-3-(amιnomethyl)cyclopentyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 356) (53 mg) and diisopropylethylamme (30 μL) in anhydrous tetrahydrofuran (3 mL) The mixture was stirred at room temperature for 1 hour and was then concentrated The residue was purified by reverse phase preparative HPLC (acetonitrile/water, 50/50 - 75/25) The product containing fractions were concentrated The aqueous residue was made basic with 5% aqueous sodium bicarbonate and extracted with dichloromethane (3 x 10 mL) The combined organic layers were dried over magnesium sulfate, filtered and concentrated to afford the title compound as an oil (63 mg) MS (ES+) m/z 514 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 19 (t, J=Q 2 Hz, 1 H), 8 41 (s, 1 H), 8 05 (S, 1 H), 7 22 (t, J=8 1 Hz, 1 H), 6 87 - 6 95 (m, 3 H), 6 80 (d, J=8 1 Hz, 1 H), 4 74 (d, J=I 3 Hz, 2 H), 4 49 (d, J=Q 2 Hz1 2 H), 3 71 (s, 3 H), 2 87 (t, J=Q Q Hz, 2 H), 2 83 (s, 3 H), 2 65 (s, 3 H), 2 52
- 2 62 (m, 1 H), 2 00 - 2 1 1 (m, 1 H), 1 82 - 1 92 (m, 1 H), 1 65 - 1 74 (m, 2 H), 1 28 - 1 47 (m, 2 H), 0 95 - 1 06 (m, 1 H)
Example 358 /V-(3-Methoxybenzyl)-6-methyl-4-(2-((S)-piperidin-3-ylmethyl)-2W-tetrazol-5-yl)picolinamide
Step 1 Preparation of (3S)-terf-butyl 3-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/- tetrazol-2-yl)methyl)pιperιdιne-1-carboxylate
Λ/-(3-Methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-y!)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-Methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide, Example 153) (324 mg, 1 0 mmol), polymer supported triphenylphosphine (698 mg, 1 5 mmol), and (S)-1-Boc-3-(hydroxymethyl)pιperιdιne (258 mg, 1 2 mmol) were suspended in tetrahydrofuran (16 mL) Di-tert-butyl azodicarboxylate (345 mg, 1 5 mmol) was added The mixture was allowed to stir for 18 hours The reaction mixture was filtered and the resin washed with tetrahydrofuran (20 mL) The filtrate was concentrated The crude product was purified by silica column chromatography (heptane/EtOAc, 2/1 , 1/1 ) Fractions containing the product were concentrated to afford the title compound as an oil (461 mg, 88%) MS (ES+) m/z 522 (M+H) 1H NMR (400 MHz, DMSO-CZ6) ppm 9 24 (t, J=6 4 Hz, 1 H), 8 41 (d, J=O 8 Hz, 1 H), 8 07 (d, J= 1 1 Hz, 1 H), 7 21 (t, J=8 1 Hz, 1 H), 6 90 - 6 87 (m, 2 H), 6 79 (dd, J=8 0, 2 1 Hz, 1 H), 4 77 - 4 66 (m, 2 H), 4 48 (d, J=6 6 Hz, 2 H), 3 70 (s, 3 H), 3 78 - 3 62 (m, 2 H), 2 82 (br s , 1 H), 2 65 (s, 3 H), 2 12 (br s , 1 H), 1 75 - 1 56 (m, 2 H), 1 37 - 1 17 (m, 12 H)
Step 2 Preparation of Λ/-(3-methoxybenzyl)-6-methyl-4-(2-((S)-pιperιdιn-3-ylmethyl)-2/-/-tetrazol-5- vQpicolinamide
(3S)-tert-Butyl 3-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazo!-2- yl)methyl)pιperιdιne-1-carboxylate (455 mg, 0 72 mmol) was dissolved in dichloromethane (5 0 mL) Tπfluoroacetic acid (1 0 mL, 13 0 mmol) was added and the solution was shaken for 2 hours at room temperature The solvent was removed in vacuo and the residue was dissolved in dichloromethane (100 mL) The mixture was washed with 1 N NaOH solution (2 x 10 mL) The organic layer was dried over sodium sulfate and concentrated to afford the title compound as an oil (349 mg, 94%) MS (ES+) m/z 422 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 24 (t, J=6 4 Hz, 1 H), 8 40 (d, J=O 8 Hz, 1 H), 8 05 (d, J= 1 1 Hz, 1 H), 7 21 (t, J=8 1 Hz, 1 H), 6 90 - 6 86 (m, 2 H), 6 79 (dd, J=7 9, 2 1 Hz, 1 H), 4 74 - 4 62 (m, 2 H), 4 47 (d, J=6 4 Hz, 2 H), 3 70 (s, 3 H), 2 83 - 2 74 (m, 2 H), 2 65 (s, 3 H), 2 47 - 2 40 (m, 1 H), 2 35 (dd, J=12 1 , 9 5 Hz, 1 H), 2 18 - 2 07 (m, 1 H), 1 68 - 1 52 (m, 2 H), 1 40 - 1 27 (m, 1 H), 1 16 (qd, J=11 1 , 3 2 Hz, 1 H) Example 359
W-(3-Methoxybenzyl)-6-methyl-4-(2-(((R)-1-(methylsulfonyl)piperidin-3-yl)methyl)-2W-tetrazol-5- yl)picolinamide
Λ/-(3-Methoxybenzyl)-6-rnethyl-4-(2-((S)-pιpeπdιn-3-ylmethyl)-2/-/-tetrazol-5-yl)pιcolιnamιde
(prepared as described in Example 358) (165 mg, 0 35 mmol) was dissolved in dichloromethane (5 mL) Triethylamine (98 μL, 0 71 mmol) and methanesulfonyl chloride (41 μl, 0 53 mmol) were added The reaction mixture was shaken at room temperature for 1 hour and then diluted with dichloromethane (50 mL) The mixture was washed with saturated aq sodium bicarbonate (10 mL) The organic layer was dried over sodium sulfate and concentrated The crude product was purified by silica column chromatography (heptane/EtOAc, 1/1 , 1/2, 1/4) to afford the title compound as a foaming solid (1 16 mg, 66%) MS (ES+) m/z 500 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 26 - 9 20 (m, 1 H), 8 43 (s, 1 H), 8 07 (s, 1 H), 7 24 (t, J=7 9 Hz, 1 H), 6 94 - 6 89 (m, 2 H), 6 81 (d, J=7 7 Hz, 1 H), 4 86 - 4 73 (m, 2 H), 4 51 (d, J=5 9 Hz, 2 H), 3 73 (s, 3 H), 3 48 - 3 36 (m, 2 H), 2 84 (s, 3 H), 2 83 - 2 75 (m, 1 H), 2 72 (t, J=9 9 Hz, 1 H), 2 67 (s, 3 H), 2 35 (br s , 1 H), 1 80 - 1 68 (m, 2 H), 1 57 - 1 46 (m, 1 H), 1 29 - 1 18 (m, 1 H)
Example 360
W-(3-Methoxybenzyl)-4-(2-(((S)-1-acetylpiperidin-3-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-((S)-pιperιdιn-3-ylmethyl)-2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 358) (165 mg, 0 35 mmol) was dissolved in dichloromethane (5 0 mL) Triethylamine (98 μL, 0 71 mmol), 4-(dιmethylamιno)pyrιdιne (8 6 mg, 0 07 mmol), and acetyl chloride (30 μL, 0 42 mmol) was added The mixture was allowed to stir at room temperature for 20 hours The reaction mixture was diluted with dichloromethane (50 mL) and washed with saturated aq sodium bicarbonate solution (20 mL) The organic layer was dried over sodium sulfate and concentrated The crude product was purified by silica column chromatography (CH2CI2/methanol, 100/1 , 100/2) to afford the title compound as an oil (160 mg, 100%) MS (ES+) m/z 464 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 24 (t, J=6 4 Hz, 1 H), 8 40 (s, 1 H), 8 06 (d, J=1 2 Hz, 1 H), 7 21 (t, J=8 1 Hz, 1 H), 6 91 - 6 86 (m, 2 H), 6 79 (dd, J=Q 2, 2 1 Hz, 1 H), 4 85 - 4 66 (m, 2 H), 4 48 (d, J=6 4 Hz, 2 H), 4 12 (dd, J=M 6, 3 4 Hz, 0 5 H), 4 01 (d, J=13 0 Hz, 0 5 H), 3 70 (s, 3 H), 3 64 (d, J=13 2 Hz, 0 5 H), 3 52 - 3 43 (m, 0 5 H), 3 00 (dd, J=13 4, 10 3 Hz, 1 H), 2 75 - 2 68 (m, 0 5 H), 2 65 (s, 3 H), 2 59 (dd, J=12 7, 10 3 Hz, 0 5 H), 2 26 - 2 18 (m, 0 5 H), 2 13 - 2 06 (m, 0 5 H), 1 95 (s, 1 5 H), 1 93 (s, 1 5 H), 1 74 - 1 53 (m, 2 H), 1 44 - 1 19 (m, 2 H)
Example 361 W-(3-Methoxybenzyl)-6-methyl-4-(2-((/?)-piperidin-3-y!methyl)-2H-tetrazol-5-yl)picolinamide
Step 1 Preparation of (3f?)-tert-butyl 3-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/- tetrazol-2-yl)methyl)pιperιdιne-1 -carboxylate
Λ/-(3-Methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-Methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide, Example 153) (324 mg, 1 0 mmol), polymer supported triphenylphosphine (698 mg, 1 5 mmol), and (/?)-1-Boc-3-(hydroxymethyl)pιperιdιne (258 mg, 1 2 mmol) were suspended in tetrahydrofuran (16 mL) Di-tert-butyl azodicarboxylate (345 mg, 1 5 mmol) was added The mixture was allowed to stir for 18 hours The reaction mixture was filtered and the resin washed with tetrahydrofuran (20 mL) The filtrate was concentrated The crude product was purified by silica column chromatography (heptane/EtOAc, 2/1 , 1/1 ) Fractions containing product were concentrated and repurified by silica column chromatography (CH2CI2/methanol, 100/1 ) to afford the title compound as a foaming solid (352 mg, 67%) MS (ES+) m/z 522 (M+H) 1H NMR (400 MHz, DMSOd6) ό ppm 9 24 (t, J=6 4 Hz, 1 H), 8 41 (d, J=O 8 Hz, 1 H), 8 07 (d, J= 1 2 Hz, 1 H), 7 21 (t, J=8 1 Hz, 1 H), 6 90 - 6 87 (m, 2 H), 6 79 (dd, J=8 1 , 1 8 Hz, 1 H), 4 78 - 4 66 (m, 2 H), 4 48 (d, J=6 4 Hz, 2 H), 3 70 (s, 3 H), 3 66 (br s , 2 H), 2 82 (br s , 1 H), 2 65 (s, 3 H), 2 13 (br s , 1 H), 1 74 - 1 67 (m, 1 H), 1 64 - 1 57 (m, 1 H), 1 35 - 1 21 (m, 12 H) Step 2 Preparation of Λ/-(3-methoxybenzyl)-6-methyl-4-(2-((ff)-pιperιdιn-3-ylmethyl)-2/-/-tetrazol-5- vQpicolinamide
(3R)-fert-Butyl 3-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2- yl)methyl)pιperιdιne-1 -carboxylate (348 mg, 0 65 mmol) was dissolved in dichloromethane (5 0 mL) Trifluoroacetic acid (1 0 mL, 13 0 mmol) was added and the solution was shaken for 2 hours at room temperature The solvent was removed in vacuo and the residue was dissolved in dichloromethane (100 mL) The mixture was washed with 1 N NaOH solution (2 x 10 mL) The organic layer was dried over sodium sulfate and concentrated to afford the title compound as an oil (283 mg, 96%) MS (ES+) m/z 422 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 24 (t, J=6 4 Hz, 1 H), 8 40 (d, J=O 8 Hz, 1 H), 8 05 (d, J= 1 2 Hz, 1 H), 7 21 (t, J=8 1 Hz, 1 H), 6 90 - 6 86 (m, 2 H), 6 79 (dd, J=7 9, 2 1 Hz, 1 H), 4 74 - 4 62 (m, 2 H), 4 47 (d, J=6 4 Hz, 2 H), 3 70 (s, 3 H), 2 81 - 2 74 (m, 2 H), 2 65 (s, 3 H), 2 46 - 2 39 (m, 1 H), 2 34 (dd, J= 1 1 9, 9 5 Hz, 1 H), 2 15 - 2 07 (m, 1 H), 1 66 - 1 52 (m, 2 H), 1 38 - 1 26 (m, 1 H), 1 16 (qd, J=10 5, 3 8 Hz, 1 H)
Example 362
/V-(3-Methoxybenzyl)-6-methyl-4-(2-(((S)-1-(methylsulfonyl)piperidin-3-yl)methyl)-2H-tetrazol-5- yl)picolinamide
Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-((R)-pιperιdιn-3-ylmethyl)-2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 361 ) (135 mg, 0 35 mmol) was dissolved in dichloromethane (5 mL) Triethylamine (83 μL, 0 60 mmol) and methanesulfonyl chloride (35 μL, 0 48 mmol) were added The reaction mixture was shaken at room temperature for 1 hour and then diluted with dichloromethane (50 mL) The mixture was washed with saturated aq sodium bicarbonate (10 mL) The organic layer was dried over sodium sulfate and concentrated The crude product was purified by silica column chromatography (heptane/EtOAc, 1/1 , 1/2, 1/4) to afford the title compound as a foaming solid (99 mg, 66%) MS (ES+) m/z 500 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 22 (t, J=6 2 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H), 7 24 (t, J=8 1 Hz, 1 H), 6 95 - 6 89 (m, 2 H), 6 82 (d, J=8 1 Hz, 1 H), 4 87 - 4 74 (m, 2 H), 4 51 (d, J=6 2 Hz, 2 H), 3 73 (s, 3 H), 3 48 - 3 36 (m, 2 H), 2 85 (s, 3 H), 2 79 (t, J=10 4 Hz, 1 H), 2 72 (t, J= 10 2 Hz, 1 H), 2 67 (s, 3 H), 2 36 (br s , 1 H), 1 80 - 1 68 (m, 2 H), 1 58 - 1 47 (m, 1 H), 1 29 - 1 19 (m, 1 H) Example 363
A/-(3-Methoxybenzyl)-4-(2-(((/?)-1-acetylpiperidin-3-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-((R)-pιperιdιn-3-ylmethyl)-2/-/-tetrazol-5-yl)pιcolιnamιde
(prepared as described in Example 361 ) (135 mg, 0 30 mmol) was dissolved in dichloromethane (5 0 mL) Triethylamine (83 μL, 0 60 mmol), 4-(dιmethylamιno)pyπdιne (7 3 mg, 0 06 mmol), and acetyl chloride (25 μL, 0 36 mmol) was added The mixture was allowed to stir at room temperature for 20 hours The reaction mixture was diluted with dichloromethane (50 mL) and washed with saturated aq sodium bicarbonate solution (20 mL) The organic layer was dried over sodium sulfate and concentrated The crude product was purified by silica column chromatography (CH2CI2/methanol, 100/1 , 100/2) Fractions were concentrated to afford the title compound as an oil (123 mg, 88%) MS (ES+) m/z 464 (M+H) 1H NMR (400 MHz, DMSO-d5) δ ppm 9 21 (t, J=6 2 Hz, 1 H), 8 44 (s, 1 H), 8 09 (s, 1 H), 7 24 (t, J=8 1 Hz, 1 H), 6 95 - 6 89 (m, 2 H), 6 82 (d, J=8 1 Hz, 1 H), 4 88 - 4 68 (m, 2 H), 4 51 (d, J=6 2 Hz, 2 H), 4 17 - 4 12 (m, 0 5 H), 4 06 - 4 00 (m, 0 5 H), 3 79 - 3 73 (m, 0 5 H), 3 73 (s, 3 H), 3 71 - 3 64 (m, 0 5 H), 3 08 - 3 00 (m, 1 H), 2 80 - 2 72 (m, 0 5 H), 2 68 (s, 3 H), 2 65 - 2 60 (m, 0 5 H), 2 29 - 2 23 (m, 0 5 H), 2 17 - 2 10 (m, 0 5 H), 1 98 (s, 1 5 H), 1 96 (s, 1 5 H), 1 77 - 1 59 (m, 2 H), 1 46 - 1 25 (m, 2 H)
Example 364 W-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((S)-piperidin-3-ylmethyl)-2H-tetrazol-5- yl)picolinamide
Step 1 Preparation of (3S)-tert-butyl 3-((5-(2-((4-f1uoro-3-methoxybenzyl)carbamoyl)-6-rnethylpyridin- 4-yl)-2H-tetrazol-2-yl)methyl)pιperιdιne-1 -carboxylate
/V-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((frans)-4- aminocyclohexyOmethyO^H-tetrazol-S-yO-θ-methylpicolinamide, Example 170) (342 mg, 1 0 mmol), polymer supported triphenylphosphine (698 mg, 1 5 mmol), and (S)-1-Boc-3-(hydroxymethyl)pιperιdιne (258 mg, 1 2 mmol) were suspended in tetrahydrofuran (16 mL) Di-tert-butyl azodicarboxylate (345 mg, 1 5 mmol) was added The mixture was allowed to stir for 18 hours The reaction mixture was filtered and the resin washed with tetrahydrofuran (20 mL) The filtrate was concentrated The crude product was purified by column chromatography (heptane/EtOAc, 2/1 , 1/1 ) Fractions containing the product were concentrated to afford the title compound as an oil (455 mg, 84%) MS (ES+) m/z 540 (M+H) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 9 26 (t, J=6 4 Hz1 1 H), 8 40 (d, J=O 8 Hz, 1 H), 8 07 (d, J= 1 1 Hz, 1 H), 7 15 (dd, J=8 5, 1 9 Hz, 1 H), 7 1 1 (dd, J=11 7, 8 3 Hz, 1 H), 6 87 (ddd, J=8 3, 4 4, 1 9 Hz, 1 H), 4 77 - 4 66 (m, 2 H)1 4 47 (d, J=5 9 Hz1 2 H), 3 79 (s, 3 H)1 3 72 - 3 62 (m, 2 H)1 2 85 - 2 79 (m, 1 H), 2 65 (s, 3 H), 2 17 - 2 09 (m, 1 H), 1 76 - 1 50 (m, 2 H), 1 36 - 1 21 (m, 12 H)
Step 2 Preparation of /V-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((S)-pιperιdιn-3-ylmethyl)-2H- tetrazol-5-yl)pιcolιnamιde
(3S)-tert-Butyl 3-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol-2-yl)methyl)pιperιdιne-1-carboxylate (450 mg, 0 63 mmol) was dissolved in dichloromethane (5 0 mL) Tπfluoroacetic acid (1 0 mL, 13 0 mmol) was added and the solution was shaken for 2 hours at room temperature The solvent was removed in vacuo and the residue was dissolved in dichloromethane (100 mL) The mixture was washed with 1 N NaOH solution (2 x 10 mL) The organic layer was dried over sodium sulfate and concentrated to afford the title compound as an oil (331 mg, 97%) MS (ES+) m/z 440 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 26 (t, J=6 4 Hz, 1 H)1 8 39 (d, J=O 9 Hz, 1 H)1 8 05 (d, J= 1 2 Hz1 1 H)1 7 15 (dd, J=8 5, 1 9 Hz, 1 H), 7 1 1 (dd, J=1 1 6, 8 4 Hz, 1 H), 6 87 (ddd, J=8 2, 4 4, 1 9 Hz, 1 H), 4 73 - 4 62 (m, 2 H), 4 47 (d, J=6 4 Hz, 2 H), 3 79 (s, 3 H), 2 81 - 2 74 (m, 2 H), 2 65 (s, 3 H), 2 46 - 2 39 (m, 1 H), 2 34 (dd, J=12 O1 9 5 Hz1 1 H)1 2 15 - 2 07 (m, 1 H), 1 67 - 1 52 (m, 2 H), 1 38 - 1 26 (m, 1 H), 1 16 (qd, J=10 7, 3 5 Hz, 1 H) Example 365
W-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-(((R)-1-(methylsulfonyl)piperidin-3-yl)methyl)-2H- tetrazol-5-yl)picolinamide
Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((S)-pιperιdιn-3-ylmethyl)-2/-/-tetrazol-5- yOpicolinamide (prepared as described in Example 364) (160 mg, O 34 mmol) was dissolved in dichloromethane (5 mL) Tπethylamine (95 μL, 0 68 mmol) and methanesulfonyl chloride (40 μL, 0 51 mmol) were added The reaction mixture was shaken at room temperature for 1 hour and then diluted with dichloromethane (50 mL) The mixture was washed with saturated aq sodium bicarbonate (10 mL) The organic layer was dried over sodium sulfate and concentrated The crude product was purified by silica column chromatography (heptane/EtOAc, 1/1 , 1/2, 1/4) to afford the title compound as a foaming solid (1 1 1 mg, 63%) MS (ES+) m/z 518 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 24 (t, J=6 4 Hz, 1 H), 8 44 (s, 1 H), 8 09 (s, 1 H), 7 19 (d, J=8 4 Hz, 1 H), 7 14 (dd, J= 11 5, 8 2 Hz, 1 H), 6 91 (d, J=2 2 Hz, 1 H), 4 88 - 4 75 (m, 2 H), 4 51 (d, J=6 2 Hz, 2 H), 3 82 (s, 3 H), 3 49 - 3 37 (m, 2 H), 2 85 (S, 3 H), 2 83 - 2 77 (m, 1 H), 2 72 (t, J=9 9 Hz, 1 H), 2 68 (s, 3 H), 2 42 - 2 31 (m, 1 H), 1 80 - 1 69 (m, 2 H), 1 59 - 1 47 (m, 1 H), 1 30 - 1 19 (m, 1 H)
Example 366
W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((S)-1-acetylpiperidin-3-yl)methyl)-2W-tetrazol-5-yl)-6- methylpicolinamide
Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((S)-pιperιdιn-3-ylmethyl)-2H-tetrazol-5- yOpicolmamide (prepared as described in Example 364) (160 mg, 0 34 mmol) was dissolved in dichloromethane (5 0 mL) Triethylamine (95 μL, 0 68 mmol), 4-(dιmethylamιno)pyrιdιne (8 4 mg, 0 07 mmol), and acetyl chloride (29 μL, 0 41 mmol) was added The mixture was allowed to stir at room temperature for 20 hours The reaction mixture was diluted with dichloromethane (50 mL) and washed with saturated aq sodium bicarbonate solution (20 mL) The organic layer was dried over sodium sulfate and concentrated The crude product was purified by silica column chromatography (CH2CI2/methanol, 100/1 , 100/2) Fractions were concentrated to afford the title compound as a foaming solid (123 mg, 77%) MS (ES+) m/z 482 (M+H) 1H NMR (400 MHz, DMSO-cfe) δ ppm 9 26 (t, J=Q 4 Hz, 1 H), 8 40 (s, 1 H), 8 06 (d, J= 1 2 Hz, 1 H), 7 15 (dd, J=8 5, 1 9 Hz, 1 H)1 7 1 1 (dd, J=11 6, 8 4 Hz, 1 H), 6 87 (ddd, J=8 2, 4 3, 1 9 Hz, 1 H), 4 85 - 4 66 (m, 2 H), 4 47 (d, J=6 4 Hz, 2 H), 4 1 1 (dd, J=12 6, 3 5 Hz, 0 5 H), 4 01 (d, J=13 4 Hz, 0 5 H)1 3 79 <s, 3 H), 3 73 (d, J=14 0 Hz, 0 5 H)1 3 64 (d, J=12 8 Hz, 0 5 H), 3 00 (dd, J= 13 2, 10 1 Hz, 1 H), 2 76 - 2 67 (m, 0 5 H), 2 65 (s, 3 H), 2 59 (dd, J=12 7, 10 4 Hz, 0 5 H), 2 26 - 2 19 (m, 0 5 H), 2 13 - 2 05 (m, 0 5 H), 1 95 (s, 1 5 H), 1 93 (s, 1 5 H), 1 75 - 1 54 (m, 2 H), 1 46 - 1 19 (m, 2 H)
Example 367
/V-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((/:?)-piperidin-3-ylmethyl)-2H-tetrazol-5- yl)picolinamide
Step 1 Preparation of (3f?)-/ert-butyl 3-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn- 4-yl)-2/-/-tetrazol-2-yl)methyl)pιperιdιne-1-carboxylate
Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((/rans)-4- amιnocyclohexy!)methyl)-2/-/-tetrazol-5-yl)-6-methy!pιcolιnamιde, Example 170) (342 mg, 1 0 mmol), polymer supported triphenylphosphine (698 mg, 1 5 mmol), and (/?)-1-Boc-3- (hydroxymethyl)pιperιdιne (258 mg, 1 2 mmol) were suspended in tetrahydrofuran (16 mL) Di-tert- butyl azodicarboxylate (345 mg, 1 5 mmol) was added The mixture was allowed to stir for 18 hours The reaction mixture was filtered and the resin washed with tetrahydrofuran (20 mL) The filtrate was concentrated The crude product was purified by silica column chromatography (heptane/EtOAc, 2/1 , 1/1 ) Fractions containing the product were concentrated to afford the title compound as a foaming solid (472 mg, 87%) MS (ES+) m/z 540 (M+H) 1H NMR (400 MHz, DMSOd6) 6 ppm 9 26 (t, J=6 4 Hz, 1 H), 8 40 (d, J=O 8 Hz, 1 H), 8 07 (d, J= 1 1 Hz, 1 H)1 7 15 (dd, J=8 5, 1 9 Hz, 1 H), 7 1 1 (dd, J=11 5, 8 3 Hz, 1 H), 6 87 (ddd, J=8 3, 4 4, 1 9 Hz, 1 H), 4 77 - 4 66 (m, 2 H), 4 47 (d, J=6 0 Hz, 2 H), 3 79 (s, 3 H), 3 70 - 3 62 (m, 2 H), 2 81 (br s , 1 H), 2 65 (s, 3 H), 2 12 (br s , 1 H), 1 74 - 1 56 (m, 2 H), 1 27 (br s , 12 H) Step 2 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((R)-pιperιdιn-3-ylmethyl)-2H- tetrazol-5-vDpιcolιnamιde
(3R)-tert-Butyl 3-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol-2-yl)methyl)pιperιdιne-1 -carboxylate (465 mg, 0 67 mmol) was dissolved in dichloromethane (5 0 mL) Trifluoroacetic acid (1 0 ml_, 13 0 mmol) was added and the solution was shaken for 2 hours at room temperature The solvent was removed in vacuo and the residue was dissolved in dichloromethane (100 mL) The mixture was washed with 1 N NaOH solution (2 x 10 mL) The organic layer was dried over sodium sulfate and concentrated to afford the title compound as an oil (362 mg, 96%) MS (ES+) m/z 440 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 26 (t, J=6 4 Hz, 1 H), 8 40 (d, J=O 8 Hz, 1 H), 8 05 (d, J=1 1 Hz, 1 H), 7 15 (dd, J=8 5, 1 9 Hz, 1 H), 7 11 (dd, J=11 7, 8 3 Hz, 1 H), 6 87 (ddd, J=8 2, 4 4, 2 0 Hz, 1 H), 4 73 - 4 62 (m, 2 H), 4 47 (d, J=6 4 Hz, 2 H), 3 79 (s, 3 H), 2 80 - 2 74 (m, 2 H), 2 65 (s, 3 H), 2 46 - 2 39 (m, 1 H), 2 33 (dd, J= 1 1 9, 9 5 Hz, 1 H), 2 10 (br s , 1 H), 1 66 - 1 51 (m, 2 H), 1 39 - 1 26 (m, 1 H), 1 15 (qd, J=10 6, 3 5 Hz, 1 H)
Example 368
W-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-(((S)-1 -(methylsulfonyl)piperidin-3-yl)methyl)-2W- tetrazol-5-yl)picolinamide
Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((R)-pιperιdιn-3-ylmethyl)-2W-tetrazol-5- yl)pιcolιnamιde (prepared as described in Example 367) (175 mg, 0 36 mmol) was dissolved in dichloromethane (5 mL) Triethylamine (101 μL, 0 73 mmol) and methanesulfonyl chloride (42 μL, 0 54 mmol) were added The reaction mixture was shaken at room temperature for 1 hour and then diluted with dichloromethane (50 mL) The mixture was washed with saturated aq sodium bicarbonate (10 mL) The organic layer was dried over sodium sulfate and concentrated The crude product was purified by silica column chromatography (CH2CI2/methanol, 100/1 , 100/2, 100/4) The resulting impure product was further purified by silica column chromatography (heptane/EtOAc, 1/1 , 1/2, 1/4) to afford the title compound as a foaming solid (99 mg, 53%) MS (ES+) m/z 518 (M+H) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 9 24 (t, J=6 2 Hz, 1 H), 8 44 (s, 1 H), 8 08 (s, 1 H), 7 18 (d, J=8 4 Hz, 1 H), 7 13 (dd, J= 1 1 5, 8 2 Hz, 1 H), 6 94 - 6 88 (m, 1 H), 4 87 - 4 74 (m, 2 H), 4 51 (d, J=6 2 Hz, 2 H), 3 82 (s, 3 H), 3 49 - 3 37 (m, 2 H), 2 85 (s, 3 H), 2 84 - 2 76 (m, 1 H), 2 75 - 2 69 (m, 1 H), 2 68 (s, 3 H), 2 36 (br s , 1 H), 1 81 - 1 68 (m, 2 H), 1 58 - 1 47 (m, 1 H), 1 30 - 1 18 (m, 1 H) Example 369
Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((R)-1-acetylpiperidin-3-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((R)-pιperιdιn-3-ylmethyl)-2H-tetrazol-5- yl)pιcolιnamιde (prepared as described in Example 367) (175 mg, 0 36 mmol) was dissolved in dichloromethane (5 0 mL) Tπethylamine (73 μL, 0 73 mmol), 4-(dιmethylamιno)pyrιdιne (8 9 mg, 0 06 mmol), and acetyl chloride (31 μL, 0 36 mmol) was added The mixture was allowed to stir at room temperature for 20 hours The reaction mixture was diluted with dichloromethane (50 mL) and washed with saturated aq sodium bicarbonate solution (20 mL) The organic layer was dried over sodium sulfate and concentrated The crude product was purified by silica column chromatography (CH2CI2/methanol, 100/1 , 100/2) to afford the title compound as a foaming solid (134 mg, 79%) MS (ES+) m/z 482 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 24 (t, J=Q 2 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H), 7 18 (d, J=8 4 Hz, 1 H), 7 13 (dd, J=11 7, 8 4 Hz, 1 H), 6 93 - 6 88 (m, 1 H), 4 88 - 4 69 (m, 2 H), 4 50 (d, J=Q 2 Hz, 2 H), 4 17 - 4 12 (m, 0 5 H), 4 06 - 4 00 (m, 0 5 H), 3 82 (s, 3 H), 3 79 - 3 73 (m, 0 5 H), 3 70 - 3 64 (m, 0 5 H), 3 04 (t, .7=12 8 Hz, 1 H), 2 80 - 2 72 (m, 0 5 H), 2 68 (s, 3 H), 2 67 - 2 60 (m, 0 5 H), 2 30 - 2 22 (m, 0 5 H), 2 18 - 2 09 (m, 0 5 H), 1 98 (s, 1 5 H), 1 96 (s, 1 5 H), 1 77 - 1 59 (m, 2 H), 1 47 - 1 24 (m, 2 H)
Example 370 W-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((/?)-pyrrolidin-3-ylmethyl)-2W-tetrazol-5- yl)picolinamide
Step 1 Preparation of (3/?)-tert-butyl 3-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyridin- 4-yl)-2/-/-tetrazol-2-yl)methyl)pyrrolιdιne-1-carboxylate
A mixture of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared s described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((frans)-4- amιnocyclohexyl)methyl)-2/-/-tetrazo!-5-yl)-6-methylpιcolιnamιde, Example 170) (0 45 g, 1 3 mmol), (R)-tert-butyl 3-(hydroxymethyl) pyrrolιdιne-1 -carboxylate (O 27 g, 1 3 mmol), and polymer supported- tnphenylphosphine (0 73 g, 1 6 mmol) in anhydrous tetrahydrofuran (15 mL) was cooled to 0 0C in an ice bath for 15 mm and then di-tert-butyl azodicarboxylate (0 45 g, 2 0 mmol) was added The mixture was allowed to warm to room temperature while stirring over 15 hours The reaction mixture was filtered and the filtrate was concentrated The residue was purified by silica column chromatography (0-50%, ethyl acetate/heptane) to afford the title compound
Step 2 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((ff)-pyrrolιdιn-3-ylmethyl)-2/-/- tetrazol-5-yl)pιcolιnamιde
Trifluoroacetic acid (3 mL) was added to a solution of (3R)-tert-butyl 3-((5-(2-((4-fluoro-3- methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)pyrrolιdιne-1 -carboxylate in dichloromethane (5 mL) After 30 mm at ambient temperature, the reaction mixture was neutralized to pH 7 with 2 5 N aqueous sodium hydroxide The mixture was extracted with ethyl acetate (3 x 10 mL) The combined organic layers were washed with water (2 x 10 mL) followed by brine (10 mL), dried over sodium sulfate, and concentrated to afford the title compound (0 35g, 63%) LC/MS (5-100% CH3CN/H2O, 5 mm) 2 05 mm, m/z 426 (M+H)
Example 371
/V-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl)methyl)-2H- tetrazol-5-yl)picolinamide
Triethylamine (0 037 mL) and methane sulfonyl chloride (0 028 mg, 0 21 mmol) were added to a solution of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((R)-pyrrolιdιn-3-ylmethyl)-2/-/-tetrazol-5- y!)pιcolιnamιde (prepared as described in Example 370) (0 075 g, 0 18 mmol) in dichloromethane (3 mL) The mixture was stirred at ambient temperature for 4 hours The reaction mixture was concentrated in vacuo and the residue was purified via reverse phase preparative HPLC to afford the title compound as an oil (15 mg, 17%) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 24 (br s , 1 H), 8 44 (s, 1 H), 8 08 (s, 1 H), 7 10 - 7 21 (m, 2 H), 6 91 (br s , 1 H), 4 90 (d, J=I 0 Hz, 2 H), 4 51 (d, J=5 9 Hz, 2 H), 3 82 (s, 3 H), 3 46 (br s , 1 H), 3 07 - 3 17 (m, 1 H), 2 91 (s, 5 H), 2 68 (s, 4 H), 2 05 (br s , 1 H), 1 81 (d, J=7 7 Hz, 1 H) Example 372
W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((R)-1-acetylpyrrolidin-3-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Triethylamine (0 037 mL) and acetyl chloride (0 017 mg, 0 21 mmol) were added to a solution of /V-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((f?)-pyrrolιdιn-3-ylmethyl)-2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 370) (0 075 g, 0 18 mmol) in dichloromethane (3 mL) The mixture was stirred at ambient temperature for 4 hours The reaction mixture was concentrated in vacuo and the residue was purified via reverse phase preparative HPLC to afford the title compound as an oil (15 mg, 18%) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 24 (br s , 1 H), 8 44 (s, 1 H), 8 08 (s, 1 H), 7 14 (d, J=2 9 Hz, 1 H), 7 10 - 7 21 (m, 1 H), 6 91 (br s , 1 H), 4 88 (t, 2 H), 4 51 (d, J=6 2 Hz, 2 H), 3 82 (s, 3 H), 3 42 - 3 51 (m, 3 H), 3 12 - 3 18 (m, 1 H), 2 83 - 2 99 (m, 1 H), 2 68 (s, 3 H), 1 97 - 2 13 (m, 1 H), 1 92 (br s , 3 H), 1 64 - 1 86 (m, 1 H)
Example 373 2-((/?)-3-((5-(2-((4-Fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)pyrrolidin-1 -yl)-2-oxoethyl acetate
Triethylamine (0 037 mL) and acetoxy acetyl chloride (0 029 mg, 0 21 mmol) were added to a solution of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((f?)-pyrrolιdιn-3-ylmethyl)-2H-tetrazol-5- yl)pιcolιnamιde (prepared as described in Example 370) (0 075 g, 0 18 mmol) in dichloromethane (3 mL) The mixture was stirred at ambient temperature for 4 hours The reaction mixture was concentrated in vacuo and the residue was purified by reverse phase preparative HPLC to afford the title compound
Example 374 Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((R)-1-(2-hydroxyacetyl)pyrrolidin-3-yl)methyl)-2H-tetrazol-
5-yl)-6-methylpicolinamide
A mixture of 2-((R)-3-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2AY- tetrazol-2-yl)methyl)pyrrolιdιn-1 -yl)-2-oxoethyl acetate (prepared as described in Example 373) and 2 5 N aqueous sodium hydroxide (1 mL) in acetonitrile (3 mL) was stirred for 2 hours at room temperature The acetonitrile was removed in vacuo and the aqueous residue was acidified to pH 5 with 10% aqueous hydrochloric acid The resulting solid was filtered and dried to afford 9 mg (10%) of the title compound as a white solid 1H NMR (400 MHz, DMSO-d6) δ ppm 9 24 (br s , 1 H), 8 44 (s, 1 H), 8 08 (s, 1 H), 7 17 (br s , 1 H), 7 1 1 (s, 1 H), 6 91 (br s , 1 H), 4 89 (d, J=6 2 Hz, 2 H), 4 51 (d, J=6 2 Hz, 3 H), 3 97 (br s , 2 H), 3 82 (s, 3 H), 3 57 (br s , 2 H), 3 37 (br s , 2 H), 2 82 - 3 07 (m, 1 H), 2 68 (s, 3 H), 1 98 - 2 12 (m, 1 H)
Example 375 rac-W-(4-Fluoro-3-methoxybenzyl)-4-(2-((1-benzyl-5-oxopyrrolidin-3-yl)methyl)-2H-tetrazol-5-yl)-
6-methylpicolinamide
A mixture of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((frans)-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 170) (0 17 g, 0 48 mmol), 1- benzyl-4-(hydroxymethy!)pyrrolιdιn-2-one (0 99 g, 0 48 mmol) (Org Lett 1999, 7, 799-801 ), and polymer supported-tπphenylphosphine (0 32 g, 0 72 mmol) in anhydrous tetrahydrofuran (10 mL) was cooled to 00C in an ice bath for 15 minutes Di-tert-butyl azodicarboxylate (0 13 g, 0 58 mmol) was added and the reaction was allowed to warm to room temperature over 15 hours The reaction mixture was filtered and the filtrate was concentrated The residue was purified by reverse phase preparative HPLC (5-95% acetonitrile/water) to afford the title compound as a beige oil (0 18 g, 71 %) 1H NMR (400 MHz, DMSOd6) δ ppm 9 19 - 9 29 (m, 1 H), 8 41 (s, 1 H), 8 04 (s, 1 H), 7 32 (t, J=I 69 Hz, 2 H), 7 20 (d, J=6 95 Hz, 2 H), 7 17 - 7 27 (m, 1 H), 7 14 (dd, J=11 71 , 8 42 Hz, 1 H), 6 91 (d,
J=6 22 Hz, 1 H), 4 89 (d, J=Q 95 Hz, 2 H), 4 51 (d, J=6 22 Hz, 2 H)1 4 35 (s, 2 H), 3 82 (s, 3 H), 3 40 (t, J=8 97 Hz, 1 H), 3 13 - 3 19 (m, 1 H), 2 67 (s, 3 H), 2 57 (d, J=I 69 Hz, 1 H), 2 35 (dd, J=16 65, 6 77 Hz, 1 H), 1 37 (d, J=15 37 Hz, 1 H), 1 24 (dd, J=12 63, 5 67 Hz, 1 H) Example 376 yV-(3-(2-Hydroxyethoxy)benzyl)-6-methyl-4-(2-((1-(methylsulfonyl)piperidin-4-yl)methyl)-2H- tetrazol-5-yl)picolinamide
Step 1 Preparation of methyl 6-methyl-4-(2-(pιperιdιn-4-ylmethyl)-2/-/-tetrazol-5-yl)pιcolιnate trifluoroacetate
Methyl 6-methyl-4-(2H-tetrazol-5-yl)pιcolιnate (prepared as described in step 4 of the synthesis of /V-(3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide, Example 153) (1 99 g, 9 08mmol) and tert-butyl 4-(hydroxymethyl)pιperιdιne-1- carboxylate (1 95 g, 9 08 mmol) were suspended in anhydrous tetrahydrofuran (50 mL) along with polymer supported-tπphenylphosphine (6 05 g, 13 6 mmol) The mixture was cooled to 0 0C in an ice bath for 15 minutes and then di-tert-butyl azodicarboxylate (2 51 g, 10 9 mmol) was added The mixture was allowed to warm to room temperature while stirring over 15 hours The reaction mixture was filtered and the filtrate was concentrated The residue was purified on silica (70 g, 0-50 % ethyl acetate/heptane) The resulting intermediate was dissolved in dichloromethane (15 mL) and stirred with trifluoroacetic acid (5 0 mL) for 1 hour at room temperature The reaction mixture was concentrate to 1/3 volume and tert-butyl methyl ether (5 mL) was slowly added to cause precipitation The resulting solids were collected by filtration, washed with diethyl ether (3 x 5 mL) and dried to afford the title compound as a beige solid (3 3 g, 84%) MS (ES+) m/z 317 (M+H) 1H NMR (400
MHz, DMSO-c/6) δ ppm 8 72 (br s , 1 H), 8 37 (s, 1 H), 8 09 (s, 1 H)1 4 78 (d, J=6 7 Hz, 2 H), 3 90 (s, 3 H), 3 27 (d, J=12 4 Hz, 2 H), 2 87 (d, J=10 8 Hz, 2 H), 2 63 (s, 3 H), 2 22 - 2 41 (m, 1 H), 1 66 - 1 82 (m, 2 H), 1 30 - 1 57 (m, 2 H)
Step 2 Preparation of methyl 6-methyl-4-(2-((1-(methylsulfonyl)pιperιdιn-4-yl)methyl)-2H-tetrazol-5- vDpicolinate
Triethylamine (0 34 mL, 2 4 mmol) was added to a solution of methyl 6-methyl-4-(2-(pιperιdιn- 4-ylmethyl)-2H-tetrazol-5-yl)pιcolιnate trifluoroacetate (0 50 g, 1 2 mmol) in 2-methyltetrahydrofuran (5 mL) A solution of methane sulfonyl chloride (0 16 mL) in 2-methyltetrahydrofuran (2 mL) was added and the mixture was allowed to stir at room temperature for 2 hours The reaction mixture was concentrated and the residue was purified by silica gel chromatography (0-50 % ethyl acetate/heptane) to afford the title compound (0 46 g, 100%) MS (ES+) m/z 395 (M+H)
Step 3 Preparation of 6-methyl-4-(2-((1 -(methylsulfonylbiperidin-4-yl)methyl)-2H-tetrazol-5-yl)picolinic acid
An aqueous sodium hydroxide solution (2 5 N, 2 5 mL) was added to a solution of methyl 6- methyl-4-(2-((1-(methylsulfonyl)pιperιdιn-4-yl)methyl)-2H-tetrazol-5-yl)pιcolιnate (0 46g, 1 2 mmol) in tetrahydrofuran (5 mL) The mixture was stirred at room temperature for 3 hours The tetrahydrofuran was removed in vacuo and the aqueous residue was acidified with concentrated hydrochloric acid to pH 6 The resulting precipitate was filtered, washed with water (3 x 10 mL), and then dried to afford the title compound (0 41 g, 93%) MS (ES+) m/z 381 (M+H)
Step 4 Preparation of /V-(3-(2-hvdroxyethoxy)benzyl)-6-methyl-4-('2-(('1-('methylsulfonvπpιperιdιn-4- yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde
1-Hydroxybenzatπazole (22 mg, 0 16 mmol) was added to a solution of 6-methyl-4-(2-((1- (methylsulfonyl)pιperιdιn-4-yl)methyl)-2H-tetrazol-5-yl)pιcolιnιc acid ( 0 050 g, 0 13 mmol) in 2-methyl tetrahydrofuran (5 mL) After 15 minutes, 2-(3-(amιnomethyl)phenoxy) ethanol (27 mg, 0 16 mmol) and polymer supported carbodiimide (0 16 g, 0 20 mmol) were added The mixture was stirred for 18 hours at room temperature The reaction mixture was filtered and the filtrate was concentrated The residue was purified via reverse phase preparative HPLC to afford the title compound (25 mg, 36%) 1H NMR (400 MHz, DMSOd6) δ ppm 9 20 (t, J=Q 6 Hz1 1 H), 8 41 (s, 1 H), 8 06 (s, 1 H), 7 20 (t, J=Q 1 Hz, 1 H), 6 85 - 6 96 (m, 2 H), 6 79 (d, J=I 3 Hz, 1 H), 4 76 (d, J=I 3 Hz, 2 H), 4 49 (d, J=6 6 Hz, 2 H), 3 93 (t, J=5 1 Hz, 2 H), 3 67 (q, J=5 1 Hz, 2 H), 3 55 (d, J=11 7 Hz, 2 H), 2 81 (s, 3 H), 2 59 - 2 77 (m, 5 H), 2 07 - 2 27 (m, 1 H), 1 67 (d, J=12 4 Hz1 2 H), 1 25 - 1 46 (m, 2 H)
Example 377
W-(3-Ethoxybenzyl)-6-methyl-4-(2-((1 -(methylsulfonyl)piperidin-4-yl)methyl)-2H-tetrazol-5- yOpicotinamide
The title compound was prepared in a similar manner to Λ/-(3-(2-hydroxyethoxy)benzyl)-6- methy!-4-(2-((1 -(methylsulfonyl)pιperιdιn-4-y!)methyl)-2H-tetrazol-5-yl)pιcolιnamιde (Example 376, step 4) by reaction with (3-ethoxyphenyl)methanamιne (prepared as described in step 2 of the synthesis of W-(3-ethoxybenzyl)-6-methyl-4-(2-(((frans)-4-(methylsulfonamido)cyclohexyl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde, Example 180) to afford 28 mg (42%) 1H NMR (400 MHz, DMSOd6) δ ppm 9 19 (t, J=Q 2 Hz, 1 H), 8 41 (s, 1 H), 8 06 (s, 1 H), 7 20 (t, J=Q 1 Hz, 1 H), 6 88 (d, J=5 9 Hz, 2 H), 6 78 (d, J=Q 8 Hz, 1 H), 4 76 (d, J=I 3 Hz, 2 H), 4 48 (d, J=Q 6 Hz, 2 H), 3 97 (q, J=Q 8 Hz, 2 H), 3 55 (d, J=1 1 7 Hz, 2 H), 2 81 (s, 3 H), 2 58 - 2 77 (m, 5 H), 2 10 - 2 28 (m, 1 H), 1 67 (d, J=1 1 7 Hz, 2 H), 1 31 - 1 44 (m, 2 H), 1 28 (t, J=I 0 Hz, 3 H)
Example 378
/V-(4-Fluoro-3-methylbenzyl)-6-methyl-4-(2-((1-(methylsulfonyl)piperidin-4-yl)methyl)-2H- tetrazol-5-yl)picolinamide
The title compound was prepared in a similar manner to Λ/-(3-(2-hydroxyethoxy)benzyl)-6- methyl-4-(2-((1-(methylsulfonyl)pιperιdιn-4-yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde (Example 376, step 4) by reaction with (4-fluoro-3-methylphenyl)methanamιne to afford 25 mg (39%) 1H NMR (400 MHz, DMSO-cfe) δ ppm 9 21 (t, J=Q 2 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 23 (d, J=Q 6 Hz, 1 H), 7 12 - 7 20 (m, 1 H), 6 99 - 7 10 (m, 1 H), 4 76 (d, J=6 6 Hz, 2 H), 4 46 (d, J=Q 6 Hz, 2 H), 3 55 (d, J=11 7 Hz, 2 H), 2 81 (s, 3 H), 2 59 - 2 75 (m, 5 H), 2 07 - 2 27 (m, 4 H), 1 67 (d, J=13 2 Hz, 2 H), 1 26 - 1 45 (m, 2 H)
Example 379 Λ/-(3-Mβthoxybenzyl)-6-methyl-4-(2-(piperidin-4-ylmethyl)-2H-tetrazol-5-yl)picolinamide
Step 1 Preparation of tert-butyl 4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/- tetrazol-2-yl)methyl)pιperιdιne-1 -carboxylate
A mixture of Λ/-(3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of A/-(3-methoxybenzyl)-4-(2-(((<rans)-4-amιnocyclohexyl)methyl)- 2H-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (1 00 g, 3 10 mmol), tert-butyl 4-(hydroxymethyl) pιperιdιne-1-carboxylate (0 81 g, 3 8 mmol), and polymer supported-tnphenylphosphine (2 90 g, 6 21 mmol) were suspended in anhydrous tetrahydrofuran (32 mL) The mixture was cooled to 0 0C in an ice bath for 15 minutes and then di-tert-butyl azodicarboxylate (1 1 1 g, 4 82 mmol) was added The mixture was allowed to warm to room temperature while stirring over 15 hours The reaction mixture was filtered and the filtrate was concentrated The residue was purified by silica gel chromatography (20 g, 0-50% gradient ethyl acetate/heptane) to afford the title compound as a white solid (1 52 g, 94%) LC/MS (5-100% CH3CN/H2O, 8 mm) 6 24 mm, m/z 544 (M+Na)
Step 2 Preparation of Λ/-(3-methoxybenzyl)-6-methyl-4-(2-(pιperιdιn-4-ylmethyl)-2/-/-tetrazol-5- yQpicolinamide
Trifluoroacetic acid (6 mL) was added to a solution of tert-butyl 4-((5-(2-((3-methoxybenzyl)- carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)pιperιdιne-1-carboxylate (1 51 g, 2 89 mmol) in dichloromethane (20 mL) The reaction mixture was stirred for 1 hour at room temperature and was then concentrated The residue was purified by reverse phase preparative HPLC to afford the title compound as the tπfluoroacetate salt (0 83 g, 56%) LC/MS (5-100% CH3CN/H2O, 8 mm) 5 33 mm, m/z 422 (M+H)
Example 380
Λ/-(3-Methoxybenzyl)-4-(2-((1 -(2-hydroxy-2-methylpropanoyl)piperidin-4-yl)methyl)-2H-tetrazol- 5-yl)-6-methylpicolinamide
Triethylamine (31 mg, 0 31 mmol) and 1 -chloro-2-methyl-1-oxopropan-2-yl acetate (O 023 g, O 14 mmol) were added to a solution of Λ/-(3-methoxybenzyl)-6-methyl-4-(2-(pιperιdιn-4-ylmethyl)-2/-/- tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 379) (75 mg, 0 14 mmol) in N1N- dimethylacetamide (2 mL), and the mixture was stirred for 1 hour at room temperature The reaction mixture was diluted with water (2 mL) and extracted with ethyl acetate (3 x-5 mL) The organic layer was washed with water (3 x 5 mL) followed by brine (5 mL), dried over anhydrous sodium sulfate, and concentrated The residue was purified by silica gel chromatography (10 g, 0-50% ethyl acetate/heptane) The intermediate was dissolved in a mixture of methanol/water (4 mL, 3/1 )and potassium carbonate (41 mg, 0 30 mmol) was added The mixture was stirred for 10 hours at 6O0C The methanol was removed in vacuo and the aqueous residue was acidified with a 10% aqueous solution of hydrochloric acid This mixture was extracted with ethyl acetate (3 x 5 mL) The combined organic layers were washed with water (5 mL) followed by brine (5 mL), dried over anhydrous sodium sulfate, and concentrated The residue that was purified by reverse phase preparative HPLC to afford the title compound (21 mg, 30%) MS (ES+) m/z 508 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 19 (t, J=Q 2 Hz, 1 H), 8 41 (s, 1 H), 8 06 (s, 1 H), 7 22 (t, J=Q 1 Hz, 1 H), 6 90 (br s , 2 H), 6 80 (d, J=8 1 Hz, 1 H), 5 26 (s, 1 H), 4 71 (d, J=I 3 Hz, 2 H), 4 49 (d, J=Q 6 Hz, 2 H), 3 71 (s, 3 H), 2 65 (s, 3 H), 2 30 (d, J=2 9 Hz, 1 H), 1 58 (d, J=13 2 Hz, 4 H), 1 22 - 1 33 (m, 6 H), 1 19 (br s , 4 H)
Example 381 /V-(3-Methoxybenzyl)-4-(2-((1-(3-aminopropanoyl)piperidin-4-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
1 -Hydroxybenzotrιazole (3 2 mg, 0 024 mmol) was added to a solution of 3-(tert- butoxycarbonyl)propanoιc acid (27 2 mg, 0 144 mmol) in Λ/,Λ/-dιmethylformamιde (2 mL) Carbodiimide resin (138 mg, 0 18 mmol, 1 30 mmol/g loading), Λ/-(3-methoxybenzyl)-6-methyl-4-(2- (pιperιdιn-4-ylmethyl)-2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 379) (50 6 mg, 0 120 mmol), and Λ/-methylmorpholιne (0 066 mL, 0 60 mmol) were added with dichloromethane (2 mL), and the mixture was agitated overnight at room temperature The reaction mixture was filtered and the resin was washed with Λ/,W-dιmethylformamιde followed by dichloromethane The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm ) The intermediate was added to a 1 1 mixture of trifluoroacetic acid and dichloromethane and stirred for 1 hour The reaction mixture was concentrated The residue was dissolved in dichloromethane, neutralized with MP-carbonate resin, and concentrated to afford the title compound (10 mg, 17%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 572 mm , m/z 493 (M+H)
Example 382
N-(3-Methoxybenzyl)-4-(2-((1-(2-aminoacetyl)piperidin-4-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-4-(2-((1-(3- amιnopropanoyl)pιperιdιn-4-yl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 381 ) by reaction with 2-(tert-butoxycarbonyl)acetιc acid to afford 10 mg (17%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 543 mm , m/z 479 (M+H)
Example 383 N-(3-Methoxybenzyl)-4-(2-((1-acetylpiperidin-4-yl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide
Acetic anhydride (0 034 ml_, 0 356 mmol) and 4-(dιmethy!amιno)pyπdιne Si bound (862 0 mg, 0 595 mmol, 0 69 mmol/g loading) were added to a solution of Λ/-(3-methoxybenzyl)-6-methyl-4-(2- (pιperιdιn-4-ylmethyl)-2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 379) (50 2 mg, 0 119 mmol) in dichloromethane (2 mL), and the mixture was agitated overnight at room temperature The reaction mixture was filtered and the resin was washed with Λ/,W-dιmethylformamιde The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm ) to afford the title compound as a solid (24 5 mg, 44%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 2 959 mm , m/z 464 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 0 98 - 1 35 (m, 4 H), 1 57 (m, 2 H), 1 94 (s, 3 H), 2 16 - 2 37 (m, 1 H), 2 44 - 2 57 (m, 2 H), 2 65 (s, 3 H), 3 71 (s, 3 H), 4 49 (d, J=6 6 Hz, 2 H), 4 71 (d, J=I 3 Hz, 2 H), 6 80 (m, 1 H), 6 86 - 6 95 (m, 2 H), 7 14 - 7 28 (m, 1 H), 8 05 (s, 1 H), 8 41 (s, 1 H), 9 1 1 - 9 27 (m, 1 H)
Example 384
Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-((1-(methylsulfonyl)piperidin-4-yl)methyl)-2H-tetrazol-5- yl)picolinamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-4-(2-((1 -acetyl- pιperιdιn-4-yl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 383) by reaction with methane sulfonylchloride to afford 32 5 mg (55%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 154 mm , m/z 500 (M+H) 1H NMR (400 MHz1 DMSO-cfe) δ ppm 1 24 - 1 48 (m, 4 H), 1 61 - 1 72 (m, 2 H), 2 07 - 2 27 (m, 1 H), 2 65 (s, 3 H), 2 81 (s, 3 H), 3 47 - 3 60 (m, 2 H), 3 71 (s, 3 H), 4 49 (d, J=6 6 Hz, 2 H), 4 76 (d, J=I 3 Hz, 2 H), 6 73 - 6 83 (m, 1 H), 6 86 - 6 95 (m, 2 H), 7 15 - 7 27 (m, 1 H), 8 05 (S, 1 H), 8 41 (s, 1 H), 9 19 (s, 1 H)
Example 385 N-(3-Methoxybenzyl)-4-(2-((1 -isobutyrylpiperidin-4-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
The title compound was prepared in a similar manner to /V-(3-methoxybenzyl)-4-(2-((1 -acetyl- pιperιdιn-4-yl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde (Example 383) by reaction with isobutyryl chloride to afford 37 2 mg (63%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm )
3 296 mm , m/z 492 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 1 00 - 1 37 (m, 6 H), 1 47 - 1 72 (m, 2 H), 2 28 (s, 1 H), 2 65 (s, 3 H)1 2 74 - 2 90 (m, 1 H), 2 90 - 3 10 (m, 2 H)1 3 71 (s, 3 H)1 4 49 (d, J=6 6 Hz, 2 H)1 4 72 (d, J=I 3 Hz, 2 H), 6 80 (s, 1 H), 6 86 - 6 97 (m, 2 H), 7 22 (s, 1 H), 8 05 (s, 1 H), 8 41 (S1 1 H), 9 19 (s, 1 H)
Example 386
W-(3-Methoxybenzyl)-6-methyl-4-(2-((1-(methylcarbamoyl)piperidin-4-yl)methyl)-2H-tetrazol-5- yl)picolinamide
Methylisocyanate (4M solution in dichloromethane, 1 mL) and 4-(dιmethy!amιno)pyrιdιne Si bound (862 0 mg, 0 595 mmol, 0 69 mmol/g loading) were added to a solution of Λ/-(3-methoxybenzyl)-6- methyl-4-(2-(pιperιdιn-4-ylmethyl)-2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 379) in dichloromethane (1 m!_), and the mixture was agitated overnight at room temperature The reaction mixture was filtered and the resin was washed with Λ/,Λ/-dιmethylformamιde The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm ) to afford the title compound (35 5 mg, 62%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN , 1 5 mm ) 2 887 mm , m/z 479 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 01 - 1 24 (m, 4 H), 1 44 - 1 55 (m, 2 H), 2 20 (s, 1 H), 2 50 - 2 54 (m, 3 H), 2 56 - 2 63 (m, 2 H), 2 65 (s, 3 H), 3 71 (s, 3 H), 4 49 (d, J=6 6 Hz, 2 H), 4 70 (d, J=6 6 Hz, 2 H), 6 30 (s, 1 H), 6 80 (m, 1 H), 6 85 - 6 95 (m, 2 H), 7 22 (s, Hz, 1 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 09 - 9 26 (m, 1 H)
Example 387 W-(3-Chloro-4-fluorobenzyl)-6-methyl-4-(2-(piperidin-4-ylmethyl)-2H-tetrazol-5-yl)picolinamide
Step 1 Preparation of 4-(2-((1-(teff-butoxycarbonyl)piperιdιn-4-yl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinic acid
A flask was charged with methyl 6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)- 2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (1 0 g, 4 6 mmol), tert-butyl 4-(hydroxymethyl) pιperιdιne-1 -carboxylate (2 0 g, 9 1 mmol), polymer supported triphenylphosphine resin (4 2 g, 9 1 mmol, 2 15 mmol/g loading) and tetrahydrofuran (60 mL) The mixture was cooled in an ice bath and di-tert-butylazodicarbxylate (2 1 g, 9 1 mmol) was added The mixture was stirred for 30 minutes and then allowed to warm to room temperature over 18 hours The reaction mixture was filtered and the resin was washed with methanol The filtrate was concentrated and the residue was dissolved in a mixture of tetrahydrofuran/water (25 ml_/5 mL) LiOH (660 mg, 28 0 mmol) was added and the resulting mixture was stirred at room temperature over 3 days The tetrahydrofuran was removed in vacuo and the aqueous residue was treated with 4N hydrochloric acid carefully until pH 5-6 The mixture was extracted with dichloromethane The organic layer was dried over magnesium sulfate and concentrated The residue was purified by reverse phase preparative HPLC and then recrystallized from methanol/water to afford the title compound as a white solid (1 21 g, 65%) MS (ES+) m/z 508 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 1 12 - 1 24 (m, 2 H), 1 34 - 1 43 (m, 1 1 H), 1 55 (m, 2 H), 2 14 - 2 28 (m, 1 H), 2 65 (s, 3 H), 3 89 - 3 98 (m, 2 H)1 4 73 (d, J=6 98 Hz, 2 H), 8 09 (d, J= 1 07 Hz, 1 H), 8 39 (s, 1 H), 8 55 - 8 64 (m, 1 H) Step 2 Preparation of fert-butyl 4-((5-(2-((3-chloro-4-fluorobenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H- tetrazol-2-yl)methyl)pιperιdιne-1-carboxylate
2-(1H-Benzotrιazo!e-1-yl)-1 ,1 ,3,3-tetramethyluronιum hexafluorophosphate (141 mg, 0 37 mmol) was added to a mixture of 4-(2-((1-(tert-butoxycarbonyl)pιperιdιn-4-yl)methyl)-2H-tetrazol-5-yl)- 6-methylpιcolιnιc acid (100 mg, 0 25 mmol), (3-chloro-4-fluorophenyl)methanamιne (47 mg, 0 30 mmol), and triethylamine (0 05 mL, 0 37 mmol) in /V,/V-dιmethylformamιde (2 mL), and the mixture was stirred at room temperature for 18 hours The reaction mixture was purified by reverse phase preparative HPLC The product was dissolved in methanol, passed through a carbonate cartridge, and concentrated to afford the title compound as a solid (59 mg, 43%) LCMS (ES+) m/z 544 (M+H)
Step 3 Preparation of Λ/-(3-chloro-4-fluorobenzyl)-6-methyl-4-(2-(pιperιdιn-4-ylmethyl)-2/-/-tetrazol-5- vDpicolinamide
A vial was charged with terf-butyl 4-((5-(2-((3-chloro-4-fluorobenzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)pιperιdιne-1 -carboxylate (59 mg, 0 12 mmol), methanol (1 mL), and a 4N solution of hydrochloric acid in dioxane (0 5 mL) The resulting solution was stirred at room temperature for 18 hours The reaction mixture was then passed through a carbonate cartridge eluting with methanol and concentrated to afford the title compound as a solid (49 mg, 95%) MS (ES+) m/z 444 (M+H) 1H NMR (400 MHz, CDCI3) δ ppm 1 38 - 1 53 (m, 2 H), 1 69 (s, J=12 08 Hz, 2 H), 2 20 - 2 34 (m, 1 H), 2 60 - 2 72 (m, 5 H), 3 17 - 3 25 (m, 2 H), 4 57 (d, J=6 98 Hz, 2 H), 4 63 (d, J=Q 44 Hz, 2 H), 7 10 (t, J=8 59 Hz, 1 H), 7 21 - 7 28 (m, 1 H), 7 41 (dd, J=6 98, 2 15 Hz, 1 H), 8 05 (d, J=1 34 Hz, 1 H), 8 46 (t, J=6 31 Hz, 1 H), 8 70 (s, 1 H)
Example 388
W-(3-Ch!oro-4-fluorobenzyl)-6-methyl-4-(2-((1-(methylsulfonyl)piperidin-4-yl)methyl)-2H-tetrazol- 5-yl)picolinamide
Methane sulfonylchlonde (0 007 mL, 0 08 mmol) was added to a mixture of Λ/-(3-ch!oro-4- fluorobenzyl)-6-methyl-4-(2-(pιperιdιn-4-ylmethyl)-2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 387) (25 mg, 0 06 mmol) and triethylamine (0 016 mL, 0 11 mmol) in dichloromethane (1 mL), and the mixture was stirred at room temperature for 2 hours The reaction mixture was purified by reverse phase preparative HPLC Fractions containing desired product were combined and concentrated The residue was dissolved in methanol and passed through a carbonate cartridge Concentration of the resulting solution afforded the title compound as a solid (16 mg, 55%) MS (ES+) m/z 522 (M+H) 1H NMR (400 MHz1 DMSOd6) δ ppm 1 01 - 1 27 (m, 3 H), 1 51 (d, J= 11 71 Hz, 2 H), 1 93 - 2 10 (m, 2 H), 2 51 - 2 60 (m, 1 H), 2 65 (s, 3 H), 3 05 - 3 16 (m, 1 H), 3 38 (d, J=1 1 71 Hz, 3 H), 4 33 (d, J=5 86 Hz, 2 H), 4 60 (d, J=7 32 Hz, 2 H), 7 18 (d, J=7 32 Hz, 2 H), 7 31 - 7 44 (m, J=8 05 Hz, 1 H), 7 90 (S, 1 H), 8 24 (s, 1 H), 9 18 (t, J=6 59 Hz, 1 H)
Example 389
Λ/-(4-Fluoro-3-(trifluoromethyl)benzyl)-6-methyl-4-(2-(piperidin-4-ylmethyl)-2H-tetrazol-5- yl)picolinamide
Step 1 Preparation of tert-butyl 4-((5-(2-((4-fluoro-3-(trιfluoromethyl)benzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)pιperιdιne-1-carboxylate
2-(1H-Benzotrιazole-1-yl)-1 ,1 ,3,3-tetramethyluronιum hexafluorophosphate (141 mg, 0 37 mmol) was added to a mixture of 4-(2-((1-(tert-butoxycarbonyl)pιperιdιn-4-y!)methyl)-2/-/-tetrazol-5-yl)- 6-methylpιcotιnιc acid (prepared as described in step 1 of the synthesis of Λ/-(3-chloro-4-fluorobenzyl)- 6-methyM-(2-(pιperιdιn-4-ylmethyl)-2H-tetrazol-5-yl)pιcolιnamιde, Example 387) (100 mg, 0 25 mmol), (4-fluoro-3-(trιfluoromethyl)phenyl)methanamιne (58 mg, 0 30 mmol), and triethylamine (0 05 mL, 0 37 mmol) in Λ/,Λ/-dιmethylformamιde (2 mL), and the mixture was stirred at room temperature for 18 hours The reaction mixture was purified by reverse phase preparative HPLC The product was dissolved in methanol, passed through a carbonate cartridge, and concentrated to afford the title compound as a solid (61 mg, 43%) LCMS (ES+) m/z 578 (M+H)
Step 2 Preparation of Λ/-(4-fluoro-3-(trιfluoromethyl)benzyl)-6-methyl-4-(2-(pιperιdιn-4-ylmethyl)-2/-/- tetrazol-5-yl)pιcolιnamιde
A vial was charged with tert-butyl 4-((5-(2-((4-fluoro-3-(trιflυoromethyl)benzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)pιperιdιne-1-carboxylate (63 mg, 0 12 mmol), methanol (1 mL), and a 4N solution of hydrochloric acid in dioxane (0 5 mL) The resulting solution was stirred at room temperature for 18 hours The reaction mixture was then passed through a carbonate cartridge eluting with methanol and concentrated to afford the title compound as a solid (49 mg, 100%) MS (ES+) m/z 478 (M+H) 1H NMR (400 MHz, DMSO-cfe) 6 ppm 1 11 - 1 24 (m, 3 H), 1 50 (d, J= 1 1 72 Hz, 2 H), 2 04 - 2 17 (m, 1 H), 2 42 - 2 50 (m, 2 H), 2 64 (s, 3 H), 2 95 (d, J=11 72 Hz, 2 H), 4 54 (d, J=I 33 Hz, 2 H)1 4 66 (d, J=5 86 Hz, 2 H), 7 34 - 7 49 (m, 1 H), 7 63 - 7 79 (m, J=19 78, 6 59 Hz, 2 H), 8 05 (S, 1 H), 8 38 (s, 1 H), 9 39 (t, J=6 59 Hz1 1 H)
Example 390
W-(4-Fluoro-3-(trιfluoromethyl)benzyl)-6-methyl-4-(2-((1-(methylsulfonyl)piperidin-4-yl)methyl)-
2H-tetrazol-5-yl)pιcolinamide
Methane sulfonylchloride 0 006 mL, 0 07 mmol) was added to a mixture of Λ/-(4-fluoro-3- (trιfluoromethyl)benzyl)-6-methyl-4-(2-(pιperιdιn-4-ylmethyl)-2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 389) (23 mg, 0 05 mmol) and triethylamine (0 013 mL, 0 10 mmol) in dichloromethane (1 mL), and the mixture was stirred at room temperature for 2 hours The reaction mixture was purified by reverse phase preparative HPLC Fractions containing desired product were combined and concentrated The residue was dissolved in methanol and passed through a carbonate cartridge Concentration of the resulting solution afforded the title compound as a solid (16 mg, 58%) MS (ES+) m/z 556 (M+H) 1H NMR (400 MHz, DMSO-Of6) δ ppm 1 19 - 1 43 (m, 3 H), 1 67 (d, J= 11 71 Hz, 2 H)1 2 08 - 2 24 (m, 2 H), 2 66 - 2 75 (m, 2 H)1 2 81 (s, 3 H)1 3 54 (d, J=11 71 Hz1 3 H), 4 55 (d, J=5 86 Hz, 2 H), 4 75 (d, J=7 32 Hz1 2 H), 7 38 - 7 51 (m, 1 H)1 7 64 - 7 81 (m, 2 H), 8 06 (s, 1 H), 8 40 (S, 1 H), 9 40 (t, J=6 22 Hz, 1 H) Example 391 W-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-(piperidin-4-ylmethyl)-2H-tetrazol-5-yl)picolinamide
Step 1 Preparation of tert-butyl 4-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)- 2/-/-tetrazol-2-yl)methyl)pιperιdιne-1-carboxylate
2-(1H-Benzotrιazole-1-yl)-1 ,1 ,3,3-tetramethyluronιum hexafluorophosphate (141 mg, 0 37 mmol) was added to a mixture of 4-(2-((1-(tert-butoxycarbonyl)pιperιdιn-4-yl)methyl)-2H-tetrazol-5-yl)- 6-methylpιcolιnιc acid (prepared as described in step 1 of the synthesis of Λ/-(3-chloro-4-fluorobenzyl)- 6-methyl-4-(2-(pιperιdιn-4-ylmethyl)-2H-tetrazol-5-yl)pιcolιnamιde, Example 387) (100 mg, 0 25 mmol), 4-fluoro-3-methoxybenzylamιne hydrochloride (prepared as described in step 3 of the synthesis of N- (4-fluoro-3-methoxybenzyl)-6-(2-((<rans-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)pyrιmιdιne-4- carboxamide, Example 1 ) (46 mg, 0 30 mmol), and triethylamine (0 05 mL, 0 37 mmol) in N, N- dimethylformamide (2 mL), and the mixture was stirred at room temperature for 18 hours The reaction mixture was purified by reverse phase preparative HPLC The product was dissolved in methanol, passed through a carbonate cartridge, and concentrated to afford the title compound as a solid (63 mg, 47%) MS (ES+) m/z 540(M+H)
Step 2 Preparation of /V-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-(pιperιdιn-4-ylmethyl)-2/-/-tetrazol- 5-yl)pιcolιnamιde
A vial was charged with tert-butyl 4-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6- methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)pιperιdιne-1-carboxylate (53 mg, 0 10 mmol), methanol (1 mL), and a 4N solution of hydrochloric acid in dioxane (0 5 mL) The resulting solution was stirred at room temperature for 18 hours The reaction mixture was then passed through a carbonate cartridge eluting with methanol and concentrated to afford the title compound as a solid (43 mg, 100%) MS (ES+) m/z 440 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 1 07 - 1 26 (m, 3 H), 1 49 (d, J= 1 1 72 Hz, 2 H), 2 03 - 2 18 (m, 2 H), 2 44 - 2 52 (m, 2 H), 2 65 (s, 3 H), 2 94 (d, J= 1 1 72 Hz, 2 H), 3 80 (s, 3 H), 4 48 (d, J=T 33 Hz, 2 H), 4 67 (d, J=5 86 Hz, 2 H), 6 85 - 6 93 (m, 1 H), 7 04 - 7 22 (m, 2 H), 8 05 (s, 1 H), 8 40 (s, 1 H), 9 21 (t, J=5 86 Hz, 1 H)
Example 392
A/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((1-(methylsulfonyl)piperidin-4-yl)methyl)-2H- tetrazol-5-yl)picolinamide
Methane sulfonylchloride 0 006 mL, 0 07 mmol) was added to a mixture of Λ/-(4-fluoro-3- methoxybenzyl)-6-methyl-4-(2-(pιperιdιn-4-ylmethyl)-2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 391 ) (20 mg, 0 05 mmol) and triethylamine (0 013 mL, 0 10 mmol) in dichloromethane (1 mL), and the mixture was stirred at room temperature for 2 hours The reaction mixture was purified by reverse phase preparative HPLC Fractions containing desired product were combined and concentrated The residue was dissolved in methanol and passed through a carbonate cartridge Concentration of the resulting solution afforded the title compound as a solid (15 mg, 61 %) MS (ES+) m/z 518 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 1 18 - 1 43 (m, 3 H), 1 67 (d, J=11 71 Hz, 2 H), 2 09 - 2 24 (m, 2 H), 2 62 - 2 76 (m, 2 H)1 2 81 (s, 3 H), 3 54 (d, J=12 45 Hz, 3 H), 3 80 (s, 3 H), 4 48 (d, J=5 86 Hz, 2 H), 4 76 (d, J=6 59 Hz, 2 H), 6 82 - 6 92 (m, 1 H), 7 05 - 7 20 (m, 2 H), 8 06 (S, 1 H), 8 41 (s, 1 H), 9 22 (t, J=6 22 Hz, 1 H)
Example 393
W-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((/?)-morpholin-2-ylmethyl)-2H-tetrazol-5- yl)picolinamide
Step 1 Preparation of (2R)-tert-butyl 2-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn- 4-yl)-2H-tetrazol-2-yl)methyl)morpholιne-4-carboxylate
A mixture of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((frans)-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 170) (0 070 g, 0 19 mmol), (R)-tert-butyl 2-(hydroxymethyl)morpholιne-4-carboxylate (0 050 g, 0 23 mmol), and polymer supported-tπphenylphosphine (0 60 g, 0 29 mmol) in anhydrous tetrahydrofuran (5 mL) was cooled to 0 0C in an ice bath for 15 mm and then di-tert-butyl azodicarboxylate (0 053 g, 0 23 mmol) was added The mixture was allowed to warm to room temperature while stirring over 15 hours The reaction mixture was filtered and the filtrate was concentrated The residue was purified by silica column chromatography (0-2% methanol/dichloromethane) to afford the title compound as a beige oil (65 mg, 62%) LC/MS (5-100% CH3CN/H2O, 8 mm) 5 58 mm, m/z 564 (M+Na)
Step 2 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((R)-morpholιn-2-ylmethyl)-2H- tetrazol-5-yl)pιcolιnamιde
Trifluoroacetic acid (0 5 mL) was added to a solution of (2R)-tert-butyl 2-((5-(2-((4-fluoro-3- methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)morpholιne-4-carboxylate in dichloromethane (2 mL), and the mixture was stirred for 1 hour at room temperature The reaction mixture was concentrated, and the residue was triturated with diethyl ether (4 x 5 mL) to afford the title compound
Example 394
W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((/?)-4-acetylmorpholin-2-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Triethylamine (0 037 mL, 0 26 mmol) and a solution of acetyl chloride (13 mg in 0 5 mL dichloromethane) were added to a solution of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((/?)- morpholιn-2-ylmethyl)-2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 393) (0 065 g, 0 12 mmol) in dichloromethane (2 mL) The mixture was stirred for 1 hour at room temperature and then was concentrated The residue was purified by reverse phase preparative HPLC (10-90 % acetonitπle/water) to afford the title compound (26 mg, 45%) 1H NMR (400 MHz1 DMSO-d6) δ ppm 9 22 (br s , 1 H), 8 41 (br s , 1 H), 8 06 (br s , 1 H), 7 13 (dd, J=23 4, 10 3 Hz, 1 H), 6 89 (d, J=5 1 Hz, 1 H), 4 82 - 5 04 (m, 2 H), 4 48 (d, J=6 6 Hz, 2 H), 4 37 (d, J= 1 1 7 Hz, 1 H), 3 97 (br s , 2 H), 3 80 (s, 3 H), 3 61 (br s , 1 H), 3 39 (br s , 1 H), 3 11 (br s , 1 H), 2 66 (s, 5 H), 2 01 (d, J=16 1 Hz, 3 H)
Example 395
Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((S)-morpholin-2-ylmethyl)-2H-tetrazol-5- yl)picolinamide
Step 1 Preparation of (2S)-tert-butyl 2-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn- 4-yl)-2/-/-tetrazol-2-yl)methyl)morpholιne-4-carboxylate
A mixture of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 2 of the synthesis of /V-(4-fluoro-3-methoxybenzyl)-4-(2-(((frans)-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 170) (0 070 g, 0 19 mmol), (S)-tert-butyl 2-(hydroxymethyl)morpholιne-4-carboxylate (0 050 g, 0 23 mmol), and polymer supported-tnphenylphosphine (0 60 g, 0 29 mmol) in anhydrous tetrahydrofuran (5 mL) was cooled to 0 0C in an ice bath for 15 mm and then di-tert-butyl azodicarboxylate (0 053 g, 0 23 mmol) was added The mixture was allowed to warm to room temperature while stirring over 15 hours The reaction mixture was filtered and the filtrate was concentrated The residue was purified by silica column chromatography (0-2% methanol/dichloromethane) to afford the title compound as a beige oil (63 mg, 61 %) LC/MS (5-100% CH3CN/H2O, 8 mm) 5 57 mm, m/z 564 (M+Na)
Step 2 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((S)-morpholιn-2-ylmethyl)-2H- tetrazol-5-yl)pιcolιnamιde
Trifluoroacetic acid (0 5 mL) was added to a solution of (2S)-tert-butyl 2-((5-(2-((4-fluoro-3- methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2-yl)methyl)morpholιne-4-carboxylate in dichloromethane (2 mL), and the mixture was stirred for 1 hour at room temperature The reaction mixture was concentrated, and the residue was triturated with diethyl ether (4 x 5 mL) to afford the title compound
Example 396
/V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((S)-4-acetylmorpholin-2-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Triethylamine (0 037 mL, 0 26 mmol) and a solution of acetyl chloride (13 mg in 0 5 mL dichloromethane) was added to a solution of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((S)- morpholιn-2-ylmethyl)-2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 395) (0 063 g, 0 12 mmol) in dichloromethane (2 mL) The mixture was stirred for 1 hour at room temperature and then was concentrated The residue was purified by reverse phase preparative HPLC (10-90 % acetonitrile/water) to afford the title compound (29 mg, 50%) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 21 (d, J=5 9 Hz, 1 H)1 8 41 (br s , 1 H), 8 06 (br s , 1 H), 7 05 - 7 22 (m, 2 H), 6 80 - 6 95 (m, 1 H), 4 80 - 5 08 (m, 2 H), 4 48 (d, J=6 6 Hz, 3 H), 4 37 (d, J=13 9 Hz, 1 H), 3 90 - 4 15 (m, 2 H), 3 80 (s, 3 H), 3 63 (d, J=13 2 Hz, 1 H), 3 33 - 3 47 (m, 1 H), 3 02 - 3 20 (m, 1 H), 2 66 (s, 3 H), 2 02 (d, J=16 8 Hz, 3 H)
Example 397
W-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-(((R)-4-(methylsulfonyl)morpholin-2-yl)methyl)-2H- tetrazol-5-yl)picolinamide
Triethylamine (0 037 ml_, 0 26 mmol) and a solution of methanesulfonyl chloride (18 mg in 0 5 mL dichloromethane) was added to a solution of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((S)- morpholιn-2-ylmethyl)-2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 395) (0 075 g, 0 18 mmol) in dichloromethane (2 mL) The mixture was stirred for 1 hour at room temperature and then was concentrated The residue was purified by reverse phase preparative HPLC (10-90 % acetonitrile/water) to afford the title compound (18 mg, 20%) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 22 (t, J=6 2 Hz, 1 H), 8 42 (s, 1 H), 8 07 (s, 1 H), 7 06 - 7 22 (m, 2 H), 6 89 (br s , 1 H), 5 04 (dd, J=14 3, 3 3 Hz, 1 H), 4 91 (dd, J=13 9, 8 1 Hz, 1 H), 4 48 (d, J=6 6 Hz, 2 H), 4 06 - 4 17 (m, 1 H), 3 89 (d, J=12 4 Hz, 1 H), 3 80 (s, 3 H), 3 67 (d, J= 1 1 7 Hz, 1 H), 3 44 - 3 55 (m, 1 H), 3 32 (d, J= 1 1 0 Hz, 1 H), 2 91 (s, 3 H), 2 73 - 2 88 (m, 2 H), 2 66 (s, 3 H)
Example 398 W-(3-Methoxybenzyl)-6-methyl-4-(2-((S)-morpholin-2-ylmethyl)-2H-tetrazol-5-yl)picolinamide
Step 1 Preparation of (2S)-tert-butyl 2-((5-(2-((3-methoxybenzyl)carbamoγl)-6-methylpyrιdιn-4-yl)-2H- tetrazol-2-yl)methyl)morpholιne-4-carboxylate
A mixture of Λ/-(3-methoxybenzyl)-6-methyl-4-(2W-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of /V-(3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)- 2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (0 75 g, 2 3 mmol), (S)-tert-butyl 2- (hydroxymethyl)morpholιne-4-carboxylate (0 53 g, 2 4 mmol), and polymer supported- tπphenylphosphine (1 29 g, 2 77 mmol) in anhydrous tetrahydrofuran (20 mL) was cooled to 0 0C in an ice bath for 15 mm and then di-tert-butyl azodicarboxylate (0 80 g, 3 5 mmol) was added The reaction mixture was filtered and the filtrate was concentrated The residue was purified by silica column chromatography (0-2% methanol/dichloromethane) to afford the protected amine as a beige oil Step 2 Preparation of Λ/-(3-methoxybenzyl)-6-methyl-4-(2-((S)-morpholιn-2-ylmethyl)-2H-tetrazol-5- vQpicolinamide
Tnfluoroacetic acid (1 0 mL) was added to a solution of (2S)-tert-buty! 2-((5-(2-((3- methoxybenzyOcarbamoyO-β-methylpyridin^-yl^H-tetrazol^-yOmethyOmorpholine^-carboxylate in dichloromethane (5 mL), and the mixture was stirred for 1 hour at room temperature The reaction mixture was concentrated, and the residue was triturated with diethyl ether (4 x 5 mL) to afford the title compound The reaction mixture was diluted with dichloromethane (10 mL) and neutralized to pH 7 with a 2 5 N aqueous solution of sodium hydroxide The organic phase was separated and washed with water (10 mL) followed by brine (10 mL), dried over anhydrous sodium sulfate, and concentrated to afford the title compound (0 43 g, 44%)
Example 399
W-(3-Methoxybenzyl)-4-(2-(((S)-4-acetylmorpholin-2-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
Triethylamine (0 037 mL, 0 26 mmol) and a solution of acetyl chloride (17 mg in 0 5 mL dichloromethane) was added to a solution of Λ/-(3-methoxybenzyl)-6-methyl-4-(2-((S)-morpholιn-2- ylmethyl)-2W-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 398) (0 075 g, 0 18 mmol) in dichloromethane (2 mL) The mixture was stirred for 1 hour at room temperature and then was concentrated The residue was purified by reverse phase preparative HPLC (10-90 % acetonitrile/water) to afford the title compound (44 mg, 54%) 1H NMR (400 MHz, DMSOd6) δ ppm 9 19 (t, J=5 9 Hz, 1 H), 8 41 (s, 1 H), 8 06 (s, 1 H), 7 22 (t, J=Q 1 Hz, 1 H), 6 90 (br s , 2 H), 6 80 (d, J=Q 1 Hz, 1 H), 4 95 - 5 04 (m, 1 H), 4 85 - 4 95 (m, 1 H), 4 49 (d, J=6 6 Hz, 2 H), 3 90 - 4 13 (m, 2 H), 3 79 (d, J=10 3 Hz, 1 H), 3 71 (s, 3 H), 3 43 (d, J=9 5 Hz, 1 H), 3 05 - 3 20 (m, 2 H), 2 62 - 2 73 (m, 4 H), 2 01 (d, J=16 8 Hz, 3 H)
Example 400
W-(3-Methoxybenzyl)-6-methyl-4-(2-(((R)-4-(methylsulfonyl)morpholin-2-yl)methyl)-2H-tetrazol-5- yOpicolinamide
Triethylamine (0 022 mL, 0 16 mmol) and a solution of methanesulfonyl chloride (15 mg in 0 5 mL dichloromethane) was added to a solution of /V-(3-methoxybenzyl)-6-methyl-4-(2-((S)-morpholιn-2- ylmethyl)-2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in Example 398) (0 045 g, 0 11 mmol) in dichloromethane (2 mL) The mixture was stirred for 1 hour at room temperature and then was concentrated The residue was purified by silica column chromatography (0-75%ethyl acetate/heptane) to afford the title compound (20 mg, 37%) 1H NMR (400 MHz, DMSO-d6) 6 ppm 9 19 (t, J=6 2 Hz, 1 H), 8 42 (s, 1 H), 8 07 (s, 1 H), 7 22 (t, J=8 1 Hz, 1 H), 6 90 (br s , 2 H), 6 80 (d, J=I 3 Hz, 1 H), 4 98 - 5 09 (m, 1 H), 4 91 (dd, J=14 6, 8 1 Hz, 1 H), 4 49 (d, J=6 6 Hz, 2 H), 4 1 1 (d, J=9 5 Hz, 1 H), 3 89 (d, J= 1 1 7 Hz, 1 H), 3 71 (s, 3 H), 3 67 (d, J= 1 1 0 Hz, 1 H), 3 50 (t, J=10 3 Hz, 1 H), 3 32 (d, J= 11 7 Hz, 1 H), 2 91 (s, 3 H), 2 75 - 2 88 (m, 2 H), 2 66 (s, 3 H)
Example 401 rac-4-(2-((1 ,4-Dioxan-2-yl)methyl)-2W-tetrazol-5-yl)-/V-(4-fluoro-3-methoxybenzyl)-6- methylpicolinamide
rac-2-(lodomethyl)-1 ,4-dιoxane (57 mg, 0 25 mmol) was added to a mixture of N-(4-fluoro-3- methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)- 6-methylpιcolιnamιde, Example 170) (79 mg, 0 23 mmol) and triethylamine (23 mg, 0 23 mole) in anhydrous acetonitrile (1 mL) The mixture was stirred at reflux temperature in a capped vial for two days and then was purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing the product were passed through a carbonate resin column and the filtrate was concentrated The residue was slurried with ether, decanted, and dried in a vacuum desiccator to afford the title compound as a white solid (39 mg) MS (ES+) m/z 443 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 24 (t, J=6 0 Hz, 1 H), 8 43 (s, 1 H)1 8 08 (s, 1 H), 7 10-7 24 (m, 2 H), 6 91 (br s, 1 H), 4 85-4 95 (m, 2 H), 4 52 (d, J=6 2 Hz, 2 H), 4 05-4 20 (m, 1 H), 3 85-3-95 (m, 1 H), 3 82 (s, 3 H), 3 30-3-80 (m, 5 H), 2 68 (s, 3 H)
Example 402 rac-4-(2-((1,4-Dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-W-(4-fluoro-3-methylbenzyl)-6- methylpicolinamide rac-2-(lodomethyl)-1 ,4-dιoxane (1 14 mg, 0 5 mmol) was added to a mixture of Λ/-(4-fluoro-3- methylbenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as describe in step 1 of the synthesis of Λ/-(4-fluoro-3-methylbenzyl)-4-(2-(((/rans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide, Example 185) (150 mg, 0 46 mmol) and triethylamine (46 mg, 0 46 mmol) in anhydrous acetonitrile (2 mL) The mixture was stirred at reflux temperature in a capped vial for two days and then was purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing the product were passed through a carbonate resin column and the filtrate was concentrated The residue was slurried with ether, decanted, and dried in a vacuum desiccator to afford the title compound as a white solid (61 mg) MS (ES+) m/z 427 (M+H) 1H NMR (400 MHz,
DMSO-d6) δ ppm 9 24 (t, J=6 0 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H), 7 00-7 30 (m, 3 H), 4 85-4 95 (m, 2 H), 4 52 (d, J=Q 2 Hz, 2 H), 4 05-4 20 (m, 1 H), 3 85-3-95 (m, 1 H), 3 30-3-80 (m, 5 H), 2 68 (s, 3 H), 2 20 (s, 3 H)
Example 403 rac-W-(3-Methoxybenzyl)-4-(2-(((2S*,5/?*)-5-(hydroxymethyl)-1 )4-dioxan-2-yl)methyl)-2H-tetrazol-
5-yl)-6-methylpicolinamide
rac-((2/?*,5/?*)-5-(Hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 4 of the synthesis of rac-Λ/-(3-methoxybenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)- 1 ,4-dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 61 ) (1 4 g, 4 3 mmol) was added to a mixture of /V-(3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)picolinamide (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((fraπs)-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (1 O g, 3 1 mmol) and triethylamine (0 4 g, 4 0 mmole) in anhydrous W,Λ/-dιmethylacetamιde (1 mL) The mixture was stirred at 85°C in a capped vial overnight and then was purified by reverse phase preparative HPLC
(water/acetonitrile) Fractions containing the product were passed through a carbonate resin column and the filtrate was concentrated The residue was slurried with ether, decanted, and dried in a vacuum desiccator to afford the title compound as a white solid (1 04 g) MS (ES+) m/z 455 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 20 (t, J=6 2 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H), 7 24 (t, J=8 1 Hz, 1 H), 6 93 (br s , 2 H), 6 83 (d, J=1 5 Hz, 1 H), 4 80-4 95 (m, 2 H), 4 65 (t, J=5 7 Hz, 1 H), 4 52 (d, J=6 2 Hz, 2 H), 4 05-4 15 (m, 1 H), 3 99 (dd, J=1 1 3, 1 8 Hz, 1 H), 3 77 (d, J=1 1 3Hz, 1 H), 3 73 (s, 3 H), 3 30-3 50 (m, 4 H), 2 68 (s, 3 H) Example 404
W-(3-Methoxybenzyl)-4-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-
6-methylpicolinamide
rac-/V-(3-Methoxybenzyl)-4-(2-(((2S*,5f?*)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 403) was separated by chiral supercritical-fluid chromatography (AS-H, 30 x 250 mm, 20% methanol, 70 mUmin) and the first eluting isomer was isolated to afford the title compound (50 mg) MS (ES+) m/z 455 (M+H) 1H NMR (400 MHz, DMSO-Of6) δ ppm 9 20 (t, J=Q 2 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H), 7 24 (t, J=Q 1 Hz, 1 H), 6 93 (br s , 2 H), 6 83 (d, J=\ 5 Hz, 1 H), 4 80-4 95 (m, 2 H), 4 65 (t, J=5 7 Hz, 1 H), 4 52 (d,
J=6 2 Hz, 2 H), 4 05-4 15 (m, 1 H), 3 99 (dd, J=1 1 3, 1 8 Hz, 1 H), 3 77 (d, J=1 1 3 Hz, 1 H), 3 73 (s, 3 H)1 3 30-3-50 (m, 4 H), 2 68 (s, 3 H)
Example 405
W-(3-Methoxybenzyl)-4-(2-(((2/?,5S)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)- 6-methylpicolinamide
rac-Λ/-(3-Methoxybenzyl)-4-(2-(((2S*,5f?*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2/-/- tetrazol-5-yl)-6-methylpιcolιnamιde (prepared as described in Example 403) was separated by chiral supercritical-fluid chromatography (AS-H, 30 x 250 mm, 20% methanol, 70 mUmin) and the second eluting isomer was isolated to afford the title compound (50 mg) MS (ES+) m/z 455 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 20 (t, J=6 2 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H), 7 24 (t, J=Q 1 Hz, 1 H), 6 93 (br s , 2 H), 6 83 (d, J=1 5 Hz, 1 H), 4 80-4 95 (m, 2 H), 4 65 (t, J=5 7 Hz, 1 H), 4 52 (d, J=Q 2 Hz, 2 H), 4 05-4 15 (m, 1 H), 3 99 (dd, J=1 1 3, 1 8 Hz, 1 H), 3 77 (d, J=11 3 Hz, 1 H), 3 73 (s, 3 H), 3 30-3-50 (m, 4 H), 2 68 (s, 3 H)
Example 406 rac-(2S*,5S*)-Methyl 5-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)-1 ,4-dioxane-2-carboxylate rac-(2S*,5/?*)-Methyl 5-((tosyloxy)methyl)-1 ,4-dιoxane-2-carboxylate (prepared as described in step 1 of the synthesis of rac-(2S*,5S*)-methyl 5-((5-(6-((3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2H-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylate, Example 85) (1 22 g, 3 7 mmol) was added to a mixture of Λ/-(3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-y!)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((/rans)-4- amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (1.2 g, 3 7 mmol) and triethylamine (749 mg, 7 4 mmol) in anhydrous N,N-dιmethylacetamιde (2.3 mL) The mixture was stirred at 850C in a capped vial overnight and then was purified by reverse phase preparative HPLC (water/acetonitrile) to afford the title compound as a white solid (1 7 g)
Example 407 fac-(2S*,5S*)-5-((5-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)-1 ,4-dioxane-2-carboxylic acid
Sodium hydroxide (10 pellets) was added to rac-(2S*,5S*)-methyl 5-((5-(2-((3-methoxybenzyl)- carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylate (prepared as described in Example 406) (1 35 g, 2 8 mmol) in a mixture of tetrahydrofuran/water (6 mL, 1/1 ) and the mixture was stirred at room temperature overnight The reaction mixture was acidified with trifluoroacetic acid and purified by reverse-phase preparative HPLC (water/ acetonitrile). The resulting product was slurried and decanted from ether several times and dried in a vacuum desiccator to afford the title compound as a white solid (1.09 g) MS (ES+) m/z 469 (M+H). 1H NMR (400 MHz, DMSOd6) δ ppm 9 20 (t, J=6.2 Hz, 1 H), 8.43 (s, 1 H), 8 08 (s, 1 H), 7.24 (t, J=B 1 Hz, 1 H), 6 93 (br. s , 2 H), 6 83 (d, J=1 5 Hz, 1 H), 4 85-4.99 (m, 2 H), 4 52 (d, J=6.2 Hz, 2 H), 4 05-4.20 (s, 3 H), 3 90-3.99 (m, 1 H), 3 73 (s, 3 H), 3 45-3-60 (m, 2 H), 2.68 (s, 3 H)
Example 408 rac-N-(3-Methoxybenzyl)-4-(2-(((2S*,5S*)-5-(2-hydroxypropan-2-yl)-1,4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
A solution of methyl magnesium iodide (3M in ether, 0 16 mL, 0 48 mmol) was added dropwise at room temperature to a solution of rac-(2S*,5S*)-methyl 5-((5-(2-((3- methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylate (prepared as described in Example 406) (75 mg, 0 15 mmol) in anhydrous tetrahydrofuran (1 mL) Additional tetrahydrofuran (0 5 mL) was added and the mixture was stirred at room temperature for 2 hours The reaction mixture was cooled to ice bath temperature and saturated aqueous ammonium chloride solution (0 5 mL) was added dropwise The product was purified by reverse phase preparative HPLC (water/ acetonitrile) Fractions containing the product were passed through a carbonate resin column and the filtrate was concentrated The residue was slurried and decanted from ether several times and then dried in a vacuum desiccator to afford the title compound as a white solid (25 mg) MS (ES+) m/z 483 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 22 (t, J=6 2 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H), 7 24 (t, J=8 1 Hz, 1 H), 6 93 (br s , 2 H), 6 83 (d, J=1 5 Hz, 1 H), 4 80- 4 99 (m, 2 H), 4 52 (d, J=Q 2 Hz, 2 H), 4 00-4 15 (m, 2 H), 3 90-3 99 (m, 1 H), 3 73 (s, 3 H), 3 33-3 45 (m, 2 H), 3 12-3 19 (m, 1 H), 2 68 (s, 3 H), 1 07 (s, 3 H), 1 01 (s, 3 H)
Example 409 rac-W-(3-Methoxybenzyl)-4-(2-(((2S*,5S*)-5-carbamoyl-1 ,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-
— 6-methylpicolinamide
Formamide (300 mg) was added to a solution of rac-(2S*,5S*)-methyl 5-((5-(2-((3- methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2AY-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylate (prepared as described in Example 406) (149 mg, 0 3 mmol) in anhydrous tetrahydrofuran (3 mL) at reflux temperature A solution of sodium methoxide (25% in methanol, 300 mg) was added and the mixture was stirred at reflux for 1 5 hours The reaction mixture was purified by reverse phase preparative HPLC (water/ acetonitrile) Fractions containing the product were passed through a carbonate resin column and the filtrate was concentrated The residue was slurried and decanted from ether several times and then dried in a vacuum desiccator to afford the title compound as a white solid (106 mg) MS (ES+) m/z 468 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 20 (t, J=6 2 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H), 7 24 (t, J=8 1 Hz, 1 H), 6 93 (br s , 2 H), 6 83 (d, J=1 5 Hz, 1 H), 4 85- 4 99 (m, 2 H), 4 52 (d, J=6 2 Hz, 2 H), 4 05-4 20 (m, 3 H), 3 90-3 99 (m, 1 H), 3 73 (s, 3 H), 3 45-3-60 (m, 2 H), 2 68 (S1 3 H) Example 410 rac-W-(3-Methoxybenzyl)-4-(2-(((2S*,5S*)-5-cyano-1,4-dioxan-2-yl)methy|)-2H-tetrazol-5-yl)-6- methylpicolinamide
Polymer supported triphenylphosphine (Argonaut, 2 15 mmol/g, 300 mg) was added to rac-N-
(3-methoxybenzyl)-4-(2-(((2S*,5S*)'5-carbamoyl-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
(Example 409) (85 mg, 0 18 mmol) in a mixture of carbon tetrachloride (0 5 mL) and dichloroethane (4 5 mL) and the mixture was heated at 80 0C for 3 hours The reaction mixture was filtered and the resin was washed with dichloroethane The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC Fractions containing the first eluting isomer were passed through a carbonate resin column and were concentrated The product was slurried and decanted several times from ether and the solid was dried in a vacuum desiccator to afford the title compound as a white solid (23 mg) MS (ES+) m/z 450 (M+H) 1H NMR (400 MHz1 DMSO-^6) δ ppm 9 29 (t, J=Q 4 Hz, 1 H), 8 44 (s, 1 H), 8 11 (s, 1 H), 7 25 (t, J=8 1 Hz, 1 H), 6 90 - 6 94 (m, 2 H), 6 83 (dd, J=Q 1 , 2 0 Hz, 1 H), 5 04 (d, J=2 7 Hz, 1 H), 4 99 (br s , 1 H), 4 97 (d, J=3 6 Hz, 1 H), 4 51 (d, J=Q 3 Hz, 2 H), 4 24 - 4 31 (m, 1 H), 4 08 (dd, J=11 9, 2 6 Hz, 1 H), 3 95 (d, J=12 5 Hz, 1 H), 3 81 (dd, J=12 5, 3 2 Hz, 1 H), 3 74 (s, 3 H), 3 71 - 3 75 (m, 1 H), 2 69 (s, 3 H)
Example 411 rac-A/-(3-Methoxyben2yl)-4-(2-(((2S*,5R*)-5-cyano-1 ,4-dioxan-2-yl)methy|)-2H-tetrazol-5-yl)-6- methylpicolinamide
Isolation of the second eluting isomer by reverse phase preparative HPLC from the reaction mixture described in Example 410 afforded the title compound as a white solid (24 mg) MS (ES+) m/z 450 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 20 (t, J=6 4 Hz, 1 H), 8 41 (s, 1 H), 8 06 (s, 1 H), 7 22 (t, J=Q 1 Hz, 1 H), 6 87 - 6 93 (m, 2 H), 6 80 (d, J=Q 1 Hz, 1 H), 4 92 - 5 02 (m, 2 H), 4 77 (dd, J=Q 4, 2 9 Hz, 1 H), 4 49 (d, J=6 2 Hz, 2 H), 4 21 - 4 30 (m, 1 H), 4 05 - 4 13 (m, 2 H), 3 71 (s, 3 H), 3 64 (ddd, J=22 0, 12 0, 8 4 Hz, 2 H), 2 66 (s, 3 H) Example 412 rac-W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-
2H-tetrazol-5-yl)-6-methylpicolinamide
rac-((2/?*,5R*)-5-(Hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl 4-methylbenzenesulfonate (prepared as described in step 4 of the synthesis of rac-Λ/-(3-methoxybenzyl)-6-(2-(((2S*,5/?*)-5-(hydroxymethyl)- 1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4-carboxamιde, Example 61 ) (3 03 g, 10 0 mmol) was added to a mixture of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5- yOpicolmamide (prepared as described in step 2 of the synthesis of /V-(4-fluoro-3-methoxybenzyl)-4-(2- (((frans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 170) (1 9 g, 5 0 mmol) and triethylamine (2 8 g, 27 0 mmol) in anhydrous DMA (3 mL) The mixture was stirred at 9O0C in a capped vial overnight The reaction mixture is allowed to cool, diluted with excess dichloromethane, and washed with 2N aqueous sodium hydroxide solution (2x) and water (4x) The organic layer was concentrated and the residue was crystallized from a mixture of methanol/ethyl acetate (70/30) over 48 hours in a refrigerator to afford the title compound as a white solid (1 03 g) MS (ES+) m/z 473 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 24 (t, J=6 0 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H), 7 10-7 24 (m, 2 H), 6 91 (br s 1 H), 4 80-4 95 (m, 2 H), 4 65 (t, J=5 7 Hz, 1 H), 4 52 (d, J=6 2 Hz, 2 H), 4 05-4 15 (m, 1 H), 3 99 (dd, J= 1 1 3, 1 8 Hz, 1 H), 3 77 (d, J=11 3 Hz, 1 H), 3 82 (s, 3 H), 3 30-3-50 (m, 4 H), 2 68 (s, 3 H)
Example 413 rac-(2S*,5S*)-Methyl 5-((5-(2-((4-fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H- tetrazol-2-yl)methyl)-1 ,4-dioxane-2-carboxylate
rac-(2S*,5R*)-Methyl 5-((tosyloxy)methyl)-1 ,4-dιoxane-2-carboxylate (prepared as described in step 1 of the synthesis of rac-(2S*,5S*)-methyl 5-((5-(6-((3-methoxybenzyl)carbamoy!)-2- methylpyrιmιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylate, Example 85) (77 mg, 0 23 mmol) was added to a mixture of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5- yOpicolmamide (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2- (((<rans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 170) (80 mg, 0 23 mmol) and triethylamine (24 mg, 0 23 mmol) in anhydrous acetonitπle (2 mL) The mixture was stirred at 800C in a capped vial overnight and then was purified by reverse phase preparative HPLC (water/acetonitrile) to afford the title compound as a white solid (65 mg) Example 414 rac-(2S*,5S*)-5-((5-(2-((4-Fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-
2-yl)methyl)-1 ,4-dioxane-2-carboxylic acid
Sodium hydroxide (2 pellets) was added to rac-(2S*,5S*)-methyl 5-((5-(2-((4-fluoro-3- methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylate (prepared as described in Example 413) (65 mg, 0 13 mmol) in a mixture of tetrahydrofuran/water (1 mL, 1/1 ) and the mixture was stirred at room temperature for 3 hours The reaction mixture was acidified with tπfluoroacetic acid and purified by reverse-phase preparative HPLC (water/ acetonitrile) The resulting product was slurried and decanted from ether several times and then dried in a vacuum desiccator to afford the title compound as a white solid (50 mg) MS (ES+) m/z 487 (M+H) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 9 24 (t, J=6 0 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H)1 7 10-7 24 (m, 2 H)1 6 91 (br S , 1 H), 4 85-4 99 (m, 2 H), 4 52 (d, J=6 2 Hz1 2 H)1 4 05-4 20 (m, 3 H)1 3 90-3 99 (m, 1 H), 3 82 (s, 3 H), 3 45-3-60 (m, 2 H), 2 68 (s, 3 H)
Example 415 rac-W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((2S*,5S*)-5-(2-hydroxypropan-2-yl)-1 ,4-dioxan-2- yl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide
A solution of methyl magnesium iodide (3M in ether, 0 1 mL, 0 3 mmol) was added dropwise at room temperature to a solution of rac-(2S*,5S*)-methyl 5-((5-(2-((4-fluoro-3- methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylate (prepared as described in Example 413) (35 mg, 0 07 mmol) in anhydrous tetrahydrofuran (1 mL) Additional tetrahydrofuran (0 5 mL) was added and the mixture was stirred at room temperature for 2 hours The reaction mixture was cooled to ice bath temperature and saturated aqueous ammonium chloride solution (0 5 mL) was added dropwise The product was purified by reverse phase preparative HPLC (water/ acetonitrile) Fractions containing the product were passed through a carbonate resin column and the filtrate was concentrated The residue was slurried and decanted from ether several times and then dried in a vacuum desiccator to afford the title compound as a white solid (21 mg) MS (ES+) m/z 501 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 24 (t, J=6 2 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H), 7 1 -7 25 (m, 2 H), 6 91 (br s , 1 H), 4 80-4 99 (m, 2 H1 m), 4 52 (d,
J=6 2 Hz, 2 H), 4 00-4 15 (m, 2 H), 3 90-3 99 (m, 1 H), 3 82 (s, 3 H), 3 33-3 45 (m, 2 H), 3 12-3 19 (m, 1 H), 2 68 (S1 3 H)1 1 07 (s, 3H)1 1 01 (S1 3H) Example 416 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((2S*,5S*)-5-carbamoyl-1,4-dioxan-2-yl)methyl)-2W- tetrazol-5-yl)-6-methylpicolinamιde
Formamide (200 mg) was added to a solution of rac-(2S*,5S*)-methyl 5-((5-(2-((4-fluoro-3- methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylate (prepared as described in Example 413) (123 mg, 0 3 mmol) in anhydrous tetrahydrofuran (1 5 ml) at reflux temperature A solution of sodium methoxide (25% in methanol, 200 mg) was added and the mixture was stirred at reflux for 1 5 hours The reaction mixture was purified by reverse phase preparative HPLC (water/ acetonitπle) Fractions containing the product were passed through a carbonate resin column and the filtrate was concentrated The residue was slurried and decanted from ether several times and then dried in a vacuum desiccator to afford the title compound as a white solid (78 mg) MS (ES+) m/z 486 (M+H) 1H NMR (400 MHz, DMSO-cfe) <* PPm 9 24 (t, J=6 0 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H), 7 10-7 24 (m, 2 H), 6 91 (br S , 1 H), 4 85-4 99 (m, 2 H), 4 52 (d, J=6 2 Hz, 2 H), 4 05-4 20 (m, 3 H), 3 90-3 99 (m, 1 H), 3 82 (s, 3 H), 3 45-3-60 (m, 2 H), 2 68 (s, 3 H)
Example 417 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((2S*,5S*)-5-cyano-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5- yl)-6-methylpicolinamide
Polymer supported triphenylphosphine (Argonaut, 2 15 mmol/g, 200 mg) was added to rac-Λ/-
(4-fluoro-3-methoxybenzyl)-4-(2-(((2S*,5S*)-5-carbamoyl-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide (Example 416) (65 2 mg, 0 13 mmol) in a mixture of carbon tetrachloride (0 25 mL) and dichloroethane (2 25 mL) and the mixture was heated at 80 0C for 3 hours The reaction mixture was filtered and the resin was washed with dichloroethane The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC Fractions containing the first eluting isomer were passed through a carbonate resin column and were concentrated The product was slurried and decanted several times from ether and the solid was dried in a vacuum desiccator to afford the title compound as a white solid (23 mg) MS (ES+) m/z 468 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 31 (t, J=6 3 Hz, 1 H), 8 44 (s, 1 H), 8 11 (d, J=1 O Hz, 1 H), 7 19 (dd, J=9 1 , 2 5 Hz, 1 H), 7 15 (dd, J= 11 7, 8 4 Hz, 1 H), 6 87 - 6 94 (m, 1 H), 5 04 (d, J=2 7 Hz, 1 H), 4 99 (br s , 1 H), 4 97 (d, J=4 1 Hz, 1 H), 4 51 (d, J=6 3 Hz, 2 H), 4 23 - 4 31 (m, 1 H), 4 08 (dd, J= 11 9, 2 6 Hz, 1 H), 3 95 (d, J=12 5 Hz, 1 H), 3 83 (s, 3 H), 3 71 - 3 82 (m, 2 H), 2 69 (s, 3 H)
Example 418 rac-W-(4-Fluoro-3-methoxybenzyl)-4-(2-(((2S*,5/?*)-5-cyano-1,4-dioxan-2-yl)methyl)-2H-tetrazol- 5-yl)-6-methylpicolinamide
Isolation of the second eluting isomer by reverse phase preparative HPLC from the reaction mixture described in Example 417 afforded the title compound as a white solid (18 mg) MS (ES+) m/z 468 (M+H) 1H NMR (400 MHz, DMSO-d6) 6 ppm 9 22 (t, J=Q 0 Hz, 1 H), 8 41 (s, 1 H), 8 06 (s, 1 H), 7 87 (s, 1 H), 7 16 (d, J=8 1 Hz, 1 H), 7 1 1 (dd, J= 1 1 5, 8 2 Hz, 1 H), 6 85 - 6 91 (m, 1 H), 4 74 - 5 00 (m, 2 H)1 4 48 (d, J=Q 2 Hz1 2 H), 4 05 - 4 17 (m, 2 H), 4 02 (d, J=8 1 Hz, 1 H)1 3 89 (dd, J= 1 1 5, 2 7 Hz, 1 H), 3 80 (s, 3 H), 3 62 - 3 72 (m, 1 H), 2 65 (s, 3 H)
Example 419 rac-Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-(((2S*,5S*)-5-(2-hydroxyacetyl)-1 ,4-dioxan-2-yl)methyl)- 2H-tetrazol-5-yl)-6-methylpicolinamide
Oxalyl chloride (10 mL) was added to a stirred solution of rac-(2S*,5S*)-5-((5-(2-((4-fluoro-3- methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylιc acid (prepared as described in Example 414) (820 mg, 1 69 mmol) in dichloromethane (10 mL) The mixture was stirred at room temperature for 18 hours and then concentrated The residue was repeatedly taken up in dichloromethane and concentrated to remove excess oxalyl chloride The resulting residue was then taken up in dioxane (5 mL) and treated with trιs(trιmethylsι!oxy)ethylene (5 O g, 17 0 mmol) The mixture was heated to 950C for 18 hours Additional trιs(trιmethylsιloxy)ethylene (5 O g, 17 0 mmol) was added and heating at 95°C was continued for 1 week The mixture was treated with several drops of 3 N hydrochloric acid until gas evolution stopped The reaction mixture was purified by reverse phase preparative HPLC Fractions containing desired product were combined and concentrated The residue was dissolved in methanol and passed through a carbonate cartridge The filtrate was concentrated to afford the title compound as a solid (29 mg, 3%) MS (ES+) m/z 501 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 2 66 (s, 3 H), 3 43 - 3 58 (m, 2 H), 3 63 (s, 2 H), 3 80 (s, 3 H), 3 90 - 4 00 (m, 1 H), 4 02 - 4 19 (m, 2 H), 4 19 - 4 27 (m, 1 H), 4 48 (d, J=5 86 Hz, 2 H), 4 79 - 4 99 (m, 3 H), 6 83 - 6 94 (m, 1 H), 7 06 - 7 20 (m, 2 H), 8 06 (br s , 1 H), 8 41 (br s , 1 H), 9 16 - 9 26 (m, 1 H)
Example 420 rac-(2S*,5S*)-Methyl 5-((5-(2-((3-chloro-4-fluorobenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H- tetrazol-2-yl)methyl)-1,4-dioxane-2-carboxylate
rac-(2S*,5/?*)-Methyl 5-((tosyloxy)methyl)-1 ,4-dιoxane-2-carboxylate (prepared as described in step 1 of the synthesis of rac-(2S*,5S*)-methyl 5-((5-(6-((3-methoxybenzyl)carbamoyl)-2- methylpyrιmιdιn-4-yl)-2H-tetrazol-2-yl)methyl)-1 ,4-dιoxane-2-carboxylate, Example 85) (83 mg, O 25 mmol) was added to a mixture of /V-(3-chloro-4-fluorobenzyl)-6-methyl-4-(2W-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 1 of the synthesis of Λ/-(3-chloro-4-fluorobenzyl)-4-(2-(((<rans)-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 194) (75 mg, 0 22 mmol) and tπethylamine (109 mg, 1 0 mmol) in anhydrous Λ/,Λ/-dιmethylacetamιde (0 3 mL) The mixture was stirred at 850C in a capped vial overnight and then was purified by reverse phase preparative HPLC (water/acetonitrile) to afford the title compound as a white solid (99 mg)
Example 421 rac-(2S*,5S*)-5-((5-(2-((3-Chloro-4-fluorobenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)-1 ,4-dioxane-2-carboxylic acid
Sodium hydroxide (3 pellets) was added to rac-(2S*,5S*)-methyl 5-((5-(2-((3-chloro-4- (prepared as described in Example 420) (99 mg, 0 2 mmol) in a mixture of tetrahydrofuran/water (0 8 mL, 1/1 ) and the mixture was stirred at room temperature overnight The reaction mixture was acidified with trifluoroacetic acid and purified by reverse-phase preparative HPLC (water/acetonitrile) The resulting product was slurried and decanted from ether several times and then dried in a vacuum desiccator to afford the title compound as a white solid (68 mg) MS (ES+) m/z 491 (M+H) 1H NMR (400 MHz, DMSO-cfe) δ ppm 9 36 (t, J=6 0 Hz, 1 H), 8 42 (s, 1 H), 8 09 (s, 1 H), 7 55-7 6 (m, 1 H), 7 35-7 45 (m, 2 H), 4 85-4 99 (m, 2 H), 4 52 (d, J=6 2 Hz, 2 H), 4 05-4 20 (m, 3 H), 3 90-3 99 (m, 1 H), 3 45-3-60 (m, 2 H), 2 68 (s, 3 H) Example 422 rac-/V-(3-Methoxybenzyl)-4-(2-(((2/?*,5S*)-5-(aminomethyl)-1,4-dioxan-2-yl)methyl)-2H-tetra2ol-5- yl)-6-methylpicolinamide
Step 1 Preparation of rac-((2/?*.5f?*)-5-((5-(2-((3-methoxyben2yl)carbamoyl)-6-methylpγrιdιn-4-yl)-2H- tetrazol-2-yl)methyl)-1 ,4-dιoxan-2-yl)methyl methanesulfonate
Methane sulfonyl chloride (172 mg, 1 5 mmol) was added to a solution of rac-Λ/-(3- methoxybenzyl)-4-(2-(((2S*,5/?*)-5-(hydroxymethyl)-1 )4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide (prepared as described in Example 403) (620 mg, 1 36 mmol) in anhydrous pyridine (2 ml) at 0 0C The mixture was allowed to stir at room temperature overnight The reaction mixture was cooled to 0 0C, diluted with water, and extracted with dichloromethane The organic layer was dried over magnesium sulfate and concentrated to afford the title compound (546 mg)
Step 2 Preparation of rac-A/-(3-methoxybenzyl)-4-(2-(((2f?*.5S*)-5-(aminomethyl)-1.4-dioxan-2- yl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde
Concentrated ammonium hydroxide (50 mg, 1 40 mmol) was added to a solution of rac- ((2f?*,5R*)-5-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2-yl)methyl)-1 ,4- dιoxan-2-yl)methyl methanesulfonate (140 mg, 0 263 mmol) in tetrahydrofuran (5 mL) and the mixture was heated to 100 0C overnight The reaction mixture was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound as a white solid (25 mg, 16%) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 3 690 mm , m/z 568 (M+H) 1H NMR (400 MHz, methanol-^) 6 ppm 2 65 - 2 69 (m, 2 H), 2 78 - 2 90 (m, 2 H), 2 94 - 3 10 (m, 2 H), 3 32 - 3 46 (m, 1 H), 3 55 - 3 68 (m, 1 H), 3 74 - 3 77 (m, 3 H), 3 78 - 3 84 (m, 1 H), 4 07 - 4 14 (m, 1 H), 4 17 - 4 27 (m, 1 H), 4 56 - 4 63 (m, 2 H), 6 81 (dd, J=I 79, 2 15 Hz, 1 H), 6 77 - 6 83 (m, 1 H), 6 90 - 6 96 (m, 2 H), 7 22 (t, J=8 19 Hz, 1 H), 8 09 (s, 1 H), 8 56 (s, 1 H) Example 423 rac-/V-(3-Methoxybenzyl)-6-methyl-4-(2-(((2/?*,5S*)-5-(methylsulfonamidomethyl)-1,4-dioxan-2- yl)methyl)-2W-tetrazol-5-yl)picolinamide
Diisopropylethylamine (157 mg, 1 21 mmol) was added to a solution of rac-N-(3- methoxybenzyl)-4-(2-(((2R*,5S*)-5-(amιnomethyl)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide (prepared as described in Example 422) (55 mg, O 12 mmol) in N, N- dimethylformamide (5 O mL) After 20 minutes, methanesulfonyl chloride (69 5 mg, O 606 mmol) was added and the mixture was stirred at room temperature overnight The reaction mixture was concentrated, and the residue was purified by reverse phase preparative HPLC to afford the title compound as a solid (36 4 mg, 46%) LCMS (5%-95% CH3CN/H2O, 5 mm ) 4 923 mm , m/z 532 (M+H) 1H NMR (400 MHz, DMSO-Of6) δ ppm 2 66 (s, 3 H), 2 87 (s, 3 H), 2 94 (t, J=5 86 Hz, 3 H), 3 46 (d, J=IO 98 Hz, 4 H), 3 42 (br s , 1 H), 3 71 (s, 3 H), 3 76 (d, J=11 71 Hz, 3 H), 4 49 (d, J=6 59 Hz, 4 H), 4 78 - 4 94 (m, 5 H)
Example 424 rac-W-(3-Methoxybenzyl)-4-(2-(((2R*,5S*)-5-(acetamidomethyl)-1,4-dioxan-2-yl)methyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
Diisopropylethylamine (0 45 mL, 0 97 mmol) was added to a solution of rac-N-(3- methoxybenzyl)-4-(2-(((2/?*,5S*)-5-(amιnomethyl)-1 ,4-dιoxan-2-yl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide (prepared as described in Example 422) (55 mg, 0 12 mmol) in N1N- dimethylformamide (5 0 mL) After 20 minutes, acetic anhydride (0 34 mL, 0 364 mmol) was added and the mixture was stirred at room temperature overnight The reaction mixture was concentrated, and the residue was purified by reverse phase preparative HPLC to afford the title compound as a solid (36 7 mg, 50%) LC/MS (5%-95% CH3CN/H2O, 5 mm ) 3 17 mm , m/z 496 (M+H) 1H NMR (400 MHz, DMSO-Oe) δ ppm 1 78 (s, 3 H), 2 49 (s, 1 H), 2 67 (s, 1 H), 2 97 - 3 08 (m, 1 H), 3 38 - 3 51 (m, 3 H), 3 65 - 3 75 (m, 4 H), 3 92 - 4 02 (m, 2 H), 4 02 - 4 09 (m, 2 H), 4 44 - 4 53 (m, 3 H), 4 75 - 4 95 (m, 4 H), 6 76 - 6 82 (m, 1 H), 6 85 - 6 93 (m, 1 H), 7 16 - 7 26 (m, 1 H), 7 78 - 7 89 (m, 1 H), 8 05 (s, 1 H), 8 40 (S, 1 H), 9 12 - 9 25 (m, 1 H)
Example 425
W-(3-Methoxybenzyl)-6-methyl-4-(2-((tetrahydrofuran-2-yl)methyl)-2H-tetrazol-5-yl)picolinamide
Di-tert-butylazodicarboxylate (74 0 mg, 0 320 mmol) was added to a cooled (ice bath) mixture of (tetrahydrofuran-2-yl)methanol (32 68 mg, 0 320 mmol), N-(3-methoxybenzyl)-6-methyl-4-(2H- tetrazol-5-yl)pιcolιnamιde (52 0 mg, 0 160 mmol) (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((^ans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153), and triphenylphosphine resin (186 0 mg, 0 400 mmol, 2 15 mmol/g loading) in anhydrous tetrahydrofuran (3 mL) The mixture was allowed to warm to room temperature and agitated overnight Trifluoroacetic acid (2 mL) was added and the mixture was agitated for 1 hour The reaction mixture was filtered and the resin was washed with trifluoroacetic acid (1 mL) The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC (5%-95% CH3CN/H2O, 8 mm ) to afford the title compound as a solid (30 8 mg, 47%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN, 1 5 mm ) 3 198 mm , m/z 409 (M+H)
Example 426
W-(4-Fluoro-3-methylbenzyl)-6-methyl-4-(2-((tetrahydro-2H-pyran-4-yl)methyl)-2H-tetrazol-5- yl)picolinamide
4-(Bromomethyl)-tetrahydro-2H-pyran (90 mg, 0 5 mmol) was added to a mixture of Λ/-(4- fluoro-3-methylbenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as describe in step 1 of the synthesis of Λ/-(4-fluoro-3-methylbenzyl)-4-(2-(((/rans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide, Example 185) (150 mg, 0 46 mmol) and triethylamine (46 mg, 0 46 mmol) in anhydrous acetonitrile (2 mL) The mixture was stirred at reflux temperature in a capped vial for two days and then was purified by reverse phase preparative HPLC (water/acetonitrile) Fractions containing the product were passed through a carbonate resin column and the filtrate was concentrated The residue was slurried with ether, decanted, and dried in a vacuum desiccator to afford the title compound as a white solid (135 mg) MS (ES+) m/z 425 (M+H)
Example 427 rac-W-(3-Methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2H-pyran-2-yl)methyl)-2H-tetrazol-5- yl)picolinamide
To a vial containing tetrahydropyran-2-methanol (0 348 ml_, 3 08 mmol), a solution of N-(Z- methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of /V-(3-methoxybenzyl)-4-(2-(((frans)-4-aminocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide, Example 153) (500 0 mg, 1 54 mmol) in anhydrous tetrahydrofuran (25 mL) and triphenylphosphine resin (1 791 g, 3 85 mmol, 2 15 mmol/g loading) was added The reaction mixture was chilled in an ice bath, and di-tert-butylazodicarboxylate (709 0 mg, 3 08 mmol) was added The ice bath was removed and the reaction mixture was agitated (orbital) overnight at room temperature Volatiles were removed under a nitrogen stream The residue was purified by silica gel chromatography to afford the title compound as a solid (350 mg, 54%) LC/MS (5%-95% CH3CN/H2O, 4 5 mm , 95% CH3CN1I 5 mm ) 3 506 mm , m/z 423 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 23 (m, 1 H), 8 40 (s, 1 H), 8 05 (s, 1 H), 7 23 - 7 19 (m, 1 H), 6 89 - 6 87 (m, 2 H), 6 80 - 6 77 (m, 1 H), 4 79 - 4 74 (m, 2 H), 4 48 (d, J=6 0 Hz, 2 H), 3 93 - 3 75 (m), 3 70 (s, 3 H), 2 65 (s, 3 H), 1 80 - 1 25 (m)
Example 428
(-)-W-(3-Methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2H-pyran-2-yl)methyl)-2H-tetrazol-5- yl)picolinamide
rac-Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2/-/-pyran-2-yl)methyl)-2H-tetrazol-5- yl)pιcolιnamιde was resolved by supercritical fluid chromatography (Chiralcel OD-H, 30 x 250 mm, 25/75 ethanol/C02, 70 mUmin) to afford the title compound as an oil (0 25 g) Chiralcel OD-H analytical column (4 6 x 250 mm, 20/80, ethanol/CO2), 8 06 mm, > 99% ee, [σ]D 21'c = 22 7° (c = 8 3, DMF)
Example 429 (+)-W-(3-Methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2H-pyran-2-yl)methyl)-2H-tetrazol-5- yl)picolinamide rac-Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2H-pyran-2-yl)methyl)-2/-/-tetrazol-5- yl)pιcolιnamιde was resolved by supercritical fluid chromatography (Chiralcel OD-H, 30 x 250 mm, 25/75 ethanol/CO2, 70 mUmm) to afford the title compound as an oil (0 26 g) Chiralcel OD-H analytical column (4 6 x 250 mm, 20/80, ethanol/CO2), 9 99 mm, > 99% ee, (σ]D 2rc = 19 0° (c = 9 8, DMF)
Example 430 rac-W-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2H-pyran-2-yl)methyl)-2H-tetrazol-
5-yl)picolinamide
Step 1 Preparation of methyl 6-methyl-4-(2-((tetrahvdro-2H-pyran-2-yl)methyl)-2H-tetrazol-5- vDpicohnate
Methyl 6-methyl-4-(2/-/-tetrazot-5-yl)pιcolιnate (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5-yl)-6- methylpicolinamide, Example 153) (0 50 g, 2 0 mmol), tetrahydropyran-2- methanol (0 27 g, 2 28 mmol), and polymer supported-tπphenylphosphine (2 65 g, 5 70 mmol) were suspended in tetrahydrofuran (100 mL) The mixture was cooled to 0 0C in an ice bath for 15 mm and then dι-tert- butyl azodicarboxylate (1 05 g, 4 56 mmol) was added The reaction was allowed to warm to room temperature and was stirred for 15 hours The mixture was filtered through a Celite™ pad and washed with tetrahydrofuran (15 mL) The filtrate was concentrated and purified by silica gel column chromatography (0-50 % ethyl acetate/hexanes) to afford the title compound as an oil (0 58 g, 81%) LC/MS (5-100% CH3CN/H2O, 8 mm) 4 88 mm, m/z 318 (M+H) Step 2 Preparation of 6-methyl-4-(2-((tetrahvdro-2H-pyran-2-yl)methyl)-2H-tetrazol-5-yl)pιcolιnιc acid
6-Methyl-4-(2-((tetrahydro-2H-pyran-2-yl)methyl)-2H-tetrazol-5-yl)pιcolιnate (0 54 g, 1 84 mmol) was dissolved in tetrahydrofuran (5 mL) and then treated with an aqueous sodium hydroxide solution (2 5 N) The mixture was stirred at ambient temperature for 2 hours and then the tetrahydrofuran was removed in a stream of nitrogen The aqueous residue was acidified to pH 3 with concentrated hydrochloric acid and extracted with ethyl acetate (2 x 15 mL) The combined organic layers were dried over anhydrous sodium sulfate and concentrated to afford the title compound (0 48 g, 86%) LC/MS (5-100% CH3CN/H2O, 8 mm) 3 88 mm, m/z 304 (M+H) Step 3 Preparation of rac-/V-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((tetrahvdro-2/-/-pyran-2- yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde
1-Hydroxybenzatrιazole (22 mg, 0 16 mmol) was added to a solution of 6-methyl-4-(2- ((tetrahydro-2H-pyran-2-yl)methyl)-2/-/-tetrazol-5-yl)pιcolιnιc acid (0 035g, 0 12 mmol) in N1N- dimethylformamide (0 5 mL) After being stirred for 5 mm, Λ/-methylmorpholιne (0 051 mL, 0 46 mmol) was then added followed by a solution of 4-fluoro-3-methoxybenzylamιne hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-((frans-4- aminocyclohexyOmethyl^H-tetrazol-S-yOpyrimidine^-carboxamide, Example 1 ) (18 mg, 0 12 mmol) in AZ.AZ-dimethylformamide (0 5 mL) 1 -Ethyl-3-(3'-dιmethylamιnopropyl)carbodιιmιde hydrochloride (31 mg, 0 16 mmol) was then added The mixture was stirred at room temperature for 18 hours and then purified by reverse phase preparative HPLC to afford the title compound as an oil (6 5 mg, 13%) 1H NMR (400 MHz, DMSOd6) δ ppm 9 21 (t, J=Q 2 Hz1 1 H)1 8 40 (s, 1 H)1 8 06 (s, 1 H), 7 21 - 7 06 (m, 2 H)1 6 89 (s, 1 H), 4 72 - 4 86 (m, 2 H), 4 48 (d, J=5 9 Hz1 2 H)1 3 92 (dd, J= 11 0, 5 1 Hz, 1 H), 3 84 - 3 74 (m, 3 H), 2 66 (s, 3 H), 1 80 (d, J=12 5 Hz, 2 H), 1 71 (d, J= 11 7 Hz1 2 H)1 1 58 - 1 16 (m, 4 H)
Example 431 rac-ZV-(4-Fluoro-3-methylbenzyl)-6-methyl-4-(2-((tetrahydro-2W-pyran-2-yl)methyl)-2W-tetrazol-5- yl)picolinamide
1 -Hydroxybenzatrιazole (22 mg, 0 16 mmol) was added to a solution of 6-methyl-4-(2- ((tetrahydro-2H-pyran-2-yl)methyl)-2H-tetrazol-5-yl)pιcolιnιc acid (prepared as described in step 2 of the synthesis of rac-Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2/-/-pyran-2-yl)methyl)- 2H-tetrazo!-5-y!)pιco!ιnamιde, Example 430) (0 035g, 0 12 mmol) in Λ/,Λ/-dιmethylformamιde (0 5 mL) After being stirred for 5 mm, Λ/-methylmorpholιne (0 051 mL, 0 46 mmol) was then added followed by a solution of (4-fluoro-3-methylphenyl)methanamιne ( 16 mg, 0 12 mmol) in Λ/,Λ/-dιmethylformamιde (0 5 mL) 1 -Ethyl-3-(3'-dιmethylamιnopropyl)carbodιιmιde hydrochloride (31 mg, 0 16 mmol) was then added The mixture was stirred at room temperature for 18 hours and then purified by reverse phase preparative HPLC to afford the title compound as an oil (5 1 mg, 10%) 1H NMR (400 MHz, DMSOd6) δ ppm 9 18 (t, J=6 2 Hz, 1 H), 8 40 (s, 1 H), 8 06 (s, 1 H), 7 20 (t, J=8 1 Hz, 1 H), 6 87 (s, 2 H), 6 77 (d, J=Q 8 Hz, 1 H), 4 68 - 4 90 (m, 2 H), 4 48 (d, J=6 6 Hz, 2 H), 3 86 - 4 06 (m, 4 H), 3 78 (d, J= 1 1 0 Hz, 1 H), 2 65 (s, 3 H), 1 75 (dd, J=34 8, 12 8 Hz, 2 H), 1 13 - 1 58 (m, 4 H)
Example 432 rac-/V-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2W-pyran-3-yl)methyl)-2H-tetrazol-
5-yl)picolinamide
Step 1 Preparation of rac-(tetrahvdro-2H-pyran-3-yl)methanol Tetrahydro-2/-/-pyran-3-carbaldehyde (0 40 g, 3 5 mmol) was dissolved in anhydrous methanol (7 mL) and cooled to -10 0C Sodium borohydride (0 53 g, 14 mmol) was added in three portions The reaction was stirred 1 hour at 0 0C and was then quenched with a saturated aqueous solution of ammonium chloride (5 mL) The mixture was filtered and the filtrate was concentrated to aqueous in vacuo without heat The residue was then diluted with water (5 mL) and ethyl acetate (15 mL), and the mixture was again filtered The filtrate was transferred to a separatory funnel and the phases separated The aqueous layer was re-extracted with ethyl acetate (2 x 10 mL) The combined organic layers were washed with water (4 x 10 mL) followed by brine (10 mL), dried over sodium sulfate, and concentrated at 30 0C under vacuum to afford the title compound as an oil (0 31 g, 76%) LC/MS (5-100% CH3CN/H2O, 8 mm) 0 85 mm, m/z 117 (M+H) Step 2 Preparation of rac-(tetrahvdro-2/-/-pyran-3-yl)methyl 4-nιtrobenzenesulfonate
4-Nιtrobenzene-1 -sulfonyl chloride (0 62 g, 2 8 mmol) and pyridine (253 mg, 3 20 mmol) were added to a solution of rac-(tetrahydro-2/-/-pyran-3-yl)methanol (0 31 g, 2 67 mmol) in dichloromethane (5 mL), and the mixture was stirred at room temperature for 15 hours The reaction mixture was diluted with dichloromethane (10 mL) and washed with water (2 x 10 mL), brine (10 mL), dried over sodium sulfate, and concentrating The residue was purified on silica gel column chromatography (0- 50% ethyl acetate/heptane) to afford the title compound as an oil (0 65 g, 81 %) LC/MS (5-100% CH3CN/H2O, 5 mm) 2 56 mm, m/z 302 (M+H) Step 3 Preparation of rac-Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2-((tetrahvdro-2H-pyran-3- yl)methyl)-2H-tetrazol-5-yl)pιcolιnamιde
A mixture of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((/raπs)-4- aminocyclohexyOmethyO^H-tetrazol-δ-yO-e-methylpicolinamide, Example 170) (79 mg, 0 23 mmol), rac-(tetrahydro-2/-/-pyran-3-yl)methyl 4-nιtrobenzenesulfonate (77 mg, 0 25 mmol), and triethylamine (0 40 mL) in Λ/,Λ/-dιmethylacetamιde (0 1 mL) was stirred at 85 0C for 15 hours The reaction mixture was purified by reverse phase preparative HPLC to afford the title compound as a beige solid (68 mg, 69%) 1H NMR (400 MHz, DMSOd6) δ ppm 9 22 (t, J=Q 2 Hz, 1 H), 8 43 (s, 1 H), 8 08 (s, 1 H), 7 12 (d, J=8 4 Hz, 1 H), 7 16 (dd, J=13 4, 8 2 Hz, 2 H), 6 91 (d, J=A 0 Hz, 1 H), 4 74 (dd, J=12 6, 7 1 Hz, 2 H), 4 51 (d, J=Q 2 Hz, 2 H), 3 82 (s, 3 H), 3 72 (t, J=M 4 Hz, 2 H), 3 39 (t, J=9 0 Hz, 1 H), 2 68 (s, 3 H), 2 28 (br s , 1 H), 1 74 (d, J=12 4 Hz, 1 H), 1 63 (d, J=A 0 Hz, 1 H), 1 49 (dd, J=9 5, 4 0 Hz, 1 H), 1 35 (d, J=9 5 Hz, 1 H)
Example 433 rac-W-(3-Methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2H-pyran-3-yl)methyl)-2H-tetrazol-5- yl)picolinamide
A mixture of W-(3-methoxybenzy!)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((rrans)-4-amιnocyclohexyl)methyl)- 2/-/-tetrazol-5-yl)-6-methy!pιcolιnamιde, Example 153) (79 mg, 0 23 mmol), rac-(tetrahydro-2/-/-pyran-3- yl)methyl 4-nιtrobenzenesulfonate (prepared as described in step 2 of the synthesis of rac-Λ/-(4-fluoro- 3-methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2/-/-pyran-3-yl)methyl)-2/-/-tetrazol-5-yl)pιcolιnamιde, Example 432) (77 mg, 0 25 mmol), and triethylamine (0 40 mL) in Λ/,Λ/-dιmethylacetamιde (0 1 mL) was stirred at 85 0C for 15 hours The reaction mixture was purified by reverse phase preparative HPLC to afford the title compound as a beige solid (62 mg, 61%) 1H NMR (400 MHz, DMSOd6) δ ppm 9 20 (br s , 1 H), 8 08 (s, 1 H), 7 24 (t, J=8 1 Hz, 1 H), 6 93 (br s , 2 H), 6 82 (d, J=I 7 Hz, 1 H), 4 75 <dq, ./=13 0, 6 8 Hz, 2 H), 4 51 (d, J=Q 2 Hz, 2 H), 3 73 (s, 5 H), 3 68 (br s , 1 H), 3 41 (br s , 1 H), 3 37 (d, J=2 2 Hz, 1 H), 2 68 (s, 3 H), 2 28 (br s , 1 H), 1 74 (br s , 1 H), 1 62 (br s , 1 H), 1 50 (d, J=Q 8 Hz, 1 H), 1 35 (d, J=9 5 Hz, 1 H)
Example 434 fac-/V-(4-Fluoro-3-methoxybenzyl)-4-(2-(((2S*,5R*)-5-hydroxy-tetrahydro-2H-pyran-2-yl)methyl)-
2H-tetrazol-5-yl)-6-methylpicolinamide
Step 1 Preparation of rac-(3f?*,6S*)-6-(hvdroxymethyl)-tetrahvdro-2/-/-pyran-3-ol
Tetrabutylammonium fluoride (23 0 g, 88 0 mmol) was added to a suspension of rac- (3/?*,6S*)-6-((fert-butyldιphenylsιlyloxy)methyl)-tetrahydro-2H-pyran-3-ol (Bioorg Med Chem 2006, 14, 3953-3966) (16 3 g, 44 0 mmol) in tetrahydrofuran (700 mL) The mixture was allowed to stir at room temperature for 6 hours and was then concentrated The residue was purified by silica gel column chromatography (hexanes/ethyl acetate, 2/1 , ethyl acetate/ethanol, 40/1) The crude product was further purified by silica gel chromatography (ethyl acetate) to afford a waxy solid which was repeatedly triturated with chloroform and then filtered to provide the title compound as a white solid (2 44 g, 42%) Step 2 Preparation of rac-Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((2S*,5f?*)-5-hvdroxy-tetrahvdro-2/-/- pyran-2-yl)methyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde
A mixture of A/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared s described in step 2 of the synthesis of W-(4-flυoro-3-methoxybenzyl)-4-(2-(((fraπs)-4- aminocyclohexyOmethyl^H-tetrazol-S-yO-θ-methylpicolinamide, Example 170) (1 50 g, 3 96 mmol), rac-(3/?*,6S*)-6-(hydroxymethyl)-tetrahydro-2/-/-pyran-3-ol (1 05 g, 7 92 mmol), and polymer supported tπphenylphosphine resin (3 68 g, 7 92 mmol) in tetrahydrofuran (20 mL) was cooled in an ice bath Di- terf-butyl-azodicarboxylate (1 82 g, 7 92 mmol) was added and the resulting mixture was stirred in the ice bath for 30 mm The ice bath was removed and the mixture stirred at room temperature for 18 hours Tπfluoroacetic acid (5 mL) was added and the reaction mixture was filtered The resin washed with tetrahydrofuran, methanol, and acetonitrile The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound as a white solid (251 mg, 1 1 %) 1H NMR (400 MHz, DMSO-d6) δ ppm 1 27 - 1 47 (m, 2 H), 1 78 - 1 88 (m, 1 H), 1 93 - 2 04 (m, 1 H), 2 68 (s, 3 H), 2 90 (t, J=10 25 Hz, 1 H), 3 37 - 3 47 (m, 1 H), 3 68 - 3 77 (m, 1 H), 3 78 - 3 92 (m, 4 H), 4 51 (d, J=6 59 Hz, 2 H), 4 74 - 4 93 (m, 3 H), 6 85 - 6 95 (m, 1 H), 7 08 - 7 24 (m, 2 H), 8 08 (s, 1 H), 8 43 (s, 1 H), 9 24 (t, J=Q 22 Hz, 1 H)
Example 435
W-(4-Fluoro-3-methoxybenzyl)-4-(2-((1 S*,2S*,4/?*)-7-oxa-bicyclo[2.2.1]heptan-2-ylmethyl)-2H- tetrazol-5-yl)-6-methylpicolinamide
Step 1 Preparation of (1 S*,2S*,4ff*)-7-oxa-bιcvclof2 2 11heptan-2-ylmethanol
A mixture of (1 S*,2f?*,4/?*)-7-oxa-bιcyclo[2 2 1]heptane-2-carboxylιc acid {J Med Chem 1971 , 14, 698-702) (0 25 g, 1 8 mmol) and carbodiimidazole ( 0 29 g, 1 8 mmol) in tetrahydrofuran (5 mL) was stirred for 15 minutes A solution of sodium borohydride (0 11 g, 2 8 mmol) in water (1 mL) was slowly added and the mixture was allowed to stir at room temperature for 15 hours The reaction mixture was diluted with an aqueous 10% hydrochloric acid solution (2 mL) and brine (2 mL) and then extracted with ethyl acetate (3 x 10 mL) The combined organic layers were washed with brine (2 x 5 mL), dried over sodium sulfate and concentrated to afford the title compound as an oil 1H NMR (400 MHz, DMSOd6) δ ppm 3 29 (br s , 1 H), 2 94 - 3 13 (m, 2 H), 1 68 - 1 82 (m, 2 H), 1 40 - 1 60 (m, 4 H), 1 28 - 1 40 (m, 2 H), 0 89 - 1 01 (m, 1 H) Step 2 Preparation of Λ/-(4-fluoro-3-rnethoxybenzyl)-4-(2-((1 S*.2S*.4f?*)-7-oxa-bιcvclof2 2 Hheptan-2- ylmethyl)-2H-tetrazol-5-yl)-6-methylpιcolιnamιde
A mixture of (1 S\2S*,4R*)-7-oxa-bιcyclo[2 2 1]heptan-2-ylmethanol (0 13 g, 0 98 mmol), N-(4- fluoro-3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((<rans)-4-amιnocyclohexyl)methyl)-2H-tetrazol-5- yl)-6-methylpιcolιnamιde, Example 170) (0 31 g, 0 81 mmol), and polymer supported- tπphenylphosphine (0 58 g, 1 22 mmol) in anhydrous tetrahydrofuran (10 mL) was cooled to 00C in an ice bath for 15 minutes Di-tert-butyl azodicarboxylate (0 23 g, 0 98 mmol) was added and the mixture was allowed to warm to room temperature and stir for 15 hours The reaction mixture was filtered and the filtrate was concentrated The residue was purified by reverse phase preparative HPLC (5-95% acetonitrile/water) to afford the title compound as a beige oil (66 mg, 18%) 1H NMR (400 MHz, DMSO-CZ6) δ ppm 9 08 - 9 26 (m, 1 H), 8 40 (br s , 1 H), 8 05 (br s , 1 H), 7 05 - 7 21 (m, 2 H), 6 88 (br s , 1 H), 4 64 (dd, J=13 18, 8 05 Hz, 1 H), 4 42 - 4 56 (m, 4 H), 4 33 (d, J=5 12 Hz, 1 H), 3 79 (s, 3 H), 3 22 (br s , 1 H), 2 64 (s, 3 H), 1 63 (dd, J= 11 35, 8 42 Hz, 1 H), 1 49 - 1 57 (m, 2 H), 1 38 - 1 48 (m, 2 H), 1 34 (d, J=13 18 Hz, 1 H)
Example 436
Ethyl 4-((5-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)bicyclo[2.2.2]octane-1-carboxylate
A mixture of Λ/-(3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)- 2H-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (130 mg), ethyl 4- ((tosyloxy)methyl)bιcyclo[2 2 2]octane-1-carboxylate (J Amer Chem Soc 1965, 87, 2404) (147 mg), and dnsopropylethylamine (0 090 mL) in dimethylsulfoxide (2 0 mL) was heated to 115 0C for 5 days The reaction mixture was purified by reverse phase preparative HPLC (acetonitrile/water, 70/30 - 90/10) Fractions containing the product were concentrated and extracted with dichloromethane (3 x 8 mL) The combined organic layers were dried over magnesium sulfate, filtered, and concentrated to afford the title compound (1 18 mg) MS (ES+) m/z 519 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 20 (t, J=6 4 Hz, 1 H), 8 40 (s, 1 H), 8 05 (s, 1 H), 7 22 (t, J=8 1 Hz, 1 H), 6 88 - 6 92 (m, 2 H), 6 80 (d, J=8 4 Hz, 1 H), 4 54 (s, 2 H), 4 49 (d, J=6 2 Hz, 2 H), 3 98 (q, J=7 0 Hz, 2 H), 3 71 (s, 3 H), 2 65 (s, 3 H), 1 63 - 1 71 (m, 6 H), 1 43 - 1 50 (m, 6 H), 1 1 1 (t, J=7 0 Hz, 3 H) Example 437
4-((5-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)bicyclo[2.2.2]octane-1 -carboxylic acid
Water (0 5 mL) and lithium hydroxide-monohydrate (21 4 mg) was added to a solution of ethyl 4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2/-/-tetrazol-2- yl)methyl)bιcyclo[2 2 2]octane-1 -carboxylate (prepared as described in Example 436) (75 mg) in tetrahydrofuran (1 0 mL) The mixture was heated at reflux for 3 days and then allowed to cool to room temperature The reaction mixture was filtered and the pH was adjusted to 4 with 1 N aqueous hydrochloric acid The resulting slurry was filtered, washed with water, and dried to afford the title compound as a white solid (54 mg) MS (ES+) m/z 491 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 19 (t, J=6 4 Hz, 1 H), 8 40 (s, 1 H), 8 05 (s, 1 H), 7 22 (t, J=8 1 Hz, 1 H), 6 87 - 6 92 (m, 2 H), 6 80 (d, J=Q 1 Hz, 1 H), 4 54 (s, 2 H), 4 49 (d, J=Q 6 Hz, 2 H), 3 71 (s, 3 H), 2 65 (s, 3 H), 1 61 - 1 70 (m, 6 H), 1 41 - 1 50 (m, 6 H)
Example 438
W-(3-Methoxybenzyl)-4-(2-((4-(hydroxymethyl)bicyclo[2.2.2]octan-1 -yl)methyl)-2H-tetrazol-5-yl)-
6-methylpicolinamide
A solution of 4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-2H-tetrazol-2- yl)methyl)bιcyclo[2 2 2]octane-1 -carboxylic acid (prepared as described in Example 437) (102 mg) in 2-methyltetrahydrofuran (5 mL) was cooled in an ice bath and a solution of lithium aluminum hydride (1 M in tetrahydrofuran, 0 30 mL) was added After 5 minutes the reaction was quenched with water The layers were separated and the aqueous layer was extracted with 2-methyltetrahydrofuran (2 x 3 mL) The combined organic layers were dried over magnesium sulfate and concentrated The residue was purified by reverse phase preparative HPLC to afford the title compound (30 7 mg) MS (ES+) m/z All (M+H) 1H NMR (400 MHz, DMSO-cfe) <5 ppm 9 19 (t, J=6 2 Hz, 1 H), 8 40 (s, 1 H), 8 05 (s, 1 H), 7 22 (t, J=Q 1 Hz, 1 H), 6 90 (br s , 2 H), 6 80 (dd, J=I 7, 1 5 Hz, 1 H), 4 47 - 4 53 (m, 4 H), 4 24 (t, J=5 5 Hz, 1 H), 3 71 (s, 3 H), 2 99 (d, J=5 1 Hz, 2 H), 2 65 (s, 3 H), 1 26 - 1 45 (m, 12 H) Example 439
4-(2-((4-(Hydroxymethyl)pentacyclo[4.2.0.02'5.03 β.04J]oct-1-yl)methyl)-2H-tetrazol-5-yl)-W-(3- methoxybenzyl)-6-methylpyridine-2-carboxamide
A mixture of Λ/-(3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of /V-(3-methoxybenzyl)-4-(2-(((<rans)-4-amιnocyclohexyl)methyl)- 2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (52 mg, 0 16 mmol), 1 ,4- bιs(hydroxymethyl)cυbane (J Amer Chem Soc 1991 , 113, 7692) (52 mg, 0 32 mmol), and polymer supported triphenylphosphine (190 mg, 0 4 mmol) in anhydrous tetrahydrofuran (3 mL) was cooled in an ice bath and di-terf-butyl azodicarboxylate (74 mg, 0 32 mmol) was added The mixture was placed in an ultrasonic bath for 10 mm and then filtered The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound (14 6 mg) MS (ES+) m/z 471 (M+H) 1H NMR (400 MHz, DMSO-Qf6) δ ppm 9 24 (t, J=Q 4 Hz, 1 H), 8 38 (s, 1 H), 8 04 (s, 1 H), 7 2 (t, J= 8 1 Hz, 1 H), 6 88 (s, 2 H), 6 78 (d, J=8 1 Hz, 1 H), 5 01 (s, 2 H), 4 46 (d, J=6 2 Hz, 3 H), 3 79 - 3 74 (m, 3 H), 3 71 - 3 64 (m, 6 H), 3 46 (d, J=5 5 Hz, 2 H), 2 63 (s, 3 H)
Example 440
4-((5-(2-(((3-Methoxybenzyl)amino)carbonyl)-6-methylpyridin-4-yl)-2H-tetrazol-2- yl)methyl)cubane-1 -carboxylic acid
A mixture of Λ/-(3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of Λ/-(3-methoxybenzyl)-4-(2-(((fraπs)-4-amιnocyclohexyl)methyl)- 2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (155 mg), methyl 4- hydroxymethylcubanecarboxylate (136 mg), and polymer supported triphenylphosphine (453 mg) in anhydrous tetrahydrofuran (10 mL) was cooled in an ice bath and di-tert-butyl azodicarboxylate (165 mg) was added The mixture was placed in an ultrasonic bath for 30 mm and then filtered The filtrate was acidified with trifluoroacetic acid (0 5 mL) and then concentrated The residue was purified by reverse phase preparative HPLC (acetonitrile/water, 50/50 - 80/20) The fractions containing product were concentrated and extracted with methylene chloride (3 x 5 mL) The combined organic layers were dried over magnesium sulfate, filtered and concentrated to afford the title compound as a white solid (146 mg) MS (ES+) m/z 485 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 12 26 (S, 1 H), 9 24 (t, J=S 4 Hz, 1 H), 8 39 (s, 1 H), 8 05 (d, J=1 3 Hz, 1 H), 7 21 (t, J=Q 1 Hz, 1 H), 6 87 - 6 90 (m, 2 H), 6 79 (dd, J=8 1 , 2 1 Hz, 1 H), 5 06 (s, 2 H), 4 47 (d, J=6 4 Hz, 2 H), 4 01 - 4 05 (m, 3 H), 3 88 - 3 92 (m, 3 H), 3 70 (s, 3 H), 2 65 (s, 3 H)
Example 441
4-(2-((4-(Aminocarbonyl)pentacyclo[4.2.0.02 5.03'8.04'7]oct-1-yl)methyl)-2H-tetrazol-5-yl)-W-(3- methoxybenzyl)-6-methylpyridine-2-carboxamide
4-((5-(2-(((3-Methoxybenzyl)amιno)carbonyl)-6-methylpyπdιn-4-yl)-2H-tetrazol-2- yl)methyl)cubane-1-carboxylιc acid (prepared as described in Example 440) (92 mg) was dissolved in anhydrous tetrahydrofuran (5 mL) under nitrogen and oxalyl chloride (0 100 ml_) was added followed by Λ/,/V-dιmethylformamιde (one drop) The mixture was stirred at room temperature for 30 minutes and then concentrated The residue was dissolved in anhydrous tetrahydrofuran (4 0 mL) and a solution of 7N ammonia in methanol (0 30 mL) was added in one portion The mixture was diluted with water (5 mL), acidified with trifluoroacetic acid, and concentrated The residue was purified by reverse phase preparative HPLC (acetonitrile/water, 40/60 - 65/35) to afford the title compound as a white solid (52 mg) MS (ES+) m/z 484 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 22 (t, J=6 0 Hz, 1 H), 8 43 (s, 1 H), 8 07 (s, 1 H), 7 24 (t, J=Q 1 Hz, 1 H), 7 17 (br s , 1 H), 6 93 (br s , 2 H), 6 87 (br s , 1 H), 6 82 (d, J=6 2 Hz, 1 H), 5 07 (s, 2 H), 4 51 (d, J=6 2 Hz, 2 H), 4 00 - 4 05 (m, 3 H), 3 86 - 3 91 (m, 3 H), 3 73 (s, 3 H), 2 68 (S1 3 H)
Example 442
4-(2-((4-Cyanopentacyclo[4.2.0.02 5.03 8.04'7]oct-1-yl)methyl)-2H-tetra2ol-5-yl)-W-(3- methoxybenzyl)-6-methylpyridine-2-carboxamide
Phosphorus oxychloride (0 030 mL) was added to a solution of 4-(2-((4-(amιnocarbonyl)- pentacyclo[4 2 0 O2 5 O3 8 O4 ^oct-i-yOmethyl^H-tetrazol-δ-yO-ΛHS-methoxybenzyO-e-methylpyridine- 2-carboxamιde (prepared as described in Example 441 ) (32 mg) in DMF (0 8 mL) The mixture was stirred for 2 minutes and then a solution of 5% aqueous sodium bicarbonate (2 mL) was slowly added The liquid was decanted and the solid was stirred with water (2 mL) and placed in an ultrasonic bath for 1 hour The resulting slurry was filtered, washed with water, and dried to afford the title compound as a white solid (26 mg) MS (ES+) m/z 466 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 22 (t, J=5 5 Hz, 1 H), 8 42 (s, 1 H), 8 06 (s, 1 H), 7 24 (t, J=B 1 Hz, 1 H), 6 93 (br s , 2 H), 6 82 (d, J=8 4 Hz, 1 H), 5 09 (s, 2 H)1 4 51 (d, J=Q 2 Hz, 2 H), 4 25 - 4 29 (m, 3 H), 4 01 - 4 06 (m, 3 H), 3 73 (s, 3 H),
2 68 (S, 3 H)
Example 443 Λ/-(3-Methoxybenzyl)-6-methyl-4-(2-((S)-3-methylbutan-2-yl)-2H-tetrazol-5-yl)picolinamide
A mixture of /V-(3-methoxybenzyl)-6-methyl-4-(2H-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 5 of the synthesis of W-(3-methoxybenzyl)-4-(2-(((frans)-4-amιnocyclohexyl)methyl)- 2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 153) (100 mg, 0 31 mmol), polymer supported triphenylphosphine (287 mg, 0 62 mmol), and (/?)-(-)-3-methyl-2-butanol(54 mg, 0 62 mmol) in tetrahydrofuran (100 mL) was cooled to 0 0C and di-tert-butyl azodicarboxylate (142 mg, 0 62 mmol) was added The mixture was allowed to warm to room temperature and stir for 18 hours The reaction mixture was filtered and the resin washed with tetrahydrofuran (20 mL) The filtrate was concentrated The crude product was purified by silica column chromatography (hexane/EtOAc, 8/1 , 4/1 ) Fractions containing product were concentrated and further purified by reverse phase preparative HPLC (acetonitrile/water, 0 05% TFA, 15/85 - 85/15) Combined fractions were neutralized with 2 5 N NaOH solution and acetonitrile was removed in vacuo The remaining aqueous solution was extracted with EtOAc (50 mL) The organic layer was dried over sodium sulfate and concentrated to afford the title compound as an oil (16 mg, 13%) MS (ES+) m/z 395 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 26 (t, J=Q 4 Hz1 1 H), 8 43 (d, J=O 9 Hz, 1 H), 8 09 (d, J=1 1 Hz, 1 H), 7 24 (t, J=8 1 Hz, 1 H), 6 90 - 6 93 (m, 2 H), 6 82 (ddd, J=B 2, 2 5, 0 8 Hz, 1 H), 4 95 (qd, J=Q 9, 6 8 Hz, 1 H), 4 51 (d, J=Q 4 Hz, 2 H), 3 73 (s, 3 H), 2 68 (s, 3 H), 2 31 - 2 18 (m, 1 H), 1 62 (d, J=Q 9 Hz1 3 H), 0 97 (d, J=Q 9 Hz, 3 H), 0 78 (d, J=6 7 Hz, 3 H)
Example 444
W-(4-Fluoro-3-methoxybenzyl)-4-(2-((R)-3-hydroxy-2-methylpropyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
A mixture of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((<rans)-4- aminocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpicolmamide, Example 170) (45 mg, 0 13 mmol), (S)-(+)-3-bromo-2-methyl-1 -propanol (33 mL, 0 20 mmol), and triethylamine (33 mL, 0 24 mmol) in acetonitrile (3 ml.) was stirred at 80 0C for 15 hours The reaction mixture was concentrated and the residue was purified by reverse-phase preparative HPLC to afford the title compound as a beige solid (35 mg, 65%) 1H NMR (400 MHz, DMSO-cfe) 6 ppm 9 12 - 9 34 (m, 1 H), 8 45 (s, 1 H), 8 19 (s, 1 H), 8 05 (s, 1 H), 7 90 (s, 1 H), 7 06 - 7 21 (m, 2 H), 6 88 (d, J=I 3 Hz, 1 H), 4 59 (dd, J=14 3, 6 2 Hz, 1 H), 4 49 (d, J=5 9 Hz1 2 H), 4 31 (dd, ./=13 9, 8 1 Hz, 1 H), 3 80 (s, 3 H), 3 32 (s, 1 H), 2 65 (d, J=3 7 Hz, 3 H), 2 02 - 2 22 (m, 1 H), 0 75 (d, J=6 6 Hz, 3 H)
Example 445
A/-(4-Fluoro-3-methoxybenzyl)-4-(2-((S)-3-hydroxy-2-methylpropyl)-2H-tetrazol-5-yl)-6- methylpicolinamide
A mixture of /V-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(2/-/-tetrazol-5-yl)pιcolιnamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-4-(2-(((frans)-4- amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6-methylpιcolιnamιde, Example 170) (45 mg, 0 13 mmol), (/?)-(-)-3-bromo-2-methyl-1 -propanol (33 ml_, 0 20 mmol), and triethylamine (33 mL, 0 24 mmol) in acetonitrile (3 mL) was stirred at 80 0C for 15 hours The reaction mixture was concentrated and the residue was purified by reverse-phase preparative HPLC to afford the title compound as a beige solid (38 mg, 70%) 1H NMR (400 MHz, DMSOd6) δ ppm 9 12 - 9 33 (m, 1 H), 8 19 (s, 1 H), 7 90 (s, 1 H), 7 02 - 7 24 (m, 2 H), 6 89 (d, J=5 86 Hz, 1 H), 4 59 (dd, J=14 3, 6 2 Hz, 1 H), 4 48 (d, J=5 9 Hz, 2 H), 4 31 (dd, J= 14 3, 7 7 Hz, 1 H), 3 80 (s, 3 H), 3 29 (s, 1 H), 2 62 - 2 74 (m, 3 H), 2 52 (s, 2 H), 2 1 1 (dd, J=13 5, 6 2 Hz, 1 H)1 0 75 (d, J=6 6 Hz, 3 H)
Example 446 W-(4-Fluoro-3-methylbenzyl)-4-(2-isobutyl-2H-tetrazol-5-yl)-6-methylpicolinamide
Step 1 preparation methyl 4-(2-ιsobutyl-2H-tetrazol-5-yl)-6-methylpιcolιnate
A suspension of methyl 6-methyl-4-(2H-tetrazol-5-yl)pιcolιnate (prepared as described in step
4 of the synthesis of A/-(3-methoxybenzyl)-4-(2-(((^ans)-4-amιnocyclohexyl)methyl)-2/-/-tetrazol-5-yl)-6- methylpicolinamide, Example 153) (1 00 g, 4 56 mmol), 2-methylpropan-1 -ol (0 34 g, 4 6 mmol), and polymer supported-triphenylphosphine (3 04 g, 6 84 mmol) in anhydrous tetrahydrofuran (25 mL) was cooled to 0 0C in an ice bath for 15 mm and then di-tert-butyl azodicarboxylate (1 26 g, 5 47 mmol) was added The mixture was allowed to warm to room temperature while stirring over 15 hours The reaction mixture was filtered and the filtrate was concentrated The residue was purified by silica chromatography (0-50% ethyl acetate /heptane) to afford the title compound as a beige oil
Step 2 Preparation of 4-(2-ιsobutyl-2/-/-tetrazol-5-yl)-6-methylpιcolιnιc acid
A mixture of methyl 4-(2-ιsobutyl-2H-tetrazol-5-yl)-6-methylpιcolιnate and an aqueous solution of sodium hydroxide ( 2 5N, 4 0 mL) in tetrahydrofuran (10 mL) was stirred for 2 hours at room temperature Tetrahydrofuran was removed in vacuo and the aqueous residue was acidified to pH 6 with concentrated hydrochloric acid The mixture was extracted with ethyl acetate (3 x 15 mL) The combined organic layers were washed with water (2 x 10 mL) followed by brine (10 mL), dried over anhydrous sodium sulfate, and concentrated to afford the title compound (1 05 g, 88%) LC/MS (5- 100% CH3CN/H2O, 8 mm) 4 03 mm, m/z 262 (M+H)
Step 3 Preparation of Λ/-(4-fluoro-3-methylbenzyl)-4-(2-ιsobutyl-2H-tetrazol-5-yl)-6-methylpιcolιnamιde
A mixture of 4-(2-ιsobutyl-2H-tetrazol-5-yl)-6-methylpιcolιnιc acid (0 050 g, 0 19 mmol) and 1- hydroxybenzatnazole (31 mg, 0 23 mmol) in tetrahydrofuran (5 mL) was stirred for 5 mm (4-Flυoro-3- methylphenyl)methanamιne (27 mg, 0 19 mmol) and polymer supported carbodiimide (0 23 g, 0 29 mmol) were then added The mixture was stirred for 18 hours at room temperature and was then filtered The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound (23 mg, 32%) 1H NMR (400 MHz, DMSOd6) δ ppm 9 20 (t, J=Q 6 Hz, 1 H), 8 41 (s, 1 H), 8 05 (s, 1 H), 7 23 (d, J=7 3 Hz, 1 H), 7 12 - 7 20 (m, 1 H), 6 93 - 7 10 (m, 1 H), 4 61 (d, J=6 6 Hz, 2 H), 4 46 (d, J=5 9 Hz, 2 H), 2 65 (s, 3 H), 2 27 - 2 40 (m, 1 H), 2 19 (s, 3 H), 0 92 (d, J=6 6 Hz, 6 H)
Example 447 Λ/-(4-Fluoro-3-methoxybenzyl)-4-(2-isobutyl-2H-tetrazol-5-yl)-6-methylpicolinamide
A mixture of 4-(2-ιsobutyl-2/-/-tetrazol-5-yl)-6-methylpιcolιnιc acid (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methylbenzyl)-4-(2-ιsobutyl-2H-tetrazol-5-yl)-6- methylpicolinamide, Example 446) (0.050 g, 0.19 mmol) and 1 -hydroxybenzatrιazole (31 mg, 0 23 mmol) in tetrahydrofuran ( 5 mL) was stirred for 5 minutes 4-Fluoro-3-methoxybenzylamιne hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2- ((frans^-aminocyclohexyOmethyO^H-tetrazol-S-yOpyπmidine^-carboxamide, Example 1 ) (31 mg, 0.19 mmol) and polymer supported carbodiimide (0.23 g, 0.29 mmol) were added. The mixture was stirred for 18 hours at room temperature and was then filtered. The filtrate was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound (18 mg, 24%). 1H NMR (400 MHz, DMSOd6) δ ppm 9 21 (t, J=6.22 Hz, 1 H), 8.41 (s, 1 H), 8.06 (s, 1 H), 7.05 - 7 21 (m, 2 H), 6.89 (d, J=2.9 Hz, 1 H), 4.61 (d, J=6.6 Hz, 2 H), 4 48 (d, J=5.9 Hz, 2 H), 3.80 (s, 3 H), 2.65 (s, 3 H), 2.19 - 2 40 (m, 1 H), 0 92 (d, J=7.3 Hz, 6 H).
Example 448 W-(3-Methoxybenzyl)-4-(2-isobutyl-2H-tetrazol-5-yl)-6-methylpicolinamide
The title compound was prepared in a similar manner to Λ/-(3-methoxybenzyl)-6-methyl-4-(2- ((tetrahydrofuran-2-yl)methyl)-2/-/-tetrazol-5-yl)pιcolιnamιde (Example 425) by reaction with 2- methylpropan-1 -ol and afforded 20.9 mg (34%) as a solid. LC/MS (5%-95% CH3CN/H2O, 4.5 mm.; 95% CH3CN, 1.5 mm.): 3.638 mm., m/z 381 (M+H).
Example 449 6-((4-(2-lsobutyl-2H-tetrazol-5-yl)-2-methylpicolinamido)methyl)-1 H-indole-2-carboxamide
Step 1 Preparation of methyl 6-((4-(2-isobutyl-2H-tetrazol-5-yl)-2-methylpicolinamido)methyl)-1 H- ιndole-2-carboxylate
A mixture of 4-(2-ιsobutyl-2H-tetrazol-5-yl)-6-methylpιcolιnιc acid (prepared as described in step 2 of the synthesis of /V-(4-flυoro-3-methylbenzyl)-4-(2-ιsobutyl-2H-tetrazol-5-yl)-6- methylpicohnamide, Example 446) (0 090 g, 0 34 mmol) and 1-hydroxybenzatrιazole (56 mg, 0 41 mmol) in N,/V-dιmethylacetamιde (3 mL) was stirred for 5 minutes Methyl 6-(amιnomethyl)-1 H-ιndole- 2-carboxylate (71 mg, 0 34 mmol) was then added followed by triethylamine (0 106 mL, 0 758 mmol) and 1-(3-dιmethylamιnopropyl)-3-ethylcarbodιιmιde hydrochloride (99 mg, 0 52 mmol) The mixture was stirred at room temperature for 18 hours The reaction mixture was diluted with water (3 mL) and extracted with ethyl acetate (3 x 5 mL) The combined organic layers were washed with water (2 x 5 mL) followed by brine (5 mL), dried over anhydrous sodium sulfate and concentrated The residue was purified by silica column chromatography (0-50% ethyl acetate/heptane) to afford the title compound (140 mg, 93%) 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 25 (t, J=Q 22 Hz, 1 H), 8 52 (br s , 2 H), 8 43 (S, 1 H), 8 06 (s, 1 H), 7 58 (d, J=8 78 Hz1 1 H), 7 41 (s, 1 H), 6 97 - 7 16 (m, 1 H), 4 62 (d, J=I 32 Hz, 4 H), 3 83 (s, 3 H), 2 65 (s, 3 H), 2 26 - 2 38 (m, 1 H), 0 92 (d, J=Q 59 Hz, 6 H)
Step 2 Preparation of methyl 6-((4-(2-ιsobutyl-2H-tetrazol-5-yl)-2-methylpιcolιnamιdo)methyl)-1^/- ιndole-2-carboxylate
A solution of ammonia in methanol (7 N, 15 mL) was added to methyl 6-((4-(2-ιsobutyl-2H- tetrazol-5-yl)-2-methylpιcolιnamιdo)methyl)-1 /-/-ιndole-2-carboxylate (0 13 g, 0 29 mmol) and the mixture was heated to 60 0C in a sealed vial for 30 hours The reaction mixture was concentrated and the residue was purified by reverse phase preparative HPLC to afford the title compound (15 mg, 10%) 1H NMR (400 MHz, DMSOd6) δ ppm 11 40 (s, 1 H), 9 19 (t, J=Q 59 Hz, 1 H), 8 42 (s, 1 H), 8 11 (s, 1 H), 8 06 (s, 1 H), 7 84 (br s , 1 H), 7 52 (d, J=B 05 Hz, 1 H), 7 39 (s, 1 H), 7 23 (br s , 1 H), 6 93 - 7 10 (m, 1 H), 4 61 (t, J=I 69 Hz, 4 H), 2 64 (s, 3 H), 2 22 - 2 42 (m, 1 H), 0 92 (d, J=Q 59 Hz, 6 H) Example 450
W-(3-methoxybenzyl)-4-(1-(((frans)-4-aminocyclohexyl)methyl)-1H-1 ,2,4-triazol-3-yl)-6- methylpicolinamide
Step 1 Preparation of β-methylpyπdine^^-dicarboxylic acid
A solution of ammonia in ethanol (2 M, 400 mL) was cooled to 0 0C Pyruvic acid (29 6 mL, 425 mmol) was added dropwise maintaining the temperature below 5 0C After complete addition, the mixture was stirred for 30 mm and then filtered The resulting solid was washed with cold ethanol and immediately transferred to a 2 L Erlenmeyer The above procedures are repeated and the resulting solids were combined and dissolved in water (100 mL) The mixture was heated to reflux for 30 mm and then diluted with 1 N hydrochloric acid (200 mL) The mixture was cooled in an ice bath and further acidified until acidic The resulting precipitate was filtered and washed with ethyl ether to afford the title compound as a solid (10 97 g, 27%) 1H NMR (400 MHz, DMSO-d6) δ ppm 13 52 (br, 2 H), 8 20 (d, J=O 7 Hz, 1 H), 7 90 (d, J=1 0 Hz, 1 H), 2 62 (s, 3H)
Step 2 Preparation of bιs(perfluorophenvD 6-methylpyrιdιne-2.4-dιcarboxvlate
6-Methylpyrιdιne-2,4-dιcarboxylιc acid (10 87 g, 60 0 mmol) and 1 ,3-dιcyclohexylcarbodιιmιde (27 24 g, 132 0 mmol) were dissolved in Λ/,Λ/-dιmethylformamιde (400 mL) Pentafluorophenol (33 13 g, 180 mmol) was added in Λ/,Λ/-dιmethylformamιde (25 mL) The mixture was allowed to stir at room temperature for 18 hours and then the solvent was removed in vacuo The residue was diluted with dioxane (500 mL) and filtered The filtrate was concentrated, dissolved in dichloromethane/hexane (2/1 , 100 mL), and filtered through a silica plug (5 cm x 8 cm) eluting with dichloromethane/hexane (2/1 ) The filtrate was concentrated, dissolved in ethyl acetate (500 mL), and washed with saturated aqueous sodium bicarbonate (2 x 50 mL) The organic layer was dried over sodium sulfate and concentrated The residue was purified by silica column chromatography (CH2CI2/hexane, 1/2, 1/1 ) After concentration, the residue was triturated with hexanes and filtered to afford the title compound as a solid (8 45 g, 27%) MS (ES+) m/z 514 (M+H) Step 3 Preparation of Λ/-(3-methoxybenzyl)-6-methylpyrιdιne-2.4-dιcarboxamιde
A solution of bιs(perfluorophenyl) 6-methylpyrιdιne-2,4-dιcarboxylate (4 23 g, 8 24 mmol) in dichloromethane (150 mL) was cooled to -78 0C A solution of 3-methoxybenzylamιne (1 24 g, 9 07 mmol) and diisopropylethylamine (1 12 mL, 9 07 mL) in dichloromethane (10 mL) was added The mixture was allowed to slowly warm to room temperature over 20 hours The solvent was removed in vacuo and the residue was dissolved in tetrahydrofuran (50 mL) A solution of ammonia (0 5 M in dioxane, 18 1 mL, 9 07 mmol) was added followed by diisopropylethylamine (1 12 mL, 9 07 mmol) The mixture was stirred at room temperature for 2 h, and then the solvent was removed in vacuo The resulting residue was suspended in ethyl acetate and filtered to afford the title compound as a white solid (2 36 g, 96%) MS (ES+) m/z 300 (M+H) 1H NMR (400 MHz, DMSO-Cf6) 6 ppm 9 16 (t, J=6 4 Hz, 1 H), 8 31 (s, 1 H), 8 22 (d, J=O 8 Hz, 1 H), 7 81 (d J= 1 1 Hz, 1 H), 7 70 (s, 1 H), 7 20 (t, J=8 1 Hz, 1 H), 6 89-6 85 (m, 2 H), 6 78 (dd, J=8 2, 1 9 Hz, 1 H), 4 46 (d, J=6 4, 2 H), 3 69 (s, 3 H), 2 59 (s, 3 H)
Step 4 Preparation of /V-(3-methoxybenzyl)-6-methyl-4-(1 H-1.2,4-trιazol-3-yl)pιcoltnamιde
Λ/-(3-Methoxybenzyl)-6-methylpyrιdιne-2,4-dιcarboxamιde (599 mg, 2 0 mmol) and N,N- dimethylformamide dimethylacetal (26 5 mL) was heated at 1 10 0C such that any methanol formed is collected through a short path condenser After 2 h, the remaining ,Λ/-dιmethylformamιde dimethylacetal was removed in vacuo The residue was dissolved in glacial acetic acid (20 mL) and hydrazine hydrate (344 μL, 6 0 mmol) was added The mixture was heated at 90 0C for 2 hours and then allowed to cool to room temperature The reaction mixture was poured into water (20 mL), cooled in an ice bath, and adjusted to pH 7 with 2 5 N sodium hydroxide solution The mixture was extracted with ethyl acetate (3 x 50 mL) The combined organic layers were washed with brine (25 mL), dried over sodium sulfate, and concentrated The residue was crystallized from ethyl acetate/ether ether/hexane to afford the title compound as a white solid (486 mg, 75%) MS (APCI+) m/z 324 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 14 48 (s, 1 H), 9 19 (t, J=6 1 Hz, 1 H), 8 74 (s, 1 H), 8 44 (s, 1 H), 8 02 (s, 1 H), 7 24 (t, J=8 1 Hz1 1 H), 6 94-6 89 (m, 2 H), 6 82 (dd, J=8 1 , 1 9 Hz, 1 H), 4 50 (d, J=6 4 Hz, 2 H), 3 73 (s, 3 H), 2 64 (s, 3 H) Step 5 Preparation of tert-butyl (fran5)-4-((3-(2-((3-methoxybenzyl)carbamoylV6-methylpyrιdιn-4-yl)- 1/-/-1 ,2.4-tπazol-1 -yl)methyl)cvclohexylcarbamate
Ay-(3-Methoxybenzyl)-6-methyl-4-(1H-1 ,2,4-trιazol-3-yl)pιcolιnamιde (323 mg, 1 OO mmol), polymer supported triphenylphosphine (698 mg, 1 50 mmol), and tert-butyl trans-(4- hydroxymethyl)cyclohexylcarbamate (275 mg, 1 20 mmol) were suspended in THF (16 ml) Dι-tert- butyl azodicarboxylate (345 mg, 1 50 mmol) was added The mixture was allowed to warm to room temperature and stir for 18 hours The reaction mixture was filtered and the resin washed with THF (20 mL) The filtrate was concentrated The crude product was purified by silica column chromatography (CH2CI2/methanol, 100/1 , 100/2, 100/4) Combined fractions were concentrated to afford the title compound as a foaming white solid (491 mg, 92%) MS (ES+) m/z 535 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 18 (t, J=6 4 Hz, 1 H), 8 69 (s, 1 H), 8 39 (s, 1 H), 7 97 (d, J=1 1 Hz, 1 H), 7 24 (t, J=Q 1 Hz, 1 H), 6 93 - 6 89 (m, 2 H), 6 82 (dd, J=8 1 , 1 9 Hz1 1 H), 6 70 (d, J=I 8 Hz, 1 H), 4 50 (d, J=64 Hz, 2 H), 4 12 (d, J=I 0 Hz, 2 H), 3 73 (s, 3 H), 3 21 - 3 11 (m, 1 H), 2 63 (s, 3 H), 1 82 - 1 71 (m, 3 H), 1 59 - 1 53 (m, 2 H)1 1 36 (s, 9 H), 1 15 - 1 01 (m, 4 H)
Step 6 Preparation of Λ/-(3-methoxybenzyl)-4-(1-(((/rans)-4-amιnocvclohexyl)methyl)-1/-/-1.2,4-trιazol- 3-yl)-6-methylpιcolιnamιde
tert-Butyl (frans)-4-((3-(2-((3-methoxybenzyl )carbamoyl )-6-methylpyrιdιn-4-yl)-1 H- 1 ,2,4-trιazol- i-y^methyOcyclohexylcarbamate (380 mg, 0 71 mmol) was dissolved in dichloromethane (5 mL) and tπfluoroacetic acid (1 06 mL, 14 2 mmol) was added The mixture was allowed to stand for 2 hours and was then concentrated The residue was dissolved in dichloromethane (100 mL) and washed with 1N NaOH solution (2 x 10 mL) The organic layer was dried over sodium sulfate and concentrated to afford the title compound as a glass which slowly solidified (276 mg, 89%) MS (ES+) m/z 435 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 17 (t, J=Q 4 Hz, 1 H), 8 68 (s, 1 H), 8 39 (d, J=O 9 Hz, 1 H), 7 97 (d, J=1 2 Hz, 1 H), 7 24 (t, J=8 1 Hz, 1 H), 6 93 - 6 89 (m, 2 H), 6 82 (ddd, J=Q 2, 2 5, 0 8 Hz, 1 H), 4 50 (d, J=Q 4 Hz, 2 H), 4 1 1 (d, J=I 1 Hz, 2 H), 3 73 (s, 3 H)1 2 63 (s, 3 H)1 2 48 - 2 40 (m, 1 H), 1 84 - 1 71 (m, 3 H), 1 57 - 1 51 (m, 2 H), 1 40 (br s , 1 H), 1 09 - 0 90 (m, 4 H)
Example 451 N-(3-Methoxybenzyl)-6-methyl-4-(1 -(((trans)-4-(methylsulfonamido)cyclohexyl)methyl)-1 H-1 ,2,4- triazol-3-yl)picolιnamide
Λ/-(3-Methoxybenzyl)-4-(1-(((^rans)-4-amιnocyclohexyl)methyl)-1H-1 ,2,4-trιazol-3-yl)-6- methylpicolinamide (prepared as described in Example 450) (135 mg, 0 31 mmol) was dissolved in dichloromethane (5 mL) Triethylamine (86 6 μL, 0 62 mmol) and methanesulfonyl chloride (28 9 μL, 0 37 mmol) were added The reaction mixture was shaken at room temperature for 1 hour and then diluted with dichloromethane (50 mL) The mixture was washed with saturated aq sodium bicarbonate (10 mL) The organic layer was dried over sodium sulfate and concentrated on to silica The crude product was purified by silica column chromatography (CH2Cl2/methanol, 100/1 , 100/2, 100/4) to afford the title compound as a white solid (115 mg, 72%) MS (ES+) m/z 513 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 17 (t, J=6 4 Hz, 1 H), 8 69 (s, 1 H), 8 39 (s, 1 H), 7 97 (d, J=1 1 Hz, 1 H),
7 24 (t, J=8 1 Hz, 1 H), 6 98 (d, J=I 4 Hz, 1 H), 6 93 - 6 89 (m, 2 H), 6 82 (dd, J=8 2, 1 7 Hz, 1 H), 4 50 (d, J=6 4 Hz, 2 H), 4 13 (d, J=I 0 Hz, 2 H), 3 73 (s, 3 H), 3 09 - 3 00 (m, 1 H), 2 88 (s, 3 H), 2 63 (s, 3 H), 1 90 (d, J=12 1 Hz, 2 H), 1 85 - 1 76 (m, 1 H), 1 59 (d, J=12 0 Hz1 2 H), 1 26 - 1 02 (m, 4 H)
Example 452 W-(3-Methoxybenzyl)-4-(1 -(((frans)-4-acetamidocyclohexyl)methyl)-1 H- 1 ,2,4-trιazol-3-yl)-6- methylpicolinamide
Λ/-(3-Methoxybenzyl)-4-(1-(((<rans)-4-amιnocyclohexyl)methyl)-1 /-/-1 ,2,4-trιazol-3-yl)-6- methylpicolinamide (prepared as described in Example 450) (135 mg, 0 31 mmol) was dissolved in dichloromethane (5 mL) Triethylamine (86 6 μL, 0 62 mmol), DMAP (7 6 mg, 0 062 mmol), and acetyl chloride (26 5 μL, 0 37 mmol) was added The reaction mixture was shaken at room temperature for 1 hour and then diluted with dichloromethane (50 mL) The mixture was washed with saturated aq sodium bicarbonate (10 mL) The organic layer was dried over sodium sulfate and concentrated onto silica The crude product was purified by silica column chromatography (CH2CI2/methanol, 100/1 , 100/2, 100/4, 100/5) to afford the title compound as a white foaming solid (105 mg, 71%) MS (ES+) m/z 477 (M+H) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 18 (t, J=6 4 Hz, 1 H), 8 69 (s, 1 H), 8 40 (s, 1 H), 7 97 (s, 1 H), 7 69 (d, J=I 7 Hz, 1 H), 7 24 (t, J=B 1 Hz, 1 H), 6 94 - 6 90 (m, 2 H), 6 82 (dd, J=8 1 , 2 1 Hz, 1 H), 4 50 (d, J=6 3 Hz, 2 H), 4 13 (d, J=I 0 Hz, 2 H), 3 73 (s, 3 H), 3 46 (br s , 1 H), 2 63 (s, 3 H), 1 88 - 1 72 (m, 6 H), 1 62 - 1 55 (m, 2 H), 1 15 - 1 02 (m, 4 H) Example 453
2-(((rans)-4-((3-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-1 H-1 ,2,4-triazol-1 - yl)methyl)cyclohexylamino)-2-oxoethyl acetate
A/-(3-Methoxybenzyl)-4-(1-(((/rans)-4-aminocyclohexyl)methyl)-1 /-/-1 ,2,4-triazo!-3-yl)-6- methylpicolinamide (prepared as described in Example 450) (335 mg, 0 77 mmol) was dissolved in dichloromethane (20 mL) Tπethylamine (215 μL, 1 54 mmol), DMAP (18 8 mg, 0 15 mmol), and acetoxyacetyl chloride (99 5 μl_, 0 93 mmol) were added The mixture was allowed to stir at room temperature for 18 hours The reaction mixture was diluted with dichloromethane (80 mL) and washed with saturated aq sodium bicarbonate solution (2 x 20 mL) The organic layer was dried over sodium sulfate and concentrated The crude product was purified by silica column chromatography (CH2CI2/methanol, 100/1 , 100/2, 100/4) Fractions were concentrated, and upon addition of EtOAc, the product crystallized The resulting slurry was filter to afford the title compound as a white crystalline solid (288 mg, 70%) MS (ES+) m/z 535 (M+H) 1H NMR (400 MHz, DMSO-cfe) δ ppm 9 19 (t, J=6 4 Hz, 1 H), 8 70 (s, 1 H), 8 40 (s, 1 H), 7 97 (d, J=1 1 Hz, 1 H), 7 85 (d, J=7 9 Hz, 1 H), 7 24 (t, J=8 1 Hz, 1 H), 6 94 - 6 88 (m, 2 H), 6 82 (dd, J=8 1 , 2 1 Hz, 1 H), 4 50 (d, J=6 4 Hz, 2 H), 4 38 (s, 2 H), 4 14 (d, J=7 0 Hz, 2 H), 3 73 (s, 3 H), 3 55 - 3 46 (m, 1 H), 2 63 (s, 3 H), 2 06 (s, 3 H), 1 89 - 1 73 (m, 3 H), 1 63 - 1 57 (m, 2 H), 1 24 - 1 04 (m, 4 H)
Example 454 N-(3-Methoxybenzyl)-4-(1 -(((frans)-4-(2-hydroxyacetamido)cyclohexyl)methyl)-1 H-1 ,2,4-triazol-3- yl)-6-methylpicolinamide
2-((frans)-4-((3-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-1 /-/-1 ,2,4-trιazol-1- yl)methyl)cyclohexylamιno)-2-oxoethyl acetate (prepared as described in Example 453) (200 mg, 0 375 mmol) was dissolved in THF (15 mL) Lithium hydroxide (26 9 mg, 1 12 mmol) followed by water (5 0 mL) were added The mixture was stirred for 1 hour and then the THF was removed in vacuo The residue was added to dichloromethane (100 mL) and washed with water (2 x 20 mL) The organic layer was dried over sodium sulfate and concentrated to afford an oil The residue was dissolved in ethyl acetate/methanol (4/1 ) and partially concentrated until solids formed The suspension was filtered to afford the title compound as a white solid (165 mg, 89%) MS (ES+) m/z 493 (M+H) 1H NMR (400 MHz, DMSOd6) 6 ppm 9 19 (t, J=6 4 Hz, 1 H), 8 70 (s, 1 H), 8 40 (d, J=O 8 Hz, 1 H), 7 97 (d, J= 1 2 Hz, 1 H), 7 44 (d, J=8 3 Hz, 1 H), 7 24 (t, J=8 1 Hz, 1 H), 6 89 - 6 93 (m, 2 H), 6 82 (dd, J=8 1 , 1 8 Hz, 1 H), 5 39 (t, J=5 6 Hz, 1 H), 4 50 (d, J=6 3 Hz, 2 H), 4 14 (d, J=7 0 Hz1 2 H), 3 75 (d, J=5 6 Hz, 2 H), 3 73 (s, 3 H), 3 61 - 3 51 (m, 1 H), 2 63 (s, 3 H)1 1 88 - 1 77 (m, 1 H), 1 74 (d, J=12 5 Hz, 2 H), 1 59 (d, J= 12 5 Hz, 2 H), 1 27 (qd, J= 12 4, 2 6 Hz, 2 H), 1 10 (qd, J=12 7, 2 4 Hz, 2 H)
Example 455
W-(4-Fluoro-3-methoxybenzyl)-4-(1-(((fraπs)-4-aminocyclohexyl)methyl)-1H-1,2,4-triazol-3-yl)-6- methylpicolinamide
Step 1 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-methylpyrιdιne-2,4-dιcarboxamιde
A solution of bιs(perfluorophenyl) 6-methy!pyrιdιne-2,4-dιcarboxylate (prepared as described in step 2 of the synthesis of Λ/-(3-methoxybenzyl)-4-(1-(((^ans)-4-amιnocyclohexyl)nnethyl)-1 H-1 ,2,4- trιazol-3-y!)-6-methylpιcolιnamιde, Example 450) (104 g) in dichloromethane (945 mL) was cooled to - 70 0C A solution of 4-fluoro-3-methoxybenzylamιne hydrochloride (prepared as described in step 3 of the synthesis of Λ/-(4-fluoro-3-methoxybenzyl)-6-(2-((<rans-4-amιnocyclohexyl)methyl)-2H-tetrazol-5- yl)pyrιmιdιne-4-carboxamιde, Example 1 ) (23 5 g, 123 mmol) and triethylamine (33 4 mL, 240 mmol) in dichloromethane (140 mL) was added The mixture was allowed to slowly warm to room temperature over 20 hours The solvent was removed in vacuo and the residue was dissolved in tetrahydrofυran (575 mL) Triethylamine (18 4 mL, 132 mmol) was added followed by a solution of ammonia (0 5 M in dioxane, 260 mL, 130 mmol) The mixture was stirred at room temperature for 20 h, and then the solvent was removed in vacuo The resulting residue was suspended in ethyl acetate and filtered The resulting solid was again suspended in methanol and filtered to afford the title compound as a white solid (27 7 g, 75%) MS (ES+) m/z 318 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 19 (t, J=6 4 Hz, 1 H), 8 32 (br s , 1 H), 8 22 (d, J=O 8 Hz, 1 H), 7 81 (d, J=1 2 Hz, 1 H), 7 71 (br s , 1 H), 7 14 (dd, J=8 5, 1 9 Hz, 1 H), 7 10 (dd, J=1 1 5, 8 3 Hz, 1 H), 6 82 - 6 87 (m, 1 H), 4 45 (d, J=6 4 Hz, 2 H), 3 78 (S, 3 H), 2 59 (s, 3 H) Step 2 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-6-methyl-4-(1 H-1 ,2.4-trιazol-3-yl)pιcolιnamιde
Λ/-(4-Fluoro-3-methoxybenzyl)-6-methylpyrιdιne-2,4-dιcarboxamιde (27 67 g, 87 mmol) and Λ/,Λ/-dιmethylformamιde dimethylacetal (290 mL) was heated at 1 10 0C such that any methanol formed is collected through a short path condenser After 2 h, the remaining ,Λ/-dιmethylformamιde dimethylacetal was removed in vacuo The residue was dissolved in glacial acetic acid (293 mL) and hydrazine hydrate (15 6 mL, 323 mmol) was added The mixture was heated at 90 0C for 2 hours and then allowed to cool to room temperature The reaction mixture was poured into water (250 mL) and filtered to afford the title compound as a solid (24 1 g, 81 %) MS (ES+) m/z 342 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 14 47 (br s , 1 H), 9 19 (t, J=6 4 Hz, 1 H), 8 67 (br s , 1 H), 8 41 (s, 1 H), 7 98 (d, J=1 2 Hz, 1 H), 7 15 (dd, J=8 3, 1 9 Hz, 1 H), 7 11 (dd, J=11 7, 8 5 Hz, 1 H), 6 89 - 6 84 (m, 1 H), 4 46 (d, J=Q 4 Hz, 2 H), 3 79 (s, 3 H), 2 60 (s, 3 H)
Step 3 Preparation of /erf-butyl (frans)-4-((3-(2-((4-f1uoro-3-methoxybenzyl)carbamoyl)-6-
Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(1H-1 ,2,4-trιazol-3-yl)pιcolιnamιde (683 mg, 2 00 mmol), polymer supported triphenylphosphine (1 40 g, 3 00 mmol), and tert-butyl trans-(4- hydroxymethyl)cyclohexylcarbamate (550 mg, 2 40 mmol) were suspended in tetrahydrofuran (32 mL) Di-tert-butyl azodicarboxylate (691 mg, 3 00 mmol) was added The mixture was allowed to warm to room temperature and stir for 18 hours The reaction mixture was filtered and the resin washed with tetrahydrofuran (40 mL) The filtrate was concentrated The crude product was purified by silica column chromatography (CH2CI2/methanol, 100/1 , 100/2, 100/4) Combined fractions were concentrated to afford the title compound as a foaming white solid (955 mg, 86%) MS (ES+) m/z 533 (M+H) 1H NMR (400 MHz, DMSO-c/6) δ ppm 9 18 (t, J=6 4 Hz, 1 H), 8 66 (s, 1 H), 8 36 (d, J=O 8 Hz, 1 H), 7 94 (d, J=1 1 Hz1 1 H), 7 15 (dd, J=8 5, 1 9 Hz, 1 H), 7 11 (dd, J=1 1 7, 8 3 Hz, 1 H), 6 86 (ddd, J=Q 3, 4 4, 1 9 Hz, 1 H), 6 67 (d, J=I 9 Hz, 1 H), 4 46 (d, J=6 4 Hz, 2 H), 4 09 (d, J=I 0 Hz, 2 H), 3 79 (s, 3 H), 3 12 (br s , 1 H), 2 60 (s, 3 H), 1 74 (br s , 3 H), 1 57 - 1 50 (m, 2 H), 1 33 (s, 9 H), 1 12 - 0 98 (m, 4 H) Step 4 Preparation of Λ/-(4-fluoro-3-methoxybenzyl)-4-(1 -^((rans)-4-amιnocvclohexyπmethyl)-1 H- 1 ,2,4-trιazol-3-yl)-6-methylpιcolιnamιde
tert-Butyl (^ans)-4-((3-(2-((4-fluoro-3-methoxybenzy!)carbamoyl)-6-methylpyrιdιn-4-yl)-1 /-/- 1 ,2,4-trιazol-1 -yl)methyl)cyclohexylcarbamate (950 mg, 1 72 mmol) was dissolved in dichloromethane (10 mL) and trifluoroacetic acid (2 55 mL, 34 4 mmol) was added The mixture was allowed to stand for 2 hours and was then concentrated The residue was dissolved in dichloromethane (100 mL) and washed with 1 N NaOH solution (2 x 20 mL) The organic layer was dried over sodium sulfate and concentrated to afford the title compound as a foaming solid (730 mg, 94%) MS (ES+) m/z 453 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 18 (t, J=6 4 Hz, 1 H), 8 65 (s, 1 H), 8 36 (d, J=O 8 Hz,
1 H), 7 94 (d, J= 1 1 Hz, 1 H), 7 15 (dd, J=8 6, 2 0 Hz, 1 H), 7 1 1 (dd, J= 1 1 7, 8 3 Hz1 1 H), 6 86 (ddd, J=8 3, 4 4, 2 0 Hz, 1 H), 4 46 (d, J=6 4 Hz, 2 H), 4 08 (d, J=7 0 Hz, 2 H), 3 79 (s, 3 H), 2 60 (s, 3 H),
2 44 - 2 38 (m, 1 H), 1 81 - 1 61 (m, 3 H), 1 55 - 1 34 (m, 4 H), 1 06 - 0 82 (m, 4 H)
Example 456 /V^-Fluoro-S-methoxybenzyO-e-methyM^I-t^fransJ^^methylsulfonamidoJcyclohexylJmethyl)-
1 H-1 ,2,4-triazol-3-yl)picolinamide
Λ/-(4-Fluoro-3-methoxybenzyl)-4-(1-(((^rans)-4-amιnocyclohexyl)methyl)-1H-1 ,2,4-trιazol-3-yl)- 6-methylpιcolιnamιde (prepared as described in Example 455) (725 mg, 1 6 mmol) was dissolved in dichloromethane (30 mL) Triethylamine (447 μl, 3 2 mmol) and methanesulfonyl chloride (149 μL, 1 92 mmol) were added The reaction mixture was stirred at room temperature for 1 hour and then diluted with dichloromethane (100 mL) The mixture was washed with saturated aq sodium bicarbonate (20 mL) The organic layer was dried over sodium sulfate and concentrated onto silica The crude product was purified by silica column chromatography (CH2C!2/methanol, 100/1 , 100/2, 100/4) Fractions were concentrated and the resulting oil crystallized from ethyl acetate to afford the title compound as a white solid (623 mg, 73%) MS (ES+) m/z 531 (M+H) 1H NMR (400 MHz, DMSO- d6) δ ppm 9 18 (t, J=6 4 Hz, 1 H), 8 66 (s, 1 H), 8 36 (d, J=O 8 Hz, 1 H), 7 94 (d, J=1 1 Hz, 1 H), 7 15 (dd, J=8 5, 1 7 Hz, 1 H), 7 11 (dd, J=11 5, 8 3 Hz, 1 H), 6 95 (d, J=7 4 Hz, 1 H), 6 86 (ddd, J=8 4, 4 3, 1 9 Hz, 1 H), 4 46 (d, J=6 3 Hz, 2 H), 4 10 (d, J=6 8 Hz, 2 H), 3 79 (s, 3 H), 3 05 - 2 97 (m, 1 H), 2 85 (s, 3 H), 2 60 (s, 3 H), 1 87 (d, J=1IQ 5 Hz, 2 H), 1 82 - 1 71 (m, 1 H), 1 56 (d, J=12 4 Hz, 2 H), 1 22 - 1 00 (m, 4 H)
Example 457
N-(4-Fluoro-3-methoxybenzyl)-4-(1 -(((frans)-4-acetamidocyclohexyl)methyl)-1 HA ,2,4-triazol-3- yl)-6-methylpicolinamide
Λ/-(4-Fluoro-3-methoxybenzy!)-4-(1 -(((<rans)-4-amιnocyclohexyl)methyl)-1 H-1 ,2,4-trιazol-3-yl)- 6-methylpιcolιnamιde (prepared as described in Example 455) ( 115 mg, 0 25 mmol) was dissolved in dichloromethane (5 mL) Triethylamine (70 8 μL, 0 51 mmol), DMAP (6 2 mg, 0 051 mmol), and acetyl chloride (21 7 μL, 0 31 mmol) was added The reaction mixture was shaken at room temperature for 1 hour and then diluted with dichloromethane (50 mL) The mixture was washed with saturated aq sodium bicarbonate (10 mL) The organic layer was dried over sodium sulfate and concentrated on to silica The crude product was purified by silica column chromatography (Biotage 4OS, CH2CI2/methanol, 100/2 x 0 75 L, 100/4 x 0 75 L, 100/5 x 0 75 L) to afford the title compound as a white foaming solid (109 mg, 87%) MS (ES+) m/z 495 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 20 (t, J=Q 4 Hz, 1 H), 8 69 (s, 1 H), 8 40 (s, 1 H), 7 97 (s, 1 H), 7 69 (d, J=7 8 Hz, 1 H), 7 18 (dd, J=8 5, 1 7 Hz, 1 H), 7 17 - 7 11 (m, J=1 1 6, 8 3 Hz, 1 H), 6 89 (ddd, J=Q 2, 4 3, 1 9 Hz, 1 H), 4 49 (d, J=Q 3 Hz, 2 H), 4 13 (d, J=I 0 Hz, 2 H), 3 82 (s, 3 H), 3 45 (br s , 1 H), 2 63 (s, 3 H), 1 88 - 1 73 (m, 6 H), 1 62 - 1 56 (m, 2 H), 1 17 - 1 02 (m, 4 H)
Example 458
2-(((rans)-4-((3-(2-((4-Fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-1H-1,2,4-triazol-
1 -yl)methyl)cyclohexylamino)-2-oxoethyl acetate
W-(4-Rluoro-3-methoxybenzyl)-4-(1 -(((frans)-4-amιnocyclohexyl)methy!)-1 H-1 ,2,4-trιazol-3-yl)- 6-methylpιcolιnamιde (prepared as described in Example 455) (349 mg, 0 77 mmol) was dissolved in dichloromethane (20 mL) Triethylamine (215 μL, 1 54 mmol), DMAP (18 8 mg, 0 15 mmol), and acetoxyacetyl chloride (99 5 μL, 0 93 mmol) were added The mixture was allowed to stir at room temperature for 18 hours The reaction mixture was diluted with dichloromethane (80 mL) and washed with saturated aq sodium bicarbonate solution (2 x 20 mL) The organic layer was dried over sodium sulfate and concentrated The crude product was purified by silica column chromatography (CH2CI2/methanol, 100/1 , 100/2, 100/4) Fractions were concentrated, and upon addition of EtOAc, the product crystallized The resulting slurry was filter to afford the title compound as a white solid (290 mg, 68%) MS (ES+) m/z 553 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 21 (t, J=Q 4 Hz, 1 H), 8 70 (s, 1 H), 8 40 (s, 1 H), 7 97 (s, 1 H), 7 85 (d, J=I 9 Hz, 1 H), 7 18 (dd, J=Q 1 , 1 7 Hz, 1 H), 7 14 (dd, J=1 1 5, 8 3 Hz, 1 H), 6 89 (ddd, J=8 1 , 4 6, 1 9 Hz, 1 H), 4 49 (d, J=6 3 Hz, 2 H), 4 38 (s, 2 H), 4 14 (d, J=I 0 Hz, 2 H), 3 82 (s, 3 H), 3 55 - 3 46 (m, 1 H), 2 63 (s, 3 H), 2 06 (s, 3 H), 1 88 - 1 74 (m, 3 H), 1 63 - 1 56 (m, 2 H), 1 24 - 1 03 (m, 4 H)
Example 459 W-(4-Fluoro-3-methoxybenzyl)-4-(1 -(((<raπs)-4-(2-hydroxyacetamido)cyclohexyl)methyl)-1 H-
1,2,4-triazol-3-yl)-6-methylpicolinamide
2-((frans)-4-((3-(2-((4-Fluoro-3-methoxybenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-1 /-/-1 ,2,4- trιazol-1 -yl)methyl)cyclohexylamιno)-2-oxoethyl acetate (prepared as described in Example 458) (207 mg, 0 375 mmol) was dissolved in THF (15 mL) Lithium hydroxide (26 9 mg, 1 12 mmol) followed by water (5 0 mL) were added The mixture was stirred for 1 hour and then the tetrahydrofuran was removed in vacuo The residue was added to dichloromethane (100 mL) and washed with water (2 x 20 mL) The organic layer was dried over sodium sulfate and concentrated to afford an oil The residue was dissolved in acetonitrile and partially concentrated, and upon standing, the product crystallizes The slurry was filtered to afford 63 mg of a white solid The filtrate was concentrated, dissolved in a minimum amount of acetonitrile, and seeded to afford a second crop of 79 mg The two crops were combined to afford the title compound as a white solid (142 mg, 74%) MS (ES+) m/z 51 1 (M+H) 1H NMR (400 MHz, DMSOd6) δ ppm 9 21 (t, J=Q 4 Hz, 1 H), 8 70 (s, 1 H), 8 40 (s, 1 H), 7 97 (d, J=O 9 Hz, 1 H), 7 44 (d, J=Q 3 Hz, 1 H), 7 18 (dd, J=Q 5, 1 7 Hz, 1 H), 7 14 (dd, J=\ 1 7, 8 3 Hz, 1 H), 6 89 (ddd, J=8 3, 4 5, 1 9 Hz, 1 H), 5 40 (t, J=5 7 Hz, 1 H)1 4 49 (d, J=6 3 Hz, 2 H), 4 14 (d, J=I 0 Hz, 2 H), 3 82 (s, 3 H), 3 75 (d, J=5 6 Hz, 2 H), 3 60 - 3 52 (m, 1 H), 2 63 (s, 3 H), 1 88 - 1 77 (m, 1 H), 1 74 (d, J=10 1 Hz, 2 H), 1 59 (d, J=\7 8 Hz, 2 H), 1 27 (dq, J=12 4, 2 3 Hz, 2 H), 1 10 (qd, J=M 5, 2 0 Hz, 2 H)
Example 460 N-(4-Fluoro-3-methylbenzyl)-4-(1 -(((frans)-4-aminocyclohexyl)methyl)-1 H-1 ,2,4-triazol-3-yl)-6- methylpicolinamide
Step 1 Preparation of Λ/-(4-fluoro-3-methylbenzyl)-6-methylpyrιdιne-2,4-dιcarboxamιde
A solution of bιs(perfluorophenyl) 6-methylpyrιdιne-2,4-dιcarboxylate (prepared as described in step 2 of the synthesis of Λ/-(3-methoxybenzyl)-4-(1-(((frans)-4-amιnocyclohexyl)methyl)-1 H-1 ,2,4- tnazol-3-yl)-6-methylpιco!ιnamιde, Example 450) (104 g) in dichloromethane (945 mL) was cooled to - 70 0C A solution of 4-fluoro-3-methylbenzylamιne (16 92 g, 122 mmol) and triethylamine (17 0 mL, 122 mmol) in dichloromethane (140 mL) was added The mixture was allowed to slowly warm to room temperature over 20 hours The solvent was removed in vacuo and the residue was dissolved in tetrahydrofuran (575 mL) Triethylamine (19 2 mL, 138 mmol) was added followed by a solution of ammonia (0 5 M in dioxane, 271 mL, 135 mmol) The mixture was stirred at room temperature for 20 h, and then the solvent was removed in vacuo The resulting residue was suspended in ethyl acetate and filtered to afford the title compound as a white solid (35 4 g, 62%) MS (ES+) m/z 302 (M+H) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 18 (t, J=6 3 Hz, 1 H), 8 32 (br s , 1 H), 8 22 (d, J=O 9 Hz, 1 H), 7 81 (d, J= 1 2 Hz, 1 H), 7 71 (br s , 1 H), 7 20 (d, J=7 7 Hz, 1 H), 7 12 - 7 17 (m, 1 H), 7 04 (t, J=9 7 Hz, 1 H), 4 42 (d, J=6 4 Hz, 2 H), 2 58 (s, 3 H), 2 17 (d, J=1 6 Hz, 3 H)
Step 2 Preparation of Λ/-(4-fluoro-3-methylbenzyl)-6-methyl-4-(1/-/-1.2.4-trιazol-3-vπpιcolιnamιde
A/-(4-Fluoro-3-methylbenzyl)-6-methylpyrιdιne-2,4-dιcarboxamιde (35 O g, 116 mmol) and N1N- dimethylformamide dimethylacetal (387 mL) was heated at 110 0C such that any methanol formed is collected through a short path condenser After 2 h, the remaining ,Λ/-dιmethylformamιde dimethylacetal was removed in vacuo The residue was dissolved in glacial acetic acid (370 mL) and hydrazine hydrate (21 5 mL, 430 mmol) was added The mixture was heated at 90 0C for 2 hours and then allowed to cool to room temperature The reaction mixture was poured into water (375 mL) and filtered to afford the title compound as a white solid (20 7 g, 55%) MS (ES+) m/z 326 (M+H) Step 3 Preparation of tert-butyl (frans)-4-((3-(2-((4-fluoro-3-methylbenzyl)carbamoyl)-6-methylpyridin- 4-yl)-1 /-/-1.2.4-trιazol-1 -yl)methyl)cvclohexylcarbamate
Λ/-(4-Fluoro-3-methylbenzyl)-6-methyl-4-(1 H-1 ,2,4-tπazol-3-yl)pιcolmamιde (2 50 g, 7 68 mmol), tert-butyl frans-(4-hydroxymethyl)cyclohexyl carbamate (2 29 g, 10 0 mmol), and polymer supported-triphenylphosphine (5 12g, 11 5 mmol) were suspended in anhydrous tetrahydrofuran (100 mL) The mixture was cooled to 0 0C in an ice bath for 15 mm and then di-tert-butyl azodicarboxylate (2 12 g, 9 22 mmol) was added The reaction was allowed to warm to room temperature while stirring over 15 hours The reaction was filtered and the filtrate was concentrated The crude residue was purified by silica gel column chromatography (50 g, 0-2% methanol/dichloromethane) to afford the title compound as a beige oil
Step 4 Preparation of Λ/-(4-fluoro-3-methylbenzyl)-4-(1-(((frans)-4-amιnocyclohexyl)methyl)-1 /-H .2.4- trιazol-3-yl)-6-methylpιcolιnamιde
tert-Butyl (fra/is)-4-((3-(2-((4-fluoro-3-methylbenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-1H-1 ,2,4- trιazol-1-yl)methyl)cyclohexylcarbamate was dissolved in dichloromethane (15 mL) and stirred with trifluoroacetic acid (4 mL) for 1 hour at room temperature The reaction was concentrated and then triturated with diethyl ether to afford the title compound (2 76 g, 65%) LC/MS (5-95% CH3CN/H2O, 6 mm) 3 99 mm, m/z 437 (M+H)
Example 461
W-(4-Fluoro-3-methylbenzyl)-6-methyl-4-(1-(((frans)-4-(methylsulfonamido)cyclohexyl)methyl)-
1 H-1 ,2,4-triazol-3-yl)picolinamide
Triethylamine (0 1 1 mL, 0 77 mmol) was added to a solution of Λ/-(4-fluoro-3-methylbenzyl)-4- (1 -(((/ransH-aminocyclohexyOmethyO-i H- 1 ,2,4-trιazol-3-yl)-6-methylpιcolιnamιde (prepared as described in Example 460) (96 mg, 0 22 mmol) in dichloromethane (2 mL) A solution of methane sulfonyl chloride (30 mg) in dichloromethane (0 5 mL) was then added The reaction mixture was stirred for 1 hour at room temperature and then was concentrated The residue was purified by reverse phase preparative HPLC (10-90 % acetonitrile/water) to afford the title compound (17 mg, 15%) 1H NMR (400 MHz, DMSOd6) 6 ppm 9 01 - 9 20 (m, 1 H), 8 65 (s, 1 H), 8 37 (s, 1 H), 7 94 (br s , 1 H), 6 99 - 7 30 (m, 3 H), 6 92 (d, J=7 3 Hz, 1 H), 4 45 (d, J=5 9 Hz, 2 H), 4 11 (d, J=7 3 Hz, 2 H)1 3 03 (s, 1 H), 2 86 (s, 3 H), 2 60 (s, 3 H), 2 19 (s, 3 H), 1 88 (d, J=IO 3 Hz, 2 H), 1 79 (s, 1 H), 1 58 (d, J= 13 2 Hz, 2 H), 0 96 - 1 29 (m, 4 H)
Example 462
W-(4-Fluoro-3-methylbenzyl)-4-(1-(((frans)-4-acetamidocyclohexyl)methyl)-1H-1,2,4-triazol-3-yl)-
6-methylpicolinamide
Triethylamine (0 22 mL, 1 5 mmol) was added to a solution of Λ/-(4-fluoro-3-methylbenzyl)-4- (^(((fransH-aminocyclohexyOmethyO-IH-i ^^-tπazol-S-yO-θ-methylpicolinamide (prepared as described in Example 460) (96 mg, 0 22 mmol) in dichloromethane (2 mL) A solution of acetyl chloride (21 mg) in dichloromethane (0 5 mL) was then added The mixture was stirred for 1 hour at room temperature and was then concentrated The residue was purified by reverse phase preparative HPLC (10-90 % acetonitrile/water) to afford the title compound (18 mg, 17%) 1H NMR (400 MHz, DMSOd6) δ ppm 9 13 (t, J=5 9 Hz, 1 H), 8 65 (s, 1 H), 8 37 (br s , 1 H), 7 94 (s, 1 H), 7 63 (d, J=8 1 Hz, 1 H), 7 19 (dd, J=26 7, 6 2 Hz, 2 H), 6 92 - 7 11 (m, 1 H), 4 45 (d, J=5 9 Hz, 2 H), 4 11 (d, J=6 6 Hz, 2 H), 3 43 (br s , 1 H), 2 60 (s, 3 H), 2 19 (s, 3 H), 1 69 - 1 88 (m, 5 H), 1 58 (br s , 2 H), 0 95 - 1 20 (m, 5 H)
Example 463
2-(((rans)-4-((3-(2-((4-Fluoro-3-methylbenzyl)carbamoyl)-6-methylpyridin-4-yl)-1 H-1,2,4-tπazol-1- yl)methyl)cyclohexylamino)-2-oxoethyl acetate
Triethylamine (0 22 ml_, 1 5 mmol) was added to a solution of /V-(4-fluoro-3-methylbenzyl)-4- (1 -(((^rans)-4-amιnocyclohexyl)methyl)-1/-/-1 ,2,4-tπazol-3-yl)-6-methylpιcolιnamιde (prepared as described in Example 460) (96 mg, 0 22 mmol) in dichloromethane (2 mL) A solution of acetoxy acetyl chloride (36 mg) in dichloromethane (0 5 mL) was added The mixture was stirred for 1 hour at room temperature and was then concentrated The residue was purified by reverse phase preparative HPLC (10-90 % acetonitrile/water) to afford the title compound (26 mg)
Example 464
N^-FJuoro-S-methylbenzyO^I-^fransJ^^-hydroxyacetamidoJcyclohexylJmethyO-IW-i ,2,4- triazol-3-yl)-6-methylpicolinamidemide
2-((rraπs)-4-((3-(2-((4-Fluoro-3-methylbenzyl)carbamoyl)-6-methylpyrιdιn-4-yl)-1 /-/-1 ,2,4-trιazol- 1-yl)methyl)cyclohexylamιno)-2-oxoethyl acetate (prepared as described in Example 464) (26 mg) was dissolved in acetonitrile (amount) A 2 5N sodium hydroxide solution (amount) was added and the mixture was stirred for 2 hours The mixture was acidified to ph 6-7 and extracted with ethyl acetate The organic layer was washed with brine, dried over sodium sulfate, and concentrated to 18 mg of the title compound 1H NMR (400 MHz, DMSO-d6) δ ppm 9 13 (t, J=6 2 Hz, 1 H), 8 66 (s, 1 H), 8 37 (br s , 1 H), 7 94 (s, 1 H), 7 36 (d, J=8 8 Hz, 1 H), 6 94 - 7 26 (m, 3 H), 5 32 (d, J=5 1 Hz, 1 H), 4 45 (d, J=6 6 Hz, 2 H), 4 11 (d, J= 7 3 Hz, 2 H), 3 73 (d, J=5 1 Hz, 3 H), 3 53 (d, J=8 8 Hz, 1 H), 2 60 (s, 3 H), 2 19 (s, 2 H), 1 81 (br s , 1 H), 1 73 (d, J=11 0 Hz, 2 H), 1 58 (d, J=11 7 Hz, 2 H), 1 17 - 1 34 (m, 2 H), 0 99 - 1 17 (m, 2 H)
Example 465
/V-(3-Methoxybenzyl)-4-(1-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-1W-1,2,4-tria2ol-3-yl)-6- methylpicolinamide
Λ/-(3-Methoxyben2yl)-6-methyl-4-(1 /-/-1 ,2,4-trιazol-3-yl)pιcolιnamιde (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-4-(1-(((/rans)-4-amιnocyclohexyl)methyl)-1/-/-1 ,2,4- trιazol-3-y!)-6-methylpιcolιnamιde, Example 450) (0 20 g, 0 6 mmol), fraπs-1 ,4 cyclohexylenedimethanol (0 18 g, 1 24 mmol), and polymer supported-tπphenylphosphine (0 72 g, 1 6 mmol) were suspended in anhydrous tetrahydrofuran (5 mL) The mixture was cooled to 0 °C in an ice bath for 15 mm and then di-tert-butyl azodicarboxylate (0 29 g, 1 2 mmol) was added The reaction was allowed to warm to room temperature while stirring over 15 hours The reaction was filtered and the filtrate was concentrated The crude residue was purified by reverse phase preparative HPLC (5- 95% gradient acetonitrile/water) to afford the title compound as a white solid (97 mg, 35%) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 1 1 (t, J=6 2 Hz, 1 H), 8 65 (s, 1 H), 8 37 (s, 1 H), 7 94 (s, 1 H), 7 22 (t, J=8 1 Hz, 1 H)1 6 90 (br s , 2 H), 6 80 (d, J=8 1 Hz, 1 H), 4 48 (d, J=5 9 Hz, 2 H), 4 24 - 4 32 (m, 1 H), 4 19 (d, J=5 9 Hz, 1 H), 4 01 - 4 15 (m, 2 H), 3 71 (s, 3 H), 2 60 (s, 3 H), 1 81 (dd, J=11 4, 4 0 Hz, 1 H), 1 71 (d, J=11 7 Hz, 2 H), 1 58 (d, J=13 2 Hz, 2 H), 1 20 - 1 35 (m, 1 H), 0 91 - 1 06 (m, 2 H), 0 74 - 0 91 (m, 2 H)
Example 466 rac-/V-(3-Methoxybenzyl)-4-(1 -(((2S*,5/?*)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-1 H-1 ,2,4- triazol-3-yl)-6-methylpicolinamide
Λ/-(3-Methoxybenzyl)-6-methyl-4-(1 H-1 ,2,4-trιazol-3-yl)pιcolιnamιde (prepared as described in step 4 of the synthesis of Λ/-(3-methoxybenzyl)-4-(1-(((frans)-4-amιnocyclohexyl)methyl)-1 /-/-1 ,2,4- trιazol-3-yl)-6-methylpιcolιnamιde, Example 450) (32 mg, 0 10 mmol), /raπs-2, 5-bιs-(hydroxymethyl)- 1 ,4-dιoxane (prepared as described in step 3 of the synthesis of rac-/V-(3-methoxybenzyl)-6-(2- (((2S*,5f?*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrιmιdιne-4- carboxamide, Example 61 ) ( 22 mg, 0 15 mmol), and polymer supported-tπphenylphosphine (0 071 g, 0 15 mmol) were suspended in anhydrous tetrahydrofuran (2 mL) The mixture was cooled to 0 0C in an ice bath for 15 mm and then di-tert-butyl azodicarboxylate (28 mg, 0 12 mmol) was added The reaction was allowed to warm to room temperature while stirring over 15 hours The reaction was filtered and the filtrate was concentrated The crude residue was purified by reverse phase preparative HPLC (5-95% gradient acetonitrile/water) to afford the title compound as a white solid (15 mg, 33%) 1H NMR (400 MHz, DMSOd6) δ ppm 9 12 (t, J=6 2 Hz, 1 H), 8 63 (s, 1 H), 8 37 (s, 1 H), 7 95 (s, 1 H), 7 22 (t, J=8 1 Hz, 1 H), 6 90 (br s , 2 H), 6 80 (d, J=8 8 Hz, 1 H), 4 60 - 4 70 (m, 1 H), 4 48 (d, J=6 6 Hz, 2 H), 4 18 - 4 39 (m, 5 H), 3 88 (d, J=9 5 Hz, 2 H), 3 78 (d, J= 1 1 0 Hz, 1 H), 3 71 (s, 3 H), 2 56 - 2 71 (m, 4 H), 1 32 - 1 44 (m, 1 H)
Example 467 rac-Λ/^-Fluoro-S-methoxybenzyO^I^^Z^.S^-S-ihydroxymethyO-i^-dioxan^-yOmethyl)-
1 H-1 ,2,4-triazol-3-yl)-6-methylpicolinamide
Λ/-(4-Fluoro-3-methoxybenzyl)-6-methyl-4-(1/-/-1 ,2,4-trιazol-3-y!)pιcolιnamιde (prepared as described in step 1 of the preparation of Λ/-(4-fluoro-3-methoxybenzyl)-4-(1 -(((fraπs)-4- aminocyclohexyOmethyO-I H-i ^^-triazol-S-yO-β-methylpicolinamide, Example 455) (34 mg, 0 10 mmol), frans-2, 5-bιs-(hydroxymethyl)-1 ,4-dιoxane (prepared as described in step 3 of the synthesis of rac-Λ/-(3-methoxybenzyl)-6-(2-(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)- 2-methylpyrιmιdιne-4-carboxamιde, Example 61 ) (22 mg, 0 15 mmol), and polymer sυpported- tπphenylphosphine (0 071 g, 0 15 mmol) were suspended in anhydrous tetrahydrofuran (2 mL) The mixture was cooled to 0 0C in an ice bath for 15 mm then di-tert-butyl azodicarboxylate (28 mg, 0 12 mmol) was added The reaction was allowed to warm to room temperature while stirring over 15 hours The reaction was filtered and the filtrate was concentrated The crude residue was purified by reverse phase preparative HPLC (5-95% gradient acetonitrile/water) to afford the title compound as a white solid (22 mg, 47%) 1H NMR (400 MHz, DMSO-d6) δ ppm 9 14 (t, J=6 6 Hz, 1 H), 8 63 (s, 1 H), 8 37 (s, 1 H), 7 95 (s, 1 H), 7 05 - 7 22 (m, 2 H), 6 88 (br s , 1 H), 4 64 (t, J=5 1 Hz, 1 H), 4 47 (d,
J=6 6 Hz, 2 H), 4 18 - 4 40 (m, 5 H), 3 88 (d, J=9 5 Hz, 2 H), 3 67 - 3 83 (m, 5 H)1 2 61 <s. 3 H), 1 30 - 1 45 (m, 1 H)
Example 468 rac-W-(4-Fluoro-3-methylbenzyl)-4-(1 -(((2S*,5R*)-5-(hydroxymethyl)-1 ,4-dioxan-2-yl)methyl)-1 H- 1 ,2,4-triazol-3-yl)-6-methylpicolinamide
Λ/-(4-F!uoro-3-methylbenzyl)-6-methyl-4-(1 H- 1 ,2,4-trιazol-3-y!)pιcolιnamιde (prepared as described in step 2 of the synthesis of Λ/-(4-fluoro-3-methylbenzyl)-4-(1 -(((?rans)-4- amιnocydohexyl)methyl)-1 H-1 ,2,4-trιazol-3-yl)-6-methylpιcolιnamιde, Example 460) (33 mg, 0 10 mmol), trans-2, 5-bιs-(hydroxymethyl)-1 ,4-dιoxane (prepared as described in step 3 of the synthesis of rac-/V-(3-methoxybenzyl)-6-(2-(((2S*,5f?*)-5-(hydroxymethyl)-1 ,4-dιoxan-2-yl)methyl)-2H-tetrazol-5-yl)- 2-methylpyrιmιdιne-4-carboxamιde, Example 61 ) (22 mg, 0 15 mmol), and polymer supported- tπphenylphosphine (0 071 g, 0 15 mmol) were suspended in anhydrous tetrahydrofuran (2 mL) The mixture was cooled to 0 0C in an ice bath for 15 mm and then di-tert-butyl azodicarboxylate (28 mg, 0 12 mmol) was added The reaction was allowed to warm to room temperature while stirring over 15 hours The reaction mixture was filtered and the filtrate was concentrated The crude residue was purified by reverse phase preparative HPLC (5-95% gradient acetonitrile/water) to afford the title compound as a white solid (20 mg, 44%) 1H NMR (400 MHz, DMSO-Cf6) δ ppm 9 13 (t, J=6 2 Hz, 1 H), 8 63 (s, 1 H), 8 37 (s, 1 H), 7 94 (s, 1 H), 7 19 (dd, J=27 1 , 6 6 Hz, 2 H), 7 04 (t, J=9 2 Hz, 1 H), 4 64 (t, J=5 1 Hz, 1 H), 4 45 (d, J=6 6 Hz, 2 H), 4 18 - 4 40 (m, 5 H), 3 88 (d, J=9 5 Hz, 2 H), 3 78 (d, J=11 7 Hz, 2 H), 2 60 (s, 3 H), 2 19 (s, 3 H), 1 37 (br s , 1 H)
In Vitro MMP Inhibition Analysis
Matrix Metalloproteinase inhibitor compounds were analyzed in in vitro MMP Inhibition assays to determine their ability to inhibit the MMP cleavage of peptide substrates Inhibition constants (K1) were calculated from the assayed compound-MMP interactions
Human recombinant MMP-1 , MMP-2, MMP-3, MMP-7, MMP-9, MMP-12, MMP-13, MMP-14 and MMP-15 were used in these assays The enzymes are prepared following known laboratory procedures Protocols for the preparation and use of these enzymes are available in the scientific literature See, for example, Fnje et al , J Biol Chem , 269(24), 16766-73 (1994)
In addition, many MMPs may be purchased from suppliers For example, MMP-1 , MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-11 , MMP-12, MMP-13, MMP-14, MMP-15, MMP-16, MMP-24, MMP-25, and MMP-26 are commercially available from R&D Systems in their 2006 catalog Available in the 2006 Millipore Chemicon catalog are MMP-1 , MMP-2, MMP-3, MMP-7, MMP-8, MMP- 9, MMP-13, MMP-14, MMP-15, MMP-16, MMP-17 and MMP-24
The MMP-1 proenzyme may be purified from spent media of MMP-1 -transfected HT-1080 cells and the protein purified on a zinc chelating column The MMP-2 proenzyme may be purified by gelatin Sepharose chromatography from MMP-2-transfected p2AHT2 cells The MMP-9 proenzyme may be purified by gelatin Sepharose chromatography from spent media of MMP-9-transfected HT1080 cells
The catalytic domain MMP-3 cDNA may be used to express the catalytic domain enzyme in E coli inclusion bodies Then the enzyme is solubihzed in urea, purified on a preparative C-14 reverse phase HPLC column, and refolded in the presence of zinc acetate and purified for use
The MMP-7 cDNA may be used to express the enzyme in E coli inclusion bodies Then the enzyme is solubihzed in urea, purified on a preparative C-14 reverse phase HPLC column, and refolded in the presence of zinc acetate and purified for use
The MMP-13 may be obtained as a proenzyme from a full-length cDNA clone using baculovirus expression The expressed proenzyme was first purified over a heparin agarose column, and then over a chelating zinc chloride column Further details on baculovirus expression systems may be found in, for example, Luckow et al , J. Virol , 67, 4566-79 (1993)
The MMP-14 cDNA may be used to express the catalytic domain enzyme in E coli inclusion bodies Then the enzyme is solubihzed in urea, purified on a preparative C-14 reverse phase HPLC column, and refolded in the presence of zinc acetate and purified for use
The catalytic domain of MMP-12 and MMP-15 enzymes were purchased commercially for these assays
All full length MMPs were activated using 4-amιnophenylmercυrιc acetate ("APMA", Sigma Chemical, St Louis, Mo ) or trypsin MMP-9 also was activated using human recombinant MMP-3 following standard cloning and purification techniques
The fluorogenic, methoxycoumarin-containing polypeptide substrate MCA-
ArgProLeuGlyLeuDpaAlaArgGluArgNH2 was used as the MMP substrate in the MMP inhibition assays for human recombinant MMP-1 , MMP-2, MMP-7, MMP-9, MMP-12, MMP-13, MMP-14 and MMP-15 Here, "MCA" is 7-methoxycoumaπn-4-yl acetyl and "Dpa" is 3-(2,4-dιnιtrophenyl)-L-2,3-dι- aminopropionyl group In the absence of MMP inhibitory activity, the substrate is cleaved at the GIy- Leu peptide bond The cleavage separates the highly fluorogenic peptide from the 2,4-dιnιtrophenyl quencher, resulting in an increase of fluorescent intensity
For the human MMP-1 , MMP-2, MMP-7, MMP-9, MMP-12, MMP-13, MMP-14 and MMP-15 assays, dilutions of the inhibitors (or salts thereof) were prepared in 100% dimethyl sulfoxide (DMSO) The stock solutions were diluted in Buffer A (100 mM Tris-HCI, 100 mM NaCI, 10 mM CaCI2, 0 005% polyoxyethylene 23 lauryl ether, pH 7 5) to obtain solutions with different compound concentrations, i e , assay solutions with different concentrations of the assayed MMP inhibitory compound in 1% DMSO The experiment controls contained the same amount of Buffer A /DMSO as the assayed sample, but contained no inhibitor The fluorogenic, methoxycoumarin-containing polypeptide substrate Mca-Arg-Pro-Lys-Pro-
Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2 (Bachem catalog number M-2110) was used as the MMP substrate in the MMP inhibition assays for catalytic domain of human recombinant MMP-3 (which refers to the catalytic domain of stromelysin) Here, "MCA" is 7-methoxycoumarιn-4-yl acetyl and "Dpa" is 3-(2,4-dιnιtrophenyl)-L-2,3-dι- aminopropionyl group In the absence of MMP inhibitory activity, the substrate is cleaved at the Gly-Leu peptide bond The cleavage separates the highly fluorogenic peptide from the 2,4-dιnιtrophenyl quencher, resulting in an increase of fluorescent intensity
For the human MMP-3 assay, dilutions of the inhibitors (or salts thereof) were prepared in 100% DMSO The stock solutions were diluted in Buffer B (50 mM Λ/-morpholιnoethane sulfonate ("MES"), 100 mM NaCI, 10 mM CaCI2, 0 005% polyoxyethylene 23 lauryl ether, pH 6 0) ) to obtain solutions with different compound concentrations, i e , assay solutions with different concentrations of the assayed MMP inhibitory compound in 1 % DMSO The experiment controls contained the same amount of Buffer B /DMSO as the assayed sample, but contained no inhibitor
To determine K1, the inhibitor samples are incubated at room temperature for 1 hr in the presence of enzyme and then 4 μM of appropriate MMP substrate was added, and samples were analyzed on a Tecan SpectraFlour Plus plate reader The excitation wavelength is 330 nm, and the emission (fluorescence) wavelength is 420 nm In the absence of MMP inhibitory activity, the substrate is cleaved at the Gly-Leu bond resulting in an increase of relative fluorescence Inhibition is observed as a reduced rate of increase in relative fluorescence
The inhibitors are analyzed using a single low enzyme concentration with a single substrate concentration fixed at or below the Km This protocol is a modification of method by Knight et al , FEBS Lett , 296(3), 263-266 (1992) Apparent inhibitory constants are determined by non-linear regression of reaction velocity as a function of inhibitor and enzyme concentration using Morrison's equation, as described by Kuzmic, Anal Biochem 286, 45-50 (2000) Modifications were made in the non-linear regression method to allow a common control reaction rate and effective enzyme concentration to be shared between all dose-response relationships on a given assay plate Since the substrate concentration was chosen to be at or below the Kn,, the apparent K,'s from this analysis were reported as K,'s without correction for the influence of substrate
Cartilage damage in vitro assay
Human articular cartilage (HAC) was dissected from knees obtained from Asterand from patients undergoing knee replacement Apparently normal (not fibrillated) cartilage was cut in small pieces (- 2 mm) and cultured in 96 well plates with 200 μl of DMEM media (Gibco BRL high glucose, 25 mM Hepes, containing 2 mM L-glutamine and 1 mM Sodium Pyruvate) freshly supplemented with 1x HL-1 (Bio Whitaker) and 5 μg/ml ascorbic acid (Sigma), and with or without 0 1 ng/ml IL-1/? (R &D Systems, Minneapolis, MN) + 50 μg/ml Oncostatin M (R & D Systems) Some cartilage wells were incubated in the presence of serially diluted MMP inhibitors, tested in quadruplicate at 6 concentrations Media were replaced every 3 to 5 days and cartilage was cultured for a total of 18-22 days Conditioned media were frozen and analyzed later for hydroxyproline content (or type Il collagen degradation biomarker TIINE)
TIINE sandwich immunoassay for culture media.
A chemiluminescent sandwich immunoassay was developed with the neoepitope 9A4 antibody (recognizing the conserved sequence at the C-terminus of the V* type Il collagen fragment GPPGPQG following collagenase cleavage) and the capture 5109 antibody (recognizing the type Il collagen specific epitope GEPGDDGPS) as detailed elsewhere (Nemirovskiy et al , Anal Biochem 2007,361 (1 ) 93-101 ) utilizing the proprietary, chemiluminescent Bioveπs technology (Biovens Corporation, Gaithersburg, MD) This immunoassay utilizes a sandwich format on a paramagnetic bead support phase in which the sandwich complex is bound to the bead in suspension, passed through a flow cell, and captured by a magnet The process effectively separates the analyte from the sample, decreasing background interference and eliminating wash steps required in other formats Briefly, serially diluted culture supernatant samples were assayed in a 96-well plate In this one step assay, 25 μl of sample, 25 μl of streptavidin beads (0 4 mg/mL), 25 μl of each antibody at 1/yg/mL (Biotin conjugated mouse 5109 anti-capture and BVTAG labeled 9A4 anti-neoepitope) and 10O pL of assay buffer (DPBS, 0 1 % BSA, 0 05% Tween 20, pH 7 4) were incubated for 2 hours at room temperature before reading on the Bioveπs M384 Analyzer Values were calculated from a standard curve prepared from either human 45-mer or bovine 30-mer (0 14-100 ng/ml) neoepitope peptide
Cartilage damage and/or joint degeneration in vivo assay: surαical-inducβ medial meniscus tear rat OA model Adult male Sprague Dawley rats (Charles River, Wilmington, MA) weighing 275-300 g were allowed to acclimate for 1 week prior to surgery OA was surgically induced as described (Bendele, "Animal models of osteoarthritis," J. Musculoskelet Neuronal. Interact. 1 (2001 ) (4), pp 363-376) Briefly, animals were anesthetized with isoflurane and the right knee joint prepped for surgery The medial collateral ligament (MCL) was exposed by blunt dissection and transected to reflect the meniscus toward the femur The joint space was visualized and the meniscus was cut through the full thickness at its narrowest point to simulate a complete tear. The skin was closed with stainless steel staples Compound or vehicle treatment started the day of surgery and continued for 3 to 4 weeks The animals are then sacrificed, the femoro-tibial joint space lavaged with 100ul sterile saline to collect synovial fluid, and the total joint removed and fixed in 10% formalin for histology Scoring was performed by hispopathology quantification

Claims

Claims
1 A compound of Formula I
wherein G is (C1 3 alkylenyl)-Ra or Ra, wherein said C1 3 alkylenyl may be substituted by one or more substituents selected from OH and F,
Ra is C1-6 alkyl, 3- to 7-membered heterocycloalkyl, or 3- to 8-membered cycloalkyl, wherein said C1* alkyl may be substituted by one or more substituents selected from F, -OR34, -SR34, -C(O)NR34R35, -NR34R35, -NR34C(O)R35, or -NR34SO2R36, and wherein said heterocycloalkyl and cycloalkyl may be substituted by one or more substituents selected from R2, R3, R4, R5, R10, R11, and R21,
M is N or C-Rb,
Q is N or C-Rc, provided that if Q is C-Rc, then M is N,
W is phenyl-(C1-6 alkylenyl), pyridyl-(Cr6 alkylenyl), or 9-membered heteroaryl-(C1-6 alkylenyl), wherein said phenyl, pyridyl, or 9-membered heteroaryl is substituted by one or more groups selected from R30 and R31,
Y is Cr6 alkyl, Cr6 haloalkyl, or Cr6 hydroxyalkyl,
L is 5-membered heteroaryl,
R2 is H, F, CN, -OR5, R12, -C(=O)R7, -NR8R33, -NR8C(O)R9, -NR8SO2R36, or -SO2R12, R3 Is H1 F1 CN1 Or -OR22,
R4 is H1 -(C1-6 alkylene)R6, -C(O)R9, or -SO2R12,
R5 is H or -(C1-6 alkyl), wherein said C1-6 alkyl may be substituted by one or more R26 substituents,
1 \\ //
R6 is H, CN, -OR23, -SO2R37, -NR24C(O)R23, -NR24SO2R37, or N~N R7 is -(C1* alkyl), -(C1* haloalkyl), -(C1-6 alkylene)OH, -NR38R39, -NHSO2CH3, or -OR25,
R9 is -(C1* alkylene)R28, -NHR24, or -OR25, R10 is H, F, CN, R12, or -C(O)R7,
R11 is H, F, CN, -OR5, R12, -C(O)R7, -NR8R33, -NR8C(O)R9, -NR8SO2R36, or -SO2R12, R12 is -(C1* alkyl), wherein said C1* alkyl may be substituted by one or more substituents selected from CN, -OR23, -SR23, -SO2R37, -NR8R33, -NR24C(O)R23, and -NR24SO2R23, provided that any one carbon atom of said C1* alkyl is not substituted by more than one CN or more than one -OR23,
Rb, Rc, R8, R20, R22, R24, R25, R33, R34, and R35 are independently H or -(C1* alkyl), R21 Is H, F, or R12, R23 is H, -(C,* alkyl), or -(C1* alkylene)OH, R26 is H, OH, halo, NH2, or SH, R28 is H, NH2, or -OR29, R29 is H, (C1-6 alkyl), or -C(=O)(C1J6 alkyl), R30 is H or F, R31 is F, Cl, Br, -CN, -C(=O)NH2, -OH, -OR32, -OCH2CH2OR25, R32, ,or (C1^ alkyl) optionally substituted by -OR25 or -OCH2CH2OR25 where R30 and R31 when adjacent may be taken together to constitute a group of the formula - O-(CH2)n- or -0-(CH2)n-0-, n is 1 or 2, R32 is -(Ci-6 alkyl) optionally substituted with one, two, or three F,
R36 is -(C1-6 alkyl) or -(C3^ cycloalkyl), and R37 is -(C1-6 alkyl), -(C3-6 cycloalkyl), or -(C1-6 alkylene)OH,
R38 and R39 are independently H, -(C1^ alkyl), or R38 and R39 taken together form a 5- or 6- membered heterocycloalkyl, or a pharmaceutically-acceptable salt thereof
2 A compound according to claim 1 wherein Ra is C1-6 alkyl, 1 ,4-dιoxanyl, piperidinyl, cyclohexyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydropyranonyl, pyrrolidinyl, cyclopentyl, 7-oxa-bιcyclo[2 2 1]heptanyl, piperazinyl, 1 ,1 '-dιoxothιomorpholιnyl, tetrahydro-1 ,1 '- dioxothiopyranyl, tetrahydrothiopyranyl, piperidinonyl, tetrahydrofuryl, pyrrolidinonyl, or oxazolidinonyl, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -C(O)NR34R35, -NR34R35, -NR34C(O)R35, or -NR34SO2R35, and wherein said 1 ,4- dioxyl, piperidinyl, cyclohexyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydropyranonyl, pyrrolidinyl, cyclopentyl, 7-oxa-bιcyclo[2 2 1]heptanyl, piperazinyl, 1 ,1 '-dιoxothιomorpholιnyl, tetrahydro-1 ,1 '-dioxothiopyranyl, tetrahydrothiopyranyl, piperidinonyl, tetrahydrofuryl, pyrrolidinonyl, or oxazolidinonyl may be substituted by one or more substituents selected from R2, R3, R4, R5, R10, R11, and R21
3 A compound according to claim 1 wherein Ra is C1^ alkyl, 1 ,4-dιoxanyl substituted by R10 and R21, piperidinyl substituted by R2 and R3 or by R4, cyclohexyl substituted by R2 and R3 or by
R4, morpholinyl substituted by R4, thiomorpholinyl substituted by R10 and R21, tetrahydropyranyl substituted by R3 and R11 or by R10 and R21, tetrahydropyranonyl, pyrrolidinyl substituted by R2 and R3 or by R4, cyclopentyl substituted by R2 and R3, 7-oxa-bιcyclo[2 2 1]heptanyl, piperazinyl substituted by R4 and R5, 1 ,1 '-dιoxothιomorpholιnyl, tetrahydro-1 ,1 '-dioxothiopyranyl, tetrahydrothiopyranyl, piperidinonyl substituted by R5, tetrahydrofuryl substituted by R3 and R11, pyrrolidinonyl substituted by R5, oxazolidinonyl substituted by R5, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34C(O)R35, or -NR34SO2R35
4 A compound according to claim 3 wherein Ra is C1^ alkyl, substituents selected from -OR34, -SR34, -Cf=O)NR34R , -NR34R35, -NR34Cf=O)R , or -NR34SO2R3 and
X is N or CH, provided that when X is N, G is (C2-3 alkylenyl)-Ra, wherein said C,.3 alkylenyl may be substituted by one or more substituents selected from OH and F
A compound according to claim 4 wherein Ra is C1^3 alkyl,
, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -Cf=O)NR34R35, -NR34R35, -NR34Cf=O)R35, or -NR34SO2R35
6 A compound according to claim 5 wherein R3 is C1^ alkyl, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -Cf=O)NR34R35, -NR34R35, -NR34Cf=O)R35, or -NR34SO2R35
A compound according to claim 6 wherein Ra is C1^ alkyl, wherein said alkyl may be
,34 substituted by one or more -OR 8 A compound according to claim 5 wherein Ra is
A compound according to claim 8 wherein R is
10 A compound according to claim 1 wherein
G is -CH2R3, -CH2CH2R3, -CH(Ra)CH3, -CH2CH2CH2R3, -CH2CH(CH3)R3,
-CH(R3)CH2CH3, or Ra, wherein said CH, CH2, and CH3 groups may be substituted by one or more substituents selected from OH and F,
Ra is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1 -hexyl, aziridinyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, oxiranyl, oxetanyl, tetrahydrofuryl, dioxolyl, tetrahydropyranyl, dioxanyl, oxazetidinyl, isoxazolidinyl, oxazolidinyl, morpholinyl, oxazinanyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl may be substituted by one or more substituents selected from -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R36, and wherein said aziridinyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, oxiranyl, oxetanyl, tetrahydrofuryl, dioxolyl, tetrahydropyranyl, dioxanyl, oxazetidinyl, isoxazolidinyl, oxazolidinyl, morpholinyl, oxazinanyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl may be substituted by one or more substituents selected from R2, R3, R4, R5, R10, R11, and R21, W is phenyl-(C1-6 alkylenyl), pyrιdyl-(C1-6 alkylenyl), or ιndolyl-(C1-6 alkylenyl), wherein said Ci.
6 alkylene is methylene, ethylene, 1 -propylene, 2-propylene, 1 -butylene, 2-butylene, 2,2- dimethylethylene, 1 -pentylene, 2-pentylene, 2,2-dιmethylpropylene, or 1 -hexylene, and wherein said phenyl, pyridyl, or indolyl is substituted by one or more groups selected from R30 and R31, Y is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2- dimethylpropyl, or 1-hexyl, wherein Y may be substituted by OH or by one or more substituents selected from F, Cl1 and Br,
L is triazolyl, tetrazolyl, or oxadiazolyl, R4 is H, -(C1^ alkylene)R6, -C(=O)R9, or -SO2R12, wherein said C1-6 alkylene is methylene, ethylene, 1 -propylene, 2-propylene, 1 -butylene, 2-butylene, 2,2-dιmethylethylene, 1 -pentylene, 2- pentylene, 2,2-dιmethylpropylene, or 1-hexylene, and wherein said phenyl, pyridyl, or indolyl is substituted by one or more groups selected from R30 and R31,
R5 is H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, may be substituted by one or more R26 substituents,
R7 is methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, -NHR24, or -OR25, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl may be substituted by OH or by one or more substituents selected from F, Cl, and Br1 R9 is -(C1* alkylene)R28, -NHR24, or -OR25,
R12 is methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein R12 may be substituted by one or more substituents selected from CN, -OR23, -SO2R37, -NR8R33, -NR24C(=O)R23, and -NR24SO2R23, provided that any one carbon atom of R12 is not substituted by more than one CN or more than one -OR23,
Rb, Rc, R8, R20, R22, R24, R25, R33, R34, and R35 are independently H, methyl, ethyl, 1-propyl, 2- propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl,,
R23 is H, methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2- dimethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1 -hexyl, may be substituted by OH, R26 is H, OH, F, Cl, Br, NH2, or SH,
R29 is H, -C(=O)CH3, -C(=O)CH2CH3l -C(=O)(CH2)2CH3l -C(=O)CH(CH3)2, -C(=O)(CH2)3CH3, -C(O)CH(CH3)CH2CH3, -C(=O)CH2CH(CH3)2, -C(=O)(CH2)4CH3, -C(=O)CH2CH(CH3)CH2CH3, -C(=O)CH2C(CH3)3, or -C(=O)(CH2)5CH3,
R31 is Cl, Br, -OR32, methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1 - pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, or -OCH2CH2OR25,
R32 is methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl, wherein R32 may be substituted with one, two, or three F, R36 is methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl,
2,2-dιmethylpropyl, or 1-hexyl, and
R37 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, may be substituted by OH, or a pharmaceutically-acceptable salt thereof 1 1 A compound according to claim 1 having Formula
12 A compound according to claim 11 having Formula UA
13 A compound according to claim 12 wherein L is triazolyl, tetrazolyl, or oxadiazolyl
14 A compound according to claim 13 wherein L is
15 A compound according to claim 14 wherein L is
16 A compound according to claim 14 of Formula IIA-1
17 A compound according to claim 14 of Formula IIA-2
18 A compound according to claim 14 of Formula IIA-3 IIA-3
19 A compound according to claim 14 of Formula IIA-4
20 A compound according to any one of claims 13 through 19 wherein Ra is C1-6 alkyl,
, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR". 21 A compound according to claim 20 wherein R is C1-6 alkyl.
, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -Cf=O)NR34R35, -NR34R35, -NR34Cf=O)R35, or -NR34SO2R35
22 A compound according to claim 20 wherein Ra is Ci-6 alkyl, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -Cf=O)NR34R35, -NR34R35, -NR34Cf=O)R35, or -NR34SO2R35
23 A compound according to claim 22 wherein Ra is C1-6 alkyl, wherein said alkyl may be substituted by one or more -OR34
24 A compound according to claim 21 wherein Ra is
25 A compound according to any one of claims 15 through 19 wherein
Ra is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1 -hexyl, aziridinyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, oxiranyl, oxetanyl, tetrahydrofuryl, dioxolyl, tetrahydropyranyl, dioxanyl, oxazetidinyl, isoxazolidinyl, oxazolidinyl, morpholinyl, oxazinanyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl may be substituted by one or more substituents selected from -OR34, -SR3VCf=O)NR34R35,
-NR34R35, -NR34Cf=O)R35, or -NR34SO2R36, and wherein said aziridinyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, oxiranyl, oxetanyl, tetrahydrofuryl, dioxolyl, tetrahydropyranyl, dioxanyl, oxazetidinyl, isoxazolidinyl, oxazolidinyl, morpholinyl, oxazinanyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl may be substituted by one or more substituents selected from R2, R3, R4, R5, R10, R11, and R21,
W is phenyl-(Cr6 alkylenyl), pyrιdyl-(Cr6 alkylenyl), or ιndo!yl-(Cr6 alkylenyl), wherein said C1. 6 alkylene is methylene, ethylene, 1 -propylene, 2-propylene, 1-butylene, 2-butylene, 2,2- dimethylethylene, 1 -pentylene, 2-pentylene, 2,2-dιmethylpropylene, or 1-hexylene, and wherein said phenyl, pyridyl, or indolyl is substituted by one or more groups selected from R30 and R31,
Y is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2- dimethylpropyl, or 1-hexyl, wherein Y may be substituted by OH or by one or more substituents selected from F, Cl, and Br, L is triazolyl, tetrazolyl, or oxadiazolyl,
R4 is H, -(Ci-s alkylene)R6, -C(=O)R9, or -SO2R12, wherein said C1-6 alkylene is methylene, ethylene, 1 -propylene, 2-propylene, 1-butylene, 2-butylene, 2,2-dιmethylethylene, 1-pentylene, 2- pentylene, 2,2-dιmethylpropylene, or 1 -hexylene, and wherein said phenyl, pyridyl, or indolyl is substituted by one or more groups selected from R30 and R31, R5 is H1 methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl,
2,2-dιmethylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl, may be substituted by one or more R26 substituents,
R7 is methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1 -hexyl, -NHR24, or -OR25, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl may be substituted by OH or by one or more substituents selected from F, Cl, and Br; R9 is -(C6 alkylene)R28, -NHR24, or -OR25,
R12 is methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein R12 may be substituted by one or more substituents selected from CN1 -OR23, -SO2R37, -NR8R33, -NR24C(=O)R23, and -NR24SO2R23, provided that any one carbon atom of R12 is not substituted by more than one CN or more than one -OR23,
Rb, Rc, R8, R20, R22, R24, R25, R33, R34, and R35 are independently H, methyl, ethyl, 1 -propyl, 2- propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl,, R23 is H, methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl,
2,2-dιmethylpropyl, or 1 -hexyl, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, may be substituted by OH, R26 is H, OH, F, Cl, Br, NH2, or SH,
R29 is H, -C(=0)CH3, -C(=O)CH2CH3l -C(=O)(CH2)2CH3, -C(=O)CH(CH3)2, -C(=O)(CH2)3CH3, -C(=O)CH(CH3)CH2CH3, -C(=O)CH2CH(CH3)2, -C(=O)(CH2)4CH3, -C(=O)CH2CH(CH3)CH2CH3, -C(=O)CH2C(CH3)3, or -C(=O)(CH2)5CH3l
R31 is Cl, Br1 -OR32, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1- pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1 -hexyl, or -OCH2CH2OR25,
R32 is methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein R32 may be substituted with one, two, or three F, R36 is methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl, and
R37 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, may be substituted by OH, or a pharmaceutically-acceptable salt thereof
26 A compound according to any one of claims 11 through 25 wherein Y is methyl
27 A compound according to any one of claims 11 through 26 wherein W is phenyl-(d-6 alkylenyl), wherein said phenyl is substituted by one or more groups selected from R30 and R31
28 A compound according to claim 27 wherein W is phenylmethyl, wherein said phenyl is substituted by one or more groups selected from R30 and R31
29 A compound having the structure
30 A compound having the structure
31 A compound having the structure A compound having the structure A compound having the structure A compound having the structure A compound having the structure A compound having the structure A compound having the structure A compound having the structure A compound having the structure
40 A compound according to claim 1 having Formula
41 A compound according to claim 40 having Formula IHA
42 A compound according to claim 41 wherein L is triazolyl, tetrazolyl, or oxadiazolyl
43 A compound according to claim 42 wherein L is
44 A compound according to claim 43 wherein L is
45 A compound according to claim 41 of Formula IIIA-1
46 A compound according to claim 41 of Formula IIIA-2
47 A compound according to claim 41 of Formula IIIA-3
48 A compound according to claim 41 of Formula IIIA-4
49 A compound according to any one of claims 42 through 48 wherein R is C1^ alkyl,
, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -Ci=O)NR34R35, -NR34R35, -NR34C(O)R35, or -NR34SO2R3
50 A compound according to claim 49 wherein Ra is C1^ alkyl,
, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -C(O)NR34R35, -NR34R35, -NR34C(O)R35, or -NR34SO2R35
51 A compound according to claim 49 wherein Ra is d-6 alkyl, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -C(O)NR34R35, -NR34R35, -NR34C(O)R35, or -NR34SO2R35
52 A compound according to claim 51 wherein Ra is C1-6 alkyl, wherein said alkyl may be substituted by one or more -OR34, 53 A compound according to claim 50 wherein Ra is
54 A compound according to any one of claims 44 through 48 wherein R3 is methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl,
2,2-dιmethylpropyl, 1-hexyl, aziridinyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, oxiranyl, oxetanyl, tetrahydrofuryl, dioxolyl, tetrahydropyranyl, dioxanyl, oxazetidinyl, isoxazolidinyl, oxazolidinyl, morpholinyl, oxazinanyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl may be substituted by one or more substituents selected from -OR34, -SR34, -Ci=O)NR34R35,
-NR34R35, -NR34C(=O)R35, or -NR34SO2R36, and wherein said aziridinyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, oxiranyl, oxetanyl, tetrahydrofuryl, dioxolyl, tetrahydropyranyl, dioxanyl, oxazetidinyl, isoxazolidinyl, oxazolidinyl, morpholinyl, oxazinanyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl may be substituted by one or more substituents selected from R2, R3, R4, R5, R10, R11, and R21,
W is phenyHCrβ alkylenyl), pyridyKCVβ alkylenyl), or alkylenyl), wherein said C1. 6 alkylene is methylene, ethylene, 1 -propylene, 2-propylene, 1-butylene, 2-butylene, 2,2- dimethylethylene, 1-pentylene, 2-pentylene, 2,2-dιmethylpropylene, or 1-hexylene, and wherein said phenyl, pyridyl, or indolyl is substituted by one or more groups selected from R30 and R31,
Y is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2- dimethylpropyl, or 1 -hexyl, wherein Y may be substituted by OH or by one or more substituents selected from F, Cl, and Br,
L is triazolyl, tetrazolyl, or oxadiazolyl, R4 is H, -(C1-6 alkylene)R6, -C(=O)R9, or -SO2R12, wherein said C1^ alkylene is methylene, ethylene, 1 -propylene, 2-propylene, 1-butylene, 2-butylene, 2,2-dιmethylethylene, 1-pentylene, 2- pentylene, 2,2-dιmethylpropylene, or 1-hexylene, and wherein said phenyl, pyridyl, or indolyl is substituted by one or more groups selected from R30 and R31,
R5 is H, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl, may be substituted by one or more R26 substituents,
R7 is methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, -NHR24, or -OR25, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl may be substituted by OH or by one or more substituents selected from F, Cl, and Br, R9 is -(C1^ alkylene)R28, -NHR24, or -OR25,
R12 is methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein R12 may be substituted by one or more substituents selected from CN, -OR23, -SO2R37, -NR8R33, -NR24C(=O)R23, and -NR24SO2R23, provided that any one carbon atom of R12 is not substituted by more than one CN or more than one -OR23,
Rb, Rc, R8, R20, R22, R24, R25, R33, R34, and R35 are independently H, methyl, ethyl, 1 -propyl, 2- propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl,,
R23 is H, methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1 -hexyl, may be substituted by OH, R26 is H, OH, F, Cl, Br, NH2, or SH,
R29 is H, -C(=O)CH3, -C(=O)CH2CH3, -C(=O)(CH2)2CH3, -C(=O)CH(CH3)2, -C(=O)(CH2)3CH3, -C(=O)CH(CH3)CH2CH3, -C(=O)CH2CH(CH3)2, -C(=O)(CH2)4CH3, -C(=O)CH2CH(CH3)CH2CH3, -C(=O)CH2C(CH3)3, or -C(=O)(CH2)5CH3, R31 is Cl, Br, -OR32, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1- pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, Or -OCH2CH2OR25,
R32 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein R32 may be substituted with one, two, or three F, R36 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl,
2,2-dιmethylpropyl, or 1 -hexyl, and
R37 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1 -hexyl, may be substituted by OH, or a pharmaceutically-acceptable salt thereof
55 A compound according to any one of claims 40 through 54 wherein Y is methyl
56 A compound according to claim 1 having Formula IV
57 A compound according to claim 56 having Formula IVA
58 A compound according to claim 57 wherein L is triazolyl, tetrazolyl, or oxadiazolyl
59 A compound according to claim 58 wherein L is
60 A compound according to claim 59 wherein L is
61 A compound according to claim 59 of Formula IVA-1
62 A compound according to claim 59 of Formula IVA-2
63 A compound according to claim 59 of Formula IVA-3
64 A compound according to claim 59 of Formula IVA-4
65 A compound according to any one of claims 58 through 64 wherein Ra is C1^ alkyl, , or wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -Q=O)NR34R35, -NR34R35, -NR34Q=O)R35, or -NR34SO2R35
66 A compound according to claim 65 wherein Ra is Ci-6 alkyl,
, wherein said alkyl may be substituted by one or more substituents selected from -OR34, -SR34, -Q=O)NR34R35, -NR34R35, -NR34Q=O)R35, or -NR34SO2R35
67 A compound according to claim 65 wherein Ra is C1^ alkyl, wherein said alkyl may be substituted by one or more substituents selected from -OR", -SRΛ or -NR-54SO2R
68 A compound according to claim 67 wherein Ra is C1-3 alkyl, wherein said alkyl may be
34 substituted by one or more -OR ,
69 A compound according to claim 66 wherein Ra is
70 A compound according to claim 69 wherein Ra is
R2 is CH(CH3)OH, C(CHs)2OH, -NR8C(=O)(C,^ alkylene)R28, or -NR8SO2R36, R10 is CH(CH3)OH, or C(CH3)2OH, and R11 is CH(CH3)OH, C(CH3)2OH, -NR8C(=O)(C1-6 alkylene)R28, or -NR8SO2R36
71 A compound according to any one of claims 60 through 64 wherein Ra is methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1 -hexyl, aziridinyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, oxiranyl, oxetanyl, tetrahydrofuryl, dioxolyl, tetrahydropyranyl, dioxanyl, oxazetidinyl, isoxazolidinyl, oxazolidinyl, morpholinyl, oxazinanyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl may be substituted by one or more substituents selected from -OR34, -SR34, -C(=O)NR34R35, -NR34R35, -NR34C(=O)R35, or -NR34SO2R36, and wherein said aziridinyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, oxiranyl, oxetanyl, tetrahydrofuryl, dioxolyl, tetrahydropyranyl, dioxanyl, oxazetidinyl, isoxazolidinyl, oxazolidinyl, morpholinyl, oxazinanyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl may be substituted by one or more substituents selected from R2, R3, R4, R5, R10, R11, and R21, W is phenyl-(d-6 alkylenyl), pyridyl-(Cr6 alkylenyl), or ιndolyl-(C1-6 alkylenyl), wherein said C1.
6 alkylene is methylene, ethylene, 1 -propylene, 2-propylene, 1-butylene, 2-butylene, 2,2- dimethylethylene, 1-pentylene, 2-pentylene, 2,2-dιmethylpropylene, or 1-hexylene, and wherein said phenyl, pyridyl, or indolyl is substituted by one or more groups selected from R30 and R31,
Y is methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2- dimethylpropyl, or 1 -hexyl, wherein Y may be substituted by OH or by one or more substituents selected from F, Cl, and Br,
L is triazolyl, tetrazolyl, or oxadiazolyl,
R4 is H, -(C1^ alkylene)R6, -C(=O)R9, or -SO2R12, wherein said C1^ alkylene is methylene, ethylene, 1 -propylene, 2-propylene, 1 -butylene, 2-butylene, 2,2-dιmethylethylene, 1-pentylene, 2- pentylene, 2,2-dιmethylpropylene, or 1 -hexylene, and wherein said phenyl, pyridyl, or indolyl is substituted by one or more groups selected from R30 and R31,
R5 is H, methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl, may be substituted by one or more R26 substituents,
R7 is methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, -NHR24, or -OR25, wherein said methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl may be substituted by OH or by one or more substituents selected from F, Cl, and Br, R9 is -(Ce alkylene)R28, -NHR24, or -OR25,
R12 is methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl, wherein R12 may be substituted by one or more substituents selected from CN, -OR23, -SO2R37, -NR8R33, -NR24C(=O)R23, and -NR24SO2R23, provided that any one carbon atom of R12 is not substituted by more than one CN or more than one -OR23,
Rb, Rc, R8, R20, R22, R24, R25, R33, R34, and R35 are independently H, methyl, ethyl, 1-propyl, 2- propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl,, R23 is H, methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1-pentyl, 2-pentyl,
2,2-dιmethylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1 -hexyl, may be substituted by OH, R26 is H, OH, F, Cl1 Br, NH2, or SH,
R29 is H, -C(=O)CH3, -C(=O)CH2CH3, -C(=O)(CH2)2CH3, -C(=O)CH(CH3)2, -C(=O)(CH2)3CH3, -C(=O)CH(CH3)CH2CH3, -C(=O)CH2CH(CH3)2, -C(=O)(CH2)4CH3, -C(=O)CH2CH(CH3)CH2CH3l -C(=O)CH2C(CH3)3, or -C(=O)(CH2)5CH3l
R31 is Cl, Br, -OR32, methyl, ethyl, 1-propyl, 2-propyl, 1 -butyl, 2-butyl, 2,2-dιmethylethyl, 1- pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, or -OCH2CH2OR25,
R is methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1 -hexyl, wherein R32 may be substituted with one, two, or three F,
R36 is methyl, ethyl, 1 -propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, and
R37 is methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2-dιmethylethyl, 1 -pentyl, 2-pentyl, 2,2-dιmethylpropyl, or 1-hexyl, wherein said methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2,2- dimethylethyl, 1-pentyl, 2-pentyl, 2,2-dιmethylpropyl, 1-hexyl, may be substituted by OH, or a pharmaceutically-acceptable salt thereof
72 A compound according to any one of claims 56 through 71 wherein Y is methyl
73 A compound according to any one of claims 56 through 71 wherein W is phenyl-(C1-6 alkylenyl), wherein said phenyl is substituted by one or more groups selected from R30 and R31
74 A compound according to claim 73 wherein W is phenylmethyl, wherein said phenyl is substituted by one or more groups selected from R30 and R31
75 A compound which is [pyridine triazole names - update or remove]
76 A compound which is [pyridine tetrazole names - update or remove]
77 A compound having the structure
78 A compound having the structure
79 A compound having the structure
80 A compound having the structure
81 A compound having the structure 82 A pharmaceutical composition, comprising a compound according to any one of claims 1 through 81 , or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent
83 A method for inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal an MMP-13 inhibiting amount of a compound according to any one of claims 1 through 81 , or a pharmaceutically acceptable salt thereof
84 A method for treating a disease mediated by an MMP-13 enzyme, comprising administering to a patient suffering from such a disease a nontoxic effective amount of a compound according to any one of claims 1 through 81 , or a pharmaceutically acceptable salt thereof
85 A method for treating arthritis, comprising administering to a patient suffering from an arthritis disease a nontoxic antiarthritic effective amount of a compound according to any one of claims 1 through 81 , or a pharmaceutically acceptable salt thereof
86 A method for treating osteoarthritis, comprising administering to a patient suffering from osteoarthritis a nontoxic effective amount of a compound according to any one of claims 1 through 79, or a pharmaceutically acceptable salt thereof
87 A method for treating rheumatoid arthritis, comprising administering to a patient suffering from rheumatoid arthritis a nontoxic effective amount of a compound according to any one of claims 1 through 81 , or a pharmaceutically acceptable salt thereof
88 A method for treating psoriatic arthritis, comprising administering to a patient suffering from psoriatic arthritis a nontoxic effective amount of a compound according to any one of claims 1 through 79, or a pharmaceutically acceptable salt thereof
89 A method for treating a cancer, comprising administering to a patient suffering from a cancer a nontoxic anti-cancer effective amount of a compound according to any one of claims 1 through 81 , or a pharmaceutically acceptable salt thereof
90 A method for treating inflammation, comprising administering to a patient suffering from inflammation a nontoxic effective amount of a compound according to any one of claims 1 through 81 , or a pharmaceutically acceptable salt thereof
91 A method for treating chronic obstructive pulmonary disease, comprising administering to a patient suffering from chronic obstructive pulmonary disease a nontoxic effective amount of a compound according to any one of claims 1 through 81 , or a pharmaceutically acceptable salt thereof 92 A method for treating psoriasis, comprising administering to a patient suffering from psoriasis a nontoxic effective amount of a compound according to any one of claims 1 through 81 , or a pharmaceutically acceptable salt thereof
93 A method for treating asthma, comprising administering to a patient suffering from asthma a nontoxic effective amount of a compound according to any one of claims 1 through 81 , or a pharmaceutically acceptable salt thereof
94 A method for treating inflammatory bowel disease, comprising administering to a patient suffering from inflammatory bowel disease a nontoxic effective amount of a compound according to any one of claims 1 through 81 , or a pharmaceutically acceptable salt thereof
EP08789003A 2007-08-02 2008-07-29 Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions Withdrawn EP2185537A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95360407P 2007-08-02 2007-08-02
US1553307P 2007-12-20 2007-12-20
PCT/IB2008/002046 WO2009016498A1 (en) 2007-08-02 2008-07-29 Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions

Publications (1)

Publication Number Publication Date
EP2185537A1 true EP2185537A1 (en) 2010-05-19

Family

ID=39884254

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08789003A Withdrawn EP2185537A1 (en) 2007-08-02 2008-07-29 Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions

Country Status (8)

Country Link
EP (1) EP2185537A1 (en)
JP (1) JP2010535192A (en)
KR (1) KR20100045497A (en)
CN (1) CN101815710A (en)
AU (1) AU2008281509A1 (en)
CA (1) CA2695304A1 (en)
MX (1) MX2010001338A (en)
WO (1) WO2009016498A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056832B2 (en) * 2010-09-17 2015-06-16 Purdue Pharma L.P. Pyridine compounds and the users thereof
AR086113A1 (en) 2011-04-30 2013-11-20 Abbott Lab ISOXAZOLINS AS THERAPEUTIC AGENTS
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
EP3285581B1 (en) 2015-03-26 2021-08-11 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
EP3291817B1 (en) 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
EP3313852B1 (en) 2015-06-25 2021-01-20 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
EP3484876A1 (en) 2016-07-14 2019-05-22 Pfizer Inc Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
CN111574405A (en) * 2020-06-11 2020-08-25 烟台显华化工科技有限公司 Diene negative liquid crystal compound and preparation method and application thereof
US20230113202A1 (en) * 2021-02-02 2023-04-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2023238930A1 (en) * 2022-06-10 2023-12-14 大鵬薬品工業株式会社 Analogues of azabicyclic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
PA8578101A1 (en) * 2002-08-13 2004-05-07 Warner Lambert Co HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS
GB0403155D0 (en) * 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
WO2006061706A1 (en) * 2004-12-08 2006-06-15 Warner-Lambert Company Llc Tetrazolyl-methylene amino acid derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009016498A1 *

Also Published As

Publication number Publication date
MX2010001338A (en) 2010-04-21
JP2010535192A (en) 2010-11-18
CA2695304A1 (en) 2009-02-05
CN101815710A (en) 2010-08-25
AU2008281509A1 (en) 2009-02-05
WO2009016498A8 (en) 2010-11-11
KR20100045497A (en) 2010-05-03
WO2009016498A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
EP2185537A1 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
AU2020273302B2 (en) Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
EP2016058B1 (en) Inhibitors of c-fms kinase
JP5453437B2 (en) Sulfonyl compounds that selectively modulate the CB2 receptor
WO2007124318A1 (en) Inhibitors of c-fms kinase
AU2008223794A1 (en) 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
JP6356790B2 (en) Novel CYP17 inhibitor / antiandrogen
AU2015414743B2 (en) Process for the preparation of kinase inhibitors and intermediates thereof
EP3868756A1 (en) Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors
EP2909170A1 (en) Substituted carbamate compounds and their use as transient receptor potential (trp) channel antagonists
WO2008149191A1 (en) Hetero bicyclic carboxamide derivatives and their pharmaceutical use and compositions
JPH07291965A (en) Novel pyrrolidine derivative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100302

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100729

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110209